"Rank","NCT Number","Title","Acronym","Status","Study Results","Conditions","Interventions","Outcome Measures","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Type","Study Designs","Other IDs","Start Date","Primary Completion Date","Completion Date","First Posted","Results First Posted","Last Update Posted","Locations","Study Documents","URL"
1,"NCT02735798","64-Cu Labeled Brain PET/MRI for MM-302 in Advanced HER2+ Cancers With Brain Mets",,"Withdrawn","No Results Available","Brain Metastases|Documented Her2 Overexpression|Advanced Solid Tumor|Neurologically Stable","Drug: MM-302|Drug: Trastuzumab","MM-302 drug penetration into the brain|Adverse event|Overall response rate|Progession-free survival|CNS response rate|Systemic response rate|Adverse Event","Pamela Munster|University of California, San Francisco","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15952","April 2016","June 2017","June 2018","April 13, 2016","null","May 4, 2017","","","https://ClinicalTrials.gov/show/NCT02735798"
2,"NCT03582254","Role of [18F]-FDG Brain PET in Newly Diagnosed Primary Cerebral Lymphoma, in Immunocompetent Patient Older Than 60 Years","LOCALYSE","Recruiting","No Results Available","Primary Central Nervous System Lymphoma","Radiation: [18F]-FDG PET/MR","Progression free survival calculated from the date of completion of the end of chemotherapy PET","Assistance Publique - Hôpitaux de Paris","All","18 Years to 60 Years   (Adult)","Not Applicable","56","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","AOR14101|2014-002597-37","June 13, 2016","May 12, 2020","May 12, 2020","July 10, 2018","null","July 10, 2018","Pitié Salpêtrière Hospital, Paris, France","","https://ClinicalTrials.gov/show/NCT03582254"
3,"NCT00800709","Memantine and Changes of Biological Markers and Brain PET Imaging in Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Drug: Memantine","biological markers of CSF|18[F]-FDG-PET of brain|cognitive function|behavior and activities of daily living|short term memory","Shanghai Mental Health Center|H. Lundbeck A/S","All","50 Years to 90 Years   (Adult, Older Adult)","Phase 4","26","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IIT_12484A","July 2008","October 2010","October 2010","December 2, 2008","null","December 3, 2010","Department of Psychogeriatrics，Shanghai Mental Health Center, Shanghai, Shanghai, China","","https://ClinicalTrials.gov/show/NCT00800709"
4,"NCT01801371","68Ga-BNOTA-PRGD2 PET/CT in Diagnosis and Evaluation of Glioma","GRGDG","Recruiting","No Results Available","Glioma","Drug: 68Ga-BNOTA-PRGD2","Semiquantitative measurement of standardized uptake values (SUVs) of lesions|Number of participants with adverse events as a measure of safety","Peking Union Medical College Hospital|Beijing Tiantan Hospital","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","PUMCHNM6","October 2012","December 2017","December 2017","February 28, 2013","null","April 7, 2017","Peking Union Medical College Hospital, Beijing, Beijing, China","","https://ClinicalTrials.gov/show/NCT01801371"
5,"NCT03370809","Assessment of Positron Emission Tomography to Early Detect Frailty in Onco-geriatry","FOGTEP","Not yet recruiting","No Results Available","Patients Over 75 Years Old With a Cancer Discovery","Radiation: Brain PET/CT step","Volume of brain with damages detected by quantitative analysis SPM (Statistical Parametric Mapping)|Volume of brain with damages detected by quantitative analysis SPM between 2 patient's group with MMSE (MiniMental State Examination) results and threshold value as 24|Volume of brain with damages detected by quantitative analysis SPM between 2 patient's groups with GDS (Geriatric Depression Scale) results and threshold value as 5|Volume of brain with damages detected by quantitative analysis SPM between different groups according to the SIOG-2 scale|Volume of brain with damages detected by quantitative analysis SPM between 2 patient's groups according to an unscheduled hospitalisation over 6 months or no|Volume of brain with damages detected by quantitative analysis SPM between 2 patient's groups according to non cancer related death at 12 months or no","Central Hospital, Nancy, France","All","75 Years and older   (Older Adult)","Not Applicable","160","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","PSS2017/FOGTEP-VERGER/VS","July 18, 2018","March 2019","March 2020","December 12, 2017","null","July 23, 2018","","","https://ClinicalTrials.gov/show/NCT03370809"
6,"NCT01607476","Bridging Study of C11 Pittsburgh Compound B (PiB) and F18 Flutemetamol Brain Positron Emission Tomography (PET)",,"Completed","Has Results","Alzheimer's Disease","Drug: C11 PiB|Drug: F18 Flutametamol","Global Distribution of C11 PiB in the Brain|Global Distribution of F18 Flutemetamol in the Brain","Mayo Clinic","All","30 Years and older   (Adult, Older Adult)","Phase 2","89","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","12-000118","July 2012","December 2014","March 2016","May 30, 2012","November 1, 2016","April 18, 2017","Mayo Clinic Rochester, Rochester, Minnesota, United States","","https://ClinicalTrials.gov/show/NCT01607476"
7,"NCT03305705","Effect of Iron on Cerebral Dopamine Receptor Density in Non-anaemic Premenopausal Women With Low Ferritin and Fatigue",,"Not yet recruiting","No Results Available","Fatigue|Iron-deficiency","Drug: Iron Carboxymaltose|Drug: Sodium chloride 0.9%","Dopamine (DA) receptor density|Fatigue|Neuropsychological symptoms","Albina Nowak, MD|University of Zurich","Female","18 Years to 55 Years   (Adult)","Phase 4","20","Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Basic Science","BASEC-Nr. PB_2017-00429|KEK-ZH-Nr. 2014-0217","October 23, 2017","August 31, 2019","August 31, 2019","October 10, 2017","null","October 13, 2017","University Hospital Zurich, Zürich, Switzerland","","https://ClinicalTrials.gov/show/NCT03305705"
8,"NCT03368677","Effect of Teriflunomide Treatment on Microglial Activation in an MS Patient Cohort at Risk of Progression","TERIPET","Recruiting","No Results Available","Multiple Sclerosis","","Change of 11C-PK11195-radioligand binding using PET|MRI metrics|EDSS|BICAMS","Turku University Hospital","All","40 Years to 55 Years   (Adult)","","30","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","TERIPET","December 1, 2017","November 2022","November 2024","December 11, 2017","null","February 8, 2018","Turku PET Centre, Turku, Finland Proper, Finland","","https://ClinicalTrials.gov/show/NCT03368677"
9,"NCT02139696","Sphingosine-1 Phosphate -Receptor Targeting and Microglial Activation","FINGOPET","Completed","No Results Available","Multiple Sclerosis","Radiation: PET and MRI","Change of 11C-PK11195-radioligand binding using PET|MRI metrics","Turku University Hospital","All","18 Years to 58 Years   (Adult)","","10","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","FINGOPET","September 2013","January 2015","October 2016","May 15, 2014","null","May 10, 2018","Turku University Hospital, Turku, Finland","","https://ClinicalTrials.gov/show/NCT02139696"
10,"NCT01886820","A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of [18F]NAV4694 PET for Detection of Cerebral Beta-Amyloid When Compared With Postmortem Histopathology",,"Active, not recruiting","No Results Available","Dementia|Alzheimer's Disease","Drug: [18F]NAV4694","Incidence of [18F]NAV4694 Brain PET scan positivity compared to histopathology|Quantification of [18F]NAV4694 brain PET Scan positivity compared to histopathology|Incidence of [18F]NAV4694 PET Scan positivity in 6 pre-specified brain regions compared to histopathology|Quantification of [18F]NAV4694 PET Scan positivity in 6 pre-specified brain regions compared to histopathology|Incidence of adverse events","Navidea Biopharmaceuticals","All","21 Years and older   (Adult, Older Adult)","Phase 3","290","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","NAV4-02","June 2013","June 2018","September 2018","June 26, 2013","null","July 26, 2017","Banner Sun Health Research Institute, Sun City, Arizona, United States|University of California San Diego, La Jolla, California, United States|Neuropsychiatric Research Center of Southwest Florida, Fort Myers, Florida, United States|Mount Sinai Medical Center of Florida, Miami Beach, Florida, United States|Galiz Research, Miami Springs, Florida, United States|Compass Research, Orlando, Florida, United States|Physicians Care Clinical Research, Sarasota, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|Southern Illinois University School of Medicine, Springfield, Illinois, United States|Biomedical Research Foundation, Shreveport, Louisiana, United States|Las Vegas Radiology, Las Vegas, Nevada, United States|Albert Einstein College of Medicine, The Bronx, New York, United States|The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Wake Forest Baptist Health-Gerontology, Winston-Salem, North Carolina, United States|Valley Medical Center, Centerville, Ohio, United States","","https://ClinicalTrials.gov/show/NCT01886820"
11,"NCT01165554","Positron Emission Tomography (PET) Imaging of Brain Amyloid Compared to Post-Mortem Levels",,"Completed","Has Results","Brain Fibrillarab Levels","Drug: [18F] Flutemetamol","The Sensitivity of Blinded Visual Interpretations of [18F]Flutemetamol Positron Emission Tomography (PET) Images Without Anatomic Brain Images for Detecting Brain Fibrillar Amyloid β.|Blinded Visual Interpretation of Each Subject's Flutemetamol F 18 Injection Brain PET Images as Normal, Without Anatomic Brain Images.|Blinded Visual Interpretation of Each Subject's Flutemetamol F 18 Injection Brain PET Images as Abnormal, With Anatomic CT Brain Images for Reference.|Blinded Visual Interpretation of Each Subject's Flutemetamol F 18 Injection Brain PET Images as Normal, With Anatomic CT Brain Images for Reference.","GE Healthcare|i3 Statprobe|Covance","All","55 Years and older   (Adult, Older Adult)","Phase 3","203","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","GE-067-007","May 2010","November 2011","November 2011","July 20, 2010","December 4, 2013","December 4, 2013","GE Healthcare, Princeton, New Jersey, United States","","https://ClinicalTrials.gov/show/NCT01165554"
12,"NCT01924858","A Positron Emission Tomography (PET) Study to Investigate the Brain Biodistribution of 18F GSK2647544 in Healthy Subjects to Determine Its Ability to Cross the Blood-brain-barrier.",,"Terminated","No Results Available","Alzheimer's Disease","Drug: GSK2647544 oral|Drug: [18F]GSK2647544 IV bolus","Whole brain PET VT of [18F]-GSK2647544|Safety and tolerability assessment following oral administration of GSK2647544|GSK2647544 PK assessment","GlaxoSmithKline","Male","30 Years to 55 Years   (Adult)","Phase 1","4","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","117155","August 19, 2013","March 3, 2014","March 3, 2014","August 19, 2013","null","October 19, 2017","GSK Investigational Site, London, United Kingdom|GSK Investigational Site, London, United Kingdom","","https://ClinicalTrials.gov/show/NCT01924858"
13,"NCT03106740","Evaluating the Role of Neuroinflammation in Low Back Pain","IGNITE","Recruiting","No Results Available","Low Back Pain|Back Pain With Radiation|Back Pain Without Radiation|Back Pain Lower Back Chronic|Back Ache|Pain, Chronic","Drug: Minocycline Hydrochloride 100mg Capsule|Diagnostic Test: Magnetic Resonance-Positron Emission Tomography Imaging|Other: Placebo Capsule","Changes in brain PET signal|Changes in spinal PET signal|Changes in pain outcomes as measured by self report on a 0-100 numerical pain rating scale","Marco Loggia|National Institute of Neurological Disorders and Stroke (NINDS)|Massachusetts General Hospital","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","145","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","2017P000179|1R01NS095937-01A1","October 10, 2017","September 2021","September 2021","April 10, 2017","null","March 21, 2018","Massachusetts General Hospital, Charlestown, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT03106740"
14,"NCT01009359","Evaluation of the Neuroinflammation Pattern of BAY85-8102 F-18, DPA-714 in Probable Alzheimers Disease Patients Versus Healthy Volunteers and Radiation Dosimetry of F 18, DPA-714 in Healthy Volunteers",,"Completed","No Results Available","Diagnostic Imaging","Drug: F-18 DPA-714 (BAY85-8102)","Discrimination of probable Alzhemimer disease patients from healthy volunteers by BAY85-81 F-18, DPA-714 brain PET imaging as evaluated by different quantification approaches|Discrimination of probable Alzhemimer disease patients from healthy volunteers by BAY85-81 F-18, DPA-714 brain PET imaging as evaluated by visual analysis and standard parameters(e.g. Standardized Uptake Values = SUV)|Electrocardiogram (ECG)|Blood pressure|Serum protein|Serum creatinine|Serum GOT (Glutamat-Oxalacetate-Transaminase)|Adverse events collection","Bayer","All","50 Years and older   (Adult, Older Adult)","Phase 1","22","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","13150|2009-009358-26","October 2009","July 2010","October 2010","November 6, 2009","null","July 31, 2013","Turku, Finland|Amsterdam, Netherlands","","https://ClinicalTrials.gov/show/NCT01009359"
15,"NCT00329706","Metabolic Cerebral Imaging in Incipient Dementia (MCI-ID)",,"Completed","No Results Available","Dementia","Procedure: FDG-PET brain scan","change from baseline in neuropsychological (cognitive,functional) test results|utilization of healthcare resources|PET results, compared with working diagnoses made before and after time of PET|rates of prescription of AD-specific therapies","University of California, Los Angeles|Centers for Medicare and Medicaid Services","All","65 Years and older   (Older Adult)","Not Applicable","710","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Diagnostic","02-10-079, 03-04-026","June 2006","January 2017","January 2017","May 25, 2006","null","May 2, 2017","Mayo Clinic, Phoenix, Arizona, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|UCLA Medical Center, Los Angeles, California, United States|Santa Monica-UCLA Medical Center, Santa Monica, California, United States|Gene E. Myers Cardiac and Vascular Consultants, Sarasota, Florida, United States|Lahey Clinic Hospital, Burlington, Massachusetts, United States|University of Buffalo, Buffalo, New York, United States|Medical University of South Carolina, Charleston, South Carolina, United States|University of Utah, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT00329706"
16,"NCT02236897","PET Imaging in ALS Patients",,"Completed","No Results Available","Amyotrophic Lateral Sclerosis (ALS)","Other: PET Scanning","Glutamate Receptor Distribution","Johns Hopkins University|ALS Association","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","36","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","NA_00073452","August 2013","March 2017","March 2017","September 11, 2014","null","March 7, 2017","Johns Hopkins University, Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT02236897"
17,"NCT00613119","PET Evaluation of Brain Peripheral Benzodiazepine Receptors Using [11C]PBR28 in Frontotemporal Dementia",,"Completed","No Results Available","Frontotemporal Lobar Degeneration|Dementia","","Outcome measures will be the amount of [11C]PBR28 binding in the brain in FTD patients and in healthy controls.|We will quantify the radioligand's brain uptake, washout, plasma clearance, and distribution volume using compartmental modeling.","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","35 Years and older   (Adult, Older Adult)","","108","NIH","Observational","Time Perspective: Prospective","080066|08-M-0066","January 31, 2008","null","July 13, 2017","February 12, 2008","null","August 23, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00613119"
18,"NCT01656785","68Ga-BNOTA-PRGD2 PET/CT in Evaluation of Stroke","GRGDS","Unknown status","No Results Available","Stroke","Drug: 68Ga-BNOTA-PRGD2","Visual and semiquantitative assessment (Standardized Uptake Values = SUVs) of cerebral infarction region, SUV ratios (SUVinfarction/SUV contralateral)|Adverse events collection","Peking Union Medical College Hospital","All","30 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","PUMCHNM004","February 2012","December 2017","December 2017","August 3, 2012","null","April 7, 2017","Department of Nuclear Medicine, Peking Union Medical College Hospital, Beijing, Beijing, China","","https://ClinicalTrials.gov/show/NCT01656785"
19,"NCT03451123","FET-PET/MRI for Surgical Assessment of Pediatric Brain Tumors",,"Recruiting","No Results Available","Pediatric Brain Tumors","Drug: FET PET/MRI","Percentage of patients whose surgical plan change with FET-PET/MRI compared to MRI alone.|Percentage of patients who have residual tumor after surgery detected with FET-PET/MRI","University of Alabama at Birmingham","All","6 Years to 18 Years   (Child, Adult)","Early Phase 1","12","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","R17-077","April 23, 2018","February 2021","February 2021","March 1, 2018","null","May 15, 2018","UAB Advanced Imaging Facility, Birmingham, Alabama, United States","","https://ClinicalTrials.gov/show/NCT03451123"
20,"NCT02743377","PET Imaging of Phosphodiesterase-4 (PDE4) in Brain and Peripheral Organs of McCune-Albright Syndrome",,"Recruiting","No Results Available","Nervous System Disease","Other: PET|Other: MRI","Rolipram binding in brain|Rolipram uptake in peripheral organs","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 1|Phase 2","35","NIH","Interventional","Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","160093|16-M-0093","April 15, 2016","June 16, 2016","March 25, 2020","April 19, 2016","null","July 4, 2018","National Institutes of Health Clinical Center, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT02743377"
21,"NCT02230592","PET Imaging of Brain mGluR1 Receptors Using [18F]FIMX",,"Completed","No Results Available","Anxiety Disorder|Major Depressive Disorder","","Ability to measure mGluR1 in brain","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years to 55 Years   (Adult)","","19","NIH","Observational","Time Perspective: Prospective","140016|14-M-0016","November 8, 2013","June 16, 2016","June 16, 2016","September 3, 2014","null","July 4, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT02230592"
22,"NCT01198197","PET Brain and Whole Body Distribution Studies for Nociceptin/Orphanin FQ Peptide (NOP) Receptor Using [11C]NOP-1A",,"Completed","No Results Available","Pain|Anxiety|Depression","Drug: NOP-1A","For the PET scans, we will measure the regional densities of NOP receptors as distribution volume (VT). Distribution volume is the ratio at equilibrium of brain uptake to the concentration of parent radioligand in plasma.","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years to 50 Years   (Adult)","Early Phase 1","41","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","100204|10-M-0204","September 3, 2010","null","February 28, 2014","September 9, 2010","null","July 4, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT01198197"
23,"NCT03389100","Tau PET Imaging in the Northern Manhattan Study of Metabolism and Mind.","NOMEM-Tau","Enrolling by invitation","No Results Available","Diabetes Mellitus, Type 2|Pre-diabetes","Drug: 18F-MK6240 injection","18F-MK6240 standardized update value ratio (SUVR)","Columbia University|Hebrew Home at Riverdale|National Institute on Aging (NIA)","All","55 Years to 69 Years   (Adult, Older Adult)","Phase 2","150","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","AAAR1419b|R01AG050440|R01AG055299|RF1AG051556","March 5, 2018","December 2020","June 2021","January 3, 2018","null","March 15, 2018","Columbia University Medical Center, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT03389100"
24,"NCT02562989","[18F]MK-6240 Positron Emission Tomography (PET) Tracer First-in-Human Validation Study (MK-6240-001)",,"Completed","Has Results","Alzheimer's Disease|Amnestic Mild Cognitive Impairment","Drug: [18F]MK-6240, ~185 MBq|Drug: [18F]MK-6240, ~160 MBq","Number of Participants With Adverse Events (AEs)|Number of Participants Who Discontinued Study Due to an AE|Effective Dose of [18F]MK-6240|Organ Effective Dose of [18F]MK-6240|Standardized Uptake Value Ratio (SUVR) of [18F]MK-6240 in Brain Regions of Interest|Intra-subject Test-Retest (T-RT) Variability of Standardized Uptake Value Ratio (SUVR) in Brain Regions of Interest","Merck Sharp & Dohme Corp.","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 1","13","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","6240-001|2015-001659-58|MK-6240-001","October 19, 2015","December 27, 2016","December 27, 2016","September 29, 2015","July 23, 2018","July 23, 2018","","","https://ClinicalTrials.gov/show/NCT02562989"
25,"NCT01974037","Capsaicin on Salty Gustatory Cortices",,"Completed","No Results Available","Volunteers","Dietary Supplement: Capsaicin|Dietary Supplement: NaCl","Neuroimaging changes of salty gustatory cortices","Zhiming Zhu|Third Military Medical University","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","80","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","SATIETY-2","May 2013","October 2013","December 2013","November 1, 2013","null","January 11, 2016","Daping Hospital, The Third Military Medical University, Chongqing, Chongqing, China","","https://ClinicalTrials.gov/show/NCT01974037"
26,"NCT01894646","PET Imaging of Extrathalamic α4β2-nicotinic Acetylcholine Receptors in Health and Disease With [18F]XTRA",,"Active, not recruiting","No Results Available","Measure of Uptake of XTRA in the Brain","Radiation: Positron Emission Tomography (PET) Imaging","PET Imaging of extrathalamic α4β2-nicotinic acetylcholine receptors in health and disease with [18F]XTRA","Johns Hopkins University|National Institutes of Health (NIH)","All","18 Years to 85 Years   (Adult, Older Adult)","Not Applicable","60","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","NA_00076249","February 2013","August 2018","August 2018","July 10, 2013","null","November 20, 2017","Johns Hopkins University, Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT01894646"
27,"NCT02108015","Evaluation of a Novel Positron Emission Tomography (PET Radiotracer for TARP Gamma-8",,"Terminated","No Results Available","Healthy Volunteers","Procedure: Brain Imaging (PET)|Procedure: Aterial Line|Procedure: Blood Sampling","Binding of 18F-TARP252 in brain","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years to 55 Years   (Adult)","Phase 1","6","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","140068|14-M-0068","March 5, 2014","September 5, 2014","December 1, 2016","April 9, 2014","null","August 8, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT02108015"
28,"NCT02144792","Development and Clinical Application of [11C]Verapamil-PET",,"Unknown status","No Results Available","Epilepsy","Drug: [11C] -verapamil PET","Measured Asymmetric index[(SUV in Right regions - SUV in Left regions)/(SUV in Right regions+ SUV in left regions)] in all three groups|Number of patients with side effect of cyclosporine and [11C]-verapamil PET","Seoul National University Hospital","All","16 Years and older   (Child, Adult, Older Adult)","Phase 2","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","0720130520","May 2013","May 2014","December 2014","May 22, 2014","null","May 22, 2014","Seoul National University Hospital, Seoul, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT02144792"
29,"NCT01035164","Evaluation of ZK 6032924 in Probable Alzheimer's Disease Patients Versus Healthy Volunteers and the Radiation Dosimetry of ZK 6032924 in Healthy Volunteers",,"Completed","No Results Available","Positron-Emission Tomography|Alzheimer's Disease","Drug: F-18 FEDAA1106 (BAY85-8101)","Visual analysis/description of the uptake and description of brain PET scans|Standardized uptake value (SUV) in various cerebral regions/volumes of interest (ROI/VOI) assumed and found to be involved in the pathophysiology of Alzheimer's disease.|Standard quantification variables derived from 3D PET imaging and brain modeling|Standard Safety Measurement:adverse event collection|Standard Safety Measurement:electrocardiogram|Standard Safety Measurement:safety laboratory|Standard Safety Measurement: vital signs","Bayer","All","50 Years and older   (Adult, Older Adult)","Phase 1","25","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","91683|2006-006045-14|311401","June 2007","January 2010","January 2010","December 18, 2009","null","January 8, 2015","Amsterdam, Netherlands|Stockholm, Sweden|Stockholm, Sweden","","https://ClinicalTrials.gov/show/NCT01035164"
30,"NCT03109626","Docosahexaenoic Acid (DHA) Replacement for Treatment in Spinocerebellar Ataxia 38","SCA38DHA","Active, not recruiting","No Results Available","SCA38","Dietary Supplement: DHA","Change from Baseline SARA score at 16 weeks and 40 weeks|Change from Baseline ICARS score at 16 weeks and 40 weeks|Brain FDG-PET","Barbara Borroni|Azienda Ospedaliera Spedali Civili di Brescia","All","18 Years and older   (Adult, Older Adult)","Not Applicable","10","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CE NP1821","June 17, 2015","September 17, 2015","August 30, 2018","April 12, 2017","null","May 24, 2018","AO Spedali Civili, Brescia, BS, Italy","","https://ClinicalTrials.gov/show/NCT03109626"
31,"NCT03632226","Evaluation of a Novel PET Radioligand to Image OGA",,"Recruiting","No Results Available","Pharmacokinetics|Adult","","The indentifiability and time stability of the distribution volume calculated with compartmental modeling of [F18 OGA-1]. In the test-retest study the retest variability will be calculated.|Whole-body distribution and dosimetry of [18F]OGA-1","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years to 100 Years   (Adult, Older Adult)","","31","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","160105|16-M-0105","May 2, 2016","December 31, 2018","December 31, 2019","August 15, 2018","null","August 15, 2018","National Institutes of Health Clinical Center, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT03632226"
32,"NCT03287765","Evaluating the Relationship Between Tau PET Imaging and CSF Biomarkers of AD (Alzheimer Disease) in Humans","ADRC proj 1","Recruiting","No Results Available","Alzheimer Disease","Drug: 18F-AV-1451","Examine the association among T807-PET measures of PHF-tau.|Characterize the amount and spatial distribution of T807-PET measures in healthy aging. preclinical AD, and early symptomatic AD.|Characterize the amount and spatial distribution of T807-PET measures in preclinical AD.|Characterize the amount and spatial distribution of T807-PET measures in early symptomatic AD.|Examine the association among T807-PET measures of concentrations of CSF biomarkers. and cognitive performance.|Examine the association among T807-PET measures of cognitive performance.|Evaluate the change in T807-PET measures over time in asymptomatic amyloid-positive individuals and its association with changes in concentrations of CSF biomarkers.","Washington University School of Medicine","All","65 Years and older   (Older Adult)","Phase 2","80","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","IND 123119, Protocol F","May 2016","May 2021","November 2021","September 19, 2017","null","September 19, 2017","Washington University School of Medicine, Saint Louis, Missouri, United States","","https://ClinicalTrials.gov/show/NCT03287765"
33,"NCT01031199","Evaluation of the Positron Emission Tomography (PET) Tracer ZK 6032924 in Patients With Multiple Sclerosis Compared to Healthy Volunteers",,"Completed","No Results Available","Positron-Emission Tomography|Multiple Sclerosis","Drug: F-18 FEDAA1106 (BAY85-8101)","Standard quantification variables derived from 3D PET imaging and brain modeling.|Visual analysis/description of the uptake and description of brain PET scans.|Standard Safety Parameter: Adverse Event Collection|Standard Safety Parameter: Electrocardiogram|Standard Safety Parameter: Safety laboratory|Standard Safety Parameter: Vital signs","Bayer","All","20 Years to 55 Years   (Adult)","Phase 1","16","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","13101|2008-000981-22","January 2009","December 2009","December 2009","December 14, 2009","null","April 2, 2014","Heidelberg, Victoria, Australia|Stockholm, Sweden","","https://ClinicalTrials.gov/show/NCT01031199"
34,"NCT00791063","18F ML-10 for Early Detection of Response of Brain Metastases to WBRT",,"Completed","No Results Available","Solid Tumors|Brain Metastases","Other: 18F ML-10","Assessment of a change in the uptake of [18F]- ML-10 by the tumor as observed in comparing the PET scans before and after WBRT.|Assessment of a relationship between the change in uptake of [18F]- ML-10 by the tumor, observed in the PET scans obtained during the study, and tumor shrinkage in response to treatment, as assessed by MRI or CT according to the RECIST criteria.|Detection of a potential change in the uptake of [18F]- ML-10 by the healthy brain tissue, as observed in comparing the PET/CT scans before and after WBRT, reflecting potential damage to intact brain tissue, as an adverse effect of the irradiation.|Assessment of the correlation between the PET/CT region of interest (ROI), delineated by [18F]-ML-10 imaging, and the corresponding anatomical imaging.|Assessment of the safety of [18F]-ML-10 when administered to cancer patients undergoing WBRT.","Aposense Ltd.","All","18 Years and older   (Adult, Older Adult)","Phase 2","10","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","NST-CA001CTIL","March 2008","December 2008","December 2008","November 14, 2008","null","February 13, 2013","","","https://ClinicalTrials.gov/show/NCT00791063"
35,"NCT00605254","PET Imaging of P-glycoprotein Function Using [11C]dLop",,"Completed","No Results Available","Healthy","","PET","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years to 51 Years   (Adult)","","58","NIH","Observational","Observational Model: Case-Crossover|Time Perspective: Prospective","080062|08-M-0062","January 24, 2008","null","September 4, 2014","January 31, 2008","null","August 17, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00605254"
36,"NCT01106976","Imaging Biomarkers of Progression of Mobility Impairment in Parkinson Disease",,"Completed","Has Results","Parkinson's Disease","","AChE PET Neuroimaging","VA Office of Research and Development|University of Michigan","All","50 Years and older   (Adult, Older Adult)","","67","U.S. Fed|Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","E7285-R","May 2010","September 2014","March 2015","April 20, 2010","February 1, 2016","February 1, 2016","VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor, Michigan, United States","","https://ClinicalTrials.gov/show/NCT01106976"
37,"NCT02090855","Re-Read Study to Compare the Brain Uptake of [18F]Flutemetamol With Brain Neuritic Plaque Density Determined Postmortem",,"Completed","Has Results","Cognitive Impairment","","The Number of Abnormal Blinded Visual PET Image Interpretations.|Sensitivity Percentage of Blinded Visual PET Image Interpretations of Subjects With Abnormal Scans|Number of Blinded Visual PET Image Interpretations|Specificity Percentage of Blinded Visual PET Image Interpretations","GE Healthcare|Covance|H2O Clinical LLC","All","55 Years and older   (Adult, Older Adult)","","108","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","GE-067-026","September 2013","February 2014","February 2014","March 18, 2014","August 27, 2014","March 27, 2017","GE Healthcare, Princeton, New Jersey, United States","","https://ClinicalTrials.gov/show/NCT02090855"
38,"NCT03440112","Modulation of GABA-A Receptors in Parkinson Disease-Clarithromycin Arm","GABA-A","Recruiting","No Results Available","Parkinson Disease","Drug: Clarithromycin|Drug: Placebo","Change in [11-Carbon]-flumazenil ([11C]FMZ) PET Binding|Change in quantitative biomechanics","Nicolaas Bohnen, MD, PhD|National Institute of Neurological Disorders and Stroke (NINDS)|University of Michigan","All","50 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","30","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Other","HUM00360361-A|R01NS099535","January 29, 2018","November 15, 2021","November 15, 2021","February 20, 2018","null","July 9, 2018","University of Michigan Health System Functional Neuroimaging, Cognitive and Mobility Laboratory, Ann Arbor, Michigan, United States","","https://ClinicalTrials.gov/show/NCT03440112"
39,"NCT02599753","Investigating the Microstructural and Functional Alterations of Brain in Parkinson's Disease Patients",,"Completed","No Results Available","Parkinson's Disease","Drug: 18-FDTBZ","The difference of specific uptake ratio (SUR) of 18F- DTBZ between each diagnostic group|The difference of eigenvalues obtained from diffusion tensor imaging (DTI) between each diagnostic group.","Chang Gung Memorial Hospital","All","20 Years to 80 Years   (Adult, Older Adult)","Phase 2","35","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","101-4874A","August 2015","July 31, 2018","July 31, 2018","November 9, 2015","null","August 6, 2018","Chang Gung Memory Hospital, Taoyuan, Taiwan","","https://ClinicalTrials.gov/show/NCT02599753"
40,"NCT01301040","Early Cardiac Toxicity of Adjuvant CT in Elderly BC.",,"Terminated","No Results Available","Breast Cancer","Drug: epirubicin, cyclophosphamide, docetaxel","The difference between cardiac strain rates measured at baseline and after 4 cycles of chemotherapy.","Jules Bordet Institute|Sanofi","Female","65 Years and older   (Older Adult)","Phase 2","2","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","IJB 11-01|2011-000562-35","March 2011","March 2013","March 2016","February 23, 2011","null","August 30, 2013","Institut Jules Bordet, Brussels, Belgium","","https://ClinicalTrials.gov/show/NCT01301040"
41,"NCT02207075","Measuring Active Microglia in Progressive Multiple Sclerosis",,"Active, not recruiting","No Results Available","Secondary Progressive Multiple Sclerosis","Radiation: [C11]PK-1195 PET scan","Measure the level of baseline and change of whole brain uptake of [11C]PK-11195 at 6, 12 and 24 months in SPMS subjects.|To correlate the change in T2-hyperintense lesion volume at 6,12 and 24 months of with whole brain uptake of [11C]PK-11195 on PET (at the 6,12 and 24 months) in SPMS subjects.|To correlate the change of conventional MRI measures of neuronal integrity (Gray Matter Fraction, White Matter Fraction, whole brain volume, T1-hypointense lesion volume) at 6,12 and 24 months with whole brain PET uptake of [11C]PK-11195 (at the 6,12 and|To correlate the change in whole brain PET uptake of [11C]PK-11195 (at the 6,12 and 24 months) and level in disability, as measured by a change in EDSS at 6, 12, and 24 months in SPMS subjects.","Weill Medical College of Cornell University|Genzyme, a Sanofi Company","All","18 Years to 80 Years   (Adult, Older Adult)","","26","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","1309014365","July 2014","March 2020","March 2020","August 1, 2014","null","February 14, 2018","Weill Cornell Medical College, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT02207075"
42,"NCT01723488","A Phase 0, Open Label, Multi-Center, Exploratory and Safety Study of [F-18]T808","T808","Terminated","No Results Available","Alzheimers Disease","Radiation: [F18] T808","To monitor and assess the safety of IV administration of [F-18]T808|To begin collection of baseline [F-18]T808 PET/CT imaging data","Avid Radiopharmaceuticals","All","55 Years and older   (Adult, Older Adult)","Early Phase 1","12","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)","T808000","July 2012","March 2013","March 2013","November 8, 2012","null","July 19, 2013","Research Site, Irvine, California, United States|Research Site, Los Angeles, California, United States","","https://ClinicalTrials.gov/show/NCT01723488"
43,"NCT03539731","[18F]DASA-23 and PET Scan in Evaluating Pyruvate Kinase M2 Expression in Patients With Intracranial Tumors or Recurrent Glioblastoma and Healthy Volunteers",,"Recruiting","No Results Available","Healthy Subject|Intracranial Neoplasm|Recurrent Glioblastoma","Drug: Fluorine F 18 DASA-23|Procedure: Positron Emission Tomography","Change in [18F]DASA-23 PET scan signal in patients with suspected recurrent glioblastoma|Sensitivity of [18F]DASA-23 PET imaging in identifying intracranial tumors in patients with intracranial tumors.|Specificity of [18F]DASA-23 PET imaging in identifying intracranial tumors in patients with intracranial tumors.|Accuracy of [18F]DASA-23 PET imaging in identifying intracranial tumors in patients with intracranial tumors.|Progression-free survival in patients with suspected recurrent glioblastoma|Overall survival in patients with suspected recurrent glioblastoma","Sanjiv Sam Gambhir|Stanford University","All","18 Years and older   (Adult, Older Adult)","Phase 1","25","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","BRN0038|NCI-2018-00826|44597","April 23, 2018","April 23, 2020","April 23, 2020","May 28, 2018","null","May 28, 2018","Stanford University, School of Medicine, Palo Alto, California, United States","","https://ClinicalTrials.gov/show/NCT03539731"
44,"NCT02681172","Impact of FBB PET Amyloid Imaging in Change of Diagnosis in Patients With AD",,"Completed","No Results Available","Alzheimer's Disease (AD)","Drug: Neuraceq (florbetaben 18F)|Procedure: PET","Change of diagnosis comparing pre- and post-scan outcomes|Change in level of physician confidence in diagnosis|Percentage of subjects with Lumbar Puncture (LP) not feasible due to medical condition|Percentage of subjects with ambiguous CSF result|Mean age of subjects|Number of subjects with positive FBB PET scan|Number of subjects with negative FBB PET scans","Piramal Imaging Limited","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 4","218","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","FBB_01_02_2015|2015-002606-37","October 2015","September 2016","November 2016","February 12, 2016","null","November 9, 2016","Coordinating center (Hôpital de La Timone) and 18 associated centers in France, Marseille, France","","https://ClinicalTrials.gov/show/NCT02681172"
45,"NCT01565343","A Study of 18F-AV-45 in Alzheimer's Disease (AD) and Healthy Volunteers",,"Completed","Has Results","Alzheimer's Disease","Drug: florbetapir F 18","Mean Cortical to Cerebellum SUVR","Avid Radiopharmaceuticals","All","35 Years and older   (Adult, Older Adult)","Phase 1","25","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic","18F-AV-45-A04","April 2008","April 2009","April 2009","March 28, 2012","May 2, 2012","May 10, 2012","Research Site, New Haven, Connecticut, United States|Research Site, Hallandale Beach, Florida, United States|Research Site, West Palm Beach, Florida, United States|Research Site, North East, Maryland, United States","","https://ClinicalTrials.gov/show/NCT01565343"
46,"NCT03625128","18F-PM-PBB3 PET Study in Tauopathy Including Alzheimer's Disease, Other Dementias and Normal Controls",,"Active, not recruiting","No Results Available","Alzheimer's Disease|Cortical Basal Syndrome|Frontotemporal Dementia|Progressive Supranuclear Palsy|Vascular Cognitive Impairment","Drug: F-18","The primary outcome measures are to evaluate the dosimetry of novel radiotracer 18F-PM-PBB3 in human.|Optimal scanning time for brain imaging using 18F-PM-PBB3 .","Chang Gung Memorial Hospital","All","20 Years to 90 Years   (Adult, Older Adult)","Early Phase 1","36","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","201700982A0","January 2, 2018","August 3, 2018","August 3, 2018","August 10, 2018","null","August 10, 2018","Chang Gung Memorial Hospital,Linkou, Taoyuan City, Guishan Dist, Taiwan","","https://ClinicalTrials.gov/show/NCT03625128"
47,"NCT02236065","Combination Therapy of Cord Blood and G-CSF for Patients With Brain Injury or Neurodegenerative Disorders",,"Completed","No Results Available","Brain Injury|Cerebral Palsy|Amyotrophic Lateral Sclerosis|Parkinson's Disease","Procedure: Umbilical cord blood therapy|Biological: Filgrastim","Changes in Berg Balance Scale|Changes in the Level of Disability|Changes in Standardized Gross Motor Function|Changes in Motor Performance|Changes in ALSFRS-R|Changes in UPDRS|Changes in Brain MRI|Changes in Brain PET|Number of adverse events and participants with those adverse events","MinYoung Kim, M.D.|Bundang CHA Hospital","All","19 Years to 75 Years   (Adult, Older Adult)","Not Applicable","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UCBnG-CSF","August 2014","July 2016","July 2016","September 10, 2014","null","October 12, 2017","CHA Bundang Medical Center, CHA University, Seongnam-si, Gyeonggi-do, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT02236065"
48,"NCT02686216","Biodistribution, Pharmacokinetics, and Safety of F-18 THK-5351 PET in Alzheimer's Disease Patients and Healthy Subjects.(Positron Emission Tomograph )","PET","Completed","No Results Available","Alzheimer's Disease","Drug: F-18 THK-5351","The primary outcome measures are to evaluate the dosimetry of novel radiotracer F-18 THK-5351 in human.|Optimal scanning time for brain imaging using F-18 THK-5351.","Chang Gung Memorial Hospital","All","20 Years to 90 Years   (Adult, Older Adult)","Phase 1","24","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","104-2710A","December 2015","April 2016","November 2016","February 19, 2016","null","February 8, 2017","","","https://ClinicalTrials.gov/show/NCT02686216"
49,"NCT02410577","89Zr-J591 Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody in Patients With Glioblastoma Multiforme",,"Active, not recruiting","No Results Available","Glioblastoma","Drug: 89Zr-J591|Device: PET/CT Scan|Device: MRI|Other: Blood draw","binding of 89Zr-J591","Memorial Sloan Kettering Cancer Center|Weill Medical College of Cornell University","All","26 Years to 79 Years   (Adult, Older Adult)","Not Applicable","2","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","15-002","April 2015","April 2019","April 2019","April 7, 2015","null","February 8, 2018","Memorial Sloan Kettering Cancer Center, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT02410577"
50,"NCT03641768","Risk Prediction for Alzheimer Dementia With Brain Imaging and Genetics",,"Not yet recruiting","No Results Available","Alzheimer Dementia|Posttraumatic Stress Disorder|Traumatic Brain Injury","Device: MRI|Device: PET|Device: 18F-Florbetapir|Device: Radioligand 18F-AV-1451","Cortical thickness as measured by MRI scans|Beta amyloid plaques as measured by PET scans|Tau proteins as measured by PET scans","Duke University","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","80","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","Pro00100030","January 1, 2019","January 1, 2021","January 1, 2021","August 22, 2018","null","August 22, 2018","Durham VA, Durham, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT03641768"
51,"NCT00110032","Positron Emission Tomography Using Fluorine F 18 EF5 to Find Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Newly Diagnosed Brain Tumors",,"Terminated","No Results Available","Adult Anaplastic Astrocytoma|Adult Anaplastic Ependymoma|Adult Anaplastic Oligodendroglioma|Adult Brain Stem Glioma|Adult Central Nervous System Germ Cell Tumor|Adult Choroid Plexus Tumor|Adult Craniopharyngioma|Adult Diffuse Astrocytoma|Adult Ependymoblastoma|Adult Ependymoma|Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Adult Grade I Meningioma|Adult Grade II Meningioma|Adult Grade III Meningioma|Adult Medulloblastoma|Adult Meningeal Hemangiopericytoma|Adult Mixed Glioma|Adult Myxopapillary Ependymoma|Adult Oligodendroglioma|Adult Pilocytic Astrocytoma|Adult Pineoblastoma|Adult Pineocytoma|Adult Subependymoma|Adult Supratentorial Primitive Neuroectodermal Tumor (PNET)|Meningeal Melanocytoma","Drug: EF5|Procedure: conventional surgery|Procedure: positron emission tomography|Radiation: fluorine F 18 EF5|Other: pharmacological study","Safety of F-18-EF5 based on the NCI CTCAE version 3.0|Pharmacokinetics of radioactively labeled [F-18]-EF5|Extent of hypoxia, determined by [F-18]-EF5 PET imaging|IHC analysis of cold EF5|Progression-free survival","National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1","46","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","NCI-2012-02651|UPCC 01304|CDR0000423313","June 2005","January 2007","null","May 4, 2005","null","January 16, 2013","Abramson Cancer Center of The University of Pennsylvania, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT00110032"
52,"NCT01733355","A Phase 0, Open Label, Multi-center Exploratory and Safety Study of [F-18]T807",,"Terminated","No Results Available","Alzheimers Disease|AD","Radiation: [F18] T807","To evaluate the bio-distribution and radiation dosimetry of [F-18]T807 in participants with low probability of Alzheimer's disease (AD) using PET/CT whole body imaging|To evaluate the metabolism of [F-18]T807 in participants with low probability of AD using serial blood samples collected pre- and post-IP administration|To evaluate [F-18]T807 uptake and signal/background information in brain PET/CT imaging of participants with a high probability of currently being positive for AD and age-matched participants with a low probability of currently being positive for AD|To assess the safety of IV administration of [F-18]T807|To begin collection of baseline [F-18]T807 PET/CT imaging data|To gain information to improve the study design for the conduct of future trials","Avid Radiopharmaceuticals","All","55 Years and older   (Adult, Older Adult)","Early Phase 1","11","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)","T807000","July 2012","March 2013","March 2013","November 27, 2012","null","July 19, 2013","Research Site, Irvine, California, United States|Research Site, Los Angeles, California, United States","","https://ClinicalTrials.gov/show/NCT01733355"
53,"NCT02525432","Autologous Stem Cell Study for Adult TBI (Phase 2b)",,"Enrolling by invitation","No Results Available","Brain Injuries, Traumatic|Brain Injuries, Acute|TBI (Traumatic Brain Injury)","Biological: Placebo Infusion|Biological: Autologous BMMNC Infusion","Macro and micro structural properties of grey matter (GM) and white matter (WM) regions will measured using high-resolution anatomical MRI and diffusion tensorm imaging and comparisons made between groups.|Brain imaging measures of GM and WM structural integrity will be compared to functional and neurocognitive scores and comparisons made between groups.|Compare neuro-inflammatory biomarkers between groups..|Measure the number of participants with infusion related adverse events.|Measure spleen ultrasound size over time and corresponding changes in inflammatory cytokines.|Determine if microglial activation is associated with TBI and can be accurately measured with brain PET and DT-MRI imaging when compared to PET imaging data from healthy volunteers (enrolled under a different protocol).|Quantify the extent and location of microglial activation by brain PET imaging and how activity correlates with performance of neurocognitive outcomes measures.|Determine the extent to which an IV infusion of autologous BMMNC post-injury impacts microglial activation by brain PET imaging.","The University of Texas Health Science Center, Houston|United States Department of Defense|U.S. Army Medical Research and Materiel Command","All","18 Years to 55 Years   (Adult)","Phase 2","55","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","HSC-MS-16-0283","November 21, 2016","October 2019","December 2020","August 17, 2015","null","May 17, 2018","The University of Texas Health Science Center at Houston, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT02525432"
54,"NCT03252093","Evaluation of the Safety and Efficacy of Angiotensin 1-7 (Ang-(1-7)) to Enhance Cognitive Function in Participants Undergoing Coronary Artery Bypass Graft (CABG) Surgery.",,"Recruiting","No Results Available","Coronary Artery Bypass Surgery|Cognitive Impairment","Drug: Angiotensin-(1-7)|Drug: Placebo for Angiotensin-(1-7)","Demonstrate 21 days daily administration of Ang-(1-7) in participants undergoing 1st time CABG surgery is safe and efficacious as assessed by the number of related AEs grade 3 or > and change in composite neuropsychological score up to Day 90.|Demonstrated change in the neuropsychological component scores assessed at baseline, Day 21 and Day 90 in the treatment and placebo arms.|Evidence of change in fractional anisotropy from diffusion tensor imaging on Brain MRI at baseline versus post operative Day 21 will be assessed in the treatment and placebo arms as a measure of efficacy.|Demonstrated change in PBR28 VT/fP, a quantitative measure of TSPO receptor density, in a composite cerebral region-of-interest (ROI) derived from brain PET imaging in the treatment and placebo arms.|Demonstrated associations between neuropsychogical test results, MRI findings and PBR28 binding in all participants.","University of Arizona|National Institutes of Health (NIH)|Suburban Hospital","All","60 Years to 80 Years   (Adult, Older Adult)","Phase 2","104","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","HL131014","July 20, 2017","March 31, 2020","March 31, 2020","August 17, 2017","null","August 23, 2017","University of Arizona Sarver Heart Center, Tucson, Arizona, United States|Suburban Hospital, Bethesda, Maryland, United States|National Institutes of Health, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT03252093"
55,"NCT00873509","Buspirone in the Treatment of 2-6 Year Old Children With Autistic Disorder","B-ACE","Completed","No Results Available","Autistic Disorder","Drug: Buspirone|Drug: Placebo","To evaluate the effects of twice-daily oral buspirone on core features of autism in autistic children 2-6 years measuring the change from baseline in ADOS (Autism Diagnostic Observation Schedule) Composite Total scores compared to placebo at 6 months.|To evaluate the effects of twice-daily oral buspirone on the ADOS Composite calibrated severity score, social behavior, repetitive behavior, language, sensory dysfunction and anxiety.|To determine whether there are age group differences in the effects of buspirone on social interaction, repetitive behavior, language, sensory dysfunction and anxiety.|To determine whether there is a difference in the incidence of side effects and long term safety between the buspirone and placebo groups, and between the different dose groups.|To determine whether the whole brain PET measure of serotonin synthesis capacity is a predictor of buspirone effect.|To determine whether blood serotonin concentration is a predictor of buspirone effect.","Chugani, Diane C.|National Institute of Neurological Disorders and Stroke (NINDS)","All","2 Years to 6 Years   (Child)","Phase 2|Phase 3","166","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","10888|5U01NS061264","May 2009","January 2015","January 2015","April 1, 2009","null","July 26, 2016","University California Davis M.I.N.D. Institute, Sacramento, California, United States|Children's Hospital of Michigan Wayne State University, Detroit, Michigan, United States|New York University Langone Medical Center, New York, New York, United States|Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States|Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio, United States|University of Texas Southwestern, Dallas, Texas, United States","","https://ClinicalTrials.gov/show/NCT00873509"
56,"NCT03112096","A Phase I [18F]THK-5351 Positron Emission Tomography Study in Healthy Subjects and Alzheimer's Disease",,"Recruiting","No Results Available","Alzheimer Disease","Drug: [18F]THK-5351","Pharmacokinetics: Maximum Serum Concentration (Cmax) of [18F]THK-5351|Assess global and regional tau deposition as measured by standard uptake value ratio (SUVR) of [18F]THK-5351|Correlation between standard uptake value ratio (SUVR) and distribution volume of ratio(DVR) of [18F]THK-5351 positron emission computed tomography|Optimal scanning time for brain imaging using F-18 THK-5351.|Concentrations of metabolite in plasma of [18F]THK-5351|Number of participants with treatment related adverse events as a measure of safety","Asan Foundation","All","20 Years to 80 Years   (Adult, Older Adult)","Phase 1","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Diagnostic","THK-15001","May 17, 2017","August 30, 2018","August 30, 2018","April 13, 2017","null","May 24, 2018","Asan Medical Center, Seoul, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT03112096"
57,"NCT01604512","A Comparison of MRI Perfusion and FDG PET/CT to Distinguish Between Radiation Injury and Tumor Progression",,"Recruiting","No Results Available","Brain Cancer","Other: MRI perfusion and PET/CT scans","imaging techniques|predicting tumor progression","Memorial Sloan Kettering Cancer Center","All","18 Years and older   (Adult, Older Adult)","Not Applicable","150","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","12-067","May 2012","May 2019","May 2019","May 23, 2012","null","August 15, 2018","Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States|Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States|Memorial Sloan Kettering Commack, Commack, New York, United States|Memorial Sloan Kettering Westchester, Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Memorial Sloan Kettering Rockville Centre, Rockville Centre, New York, United States","","https://ClinicalTrials.gov/show/NCT01604512"
58,"NCT02328300","FLT PET/MR for Evaluation of Pseudoprogression in Patients With Brain Lesions",,"Recruiting","No Results Available","Brain Lesions|Brain Metastasis|Brain Metastases","Drug: FLT PET/MR","Sensitivity and specificity of FLT-PET-MRI in distinguishing between recurrence and radiation necrosis, with surgical biopsy as gold standard","UNC Lineberger Comprehensive Cancer Center","All","18 Years and older   (Adult, Older Adult)","","15","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","LCCC1327","May 7, 2014","June 2018","June 2018","December 31, 2014","null","October 4, 2017","University of North Carolina-Chapel Hill, Chapel Hill, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT02328300"
59,"NCT02601547","PET-based Evaluation of Chemotherapy-induced Brain Damage in Lymphoma","LYMCOTEP","Completed","No Results Available","Lymphoma","Device: PET-FDG brain imaging and NPT","Change of Standard Uptake Value|change of functional learning test (WAIS)|change of depression scale","University Hospital, Toulouse","All","18 Years to 85 Years   (Adult, Older Adult)","Not Applicable","18","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)","09 154 02","September 2010","March 2013","March 2013","November 10, 2015","null","November 10, 2015","CHU de Toulouse, Toulouse, France","","https://ClinicalTrials.gov/show/NCT02601547"
60,"NCT02433171","Methionine and PBR28-PET (Peripheral Benzodiazepine Receptors) in Brain Metastases Following Radiosurgery",,"Recruiting","No Results Available","Brain Metastasis","Procedure: Standard of Care FDG-PET Imaging","Change in Regrowing Tumor Rate from Radiation Effect","Yale University","All","18 Years to 80 Years   (Adult, Older Adult)","","40","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","1401013294","January 2015","December 2019","December 2019","May 4, 2015","null","December 16, 2016","Yale University, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT02433171"
61,"NCT03441516","Effect of Choline Alphoscerate on Cognitive Function in Alzheimer's Dementia","ALFO-AD","Not yet recruiting","No Results Available","Alzheimer's Disease","Drug: Alfoatirin® Tab. + Aripezil® Tab.|Drug: Aripezil® Tab.","ADAS-cog|K-MMSE (Korean version of Mini-Mental State Examination)|FAB (Frontal Assessment Battery)|S-IADL (Seoul-Instrumental Activities of Daily Living)|CGA-NPI (Caregiver-Administered Neuropsychiatric Inventory)|Changes in brain metabolism by F-18 FDG brain PET","Yuhan Corporation","All","50 Years to 90 Years   (Adult, Older Adult)","Phase 4","80","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","YMC034","March 5, 2018","December 31, 2019","December 31, 2019","February 21, 2018","null","February 21, 2018","Dong-A University Hospital, Busan, Korea, Republic of|Gyeongsang National University Hospital, Busan, Korea, Republic of|Inje University Busan Paik Hospital, Busan, Korea, Republic of|Inje University Haeundae Paik Hospital, Busan, Korea, Republic of|Pusan National University Yangsan Hospital, Busan, Korea, Republic of|Samsung Changwon Hospital, Busan, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT03441516"
62,"NCT03216148","18F-FET PET in Childhood Brain Tumours",,"Recruiting","No Results Available","Brain Neoplasm","Diagnostic Test: FET-PET","Differentiating biologically active Tumor tissue from therapy related changes by using MRI (Magnetic Resonance Imaging) and FET PET|Sensitivity of FET-PET when differentiating biologically active Tumor tissue from therapy-related changes by using MRI (Magnetic Resonance Imaging) and FET PET|Assessment of the predictive value of FET-PET when differentiating biologically active Tumor tissue from therapy-related changes by using MRI (Magnetic Resonance Imaging) and FET PET|Assessment of Tumor grading by FET-PET when differentiating biologically active Tumor tissue from therapy-related changes by using MRI (Magnetic Resonance Imaging) and FET PET|Safety data on FET-PET in children with brain tumors","Charite University, Berlin, Germany","All","1 Year to 17 Years   (Child)","Phase 2","160","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","FET PET 2010|2008-005786-60","July 2015","July 2018","July 2019","July 13, 2017","null","July 21, 2017","Klinikum Augsburg, Onkologie, Augsburg, Germany|Charité Universitätsmedizin Berlin, CVK, Onkologie, Berlin, Germany|Evangelisches Krankenhaus Bielefeld gGmbH, Onkologie, Bielefeld, Germany|Universitätsklinikum Bonn, Onkologie, Bonn, Germany|Klinikum Bremen-Mitte gGmbH, Onkologie, Bremen, Germany|Universitätsklinikum Düsseldorf, Onkologie, Düsseldorf, Germany|Universitätsklinikum Essen, Onkologie, Essen, Germany|Klinik für Nuklearmedizin, Freiburg, Germany|Klinik für Pädiatrische Hämatologie und Onkologie, Freiburg, Germany|Zentrum für Kinder- und Jugendmedizin, Angelika-Lautenschläger-Klinik, Onkologie, Heidelberg, Germany|Institut für Neurowissenschaften und Medizin, Physik der medizinischen Bildgebung, Forschungszentrum Jülich, Nuklearmedizin, Jülich, Germany|Uniklinik Köln, Pädiatrische Onkologie, Köln, Germany|Kliniken der Stadt Köln gGmbH, Köln, Germany|Universitätsklinikum Mainz, Onkologie, Mainz, Germany|Kinderklinik München Schwabing, Onkologie, München, Germany|Nuklearmedizinische Klinik und Poliklinik, München, Germany|Klinik für Kinder- und Jugendmedizin - Pädiatrische Hämatologie und Onkologie, Münster, Germany|Klinik für Nuklearmedizin, Münster, Germany|Klinikum Stuttgart - Olgahospital, Onkologie, Stuttgart, Germany|Klinikum Stuttgart, Nuklearmedizin, Stuttgart, Germany|Universitätsklinikum Tübingen, Onkologie, Tübingen, Germany|Universitäts-Kinderklinik Würzburg, Würzburg, Germany","","https://ClinicalTrials.gov/show/NCT03216148"
63,"NCT01244737","FLT-PET Imaging of Brain Tumors in Children",,"Enrolling by invitation","No Results Available","Brain Neoplasms","Drug: [18F] FLT","[18F] FLT uptake as a marker of cellular proliferation|Biodistribution of [18F]FLT|Preliminary evaluation of clinical utility of [18F] FLT PET","Frederick Daniel Grant|Dana-Farber Cancer Institute|Boston Children’s Hospital","All","up to 21 Years   (Child, Adult)","Phase 2","75","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic","IND 104365|R01FD003718","October 2010","April 2019","December 2019","November 19, 2010","null","April 17, 2018","Children's Hospital, Boston, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT01244737"
64,"NCT02266563","Amyloid and Tauopathy PET Imaging in Acute and Chronic Traumatic Brain Injury",,"Active, not recruiting","No Results Available","Traumatic Brain Injury|Chronic Traumatic Encephalopathy|Mild Cognitive Impairment","Drug: Amyvid PET Scan|Drug: T807 PET scan","Uptake of [18F]T807 in the brain|Uptake of [18F]AV-45 in the brain|Neuropsychological data composite score","Samuel Gandy|Icahn School of Medicine at Mount Sinai","Male","40 Years to 85 Years   (Adult, Older Adult)","","46","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","GCO 14-0732","January 2015","February 2018","February 2018","October 17, 2014","null","January 4, 2018","Icahn School of Medicine at Mount Sinai, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT02266563"
65,"NCT00850278","Assessment of [18F]FLT-PET Imaging for Diagnosis and Prognosis of Brain Tumors","FLT","Completed","No Results Available","Cancer|Brain Tumors","Other: FLT-PET imaging","To evaluated the aggressive potential of brain tumors related to cell proliferation index measured by [18F]FLT|To compare the efficiency of [18F]FLT with [11C]MET|To define relations between [18F]FLT uptake and clinical, histological and radiological parameters|To define relations between [18F]FLT uptake and patient survival","University Hospital, Caen|National Cancer Institute, France","All","18 Years and older   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2007-006265-32","October 2008","July 2011","July 2011","February 24, 2009","null","September 3, 2012","Caen University Hospital, Caen, France","","https://ClinicalTrials.gov/show/NCT00850278"
66,"NCT01621906","18F-FLT-PET Imaging of the Brain in Patients With Metastatic Breast Cancer to the Brain Treated With Whole Brain Radiation Therapy With or Without Sorafenib: Comparison With MR Imaging of the Brain",,"Recruiting","No Results Available","Metastatic Breast Cancer to the Brain","Device: 18F-FLT-PET Imaging","radiographic response|Analysis of surgical specimen","Memorial Sloan Kettering Cancer Center","All","18 Years and older   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","12-039","June 2012","June 2018","June 2018","June 18, 2012","null","January 4, 2018","Memoral Sloan Kettering Cancer Center, Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States|Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, United States|Memorial Sloan Kettering Westchester, Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Memorial Sloan Kettering at Mercy Medical Center, Rockville Centre, New York, United States","","https://ClinicalTrials.gov/show/NCT01621906"
67,"NCT01266096","PET Imaging of Patients With Melanoma and Malignant Brain Tumors Using an 124I-labeled cRGDY Silica Nanomolecular Particle Tracer: A Microdosing Study",,"Active, not recruiting","No Results Available","Newly Diagnosed or Recurrent Metastatic Melanoma Patients|Malignant Brain Tumors","Drug: PET scan with 124I-cRGDY-PEG-dots","Conduct pilot single-dose studies of 124I-cRGDY-PEG-dots†|Estimate the radiation dosimetry of i.v.-injected 124I-cRGDY-PEG-dots.|Assay particle tracer tissue distributions in tumor tissue specimens","Memorial Sloan Kettering Cancer Center","All","18 Years and older   (Adult, Older Adult)","Not Applicable","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","10-155","January 2011","December 2018","December 2018","December 24, 2010","null","October 25, 2017","Memorial Sloan Kettering Cancer Center, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT01266096"
68,"NCT03465618","A First in Human Study Using 89Zr-cRGDY Ultrasmall Silica Particle Tracers for Malignant Brain Tumors",,"Recruiting","No Results Available","Brain Cancer","Drug: 89Zr-DFO-cRGDY-PEG-Cy5-C' dots PET Imaging|Other: Blood and Urine samples","distribution within these high-grade gliomas","Memorial Sloan Kettering Cancer Center","All","18 Years and older   (Adult, Older Adult)","Phase 1","19","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic","17-599","March 7, 2018","March 2020","March 2020","March 14, 2018","null","May 23, 2018","Memorial Sloan Kettering Cancer Center, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT03465618"
69,"NCT03276676","[18F]Fluciclovine and [18F]FLT PET/CT Assessment of Primary High-Grade Brain Tumors",,"Recruiting","No Results Available","Brain Tumor","Drug: Multi-tracer PET exams of [18F]FLT and [18F]Fluciclovine","Increased Overall Survival|Association between overall survival and quantitative markers|Association between progression free survival and quantitative markers|Ability of [18F]FLT and/or [18F]Fluciclovine alone or together to predict true progression from pseudoprogression|More predictive of overall survival than an MRI|More predictive of time to progression than an MRI","University of Utah|Blue Earth Diagnostics","All","18 Years and older   (Adult, Older Adult)","Phase 2","30","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","HCI104704","March 6, 2018","November 2022","November 2022","September 8, 2017","null","May 23, 2018","Huntsman Cancer Institute, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT03276676"
70,"NCT00556153","[F-18]Fluoro-DOPA PET Imaging of Brain Tumors in Children",,"Withdrawn","No Results Available","Brain Tumors","Drug: [F-18]Fluoro-DOPA PET, a diagnostic radiopharmaceutical","Increased uptake of [F-18]FDOPA in pediatric brain tumors compared to contralateral normal brain tissue as measured by standardized uptake value and tumor/non-tumor uptake ratios","Children's Hospital Medical Center, Cincinnati","All","5 Years to 15 Years   (Child)","","0","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","CCHMC IRB# 04-09011","February 2013","null","February 2013","November 9, 2007","null","January 8, 2013","","","https://ClinicalTrials.gov/show/NCT00556153"
71,"NCT01540513","PET/CT Evaluation of Primary and Metastatic Brain Tumors With a Novel Radioiodinated Phospholipid Ether Analogue I-NM404",,"Completed","Has Results","Glioblastoma Multiforme|Brain Metastases","Drug: NM404","Tumor to Background Ratios (TBR) Post-imaging for All Lesions With PET Uptake|Tumor to Background Ratios (TBR) Post-imaging for Confirmed Malignant Tumors|Tumor to Blood Pool Ratios Post-imaging for All Lesions With PET Uptake|Tumor to Blood Pool Ratios Post-imaging for Confirmed Malignant Tumors","University of Wisconsin, Madison","All","18 Years and older   (Adult, Older Adult)","Not Applicable","12","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","RO11360","March 2012","October 2014","October 2014","February 28, 2012","December 11, 2017","March 15, 2018","University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States","","https://ClinicalTrials.gov/show/NCT01540513"
72,"NCT03068520","Can Hybrid PET-MRI Differentiate Between Radiation Effects and Disease Progression?",,"Recruiting","No Results Available","Brain Tumor","Diagnostic Test: PET MR","Distinguish between progressive tumor and treatment related effects","Assuta Medical Center|Rabin Medical Center","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","140","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","022-16-ASMC","March 1, 2017","December 31, 2017","December 31, 2018","March 3, 2017","null","March 21, 2017","Assuta Medical Centers, Tel Aviv, Israel","","https://ClinicalTrials.gov/show/NCT03068520"
73,"NCT00813566","Multi-Tracer PET Assessment of Primary Brain Tumors",,"Recruiting","No Results Available","Brain Tumors|Cancer","Radiation: Multi-tracer PET exams of 18F-FDG, 18F-FLT, 11C-ACE, and 15O-H2O","Rapid, single-scan multi-tracer PET imaging can recover PET imaging biomarker information of each tracer that are not significantly different from those obtained from conventional, single-tracer scans of each tracer.|Multi-tracer PET biomarkers, obtained in conjunction, are better able to predict tumor aggressiveness than individual-tracer biomarkers or conventional radiographic imaging.|Multi-tracer PET biomarkers, obtained in conjunction, are better able to detect functional changes in tumor state that occur in response to therapy than individual-tracer biomarkers or conventional radiographic imaging.|Characterization of multiple aspects of tumor function (glucose metabolism, proliferation, membrane growth, and perfusion) provides new insight into tumor status that can guide selection of the most appropriate therapy.","University of Utah","All","18 Years and older   (Adult, Older Adult)","","20","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","HCI31335","December 2008","July 2022","July 2022","December 23, 2008","null","August 8, 2018","Huntsman Cancer Institute, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT00813566"
74,"NCT02357550","Ketones Influence on Glucose Metabolism in Brain. A Human Positron Emission Tomography (PET) Study",,"Completed","No Results Available","Ketone Body Metabolism|Brain Metabolism","Drug: ketone|Drug: placebo","Glucose metabolism in brain, CMR|Stress metabolism|Oxygen use|cerebral blood flow|Intramuscular signaling","University of Aarhus","All","50 Years to 70 Years   (Adult, Older Adult)","Not Applicable","9","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","RM-1-10-72-106-14","March 2015","January 2016","January 2016","February 6, 2015","null","January 18, 2016","Aarhus University Hospital, Aarhus, Denmark","","https://ClinicalTrials.gov/show/NCT02357550"
75,"NCT01516905","PET/CT Imaging of Malignant Brain Tumors With 124I-NM404",,"Active, not recruiting","No Results Available","Glioblastoma|Brain Metastases","Drug: NM404","tumor to background ratios","University of Wisconsin, Madison|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","","19","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","RO11310|1R01CA158800-01","December 2011","May 17, 2016","December 2018","January 25, 2012","null","February 12, 2018","University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States","","https://ClinicalTrials.gov/show/NCT01516905"
76,"NCT02071017","PET (FDG)-MR Imaging for the Adult Patients Presented With Brain Tumor",,"Unknown status","No Results Available","Brain Tumor","","PET (FDG)-MR Imaging for the Adult Patients Presented With Brain Tumor","Seoul National University Hospital","All","20 Years and older   (Adult, Older Adult)","","6","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","D-1212-014-447","February 2013","December 2014","December 2014","February 25, 2014","null","February 25, 2014","Seoul National University Hospital, Seoul, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT02071017"
77,"NCT03279393","PPG Project 3 - PET/MRI of the Brain-hematopoiesis-atherosclerosis Axis in PTSD Patients",,"Recruiting","No Results Available","PTSD|Trauma|Healthy","Drug: fluorodeoxyglucose (FDG)-PET/MRI","Atherosclerotic burden in PTSD using PET/MRI|Degree of brain fear circuit activation|Level of circulating HPSCs|Level of circulating immune cells|Level of soluble inflammation biomarkers","Zahi Fayad|Massachusetts General Hospital|National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health (NIH)|Icahn School of Medicine at Mount Sinai","All","30 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","240","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","GCO 15-0893 P3|1P01HL131478","November 28, 2017","February 28, 2022","February 28, 2022","September 12, 2017","null","June 25, 2018","Massachusetts General Hospital, Boston, Massachusetts, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT03279393"
78,"NCT02431572","A Pilot Study to Evaluate PBR PET in Brain Tumor Patients Treated With Chemoradiation or Immunotherapy",,"Recruiting","No Results Available","Intracranial Tumors|Glioblastoma|Melanoma","Other: PBR PET|Biological: Cancer Immunotherapy|Radiation: Radiation and chemotherapy","Change in PBR uptake (changes in PBR uptake by PET)","Massachusetts General Hospital","All","18 Years and older   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","14-421","May 2015","October 2018","March 2020","May 1, 2015","null","March 5, 2018","Dana Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT02431572"
79,"NCT01486732","FLT-PET Activity Change After Allogeneic Umbilical Cord Blood (UCB) Therapy in Cerebral Palsy",,"Withdrawn","No Results Available","Cerebral Palsy","Biological: Umbilical Cord Blood Infusion|Other: Active Rehabilitation|Other: Placebo Umbilical Cord Blood","Comparison of FLT-PET Activity Change|Changes in Neurodevelopmental Outcome|Changes in Standardized Gross Motor Function|Changes in Quality of Movement","Bundang CHA Hospital","All","6 Months to 20 Years   (Child, Adult)","Phase 2","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CP FLT-PET","March 2013","April 2014","July 2014","December 6, 2011","null","November 19, 2013","CHA Bundang Medical Center, Seongnam-si, Gyeonggi-do, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT01486732"
80,"NCT02685969","Brain Characterization of Amyloid Protein and Glucose Metabolism of ALFA Project Participants",,"Recruiting","No Results Available","Alzheimer's Disease","Procedure: 18F-Flutemetamol & 18F-FDG","Prevalence of a positive 18F-Flutemetamol scan|Prevalence of the different stages of preclinical AD according to the NIA-AA criteria","Barcelonabeta Brain Research Center, Pasqual Maragall Foundation|Hospital Clinic of Barcelona|General Electric","All","45 Years to 75 Years   (Adult, Older Adult)","","440","Other|Industry","Observational","Observational Model: Case-Crossover|Time Perspective: Cross-Sectional","PET FLUTEMETAMOL-FDG/BBRC2015","March 1, 2017","March 1, 2019","March 1, 2020","February 19, 2016","null","April 4, 2018","BarcelonaBeta Brain Research Center, Barcelona, Catalunya, Spain","","https://ClinicalTrials.gov/show/NCT02685969"
81,"NCT00805636","Evaluation of the Efficacy and Safety of [18F]-ML-10, as a PET Imaging Radiotracer, in Early Detection of Response of Brain Metastases of Solid Tumors to Radiation Therapy.",,"Unknown status","No Results Available","Brain Metastases|Solid Tumors","Drug: 2-(5-fluoro-pentyl)-2-methyl-malonic-acid ([18F]-ML-10)|Radiation: Stereotactic Radio-Surgery (SRS) therapy|Procedure: Positron Emission Tomography","To assess the relationship between changes in 18FML10 uptake in the target lesions (PET/CT) obtained before and after radiotherapy (SRS), and changes of the lesions size (MRI, ~8w after SRS) in response to treatment, according to the WHO criteria|Characterization of early alterations in the voxel-based 18FML10 uptake in the target lesion in response to the single fraction high-dose Stereotactic RadioSurgery, SRS. 18FML10 uptake at 24h after SRS and at baseline, before SRS, will be compared|To identify parameters derived from the changes in 18FML10 uptake observed early after SRS that can discriminate responsive from non-responsive target lesions, and to estimate optimal cut-off values of this parameter (sensitivity and specificity)|To perform additional analyses for all other lesions with longest diameter ≥ 1.5 cm treated by SRS.","Aposense Ltd.","All","18 Years and older   (Adult, Older Adult)","Phase 2","30","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","NST-CA004CTIL","November 2008","October 2010","October 2010","December 9, 2008","null","May 12, 2010","Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Department of Radiation oncology, Memorial Sloan Kettering Cancer Center, New York city, New York, United States|UPMC Shadyside Radiation Oncology, Pittsburgh, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT00805636"
82,"NCT02409914","Brain Metabolism in Polycystic Ovary Syndrome",,"Completed","No Results Available","Insulin Resistance","Other: PET and MRI exams","Brain glucose PET uptake|Brain MR volumes","Université de Sherbrooke","Female","18 Years to 35 Years   (Adult)","","7","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","10-153","March 2010","September 2014","September 2014","April 7, 2015","null","April 7, 2015","","","https://ClinicalTrials.gov/show/NCT02409914"
83,"NCT02511691","PET/MRI Imaging of Glutamate Release in the Brain",,"Recruiting","No Results Available","Healthy","Drug: 18F-PSS232","Difference of Binding Potentials of 18F-PSS232 in different brain regions between Baseline PET and PET after medical challenge","University of Zurich","All","20 Years to 75 Years   (Adult, Older Adult)","Phase 2","60","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","KEK ZH 2014-0441","July 2015","July 2018","September 2018","July 30, 2015","null","July 30, 2015","University Hopsital Zurich, Zurich, Switzerland","","https://ClinicalTrials.gov/show/NCT02511691"
84,"NCT00775320","Assessment of Suspected Intracranial Malignancy Using 3'-Deoxy-3'18 F-flourothymidine PET",,"Terminated","No Results Available","Brain Tumor","Procedure: FLT-PET scan","","University of Oklahoma|Midwest Medical Isotopes","All","18 Years to 99 Years   (Adult, Older Adult)","","13","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","FLT- Brain Study","October 2008","August 2010","August 2010","October 20, 2008","null","May 16, 2016","University Of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States","","https://ClinicalTrials.gov/show/NCT00775320"
85,"NCT01985971","F18 EF5 PET/CT Imaging in Patients With Brain Metastases From Breast Cancer",,"Unknown status","No Results Available","Brain Metastases From Breast Cancer","Radiation: PET/CT Imaging","Number of Adverse Events","Abramson Cancer Center of the University of Pennsylvania","All","18 Years and older   (Adult, Older Adult)","Not Applicable","25","Other","Interventional","Primary Purpose: Diagnostic","UPCC 15910","March 2011","March 2014","null","November 18, 2013","null","December 15, 2015","Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT01985971"
86,"NCT02167204","18F-FLT PET/CT in Measuring Cell Proliferation in Patients With Brain Tumors",,"Terminated","No Results Available","Metastatic Malignant Neoplasm in the Brain|Primary Brain Neoplasm|Recurrent Brain Neoplasm","Procedure: Computed Tomography|Radiation: Fluorothymidine F-18|Procedure: Positron Emission Tomography","Clinical response assessed using Revised Assessment in Neuro-Oncology criteria|Percentage change in measure of FLT flux|Percentage change in measure of reflecting transport|Percentage change in measure of standard uptake value|Survival|Heterogeneity of the within-tumor proliferation","University of Washington|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","9","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","7754|NCI-2013-02162|P01CA042045|P30CA015704","November 2012","November 21, 2017","November 21, 2017","June 18, 2014","null","April 2, 2018","Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States","","https://ClinicalTrials.gov/show/NCT02167204"
87,"NCT02986815","[11C]Acetate PET in Patients With Glioma",,"Recruiting","No Results Available","Glioma","Other: [11C]Acetate Brain Imaging","Visual differences from normal brain in patients with grades 2, 3 or 4 gliomas|Decrease in [11C]Acetate uptake following treatment of grade 2 glioma|Decrease in [11C]-acetate uptake following treatment of grade 3 and 4 glioma|Change in [11C]-acetate uptake following treatment at time of progression in grade 3 and 4 gliomas","University of Texas Southwestern Medical Center","All","18 Years and older   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","STU 052016-034","January 24, 2017","December 2021","December 2021","December 8, 2016","null","May 15, 2018","University of Texas Southwestern Medical Center, Dallas, Texas, United States","","https://ClinicalTrials.gov/show/NCT02986815"
88,"NCT00696943","18F ML-10 for Early Detection of Response of Brain Metastases to SRS",,"Terminated","No Results Available","Metastasis to Brain of Unknown Primary","Drug: ([18F]-ML-10)","Assessment of the change in the uptake of [18F]-ML-10 by the target lesion(s) in response to SRS, as observed by comparing the PET/CT scans before and after SRS. Target lesion is defined as having a minimal diameter of 1.5 cm|Assessment of the relationship between the change in uptake of [18F]-ML-10 by the metastatic target lesions as observed in the PET/CT scans obtained before and after irradiation, and shrinkage of the metastatic target lesion, as assessed by MRI.|Evaluation of the safety of [18F]-ML-10 when administered for 3 consecutive PET/CT scans to patients with brain metastases undergoing SRS.","Aposense Ltd.","All","18 Years and older   (Adult, Older Adult)","Phase 2","1","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","NST-CA005CTIL","July 2008","July 2009","July 2009","June 13, 2008","null","February 15, 2013","","","https://ClinicalTrials.gov/show/NCT00696943"
89,"NCT03345290","Impact of the Central Blood Pressure Level in Cerebral Metabolic Aging: a 18F-FDG PET Study.","PACTEP","Not yet recruiting","No Results Available","Aging Disorder","Device: PET with a cerebral step|Device: Central blood pressure measurement|Other: Neurocognitive tests","volume of brain areas detected by quantitative analysis|topography of brain areas detected by quantitative analysis|central blood pressure","Central Hospital, Nancy, France","All","18 Years and older   (Adult, Older Adult)","Not Applicable","105","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","PSS2016/PACTEP-VERGER/VS","March 2018","March 2020","March 2020","November 17, 2017","null","February 12, 2018","CHRU Nancy, Vandoeuvre les Nancy, France","","https://ClinicalTrials.gov/show/NCT03345290"
90,"NCT01899170","Towards Individualized Deep Brain Stimulation Treatment of Chronic Neuropathic Pain","DBSforPain","Suspended","No Results Available","Neuralgia","Procedure: Deep brain stimulation|Device: Cervel Neurotech, Multi-coil TMS|Drug: 11C-Carfentanil","Pain relief upon deep brain stimulation of the dorsal anterior cingulate cortex.|Predictive values of PET imaging and transcranial magnetic stimulation on deep brain stimulation outcome|Effect of deep brain stimulation on cingulate opioid binding and blood flow.|Pain relief upon individualized deep brain stimulation","University of Aarhus|Stanford University|California Pacific Medical Center Research Institute","All","25 Years to 70 Years   (Adult, Older Adult)","Phase 2","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","28052013|2013-002385-39","April 2014","August 2022","August 2022","July 15, 2013","null","August 23, 2016","Aarhus University Hospital, Aarhus, Region Midtjylland, Denmark","","https://ClinicalTrials.gov/show/NCT01899170"
91,"NCT00067821","Comparison of PET and Proton MRS Imaging to Evaluate Pediatric Brain Tumor Activity",,"Recruiting","No Results Available","Brain Tumors","","Comparison|Evaluate change","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","1 Year to 21 Years   (Child, Adult)","","150","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","030278|03-C-0278","August 27, 2003","null","null","August 28, 2003","null","August 21, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00067821"
92,"NCT02524301","Evaluation of Brain Opioid Receptor Activity in Anorexia Nervosa : a PET [11C]Diprenorphine Study",,"Recruiting","No Results Available","Body Dysmorphic Disorders|Anorexia","Drug: Positron Emission Tomography using [11C]diprenorphine","[11C]diprenorphine binding potential|Correlation [11C]diprenorphine binding potential","Centre Hospitalier Universitaire de Saint Etienne|Ministry of Health, France","Female","18 Years to 35 Years   (Adult)","Not Applicable","45","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","0908019","September 2009","March 2018","September 2018","August 14, 2015","null","May 31, 2017","CHU Saint-Etienne, Saint-Etienne, France","","https://ClinicalTrials.gov/show/NCT02524301"
93,"NCT02211820","PET Imaging in Chronic Traumatic Encephalopathy",,"Completed","No Results Available","Brain Disease|Brain Mapping","","Amount of 11C-PBB3 binding in brain as measured with PET|Amount of brain atrophy as measured with MRI.Amount of 11C-PIB binding in brain as measured with PET","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years to 60 Years   (Adult)","","6","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","140164|14-M-0164","August 1, 2014","June 20, 2016","October 12, 2016","August 8, 2014","null","July 4, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT02211820"
94,"NCT00707343","[F-18] Fluorothymidine (FLT) Imaging on Patients With Primary Brain Tumors",,"Completed","Has Results","Cancer|Brain Tumors","Radiation: FLT-PET Imaging","Area Under the Receiver Operating Curve (ROC AUC) Values for PET Imaging Techniques","University of Utah","All","18 Years and older   (Adult, Older Adult)","Phase 1","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","HCI20112","May 2007","September 2014","September 2014","June 30, 2008","February 3, 2016","February 3, 2016","Huntsman Cancer Institute, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT00707343"
95,"NCT01547780","Translocator Protein and Inflammation After Traumatic Brain Injury",,"Completed","No Results Available","Traumatic Brain Injury|Healthy","Radiation: PET","Binding of [(11)C]PBR28.|Neurocognitive assessment scores and clinical evaluations","National Institute of Mental Health (NIMH)|Suburban Hospital|Uniformed Services University of the Health Sciences|National Institutes of Health Clinical Center (CC)","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","52","NIH|Other|U.S. Fed","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","120063|12-M-0063","January 20, 2012","September 28, 2017","September 28, 2017","March 8, 2012","null","July 23, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT01547780"
96,"NCT01871610","Amyloid Accumulation After Mild Traumatic Brain Injury",,"Unknown status","No Results Available","Traumatic Brain Injury","Drug: [18F]AV-45 PET amyloid binding imaging","The amyloids load in brain among mild traumatic brain injury and controls in a temporal manner.|F-18-AV-45 binding changes and cognitive function among mild traumatic brain injury and controls","Chang Gung Memorial Hospital","All","30 Years and older   (Adult, Older Adult)","Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","100-4313A","November 2012","November 2012","October 2013","June 7, 2013","null","June 7, 2013","","","https://ClinicalTrials.gov/show/NCT01871610"
97,"NCT00857415","Phase III Study of the Correlation Between Florbetapir F18 PET Imaging and Amyloid Pathology in the Brain",,"Completed","Has Results","Alzheimer's Disease","Drug: florbetapir F 18","Correlation of Florbetapir-PET Image and Amyloid Plaque Density|Specificity Analysis|Regional Correlation Analysis","Avid Radiopharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","226","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic","18F-AV-45-A07","December 2008","March 2010","May 2010","March 6, 2009","May 7, 2012","May 22, 2012","Research Site, Phoenix, Arizona, United States|Research Site, Scottsdale, Arizona, United States|Research Site, Sun City, Arizona, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Irvine, California, United States|Research Site, San Francisco, California, United States|Research Site, Fort Myers, Florida, United States|Research Site, Miami Beach, Florida, United States|Research Site, Miami Springs, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Sarasota, Florida, United States|Research Site, St. Petersburg, Florida, United States|Research Site, West Palm Beach, Florida, United States|Research Site, Baltimore, Maryland, United States|Research Site, Hattiesburg, Mississippi, United States|Research Site, St. Louis, Missouri, United States|Research Site, Albany, New York, United States|Research Site, New Hyde Park, New York, United States|Research Site, Durham, North Carolina, United States|Research Site, Centerville, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Charleston, South Carolina, United States|Research Site, Johnson City, Tennessee, United States|Research Site, Bennington, Vermont, United States","","https://ClinicalTrials.gov/show/NCT00857415"
98,"NCT03241732","PET-MRI and the Effect of N-Acetyl Cysteine (NAC) and Anti-Inflammatory Diet in Traumatic Brain Injury",,"Recruiting","No Results Available","Chronic Traumatic Brain Injury","Other: Anti-inflammatory Diet|Dietary Supplement: N-acetyl Cysteine","Fluorodeoxyglucose positron emission tomography (FDG-PET).|Quantitative EEG.|Functional magnetic resonance imaging (fMRI).|Speilberger State Trait Anxiety Inventory (STAI).|Profile of Moods Scale (POMS).|Beck Depression Inventory (BDI).|Delis Kaplan Executive Function System (DKEFS) color-word interference.|Trails A & B.|Forward and reverse digit span.|Epworth Sleepiness Scale.|Mayo-Portland Adaptability Inventory-4.|Rivermead Post-Concussion Symptoms Questionnaire.","Thomas Jefferson University","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","120","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","17D.138","June 7, 2017","February 10, 2020","February 11, 2021","August 7, 2017","null","January 17, 2018","Thomas Jefferson University, Marcus Institute of Integrative Health Centers, Philadelphia, Pennsylvania, United States|Thomas Jefferson University, Marcus Institute of Integrative Health Centers, Villanova, Pennsylvania, United States","""Study Protocol and Statistical Analysis Plan: Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/32/NCT03241732/Prot_SAP_000.pdf|""Study Protocol and Statistical Analysis Plan: Cover Page"", https://ClinicalTrials.gov/ProvidedDocs/32/NCT03241732/Prot_SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03241732"
99,"NCT00597246","Imaging Brain Tumors With FACBC and Methionine",,"Active, not recruiting","No Results Available","Brain Cancer|CNS Cancer","Drug: FACBC, Methionine|Other: PET Scan","Demonstrate [18F]-FACBC has equal or better brain tumor imaging characteristics compared to [11C]-methionine. Det biodistribution & clearance of 3-[18F]-FACBC in diff tissues/organs of body.|Look for potential correlations bet subsequent MR & PET results obtained from patients enrolled and patients' subsequent medical treatment, progression of tumor & survival.","Memorial Sloan Kettering Cancer Center","All","Child, Adult, Older Adult","Not Applicable","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","03-028","May 13, 2003","May 2019","May 2019","January 18, 2008","null","June 4, 2018","Memorial Sloan Kettering Cancer Center, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT00597246"
100,"NCT00757939","A Study to Assess Regional Cerebral Blood Flow as an Alzheimer's Disease Biomarker Compared to Positron Emission Tomography in Patients With Mild-to-Moderate Alzheimer's Disease and Cognitively Normal Elderly Subjects (Study MK-0000-068)(COMPLETED)",,"Completed","No Results Available","Alzheimer's Disease","Other: MRI|Other: FDG-PET","Regional cerebral blood flow, as measured by dASL.|Rate of cerebral glucose consumption, MRglc, as measured by fludeoxyglucose-PET (FDG-PET)|Resting state functional MRI blood-oxygen-level-dependent (fMRI BOLD) response","Merck Sharp & Dohme Corp.","All","55 Years and older   (Adult, Older Adult)","Phase 1","40","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic","0000-068|2008_547","September 2008","October 2010","October 2010","September 23, 2008","null","August 11, 2015","","","https://ClinicalTrials.gov/show/NCT00757939"
101,"NCT02370563","PET Imaging of Intracranial Cancers With 18F-FSPG",,"Terminated","No Results Available","Brain Cancer","Drug: 18F-FSPG","Location and number of lesions and their location as detected by 18F-FSPG uptake above background in the brain of each study subject following visual inspection of the 18F-FSPG PET/CT scans|Location and number of lesions detected in the whole body following visual inspection of the 18F-FSPG PET/CT scans|Location and number of lesions detected in the brain and whole body following visual inspection of the CT, MR or other available PET (e.g. 18F-FDG, 18F-FLT, etc.).|Lesion size measured by means of ROIs drawn on (contrast-enhanced) MR or CT.|18F-FSPG standardized uptake value (SUV) measured in each detected lesion and in the background (region without lesion).|SUV measured in each detected lesion and in the background using other available PET tracers (e.g. 18F-FDG, 18F-FLT, etc.).|Determination of FSPG PET/CT image quality based on visual inspection.","Piramal Imaging SA","All","18 Years and older   (Adult, Older Adult)","Phase 1","26","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","FSPG010114","November 2014","March 2016","March 2016","February 25, 2015","null","September 2, 2016","Stanford University Medical Center, Stanford, California, United States","","https://ClinicalTrials.gov/show/NCT02370563"
102,"NCT02241668","Fluoro-L-Thymidine Positron Emission Tomography (FLT PET) vs. Adv. Magnetic Resonance (MR) Techniques in Recurrent Glioma",,"Withdrawn","No Results Available","Brain Tumor","Procedure: PET Scan|Drug: 3'-Deoxy-3'-18f-Fluorothymidine","Performance of Fluoro-L-Thymidine Positron Emission Tomography (FLT PET) and Perfusion Magnetic Resonance Imaging (MRI) in the Diagnosis of Recurrent High-Grade Glial Tumor","M.D. Anderson Cancer Center|GE Healthcare","All","18 Years and older   (Adult, Older Adult)","Not Applicable","0","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2013-0283","June 2015","June 2015","null","September 16, 2014","null","February 26, 2016","","","https://ClinicalTrials.gov/show/NCT02241668"
103,"NCT01472731","Safety and Imaging Study of GC1008 in Glioma",,"Completed","No Results Available","Primary Brain Tumors","Other: 89Zr-GC1008|Drug: GC1008","Biomarker imaging|Quantification of uptake|Correlation of 89Zr-GC1008 tumor uptake|Secondary endpoints Part 2","University Medical Center Groningen|Genzyme, a Sanofi Company","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","12","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GC1008|2010-021639-15","December 2011","November 2012","November 2012","November 16, 2011","null","November 14, 2012","University Medical Center Groningen, Groningen, Netherlands","","https://ClinicalTrials.gov/show/NCT01472731"
104,"NCT02194452","Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors",,"Withdrawn","No Results Available","Acoustic Schwannoma|Adult Anaplastic Astrocytoma|Adult Anaplastic Ependymoma|Adult Anaplastic Meningioma|Adult Anaplastic Oligodendroglioma|Adult Brain Stem Glioma|Adult Choroid Plexus Tumor|Adult Craniopharyngioma|Adult Diffuse Astrocytoma|Adult Ependymoblastoma|Adult Ependymoma|Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Adult Grade I Meningioma|Adult Grade II Meningioma|Adult Medulloblastoma|Adult Meningeal Hemangiopericytoma|Adult Mixed Glioma|Adult Myxopapillary Ependymoma|Adult Oligodendroglioma|Adult Papillary Meningioma|Adult Pilocytic Astrocytoma|Adult Pineal Gland Astrocytoma|Adult Pineoblastoma|Adult Pineocytoma|Adult Subependymal Giant Cell Astrocytoma|Adult Subependymoma|Adult Supratentorial Primitive Neuroectodermal Tumor (PNET)|Childhood Choroid Plexus Tumor|Childhood Craniopharyngioma|Childhood Ependymoblastoma|Childhood Grade I Meningioma|Childhood Grade II Meningioma|Childhood Grade III Meningioma|Childhood High-grade Cerebellar Astrocytoma|Childhood High-grade Cerebral Astrocytoma|Childhood Infratentorial Ependymoma|Childhood Low-grade Cerebellar Astrocytoma|Childhood Low-grade Cerebral Astrocytoma|Childhood Medulloepithelioma|Childhood Supratentorial Ependymoma|Meningeal Melanocytoma|Newly Diagnosed Childhood Ependymoma|Recurrent Adult Brain Tumor|Recurrent Childhood Anaplastic Astrocytoma|Recurrent Childhood Anaplastic Oligoastrocytoma|Recurrent Childhood Anaplastic Oligodendroglioma|Recurrent Childhood Brain Stem Glioma|Recurrent Childhood Cerebellar Astrocytoma|Recurrent Childhood Cerebral Astrocytoma|Recurrent Childhood Diffuse Astrocytoma|Recurrent Childhood Ependymoma|Recurrent Childhood Fibrillary Astrocytoma|Recurrent Childhood Gemistocytic Astrocytoma|Recurrent Childhood Giant Cell Glioblastoma|Recurrent Childhood Glioblastoma|Recurrent Childhood Gliomatosis Cerebri|Recurrent Childhood Gliosarcoma|Recurrent Childhood Medulloblastoma|Recurrent Childhood Oligoastrocytoma|Recurrent Childhood Oligodendroglioma|Recurrent Childhood Pilocytic Astrocytoma|Recurrent Childhood Pilomyxoid Astrocytoma|Recurrent Childhood Pineoblastoma|Recurrent Childhood Pleomorphic Xanthoastrocytoma|Recurrent Childhood Protoplasmic Astrocytoma|Recurrent Childhood Subependymal Giant Cell Astrocytoma|Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor|Recurrent Childhood Visual Pathway and Hypothalamic Glioma|Recurrent Childhood Visual Pathway Glioma|Untreated Childhood Anaplastic Astrocytoma|Untreated Childhood Anaplastic Oligodendroglioma|Untreated Childhood Brain Stem Glioma|Untreated Childhood Cerebellar Astrocytoma|Untreated Childhood Cerebral Astrocytoma|Untreated Childhood Diffuse Astrocytoma|Untreated Childhood Fibrillary Astrocytoma|Untreated Childhood Gemistocytic Astrocytoma|Untreated Childhood Giant Cell Glioblastoma|Untreated Childhood Glioblastoma|Untreated Childhood Gliomatosis Cerebri|Untreated Childhood Gliosarcoma|Untreated Childhood Medulloblastoma|Untreated Childhood Oligoastrocytoma|Untreated Childhood Oligodendroglioma|Untreated Childhood Pilocytic Astrocytoma|Untreated Childhood Pilomyxoid Astrocytoma|Untreated Childhood Pineoblastoma|Untreated Childhood Pleomorphic Xanthoastrocytoma|Untreated Childhood Protoplasmic Astrocytoma|Untreated Childhood Subependymal Giant Cell Astrocytoma|Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor|Untreated Childhood Visual Pathway and Hypothalamic Glioma|Untreated Childhood Visual Pathway Glioma","Radiation: gallium Ga 68-edotreotide|Procedure: positron emission tomography|Procedure: computed tomography|Other: laboratory biomarker analysis","Change in standardized uptake value (SUV) uptake after gallium Ga 68-edotreotide|Proportion of discordance and concordance between gallium Ga 68-edotreotide and biopsy","Sue O'Dorisio|National Cancer Institute (NCI)|Ride for Kids|University of Iowa","All","6 Months to 29 Years   (Child, Adult)","Not Applicable","0","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","201302711|P30CA086862","September 2013","March 2017","March 2017","July 18, 2014","null","April 28, 2017","University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States","","https://ClinicalTrials.gov/show/NCT02194452"
105,"NCT02003183","Traumatic Brain Injury and Risk for Chronic Traumatic Encephalopathy","TBI and CTE","Active, not recruiting","No Results Available","Traumatic Brain Injury|Chronic Traumatic Encephalopathy|Concussions|Mild Cognitive Impairment","Radiation: [F-18]FDDNP","FDDNP PET will detect tau deposits in the brain of living subjects at risk for CTE|Correlation of genetic risk factors and FDDNP-PET measurements","University of California, Los Angeles","All","30 Years to 90 Years   (Adult, Older Adult)","Phase 2","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","11-001077|IND 74944","March 2013","January 2019","January 2019","December 6, 2013","null","June 16, 2017","UCLA Longevity Center, Los Angeles, California, United States","","https://ClinicalTrials.gov/show/NCT02003183"
106,"NCT02700763","[18F]Dabrafenib Molecular Imaging in Melanoma Brain Metastasis",,"Recruiting","No Results Available","Melanoma","Other: [18F]dabrafenib molecular imaging","Absolute uptake of [18F]dabrafenib|Heterogeneity of [18F]dabrafenib uptake of tumor lesions and kinetics in the brain|Intra-patient heterogeneity in [18F]dabrafenib uptake of tumor lesions|Inter-patient heterogeneity in [18F]dabrafenib uptake of tumor lesions|Correlation of [18F]dabrafenib uptake with response to dabrafenib treatment of tumor lesions|Correlation between absolute tumor tracer uptake of [18F]dabrafenib and immunohistochemical staining with VE1 mAb (anti V600-mutated BRAF).|Correlation between absolute tumor tracer uptake of [18F]dabrafenib and BRAF V600 mutation load as maesured in circulating tumor DNA (ctDNA).|Comparison between direct DNA sequencing and Droplet Digital Polymerase Chain Reaction (ddPCR) for BRAF mutation detection.","University Medical Center Groningen","All","18 Years and older   (Adult, Older Adult)","Not Applicable","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","201600134","December 6, 2016","October 2018","October 2018","March 7, 2016","null","April 27, 2018","University Medical Center Groningen, Groningen, Netherlands","","https://ClinicalTrials.gov/show/NCT02700763"
107,"NCT02037945","18F-Fluorocholine (18F-FCho) to Distinguish Necrosis From Recurrence in Brain Metastases",,"Active, not recruiting","No Results Available","Brain Metastases","Procedure: 18F-FCH PET Scan","to distinguish radiation necrosis from progressive tumor","Memorial Sloan Kettering Cancer Center|National Institutes of Health (NIH)","All","21 Years and older   (Adult, Older Adult)","Not Applicable","19","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","13-199","January 2014","January 2019","January 2019","January 16, 2014","null","February 2, 2018","Memorial Sloan Kettering Cancer Center, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT02037945"
108,"NCT01842217","Validation of [18F]FES for Imaging of Brain Estrogen Receptors",,"Unknown status","No Results Available","Psychiatric/Mood Disorder   Patient|Estrogen Receptor Levels|Premenopausal|Postmenopausal","Procedure: FES-PET","Quantification of estrogen receptors in the human brain|Evalution of the levels of circulating estradiol in two patient cohorts and to evaluate the imaging technique","A.W.J.M.Glaudemans|University Medical Center Groningen","Female","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","12","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","NL41 608.042.12","November 2013","November 2014","December 2014","April 29, 2013","null","November 13, 2013","University Medical Centre Groningen, Groningen, Netherlands","","https://ClinicalTrials.gov/show/NCT01842217"
109,"NCT02849171","Assessing 11C-Choline (11C-CH) PET to Distinguish True Tumor Progression From Pseudoprogression in High-grade Gliomas",,"Recruiting","No Results Available","Brain Cancer","Device: PET scan|Radiation: C-Choline","SUV measures","Memorial Sloan Kettering Cancer Center","All","18 Years and older   (Adult, Older Adult)","Not Applicable","6","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","16-676","July 2016","June 2019","June 2019","July 29, 2016","null","July 12, 2018","Memorial Sloan Kettering Cancer Center, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT02849171"
110,"NCT00581282","Brain Imaging Studies of the Effects of Cocaine Abstinence",,"Unknown status","No Results Available","Substance Abuse Disorder","Radiation: PET scan|Other: fMRI","PET scans, fMRI scans","University of California, Irvine|US Department of Veterans Affairs","All","21 Years to 65 Years   (Adult, Older Adult)","","30","Other|U.S. Fed","Observational","Observational Model: Cohort|Time Perspective: Prospective","HS#2004-4019","October 2006","January 2018","January 2018","December 27, 2007","null","October 15, 2010","University of California, Irvine, Brain Imaging Center, Irvine, California, United States","","https://ClinicalTrials.gov/show/NCT00581282"
111,"NCT00750282","Phase II Study of Florbetaben (BAY 94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid in Patients With Probable Alzheimer's Disease Compared to Healthy Volunteers",,"Completed","Has Results","Alzheimer Disease|Amyloid Beta-Protein","Drug: Florbetaben (BAY94-9172)","Specificity and Sensitivity of Florbetaben PET Scans Obtained in Part A Using Two Separate Algorithms and the Onsite Clinical Diagnosis as the Standard of Truth|Specificity and Sensitivity of Florbetaben PET Scans Obtained in Part B Using Two Separate Algorithms and the Onsite Clinical Diagnosis as the Standard of Truth.|Sensitivity and Specificity for All Participants Using Two Additional Imaging Windows for the Visual Assessment|Kappa Coefficient as a Measure of Agreement Between Readers Concerning the Visual Assessment of Abnormality of the Brain Scan (Based on BAPL Score)|Standard Uptake Value Ratios for Florbetaben Signal","Piramal Imaging SA","All","55 Years and older   (Adult, Older Adult)","Phase 2","422","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","311741|2007-002256-42","August 2008","November 2010","November 2010","September 10, 2008","July 16, 2014","July 24, 2014","Sun City, Arizona, United States|Stanford, California, United States|New Haven, Connecticut, United States|Bronx, New York, United States|New York, New York, United States|New York, New York, United States|Providence, Rhode Island, United States|Westmead, New South Wales, Australia|Adelaide, South Australia, Australia|Heidelberg, Victoria, Australia|Erlangen, Bayern, Germany|München, Bayern, Germany|München, Bayern, Germany|Essen, Nordrhein-Westfalen, Germany|Jülich, Nordrhein-Westfalen, Germany|Münster, Nordrhein-Westfalen, Germany|Dresden, Sachsen, Germany|Leipzig, Sachsen, Germany|Berlin, Germany|Kobe, Hyogo, Japan|Kobe, Hyogo, Japan|Bunkyo-ku, Tokyo, Japan|Zürich, Switzerland","","https://ClinicalTrials.gov/show/NCT00750282"
112,"NCT02022800","Prospective Study on Oncologic Cerebral Imagery Contribution by 18F-FDOPA Position Emission Tomography (PET)","IMOTEP","Completed","No Results Available","Glioma|Cerebral Metastases","Other: PET 18FDOPA","confidence level in the therapeutic decision regarding the results from PET 18F-FDOPA imagery, in comparison with MRI alone.|Validation of the decision taken with knowledge of the results from the PET 18F-FDOPA for post-operated patients|evaluation of PET 18F-FDOPA contribution according to clinical situations","Centre Antoine Lacassagne","All","18 Years to 85 Years   (Adult, Older Adult)","Not Applicable","85","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2012/56","November 2013","November 2015","June 2016","December 30, 2013","null","July 26, 2016","Centre Antoine Lacassagne, Nice, France","","https://ClinicalTrials.gov/show/NCT02022800"
113,"NCT03637075","Raclopride-PET/MRT",,"Recruiting","No Results Available","Diabetes Mellitus, Type 2","Other: intranasal insulin|Other: Placebo","Effects of nasal insulin vs. placebo on the insulin sensitivity of the human brain as well as effects on regional availability of dopamine receptors.|Differences between normalweight and overweight subjects regarding insulin sensitivity and availability of dopamine receptors|Effects of nasal insulin vs. placebo on changes in plasma insulin levels|Effects of nasal insulin vs. placebo on changes in plasma glucose levels|Effects of nasal insulin vs. placebo on changes in FFA levels|Effects of nasal insulin vs. placebo on changes in prolactin levels as a proxy for the dopaminergic tonus|Effects of nasal insulin vs. placebo on changes in autonomic nervous system","University Hospital Tuebingen","Male","20 Years to 40 Years   (Adult)","Not Applicable","24","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Other","GK-PET/MR Tü-014","February 20, 2017","June 30, 2020","December 31, 2020","August 17, 2018","null","August 22, 2018","University of Tuebingen, Department of Internal Medicine IV, Tuebingen, Germany","","https://ClinicalTrials.gov/show/NCT03637075"
114,"NCT01961934","C11-Sodium Acetate PET/CT Imaging Evaluation in Brain Glioma, Post Therapy Necrosis and Pseudo-progression",,"Withdrawn","No Results Available","Gliomas","Drug: Sodium Acetate C11 PET/CT Imaging","Biopsy Correlation|SUV (Standardized Uptake Value)","Phoenix Molecular Imaging","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2|Phase 3","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","AMIC-AC-003","May 2014","May 2016","May 2018","October 14, 2013","null","September 28, 2016","Phoenix Molecular Imaging, Phoenix, Arizona, United States","","https://ClinicalTrials.gov/show/NCT01961934"
115,"NCT00811122","Biodistribution of 11C-PIB PET in Alzheimer's Disease, Frontotemporal Dementia, and Cognitively Normal Elderly","11C-PIB PET","Active, not recruiting","No Results Available","Alzheimer's Disease","Radiation: 11C-PIB PET Scan|Radiation: FDG-PET Scan","The agent 11C-PIB has similar biodistribution outside the brain in AD, FTD, and cognitively normal elderly individuals.|Patients with AD scanned with 11C-PIB will have higher standardized uptake values (SUVs) than cognitively normal elderly in brain regions where beta amyloid are expected to be over-expressed.","University of Utah","All","30 Years to 90 Years   (Adult, Older Adult)","Early Phase 1","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","17991","November 2009","April 2018","April 2018","December 18, 2008","null","May 9, 2017","University of Utah, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT00811122"
116,"NCT01461083","Evaluation of [18F]MPPF as a Brain Tracer of Serotonin Receptor 5HT1a","MPPF","Completed","No Results Available","Parkinson Disease","Drug: [18F]MPPF","To assess the dynamic uptake and washout of [18F]MPPF in brain using positron emission tomography(PET) imaging|To assess the influence of dopaminergic replacement therapy on 5HT1A activity in PD subjects","Institute for Neurodegenerative Disorders","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 1","19","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)","MPPF","September 2011","November 2012","May 2014","October 27, 2011","null","June 4, 2014","Molecular NeuroImaging, LLC, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT01461083"
117,"NCT02524405","BEAM: Brain-Eye Amyloid Memory Study","BEAM","Recruiting","No Results Available","Alzheimer's Disease|Mild Cognitive Impairment|Vascular Cognitive Impairment|Parkinson's Disease|Lewy Body Disease","Other: Flutemetamol PET scan","Retinal nerve fiber layer thickness|Amyloid Depostition|Retinal artery narrowing|Retinal venular widening","Sunnybrook Health Sciences Centre|Brain Canada|Weston Brain Institute|GE Healthcare|University Health Network, Toronto|Centre for Addiction and Mental Health|Baycrest|St. Michael's Hospital, Toronto|Kensington Eye Institute","All","50 Years to 90 Years   (Adult, Older Adult)","","320","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","221-2013","February 2016","March 2019","September 2019","August 14, 2015","null","November 27, 2017","Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|University Health Network, Toronto, Ontario, Canada|Baycrest Health Sciences, Toronto, Ontario, Canada|Centre for Addiction and Mental Health (CAMH), Toronto, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT02524405"
118,"NCT03412604","Effect of Modulating Gamma Oscillations Using tACS",,"Not yet recruiting","No Results Available","Alzheimer Disease","Device: Transcranial Alternating Current Stimulation (tACS)","Incidence of Treatment-Emergent Adverse Events|PET amyloid burden|PET tau deposition|PET Microglia activation","Beth Israel Deaconess Medical Center|Defense Advanced Research Projects Agency","All","45 Years and older   (Adult, Older Adult)","Not Applicable","10","Other|U.S. Fed","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2017P000648","June 1, 2018","December 31, 2018","December 31, 2018","January 26, 2018","null","May 8, 2018","","","https://ClinicalTrials.gov/show/NCT03412604"
119,"NCT02531360","Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Tauopathies",,"Completed","No Results Available","Alzheimer's Disease (AD)|Progressive Supranuclear Palsy (PSP)|Cortical Basal Syndrome (CBS)|Frontal Temporal Dementia (FTD)","Drug: [18F]MNI-815 (MNI-815)","Brain uptake of [18F]MNI-815","Molecular NeuroImaging|Piramal Imaging SA","All","50 Years to 90 Years   (Adult, Older Adult)","Early Phase 1","7","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)","MNI-815","May 2015","July 2016","August 2016","August 24, 2015","null","December 16, 2016","Molecular NeuroImaging, LLC, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT02531360"
120,"NCT01020838","Phase III Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid Compared to Histopathology",,"Completed","Has Results","Alzheimer Disease","Drug: Florbetaben (BAY94-9172)","Sensitivity and Specificity of the Majority Read of Visual Assessment of Tracer Uptake Compared to Histological Verification of the Presence or Absence of Cerebral Beta-amyloid in Postmortem Specimens|Sensitivity and Specificity of the Majority Read ""Whole Brain"" Visual Assessment in Detecting/Excluding Cerebral Neuritic β-amyloid Plaques Compared With the Histopathological Verification With Bielschowsky Silver Staining (SOT 1).|Sensitivity and Specificity of the Majority Read ""Whole Brain"" Visual Assessment in Detecting/Excluding Cerebral Neuritic β-amyloid Plaques Compared With Histopathological Verification With Bielschowsky Silver Staining and Immunohistochemistry (SOT 2).|Sensitivity and Specificity of the Majority Read ""Whole Brain"" Visual Assessment in Detecting/Excluding Cerebral Neuritic β-amyloid Plaques Compared With the Histopathological Verification According to CERAD Criteria (SOT 3).|Sensitivity and Specificity of the Subject Level Composite SUVR Calculated Based on Pathology Results.|Subject Level Composite SUVRs by SOT for Baseline and Available Follow-Up Scans","Piramal Imaging SA","All","21 Years and older   (Adult, Older Adult)","Phase 3","218","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","14595|2009-012569-79","November 2009","September 2011","December 2013","November 26, 2009","March 25, 2015","May 27, 2016","Sun City, Arizona, United States|Stanford, California, United States|Tampa, Florida, United States|Teaneck, New Jersey, United States|Philadelphia, Pennsylvania, United States|Dallas, Texas, United States|Houston, Texas, United States|San Antonio, Texas, United States|Heidelberg, Victoria, Australia|Lille, France|Strasbourg, France|Jülich, Nordrhein-Westfalen, Germany|Leipzig, Sachsen, Germany|Toyohashi, Aichi, Japan|Toyohashi, Aichi, Japan|Toyohashi, Aichi, Japan|Isezaki, Gunma, Japan|Hamamatsu, Shizuoka, Japan|Itabashi-ku, Tokyo, Japan","","https://ClinicalTrials.gov/show/NCT01020838"
121,"NCT03542656","Application of Amyloid PET in Cerebral Amyloid Angiopathy","CAA","Recruiting","No Results Available","Cerebral Amyloid Angiopathy|Intracranial Hemorrhages|Alzheimer Disease","Drug: amyloid PET","PET imaging","National Taiwan University Hospital","All","20 Years and older   (Adult, Older Adult)","Phase 3","160","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","201404065MIND","September 11, 2014","February 17, 2016","December 2019","May 31, 2018","null","May 31, 2018","National Taiwan Univeristy Hospital, Taipei, Taiwan","","https://ClinicalTrials.gov/show/NCT03542656"
122,"NCT03485066","Simultaneous PET/MR Imaging of Human Brain Plasticity",,"Recruiting","No Results Available","Neuronal Plasticity","Behavioral: Tetris","Training induced changes in imaging parameters|Cognitive performance","Rupert Lanzenberger|Medical University of Vienna","All","21 Years to 30 Years   (Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Basic Science","PSY-NIL-0005","May 1, 2017","November 1, 2020","November 1, 2020","April 2, 2018","null","April 5, 2018","Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria","","https://ClinicalTrials.gov/show/NCT03485066"
123,"NCT01215552","Study of the Inhibition of [11C]R-rolipram Binding to Brain Phosphodiesterase - 4 (PDE-4) by HT-0712",,"Terminated","No Results Available","Healthy Elderly Volunteers","Drug: HT-0712","PET measurement of HT-0712 inhibition of [11C]R-rolipram binding|Brain uptake of [11C]R-rolipram, as determined by PET imaging, associated with both maximal plasma concentration of HT-0712 (Tmax) and overall plasma level exposure (AUC) following administration of different dose levels of HT-0712.","Dart NeuroScience, LLC","All","55 Years to 80 Years   (Adult, Older Adult)","Phase 1","3","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","HT-0712-006|BNL IRB #444","September 2010","November 2010","January 2011","October 6, 2010","null","June 1, 2011","Brookhaven National Laboratory, Upton, New York, United States","","https://ClinicalTrials.gov/show/NCT01215552"
124,"NCT00459693","PET Evaluation of Brain Peripheral Benzodiazepine Receptors Using [11C]PBR28 in HIV-Seropositive Patients With (MCMD)",,"Terminated","No Results Available","HIV-Dementia|HIV-Associated Cognitive Motor Complex|AIDS Encephalopathy|AIDS Dementia Complex|AIDS-Related Dementia Complex|HIV Infections|Healthy","Drug: [11C]PBR28","Brain uptake of [11C]PBR28 (measured as distribution volume).","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years to 50 Years   (Adult)","Not Applicable","40","NIH","Interventional","Primary Purpose: Treatment","070129|07-M-0129","April 9, 2007","April 6, 2014","April 6, 2014","April 12, 2007","null","August 17, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00459693"
125,"NCT02995902","FLT-PET/DW-MRI for Detection of Brain Metastases and Early Therapy Evaluation in Patients With Small Cell Lung Cancer","SIBES II","Completed","No Results Available","Small Cell Lung Cancer","Device: FLT-PET|Device: MRI","Overall survival|Disease free survival","Rigshospitalet, Denmark","All","18 Years and older   (Adult, Older Adult)","Not Applicable","13","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","307_14","December 11, 2014","February 8, 2017","February 8, 2018","December 19, 2016","null","May 7, 2018","Dept. of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet, Copenhagen, Denmark","","https://ClinicalTrials.gov/show/NCT02995902"
126,"NCT02053532","Functional Brain Imaging in PTSD",,"Completed","No Results Available","Post-traumatic Stress Disorder (PTSD)|Trauma","Procedure: Positron emission tomography/magnetic resonance imaging","F-18- fluorodeoxyglucose (FDG) metabolism in the brain of healthy controls (HC) vs trauma controls (TC) vs individuals with post-traumatic stress disorder (PTSD)","New York University School of Medicine","All","18 Years to 65 Years   (Adult, Older Adult)","","50","Other","Observational","Observational Model: Case Control|Time Perspective: Cross-Sectional","S13-00313","May 2013","March 2015","February 2016","February 3, 2014","null","March 3, 2016","NYU School of Medicine, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT02053532"
127,"NCT00860483","Correlation of Laparoscopic Experience and Functional Brain Activation: A PET Scan Study",,"Completed","No Results Available","Brain Function","Other: observational","Laparoscopic experience","Northwell Health","All","25 Years to 50 Years   (Adult)","Not Applicable","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","GCRC 0201","February 2008","February 2009","November 2009","March 12, 2009","null","December 5, 2012","The Feinstein Institute for Medical Research, Manhasset, New York, United States","","https://ClinicalTrials.gov/show/NCT00860483"
128,"NCT02890940","Bridging the Gap: Using Video Art to Document the Human Face of Disease & Predict Quality of Life Assessments in Brain Tumor Patients",,"Enrolling by invitation","No Results Available","Brain Tumors|Quality of Life|Animal Assisted Therapy","Behavioral: Pet Therapy","Correlation of facial expression changes with QOL questionnaire responses|Comparison of scores of QOL questionnaires before and after pet therapy","Indiana University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Intervention Model: Single Group Assignment|Primary Purpose: Supportive Care","1604467360","August 2016","May 2018","May 2018","September 7, 2016","null","August 21, 2017","","","https://ClinicalTrials.gov/show/NCT02890940"
129,"NCT03514524","Synaptic Density, Tau and Multiparametric PET-MR in Brain Trauma, Stroke and Mild Cognitive or Behavioral Impairment.",,"Enrolling by invitation","No Results Available","Neuro-Degenerative Disease","Other: PET-MR imaging","changes in synaptic density with age or due to TBI, stroke or MCI/MBI|changes in tau-depositions with age or due to TBI, stroke or MCI/MBI|Monitoring capacities of these novel functional/structural imaging techniques|Relationship between synaptic density and tau deposition and cognitive/behavioral decline in normal ageing and in TBI, stroke and MCI/MBI.","Universitaire Ziekenhuizen Leuven","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","150","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","S60721","February 1, 2018","February 2019","September 2020","May 2, 2018","null","May 11, 2018","Division of nuclear medicine and molecular imaging, University Hospital Leuven, Leuven, Belgium","","https://ClinicalTrials.gov/show/NCT03514524"
130,"NCT03100227","(18)F-FDG PET Database of Adult Healthy Individuals","BDD-FDG","Completed","No Results Available","Healthy","Other: PET [18F] FDG|Other: Anatomical MRI","Glucose Metabolism of the whole brain estimated with [18F]-FDG PET in healthy controls.|Test-reliability","Hospices Civils de Lyon","All","20 Years to 65 Years   (Adult, Older Adult)","Not Applicable","41","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","69HCL16_0689","September 15, 2014","September 16, 2015","July 6, 2017","April 4, 2017","null","July 7, 2017","Hospices Civils de Lyon, Bron, France","","https://ClinicalTrials.gov/show/NCT03100227"
131,"NCT03409549","Multi-parametric MRI/Fluorine-18 Fluciclovine PET-CT in Glioblastoma",,"Not yet recruiting","No Results Available","Tumor, Brain","Radiation: Fluciclovine PET/CT","Measurment od tumour volumes following scans","The Leeds Teaching Hospitals NHS Trust","All","18 Years to 100 Years   (Adult, Older Adult)","","12","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","RD17/101925","January 31, 2018","June 28, 2019","June 28, 2019","January 24, 2018","null","January 24, 2018","","","https://ClinicalTrials.gov/show/NCT03409549"
132,"NCT01866189","Identification of Hypoxic Brain Tissues by F-MISO PET in Acute Ischemic Stroke","STROKE F-MISO","Withdrawn","No Results Available","Ischemic Stroke","Other: PET and MRI","volume and location of F-MISO uptake in stroke patients|comparison of F-MISO uptake areas and ischemic lesions defined by weighted diffusion and FLAIR on","University Hospital, Toulouse|Institut National de la Santé Et de la Recherche Médicale, France","All","18 Years to 85 Years   (Adult, Older Adult)","Not Applicable","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","11 252 01","September 2016","September 2016","October 2016","May 31, 2013","null","May 9, 2016","","","https://ClinicalTrials.gov/show/NCT01866189"
133,"NCT01200134","HYPONCO - Hypoxia in Brain Tumors","HYPONCO","Completed","No Results Available","Anaplastic Glioma","Other: 18F-FMISO PET-scanning","hypoxia volume (HV) and degree (maximum ratio [Rmax]) defined from 18F-FMISO uptake rates","University Hospital, Caen","All","18 Years and older   (Adult, Older Adult)","Phase 2","39","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2009-015543-16","October 2010","June 2012","July 2012","September 13, 2010","null","November 19, 2012","Caen University Hospital, Caen, France","","https://ClinicalTrials.gov/show/NCT01200134"
134,"NCT02134041","Amyloid Accumulation After Mild Traumatic Brain Injury","TBI","Unknown status","No Results Available","Traumatic Brain Injury|Dementia|Alzheimer Disease","Other: traumatic brain injury","amyloid accumulation by amyloid PET|mini-mental status examination (MMSE) for cognitive function","Taipei Medical University Shuang Ho Hospital|Chang Gung Memorial Hospital","All","18 Years and older   (Adult, Older Adult)","","150","Other","Observational","Observational Model: Case Control|Time Perspective: Retrospective","DOH101-TD-PB-111-NSC017","October 2012","August 2014","December 2014","May 8, 2014","null","May 8, 2014","Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan","","https://ClinicalTrials.gov/show/NCT02134041"
135,"NCT03482115","Brain Network Disruptions Related to Traumatic Coma","Coma3D","Recruiting","No Results Available","Traumatic Coma","Radiation: PET examination with radiopharmaceutical drug [18F] DPA-714|Diagnostic Test: MRI examination|Biological: Blood samples","Matrix of the neuroimaging data in PET examination|Glasgow Coma Scale (GCS)|Coma Recovery Scale Revised (CRS-R)|FOUR score|analysis of imaging parameters obtained in MRI","University Hospital, Toulouse","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","RC31/16/8257|2017-001986-26","March 7, 2018","November 7, 2019","February 7, 2020","March 29, 2018","null","March 29, 2018","CHU Purpan - Réanimation URM, Toulouse, France","","https://ClinicalTrials.gov/show/NCT03482115"
136,"NCT03022968","Tau Brain Imaging in Typical and Atypical Alzheimer's Disease (AD)","TEPTAU","Recruiting","No Results Available","Alzheimer Disease|Benson's Disease","Drug: [18F]T807 PET","Tau density on PET imaging|Tau distribution on PET imaging|p-tau CSF biomarkers|βamyloid CSF biomarkers|Cognitive profile with Hamilton depression scale (MADRS)|Cognitive profile with Mini mental state evaluation (MMSE)","University Hospital, Tours","All","50 Years and older   (Adult, Older Adult)","Phase 2","24","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","PHAO14-CH/TEPTAU","January 10, 2017","June 2018","September 2018","January 18, 2017","null","February 23, 2017","University Hospital of Tours, Tours, France","","https://ClinicalTrials.gov/show/NCT03022968"
137,"NCT01240161","Personalized Translational Platform for Biomarker Discovery in Brain Tumors",,"Completed","No Results Available","High Grade Glioma","Drug: FLT-PET/CT: (3'deoxy-3'-[(18)F] fluorothymidine) PET/CT","Overall Survival|Progression free Survival","Marcelo F. Di Carli, MD, FACC|Society of Nuclear Medicine and Molecular Imaging|General Electric|Brigham and Women's Hospital","All","18 Years to 85 Years   (Adult, Older Adult)","","37","Other|Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","2008P000554","December 2009","March 2016","March 2016","November 15, 2010","null","August 29, 2017","University of California at San Diego, San Diego, California, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT01240161"
138,"NCT02039024","Imaging Non-motor Symptoms of Parkinson's Disease by Novel 18F-DTBZ and Florbetapir F-18 PET",,"Completed","No Results Available","Parkinson's Disease","Drug: 18F- DTBZ","To compare the amyloid deposition of brain by florbetapir F-18 PET imaging and monoaminergic function by18F- DTBZ PET","Chang Gung Memorial Hospital|National Science Council, Taiwan","All","20 Years to 80 Years   (Adult, Older Adult)","Phase 2","18","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","100-4356A","March 2012","December 2015","December 2015","January 17, 2014","null","January 13, 2016","Chang Gung Memory Hospital, Taoyuan, Taiwan","","https://ClinicalTrials.gov/show/NCT02039024"
139,"NCT01209156","Evaluation of [18F] PBR111 and PET as a Marker of Inflammation in Subjects With Neurological Conditions","PBR111","Completed","No Results Available","Alzheimer Disease","Drug: [18F] PBR111","To evaluate the cerebral distribution of [18F]PBR-111 positron emission tomography (PET) for detection/exclusion of microglial activation in patients with Alzheimer Disease compared to healthy volunteers.|To assess the dynamic uptake and washout of [18F]PBR-111, a potential imaging biomarker for inflammatory changes in brain, using positron emission tomography (PET) in Alzheimer disease subjects compared to healthy volunteers.|To perform blood metabolite characterization of [18F]PBR-111 in AD subjects compared to Healthy volunteers to determine the nature of metabolites in assessment of [18F]PBR-111 as a single positron computed tomography (PET) brain imaging agent.","Institute for Neurodegenerative Disorders","All","18 Years and older   (Adult, Older Adult)","Phase 1","11","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","PBR111 001","March 2010","June 2013","June 2013","September 27, 2010","null","November 11, 2013","Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT01209156"
140,"NCT00264641","The Impact of Renin-angiotensin System on Brain Activation During Hypoglycaemia in Healthy Men, a PET Study",,"Completed","Has Results","Hypoglycemia|Cognitive Impairment","Drug: Human insulin","Cerebral Activation During Hypoglycaemia","Hypoglycaemia Research Group|Rigshospitalet, Denmark","Male","18 Years to 40 Years   (Adult)","Not Applicable","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","2005-2-15","January 2006","February 2008","February 2008","December 13, 2005","March 29, 2017","March 29, 2017","Medical Department I, Hillerød Hospital, Hillerød, Denmark","","https://ClinicalTrials.gov/show/NCT00264641"
141,"NCT00205582","Excitatory Amino Acids and Activated Microglia After Traumatic Brain Injury: a (R)-[11C]PK11195 PET Study",,"Unknown status","No Results Available","Traumatic Brain Injury","Device: Positron Emission Tomography","Glasgow coma scale after 6 months|microglia activation","VU University Medical Center","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2001/028","May 2001","null","December 2004","September 20, 2005","null","November 4, 2005","VU University Medical Centre, Amsterdam, Netherlands","","https://ClinicalTrials.gov/show/NCT00205582"
142,"NCT00928304","Phase II Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid.",,"Completed","Has Results","Down Syndrome|Amyloid Beta-protein","Drug: Florbetaben (BAY94-9172)","Sensitivity of the Independent Visual Assessment of Detecting Cerebral Amyloid-beta in Individuals With Down Syndrome and Specificity in Subjects Without Down Syndrome|Sensitivity Results in the Down Syndrome Age Subgroups|Quantitative Parameters Standard Uptake Value Ratio|Consistency Between Visual and Quantitative Efficacy","Piramal Imaging SA","All","21 Years and older   (Adult, Older Adult)","Phase 2","109","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","14311","June 2009","January 2011","January 2011","June 25, 2009","January 28, 2014","March 5, 2014","Sun City, Arizona, United States|New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT00928304"
143,"NCT02359513","Evaluation of the Efficacy of Serotoninergic Antidepressants in Bulimia Nervosa, According to Brain Serotonin Profile Determined by Positron Emission Tomography With [18F] MPPF.",,"Recruiting","No Results Available","Bulimia Nervosa","Drug: Antidepressants|Drug: Positron Emission Tomography (PET)","Correlation between [18F]MPPF Binding Potential (BP) and efficacy of antidepressant treatment|Correlation between [18F]MPPF Binding Potential (BP) and psychometric scores|Correlation between [18F]MPPF Binding Potential (BP) and initial severity|Change from baseline in [18F]MPPF Binding Potential (BP)","Centre Hospitalier Universitaire de Saint Etienne|Ministry of Health, France","Female","18 Years and older   (Adult, Older Adult)","Phase 4","45","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1408170|2015-000365-31","November 9, 2015","November 2018","March 2019","February 10, 2015","null","October 18, 2017","Groupement Hospitalier Est - HCL, Bron, France|CHU Grenoble, Grenoble, France|Chu Saint-Etienne, Saint-Etienne, France","","https://ClinicalTrials.gov/show/NCT02359513"
144,"NCT00598390","PET Imaging of Cannabinoid CB1 Receptors Using [11C]MePPEP",,"Completed","No Results Available","Healthy","Drug: [11C]MePPEP","Reproducibility of novel PET tracer for CB1 in brain imaging.|Distribution and variance of CB1 receptors in the brain of healthy controls.","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","19","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","080048|08-M-0048","January 8, 2008","January 22, 2013","January 22, 2013","January 21, 2008","null","July 31, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00598390"
145,"NCT01222351","Measuring Brain Amyloid Plaque Load in Older Adults Using BAY 94-9172",,"Active, not recruiting","No Results Available","Late Onset Alzheimer Disease","Drug: BAY 94-9172 (Florbetaben)","Changes in amyloid plaque load in the brain of the course of 3 years","New York State Psychiatric Institute|Bayer|National Institute on Aging (NIA)","All","65 Years and older   (Older Adult)","Not Applicable","161","Other|Industry|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","6045/7130R (Bayer)|IND 78868|R01AG037212-01","December 2010","January 2020","January 2029","October 18, 2010","null","May 21, 2018","Columbia University Medical Center, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT01222351"
146,"NCT02754375","SMTr-METAB : FDG-PET Assessment of Cerebral Metabolism in Resistant Depression Treated With rTMS","SMTr-METAB","Recruiting","No Results Available","Depression","Procedure: rTMS","Variation of the regional cerebral glucose consumption between the two PET-TDM|Comparison of local glucose use between responder and non-responder patients","Centre Hospitalier Universitaire de Nice","All","40 Years to 65 Years   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","15-PP-02","May 2016","January 2017","May 2019","April 28, 2016","null","June 1, 2016","CHU de Nice, Nice, France|Hôpital Princesse Grace, Monaco, Monaco","","https://ClinicalTrials.gov/show/NCT02754375"
147,"NCT00474513","An Imaging Study to Investigate the Distribution of GSK239512 in the Brain.",,"Completed","No Results Available","Mild Cognitive Impairment|Dementia","Drug: GSK239512","Receptor occupancy in the brain after receiving a dose of GSK239512, measured using calculations from PET images at 4 hours and 24 hours post dose|Safety of drug and concentration of GSK239512 in the blood at various timepoints. Using vital signs and ECG, clinical laboratory assessments and PK sampling.","GlaxoSmithKline","Male","35 Years to 49 Years   (Adult)","Phase 1","5","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","H3B106026","March 2007","March 2008","March 2008","May 17, 2007","null","June 4, 2012","GSK Investigational Site, Toronto, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT00474513"
148,"NCT00729092","Additional Positron Emission Tomography (PET) Scan of Brain in Patients Undergoing PET Scan for Diseases Unrelated to Brain",,"Completed","No Results Available","Pain","","Pain Assessment Pain scores using the verbal rating scale, with 0 corresponding to ""no pain"" and 10 to the ""worst imaginable pain"" will be assessed prior to the primary PET scan","Asokumar Buvanendran|Rush University Medical Center","All","18 Years to 80 Years   (Adult, Older Adult)","","100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","08042105","May 2008","November 2013","December 2013","August 7, 2008","null","April 28, 2016","Rush University Medical Center, Chicago, Illinois, United States","","https://ClinicalTrials.gov/show/NCT00729092"
149,"NCT03268369","PET Study of the Nicotinic System in Epilepsy","NICOPET","Completed","No Results Available","Epilepsy","Radiation: MRI of the brain|Radiation: PET scan [18F]F-A-85380|Radiation: PET scan [18F]FDG","Comparison of the cerebral distribution of the neuronal nicotinic acetylcholine receptors (nAChR) in the 5 groups of individuals by means of voxelwise and regional 18F-FA binding potential measurements","Fabienne PICARD|University Hospital, Geneva","Male","18 Years to 60 Years   (Adult)","Not Applicable","48","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","10-041","February 2012","November 2015","November 2015","August 31, 2017","null","August 31, 2017","","","https://ClinicalTrials.gov/show/NCT03268369"
150,"NCT01315847","Positron Emission Tomography (PET) Study of Brain Calcitonin Gene-Related Peptide (CGRP) Receptor Occupancy After Telcagepant Administration (MK-0974-067)",,"Completed","Has Results","Migraine","Drug: telcagepant|Drug: [11C]MK-4232","Number of Participants With Adverse Events (AEs) (Part I)|Number of Participants With AEs (Part III)|Brain Calcitonin Gene-related Peptide (CGRP) Receptor Occupancy (RO) Post Telcagepant Obtained by PET Imaging Using [11C]MK-4232 Tracer at Baseline and After a Maximum Dose of Telcagepant (1120 mg) in Healthy Participants (Part I, Period 1)|Average Telcagepant Plasma Concentration During PET Imaging Using [11C]MK-4232 Tracer After a Maximum Dose of Telcagepant (1120 mg) in Healthy Participants (Part I, Period 1)|Brain CGRP RO Post Telcagepant Obtained by PET Imaging Using [11C]MK-4232 Tracer at Baseline and After a Therapeutic Dose of Telcagepant (140 mg) in Healthy Participants (Part I, Period 2)|Average Telcagepant Plasma Concentration During PET Imaging Using [11C]MK-4232 Tracer After a Therapeutic Dose of Telcagepant (140 mg) in Healthy Participants (Part I, Period 2)|Brain CGRP RO Post Telcagepant Obtained by PET Imaging Using [11C]MK-4232 Tracer at Baseline and After a Therapeutic Dose of Telcagepant (140 mg) in Participants With Migraine During a Migraine Attack (Ictal Phase)(Part III, Period 1)|Brain CGRP RO Post Telcagepant Obtained by PET Imaging Using [11C]MK-4232 Tracer at Baseline and After a Therapeutic Dose of Telcagepant (140 mg) in Participants With Migraine During Period When Migraine is Absent (Interictal Phase)(Part III, Period 2)","Merck Sharp & Dohme Corp.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","10","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0974-067","January 14, 2010","July 26, 2011","July 26, 2011","March 15, 2011","October 24, 2014","June 20, 2017","","","https://ClinicalTrials.gov/show/NCT01315847"
151,"NCT03503331","UAB Alzheimer's Disease Center Core Cohort - Imaging Substudy","PiB ADC","Recruiting","No Results Available","Alzheimer Disease","Drug: [C-11]PiB-PET/MRI","Measurement of pathological beta-amyloid in the brain","University of Alabama at Birmingham","All","50 Years and older   (Adult, Older Adult)","Phase 2","160","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","IRB-300001005","April 20, 2018","April 1, 2024","April 1, 2024","April 19, 2018","null","April 24, 2018","University of Alabama at Birmingham Medical Center, Birmingham, Alabama, United States","","https://ClinicalTrials.gov/show/NCT03503331"
152,"NCT00275301","PET Imaging and Olanzapine Treatment in Borderline Personality Disorder",,"Completed","Has Results","Borderline Personality Disorder","Drug: olanzapine","Change in Brain Metabolism From Baseline to Eight Weeks as Seen in PET Scan","University of Minnesota - Clinical and Translational Science Institute|Eli Lilly and Company","Female","18 Years to 45 Years   (Adult)","Not Applicable","19","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0506M70791","December 2005","April 2008","December 2008","January 11, 2006","May 23, 2017","May 23, 2017","University of Minnesota, Dept of Psychiatry, Minneapolis, Minnesota, United States","","https://ClinicalTrials.gov/show/NCT00275301"
153,"NCT01217021","Safety and Efficacy of Positron Emission Tomography (PET) Imaging With MNI-558","MNI-558","Completed","No Results Available","Alzheimer Disease","Drug: [18F] MNI-558","To evaluate the efficacy safety of MNI-558 positron emission tomography (PET) for detection/exclusion of cerebral amyloid beta in patients with Alzheimer disease (AD) compared to healthy volunteers (HV)|To assess the dynamic uptake of MNI-558, a potential imaging biomarker for B-amyloid burden in brain, using positron emission tomography (PET) in similarly aged Alzheimer (AD) subjects and healthy volunteers (HV|To determine pharmacokinetics pattern of MNI-558 in venous plasma of healthy and AD subjects.|To determine metabolite pattern of MNI-558 in venous plasma of healthy and AD subjects.","Institute for Neurodegenerative Disorders|Molecular NeuroImaging","All","55 Years and older   (Adult, Older Adult)","Early Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","MNI-558-01","September 2010","March 2011","March 2011","October 8, 2010","null","July 25, 2011","Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT01217021"
154,"NCT03525080","Comparison of 6-fluoro-[18F]-L-dihydroxyphenylalanine (18F-DOPA) Positron Emission Tomography (PET) and Multiparametric Resonance Magnetic Imagery (RMI) in Initial Exploration of Glial Tumors","GLIROPA","Not yet recruiting","No Results Available","Brain Neoplasms|Adult Brain Tumor","Diagnostic Test: PET imagery","PET pictures and MRI sequences comparison","Center Eugene Marquis","All","18 Years and older   (Adult, Older Adult)","Not Applicable","16","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2017-4-52-010","July 1, 2018","April 30, 2019","May 31, 2019","May 15, 2018","null","May 15, 2018","Centre Eugène Marquis, Rennes, Bretagne, France","","https://ClinicalTrials.gov/show/NCT03525080"
155,"NCT00407576","PET Imaging of Brain Amyloid Using [11C]MeS-IMPY",,"Completed","No Results Available","Alzheimer's Disease|Healthy","Drug: [11C]MeS-IMPY","","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)","Phase 1","30","NIH","Interventional","Primary Purpose: Treatment","070036|07-M-0036","December 1, 2006","November 7, 2008","null","December 5, 2006","null","July 2, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00407576"
156,"NCT02317250","Molecular Cerebral Imaging in Incipient Dementia (MCI-ID) II",,"Not yet recruiting","No Results Available","Mild Cognitive Impairment","Procedure: Amyloid imaging|Procedure: FDG-PET","Rate of change from baseline in neuropsychological (cognitive,functional) test results|Utilization of healthcare resources|FDG-PET and amyloid imaging results, compared with working diagnoses made before and after time of imaging|Rates of prescription of AD-specific therapies","University of California, Los Angeles|Centers for Medicare and Medicaid Services","All","65 Years and older   (Older Adult)","Phase 3","1500","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Diagnostic","11-00815-02","June 2018","October 2022","December 2022","December 15, 2014","null","October 31, 2017","","","https://ClinicalTrials.gov/show/NCT02317250"
157,"NCT01514435","Changes in Cerebral Glucose Metabolism After Electroconvulsive Therapy (ECT)",,"Completed","No Results Available","Major Depressive Disorder","Device: Electroconvulsive therapy|Device: 18-Fluoro-desoxy-glucose positron emission tomography","Brain glucose metabolism measured by FDG-PET","Medical University of Graz","All","18 Years to 85 Years   (Adult, Older Adult)","Not Applicable","13","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BRECT-2006-PET","May 2006","May 2009","July 2011","January 23, 2012","null","January 23, 2012","Medical University Graz; Department for Psychiatry, Graz, Styria, Austria","","https://ClinicalTrials.gov/show/NCT01514435"
158,"NCT02958670","Imaging Tau Deposition in the Brain of Elderly Subjects","Add-Tau","Enrolling by invitation","No Results Available","Mild Cognitive Impairment|Healthy|Alzheimer Disease|Neurocognitive Disorders","Other: 18F-AV-1451 (Tau-PET tracer)","Volume of Interest (VOI) or Voxel based assessment of 18F-AV-1451-PET-signal","University of Zurich|Avid Radiopharmaceuticals|Swiss Federal Institute of Technology","All","50 Years and older   (Adult, Older Adult)","Not Applicable","200","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","KEK-ZH_Nr_2016-01079_V5.0","November 2016","November 2020","November 2023","November 8, 2016","null","June 21, 2017","Institute for Regenerative Medicine (IREM), Schlieren, Zurich, Switzerland","","https://ClinicalTrials.gov/show/NCT02958670"
159,"NCT00870974","A PET Brain Imaging Study of mGluR5 in Subjects With Neuropsychiatric Conditions","FPEB","Completed","No Results Available","Parkinson Disease|Huntington Disease|Autistic Spectrum Disorders|Fragile X Syndrome|Alzheimer Disease|Mild Cognitive Impairment","Drug: [18F]FPEB","Does FPEB reliably represent the known distribution of MGLUR5 in the brain?","Institute for Neurodegenerative Disorders","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 1","48","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)","FPEB","March 2009","October 2016","November 2016","March 27, 2009","null","January 6, 2017","Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT00870974"
160,"NCT03080051","Evaluation of [18F]MNI-952 as a Potential PET Radioligand for Imaging Tau Protein in the Brain",,"Completed","No Results Available","Progressive Supranuclear Palsy|Alzheimer Disease|Healthy Volunteers","Drug: [18F]MNI-952|Drug: [18F]Florbetapir","Tracer uptake will be evaluated in regions of interest for analysis of regional [18F]MNI-952 binding/uptake and expressed in SUV by using established methods for normalization for 2 PSP, 2 AD, and 2 HV subjects.","Molecular NeuroImaging","All","18 Years to 90 Years   (Adult, Older Adult)","Early Phase 1","6","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","[18F]MNI-952","August 2016","March 6, 2017","March 6, 2017","March 15, 2017","null","October 6, 2017","Molecular NeuroImaging, LLC, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT03080051"
161,"NCT01465165","Use of Multiple Brain Imaging Modalities (PET and MRS) to Identify Metabolic Abnormalities in Major Depression",,"Terminated","No Results Available","Major Depressive Disorder","","high energy phosphate metabolites (Phosphocreatine (PCr)) as measured by magnetic resonance spectroscopy|regional cerebral glucose metabolism, as measured by Positron Emission Tomography (PET)|N-Acetyl-Aspartate (NAA) metabolite intensity, as measured by proton Magnetic Resonance Spectroscopy (MRS)|severity of depressive symptoms, as scored on the Montgomery-Asberg Depression Rating Scale (MADRS)","Paul Carlson|Western Institute for Biomedical Research|University of Utah|Molecular Imaging Program, Huntsman Cancer Institute","All","18 Years to 55 Years   (Adult)","","12","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","WIBR08-PJC","May 15, 2011","June 24, 2012","June 24, 2012","November 4, 2011","null","May 19, 2017","University of Utah Dept of Psychiatry, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT01465165"
162,"NCT02512029","18F-AV-1451 PET Imaging in TBI",,"Withdrawn","No Results Available","Traumatic Brain Injury","Drug: 18F-AV-1451","TBI Biomarker Analysis|Relationship Between Clinical Presentation and Tau Deposition (MMSE)|Change in tau deposition over time|Relationship Between Clinical Presentation and Tau Deposition (BIS-11)","Avid Radiopharmaceuticals","All","18 Years to 55 Years   (Adult)","Phase 1","0","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","18F-AV-1451-A12","October 2015","April 2017","April 2017","July 30, 2015","null","February 5, 2016","NIH Clinical Center, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT02512029"
163,"NCT02813070","Comparison of PET Amyloid Imaging in Japanese and Western Subjects",,"Completed","Has Results","Mild Cognitive Impairment|Alzheimer's Disease|Healthy","Drug: [18F] Flutemetamol","Blinded Visual Assessment of Positron Emission Tomography (PET) Imaging and Clinical Diagnosis by Non-Japanese Readers|Blinded Visual Assessment of Positron Emission Tomography (PET) Imaging and Clinical Diagnosis by Japanese Readers","GE Healthcare","All","25 Years and older   (Adult, Older Adult)","Phase 2","70","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","GE067-017","October 2012","May 2013","May 2013","June 24, 2016","June 5, 2017","June 5, 2017","","","https://ClinicalTrials.gov/show/NCT02813070"
164,"NCT03463525","Open-label PET Study to Determine Brain Exposure With [11C]Osimertinib in Patients With EGFRm NSCLC and Brain Metastases","ODIN-BM","Not yet recruiting","No Results Available","Non-small Cell Lung Cancer","Drug: Osimertinib|Drug: [11C]osimertinib","Brain Exposure to [11C]osimertinib in Tumour Region of Interest|Pharmacokinetics of [11C]osimertinib|Pharmacokinetics of [11C]osimertinib Brain to Plasma Ratio of Area Under the Concentration Curve (AUC)|Pharmacokinetics of [11C]osimertinib Radioactivity by Assessment of Time to Cmax (Tmax)|Pharmacokinetics of Osimertinib and its Metabolite by Assessment of AUC Metabolite to Parent Ratio|Pharmacokinetics of Osimertinib by Assessment of Maximum Plasma Concentration (Cmax)|Pharmacokinetics of Osimertinib by Assessment of Area Under the Concentration-time Curve|Pharmacokinetics of Osimertinib by Assessment of Time to Cmax (Tmax)","AstraZeneca","All","18 Years and older   (Adult, Older Adult)","Phase 1","8","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","D5160C00043","September 19, 2018","November 25, 2019","November 25, 2019","March 13, 2018","null","March 13, 2018","Karolinska University Hospital, Stockholm, Sweden","","https://ClinicalTrials.gov/show/NCT03463525"
165,"NCT03326245","Dopaminergic Modulation of Brain Activation Using Simultaneous PET/Pharmacological MRI",,"Recruiting","No Results Available","Normal Physiology","Drug: Oral Methylphenidate|Drug: IV Methylphenidate|Other: Oral Placebo|Other: IV Placebo","To assess the distribution volume ratio (DVR)|To assess the percent BOLD signal change after MP (oral and iv)|To assess the percent DVR change after MP (oral and iv)|To assess the temporal correlation between BOLD(t) and DVR(t)|To assess the correlation between DVR(t) and behavioral measures (heart rate, BP, and respiration rate).|To assess the correlation between BOLD(t) and behavioral measures (heart rate, blood pressure, and respiration rate).","National Institute on Alcohol Abuse and Alcoholism (NIAAA)|National Institutes of Health Clinical Center (CC)","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","40","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","170178|17-AA-0178","January 29, 2018","December 31, 2020","December 31, 2020","October 31, 2017","null","July 4, 2018","National Institutes of Health Clinical Center, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT03326245"
166,"NCT00538798","PET Imaging of Brain mGluR5 Receptors Using [18F]SP203",,"Completed","No Results Available","Healthy|Glutamate Receptor|mGlur5 Protein|Excitatory Amino Acid Receptors|Drug Kinetics|PET Scan","Drug: [18F]SP203","","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","50","NIH","Interventional","Primary Purpose: Treatment","070082|07-M-0082","September 28, 2007","null","March 17, 2015","October 3, 2007","null","July 4, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00538798"
167,"NCT01153802","An Open Label Positron Emission Tomography Study in Healthy Male Subjects to Investigate Brain DAT and SERT Occupancy,Pharmacokinetics and Safety of Single Oral Doses of GSK1360707, Using 11C- PE2I and 11C-DASB as PET Ligands",,"Completed","No Results Available","Depressive Disorder","Drug: GSK1360707 is a potent re-uptake inhibitor of the neurotransmitters dopamine, norepinephrine and serotonin","To estimate the degree of DAT occupancy in brain regions of interest (ROIs)following oral doses of GSK1360707 in healthy male subjects-To estimate the degree of SERT occupancy in brain ROIs following total oral doses of GSK1360707 in healthy male subject|To evaluate the relationship between the plasma concentration and the resultant DAT occupancy by GSK1360707.To evaluate the relationship between the plasma concentration and the resultant SERT occupancy by GSK1360707.|To further assess the safety and tolerability of total oral doses of GSK1360707 including the maximal tolerated dose in the FTIH study (150 mg PO)-To further assess the pharmacokinetics of GSK1360707 in healthy male subjects","GlaxoSmithKline","Male","35 Years to 55 Years   (Adult)","Phase 1","12","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","112773","April 3, 2009","October 12, 2009","October 12, 2009","June 30, 2010","null","June 27, 2017","GSK Investigational Site, Harrow, Middlesex, United Kingdom","","https://ClinicalTrials.gov/show/NCT01153802"
168,"NCT00979810","Image-Guided Stereotactic Biopsy of High Grade Gliomas",,"Active, not recruiting","No Results Available","Brain Cancer|Glioma","Drug: 18F-FLT PET Scan","invest relation btw voxel-based determ of prolif rate & obser MR imaging featu (i.e., Ktrans or microvas permeabil; fBV, tiss fract blood vol), as well with spatially reg histolog meas of tum cell prolif (Ki67) & microvas density (CD31) at corres locat.|Attempt to corroborate voxel-based parameter estimates reflecting tumor cell proliferation with estimates derived using standard ROI-based pharmaco modeling methods, for improving the characterization of high-grade gliomas using dynamic 18F-FLT PET-CT.|Assess whether static meas of 18F-FLT uptake can ade serve as non-invasive biomarker of prolif act or whether parametric images, based on compart analys of FLT pharmas, are req by correl find of both appro with region histol assays of tum cell prolife.|Evaluate whether differ in gene expression seen between areas of increas & decreas proliferative activity on parametric maps define consistent differential transcriptome signatures for comparison with known molecular subclasses of GBM & known pathways.","Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)","All","18 Years to 89 Years   (Adult, Older Adult)","Not Applicable","15","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","09-060|R21CA137896-01A1","September 2009","September 2018","September 2018","September 18, 2009","null","September 6, 2017","Memorial Sloan-Kettering Cancer Center, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT00979810"
169,"NCT00976066","[11C]Carfentanil PET Study of GSK1521498",,"Completed","No Results Available","Obesity","Drug: Part A Assessing GSK1521498|Drug: Part B Assessing GSK1521498|Drug: Part C Assessing Naltrexone","The degree and time-course of mu-opioid receptor occupancy by GSK1521498 in brain regions of interest as measured by PET|The relationship between plasma concentration and mu-opioid receptor occupancy by GSK1521498|Adverse events and clinically relevant changes in electrocardiography (ECG); vital signs (blood pressure, heart rate); POMS, Bond and Lader VAS, laboratory safety data and physical examination|Pharmacokinetic endpoints will be: AUC(0-∞), AUC(0-t), maximum observed plasma drug concentration (Cmax), time to maximum observed plasma drug concentration (Tmax), terminal elimination half-life (t½).|The degree and time-course of mu-opioid receptor occupancy by naltrexone in brain regions of interest as measured by PET|The relationship between mu-opioid receptor occupancy by GSK1521498 and naltrexone and fMRI responses during expectation and receipt of a pleasant tasting reward (juice)","GlaxoSmithKline","Male","25 Years to 65 Years   (Adult, Older Adult)","Phase 1","26","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","111848","June 15, 2009","December 7, 2009","December 7, 2009","September 14, 2009","null","June 20, 2017","GSK Investigational Site, London, United Kingdom","","https://ClinicalTrials.gov/show/NCT00976066"
170,"NCT01141764","Cerebral Metabolic Changes Associated With Thalamic Stimulation",,"Terminated","No Results Available","Epilepsy","Procedure: Positron Emission Tomography (PET) Scan|Procedure: Magnetic Resonance Imaging (MRI)|Other: Neuropsychological Testing","Areas of the brain with low activity|Brain Abnormalities|Ability to learn and understand","The Hospital for Sick Children|University Health Network, Toronto","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 3","4","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1000014496","March 2010","February 2014","February 2014","June 10, 2010","null","November 21, 2014","The Hospital for Sick Children, Toronto, Ontario, Canada|Toronto Western Hospital, Toronto, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT01141764"
171,"NCT00263523","PET Imaging of Brain 5-HT(1A) Receptors Using [(11)C](-)-RWAY",,"Completed","No Results Available","Healthy Volunteers","Drug: [11C] (-)-RWAY","","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","15","NIH","Interventional","Primary Purpose: Treatment","060042|06-M-0042","December 5, 2005","null","August 15, 2007","December 8, 2005","null","July 2, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00263523"
172,"NCT02640092","Longitudinal Evaluation of [18F]GTP1 as a PET Radioligand for Imaging Tau in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants",,"Active, not recruiting","No Results Available","Alzheimer's Disease","Drug: [18F]GTP1","Change in Standardized Uptake Value Ratio (SUVR) as Measured by [18F]GTP1|Correlation Coefficient Between Change in SUVR (as Measured by [18F]GTP1) and Change in Clinical Outcome|Correlation Coefficient Between Change in SUVR (as Measured by [18F]GTP1) and Change in Volumetric Magnetic Resonance Imaging (MRI) Measures|Correlation Coefficient Between Change in SUVR (as Measured by [18F]GTP1) and Change in Cerebrospinal Fluid (CSF) Markers|Percentage of Participants With Adverse Events (AEs)|Test-Retest Variability Based on [18F]GTP1 PET Scans","Genentech, Inc.","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 1","72","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","GN30009|G0097","December 23, 2015","May 31, 2019","May 31, 2019","December 28, 2015","null","June 29, 2018","Molecular NeuroImaging, New Haven, Connecticut, United States|KI Health Partners, LLC; New England Institute for Clinical Research, Stamford, Connecticut, United States|Neuropsychiatric Research; Center of Southwest Florida, Fort Myers, Florida, United States|Miami Jewish Health Systems, Miami, Florida, United States|Bioclinica Research, Orlando, Florida, United States|Emory University, Atlanta, Georgia, United States|NeuroStudies.net, LLC, Decatur, Georgia, United States|Acadia Clinical Research; Dr. Henderson's Office, Bangor, Maine, United States|Donald S. Marks, M.D., P.C.; Medical Center, Plymouth, Massachusetts, United States|Alzheimers Disease Center, Quincy, Massachusetts, United States|NeuroCognitive Institute, Mount Arlington, New Jersey, United States|Bio Behavioral Health, Toms River, New Jersey, United States|Advanced Medical Research, Maumee, Ohio, United States|Lehigh Center Clinical Research, Allentown, Pennsylvania, United States|Rhode Island Mood & Memory Research Institute, East Providence, Rhode Island, United States|Butler Hospital, Providence, Rhode Island, United States","","https://ClinicalTrials.gov/show/NCT02640092"
173,"NCT02919332","Delayed 18F-FDG PET/CT in Improving Visualization of Brain Tumors in Patients With Glioblastoma",,"Recruiting","No Results Available","Glioblastoma|Glioma","Procedure: Computed Tomography|Radiation: Fludeoxyglucose F-18|Procedure: Positron Emission Tomography","Tumor-to-background ratio on delayed scans (240 min after injection)|Tumor-to-background ratio on standard scans (60 min after injection)|Standard uptake value comparison","Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years to 99 Years   (Adult, Older Adult)","","100","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","16-000600|NCI-2016-01214|16-000600 JCCCID655|P30CA016042","June 8, 2016","June 2021","June 2022","September 29, 2016","null","October 13, 2017","UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States","","https://ClinicalTrials.gov/show/NCT02919332"
174,"NCT03471182","Investigation of Cocaine Addiction Using mGluR5 PET and fMRI",,"Recruiting","No Results Available","Cocaine Dependence","Behavioral: Psychiatric and Cognitive Testing|Drug: Cocaine Self-adminstration|Radiation: Positron Emission Tomography|Other: Magnetic Resonance Imaging","Glutamate receptor (mGluR5) availability|Brain activity patterns","Yale University","All","18 Years to 55 Years   (Adult)","Phase 1","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","2000021196","February 26, 2018","June 2022","June 2022","March 20, 2018","null","March 20, 2018","Connecticut Mental Health Center, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT03471182"
175,"NCT03058965","Phase 0 Evaluation of [18F]MNI-958 as a Potential PET Radioligand for Imaging Tau Protein in the Brain",,"Recruiting","No Results Available","Alzheimer Disease|Healthy Volunteers|Progressive Supranuclear Palsy","Drug: [18F]MNI-958|Drug: [18F]Florbetapir|Drug: DaTscan","Tracer uptake will be evaluated in regions of interest for analysis of regional [18F]MNI-958 binding/uptake and expressed in SUV by using established methods for normalization for 3 AD, 3 PSP, and 3 HV subjects.","Molecular NeuroImaging","All","50 Years to 90 Years   (Adult, Older Adult)","Early Phase 1","9","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","[18F]MNI-958","November 2016","November 2018","November 2018","February 23, 2017","null","March 6, 2018","Molecular NeuroImaging, LLC, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT03058965"
176,"NCT00435695","Study Of Safety, Blood Levels, And Brain Receptor Occupancy Of GSK163090 Using PET Imaging In Healthy Males",,"Completed","No Results Available","Healthy Subjects|Depressive Disorder and Anxiety Disorders","Drug: GSK163090","Brain receptor occupancy of GSK163090 Plasma concentrations of GSK163090|Vitals signs ECGs Clinical Laboratory test results","GlaxoSmithKline","Male","18 Years to 45 Years   (Adult)","Phase 1","13","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HTP103265","November 2006","December 2007","December 2007","February 15, 2007","null","June 4, 2012","GSK Investigational Site, Toronto, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT00435695"
177,"NCT02020720","18F-DOPA-PET in Planning Surgery in Patients With Gliomas",,"Recruiting","No Results Available","Malignant Glioma|Recurrent Brain Neoplasm","Procedure: Biopsy|Procedure: Computed Tomography|Procedure: Diffusion Weighted Imaging|Drug: Fluorine F 18 Fluorodopa|Other: Laboratory Biomarker Analysis|Procedure: Perfusion Magnetic Resonance Imaging|Procedure: Positron Emission Tomography|Procedure: Therapeutic Conventional Surgery","Ratios of maximum tumor standardized uptake value (SUVmax) normalized to mean SUV (SUVmean) of T/N|Differences in volumes generated from biopsy-validated thresholds evaluated by 18F-DOPA-PET, pMRI, and DTI|Histologic grade of the specimen defined as HGG, LGG, or non-malignant brain tissue|MRI contrast enhancement values|Progression free survival|Proportion of patients whose maximum 18F-DOPA uptake samples are in agreement with the final diagnostic grade","Mayo Clinic|National Cancer Institute (NCI)","All","7 Years and older   (Child, Adult, Older Adult)","Not Applicable","90","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","MC1373|NCI-2013-02373|P30CA015083","January 2014","November 2018","November 2018","December 25, 2013","null","March 15, 2018","Mayo Clinic, Rochester, Minnesota, United States","","https://ClinicalTrials.gov/show/NCT02020720"
178,"NCT00531193","Using PET Scans to Study Brain Receptor Occupancy of BIIB014 in Healthy Male Volunteers",,"Completed","No Results Available","Healthy","Drug: BIIB014|Other: [11C]SCH442416","PET scanning with [11C]SCH442416 of the putamen, caudate, nucleus accumbens, thalamus, and cerebellum.|Concentrations of BIIB014 and its N-acetyl metabolite will be measured in blood plasma","Biogen","Male","25 Years to 55 Years   (Adult)","Phase 1","32","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","204HV101|EUDRACT 2007-001575-10","September 2007","April 2008","April 2008","September 18, 2007","null","July 30, 2008","Research Site, London, United Kingdom","","https://ClinicalTrials.gov/show/NCT00531193"
179,"NCT03041870","Relationship Between Serotonin and Brain Response to Social Dominance and Emotion Perception.","SERODOM","Recruiting","No Results Available","Healthy Volunteers","Device: PET-fMRI scan","level of Blood-Oxygen-Level Dependent (BOLD) signal|level of serotonin transporter|Behavioral assessment|Testosterone Blood level|Cortisol Blood level|SLC6A4 genotyping","Hospices Civils de Lyon","Male","18 Years to 45 Years   (Adult)","Not Applicable","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","69HCL16_0014|2016-A01588-43","November 14, 2017","June 14, 2020","June 14, 2020","February 3, 2017","null","July 26, 2018","Hospices Civils de Lyon, Bron, France","","https://ClinicalTrials.gov/show/NCT03041870"
180,"NCT01265394","Positron Emission Tomography (PET) Amyloid Imaging of the Brain in Healthy Young Adult Subjects",,"Completed","Has Results","Healthy","Drug: [18F] Flutemetamol","Number of Brain Scans in Healthy Young Adults Subjects Which do Not Show Amyloid|Measurement of Amyloid Content in Different Parts of the Brain","GE Healthcare|i3 Statprobe|Medpace, Inc.","All","18 Years to 40 Years   (Adult)","Phase 3","218","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","GE-067-015","December 2010","March 2011","April 2011","December 23, 2010","June 21, 2013","July 2, 2013","GE Healthcare, Princeton, New Jersey, United States","","https://ClinicalTrials.gov/show/NCT01265394"
181,"NCT02409784","PET Study of Cerebral Metabolism of 11C-acetoacetate and 18F-FDG in Patients Under Moderate Ketosis",,"Completed","Has Results","Healthy","Dietary Supplement: Ketogenic diet","Mean in Cerebral Metabolic Rate of Acetoacetate Before or After 4 Days of Ketogenic Diet|Mean in Cerebral Metabolic Rate of Glucose Before or After 4 Days of Ketogenic Diet","Université de Sherbrooke","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","10","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","13-214","March 2014","January 2015","January 2015","April 7, 2015","April 6, 2018","April 6, 2018","","","https://ClinicalTrials.gov/show/NCT02409784"
182,"NCT01528241","Characterize the Regional Distribution of [11C] ABP688 in Brain by Positron Emission Tomography (PET)",,"Completed","No Results Available","Depression","Drug: ABP688","Binding of [11C] ABP688 to mGlu5 receptors|Blood levels of [11C] ABP688|Difference in [11C]ABP688 binding to mGlu5 receptors","Novartis Pharmaceuticals|Novartis","All","55 Years to 80 Years   (Adult, Older Adult)","Phase 1","42","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)","CABP688A2102","August 2008","May 2010","May 2010","February 7, 2012","null","February 7, 2012","Novartis Investigative Site, New York, New York, United States|Novartis Investigative Site, Pittsburgh, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT01528241"
183,"NCT00937846","Brain Uptake of GSK1034702: a Positron Emission Tomography (PET) Scan Study",,"Completed","No Results Available","Cognitive Disorders","Drug: GSK1034702","Volume of distribution of [11C]GSK1034702 at tracer and pharmacological doses.|The kinetic rate constants at tracer and pharmacological doses.|GSK1034702 PK parameters: Cmax; tmax; AUC(0-t).|Safety and tolerability endpoints consisting of: AEs; 12-lead ECG; 12 lead digital Holter and lead II telemetry; vital signs; clinical laboratory evaluations.","GlaxoSmithKline","Male","35 Years to 55 Years   (Adult)","Phase 1","4","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","110771","July 15, 2009","August 28, 2009","August 28, 2009","July 13, 2009","null","June 27, 2017","GSK Investigational Site, London, United Kingdom|GSK Investigational Site, London, United Kingdom","","https://ClinicalTrials.gov/show/NCT00937846"
184,"NCT01668147","Efavirenz and Ritonavir on Human Brain P-Glycoprotein",,"Completed","No Results Available","Drug Effects","Drug: [11C] desmethyl-loperamide","cerebral [11C]dLop distribution volume","Washington University School of Medicine","All","18 Years to 40 Years   (Adult)","Not Applicable","13","Other","Interventional","Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Other","201205135","August 2012","June 2016","August 2016","August 17, 2012","null","June 25, 2018","Washington University School of Medicine, Saint Louis, Missouri, United States","","https://ClinicalTrials.gov/show/NCT01668147"
185,"NCT00283920","PET Imaging of Brain Peripheral Benzodiazepine Receptors",,"Completed","No Results Available","Healthy Volunteer","Drug: [(11)C] PBR28","","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","25","NIH","Interventional","Primary Purpose: Treatment","060073|06-M-0073","January 26, 2006","null","October 2, 2007","January 30, 2006","null","July 2, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00283920"
186,"NCT00001363","PET Scan to Map the Areas of the Brain Involved in Planning",,"Completed","No Results Available","Cognition Disorders","","","National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult","","230","NIH","Observational","","930077|93-N-0077","January 1993","null","March 2001","December 10, 2002","null","March 4, 2008","National Institute of Neurological Disorders and Stroke (NINDS), Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00001363"
187,"NCT02637076","Xyrem and Brain Dopamine in Narcolepsy",,"Recruiting","No Results Available","Narcolepsy With Cataplexy","Drug: Xyrem","Change in PET 11C-raclopride binding from baseline to 7 hours post Xyrem|Blood gamma-hydroxybutyrate (GHB) concentration","Centre for Addiction and Mental Health","All","19 Years and older   (Adult, Older Adult)","Phase 4","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","017-2014","January 2016","October 2018","December 2018","December 22, 2015","null","November 21, 2017","Centre for Addiction and Mental Health (CAMH), Toronto, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT02637076"
188,"NCT00950430","Imaging of Brain Amyloid Plaques in the Aging Population",,"Enrolling by invitation","No Results Available","Alzheimer's Disease|Dementia With Lewy Bodies|Frontotemporal Dementia|Vascular Dementia","Drug: Pittsburgh Compound B (C-11 PiB)|Drug: F-18 FDG|Drug: Tau (18-F-AV-1451)","To understand the predictive ability of PiB PET imaging for neurodegenerative diseases.|Using PiB-PET, to ascertain cross-sectionally the magnitude and the spatial distribution of amyloid deposition in the brain in subjects who are clinically classified as CN, MCI, and demented.|To identify the relationship between amyloid burden and the risk of progression from CN at baseline to MCI.|To identify the relationship between amyloid burden and the risk of progression from MCI at baseline to dementia.|To measure longitudinal change in amyloid burden and cognition and characterize the correlation between change on serial PiB-PET measures vs. FDG measures and concurrent change on continuous measures of cognitive performance.","Mayo Clinic|National Institute on Aging (NIA)","All","30 Years to 100 Years   (Adult, Older Adult)","Phase 4","2500","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","08-005553|U01AG006786|R01AG011378","April 2008","April 2023","April 2023","July 31, 2009","null","August 14, 2018","Mayo Clinic, Rochester, Minnesota, United States","","https://ClinicalTrials.gov/show/NCT00950430"
189,"NCT01619709","Amyloid Imaging and Cognitive Impairment After Intracerebral Hemorrhage","COGHIC-AV45","Recruiting","No Results Available","Intracerebral Hemorrhage","Other: Pet AV-45","Pet-AV45 cortical binding|cerebral microbleeds number and distribution on T2EG MRI sequence|White Matter Lesions Volume on 3D-FLAIR MRI sequence|Cortical thickness and hippocampal volume on 3D-T1 MRI sequence|Neuropsychological performances","University Hospital, Toulouse|Avid Radiopharmaceuticals|Institut National de la Santé Et de la Recherche Médicale, France","All","40 Years to 90 Years   (Adult, Older Adult)","Not Applicable","70","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","11 223 02|AOL 2011","January 2012","June 2017","June 2017","June 14, 2012","null","February 23, 2017","Service de neurologie, Toulouse, France","","https://ClinicalTrials.gov/show/NCT01619709"
190,"NCT00432900","Brain Peripheral Benzodiazepine Receptors in Patients With Multiple Sclerosis",,"Completed","No Results Available","Multiple Sclerosis","Radiation: [(11)C]PBR28","Correspondence between increased PBR expression measured by [11C]PBR28 PET and gadolinium-enhancing lesions on MRI.|Correspondence between increased PBR expression and previously and/or persistently gadolinium-enhancing lesions on MRI.|Correspondence between PBR expression and other MRI defined pathology including T2-weighted hyperintense and T1-weighted hypointense lesions.|Correspondence between PBR expression and normal appearing white and gray matter on MRI.","National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","21","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","070092|07-N-0092","February 5, 2007","May 23, 2013","May 29, 2013","February 8, 2007","null","August 23, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00432900"
191,"NCT02367469","Tryptophan Metabolism in Human Brain Tumors",,"Recruiting","No Results Available","Brain Tumors","","In newly diagnosed tumors|In previously treated tumors|Tryptophan metabolism","Wayne State University|National Cancer Institute (NCI)","All","13 Years and older   (Child, Adult, Older Adult)","","105","Other|NIH","Observational","Observational Model: Case-Control|Time Perspective: Prospective","NCI Tryptophan|CA123451","February 2014","January 2019","December 2019","February 20, 2015","null","December 5, 2017","Wayne State University, Detroit, Michigan, United States","","https://ClinicalTrials.gov/show/NCT02367469"
192,"NCT02649985","Microglial Activation Positron Emission Tomography (PET) Brain Imaging in Multiple Sclerosis and Alzheimer's Disease",,"Recruiting","No Results Available","Multiple Sclerosis|Alzheimer's Disease","Drug: [F-18]PBR06","Tissue Volume of Distribution","Brigham and Women's Hospital","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2015P002329","January 2016","June 30, 2019","June 30, 2019","January 8, 2016","null","May 22, 2018","Partners MS Center, 60 Fenwood Road, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT02649985"
193,"NCT03520634","PD-L1 PET Imaging in Melanoma Patients",,"Recruiting","No Results Available","Melanoma","Other: PD-L1 PET imaging","Determine the optimal dose of tracer and timing of imaging for [18F]PD-L1 tracer imaging of inoperable melanoma.|Assess the association of PD-L1 expression as measured by PD-L1 tracer uptake on PET and PD-L1 expression as measured by immunohistochemical (IHC) staining for PD-L1 of corresponding tumor lesions.|Characterize between-subject and within-subject variability in accumulation of the [18F]PD-L1 tracer in melanoma metastases.|Correlate response to anti-PD1 treatment with differences in tumor PD-L1 and PD1 expression between baseline and after 6 weeks of treatment, as quantified by PET and IHC analysis.","University Medical Center Groningen","All","18 Years and older   (Adult, Older Adult)","Not Applicable","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","31052016","May 22, 2017","October 2018","October 2018","May 10, 2018","null","May 10, 2018","University Medical Center Groningen, Groningen, Netherlands","","https://ClinicalTrials.gov/show/NCT03520634"
194,"NCT03402425","The Diagnostic Value of 18F-FET PET/MRI for CNS Tumors in Children and Adolescents","BUF","Recruiting","No Results Available","Positron-Emission Tomography|Brain Neoplasms, Childhood","Diagnostic Test: 18F-FET PET","Change of treatment|Sensitivity and specificity|Recurrence free survival time","Rigshospitalet, Denmark|Børnecancerfonden","All","Child, Adult, Older Adult","Not Applicable","100","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","327-15","February 24, 2015","December 31, 2020","December 31, 2020","January 18, 2018","null","January 18, 2018","Copenhagen University Hospital Rigshospitalet, Copenhagen, Copenhagen O, Denmark","","https://ClinicalTrials.gov/show/NCT03402425"
195,"NCT03419312","PET Patterns, Biomarkers and Outcome in Burst SCS Treated FBSS Patients","PET-SCS","Recruiting","No Results Available","FBSS|Pain, Intractable|Low Back Pain|Radicular; Neuropathic, Lumbar, Lumbosacral","Device: Proclaim™ Elite 5: Burst - Washout - Sham|Device: Proclaim™ Elite 5: Sham - Washout - Burst","Change in regional cerebral blood flow measured with 15O-water Positron Emission. Tomography (PET)|Semiquantitative assessment of protein levels associated with inflammation.|Back and leg pain|General pain|Pain inference|Disability|Pain Catastrophizing|Pain Vigilance and Awareness|Global Impression of Change|Depression|Anxiety","Uppsala University|Linkoeping University|Boston Children’s Hospital","All","18 Years to 59 Years   (Adult)","Not Applicable","12","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","IRB 2017/110/1","February 11, 2018","June 2019","June 2019","February 1, 2018","null","March 15, 2018","Uppsala University Hospital, Uppsala University, Dept. of Surgical Sciences and Dept. of Medicinal Chemistry, Div. of Molecular Imaging., Uppsala, Sweden","","https://ClinicalTrials.gov/show/NCT03419312"
196,"NCT02983318","Molecular Imaging of Brain Inflammation in Depressive Disorders","DiME","Recruiting","No Results Available","Depressive Disorder, Major|Positron-Emission Tomography","","inflammation-related excitotoxicity in the brain","Lawson Health Research Institute","All","19 Years to 105 Years   (Adult, Older Adult)","","24","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","100128","August 28, 2017","December 20, 2018","December 31, 2019","December 6, 2016","null","June 29, 2018","St Joseph's Hospital, London, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT02983318"
197,"NCT00832598","[18F] FACBC and [18F] FLT PET Imaging in Central Nervous System Tumors",,"Completed","Has Results","Brain Cancer|Gliomas","Radiation: [18F]FACBC PET and [18F]FLT PET imaging","Determine & Comp Biodistribution, Clearance, & Dosimetry of [18F]FACBC & [18F]FLT Tissue/Organs w/i the Field of View of the Dynamic PET Imag Studies prior-to & During Anti-AKT &/or Anti-VEGF Directed Therapies Alone or in Combin With Radia for Glioma.|Compare [18F]FACBC PET & [18F]FLT PET Results With MRI Imaging in Patients With Recurrent Gliomas (n=30).|Explore if [18F]FACBC PET and [18F]FLT PET Imaging Can be Related to Molecular Markers (AKT, VEGFR, and Related Signaling/Biologic Changes by Immunohistochemistry and/or Analysis of Flash Frozen Tissue)","Memorial Sloan Kettering Cancer Center|Columbia University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","13","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","08-142","January 2009","March 21, 2017","March 21, 2017","January 30, 2009","April 27, 2018","April 27, 2018","Memorial Sloan-Kettering Cancer Center, New York, New York, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/98/NCT00832598/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT00832598"
198,"NCT01420952","Imaging of Brain Receptors Using (11C)mGlu1",,"Terminated","No Results Available","Dosimetry|Pharmacokinetics","Drug: [11C]LY2428703","","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years to 50 Years   (Adult)","Phase 1","3","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","110229|11-M-0229","July 29, 2011","November 27, 2012","November 27, 2012","August 22, 2011","null","August 23, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT01420952"
199,"NCT01613703","ONO-2952 Single-dose PET Study in Healthy Adult Subjects",,"Completed","No Results Available","Healthy Adult Subjects","Drug: ONO-2952","To evaluate the brain TSPO occupancy of ONO-2952 in healthy adult subjects after a single dose using [11C]PBR28 as a specific PET ligand for TSPO|To evaluate the relationship between TSPO occupancy and the plasma concentration of ONO-2952|To investigate the safety and tolerability of ONO-2952 in healthy adult subjects","Ono Pharma USA Inc|Ono Pharmaceutical Co. Ltd","All","18 Years to 55 Years   (Adult)","Phase 1","16","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ONO-2952POU003","August 2012","March 2013","null","June 7, 2012","null","June 3, 2013","Pittsburgh Clinical Site, Pittsburgh, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT01613703"
200,"NCT00937261","Contrasting the Brain Effects of Risperidone and Invega With Functional Magnetic Resonance Imaging (fMRI) and Positron Emission Tomography (PET) Scanning",,"Unknown status","No Results Available","Schizophrenia","Drug: Risperidone|Drug: Paliperidone","Comparison of BOLD signal activation and FDG metabolism of the DLPFC, superior temporal gyrus and amygdala, and their interaction between Invega and Risperdal","University of California, Irvine|Janssen, LP","All","18 Years to 60 Years   (Adult)","Phase 4","96","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","BIRN 2008-6382","July 2009","July 2010","January 2011","July 10, 2009","null","October 28, 2010","UC Irvine, Irvine, California, United States","","https://ClinicalTrials.gov/show/NCT00937261"
201,"NCT02379338","Study of Radiotracer [18F]Fluortriopride ([18F]FTP) by PET/CT",,"Active, not recruiting","No Results Available","Healthy","Drug: [18F]Fluortriopride","Assessing the biodistribution of the radioactive investigational drug ([18F]fluortriopride) and calculation of human dosimetry in healthy volunteers are completed with MRI results from Dynamic Brain cohort, PET/CT results and laboratory results.|The feasibility of imaging the brain with the dopamine D3 receptor imaging agent [18F]fluortriopride is reviewed on the PET/CT scan results.|Safety of the radioactive investigational drug ([18F]fluortriopride) as measured by the number of participants with adverse events and significant changes in laboratory and/or PET/CT results.","University of Pennsylvania","All","18 Years and older   (Adult, Older Adult)","Phase 1","29","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","820959","January 2015","July 2019","July 2019","March 4, 2015","null","December 21, 2017","Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT02379338"
202,"NCT02933372","Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease - Proj#3","UdallP3","Enrolling by invitation","No Results Available","Parkinson's Disease","Drug: Varenicline|Radiation: PET Scan|Other: Evaluation by Investigator","Brain Varenicline Measurements with PET Scans (1st Experiment)|Assessing Varenicline Effects on Gait (2nd Experiment)|Assessing Varenicline Effects of Balance (2nd Experiment)|Assessing Varenicline Effects on Attention (2nd Experiment)","University of Michigan","All","45 Years and older   (Adult, Older Adult)","Phase 2","45","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","HUM00093188","February 2015","January 2020","April 2020","October 14, 2016","null","August 23, 2017","","","https://ClinicalTrials.gov/show/NCT02933372"
203,"NCT02584400","Tumor Hypoxia With HX4 PET in Several Diseases","HX4 SD","Recruiting","No Results Available","Prostatic Neoplasms|Esophageal Neoplasms|Neoplasm Metastases, Brain|Rectal Neoplasms|Brain Neoplasm, Primary","Drug: Injection with the hypoxia tracer [18F]HX4,","Visualization of tumor hypoxia with [18F] HX4 PET imaging, valuated by the measurement of a tumor-to-background (T/B) ratio on the [18F]HX4 PET/CT|Quantification of tumor hypoxia with [18F] HX4 PET imaging, evaluated by the measurement of a tumor-to-background (T/B) ratio on the [18F]HX4 PET/CT|Time between [18F] HX4 uptake with local and locoregional tumor recurrence and survival|Correlation of hypoxia imaging with blood hypoxia markers will be measured by the Pearson or Spearman correlation coefficient|Correlation of hypoxia imaging with tumor tissue biomarkers will be measured by the Pearson or Spearman correlation coefficient|Evaluation of tumor hypoxia changes during treatment by comparison of the PET uptake values in the tumor, measured before and during treatment|Spatial correlation of [18F] HX4-PET with imaging pre-treatment using a correlation coefficient|Spatial correlation of [18F] HX4-PET with imaging three months after treatment using a correlation coefficient","Maastricht Radiation Oncology","All","18 Years and older   (Adult, Older Adult)","Phase 2","120","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","NL50833.068","May 2016","December 2019","June 2020","October 22, 2015","null","May 24, 2016","MAASTRO Clinic, Maastricht, Limburg, Netherlands","","https://ClinicalTrials.gov/show/NCT02584400"
204,"NCT01136213","Investigation of the Serotoninergic System in Multiple System Atrophy: a Positron Emission Tomography (PET) Study","SEROTAMS","Completed","No Results Available","Multiple System Atrophy","Radiation: PET (Positron Emission Tomography) Study|Other: Brain MRI (magnetic resonance imaging)|Drug: Fluoxétine / Placebo","18F-MPPF binding potential - Biding potential (BP) under placebo in the raphe nucleus|18F-MPPF binding potential - Biding potential (BP) in other brain areas|Clinical parameters (motor handicap, orthostatic hypotension, quality of life, sleep, pain, tiredness)|18F-MPPF binding potential - Biding potential (BP) under placebo in other brain areas|18F-MPPF binding potential - BP under fluoxetine in all brain areas","University Hospital, Bordeaux","All","30 Years to 80 Years   (Adult, Older Adult)","","53","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","CHUBX 2008/01","April 2010","March 2016","March 2016","June 3, 2010","null","August 4, 2017","CHU de Bordeaux, Bordeaux, France|CHU Limoges, Limoges, France|CHU de Toulouse, Toulouse, France","","https://ClinicalTrials.gov/show/NCT01136213"
205,"NCT00468806","Study of Safety, Blood Levels and Brain Receptor Occupancy of GSK598809 Using PET Imaging in Health Males.",,"Completed","No Results Available","Healthy Subjects","Drug: GSK598809, using [11C]-(+)-PHNO","%D3 RO at Tmax|Percentage occupancy at Tmax|Ttrough|time course of GSK598809 plasma concentration following a single oral dose of GSK598809|Prolactin/TSH levels|Akathisia|EPQ, BIS-BAS:|POMS, CRT:|VAS:|LSEQ|neuroendocrine and behavioural measures following GSK598809 administration.","GlaxoSmithKline","Male","25 Years to 55 Years   (Adult)","Phase 1","25","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DAN106589","April 2007","May 2008","May 2008","May 3, 2007","null","October 28, 2010","GSK Investigational Site, Toronto, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT00468806"
206,"NCT02855021","Prediction of Dementia in Parkinson's Disease by Measuring Cerebral Metabolism With PET Scan","PREDEMPARK","Not yet recruiting","No Results Available","Parkinson Disease","Other: Explorations","Onset of dementia authenticated by a neuropsychological assessment (MDS Task Force criteria)|Regional cerebral glucose consumption in the parietal lobes studied with fluorodeoxyglucose (FDG) Positron Emission Tomography (PET) and regional glucose consumption in the caudate nucleus and prefrontal areas studied with FDG PET|Determination of cerebral blood flow (CBF) by arterial spin labelling (ASL) perfusion 3Tesla (3T) Magnetic Resonance Imaging (MRI)|Identifying different striatal functional connectivity patterns by resting state functional MRI at 3T|Cerebral cortex trophicity by VBM technique (Voxel-based morphometry)|Number of hyperintensities in the FLAIR MR image|Concentration of iron in the mesencephalon measured with MRI|Degree of anosmia measured with the University of Pennsylvania Smell Identification Test (UPSIT)|Correlation between initial clinical, neuropsychological and biological parameters and risk of onset of dementia","Assistance Publique - Hôpitaux de Paris","All","45 Years to 75 Years   (Adult, Older Adult)","Not Applicable","138","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","P140306","September 2016","September 2019","September 2019","August 4, 2016","null","August 4, 2016","Henri Mondor Hospital, Creteil, France","","https://ClinicalTrials.gov/show/NCT02855021"
207,"NCT00814346","Effect of EGb761® on Brain Glucose Metabolism in Three Groups of Elderly Defined by Cognitive Functions",,"Completed","Has Results","Alzheimer's Disease|Cognitive Impairment","Drug: EGb761®|Drug: Placebo","Change in Brain Glucose Metabolism Measured Using 18-Fluorodeoxyglucose Positron Emission Tomography (18FDG-PET)|Change in Brain Glucose Metabolism in the MC and CNE Groups|Change in Cognitive Tests-Clinical Dementia Rating (CDR) Score in MC and CNE Groups|Change in Cognitive Tests-Geriatric Depression Scale (GDS) Score in MC and CNE Groups|Change in Cognitive Tests-Verbal Fluency in MC and CNE Groups|Change in Cognitive Tests-Mini Mental Status Examination (MMSE) Score in MC and CNE Groups|Change in Cognitive Tests-Clock Drawing Test Score in MC and CNE Groups|Change in Cognitive Tests-Cube Drawing Test Score in MC and CNE Groups|Change in Cognitive Tests in MC and CNE Groups - Total Immediate Recall and Delayed Recall Scores of the Free and Cued Selective Reminding Test (FCSRT)|Change in Cognitive Tests-Age-Adjusted Logical Memory (MEM III) in MC and CNE Groups|Change in Cognitive Tests-Age-Adjusted Wechsler Adult Intelligence Scale (WAIS) in MC and CNE Groups|Change in Cognitive Tests-Time to Perform Trail Making Test (TMT) in MC and CNE Groups|Number of Subjects Conversion to Alzheimer's Dementia Diagnosed According to the DSM IV (Diagnostic of Dementia)|Number of Subjects Conversion to Alzheimer's Dementia Diagnosed According to NINCDS-ADRDA (Diagnostic of Alzheimer's)|Change in Cognitive Tests-CDR Score in MC and CNE Groups|Change in Cognitive Tests-GDS Score in MC and CNE Groups|Change in Cognitive Tests-MMSE Score in MC and CNE Groups|Change in Cognitive Tests in MC and CNE Groups - Total Immediate Recall and Delayed Recall Scores of FCSRT|Change in Cognitive Tests-Age-Adjusted WAIS in MC and CNE Groups|Change in Cognitive Tests-Time to Perform TMT in MC and CNE Groups|Incidence of Adverse Events (AEs)|Change in Brain Morphology in the MC and CNE Groups as Determined by the Change in Voxel Size","Ipsen","All","65 Years and older   (Older Adult)","Phase 2","49","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","2-39-00240-134|2007-005377-63","October 2008","July 2012","July 2012","December 24, 2008","March 28, 2016","March 28, 2016","Hôpital Corentin Celton 4 parvis Corentin Celton, Issy-Les-Moulineaux, France|Hôpital de Juvisy, Juvisy sur Orge, France|CMPI ""Les Rives de Seine"", Le Vesinet, France|Centre Hospitalier d'Orsay 4 place du Général Leclerc, Orsay, France|Private practice, Paris, France|Hôpital Broca 54-56 rue Pascal, Paris, France|Observatoire de l'âge, Paris, France|Hôpital Paul Brousse 12 av Paul-Vaillant-Couturier, Villejuif, France","","https://ClinicalTrials.gov/show/NCT00814346"
208,"NCT01462708","Evaluation of [18F]MK-9470 as a Brain Tracer of Cannabinoid-1 Receptor in Parkinson's Disease and Healthy Subjects","MK9470","Completed","No Results Available","Parkinson Disease","Drug: [18F]MK-9470","Dynamic uptake and washout of [18F]MK-9470|To acquire safety data","Institute for Neurodegenerative Disorders","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 1","16","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","CB1-01","May 2011","May 2013","May 2013","October 31, 2011","null","November 11, 2013","Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT01462708"
209,"NCT00598286","PET Imaging of Cannabinoid CB1 Receptors Using [18F]FMPEP-d2",,"Completed","No Results Available","CB1|Cannabinoid|PET|Brain Imaging","Drug: [18F]FMPEP-d2","Efficacy of novel PET tracer for CB1 in brain imaging.|Distribution and variance of CB1 receptors in the brain of healthy controls.","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","18","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","080049|08-M-0049","January 2008","October 2009","October 2009","January 21, 2008","null","October 27, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00598286"
210,"NCT02169973","A Study to Investigate the Regional Brain Kinetics of the Positron Emission Tomography Ligand 11C-MK-3168 and the Blocking of the Retention of the Ligand in the Human Brain by JNJ-42165279",,"Completed","No Results Available","Healthy","Drug: JNJ-42165279|Drug: 11C-MK-3168","Part A: Compartmental Model of the Volume of Distribution of 11C-MK-3168 in Brain by Positron Emission Tomography (PET)|Part B: Dose Dependent Occupancy of Fatty Acid Amide Hydrolase (FAAH) After Single Dose of JNJ-42165279|Part C: Dose and Time Dependent Occupancy of FAAH After Repeat Dose of JNJ-42165279|Correlation Between Fatty Acid Amide Hydrolase (FAAH) Occupancy in Brain With Peripheral FAAH inhibition|Effect of FAAH C385A polymorphism on the distribution volume of 11C-MK-3168 in human brain|Number of participants with adverse events","Janssen Research & Development, LLC","Male","18 Years to 55 Years   (Adult)","Phase 1","15","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CR103601|42165279EDI1003|2013-004199-37","February 2014","July 2014","July 2014","June 23, 2014","null","September 28, 2015","Leuven, Belgium","","https://ClinicalTrials.gov/show/NCT02169973"
211,"NCT02103894","Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects",,"Completed","No Results Available","Alzheimer's Disease (AD)|Parkinson's Disease (PD)|Chronic Traumatic Encephalopathy (CTE)|Progressive Supranuclear Palsy (PSP)|Frontal Temporal Dementia (FTD)|Pick's Disease|Tauopathies","Drug: [18F]T807 ([18F]MNI-777)","Brain uptake of [18F]T807 ([18F]MNI-777)","Molecular NeuroImaging|Institute for Neurodegenerative Disorders","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 1","16","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)","MNI-777","February 2014","August 2016","September 2016","April 4, 2014","null","December 16, 2016","Molecular NeuroImaging, LLC, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT02103894"
212,"NCT02367482","Tryptophan Metabolism in Human Brain Tumors",,"Recruiting","No Results Available","Glioblastoma","","Interval Changes of Tumoral Metabolism|Interval changes of tumoral tryptophan metabolism","Wayne State University|NovoCure Ltd.","All","22 Years and older   (Adult, Older Adult)","","10","Other|Industry","Observational","Observational Model: Case-Control|Time Perspective: Prospective","Novocure rGBM AMT-PET","July 2014","December 2018","December 2018","February 20, 2015","null","December 21, 2017","Wayne State University, Detroit, Michigan, United States","","https://ClinicalTrials.gov/show/NCT02367482"
213,"NCT01602900","Healthy Volunteer Positron Emission Tomography (PET) Brain Occupancy Study of a Phosphodiesterase 4 (PDE4) Inhibitor in Huntington's Disease",,"Completed","No Results Available","Huntington Disease","Drug: GSK356278|Drug: Rolipram","Positron Gamma-ray emmision & voxel counts|systemic plasma concentration|Blood pressure - mm/Hg|ECG - 12-Lead & Telemetry|Heart rate - bpm","GlaxoSmithKline","Male","22 Years to 55 Years   (Adult)","Phase 1","8","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","116038","November 22, 2011","April 12, 2012","April 12, 2012","May 21, 2012","null","June 20, 2017","GSK Investigational Site, London, United Kingdom|GSK Investigational Site, London, United Kingdom","","https://ClinicalTrials.gov/show/NCT01602900"
214,"NCT02038348","Interest of the 18F-DOPA-PET Imaging in Metastatic Melanoma Treated With B-RAF Inhibitors: a Pilot Study",,"Unknown status","No Results Available","Metastatic Melanoma","Device: PET with 18F-FDOPA","brain metastases metabolic profile obtained with PET 18F-FDOPA","Assistance Publique Hopitaux De Marseille","All","18 Years and older   (Adult, Older Adult)","Phase 2","5","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","2013-003294-10|2013-35","January 2014","January 2016","June 2016","January 16, 2014","null","October 23, 2015","Assistance Publique Hopitaux de Marseille, Marseille, France","","https://ClinicalTrials.gov/show/NCT02038348"
215,"NCT01398865","Escitalopram Neuroimaging Supplement",,"Completed","No Results Available","Body Dysmorphic Disorder","Procedure: PET scan and MRI scan","BDD-YBOCS|PET FDG and MRI studies","Massachusetts General Hospital","All","18 Years to 64 Years   (Adult)","","23","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","2008P002032","December 2008","March 2013","March 2013","July 21, 2011","null","March 13, 2015","OCD & Related Disorders Clinic, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT01398865"
216,"NCT00929422","Positron Emission Tomography (PET) in Evaluating Cerebral Glucose Metabolism and Functional Change for Patients With Spinal Cord Injury",,"Unknown status","No Results Available","Spinal Cord Injury","","","National Taiwan University Hospital","Male","18 Years to 80 Years   (Adult, Older Adult)","","160","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","200612018R|NSC 96-2314-B-002-085-MY3","August 2007","August 2011","December 2011","June 29, 2009","null","December 1, 2010","National Taiwan University Hospital, Taipei, Taiwan, Taiwan","","https://ClinicalTrials.gov/show/NCT00929422"
217,"NCT02815917","Evaluation of D3 Receptor Occupancy Using FLUORTRIOPRIDE ([18F]FTP) PET/CT",,"Recruiting","No Results Available","D3 Dopamine Receptor|Cocaine-dependent|Healthy Volunteer","Drug: [18F]FTP PET/CT","Assess the difference in uptake [18F]fluortriopride in D3-rich regions in the brain after injection of lorazepam versus placebo in healthy volunteers|Measure test-retest variability of [18F]fluortriopride uptake measures in healthy volunteer subjects and cocaine-dependent subjects|Evaluate uptake of [18F]fluortriopride in D3-rich areas of the brain in cocaine-dependent volunteers and compare to uptake in healthy volunteer subjects|Correlate standard measures of cocaine craving and withdrawal to [18F]FTP uptake in cocaine-dependent subjects","University of Pennsylvania","All","18 Years to 60 Years   (Adult)","Phase 1|Phase 2","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Diagnostic","824853","June 2016","June 2019","June 2019","June 28, 2016","null","December 8, 2017","University of Pennsylvania, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT02815917"
218,"NCT02708485","Effect of Walking on Brain Fuel Consumption in Mild Alzheimer's Disease","MAL","Unknown status","No Results Available","Alzheimer's Disease","Other: Physical exercise","Brain glucose consumption|Brain acetoacetate consumption","Université de Sherbrooke","All","40 Years and older   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","09-043","April 2009","April 2017","April 2018","March 15, 2016","null","March 28, 2017","Research Centre on Aging (CSSS-IUGS - CIUSSS de l'Estrie - CHUS), Sherbrooke, Quebec, Canada","","https://ClinicalTrials.gov/show/NCT02708485"
219,"NCT02272985","Cerebral Blood Flow During Hemodialysis",,"Completed","No Results Available","Haemodialysis-induced Symptom","Other: [15O]H2O PET-CT scan|Other: NIRS (Invos)","Change in CBF from baseline (before start of the hemodialysis study session), at 20 minutes, and at the end of the hemodialysis study session, measured by [15O]H2OPET-CT|Change in rSO2 from baseline (before start of the hemodialysis study session), at 20 minutes, and at the end of the hemodialysis study session, measured by NIRS","University Medical Center Groningen|Martini Hospital Groningen","All","65 Years and older   (Older Adult)","Not Applicable","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","ABR 48969","April 2015","November 2015","November 2015","October 23, 2014","null","December 2, 2015","University Medical Center Groningen, Groningen, Netherlands","","https://ClinicalTrials.gov/show/NCT02272985"
220,"NCT02885272","Dual Time Point FDG PET-MR Imaging Optimization for the Evaluation of Glioblastoma",,"Recruiting","No Results Available","Malignant Neoplasms, Eye|Glioblastoma|Malignant Neoplasms, Brain|Malignant Neoplasms, Central Nervous System","Drug: FDG|Procedure: PET/CT|Procedure: MRI","Optimal FDG Positron Emission Tomography-Magnetic Resonance (PET-MR) Imaging Time Point","M.D. Anderson Cancer Center","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2016-0261|NCI-2016-01971","October 2016","October 2019","October 2020","August 31, 2016","null","January 29, 2018","University of Texas MD Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT02885272"
221,"NCT01397578","A Study to Evaluate the Impact of MABT5102A on Brain Amyloid Load and Related Biomarkers in Patients With Mild to Moderate Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Drug: MABT5102A|Drug: placebo","Change in brain amyloid load as assessed by amyloid PET imaging|Changes in cerebrospinal fluid (CSF) biomarkers relevant to Alzheimer's disease|Change in brain metabolism as assessed by 18F-fluorodeoxyglucose positron emission tomography (FDG PET) imaging|Change in Alzheimer's Disease Assessment Scale Cognitive Subscale (ADAS Cog) score","Genentech, Inc.","All","50 Years to 80 Years   (Adult, Older Adult)","Phase 2","91","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","ABE4955g|GN00762","August 31, 2011","April 30, 2014","April 30, 2014","July 19, 2011","null","July 12, 2017","Banner Alzheimer's Institute, Phoenix, Arizona, United States|Banner Sun Health Research Insitute, Sun City, Arizona, United States|NNS Clinical Research LLC, Tucson, Arizona, United States|Margolin Brain Institute, Fresno, California, United States|University of California Los Angeles (UCLA), Los Angeles, California, United States|Pacific Neuroscience Med Grp, Oxnard, California, United States|Stanford Univ Medical Center, Palo Alto, California, United States|Redwood Regional Medical Group, Santa Rosa, California, United States|Internal Med Assoc of Lee Cty, Fort Myers, Florida, United States|Neuropsychiatric Research; Center of Southwest Florida, Fort Myers, Florida, United States|MD Clinical, Hallandale Beach, Florida, United States|Compass Research, Orlando, Florida, United States|Dekalb Neurology Associates, Decatur, Georgia, United States|Alexian Brothers Neurosci Inst, Elk Grove Village, Illinois, United States|Hattiesburg Clinic, Hattiesburg, Mississippi, United States|Cleveland Clinic Lou Ruvo; Center for Brain Research, Las Vegas, Nevada, United States|Memory Enhancement Center of America, Inc., Eatontown, New Jersey, United States|Litwin Zucker Research Ctr.; Feinstein Inst. Med. Rsch., Manhasset, New York, United States|Neurology & Neuroscience Ctr of Ohio, Toledo, Ohio, United States|The Clinical Trial Center, LLC, Jenkintown, Pennsylvania, United States|Rhode Island Mood & Memory Research Institute, East Providence, Rhode Island, United States|Butler Hospital, Providence, Rhode Island, United States|Hopital Central-CHU de Nancy; Pharmacie, Nancy, France|Hôpital Casselardit; Cons memoire, Toulouse, France|Clinique Psychiatrique Univ, Tours Cedex 9, France|Fundació ACE, BArcelon, Barcelona, Spain|Hospital Universitario de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain|Hospital del Mar, Barcelona, Spain|Hospital Mutua De Terrasa, Barcelona, Spain","","https://ClinicalTrials.gov/show/NCT01397578"
222,"NCT01935830","LAAM-HAART PET Imaging",,"Completed","No Results Available","Healthy Volunteers","Radiation: [11c] LAAM|Drug: Ritonavir|Drug: Efavirenz","cerebral [11C]LAAM distribution volume","Washington University School of Medicine","All","18 Years to 50 Years   (Adult)","Early Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","201307040","August 2013","August 2015","September 2015","September 5, 2013","null","December 13, 2017","Washington University School of Medicine, Saint Louis, Missouri, United States","","https://ClinicalTrials.gov/show/NCT01935830"
223,"NCT03024944","TAU PET Imaging in Northern Manhattan Study of Metabolism and Mind","TAUPET","Withdrawn","No Results Available","Diabetes Mellitus|Alzheimer Dementia","Drug: 18F-THK-5351","Amount of Tau Accumulation by Measuring Standardized Uptake Value Ratio (SUVR)","Columbia University|National Institute on Aging (NIA)","All","55 Years to 75 Years   (Adult, Older Adult)","Phase 2","0","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","AAAR1419|3R01AG050440","December 2017","January 2019","January 2020","January 19, 2017","null","December 29, 2017","Columbia University Medical Center, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT03024944"
224,"NCT01385033","[18F]MK-3328 as a Possible Novel Positron Emission Tomography (PET) Tracer for the Detection of Brain Amyloid Plaques (MK-3328-002)",,"Terminated","Has Results","Alzheimer's Disease","Drug: [18F]MK-3328","Area Under the Receiver Operating Curve (AUC of ROC) for Distinguishing Between AD and HE Participants Based on Brain Cortical [18F]MK-3328 Standard Uptake Value Ratio (SUVR)|Brain Cortical [18F]MK-3328 SUVR in AD Participants and HE Participants|Amyloid Plaque Burden Threshold Determined by the Trimmed HE Sample Mean and SD Brain Cortical [18F]MK-3328 SUVR","Merck Sharp & Dohme Corp.","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 1","20","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","3328-002","August 19, 2011","May 15, 2012","May 15, 2012","June 29, 2011","February 20, 2014","July 2, 2017","","","https://ClinicalTrials.gov/show/NCT01385033"
225,"NCT03314155","Cerebral Neuroinflammation During Major Depressive Episode","InflaDep","Not yet recruiting","No Results Available","Depressive Disorder","Diagnostic Test: Cerebral neuroinflammation evaluation","distribution pattern of neuroinflammation in Positron Emission Tomography (PET) data|distribution pattern of neuroinflammation in PET data across all groups|patients with depressive symptoms and neuroinflammation (i.e. PET data).|patients with neuroinflammation (i.e. PET analysis) and MRI parameters for functional and structural integrities.|patients with neuroinflammation (i.e. PET analysis) and biological markers of neuroinflammation (i.e. cytokines).","University Hospital, Toulouse|Institut National de la Santé Et de la Recherche Médicale, France","All","25 Years to 55 Years   (Adult)","Not Applicable","60","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","RC31/16/8918|2017-001478-40","September 2018","January 2020","January 2021","October 19, 2017","null","July 12, 2018","Hôpital de Psychiatrie, Toulouse, Midi-Pyrénées, France|CHU Bordeaux, Bordeaux, Nouvelle Aquitaine, France|CHRU Lapeyronie, Montpellier, Occitanie, France|Clinique Psychiatrique Universitaire CHRU Tours, Tours, Val-De-Loire, France","","https://ClinicalTrials.gov/show/NCT03314155"
226,"NCT01638689","A PET Study to Determine Alterations in Serotonin Levels in Human Brain After a Single Dose of Escitalopram",,"Completed","No Results Available","Healthy","Drug: Escitalopram","Change in binding potential of 11C-AZ10419369 between baseline and post-dose condition","Karolinska Institutet","Male","20 Years to 30 Years   (Adult)","Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","2010-019363-11","September 2010","February 2011","July 2012","July 12, 2012","null","July 12, 2012","PET center, Department of Clinical neuroscience, Karolinska Institutet, Stockholm, Sweden","","https://ClinicalTrials.gov/show/NCT01638689"
227,"NCT02904187","Cerebral Activation and Bilateral Stimulation by Cochlear Implantation in Bilateral Deaf Adults",,"Unknown status","No Results Available","Deafness","Other: Positron Emission Tomography (PET)|Other: Electroencephalogram (EEG)","Cortical brain activation pattern","Hospices Civils de Lyon","All","18 Years and older   (Adult, Older Adult)","Not Applicable","180","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","2008-542","March 2010","September 2016","September 2017","September 16, 2016","null","September 16, 2016","Département d'ORL, Hôpital Edouard Herriot, Lyon cedex 03, France","","https://ClinicalTrials.gov/show/NCT02904187"
228,"NCT02059733","Developing a Novel Imaging Biomarker in the Differential Diagnosis of Parkinson's Disease and Parkinsonism",,"Completed","No Results Available","Parkinson's Disease","Drug: 18F-DTBZ","Analyzing the differences of monoaminergic degeneration between each group by comparing the SUVR of 18F- DTBZ measured by the VOIs methods in each brain region.|Statistical parametrical mapping will be performed to compare the early-phase and delayed-phase imaging of 18F- DTBZ PET in each group.","Chang Gung Memorial Hospital","All","20 Years to 80 Years   (Adult, Older Adult)","Phase 2","72","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","101-1273A","February 2013","July 31, 2018","July 31, 2018","February 11, 2014","null","August 6, 2018","Chang Gung Memory Hospital, Taoyuan, Taiwan","","https://ClinicalTrials.gov/show/NCT02059733"
229,"NCT01053312","PET Imaging of Brain Amyloid in Normal Pressure Hydrocephalus",,"Completed","Has Results","Normal Pressure Hydrocephalus","Drug: [18F] Flutemetamol","Quantitative Estimates of Brain Uptake [18F]Flutemetamol and the Quantitative Immunohistochemical (IHC) Estimates of Amyloid Levels in Biopsy Samples Previously Obtained.|Comparsion Between Brain Uptake of [18F] Flutemetamol Amyloid Level From Immunohistochemistry Assay and a Stained Biopsy Tissue Specimen.|Quantitative Estimates of Amyloid Levels ( Percent % Plaque Load) for the Following 7 Subjects","GE Healthcare|i3 Statprobe","All","50 Years and older   (Adult, Older Adult)","Phase 3","7","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","GE 067-008","December 2009","July 2010","August 2010","January 21, 2010","June 5, 2012","June 11, 2012","GE Healthcare, Princeton, New Jersey, United States","","https://ClinicalTrials.gov/show/NCT01053312"
230,"NCT00001972","PET Scan of Brain Metabolism in Relation to Age and Disease",,"Completed","No Results Available","Alzheimer's Disease|Brain Neoplasm|Niemann Pick Disease","Drug: 15 O Water","","National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult","","123","NIH","Observational","","940205|94-N-0205","September 1994","null","August 2002","January 19, 2000","null","March 4, 2008","National Institute of Neurological Disorders and Stroke (NINDS), Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00001972"
231,"NCT02956148","Follow-up Measurement of Brain PDE10A Enzyme Levels in Huntington´s Disease Gene Expansion Carriers","LONGPDE10","Recruiting","No Results Available","Huntington's Disease","Radiation: Radioligand [18F]MNI-659","The longitudinal changes of PDE10A enzyme availability in the caudate, putamen, and globus pallidus of Huntington's Disease Gene Expansion Carriers by comparison of the follow-up and initial PET measurements.","CHDI Foundation, Inc.","All","18 Years to 73 Years   (Adult, Older Adult)","Early Phase 1","45","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","CHDIKI1401","June 2015","June 2018","September 2018","November 7, 2016","null","November 7, 2016","The Memory Clinic, Rigshopitalet, Copenhagen, Denmark|Leiden University Medical Center, Department of Neurology, Leiden, Netherlands|University of Oslo, Nevrologisk poliklinikk, Oslo, Norway|Skane Universitetssjukhus Lund, Neurologiska kliniken, Lund, Sweden|Karolinska Universitetssjukhus, Huddinge, Stockholm, Sweden|Karolinska University Hospital, Stockholm, Sweden|Uppsala University Hospital, Uppsala, Sweden","","https://ClinicalTrials.gov/show/NCT02956148"
232,"NCT01122329","A Positron Emission Tomography (PET) Study Evaluating Brain Metabolism of a Medical Food in Alzheimer's Disease","AD","Completed","No Results Available","Alzheimer Disease","Dietary Supplement: caprylidene|Dietary Supplement: Placebo","Regional cerebral blood flow (rCBF)|Examine differences between ApoE ε4 carriers and noncarriers in changes on rCBF and cognition|To examine the effect of AC-1202 on cognition","University of California, Los Angeles|John Douglas French Foundation","All","50 Years to 90 Years   (Adult, Older Adult)","Phase 4","17","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","GG-AC-1202","October 2010","January 2015","January 2015","May 13, 2010","null","March 23, 2015","200 Medical Plaza, UCLA Medical Center, Los Angeles, California, United States|Center for Neurotherapeutics at UCLA, Los Angeles, California, United States","","https://ClinicalTrials.gov/show/NCT01122329"
233,"NCT03075007","Brain Vascular Disease in Aging and Dementia",,"Recruiting","No Results Available","Alzheimer Disease|White Matter Hyperintensities|Dementia|Aging","Radiation: Florbetaben F18|Procedure: Transcranial Doppler","PET amyloid Standard Uptake Value ratio (SUVr) values|Transcranial Doppler (TCD) dynamic autoregulatory dysfunction","Columbia University|National Institute on Aging (NIA)","All","60 Years and older   (Adult, Older Adult)","","20","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","AAAR1423|2R56AG034189-06A1","May 23, 2017","November 2019","November 2019","March 9, 2017","null","June 6, 2017","Columbia University Medical Center, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT03075007"
234,"NCT03257592","Positron Emission Tomography (PET) Imaging of Glial Activation in Psychotic Disease States",,"Active, not recruiting","No Results Available","Schizophrenia and Bipolar Disorder","Radiation: [11C]DPA-713 PET imaging","Sensitivity and Specificity of ([11C]DPA)-713 PET brain imaging in patients with recent onset schizophrenia and in patients with recent onset of mania|PET Imaging of microglial activation","Johns Hopkins University","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","NA-00037683","August 2010","August 2018","August 2018","August 22, 2017","null","August 22, 2017","Johns Hopkins University, Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT03257592"
235,"NCT01232439","A Study of Brain Receptor Occupancy in Healthy Subjects",,"Completed","No Results Available","Alcohol Dependence","Drug: opioid receptor kappa antagonist","Change in brain kappa opioid receptor occupancy (RO) by positron emission tomography (PET)|Pharmacokinetics, area under the curve (AUC)|Number of participants with clinically significant effects|Pharmacokinetics, concentration maximum (Cmax)","Eli Lilly and Company","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","13","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","12511|I2Z-MC-LAFC","December 2010","April 2011","April 2011","November 2, 2010","null","May 9, 2011","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT01232439"
236,"NCT00424957","Brain Energy Metabolism in Patients With Chronic Liver Disease and Impaired Central Nervous System",,"Completed","No Results Available","Cirrhosis|Hepatic Encephalopathy","","","University of Aarhus","All","45 Years to 65 Years   (Adult, Older Adult)","","18","Other","Observational","Observational Model: Case Control|Time Perspective: Cross-Sectional","20060120","November 2006","April 2007","October 2008","January 22, 2007","null","February 5, 2009","PET Centre, Aarhus University Hospital, Aarhus, Denmark","","https://ClinicalTrials.gov/show/NCT00424957"
237,"NCT01576276","A Brain Imaging Study of Opioid (Morphine) and Non-opioid (Ketorolac) Conditioning Effects",,"Completed","Has Results","Healthy Controls","Radiation: Integrated MR-PET scan|Drug: Ketorolac","fMRI Signal Changes|Pain Ratings","Massachusetts General Hospital","All","21 Years to 50 Years   (Adult)","Not Applicable","51","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Other","2011P000358","April 2012","February 2017","February 2017","April 12, 2012","May 28, 2018","June 29, 2018","Massachusetts General Hospital, Charlestown, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/76/NCT01576276/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT01576276"
238,"NCT03204604","The Brain Ketone Body Challenge Imaging Study",,"Recruiting","No Results Available","Alzheimer Disease","Dietary Supplement: Challenge A - low calorie Ensure®|Dietary Supplement: Challenge B - Ensure® plus ketone esters (KE)|Procedure: PET Scan|Behavioral: Cognitive Testing - FCSRT|Behavioral: Story Recall|Behavioral: BVRT|Behavioral: CogState One Card Learning","Primary Outcome - Brain Ketone Utilization|Secondary Outcome - Memory Composite Score","Wake Forest University Health Sciences","All","50 Years to 85 Years   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science","IRB00036958","August 8, 2016","December 2018","December 2018","July 2, 2017","null","July 17, 2018","Wake Forest School of Medicine, Winston-Salem, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT03204604"
239,"NCT02551419","Proof of Mechanism of a New Ketogenic Supplement Using Dual Tracer PET (Positron Emission Tomography)","BENEFIC","Recruiting","No Results Available","Mild Cognitive Impairment","Dietary Supplement: ketogenic drink|Dietary Supplement: placebo","Change in global ketone (11C-AcAc) uptake in grey matter|Change in global brain FDG uptake in grey matter (CMR-G)|Change in regional CMR-A|Change in regional CMR-G in the temporal and parietal cortex|Change in MRI-based (fMRI, diffusion MRI) parameters|Change in cognitive status","Université de Sherbrooke|Alzheimer's Association","All","55 Years and older   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","2015-509","June 2015","June 2018","June 2018","September 16, 2015","null","December 21, 2017","Research Center on Aging, Sherbrooke, Quebec, Canada","","https://ClinicalTrials.gov/show/NCT02551419"
240,"NCT02330510","Amyloid and Glucose PET Imaging in Alzheimer and Vascular Cognitive Impairment Patients With Significant White Matter Disease","MITNEC C6","Recruiting","No Results Available","Alzheimer's Disease|Small Vessel Disease White Matter Hyperintensities Subtype|Vascular Cognitive Impairment","","Change in F18 florbetapir SUVR over 2 years in patients with moderate-severe White Matter Hyperintensities, at baseline and 1 year follow-up brain uptake of Florbetapir F 18|Florbetapir F18 SUVR brain uptake, regional FDG metabolic measures and regional volutmetrics on MRI based volume including grey and white matter, small vessel disease, as well as regional cortical thickness measures.|F18 florbetapir SUVR brain uptake, with Periventricular White Matter Hyperintensity volumes and cognitive scores.|F18 florbetapir brain SUVR uptake, Periventricular White Matter Hyperintensity volumes and cognitive scores in an age-matched group of normal controls, MCI and AD subjects with minimal or mild degrees of pvWMH.|F18 florbetapir SUVR brain uptake, ApoE e4 genotype status, and White Matter Hyperintensity volumes in patients with a high burden of pvWMH.|Baseline F18 florbetapir SUVR brain uptake, cognitive score decline and increase in White Matter Hyperintensity volume at 2 year follow up.|Assess any adverse events or serious adverse events occurring with a a single intravenous dose of F18 florbetapir Injection (370 MBq +/- 10%) in subjects with significant pvWM","Dr. Sandra E Black|Sunnybrook Health Sciences Centre","All","60 Years and older   (Adult, Older Adult)","","80","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Ml1-112246","August 2014","February 2020","February 2020","January 5, 2015","null","November 27, 2017","Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT02330510"
241,"NCT02063269","Brain Changes by Rivastigmine According to Butyrylcholinesterase Alleles",,"Unknown status","No Results Available","Alzheimer's Disease","Drug: Rivastigmine","the mean changes of Standardized Uptake Values (SUVmean) in PET imaging|the mean changes of serum BuChE activity between BuChE wild type and K-variant type|the mean changes of cortical thickness in brain MRI|the cognitive changes in Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog)|the cognitive changes in Mini-Mental State Exam (MMSE)|the daily function changes by Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL)|the behavioural changes by Caregiver-Administered Neuropsychiatric Inventory (NPI)|the disease severity changes by Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB) between BuChE wild type and K-variant type","Seoul National University Hospital|Novartis Korea Ltd.","All","55 Years to 80 Years   (Adult, Older Adult)","Not Applicable","70","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","CENA713DKR15T","February 2014","June 2017","June 2017","February 14, 2014","null","May 14, 2015","Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT02063269"
242,"NCT02319382","Measure of Microglial Activation in the Brain of Parkinson Disease Patients With PET","INFLAPARK","Unknown status","No Results Available","Parkinson's Disease With LRRK2 Mutation|Healthy Controls|Parkinson's Disease Without LRRK2 Mutation","Radiation: PET with the tracer 18F-DPA-714|Radiation: PET with the tracer 11C-PE2I|Other: MRI","Accumulation of [18F]DPA-714 in the midbrain assessed through PET","Assistance Publique - Hôpitaux de Paris|France Parkinson Association","All","18 Years and older   (Adult, Older Adult)","Not Applicable","46","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","P091202","June 2012","November 2016","December 2016","December 18, 2014","null","July 14, 2015","Orsay Hospital, Orsay, France","","https://ClinicalTrials.gov/show/NCT02319382"
243,"NCT01173757","To Evaluate The Relationship Between Plasma Drug Levels And Receptor Binding In Brain Using PET (Positron Emission Tomography) In Healthy Volunteers",,"Completed","No Results Available","Healthy","Drug: PF-04995274","Exposure response of overall 5HT4 receptor occupancy of PF-04995274|5HT4 receptor occupancy by PF-04995274 at regions of interest within the human brain|Adverse events|change from baseline in vital signs|Singlet ECG post-dose|Clinical safety laboratory endpoints|Clinical examinations|Cmax, Tmax, AUClast, and AUCinf for PF-04995274 in plasma|Cmax, Tmax, AUClast, and AUCinf for PF-05082547 in plasma","Pfizer","All","18 Years to 55 Years   (Adult)","Phase 1","8","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Basic Science","B1661002","August 2010","November 2010","November 2010","August 2, 2010","null","June 1, 2011","Pfizer Investigational Site, New Haven, Connecticut, United States|Pfizer Investigational Site, New Haven, Connecticut, United States|Pfizer Investigational Site, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT01173757"
244,"NCT02822664","Analysis of Cerebral Correlates of Pedophilia With Neuroimaging Techniques","PCNI","Completed","No Results Available","Pedophilia","Behavioral: Pedophiles patients|Behavioral: Healthy subjects|Device: PET/MRI","BOLD contrast signal|Local cerebral blood flow","Hospices Civils de Lyon","Male","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","80","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","2008-535","June 2011","October 2014","October 2014","July 4, 2016","null","July 4, 2016","","","https://ClinicalTrials.gov/show/NCT02822664"
245,"NCT01730781","Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning",,"Recruiting","No Results Available","Schizophrenia|Cannabis Dependence|Prodromal for Psychotic Illness|Family History of Alcoholism","Radiation: [11-C]OMAR","PET Imaging","Yale University|National Institute on Drug Abuse (NIDA)|National Institute of Mental Health (NIMH)","Male","18 Years to 55 Years   (Adult)","","100","Other|NIH","Observational","Observational Model: Other|Time Perspective: Other","1005006735|1R21DA030702-01A1|1R21MH094961-01A1","July 2010","December 2018","December 2018","November 21, 2012","null","November 30, 2017","Connecticut Mental Health Center, Clinical Neuroscience Research Unit, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT01730781"
246,"NCT02112695","Opioid System Cerebral Activity in Endurance Sportswomen - Addiction or Denutrition ? [11C]Diprenorphine PET Study",,"Recruiting","No Results Available","Sports Nutritional Sciences","Other: [11C]diprenorphine","[11C]diprenorphine binding potential|correlation [11C]diprenorphine BP","Centre Hospitalier Universitaire de Saint Etienne|Ministry of Health, France","Female","18 Years to 35 Years   (Adult)","Not Applicable","45","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","1208051|2013-004733-32","September 15, 2014","March 2018","March 2018","April 14, 2014","null","October 18, 2017","Service d'Endocrinologie - CHU Saint-Etienne, Saint-Etienne, France","","https://ClinicalTrials.gov/show/NCT02112695"
247,"NCT01089283","Ioflupane I123 (DaTSCAN) and Positron Emission Tomography-computed Tomography Fludeoxyglucose (PET-CT FDG) to Assess Brain Function of Parkinson Patients With Different Genetic Characteristics",,"Unknown status","No Results Available","Parkinson Disease","","","Tel-Aviv Sourasky Medical Center","All","40 Years to 80 Years   (Adult, Older Adult)","","80","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","TASMC-10-EES-087-CTIL","March 2010","March 2011","null","March 18, 2010","null","March 18, 2010","Department of Nuclear Medicine, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel","","https://ClinicalTrials.gov/show/NCT01089283"
248,"NCT00362843","Protein Synthesis in the Brain of Patients With Fragile X Syndrome",,"Recruiting","No Results Available","Fragile X Syndrome|Healthy Volunteers","","Regional rates of cerebral protein synthesis","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","Male","18 Years to 24 Years   (Adult)","","150","NIH","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","060214|06-M-0214","August 8, 2006","null","null","August 10, 2006","null","August 21, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00362843"
249,"NCT02290834","Chemotherapy-induced Cognitive and Brain Changes in Older Adults With Breast Cancer",,"Active, not recruiting","No Results Available","Impaired Cognition|Chemo-brain|Breast Cancer","Other: Cognitive, functional and subjective assessments|Device: MRI|Radiation: PET Scan","Change in cognitive performance scores|Correlation between baseline amyloid accumulation in the brain and change in cognitive performance|Correlation between baseline tau accumulation in the brain and change in cognitive performance|Correlation between change in tau accumulation in the brain (from baseline to 6 months after completion of chemotherapy) and change in cognitive performance (from baseline to 6 months after completion of chemotherapy)","Massachusetts General Hospital","Female","60 Years and older   (Adult, Older Adult)","Not Applicable","200","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","14-217","March 2015","January 2020","September 2021","November 14, 2014","null","March 9, 2018","Massachusetts General Hospital, Boston, Massachusetts, United States|Massachusetts General Hospital/North Shore Cancer Center, Salem, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT02290834"
250,"NCT02176720","Response Monitoring Trial in Patients With Suspected Recurrence of Glioblastoma",,"Terminated","No Results Available","Glioma|Glioblastoma|Glioblastoma Multiforme","Drug: FDOPA PET","Diagnostic accuracy compared to standard diagnostics without PET|Impact of FDOPA PET on patient management","The Methodist Hospital System|University of California, Los Angeles","All","18 Years and older   (Adult, Older Adult)","Phase 1","31","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","Pro00009857|121638|1013-0158","May 2014","March 2016","March 2016","June 27, 2014","null","August 17, 2018","Houston Methodist Research Institute PET Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT02176720"
251,"NCT03233594","PET Imaging of Chronic Pain Syndromes",,"Enrolling by invitation","No Results Available","Chronic Pain Syndrome","Other: Chiropractic Group|Other: Healthy Control Group","Use combined PET/MRI to define pain activity pattern and inflammation.|Use combined PET/MRI to demonstrate brain and body activity in responders and non-responders.","Thomas Jefferson University","All","18 Years and older   (Adult, Older Adult)","","32","Other","Observational","Observational Model: Other|Time Perspective: Prospective","17D.163","June 7, 2017","June 6, 2019","June 6, 2020","July 28, 2017","null","January 17, 2018","Thomas Jefferson University, Marcus Institute of Integrative Health Centers, Philadelphia, Pennsylvania, United States|Thomas Jefferson University, Marcus Institute of Integrative Health Centers, Villanova, Pennsylvania, United States","""Study Protocol and Statistical Analysis Plan: Cover Page to Accompany CT.gov Registration"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT03233594/Prot_SAP_001.pdf|""Study Protocol and Statistical Analysis Plan: Protocol"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT03233594/Prot_SAP_002.pdf","https://ClinicalTrials.gov/show/NCT03233594"
252,"NCT03442413","Nicotinic Hepatic Metabolism on Neuroreceptor Substrates of Nicotine Addiction",,"Recruiting","No Results Available","Smoking, Tobacco","Drug: 2-[18F]-FA PET/CT|Drug: I.V. Nicotine","Duration of abstinence affects brain nAChR availability in smokers|How nicotine administration affects nAChR availability during early abstinence in smokers|Standard measures of cigarette craving and withdrawal to nAChR availability in smokers","University of Pennsylvania","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","828090","May 15, 2018","March 13, 2020","March 13, 2022","February 22, 2018","null","July 10, 2018","University of Pennsylvania, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT03442413"
253,"NCT03190954","Brain Dopaminergic Signaling in Opioid Use Disorders",,"Recruiting","No Results Available","Normal Physiology|Opioid-Related Disorders","Other: Placebo|Drug: Methylphenidate","To assess whether the balance between D1R and D2R in striatum is disrupted in participants with an opioid use disorder (OUD) who are being treated with an opioid medication (MAT+) and does who are not (MAT-).|To assess the impact of disruptions on striatal D1R to D2R availability on: DA release; Function of brain reward and control networks; Behavior.|To assess if DA increases as achieved with oral MP influence the brain functional measures.","National Institute on Alcohol Abuse and Alcoholism (NIAAA)|National Institutes of Health Clinical Center (CC)","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","240","NIH","Interventional","Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","170114|17-AA-0114","August 17, 2017","December 31, 2024","December 31, 2024","June 19, 2017","null","August 8, 2018","National Institutes of Health Clinical Center, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT03190954"
254,"NCT01868906","FMISO-PET in Brain Tumors and SCS Effect","FMISOPETSCS","Terminated","No Results Available","Malignant Glioma","Drug: 18F-FMISO|Procedure: PET without SCS|Device: SCS|Procedure: PET without/with SCS|Radiation: Radiotherapy|Drug: Temozolomide","Tumor hypoxia measurement using 18F-FMISO-PET (hypoxic volume and tumor/muscle ratio). Baseline measurement.|Change from baseline tumor hypoxia using 18F-FMISO-PET (hypoxic volume and tumor/muscle ratio) during SCS.|Correlation between 18F-FMISO-PET values and pathological tumor parameters|Correlation with Karnofsky scale.|Correlation with the ECOG (Eastern Cooperative Oncology Group) performance status scale|Correlation with the Quality of Life Questionnaire QLQ-C30 (EORTC)|Overall survival.|Radiological response to treatment|Radiological location of tumor relapse or progression","Bernardino Clavo, MD, PhD|Instituto Tecnologico Servicios Sanitarios, in MD Anderson Cancer Center, Madrid|Instituto de Salud Carlos III|Grupo de Investigación Clínica en Oncología Radioterapia|Instituto Canario de Investigación del Cáncer|RSbiomed|Fundación DISA, Canary Islands, Spain|Dr. Negrin University Hospital","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","6","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","TC-FMISO-PET-06-1413|2009-015852-11|PI 06/1413, PI 12/02940","June 2013","December 2018","June 2019","June 5, 2013","null","October 19, 2017","Dr. Negrin University Hospital, Las Palmas, Spain|Instituto Tecnologico Servicios Sanitarios, in MD Anderson Cancer Center, Madrid, Madrid, Spain","","https://ClinicalTrials.gov/show/NCT01868906"
255,"NCT02305264","Imaging of Intracerebral Inflammation in MS","INFLASEP","Recruiting","No Results Available","Multiple Sclerosis, Relapsing-Remitting|Multiple Sclerosis, Secondary Progressive|Multiple Sclerosis, Primary Progressive","Drug: 18F-DPA-714 and 18F-FDG","Whole brain Binding Potential (BP) of 18F-DPA-714|Binding potential of 18F-DPA-714 in segmented brain regions|Binding potential of 18F-DPA-714 in subgroups of MS patients|Predictive value of PET 18F-DPA-714 BP on neurological clinical metrics|Predictive value of PET 18F-DPA-714 BP on MRI metrics","Assistance Publique - Hôpitaux de Paris","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","65","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","P091001","February 2012","February 2018","February 2018","December 2, 2014","null","February 23, 2017","Saint Antoine Hospital, Paris, France|Pitie Salpetriere Hospital, Paris, France","","https://ClinicalTrials.gov/show/NCT02305264"
256,"NCT01123317","Brain Blood Flow Changes Elicited by Oxytocin in Volunteers With and Without Schizophrenia",,"Withdrawn","No Results Available","Schizophrenia","Drug: Oxytocin","Oxytocin induced rCBF changes","University of Maryland","All","18 Years to 55 Years   (Adult)","Not Applicable","0","Other","Interventional","Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","HP-00041288","July 2010","January 2011","January 2013","May 14, 2010","null","April 21, 2017","Maryland Psychiatric Research Center, Catonsville, Maryland, United States","","https://ClinicalTrials.gov/show/NCT01123317"
257,"NCT02582398","Influence of Light Exposure on Cerebral MAO-A in Seasonal Affective Disorder and Healthy Controls Measured by PET",,"Completed","No Results Available","Seasonal Affective Disorder","Other: Light Therapy|Other: Placebo Light","Change in MAO-A specific distribution volume (MAO-A DVs) assessed with PET","Medical University of Vienna","All","18 Years to 55 Years   (Adult)","Not Applicable","99","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","248/2011","November 2013","April 3, 2017","April 3, 2017","October 21, 2015","null","May 9, 2018","Department of Psychiatry and Psychotherapy, Vienna, Austria","","https://ClinicalTrials.gov/show/NCT02582398"
258,"NCT01399398","Imaging of CB1 Receptors Using (11C)SD5024",,"Terminated","No Results Available","Healthy","Procedure: Brain Scan-PET|Procedure: Brain Scan-MRI|Procedure: Arterial Line|Procedure: Venous Line|Procedure: Blood Sampling","For the PET scans, we will measure the regional densities of cannabinoid 1 receptors as distribution volume (VT). Distribution volume is the ratio at equilibrium of brain uptake to the concentration of parent radioligand in plasma.","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years to 50 Years   (Adult)","Phase 1","8","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","110202|11-M-0202","June 22, 2011","December 18, 2013","December 18, 2013","July 21, 2011","null","August 10, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT01399398"
259,"NCT03435861","Effect of Neflamapimod on Brain Inflammation in Alzheimer's Disease Patients","VIP","Not yet recruiting","No Results Available","Alzheimer Disease","Drug: VX-745|Drug: placebo","brain inflammation assessed by [18F]-DPA714, Standard Uptake Value (SUV)|brain inflammation assessed by [18F]-DPA714, Standard Uptake Value (SUV) 2|brain inflammation assessed by [18F]-DPA714, Standard Uptake Value (SUV)3|Neuropsychological assessment to assess the following cognitive functions 1:|Neuropsychological assessment to assess the following cognitive functions 2:|Neuropsychological assessment to assess the following cognitive functions 1.1:|Neuropsychological assessment to assess the following cognitive functions 2.2:|Neuropsychological assessment to assess the following cognitive functions 3:|Neuropsychological assessment to assess the following cognitive functions 4:|Neuropsychological assessment to assess the following cognitive functions 5:|Blood and CSF biomarkers of inflammation1|Blood and CSF biomarkers of inflammation 2|Blood and CSF biomarkers of inflammation 3|Blood and CSF biomarkers of inflammation 4|Blood and CSF biomarkers of inflammation 5|Blood and CSF biomarkers of inflammation 6|Blood and CSF biomarkers of inflammation 7|Blood and CSF biomarkers of inflammation 8|Blood and CSF biomarkers of inflammation 9|Blood and CSF biomarkers of inflammation 10|Blood and CSF biomarkers of inflammation 11|Blood and CSF biomarkers of inflammation 12|Blood and CSF biomarkers of inflammation 13|Blood and CSF biomarkers of inflammation 14|Blood and CSF biomarkers of inflammation 15|Blood and CSF biomarkers of inflammation 16|Blood and CSF biomarkers of inflammation 17|Blood and CSF biomarkers of inflammation 18|Blood and CSF biomarkers of inflammation 19|Blood and CSF biomarkers of inflammation 20|Blood and CSF biomarkers of inflammation 21|Blood and CSF biomarkers of inflammation 22|Blood and CSF biomarkers of inflammation 23|Blood and CSF biomarkers of inflammation 24|Blood and CSF biomarkers of inflammation 25|Blood and CSF biomarkers of inflammation 26|Blood and CSF biomarkers of inflammation 27|Blood and CSF biomarkers of inflammation 28","University Hospital, Toulouse|Fondation Plan Alzheimer","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","RC31/16/8371","March 28, 2018","January 30, 2020","January 30, 2021","February 16, 2018","null","February 16, 2018","","","https://ClinicalTrials.gov/show/NCT03435861"
260,"NCT02061345","PET Imaging in MCI Following ADT for PCa",,"Suspended","No Results Available","Prostate Cancer|Mild Cognitive Impairment","","PET biomarker uptake|PET biomarker volume of distribution","Imperial College London","Male","50 Years to 80 Years   (Adult, Older Adult)","","12","Other","Observational","Observational Model: Case Control|Time Perspective: Cross-Sectional","13HH0558","April 2014","December 2016","December 2016","February 12, 2014","null","August 15, 2016","Imperial College Healthcare NHS Trust, London, United Kingdom","","https://ClinicalTrials.gov/show/NCT02061345"
261,"NCT02895932","Serotonin and Amyloidopathy",,"Active, not recruiting","No Results Available","Parkinson's Disease","Radiation: PET imaging","Regional brain beta amyloid levels and regional brain serotonin terminal density as measured by PET brain imaging.","University of Michigan","All","45 Years and older   (Adult, Older Adult)","Not Applicable","27","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","HUM00094478","January 2015","January 2020","January 2020","September 12, 2016","null","August 23, 2017","University of Michigan Health System, Ann Arbor, Michigan, United States","","https://ClinicalTrials.gov/show/NCT02895932"
262,"NCT00044200","Positron Emission Tomography (PET) to Study Brain Signaling",,"Completed","No Results Available","Healthy","","","National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)","All","18 Years to 45 Years   (Adult)","","20","NIH","Observational","","000057|00-N-0057","January 10, 2000","null","June 12, 2015","August 22, 2002","null","July 4, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00044200"
263,"NCT00939315","Multimodal Diagnostic Assessment of Cerebral Gliomas With FET & FCH PET/CT, and Magnetic Resonance Imaging/Spectroscopy","Gliomes-FLP","Completed","No Results Available","Glioma","","Ability of image-guided biopsy using FET, FCH PET/CT and MRS information to target the most representative sites of tumor grade as compared to histopathological examination","University of Lausanne Hospitals|Lionel Perrier Foundation (Montreux, Switzerland)","All","18 Years and older   (Adult, Older Adult)","","51","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","196/08|Swissmedic 2009DR3123","July 2009","January 2016","January 2016","July 15, 2009","null","January 26, 2016","Centre Hospitalier Universitaire Vaudois, Lausanne, CH, Switzerland","","https://ClinicalTrials.gov/show/NCT00939315"
264,"NCT03545789","Phase 1 Test-retest Evaluation of [18F]MNI-958 PET",,"Recruiting","No Results Available","Healthy Volunteers|Alzheimer Disease|Progressive Supranuclear Palsy","Drug: [18F]MNI-958","Tracer uptake will be evaluated in regions of interest for analysis of regional [18F]MNI-958 binding/uptake and expressed in SUV by using established methods for normalization for 4 AD, 7 PSP, and 3 HV subjects.","Invicro","All","18 Years to 55 Years   (Adult)","Phase 1","14","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","[18F]MNI-958 Test-Retest","March 12, 2018","March 12, 2019","March 12, 2019","June 4, 2018","null","June 4, 2018","Invicro, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT03545789"
265,"NCT00692705","Positron Emission Tomography (PET) Study With [11C]AZD2995 and [11C]AZD2184, Candidate PET Ligands for β Amyloid","PET","Completed","No Results Available","Alzheimer´s Disease","Drug: Radioligand (11C)AZD2995|Drug: Radioligand (11C)AZD2184","Positron emission tomography using the radioligand (11C)AZD2995 or (11C)AZD2184|To assess safety and tolerability of [11C]AZD2995, [11C]AZD2184 and the study procedures, by assessment of adverse events, vital signs and laboratory variables.","AstraZeneca","All","20 Years to 85 Years   (Adult, Older Adult)","Phase 1","13","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","D0180C00018|Eudract No. 2007-004842-33","January 2008","December 2008","December 2008","June 6, 2008","null","January 23, 2009","Research Site, Stockholm, Sweden","","https://ClinicalTrials.gov/show/NCT00692705"
266,"NCT01322555","A Study of the Association Between Autism and Immune Changes in the Brain",,"Terminated","No Results Available","Autism Spectrum Disorders|Brain Disease|Autism|Healthy Volunteers","","[11C]PBR28 uptake in brain as measured using VT (volume of distribution) and VT/fp (divided by free fraction in plasma.|Compare VT in autism versus healthy volunteers","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years to 45 Years   (Adult)","","15","NIH","Observational","Time Perspective: Prospective","110118|11-M-0118","March 4, 2011","null","July 14, 2017","March 24, 2011","null","July 4, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT01322555"
267,"NCT01038245","Quantitation of Human Cerebral Nicotinie Receptors With 2[18F]FA-85380 and PET Healthy Non-smokers and Ex-Smokers and in Heavy and Light Situational Smokers",,"Completed","No Results Available","Nicotine Addiction","","","National Institute on Drug Abuse (NIDA)|National Institutes of Health Clinical Center (CC)","All","18 Years to 50 Years   (Adult)","","72","NIH","Observational","","999903383|03-DA-N383","July 8, 2003","null","November 18, 2011","December 23, 2009","null","July 2, 2017","National Institute on Drug Abuse, Biomedical Research Center (BRC), Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT01038245"
268,"NCT01778686","Evaluation of [11C]Cimbi-36 as an Agonist PET Radioligand for Imaging of 5-HT2A Receptors",,"Completed","No Results Available","Healthy","Drug: Citalopram and Pindolol|Other: Placebo|Dietary Supplement: Acute tryptophan depletion","Cerebral Cimbi-36 receptor binding in terms of binding potential (BP) at (1) baseline (2)acute tryptophan depletion (3) acute SSRI and pindolol (4) placebo","Gitte Moos Knudsen|Rigshospitalet, Denmark","All","18 Years to 100 Years   (Adult, Older Adult)","Not Applicable","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","2012-002056-16","January 2013","November 2013","November 2013","January 29, 2013","null","October 30, 2015","Neurobiology Research Unit, Rigshospitalet, Copenhagen, Denmark","","https://ClinicalTrials.gov/show/NCT01778686"
269,"NCT00001324","PET Scan to Study Brain Control of Human Movement",,"Completed","No Results Available","Ataxia|Cerebrovascular Accident|Healthy|Movement Disorder|Tremor@@","","","National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult","","510","NIH","Observational","","920119|92-N-0119","March 1992","null","July 2001","December 10, 2002","null","March 4, 2008","National Institute of Neurological Disorders and Stroke (NINDS), Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00001324"
270,"NCT02860065","CPC-201 Alzheimer's Disease Type Dementia: PET Study",,"Withdrawn","No Results Available","Alzheimer's Disease","Drug: CPC-201|Other: Positron emission tomography (PET)","Donepezil Maximum tolerated dose (MTD) change on imaging","Chase Pharmaceuticals Corporation","All","50 Years to 79 Years   (Adult, Older Adult)","Phase 2","0","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CPC-001-15","September 30, 2016","June 30, 2017","June 30, 2017","August 9, 2016","null","August 9, 2017","Henry Ford Health System--West Bloomfield Hospital, West Bloomfield Township, Michigan, United States","","https://ClinicalTrials.gov/show/NCT02860065"
271,"NCT01588418","Acute Effect of Exenatide on Brain Glucose Metabolism",,"Completed","Has Results","Impaired Glucose Tolerance (IGT)|Diabetes","Drug: Exenatide|Drug: Placebo","Effect of Exenatide on Brain (Total Gray Matter) Glucose Metabolism|Effect of Exenatide on the Liver and Adipose Tissue Glucose Uptake","The University of Texas Health Science Center at San Antonio|Amylin Pharmaceuticals, LLC.","Male","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","15","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","233-GAS-08","July 2010","July 2015","July 2015","May 1, 2012","May 25, 2017","November 24, 2017","Texas Diabetes Institute and UTHSCSA, San Antonio, Texas, United States","","https://ClinicalTrials.gov/show/NCT01588418"
272,"NCT02792179","Evaluation of [18F]RO6958948 as Tracer for Positron Emission Tomography (PET) Imaging of Tau Burden in Alzheimer's Disease Participants",,"Completed","No Results Available","Alzheimer's Disease","Drug: [18F]RO6958948","Regional Standardized Uptake Value (SUV), as Assessed by the tau PET Brain Scan|Regional Standardized Uptake Value Ratios (SUVR), as Assessed by the Tau PET Brain Scan|Change in SUV for Different Brain Regions|Change in SUVR for Different Brain Regions|Percentage of Participants with Adverse Events","Hoffmann-La Roche","All","25 Years and older   (Adult, Older Adult)","Phase 1","4","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","BP39126","July 19, 2016","September 28, 2016","September 28, 2016","June 7, 2016","null","November 1, 2017","Johns Hopkins Medical Institutions, Johns Hopkins Outpatient Center, Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT02792179"
273,"NCT00059046","Brain Imaging of Serotonin Transporters in the Brain",,"Completed","No Results Available","Healthy|Serotonin Transporter","","","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult","","20","NIH","Observational","","030159|03-M-0159","April 2003","null","January 2005","April 16, 2003","null","March 4, 2008","National Institute of Mental Health (NIMH), Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00059046"
274,"NCT00838877","Positron Emission Tomography (PET) Study With [18F]AZD4694 and [11C]AZD2184, Candidate PET Ligands for Aβ Amyloid","PET","Completed","No Results Available","Alzheimer's Disease","Drug: radioligand [18F]AZD4694|Drug: radioligand [11C]AZD2184","Positron emission tomography using the radioligand [18F]AZD4694 and/or [11C]AZD2184|To assess safety and tolerability of [18F]AZD4694 and the study procedures, by assessment of adverse events, vital signs, and laboratory variables.","AstraZeneca","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 1","26","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","D2750C00001|2008-006747-39","January 2009","null","October 2009","February 9, 2009","null","October 23, 2009","Research Site, Huddinge, Sweden|Research Site, Stockholm, Sweden","","https://ClinicalTrials.gov/show/NCT00838877"
275,"NCT01374438","3-month Study of MSDC-0160 Effects on Brain Glucose Utilization, Cognition & Safety in Subjects With Alzheimer's Disease",,"Completed","Has Results","Alzheimer's Disease","Drug: MSDC-0160|Drug: Placebo","Effects of MSDC-0160 on Cerebral Metabolic Glucose Rate or Placebo Over 12 Weeks in Pre-specified Regions of Interest Analysis Referenced to Cerebellum|Change From Baseline in Global Cognitive Function Tests|Change From Baseline in Cognitive Function as Determined by the ADAS-Cog Subscale|Change From Baseline in Cognitive Function as Estimate With the Executive Function Scale|Change From Baseline in HMW Adiponectin of MSDC-0160 or Placebo Over 12 Weeks","Metabolic Solutions Development Company","All","55 Years to 85 Years   (Adult, Older Adult)","Phase 2","29","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MSDC-0160-C006","July 2011","March 2013","May 2013","June 16, 2011","November 5, 2014","November 18, 2014","Rush Memorial University Medical Center, Chicago, Illinois, United States","","https://ClinicalTrials.gov/show/NCT01374438"
276,"NCT01638364","Dopamine Release in the Human Brain Following Alcohol Administration",,"Completed","No Results Available","Heavy Drinking","Drug: alcoholic beverage|Drug: non-alcoholic beverage","Change in PHNO Binding Potential|Subjective effects of alcohol|Objective effects of alcohol","Centre for Addiction and Mental Health","All","21 Years to 45 Years   (Adult)","Phase 1","8","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","041/2012","January 2013","June 2015","June 2015","July 11, 2012","null","July 28, 2015","Centre for Addiction and Mental Health, Toronto, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT01638364"
277,"NCT02233868","Brain Inflammation and Function in Alcoholism",,"Recruiting","No Results Available","Alcoholism","Device: MRI|Drug: C-11PBR28|Drug: F-18FDG","To assess if there is inflammation in the brain of alcoholics as measured with [11C]PBR28 and to determine if it recovers with 3 weeks of detoxification.|To assess the impact of neuroinflammation on brain function (assessed with PET and 18FDG and with MRI for fMRI with task activation and for functional connectivity).|To determine if the NP variables correlate with neuroinflammation.|To determine if the measure of neuroinflammation predicts relapse in AD participants in the 3 month follow-up period.","National Institute on Alcohol Abuse and Alcoholism (NIAAA)|National Institutes of Health Clinical Center (CC)","All","30 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","144","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","140192|14-AA-0192","September 6, 2014","December 31, 2021","December 29, 2023","September 9, 2014","null","August 3, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT02233868"
278,"NCT00801827","PET Imaging and Bariatric Surgery",,"Completed","Has Results","Obesity, Morbid","Drug: F-18 (fallypride)","Regional DRD2/3 Binding Percent Changes After Bariatric Surgery","Vanderbilt University Medical Center","All","18 Years to 60 Years   (Adult)","Phase 1","7","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","IRB#061246","January 2007","March 2011","June 2012","December 4, 2008","March 17, 2017","March 17, 2017","Vanderbilt University Medical Center, Nashville, Tennessee, United States","","https://ClinicalTrials.gov/show/NCT00801827"
279,"NCT01546155","The Influence of Pressure Pain on [11C]Diprenorphine Binding Potentials",,"Completed","Has Results","Healthy Controls","Radiation: PET imaging","PET/MRI Brain Activation","Massachusetts General Hospital","All","21 Years to 50 Years   (Adult)","Not Applicable","11","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","2011P0022171","December 2011","October 2012","December 2015","March 7, 2012","April 11, 2017","April 11, 2017","Massachusetts General Hospital, Charlestown, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT01546155"
280,"NCT01111851","Aprepitant and Fosaprepitant Time-on-Target PET (Positron Emission Tomography) Study (0869-183)",,"Completed","Has Results","Chemotherapy-Induced Nausea and Vomiting (CINV)","Drug: Fosaprepitant 150 mg|Drug: Aprepitant 165 mg|Drug: Aprepitant 250 mg|Drug: Dexamethasone (12-8-16-16 mg)|Drug: Dexamethasone (12-8-8-16 mg)|Drug: Ondansetron|Drug: MK0999","Brain NK1-receptor Occupancy at 24 Hours Post Dose|Brain NK1-receptor Occupancy at 48 Hours Post Dose|Brain NK1-receptor Occupancy at the Time of the Maximum Concentration (Tmax)|Brain NK1-receptor Occupancy at 120 Hours Post Dose","Merck Sharp & Dohme Corp.","All","18 Years to 55 Years   (Adult)","Phase 1","16","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0869-183|2010_531","April 2010","October 2010","October 2010","April 28, 2010","November 3, 2011","February 25, 2015","","","https://ClinicalTrials.gov/show/NCT01111851"
281,"NCT02456168","Development of a Novel Glutamate Receptor Ligand for PET Scans in Neuropsychiatric Systemic Lupus Erythematosus",,"Recruiting","No Results Available","Systemic Lupus Erythematosus","","Changes in brain activity|Use of PET ligand CNS 5161 tracer as an assessment and imaging biomarker for regional brain dysfunction","Northwell Health","All","18 Years to 55 Years   (Adult)","","30","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","PET CNS5161","January 2015","December 2021","December 2021","May 28, 2015","null","January 24, 2018","The Feinstein Institute for Medical Research, Manhasset, New York, United States","","https://ClinicalTrials.gov/show/NCT02456168"
282,"NCT03316898","A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease",,"Recruiting","No Results Available","Alzheimer's Disease","Drug: AGN-242071|Drug: Placebo|Drug: Donepezil|Drug: Memantine","Change from Baseline in Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) Metabolic Measure of Standard Uptake Value Ratio (SUVR) for Whole Brain, Hippocampal and Dorsolateral Prefrontal Cortices|Percentage of Participants with Treatment-Emergent Adverse Events (TEAE)|Percentage of Participants with Changes from Baseline in Clinically Significant Clinical Laboratory Values|Percentage of Participants with Changes from Baseline in Clinically Significant Vital Signs|Percentage of Participants with Changes from Baseline in Clinically Significant Electrocardiogram (ECG) Findings|Percentage of Participants who have Suicidal Ideation or Behaviours as determined by Columbia-Suicide Severity Rating Scale (C-SSRS)|Clearance of AGN-242071|Volume of Distribution of AGN-242071|Cmax: Maximum Plasma concentration for AGN-242071|AUC: Area Under the Curve for AGN-242071","Allergan","All","55 Years to 85 Years   (Adult, Older Adult)","Phase 1","56","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","3142-101-001","September 30, 2018","November 4, 2018","November 4, 2018","October 20, 2017","null","August 16, 2018","ATP Clinical Research, Costa Mesa, California, United States|Irvine Center for Clinical Research, Irvine, California, United States|Synergy Research Centers, Lemon Grove, California, United States|Collaborative Neuroscience, Long Beach, California, United States|Alliance Research, Long Beach, California, United States|Tibor Rubin VA Medical Center, Long Beach, California, United States|Syrentis Clinical Research, Santa Ana, California, United States","","https://ClinicalTrials.gov/show/NCT03316898"
283,"NCT02636634","Non Invasive Methods for Differential Diagnosis Radionecrosis/Recurrence After Radiosurgery of Brain Metastases","CV-METANEC","Completed","No Results Available","Brain Metastases|Growing Lesions After Radiosurgical Treatment","Other: imaging","the choline /N-acetyl aspartate ratio at MR spectroscopy|the lipid / lactate ratio at MR spectroscopy|peak creatine at MR spectroscopy|lesional tissue / normal tissue ratio at PET with FET|Histological result at biopsy","Assistance Publique - Hôpitaux de Paris","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","90","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","P071243|2009-014458-14","June 2010","December 2015","February 2016","December 22, 2015","null","April 11, 2016","CHU Pitié-Salpêtrière - Service de Neurochirurgie du Pr Philippe Cornu - Babinsky, Paris, France","","https://ClinicalTrials.gov/show/NCT02636634"
284,"NCT00934635","A Positron-Emission-Tomography (PET) Study to Measure the Blockade of Dopamine Receptors (D2) in Specific Areas of the Brain in Relation to the Plasma Concentrations of Paliperidone Extended Release (ER) and Oral Risperidone in Schizophrenia Patients and Healthy Controls",,"Terminated","Has Results","Schizophrenia","Drug: Paliperidone ER|Drug: Oral risperidone|Other: PET Scan","Percentage of Paliperidone or Risperidone Dopamine D2 Receptor Occupancies|Plasma Concentrations of Paliperidone and Risperidone|Assessment of the Ratio of Dopamine D2-receptor Occupancies in Two Different Areas of the Brain","Janssen-Cilag G.m.b.H","All","18 Years to 50 Years   (Adult)","Phase 4","2","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CR015277","September 2009","December 2009","December 2009","July 8, 2009","January 11, 2011","February 11, 2014","Aachen, Germany","","https://ClinicalTrials.gov/show/NCT00934635"
285,"NCT01202994","Practice Effects and Amyloid Imaging Using 18F-PIB or Flutemetamol PET and FDG-PET",,"Active, not recruiting","Has Results","Alzheimer's Disease","Drug: 18F-Flutemetamol","Amyloid Deposition Obtained on a 18F-flutemetamol Brain Scan.|Change in Participant Z-score","University of Utah","All","65 Years and older   (Older Adult)","Phase 2","27","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening","43306","May 2011","May 2016","December 2018","September 16, 2010","January 11, 2018","February 7, 2018","University of Utah Center for Alzheimer's Care, Imaging and Research, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT01202994"
286,"NCT02584569","Phase 1 TAK-915 Single-Dose Positron Emission Tomography (PET) Occupancy Study",,"Completed","No Results Available","Healthy Volunteers","Drug: TAK-915","Phosphodiesterase 2A (PDE2A) Brain Enzyme Occupancy in the Putamen as a Function of TAK-915 Plasma Concentration for each subject|Plasma PK concentrations for each subject post tracer injection for each PET scan period following TAK-915 dosing|Dose and exposure of TAK-915 that correspond to PDE2A occupancy in the putamen of at least 45%.","Takeda","All","18 Years to 55 Years   (Adult)","Phase 1","12","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TAK-915-1002|U1111-1168-0766","November 2015","April 2016","April 2016","October 22, 2015","null","July 21, 2016","New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT02584569"
287,"NCT02343757","Alzheimer's Disease Imaging With PET/MRI - Beta-amyloid",,"Unknown status","No Results Available","Dementia|Alzheimer Disease","Device: PET/MRI","To assess image quality and diagnostic performance of 18F-florbetapir (AMYVID) PET/MRI, including direct comparison to corresponding PET/CT images of the same patients.|To evaluate the incremental value of using 18F-florbetapir (AMYVID) in addition to 2-[F-18]-fluoro-2 deoxy-D-glucose (FDG) versus FDG alone.|To determine plaque burden quantitatively with 18F-florbetapir (AMYVID) in PET (form PET/CT and from PET/MR) using novel software developed specifically for these brain application;","University Hospitals Cleveland Medical Center","All","21 Years and older   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","12-12-13","October 2013","December 2016","December 2016","January 22, 2015","null","January 22, 2015","University Hospital Case Medical Center, Cleveland, Ohio, United States","","https://ClinicalTrials.gov/show/NCT02343757"
288,"NCT03071224","Phase 1 Evaluation of [18F]MK-6240 PET as an Imaging Marker for Tau Protein",,"Recruiting","No Results Available","Alzheimer Disease|Healthy Volunteers","Drug: [18F] MNI-946|Drug: [18F]Florbetapir","To determine the longitudinal change in tau burden (including SUVR and tau distribution metrics) compared to baseline in AD subjects and in similarly aged HV subjects.","Invicro","All","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","[18F] MNI-946","June 2016","June 2019","June 2019","March 6, 2017","null","July 11, 2018","Invicro, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT03071224"
289,"NCT01095029","Cerebral Responses During Bilateral/Unilateral Sacral Nerve Stimulation for Idiopathic Faecal Incontinence",,"Completed","No Results Available","Regional Cerebral Blood Flow|Fecal Incontinence","Device: Medtronic InterStim II - 3058","Changes in Regional Cerebral Blood Flow with different pacemaker settings|Changes in continence and quality of life with different pacemaker activation.","University of Aarhus","All","18 Years and older   (Adult, Older Adult)","Not Applicable","10","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Basic Science","003","February 2010","August 2012","July 2014","March 29, 2010","null","July 4, 2014","Anal Physiology Laboratory, Surgical Research Section 900, Aarhus University Hospital, Aarhus, Aarhus C, Denmark","","https://ClinicalTrials.gov/show/NCT01095029"
290,"NCT01547819","Mild Traumatic Brain Injury and Post-Traumatic Stress Disorder",,"Withdrawn","No Results Available","Posttraumatic Stress Disorder|Traumatic Brain Injury","","The main outcome measure will be (11)C-FMZ binding potential (BP) in PTSD post mTBI as compared with nTBI without PTSD and healthy control volunteers without PTSD or TBI.|Degree of correlation between 11C-FMZ BP abnormalities and time elapsed since the original physical trauma in TBI-PTSD patients.","National Institutes of Health Clinical Center (CC)|Uniformed Services University of the Health Sciences","All","18 Years to 50 Years   (Adult)","","0","NIH|U.S. Fed","Observational","Time Perspective: Prospective","120082|12-CC-0082","February 16, 2012","null","December 18, 2013","March 8, 2012","null","August 23, 2018","","","https://ClinicalTrials.gov/show/NCT01547819"
291,"NCT01185119","Effect of GLP-1 on Glucose Metabolism in CNS Assessed by PET",,"Completed","No Results Available","Healthy","Drug: native glp-1 (7-36)","steady glucose metabolism in the brain during hyperglycemia with Native GLP-1 infusion compared to placebo.","University of Aarhus","Male","20 Years to 50 Years   (Adult)","Phase 2|Phase 3","10","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","H80-CP-O015","June 2010","December 2010","March 2011","August 19, 2010","null","March 22, 2011","Aarhus University, Institute of Pharmacology, Aarhus C, Aarhus, Denmark","","https://ClinicalTrials.gov/show/NCT01185119"
292,"NCT00511524","An Imaging Study to Investigate the Distribution of GW842166X in the Brain.",,"Completed","No Results Available","Pain, Inflammatory","Drug: GW842166X|Drug: [carbonyl-^11C]GW842166","Rate at which the drug crosses from plasma to brain (ki)using images from the scan|Safety of drug","GlaxoSmithKline","Male","50 Years to 80 Years   (Adult, Older Adult)","Phase 1","6","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CBA103679","June 26, 2007","July 4, 2007","July 4, 2007","August 6, 2007","null","August 7, 2017","GSK Investigational Site, Uppsala, Sweden","","https://ClinicalTrials.gov/show/NCT00511524"
293,"NCT01420939","Developing Therapies for Traumatic Brain Injury",,"Terminated","No Results Available","Traumatic Brain Injury","","Difference in levels BMs of neovascularization, neuroinflammation, and BM of severity of TBI and epigenetic changes in TBI group in comparison to volunteer group and trauma patients.|Correlation of levels of the BMs of neovascularization, neuroinflammation and severity of TBI to TBI severity assessed by functional outcomes and imaging (MRI, PET) evaluations in TBI patients.","National Institute of Nursing Research (NINR)|National Institutes of Health Clinical Center (CC)","All","18 Years to 70 Years   (Adult, Older Adult)","","19","NIH","Observational","Time Perspective: Prospective","110213|11-NR-0213","July 21, 2011","null","May 21, 2013","August 22, 2011","null","August 21, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT01420939"
294,"NCT03331601","Evaluation of 68-GaNOTA-Anti-HER2 VHH1 Uptake in Brain Metastasis of Breast Carcinoma Patients",,"Recruiting","No Results Available","Breast Neoplasm|Breast Carcinoma|Receptor, ErbB-2","Drug: 68GaNOTA-Anti-HER2 VHH1","The tumor targeting potential in brain metastasis","Universitair Ziekenhuis Brussel","All","18 Years and older   (Adult, Older Adult)","Phase 2","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic","UZBRU_VHH1_2|2015-002328-24","February 24, 2017","September 2021","December 2021","November 6, 2017","null","June 20, 2018","Uz Brussel, Brussels, Belgium","","https://ClinicalTrials.gov/show/NCT03331601"
295,"NCT03143374","Positron Emission Tomography (PET) Imaging of Tau Pathology in Neurodegenerative Disease","PET Tau","Recruiting","No Results Available","Parkinson Disease","Device: [18F]T807 (also known as 18F-AV- 1451)","regional anatomic distribution of PET-tau uptake in dementia syndromes and PET-Tau uptake with neuropsychology and MRI regional GM atrophy at baseline.|•longitudinal neuropsychological and regional MRI decline in dementia syndromes compared to baseline regional PET-tau uptake","University of Pennsylvania|Avid Radiopharmaceuticals","All","40 Years to 85 Years   (Adult, Older Adult)","","120","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","824867","September 2016","September 2019","December 2021","May 8, 2017","null","February 28, 2018","University of Pennsylvania, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT03143374"
296,"NCT02716987","Study to Determine D-Amino Acid Oxidase Brain Enzyme Occupancy of TAK-831 After Single-Dose Oral Administration",,"Completed","No Results Available","Healthy","Drug: TAK-831|Drug: [18F]PGM299","For each PET scan, Total Volume of Distribution (Vt) of [18F]PGM299 in Regions of Interest (ROI) including, but not limited to the cerebellum|For each PET scan, Regional Non-displaceable Binding Potential (BPnd) of [18F]PGM299 in the ROI including, but not limited to the cerebellum|DAO Occupancy Estimation: Percent Difference From Baseline for each post-TAK-831 PET scan|Plasma Concentration of TAK-831 Corresponding to D-Amino Acid Oxidase (DAO) Brain Enzyme Occupancy of 50%|Dose of TAK-831 Corresponding to DAO Brain Enzyme Occupancy of 50%|Coefficient of Variation of [18F]PGM299 Binding in Brain|Plasma Concentrations of TAK-831 during each postdose PET imaging period|Percent Change From Baseline to Day 2 in AUEC(0-30)serine: Area Under the Effect-Time Curve From Time 0 to 30 Hours Postdose for Dextro-Serine (D-serine), Levo-serine (L-serine) and D-Serine/ L-Serine|Percent Change in Maximum Drug-Induced Effect (Emax,serine). From Baseline in Plasma Concentrations of Dextro-Serine (D-serine), Levo-serine (L-serine) and D-Serine/ L-Serine|Time to Reach the Maximum Pharmacodynamic (PD) Effect (time to Emax,serine) for Dextro-Serine (D-serine), Levo-serine (L-serine) and D-Serine/ L-Serine Obtained Directly From the Effect-Time Curve of Serine","Takeda","Male","25 Years to 55 Years   (Adult)","Phase 1","21","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","TAK-831-1003|2015-004509-17|U1111-1176-7493|15/LO/1916","April 2016","August 2016","August 2016","March 23, 2016","null","February 8, 2017","London, United Kingdom","","https://ClinicalTrials.gov/show/NCT02716987"
297,"NCT00204295","Study on Amino Acid Uptake in Brain Tumors",,"Unknown status","No Results Available","Brain Neoplasms","Drug: O-(2-[F-18]Fluorethyl)-L-Tyrosin (FET) - PET","Histological samples where available|CD98 staining where available|Clinical follow-up for at least one year","University Hospital Muenster","All","Child, Adult, Older Adult","Phase 2","60","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","FET-HT-MS","January 2004","null","null","September 20, 2005","null","September 14, 2006","Department of Nuclear Medicine, University Hospital Muenster, Muenster, NRW, Germany","","https://ClinicalTrials.gov/show/NCT00204295"
298,"NCT02736695","Assessment of Hyperphosphorylated Tau PET Binding in Primary Progressive Aphasia","SLD3","Completed","No Results Available","Primary Progressive Aphasia","Drug: F-18 AV 1451","The investigators will be looking at the amount of Tau protein in the brain of patients with PPA.","Mayo Clinic","All","18 Years and older   (Adult, Older Adult)","Not Applicable","45","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","16-001703","July 2016","June 1, 2018","June 1, 2018","April 13, 2016","null","June 7, 2018","Mayo Clinic, Rochester, Minnesota, United States","","https://ClinicalTrials.gov/show/NCT02736695"
299,"NCT03283449","Tau PET Imaging in Atypical Dementias",,"Recruiting","No Results Available","Primary Progressive Aphasia With Suspected Alzheimer's Disease","Drug: 18F-AV-1451|Device: PET","Tau levels in PPA participants","Northwestern University|National Institute on Aging (NIA)","All","20 Years to 100 Years   (Adult, Older Adult)","Phase 1","70","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","STU00200893|R01AG056258","February 2016","February 2022","February 1, 2023","September 14, 2017","null","June 8, 2018","Cognitive Neurology and Alzheimer's Disease Center - Northwestern University, Chicago, Illinois, United States","","https://ClinicalTrials.gov/show/NCT03283449"
300,"NCT00088569","Effect of Direct Current Polarization on Brain Function",,"Completed","No Results Available","Healthy","Drug: 0-15 Water","","National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult","","20","NIH","Observational","","040220|04-N-0220","July 2004","null","June 2006","July 30, 2004","null","March 4, 2008","National Institute of Neurological Disorders and Stroke (NINDS), Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00088569"
301,"NCT02669225","Brain Amyloid- Retention During Wakefulness and Following Emergence From Sleep in Healthy People",,"Completed","No Results Available","Normal Physiology","Radiation: [18F]florbetaben","Differences in the mean retention of [18F]florbetaben|For the results obtained with the MRI scan","National Institute on Alcohol Abuse and Alcoholism (NIAAA)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","22","NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","160059|16-AA-0059","January 29, 2016","July 11, 2018","July 11, 2018","February 1, 2016","null","August 9, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT02669225"
302,"NCT00450021","Imaging of Cannabinoid Receptors Using New Radioactive Tracer",,"Completed","No Results Available","Healthy","Drug: [(11)C] MePPEP","Efficacy of novel PET tracer for DB! in Brain imaging.|Safety and radiation dosimetry of PET tracer [11C] MePPEP; Distribution and variance of CB1 receptors in the brain of healthy controls","National Institute of Mental Health (NIMH)|National Institute of Mental Health, Eli Lilly & Co.|National Institutes of Health Clinical Center (CC)","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","25","NIH|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","070118|07-M-0118","March 19, 2007","February 6, 2008","null","March 21, 2007","null","July 2, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00450021"
303,"NCT03507569","Open Label, Adaptive, Parallel Group PET Study Using RO7017773 And [11C] RO15-4513",,"Recruiting","No Results Available","Autism Spectrum Disorder","Drug: RO7017773|Other: [11C] Ro15-4513","Percentage of Brain Alpha5-Containing GABA-A Receptors Occupied by RO7017773|Plasma Concentrations of RO701773|Number of Participants with Adverse Events (AEs)","Hoffmann-La Roche","All","23 Years to 55 Years   (Adult)","Phase 1","15","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BP40257","April 24, 2018","September 8, 2018","October 5, 2018","April 25, 2018","null","August 9, 2018","Hammersmith Medicines Research; Central Middlesex Hospital, London, United Kingdom","","https://ClinicalTrials.gov/show/NCT03507569"
304,"NCT02193425","Reliability of the Human Brain Connectome",,"Recruiting","No Results Available","Functional Connectivity","Drug: F-18FDG|Device: MRI","The overaching goal of this study is to quantify the reproducibility of multiple measures of brian functional connectivity (FC) during resting conditions and during task performance.|To assess the dynamic properties and energy requirements of the human brain connectome as ewll as the effects of physiologic noise, gender and aging on measures of brain functional connectivity at rest and druing task performance.","National Institute on Alcohol Abuse and Alcoholism (NIAAA)|National Institutes of Health Clinical Center (CC)","All","21 Years to 85 Years   (Adult, Older Adult)","Early Phase 1","180","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","140144|14-AA-0144","July 16, 2014","March 22, 2021","March 31, 2021","July 17, 2014","null","August 9, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT02193425"
305,"NCT02379767","Effects of ECT on Monoamine Oxidase A in Depression Investigated With PET",,"Recruiting","No Results Available","Major Depression","Device: Electroconvulsive therapy|Other: Positron emission tomography of the brain using [11C]harmine|Other: Structural magnetic resonance imaging","Monoamine oxidase A distribution volume in the brain|Grey matter volume","Medical University of Vienna","All","16 Years to 60 Years   (Child, Adult)","","36","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","v1.2_201502","March 2015","February 2018","February 2018","March 5, 2015","null","September 14, 2016","Department of Psychiatry and Psychotherapy, Vienna, Austria","","https://ClinicalTrials.gov/show/NCT02379767"
306,"NCT02056249","Evaluation of the Effect of Hypoglycemia With PET and a Norepinephrine Transporter Ligand",,"Completed","No Results Available","Hypoglycemia","Other: Norepinephrine Transporter (NET) ligand","norepinephrine transporter (NET) ligand concentrations at Baseline|norepinephrine transporter (NET) ligand concentrations in hyperinsulinemic-hypoglycemic Condition","Yale University","All","18 Years to 55 Years   (Adult)","","9","Other","Observational","Observational Model: Case-Crossover|Time Perspective: Prospective","1103008163","June 2011","June 2017","June 2017","February 5, 2014","null","January 11, 2018","PET Center, YCCI Hospital Research Unit (HRU), New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT02056249"
307,"NCT01459016","A Non-drug Methods Study in Participants With Alzheimer's Disease",,"Completed","Has Results","Alzheimer's Disease","Other: PET scan using florbetapir|Other: MRI Scan","Change From Baseline in Volumetric Magnetic Resonance Imaging (vMRI) - Brain Boundary Shift Integral (BBSI) and Ventricular Boundary Shift Integral (VBSI)|Change From Baseline in Volumetric Magnetic Resonance Imaging (vMRI) - Hippocampus Volume Average Percent (%) Change (Chg)|Change From Baseline in Resting State Functional Magnetic Resonance Imaging (rsfMRI)|Change From Baseline in Diffusion Tensor Imaging (DTI) Using Fractional Anisotropy (FA)|Change From Baseline in Diffusion Tensor Imaging (DTI) Using Mean Diffusivity (MD)|Baseline Brain Amyloid Load Using Positron Emission Tomography (PET) and Florbetapir|Number of Participants With Vasogenic Edema on MRI Scan at a Field Strength of 3 Tesla (3T)|Number of Participants With Microhemorrhage on MRI Scan at a Field Strength of 3T|Change From Baseline in the Mini Mental State Examination (MMSE) Total Score|Change From Baseline in the Alzheimer's Disease Assessment Scale Extended Cognitive Subscale (ADAS-Cog14) Total Score|Change From Baseline in the Clinical Dementia Rating (CDR) Total Score","Eli Lilly and Company","All","55 Years and older   (Adult, Older Adult)","Phase 1","56","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","14162|I4O-MC-BACH","December 2011","December 2014","December 2014","October 25, 2011","February 13, 2017","June 28, 2018","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cahors, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Castres, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Foix Cedex, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lavaur, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lille, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Limoges, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Léon, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Marseille, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Montauban Cedex, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nancy, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Paris, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rennes, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Strasbourg, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toulouse, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tours, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vic-En-Bigorre, France","","https://ClinicalTrials.gov/show/NCT01459016"
308,"NCT03042416","18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety",,"Recruiting","No Results Available","Congenital Hyperinsulinism|Neuroblastoma|Neuroendocrine Tumors|Parkinson Disease|Brain Glioma","Drug: 18F-DOPA","Immediate safety evaluation|Delayed safety evaluation|Delayed safety evaluation - referring physician|Biodistribution: scan interpreter will evaluate the distribution of tracer and comment if expected|Perceived clinical benefit","University of Alberta|Alberta Health Services","All","Child, Adult, Older Adult","Phase 3","400","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","Pro00055342","June 29, 2017","December 31, 2021","December 31, 2022","February 3, 2017","null","May 3, 2018","University of Alberta Hospital, Edmonton, Alberta, Canada","","https://ClinicalTrials.gov/show/NCT03042416"
309,"NCT00270803","The Effects of Marijuana on Orientation and Motor Coordination and Brain Metabolism in Regular Smokers of Marijuana",,"Completed","No Results Available","Marijuana Dependence","Drug: Tetra Hydro Cannabinol (THC)","Brain metabolic activity (FDG)|Reaction time (RTs) and errors in performance|Subjective ratings on visual analog scale","Tel-Aviv Sourasky Medical Center|Hadassah Medical Organization","All","20 Years to 65 Years   (Adult, Older Adult)","Not Applicable","12","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","TASMC-05-EE-03-124-CTIL","July 2004","December 2005","December 2005","December 28, 2005","null","May 7, 2008","Department of Nuclear Medicine, Tel Aviv, Israel","","https://ClinicalTrials.gov/show/NCT00270803"
310,"NCT02388295","AZD3241 PET MSA Trial, Phase 2, Randomized,12 Week Safety and Tolerability Trial With PET in MSA Patients",,"Completed","Has Results","Multiple System Atrophy, MSA","Drug: AZD3241|Drug: Placebo","Striatum Brain Region: Change From Baseline in Microglia Activation Via Positron Emission Tomography(PET)|Myeloperoxidase (MPO) Inhibition in Plasma (Change From Baseline), Specific Activity","AstraZeneca","All","30 Years to 80 Years   (Adult, Older Adult)","Phase 2","59","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D0490C00023","April 27, 2015","September 19, 2016","September 19, 2016","March 17, 2015","September 25, 2017","September 25, 2017","Research Site, Stanford, California, United States|Research Site, New Haven, Connecticut, United States|Research Site, Tampa, Florida, United States|Research Site, Boston, Massachusetts, United States|Research Site, Ann Arbor, Michigan, United States|Research Site, Rochester, Minnesota, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, Innsbruck, Austria|Research Site, Turku, Finland|Research Site, Bordeaux Cedex, France|Research Site, Toulouse Cedex 9, France|Research Site, Salerno, Italy|Research Site, Stockholm, Sweden|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, Oxford, United Kingdom","","https://ClinicalTrials.gov/show/NCT02388295"
311,"NCT01815112","Early Diagnosis of Alzheimer-like Dementia: Benefit of MRI and PET Imaging",,"Terminated","No Results Available","Alzheimer Disease|Mild Cognitive Impairment|Vascular Dementia","Other: Magnetic resonance imaging|Other: Positron emission tomography","Dynamic FDG (fluoro-deoxyglucose) PET|Aqueductal CSF flow|Follow-up MRI|Follow-up PET","Centre Hospitalier Universitaire, Amiens","All","65 Years and older   (Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Single (Investigator)|Primary Purpose: Diagnostic","PI07-PR-MEYER1|2007-A01009-44","February 2008","April 2013","April 2014","March 20, 2013","null","March 10, 2015","CHU Rouen, Rouen, Haute Normandie, France|CHU Amiens, Amiens, Picardie, France","","https://ClinicalTrials.gov/show/NCT01815112"
312,"NCT00306865","Brain Changes in Patients With Focal Hand Dystonia",,"Completed","No Results Available","Focal Dystonia","","","National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)","All","18 Years to 65 Years   (Adult, Older Adult)","","30","NIH","Observational","Time Perspective: Other","060031|06-N-0031","March 17, 2006","null","October 14, 2010","March 24, 2006","null","July 2, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00306865"
313,"NCT02359552","Rasagiline Rescue in Alzheimer's Disease Clinical Trial","R2","Active, not recruiting","No Results Available","Alzheimer's Disease","Drug: Rasagiline|Drug: Placebo","The primary study endpoint is the change from baseline to Week 24 in regional glucose metabolism as measured by standard uptake units regional (SUVR) obtained through the 18F-2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET).","The Cleveland Clinic","All","50 Years to 90 Years   (Adult, Older Adult)","Phase 2","27","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","14-519","May 2015","February 15, 2019","February 15, 2019","February 10, 2015","null","April 5, 2018","Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, Nevada, United States|Cleveland Clinic Main Campus, Cleveland, Ohio, United States|Cleveland Clinic Lakewood Hospital, Lakewood, Ohio, United States","","https://ClinicalTrials.gov/show/NCT02359552"
314,"NCT03030391","Novel Positron Emission Tomography (PET) Radiotracer to Image Phosphodiesterase-4B (PDE4B)",,"Terminated","No Results Available","Healthy","Other: PET|Other: MRI","Quantification of 18F-PF-06445974 binding in brain|Biodistribution of 18F-PF-06445974 in the body.","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)","Phase 1","5","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","170041|17-M-0041","January 10, 2017","March 16, 2018","March 16, 2018","January 25, 2017","null","August 8, 2018","National Institutes of Health Clinical Center, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT03030391"
315,"NCT00610064","Brain Effects of Sacral Neuromodulation",,"Completed","No Results Available","Urinary Tract Disease","Radiation: Baseline neuroimaging|Radiation: Neuroimaging during sacral neuromodulation","Effect of sacral neuromodulation on brain activity|Differences in brain activity effects of sacral neuromodulation (SNM) in patients with successful compared to failed SNM testing","University Hospital Inselspital, Berne","All","18 Years and older   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","KEK80_05|1025","October 2005","June 2009","June 2009","February 7, 2008","null","February 5, 2010","Department of Urology, University of Bern, Bern, Switzerland","","https://ClinicalTrials.gov/show/NCT00610064"
316,"NCT02147392","Assessment of [11C]ER176 to Image Translocator Protein in Brain and Whole Body of Healthy People",,"Completed","No Results Available","Pharmacokinetics|Adult","Drug: [11C]ER-176","The identifiability and time stability of distribution volume calculated with compartmental modeling and evaluate the genotype sensitivity of [11C]ER-176|Whole-body biodistribution and dosimetry of [11C]ER-176.","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","16","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","140117|14-M-0117","May 14, 2014","June 16, 2016","June 16, 2016","May 26, 2014","null","July 4, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT02147392"
317,"NCT01896843","Evaluation of Two Radioactive Chemicals to Image mGluR5 Receptors in Brain",,"Completed","No Results Available","mGluR5 Receptors","Drug: STX107","Peak brain uptake, Time-stability of distribution volume, Ratio of specific to non-displaceable brain uptake","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years to 55 Years   (Adult)","Phase 1","19","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","130166|13-M-0166","June 27, 2013","June 16, 2016","June 16, 2016","July 11, 2013","null","July 4, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT01896843"
318,"NCT03032601","Physiological Effects of N-Acetyl Cysteine in Patients With Multiple Sclerosis","MSNAC","Recruiting","No Results Available","Multiple Sclerosis","Dietary Supplement: N-acetyl Cysteine","Changes in the metabolic activity in the brain, and improved parameters with regard to the inflammation associated with the active lesions based on both MRI and PET findings.|Mini-Mental Status examination (MMSE)|Multiple Sclerosis Quality of Life Inventory (MSQLI)|Health Status Questionnaire (SF-36) standard form|Modified Fatigue Impact Scale (MFIS) standard form|MOS Pain Effects Scale (PES)|Bladder Control Scale (BLCS)|Bowel Control Scale (BWCS)|Impact of Visual Impairment Scale (IVIS)|Perceived Deficits Questionnaire (PDQ) standard form|Mental Health Inventory (MHI) standard form|MOS Modified Social Support Survey (MSSS) standard form|Sexual Satisfaction Scale (SSS)|Kurtzke Expanded Disability Status Scale (EDSS)","Thomas Jefferson University","All","30 Years to 80 Years   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","16D.672","January 5, 2017","January 5, 2019","January 5, 2020","January 26, 2017","null","January 17, 2018","Thomas Jefferson University, Philadelphia, Pennsylvania, United States","""Study Protocol and Statistical Analysis Plan: Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/01/NCT03032601/Prot_SAP_000.pdf|""Study Protocol and Statistical Analysis Plan: Cover Page"", https://ClinicalTrials.gov/ProvidedDocs/01/NCT03032601/Prot_SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03032601"
319,"NCT01727622","Arterial Spin Labeling (ASL) MRI for Cognitive Decline",,"Completed","No Results Available","Mild Cognitive Impairment|Alzheimer's Disease","Drug: FDG-PET|Other: ASL-MRI|Procedure: Lumbar Puncture","Composite region of interest (ROI) measure of cerebral blood flow (CBF) measured by ASL MRI versus composite ROI measure of cerebral metabolism measured by FDG PET|Prediction of longitudinal change in hippocampal volume|Prediction of longitudinal change in clinical status (i.e. progression to Alzheimer's Disease)","University of Pennsylvania|National Institute on Aging (NIA)","All","55 Years to 89 Years   (Adult, Older Adult)","Not Applicable","120","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","815471|5R01AG040271","August 2012","May 11, 2018","May 31, 2018","November 16, 2012","null","August 3, 2018","Penn Memory Center, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT01727622"
320,"NCT02858167","Creation of a Normal Database for FluoroDeoxyGlucose-Positron Emission Tomography (FDG-PET) Neurological Examinations","BDD TEP FDG","Completed","No Results Available","Lymphoma","Device: FDG-PET","Absence of neurological impairment detected during standard neurological examination|Mini-mental state score|Frontal Assessment Battery score|Mini International Neuropsychiatric Interview (DSM-IV) score|Montgomery-Åsberg depression rating scale|Absence of cerebral abnormalities detected with PET|Absence of cerebral abnormalities detected with X ray spiral CT|Instrumental Activities of Daily Living evaluation|Cerebral FDG distribution|FDG mean activity in cerebral sections","Central Hospital, Nancy, France","All","21 Years to 80 Years   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)","2008-A00763-52","February 2009","February 2013","February 2013","August 8, 2016","null","September 15, 2016","Service de Médecine Nucléaire, Hôpital Central, Nancy, France","","https://ClinicalTrials.gov/show/NCT02858167"
321,"NCT00083629","Use of [18F]FECNT in Positron Emission Tomography",,"Completed","No Results Available","Healthy","Procedure: PET","","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult","Phase 1","30","NIH","Interventional","Primary Purpose: Treatment","040204|04-M-0204","May 2004","null","September 2005","May 27, 2004","null","March 4, 2008","National Institute of Mental Health (NIMH), Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00083629"
322,"NCT03520543","[11C]Yohimbine PET Study of alpha2-AR","[11C]Yohimbine","Not yet recruiting","No Results Available","Healthy Controls","Drug: [11C]Yohimbine|Drug: [11C]Yohimbine (Part B1) and [11C]Yohimbine + clonidine (Part B2)","Binding potentials|Number of participants with adverse events as a measure of safety and tolerability","Hospices Civils de Lyon","Male","20 Years to 35 Years   (Adult)","Phase 1","12","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","69HCL17_0196","May 21, 2018","July 21, 2018","January 21, 2019","May 9, 2018","null","May 9, 2018","Service de Neurologie C - Hôpital Neurologique et Neurochirurgical Pierre Wertheimer, GHE, Bron, France","","https://ClinicalTrials.gov/show/NCT03520543"
323,"NCT01258751","This Study Will Evaluate The Relationship Between Plasma Drug Levels And Receptor Binding In Brain Using PET (Positron Emission Tomography) In Healthy Volunteers",,"Completed","No Results Available","Healthy","Drug: PF-05212377","To assess the central 5-HT6 receptor occupancy (RO) in the striatum in relation to systemic exposure of PF-05212377 after single oral administration in healthy adult subjects.|Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Maximum concentration (Cmax) for PF-05212377 in plasma|Time at Cmax (Tmax) for PF-05212377 in plasma|Area under the concentration-time profile from time zero to the time of the last quantifiable concentration (AUClast) for PF-05212377 in plasma|Average concentration during the first post-dose PET scan (Cavg (scan 1)) for PF-05212377 in plasma|Average concentration during the second post-dose PET scan (Cavg (scan 2)) for PF-05212377 in plasma","Pfizer|Yale University","All","18 Years to 55 Years   (Adult)","Phase 1","12","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","B2081007","December 2010","May 2011","May 2011","December 13, 2010","null","July 6, 2011","Pfizer Investigational Site, New Haven, Connecticut, United States|Pfizer Investigational Site, New Haven, Connecticut, United States|Pfizer Investigational Site, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT01258751"
324,"NCT03204305","Brain Imaging of Cannabinoid Receptors",,"Recruiting","No Results Available","Cannabis Use Disorder|Cannabis Dependence, Continuous","Drug: 11C-OMAR|Drug: Cannabis","Non-displaceable binding potential (BPND)|Peak Marijuana Withdrawal Discomfort Score","Johns Hopkins University|National Institute on Drug Abuse (NIDA)","Female","18 Years to 45 Years   (Adult)","Early Phase 1","20","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","IRB00101744|R21DA043963","September 14, 2017","May 31, 2019","May 31, 2020","July 2, 2017","null","February 12, 2018","Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT03204305"
325,"NCT00966017","Glucose Metabolic, Amyloid, and Tau Brain Imaging in Down Syndrome and Dementia",,"Unknown status","No Results Available","Down Syndrome|Alzheimer's Disease","","","National Institute on Aging (NIA)","All","45 Years and older   (Adult, Older Adult)","","108","NIH","Observational","Observational Model: Case Control|Time Perspective: Retrospective","IA0167|1R01AG033015-01","July 2009","February 2014","February 2014","August 26, 2009","null","December 29, 2009","UCLA, Los Angeles, California, United States","","https://ClinicalTrials.gov/show/NCT00966017"
326,"NCT01253655","To Evaluate The Relationship Between Plasma Drug Levels And Receptor Binding In Brain Using PET (Positron Emission Tomography) In Healthy Volunteers","3193A1-1103","Completed","No Results Available","Healthy","Drug: PF-05212365","Exposure response of 5-HT6 Receptor Occupancy (RO) of PF-05212365 in the striatum of healthy adult subjects|Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Change from baseline in orthostatic blood pressure|Change from baseline in supine blood pressure|Change from baseline in Singlet ECG|Clinically relevant levels of standard hemotology (e.g. Hemoglobin, Hematocrit RBC count), chemistry (e.g. BUN, Creatinine, fasting Glucose), and urinalysis (e.g. pH Glucose, Protein).|Abnormal findings from standard physical examination|Maximum concentration (Cmax) for PF-05212365 in plasma|Time at Cmax (Tmax) for PF-05212365 in plasma|Area under the concentration-time profile from time zero to the time of the last quantifiableconcentration (AUClast) for PF-05212365 in plasma|Average concentration during the first post-dose PET scan (Cavg (scan 1)) for PF-05212365 in plasma|Average concentration during the second post-dose PET scan (Cavg (scan 2)) for PF-05212365 in plasma|Change from baseline in orthostatic pulse rate|Change from baseline in supine pulse rate|Abnormal findings from standard neurological examination","Pfizer|Yale University","All","18 Years to 55 Years   (Adult)","Phase 1","6","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","B1961009","November 2010","March 2011","March 2011","December 3, 2010","null","April 28, 2011","Pfizer Investigational Site, New Haven, Connecticut, United States|Pfizer Investigational Site, New Haven, Connecticut, United States|Pfizer Investigational Site, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT01253655"
327,"NCT02195154","18F-DTBZ PET and Multi-modal MRI in the Patients With Vascular Parkinsonism",,"Completed","No Results Available","Vascular Parkinsonism","Drug: 18F-DTBZ","The difference of specific uptake ratio (SUR) of 18F-DTBZ between disease and control group|The correlation between parameters from different imaging modalities and the severity of motor symptoms or cognition in disease group.","Chang Gung Memorial Hospital|National Science Council, Taiwan","All","45 Years to 80 Years   (Adult, Older Adult)","Phase 2","13","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","101-4624A","November 2013","July 31, 2017","July 31, 2017","July 21, 2014","null","January 31, 2018","Chang Gung Memory Hospital, Taoyuan, Taiwan","","https://ClinicalTrials.gov/show/NCT02195154"
328,"NCT00543322","PET Study of the Nicotinic Receptors in Human",,"Terminated","No Results Available","Healthy|Parkinson Disease|Alzheimer Disease|Epilepsy","","","Commissariat A L'energie Atomique","All","18 Years to 85 Years   (Adult, Older Adult)","","null","Other","Observational","Time Perspective: Prospective","SHFJ-100008","July 2001","null","July 2006","October 12, 2007","null","October 12, 2007","CEA, Service Hospitalier Frederic Joliot, Orsay, France","","https://ClinicalTrials.gov/show/NCT00543322"
329,"NCT02676843","Tau PET Imaging With 18F-AV-1451 in Subjects With MAPT Mutations",,"Enrolling by invitation","No Results Available","Frontotemporal Lobar Degeneration|FTLD|Frontotemporal Dementia|FTD|Tauopathies","Drug: 18F-AV-1451","Evidence of Tau deposition on PET scan","Columbia University|National Institute of Neurological Disorders and Stroke (NINDS)","All","18 Years and older   (Adult, Older Adult)","Phase 2","16","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","AAAP4551|R01NS076837","April 2016","December 2017","December 2017","February 8, 2016","null","October 27, 2016","Morton A. Kreitchman PET Center, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT02676843"
330,"NCT00397748","PET Scanning of Adults With Attention Deficit Hyperactivity Disorder (ADHD)",,"Completed","No Results Available","Volunteer|Attention Deficit Hyperactivity Disorder","","","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","Male","18 Years to 55 Years   (Adult)","","16","NIH","Observational","Time Perspective: Other","060246|06-M-0246","September 15, 2006","null","November 27, 2012","November 9, 2006","null","August 23, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00397748"
331,"NCT01632189","The Effect of Varenicline on D2/D3 Receptor Binding in Smokers",,"Completed","No Results Available","Nicotine Dependence","Drug: Varenicline","[11C]-(+)-PHNO DRD2/3 binding potential (BPND)|Relationship between ability to quit smoking and changes in DRD2/3","Centre for Addiction and Mental Health|Ontario Lung Association|Pfizer","All","21 Years to 45 Years   (Adult)","Not Applicable","8","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","040/2012","September 2012","August 2015","August 2015","July 2, 2012","null","January 27, 2016","Centre for Addiction and Mental Health, Toronto, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT01632189"
332,"NCT00094913","PET Changes in Alzheimer's Disease (AD)",,"Unknown status","No Results Available","Alzheimer Disease","","","National Institute on Aging (NIA)","All","20 Years to 90 Years   (Adult, Older Adult)","","105","NIH","Observational","Time Perspective: Prospective","IA0055|R01AG013616","May 2004","null","April 2005","October 29, 2004","null","May 27, 2009","Center for Brain Health, Silberstein Institute, New York University, New York City, New York, United States","","https://ClinicalTrials.gov/show/NCT00094913"
333,"NCT00484523","Constitution of a Standardized Neural Imaging Database in Healthy Subjects",,"Completed","No Results Available","Healthy","Procedure: SPET, PET and MRI","precise brain morphology","Assistance Publique Hopitaux De Marseille","All","20 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","60","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","2007/09","July 2007","January 2010","null","June 11, 2007","null","August 28, 2014","CHU Timone, Marseille, France","","https://ClinicalTrials.gov/show/NCT00484523"
334,"NCT01227564","Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Early Alzheimer's Disease",,"Completed","Has Results","Alzheimer's Disease","Biological: ACC-001 3 μg/ QS-21 50 μg|Biological: ACC-001 10 μg/ QS-21 50 μg|Other: Placebo- Phosphate buffered saline (PBS)","Change From Baseline in Brain Fibrillar Beta-Amyloid Protein (Aβ) at Week 104 as Measured by Standard Uptake Value Ratios (SUVRs) Over the Composite Regions of Interest (ROIs)","Pfizer|JANSSEN Alzheimer Immunotherapy Research & Development, LLC","All","50 Years to 80 Years   (Adult, Older Adult)","Phase 2","63","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","B2571010|3134K1-2208","February 2011","February 2014","February 2014","October 25, 2010","February 25, 2016","February 25, 2016","Banner Alzheimer's Institute, Phoenix, Arizona, United States|Banner Good Samaritan Medical Center, Phoenix, Arizona, United States|Banner Boswell Medical Center, Sun City, Arizona, United States|Banner Lakes Imaging Center, Sun City, Arizona, United States|Banner Sun Health Research Institute, Sun City, Arizona, United States|Southwest PET Institute, Tucson, Arizona, United States|University of Arizona, Health Sciences Center - Department of Neurology, Tucson, Arizona, United States|Universal Medical Center, Tucson, Arizona, United States|Northwest NeuroSpecialists, LLC, Tucson, Arizona, United States|Radiology Limited, Tucson, Arizona, United States|Pacific Neuroscience Medical Group, Oxnard, California, United States|GCRC (Drug administered), New Haven, Connecticut, United States|Yale University School of Medicine, Alzheimer's Disease Research Unit, New Haven, Connecticut, United States|Investigational Drug Service, New Haven, Connecticut, United States|Norman S. Werdiger, MD, New Haven, Connecticut, United States|Clinical Research Unit, Washington, District of Columbia, United States|Georgetown University Hospital, Washington, District of Columbia, United States|Georgetown University Medical Center Department of Neurology, Washington, District of Columbia, United States|Meridien Research, Brooksville, Florida, United States|Florida Neurology Group PL, Fort Myers, Florida, United States|Internal Medicine Associates of Lee County, MD, PA, Fort Myers, Florida, United States|Neuropsychiatric Research Center of Southwest Florida, Fort Myers, Florida, United States|Florida Radiology Leasing, Limited Liability Corporation, Fort Myers, Florida, United States|Radiology Regional Center, Fort Myers, Florida, United States|Mount Sinai Medical Center, Miami Beach, Florida, United States|Miami Jewish Health Systems, Miami, Florida, United States|Premiere Research Institute (Palm Beach Neurology), West Palm Beach, Florida, United States|Massachusetts General Hospital (For PET only), Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, Nevada, United States|Steinberg Diagnostic Imaging, Las Vegas, Nevada, United States|Nevada Cancer Institute, Las Vegas, Nevada, United States|Memory Enhancement Center of America, Incorporated, Eatontown, New Jersey, United States|Satatoga PET Associates, Clifton Park, New York, United States|Rhode Island Mood and Memory Research Institute, East Providence, Rhode Island, United States|Butler Hospital, Providence, Rhode Island, United States|Baylor College of Medicine, Department of Neurology, Houston, Texas, United States|The Memory Clinic, Bennington, Vermont, United States|The Pharmacy Inc., Bennington, Vermont, United States","","https://ClinicalTrials.gov/show/NCT01227564"
335,"NCT00343707","PET (Positron Emission Tomography)/Public Speaking Study With A Combination Of 2 Medications In Social Anxiety Patients",,"Completed","No Results Available","Depressive Disorder and Anxiety Disorders","Drug: vestipitant|Drug: paroxetine","To assess, by mean of Positron Emission Tomography, the degree of regional Cerebral Blood Flow in different brain regions involved in the emotional brain circuit during public speaking task before treatment and after eight weeks of treatment.|To assess symptomatic and physiological measures of anxiety induced by the public speaking task and social anxiety symptoms during eight weeks of treatment. To evaluate safety, tolerability and the effect on sexual function of treatment.","GlaxoSmithKline","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","72","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","NKP102280","November 2004","November 2005","November 2005","June 23, 2006","null","September 15, 2016","GSK Investigational Site, Uppsala, Sweden","","https://ClinicalTrials.gov/show/NCT00343707"
336,"NCT02996916","Efficacy of Olmesartan on Cerebral Glucose Metabolism, Vascular Inflammation and Adipose Tissue",,"Recruiting","No Results Available","Efficacy of Olmesartan on Cerebral Glucose Metabolism in Essential Hypertension","Drug: Olmesartan|Drug: Amlodipine","Effects of treatment on the nominal change in cerebral glucose metabolism from baseline after 6 months of treatment as measured by FDG-PET/CT|Change from baseline in vascular inflammation measured by blood-normalized standardized uptake value, known as a target-to-background ratio (TBR) by FDG-PET/CT|Change from baseline in abdominal and muscle fat volume as measured by CT|Change from baseline in circulating inflammatory markers including hsCRP (mg/L), adiponectin (µg/mL), ADMA (nmoL/mL), DPP-4 (ng/mL), advanced glycation end products (AGEs, µg/mL) and angiotensin-(1-7) (ng/mL)","Kurume University","All","20 Years and older   (Adult, Older Adult)","Phase 4","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Olme-brain","December 2015","December 2018","December 2020","December 19, 2016","null","December 20, 2016","Kurume University Hospital, Kurume, Japan","","https://ClinicalTrials.gov/show/NCT02996916"
337,"NCT00855868","Ability Of ([18F]-AV-45) PET Scan to Distinguish Alzheimer's Disease Subjects From Cognitively Normal Individuals",,"Completed","Has Results","Alzheimer's Disease","Drug: florbetapir F 18|Drug: [11C]-PIB","Differences in Standard Uptake Value Ratio (SUVR) for Frontal Cortex/Cerebellum and Whole Brain/Cerebellum of the Positron Emission Tomography (PET) Scan With [18F]-AV-45 for Probable Alzheimer's Disease (AD) Versus Cognitively Normal Subjects.","Avid Radiopharmaceuticals|American College of Radiology Imaging Network|General Electric","All","55 Years to 90 Years   (Adult, Older Adult)","Phase 2","28","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic","ACRIN PA 4003","March 2009","January 2011","January 2011","March 5, 2009","July 26, 2012","July 26, 2012","Research Site, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT00855868"
338,"NCT03307993","Positron Emission Tomography (PET) Study in Patients With Alzheimer's Disease",,"Terminated","No Results Available","Alzheimer's Disease","Drug: Idalopirdine","5-HT6 Receptor Occupancy (RO)|Idalopirdine plasma concentration (CPET)","H. Lundbeck A/S","All","50 Years and older   (Adult, Older Adult)","Phase 1","3","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17475A","September 22, 2017","February 19, 2018","February 19, 2018","October 12, 2017","null","April 4, 2018","Johns Hopkins Hospital, Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT03307993"
339,"NCT00250172","PET Whole Body Biodistribution and Test Retest Bain Imaging Studies Using a Phosphodiesterase 4 Inhibitor (R)-[11C]Rolipram",,"Completed","No Results Available","Dosimetry|Healthy","Drug: [C-11](R)-rolipram","","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","26","NIH","Interventional","Primary Purpose: Treatment","060002|06-M-0002","October 31, 2005","February 5, 2009","February 5, 2009","November 7, 2005","null","August 8, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00250172"
340,"NCT01228448","In-Room PET in Proton Radiation Therapy",,"Recruiting","No Results Available","Brain Tumor|Head and Neck Tumor|Skull Base Tumor","Procedure: PET scan","Effectiveness|Optimize the in-room PET acquisition length","Massachusetts General Hospital|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","39","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","10-241","October 2010","December 2018","December 2018","October 26, 2010","null","March 8, 2018","Massachusetts General Hospital, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT01228448"
341,"NCT01000870","Safety and Efficacy of Positron Emission Tomography Imaging With MNI-513",,"Terminated","No Results Available","Alzheimer Disease","Drug: MNI-513-01","To evaluate the efficacy and safety of MNI-513 positron emission tomography (PET) for detection/exclusion of cerebral amyloid beta in patients with Alzheimer's disease compared to healthy volunteers","Institute for Neurodegenerative Disorders","All","55 Years and older   (Adult, Older Adult)","Early Phase 1","6","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","MNI-513-01","October 2009","September 2010","September 2010","October 23, 2009","null","October 6, 2010","Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT01000870"
342,"NCT00180193","F-18-OMFD-PET for Radiotherapy Treatment Planning and Evaluation of Early Therapy Response",,"Terminated","No Results Available","Brain Tumor","","","Technische Universität Dresden|Advanced Biochemical Compounds GmbH","All","18 Years and older   (Adult, Older Adult)","","40","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","ABX-OMFD-FU","December 2003","null","null","September 16, 2005","null","August 26, 2009","Department of Nuclear Medicine, Dresden, Germany","","https://ClinicalTrials.gov/show/NCT00180193"
343,"NCT01545310","A Positron Emission Tomography Study of SLV354 in Healthy Subjects and Subjects With Schizophrenia",,"Completed","No Results Available","Schizophrenia","Drug: SLV354","Brain receptor occupancy|Pharmacokinetic profile","Abbott","Male","18 Years to 55 Years   (Adult)","Phase 1","18","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)","M12-700","May 2011","July 2012","July 2012","March 6, 2012","null","September 18, 2012","Site Reference ID/Investigator# 52162, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT01545310"
344,"NCT01028209","Evaluation of [18F] PBR06 and PET as a Marker of Inflammation in Subjects With Neurological Conditions","PBR06","Terminated","No Results Available","Alzheimer Disease|Parkinson Disease|Multiple Sclerosis","Drug: [18F] PBR06","To evaluate [18F] PBR06 PET imaging as a tool to detect microglial activation in the brain of AD, PD and MS research participants.","Institute for Neurodegenerative Disorders","All","18 Years and older   (Adult, Older Adult)","Phase 1","12","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","PBR06 001","November 2009","April 2010","September 2010","December 9, 2009","null","October 11, 2010","Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT01028209"
345,"NCT02237703","Kappa Opioid Receptor Imaging in Post-traumatic Stress Disorder (PTSD)",,"Terminated","No Results Available","Post-traumatic Stress Disorder (PTSD)|Trauma","Other: Positron emission tomography (PET) imaging","Volume of distribution (VT) of cerebral KOR expression in PTSD and healthy control subjects with and without trauma history using the KOR radioligand [11C]LY2795050 and PET","New York University School of Medicine|Yale University","All","18 Years to 55 Years   (Adult)","","17","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","S12-01521","March 2012","March 2015","August 2016","September 11, 2014","null","January 20, 2017","NYU School of Medicine, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT02237703"
346,"NCT00986973","Fluorodeoxyglucose Positron Emission Tomography (FDG PET) Findings in Patients With Phenylketonuria Before and After KUVAN Therapy","PKU","Completed","Has Results","Phenylketonuria","Drug: Sapropterin","Plasma Phenylalanine Level (mg/dl)|Hopkins Verbal Learning Test (HVLT) Total Recall|Hopkins Verbal Learning Test (HVLT) Delayed Recall|Paced Auditory Serial Addition Task (PASAT)|Symbol-Digit Modalities Test (SMTD)|Wechsler Adult Intelligence Scale (WAIS-IV)-Digit Span|Delis-Kaplan Executive Function System Verbal Fluency Subtest (D-KEFS)","Children's Hospital of Philadelphia","All","18 Years to 50 Years   (Adult)","Not Applicable","6","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","IRB 09-007154","March 2010","July 2011","September 2011","September 30, 2009","May 12, 2015","June 8, 2015","Children's Hospital of Philadelphia, Section of Metabolism,PKU program, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT00986973"
347,"NCT01359852","A Study of [11C]JNJ-42491293, a Possible PET Ligand for the mGlu2 Receptor, in Healthy Adult Volunteers",,"Completed","No Results Available","Healthy","Drug: [11C] JNJ-42491293|Drug: [11C] JNJ-42491293 + JNJ-40411813","Metabolism (uptake, distribution, and clearance) of [11C] JNJ-42491293 in brain (Part B)|Adverse events (All Parts)|Biodistribution of [11C] JNJ-42491293 (Part A)|Radiation dosimetry of [11C] JNJ-42491293 (Part A)|Peripheral metabolism of [11C] JNJ-42491293 (Part B)|Distribution of [11C] JNJ-42491293 in the brain by pre-treatment with single oral doses of JNJ-40411813 (Part C and Part D)|Clearance rate of JNJ-40411813 from the brain (Part D)","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","Male","18 Years to 45 Years   (Adult)","Phase 1","20","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)","CR017848|42491293EDI1001|2010-022063-36","December 2010","July 2011","July 2011","May 25, 2011","null","July 22, 2011","","","https://ClinicalTrials.gov/show/NCT01359852"
348,"NCT01526005","Brain Nicotine Receptor Density & Response to Nicotine Patch",,"Completed","No Results Available","Cigarette Smoking","Drug: Transdermal Nicotine Patch|Drug: Transdermal Placebo Patch","PET scanning","Brentwood Biomedical Research Institute","All","18 Years to 55 Years   (Adult)","","50","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","0015","March 2012","January 2014","null","February 3, 2012","null","January 27, 2015","West Los Angeles Veterans Affairs Medical Center, Los Angeles, California, United States","","https://ClinicalTrials.gov/show/NCT01526005"
349,"NCT01153607","Evaluation of the Diagnostic Potential of BAY1006578 in Probable Alzheimers Disease Patients Versus Healthy Volunteers and Radiation Dosimetry of BAY1006578 in Healthy Volunteers",,"Completed","No Results Available","Diagnostic Imaging","Drug: BAY1006578","Discrimination of probable Alzheimer's Disease patients from healthy volunteers by BAY1006578 brain Positron Emission Tomography (PET) imaging as evaluated by different quantification approaches|Discrimination of probable Alzheimer's Disease patients from healthy volunteers by BAY1006578 brain Positron Emission Tomography (PET) imaging as evaluated by visual analysis and by standard parameters (e.g. Standardized Uptake Values=SUV)|Electrocardiogram (ECG)|Blood pressure|Adverse events collection","Piramal Imaging SA","All","50 Years and older   (Adult, Older Adult)","Phase 1","24","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","14708|2009-017166-24","June 2010","October 2011","October 2011","June 30, 2010","null","January 21, 2013","Turku, Finland|Stockholm, Sweden","","https://ClinicalTrials.gov/show/NCT01153607"
350,"NCT01165632","Fluorine F 18 Fluorodopa-Labeled PET Scan in Planning Surgery and Radiation Therapy in Treating Patients With Newly Diagnosed High- or Low-Grade Malignant Glioma",,"Active, not recruiting","No Results Available","Adult Anaplastic Astrocytoma|Adult Anaplastic Ependymoma|Adult Anaplastic Oligodendroglioma|Adult Brain Stem Glioma|Adult Diffuse Astrocytoma|Adult Ependymoma|Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Adult Mixed Glioma|Adult Myxopapillary Ependymoma|Adult Oligodendroglioma|Adult Pilocytic Astrocytoma|Adult Pineal Gland Astrocytoma|Adult Subependymal Giant Cell Astrocytoma|Adult Subependymoma","Procedure: biopsy|Procedure: computed tomography|Procedure: therapeutic conventional surgery|Radiation: radiation therapy treatment planning/simulation|Radiation: radiation therapy|Procedure: magnetic resonance imaging|Procedure: positron emission tomography|Drug: fluorine F 18 fluorodopa","18F-FDOPA PET activity, MRI contrast enhancement, and high- or low-grade glioma biopsies|18F- FDOPA-PET metabolic imaging information|Concordance of 18F-FDOPA PET and 11C-choline activity, MRI contrast enhancement, and high- or low-grade glioma biopsies|With and without 18F- FDOPA PET, 11C-choline PET metabolic imaging information|18F-FDOPA PET activity, 11C-choline PET activity, MRI contrast enhancement, pMRI, and DTI, with high- or low-grade glioma biopsies","Mayo Clinic|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","30","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","MC1078|NCI-2010-01607|10-001904","July 2010","August 26, 2016","July 2018","July 20, 2010","null","May 1, 2018","Mayo Clinic, Rochester, Minnesota, United States","","https://ClinicalTrials.gov/show/NCT01165632"
351,"NCT02237677","CB1 Receptor PET Imaging Reveals Gender Differences in PTSD",,"Terminated","No Results Available","Post-traumatic Stress Disorder (PTSD)","Other: Positron emission tomography (PET) imaging","Volume of distribution (VT) of cerebral CB1 receptor expression in PTSD and controls within a fear circuit of brain regions that regulate stress-related behaviors using the CB1 radioligand carbon - 11 (11C) [11C]OMAR and PET.","New York University School of Medicine|Yale University","All","18 Years to 55 Years   (Adult)","","36","Other","Observational","Observational Model: Case Control|Time Perspective: Cross-Sectional","12-02787","June 2012","March 2016","March 2016","September 11, 2014","null","August 17, 2016","NYU School of Medicine, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT02237677"
352,"NCT02081482","Cerebral Metabolism in Patients With Refractory Chronic Cluster Headache Treated by Occipital Nerve Stimulation","MET-ONS","Unknown status","No Results Available","Refractory Chronic Cluster Headache","Radiation: 18F-FDG PET","Comparison of cerebral metabolism","Centre Hospitalier Universitaire de Nice","All","18 Years and older   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","13-AOI-05","March 2014","July 2015","August 2016","March 7, 2014","null","March 21, 2016","CHU -Hôpital Gabriel Montpied, Clermont Ferrand, France|Institut des Neurosciences, Marseille, France|Département d'Evaluation et Traitement de la Douleur - Pôle Neurosciences Cliniques - Centre Hospitalo-Universitaire de Nice, Nice, France|Centre d'Urgence Céphalées, Paris, France","","https://ClinicalTrials.gov/show/NCT02081482"
353,"NCT01721473","Brain Nicotine Receptor Density in Veteran Smokers","BNRDVS","Completed","No Results Available","Positron Emission Tomography","","Rating scales, 2-FA PET scan, and MRI scan","VA Office of Research and Development","All","18 Years to 65 Years   (Adult, Older Adult)","","184","U.S. Fed","Observational","Observational Model: Other|Time Perspective: Prospective","NURA-02-11S","January 1, 2013","June 30, 2018","June 30, 2018","November 5, 2012","null","July 18, 2018","VA San Diego Healthcare System, San Diego, CA, San Diego, California, United States|VA Greater Los Angeles Healthcare System, West Los Angeles, CA, West Los Angeles, California, United States","","https://ClinicalTrials.gov/show/NCT01721473"
354,"NCT02076152","FMISO PET Study of Glioblastoma",,"Recruiting","No Results Available","Recurrent Glioblastoma","Device: FMISO PET|Device: MRI|Drug: Bevacizumab|Drug: CCNU","Change in Tumor blood flow/perfusion|Change in tumor hypoxic volume|Blood vessel permeability (Ktrans change on MRI scan)|Tumor blood flow measured by MRI perfusion","Massachusetts General Hospital|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","40","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","13-482|R01CA129371","February 2014","May 2019","January 2020","March 3, 2014","null","June 11, 2018","Massachusetts General Hospital, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT02076152"
355,"NCT02424656","Alterations in the Brain's Connectome After Severe Traumatic Brain Injury","ABCinTBI","Active, not recruiting","No Results Available","Traumatic Brain Injury|Disorders of Consciousness","Procedure: MRI|Procedure: TMS-EEG|Procedure: FDG-PET|Other: Clinical scales","Changes in whole brain connectivity as a measure of recovery of consciousness","Danish Research Centre for Magnetic Resonance|University of Milan|University of Kiel|Glostrup University Hospital, Copenhagen|Lundbeck Foundation|Danish Council for Independent Research|Region Capital Denmark","All","18 Years to 65 Years   (Adult, Older Adult)","","50","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","H-4-2013-186","September 2014","December 2018","December 2018","April 23, 2015","null","August 23, 2018","Danish Research Centre for Magnetic Resonance, Copenhagen, Denmark","","https://ClinicalTrials.gov/show/NCT02424656"
356,"NCT01483469","A Human Proof of Concept Study for [11C]-RO5011232 as Radiotracer and Study of the Binding of RO4917523 to Human mGlu5 Brain Receptor at Steady-State in Healthy Volunteers",,"Completed","No Results Available","Healthy Volunteer","Drug: RO4917523|Drug: RO5011232","Part I: mGlu5 receptor binding of [11C]-RO5011232 radiotracer in human brain, assessed by positron emission tomography (PET)|Part II: Dosimetry/radiation safety of [11C]-RO5011232 assessments by whole body PET scan|Part III: Measurement of test-retest precision of PET images of regions of interest in the human brain|Part IV: Correlation between RO4917523 plasma concentration and R04917523 binding to mGlu5 receptor in brain|Safety of [11C]-RO5011232 administered intravenously at microdose level: Incidence of adverse events|Part IV: In vitro binding potential (reference region with no specific binding of radiotracer) assessed by PET|Part IV: Safety of 14-day treatment with RO4917523: Incidence of adverse events","Hoffmann-La Roche","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","56","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","BP27890","December 2011","October 2013","October 2013","December 1, 2011","null","November 2, 2016","Baltimore, Maryland, United States|Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT01483469"
357,"NCT03270579","A Study to Investigate the Regional Brain Kinetics of the Positron Emission Tomography Ligand [18F]JNJ-64511070",,"Completed","No Results Available","Healthy","Drug: [18F]JNJ-64511070","Part A: Effective Radiation Dose Following Injection of [18F]JNJ-64511070|Part B: Total and Regional Brain Compartmental Kinetics for Volume of Distribution of [18F]JNJ-64511070 in Brain|Number of Participants With Adverse Events as a Measure of Safety and Tolerability","Janssen Research & Development, LLC","Male","18 Years to 55 Years   (Adult)","Phase 1","8","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","CR108379|2017-002262-47|64140284EDI1002","September 12, 2017","February 6, 2018","February 6, 2018","September 1, 2017","null","April 12, 2018","UZ Leuven Gasthuisberg, Leuven, Belgium","","https://ClinicalTrials.gov/show/NCT03270579"
358,"NCT00814957","An Open Label Positron Emission Tomography (PET) Study of GSK618334 in Healthy Male Subjects Using 11C-PHNO as PET Ligand",,"Completed","No Results Available","Substance Dependence","Drug: GSK618334","Binding of PHNO, PET ligand, in each region of interest at each scan.|Percentage of PHNO, PET ligand, occupancy in each region of interest after a single oral dose of GSK618334 for each individual.|Time course of GSK618334 concentration in blood following a single oral dose.|Adverse events and other safety assessments such as clinically relevant changes in electrocardiography (ECG); vital signs (blood pressure, heart rate); laboratory safety data and physical examination.|Measuring GSK618334 in the body (pharmacokinetic endpoints): PK parameters of GSK618334 Cmax, AUCinf, tmax.","GlaxoSmithKline","Male","30 Years to 55 Years   (Adult)","Phase 1","12","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","110269","December 8, 2008","June 11, 2009","June 11, 2009","December 25, 2008","null","July 7, 2017","GSK Investigational Site, Harrow, Middlesex, United Kingdom","","https://ClinicalTrials.gov/show/NCT00814957"
359,"NCT01461109","Research Involving Subjects With Parkinson's Disease, Alzheimer Disease and Healthy Controls",,"Completed","No Results Available","Parkinson Disease|Alzheimer Disease","Drug: [18F] CFPyPB","To assess the dynamic uptake and washout of [18F] CFPyPB|Perform blood metabolite characterization of [18F] CFPyPB|To obtain safety data|Obtain test/retest reproductibility","Institute for Neurodegenerative Disorders","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 1","4","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)","GlyT1-01","August 2011","September 2012","May 2014","October 27, 2011","null","June 4, 2014","Institute_Neurodegenerative_Disorders, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT01461109"
360,"NCT03278119","Sleep Aging and Risk for Alzheimer's 2.0","SARA","Recruiting","No Results Available","Alzheimer Disease|Sleep Apnea","Diagnostic Test: PET Scan and nocturnal polysomnography","Establishing how mild-to-moderate OSA increases AD risk will inform novel preventive therapies for AD.|Establishing that SWS quality is associated with longitudinal amyloid deposition will identify a key mechanism by which age increases AD risk.","New York University School of Medicine","All","55 Years to 75 Years   (Adult, Older Adult)","","124","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","17-01005","May 1, 2018","May 30, 2023","May 30, 2023","September 11, 2017","null","May 9, 2018","NYU Center for Brain Health, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT03278119"
361,"NCT02497235","A Phase 1 Positron Emission Tomography Study to Measure Cholesterol 24S-Hydroxylase Target Occupancy of TAK-935",,"Completed","Has Results","Epilepsy, Molecular Mechanisms of Pharmalogical Action, Protective Agents","Drug: TAK-935|Drug: [18F]MNI-792 (tracer)","Cholesterol 24S-Hydroxylase (CH24H) Brain Enzyme Occupancy as a Function of TAK-935 Plasma Concentration at 45 Minutes Post-TAK-935 Dose|CH24H Brain Enzyme Occupancy as a Function of TAK-935 Plasma Concentration at 2 Hours Post-TAK-935 Dose|CH24H Brain Enzyme Occupancy as a Function of TAK-935 Plasma Concentration at 10 Hours Post-TAK-935 Dose|CH24H Brain Enzyme Occupancy as a Function of TAK-935 Plasma Concentration at 24 Hours Post-TAK-935 Dose|Plasma Concentration of TAK-935 During Post-TAK-935 Dosing PET Scan Periods|Percent Change From Baseline in the AUEC24 for Plasma 24S Hydroxycholesterol (24HC)","Takeda","All","19 Years to 55 Years   (Adult)","Phase 1","11","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","TAK-935_1003|U1111-1170-0452","July 2015","December 2015","January 2016","July 14, 2015","April 11, 2017","April 11, 2017","New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT02497235"
362,"NCT00788801","Exploratory Positron Emission Tomography (PET) Study to Evaluate the Effects of ABT-614 on [11C]-(+)-PHNO Binding Potential to D3 Receptors in the Brain",,"Completed","No Results Available","Healthy Volunteers","Drug: ABT-614","D3 receptor occupancy as estimated by measuring ABT-614 induced changes in [11C]-(+)-PHNO BP","Abbott","Male","18 Years to 40 Years   (Adult)","Phase 1","11","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","M10-423","December 2008","March 2009","null","November 11, 2008","null","November 2, 2010","Site Reference ID/Investigator# 12201, Toronto, Ontario, Canada|Site Reference ID/Investigator# 13961, Toronto, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT00788801"
363,"NCT01320787","18-F-Fluoroacetate as PET Imaging Agent",,"Withdrawn","No Results Available","Brain Cancer|Breast Cancer|Prostate Cancer","Drug: 18F-fluoroacetate","Biodistribution of 18F-Fluoroacetate","M.D. Anderson Cancer Center","All","18 Years and older   (Adult, Older Adult)","Phase 1","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2009-0157|NCI-2011-01066","October 2014","October 2016","null","March 22, 2011","null","October 23, 2014","","","https://ClinicalTrials.gov/show/NCT01320787"
364,"NCT00396734","The Effects of Pharmacotherapy on Brain Mechanisms Underlying Cocaine Dependence.",,"Suspended","No Results Available","Opioid-Related Disorders|Cocaine-Related Disorders","Drug: Provigil (Modafinil)|Drug: Topamax (Topiramate)","Changes in cue-induced brain glucose metabolic activity (FDG) in PET after treatment.|Changes in DRD2 receptor density measured by 11 C Raclopride in PET after treatment.|Nr.of drug-free urine samples, time to first drug use, duration of longest abstinent period.|Craving and psychosocial functioning (e.g., employment status, criminal behavior).","Hadassah Medical Organization","All","20 Years to 50 Years   (Adult)","Not Applicable","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","281006-HMO-CTIL","April 2007","April 2011","April 2011","November 7, 2006","null","June 10, 2010","Hadassah Medical Organization, Jerusalem, Israel","","https://ClinicalTrials.gov/show/NCT00396734"
365,"NCT01661127","Clinical Study of PET/CT and Association With Metabolic Syndrome/Depressive Symptoms in Psoriasis",,"Unknown status","No Results Available","Psoriasis|Metabolic Syndrome|Depression","","Beck depression inventory scoring and Korean Hamilton depression scale scoring|Brain glucose uptake using PET/CT","Pusan National University Hospital","All","18 Years and older   (Adult, Older Adult)","","10","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","PNUHDM-psoriasis","June 2012","June 2015","December 2015","August 9, 2012","null","November 4, 2014","Department of dermatology, Pusan National University Hospital, Busan, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT01661127"
366,"NCT01231295","Isotopic Imaging for Prodromal Alzheimer's Disease","ISALP","Completed","No Results Available","Alzheimer Disease","","The difference between AUCs for PET and SPECT imaging","Centre Hospitalier Universitaire de Nīmes","All","70 Years and older   (Older Adult)","","143","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","PHRC-N/2009/POK-01|2009-013476-53","February 2011","September 2016","September 2016","November 1, 2010","null","February 1, 2017","CHU d'Amiens - Hôpital Sud, Amiens Cedex 1, France|CHU d'Angers - Hôtel-Dieu, Angers, France|CHU de Besançon - Hôpital Jean Minjoz, Besançon, France|CHU de Bordeaux - Groupe Hospitalier Pellegrin, Bordeaux, France|APHP - Hôpital Albert Chenevier, Creteil Cedex, France|APHP - Hôpital Charles Foix, Ivry Sur Seine Cedex, France|CHRU de Lille - Hôpital Claude Huriez, Lille, France|CHRU de Lille - Hôpital Roger Salengro, Lille, France|APHP - Hôpital Emile Roux, Limeil Brevannes Cedex, France|APHM - Hôpital La Timone Adultes, Marseille cedex 5, France|CHU de Montpellier - Hôpital Gui de Chauliac, Montpellier Cedex 5, France|CHU de Nancy - Hôpital Central, Nancy, France|CHU de Nice - Hôpitaux L'Archet 1 et 2, Nice, France|CHU de Nîmes - Hôpital Universitaire Carémeau, Nîmes Cedex 09, France|APHP - Groupe Hospitalier Pitié-Salpetrière, Paris cedex 13, France|APHP - Hôpital Lariboisière, Paris, France|APHP - Hôpital Broca, Paris, France|Groupe Hospitalier Paris Saint-Joseph, Paris, France|CHU de Poitiers, Poitiers, France|CHU de Reims - Hôpital Maison Blanche, Reims, France|CHU de Rouen - Hôpital Charles Nicolle, Rouen, France|CHRU de Strasbourg - Hôpital de Hautepierre, Strasbourg, France|CHRU de Toulouse - Hôpital Garonne, Toulouse cedex 9, France|CHRU de Toulouse - Hôpital Purpan, Toulouse Cedex 9, France|CHRU de Tours - Hôpital Bretonneau, Tours, France","","https://ClinicalTrials.gov/show/NCT01231295"
367,"NCT00767871","Changes of Cerebral Glucose Metabolism and After 12 Weeks of Escitalpram Treatment in Panic Disorder",,"Completed","No Results Available","Panic Disorder","Drug: Lexapro","18FDG-PET, PDSS & HAM-A","Samsung Medical Center|H. Lundbeck A/S","All","20 Years to 60 Years   (Adult)","Phase 4","46","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","SMCIRB2007-01-024","March 2007","August 2007","December 2008","October 7, 2008","null","July 25, 2011","Samsung Medical Center, Seoul, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT00767871"
368,"NCT01044615","Advanced Imaging Tools in the Study of Mild Traumatic Brain Injury","mTBI","Completed","No Results Available","Mild Traumatic Brain Injury","","","Kettering Health Network|University of Cincinnati","All","18 Years to 55 Years   (Adult)","","20","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","mTBI","December 2010","null","null","January 8, 2010","null","January 14, 2013","Kettering Health Network, Kettering, Ohio, United States","","https://ClinicalTrials.gov/show/NCT01044615"
369,"NCT00970333","Evaluation of [18F] FEPPA and PET Imaging as a Marker of Inflammation in Subjects With Neurological Conditions",,"Completed","No Results Available","Alzheimer Disease|Parkinson Disease|Multiple Sclerosis","Drug: [18F]-FEPPA","The primary imaging outcome measure will be the brain regional distribution volumes expressed as a brain tissue to plasma ratio of the radioligand, [18F]-FEPPA.","Institute for Neurodegenerative Disorders","All","18 Years and older   (Adult, Older Adult)","Phase 1","3","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","FEPPA 001","August 2009","October 2010","October 2010","September 2, 2009","null","February 8, 2012","Instiute for Neurodegenerative Disorders, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT00970333"
370,"NCT03219073","Transcranial Direct Current Stimulation to Lower Neuropathic Pain in People With Multiple Sclerosis",,"Terminated","No Results Available","Multiple Sclerosis|Neuropathic Pain","Device: Active tDCS using tDCS device|Device: SHAM tDCS using tDCS device","PET FDG uptake in patients with MS with neuropathic pain|Change in neuropathic pain as recorded on a Visual Analog Scale (VAS).|Change in Quality of Life using MSQOL-54|Change in anxiety as recorded on a Visual Analog Scale (VAS).|Neuropathic Symptom Inventory","University of Colorado, Denver","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","1","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","17-0690","February 1, 2018","June 16, 2018","July 1, 2018","July 17, 2017","null","July 16, 2018","University of Colorado Denver, Aurora, Colorado, United States","","https://ClinicalTrials.gov/show/NCT03219073"
371,"NCT02798588","Improving Awakening Prognostication After Non Anoxic Coma Using PET-MRI in Intensive Care Unit","ETIC","Recruiting","No Results Available","Coma","Radiation: PET-MRI","Analysis of feasibility (pilot study) with Number of patients included during a 12-months period|Analysis of feasibility (pilot study) with ratio of patient included vs patient admissible according to the screening|Analysis of feasibility (pilot study) with respect of deadline for completion of PET MRI|Analysis of security (pilot study) with tolerance of the PET-MRI|Unfavorable clinical evolution towards awareness (dichotomic criteria : absence of awareness with functional communication)|Unfavorable clinical evolution in absence of awareness (ordinal criteria within unfavorable outcome) with Coma Recovery Scale-Revised|Functional clinical evolution in presence of awareness (ordinal criteria within favorable outcome) according to Glasgow Outcome Scale (GOS)","Hospices Civils de Lyon","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","27","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","69HCL15_0669|2015-A01886-43","February 16, 2017","August 16, 2020","August 16, 2020","June 14, 2016","null","July 26, 2018","Réanimation polyvalente neurologique Hôpital Neurologique HCL, Bron, France","","https://ClinicalTrials.gov/show/NCT02798588"
372,"NCT02148783","Dopamine Receptor Imaging to Predict Response to Stimulant Therapy in Chronic TBI",,"Unknown status","No Results Available","Traumatic Brain Injury","Drug: methylphenidate|Drug: Placebo","Relationship between tonic dopamine release (measured by displacement of [11C]-raclopride by oral methylphenidate) and change in processing speed between baseline and after methylphenidate treatment.|Relationship between D2/D3 receptor availability in ventral striatum and prefrontal cortex and neuropsychologic deficits.|Relationship between tonic dopamine release in the ventral striatum and prefrontal cortex with neuropsychologic deficits after TBI.|Relationship between D2/D3 receptor availability and functional connectivity of the prefrontal cortex with nodes of the default mode network.|Relationship between TMS-induced short-interval cortical inhibition of M1 and tonic dopamine release.|Test motivation and reward on and off methylphenidate in TBI patients.","Uniformed Services University of the Health Sciences|National Institutes of Health (NIH)","All","18 Years to 55 Years   (Adult)","Phase 2","30","U.S. Fed|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","402693-1|HJF grant","September 2014","June 2015","June 2017","May 28, 2014","null","May 28, 2014","National Institutes of Health, Clinical Center., Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT02148783"
373,"NCT01075035","Multimodal Neurodiagnostic Imaging of Traumatic Brain Injury and Post-Traumatic Stress Disorder","SANIC","Completed","No Results Available","Traumatic Brain Injury|Post-Traumatic Stress Disorder","","Neurocognitive Testing (PET/CT, MEG, fMRI w/ DTI)results","St. Louis University|United States Department of Defense","All","18 Years and older   (Adult, Older Adult)","","224","Other|U.S. Fed","Observational","Observational Model: Case Control|Time Perspective: Prospective","PT075832-R01|A-15194|IRB # 15919","August 2008","August 2014","August 2014","February 24, 2010","null","December 11, 2015","Saint Louis University, St. Louis, Missouri, United States","","https://ClinicalTrials.gov/show/NCT01075035"
374,"NCT03230526","Identification of a Biomarker Predictive of Evolution of Parkinson Disease","GLIAPARK","Recruiting","No Results Available","Parkinson Disease","Drug: [18F]DPA-714 PET scan","Coefficient of correlation between level of microglial striatal activation and the And the dopaminergic denervation kinetics|Analyze the relationship between the level of microglial activation in the black substance at the early stage of MP and the dopaminergic denervation kinetics|Evaluate the relation between the level of striatal microglial activation at inclusion and the severity of dopaminergic symptoms (motors)|Evaluate the link between the level of striatal microglial activation at inclusion and:the severity of dopaminergic symptoms (non-motors)|Evaluate the relation between the level of striatal microglial activation at inclusion and the severity of symptoms considered mainly non-dopaminergic (motor)|Evaluate the relation between the level of striatal microglial activation at inclusion and the severity of symptoms considered mainly non-dopaminergic (non-motor)|Evaluate the relation between the level of striatal microglial activation at inclusion and the severity of dopaminergic denervation at baseline (DaTscan initial)|Evaluate the link between the level of microglial activation in the black substance and outcome 3 to outcome 57|Evaluate the link between the level of striatal microglial activation and the level of activation in other brain regions (black substance, bridge and cortex)|Assess the relationship between the level of microglial activation in the extra-striatal cortical (cortex and brain stem) regions and the presence of non-motor and axial motor symptoms.|Evaluate the link between the level of nigrostriatal microglial activation and the serum level of biological markers of inflammation|Evaluate the link between the level of nigrostriatal microglial activation and the serum level of biological markers of inflammation Evaluate the relationship between the level of nigrostriatal microglial activation|Evaluate the relationship between the level of nigrostriatal microglial activation and the serum uric acid level at 0, 18 and 36 months","Nantes University Hospital","All","40 Years to 67 Years   (Adult, Older Adult)","Phase 2","64","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","RC17_0012|2017-000411-16","April 20, 2018","April 20, 2022","April 20, 2022","July 26, 2017","null","June 18, 2018","CHU de Nantes, Nantes, France|Centre Eugène Marquis, Rennes, France|CHU de Rennes, Rennes, France|CHU de Tours, Tours, France","","https://ClinicalTrials.gov/show/NCT03230526"
375,"NCT02370602","An [^11C]T-773 Positron Emission Tomography (PET) Study to Determine Phosphodiesterase10A Occupancy by TAK-063",,"Completed","Has Results","Healthy Volunteers","Drug: TAK-063|Drug: [^11C]T-773","Phosphodiesterase 10A (PDE10A) Occupancy of Brain Regions With [^11C]T-773 at 3 Hours Following a Single Dose of TAK-063|Phosphodiesterase 10A (PDE10A) Occupancy of Brain Regions With [^11C]T-773 at 23 Hours Following a Single Dose of TAK-063|Percentage of Participants Who Experienced at Least 1 Treatment-Emergent Adverse Event|Percentage of Participants With Markedly Abnormal Safety Laboratory Findings|Percentage of Participants With Markedly Abnormal Vital Sign Measurements|Percentage of Participants With Markedly Abnormal Criteria for Safety Electrocardiogram (ECG) Parameters|Cmax: Maximum Observed Plasma Concentration for TAK-063 and TAK-063 Metabolite M-I|Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-063 and TAK-063 Metabolite M-I|AUC(0-tlqc): Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-063 and TAK-063 Metabolite M-I|AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours Postdose for TAK-063 and TAK-063 Metabolite M-I|Average Plasma Concentration on Day 1 (Cavg) for TAK-063 and TAK-063 Metabolite M-I|CL/F: Oral Clearance of TAK-063|Ratio of TAK-063 Metabolite Cmax to TAK-063 Cmax|Ratio of TAK-063 Metabolite M-I AUC( 0-24) to TAK-063 AUC (0-24)|AUC During the Positron Emission Tomography (PET) Scan Period (AUC(Scan)) at 3 Hours Post-dose for TAK-063 and TAK-063 Metabolite M-I|Cavg During the Positron Emission Tomography (PET) Scan Period (AUC(Scan)) at 3 Hours Post-dose for TAK-063 and TAK-063 Metabolite M-I|AUC During the Positron Emission Tomography (PET) Scan Period (AUC(Scan)) at 23 Hours Post-dose for TAK-063 and TAK-063 Metabolite M-I|Cavg During the Positron Emission Tomography (PET) Scan Period (AUC(Scan)) at 23 Hours Post-dose for TAK-063 and TAK-063 Metabolite M-I","Takeda","Male","20 Years to 45 Years   (Adult)","Phase 1","13","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TAK-063_103|U1111-1165-3362|2012-004576-18","October 2013","February 2014","March 2014","February 25, 2015","March 20, 2015","March 20, 2015","","","https://ClinicalTrials.gov/show/NCT02370602"
376,"NCT02391246","Radionecrosis and FDG PET","DTPI FDG-PET","Recruiting","No Results Available","Malignant Glioma","Other: Positron Emission Tomography Imaging","sensitivity and specificity percentages|Cost efficiency analysis","Ottawa Hospital Research Institute","All","18 Years and older   (Adult, Older Adult)","","62","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","20150094-01H","June 2015","March 2018","March 2018","March 18, 2015","null","April 13, 2017","The Ottawa Hospital, Ottawa, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT02391246"
377,"NCT02236702","Kappa Opioid Receptor Imaging in Depression (KOR Depression)",,"Terminated","No Results Available","Major Depressive Disorder|Anhedonia","Other: Positron Emission Tomography (PET) imaging","[11C]LY2795050 volume of distribution (VT) values in specific brain regions of asymptomatic vs mildly symptomatic vs moderately symptomatic vs severely symptomatic individuals","New York University School of Medicine|Yale University","All","18 Years to 55 Years   (Adult)","","15","Other","Observational","Observational Model: Case Control|Time Perspective: Cross-Sectional","S14-00643","August 2014","March 2015","February 2016","September 10, 2014","null","August 17, 2016","NYU School of Medicine, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT02236702"
378,"NCT03193086","The Effect of Alemtuzumab on the Blood-brain-barrier and the Brain's Metabolism in Multiple Sclerosis Patients",,"Recruiting","No Results Available","Multiple Sclerosis","Drug: Alemtuzumab","Blood-Brain-Barrier Permeability|Oxygen Consumption|Cerebral perfusion|Diffusion Tensor MRI parameters and MR spectroscopy metabolite concentrations|Brain atrophy|Clinical Severity of Disease|Relapse frequency|Plasma markers of Blood-Brain-Barrier breakdown|Plasma markers of neuronal damage|Urinary markers of inflammation","Glostrup University Hospital, Copenhagen|Genzyme, a Sanofi Company","All","18 Years to 60 Years   (Adult)","","35","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","GZ-2016-11629","January 1, 2017","March 31, 2020","March 31, 2020","June 20, 2017","null","June 20, 2017","Functional Imaging Unit, Department of Clinical Physiology, Nuclear medicine and PET, Glostrup Hospital, Glostrup, Copenhagen Capital Region, Denmark","","https://ClinicalTrials.gov/show/NCT03193086"
379,"NCT02309606","Investigation of Serotonin Receptor Binding in the Migraine Brain Using Positron Emission Tomography",,"Completed","No Results Available","Migraine Without Aura","Other: PET scan with 5-HT receptor ligands","Differences in binding of the 5-HT1B radioligand|Differences in binding of the 5-HT4 radioligand|Correlation with migraine frequency and 5-HT4 receptor binding","Danish Headache Center","All","18 Years to 65 Years   (Adult, Older Adult)","","56","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","H-6-2014-057","January 2015","August 2017","December 2017","December 5, 2014","null","January 31, 2018","Danish Headache Center, Glostrup Hospital, Glostrup, Copenhagen, Denmark","","https://ClinicalTrials.gov/show/NCT02309606"
380,"NCT00397124","The Role of the Vagus Nerve in Tumor-to-Brain Communication in Lung Cancer Patients",,"Unknown status","No Results Available","Lung Cancer","Device: PET/CT imaging","the impact of the imaging modality on patients management","Rambam Health Care Campus","All","35 Years to 70 Years   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","vagusCTIL","April 2002","null","null","November 8, 2006","null","November 8, 2006","Rambam Medical Center, Haifa, Israel","","https://ClinicalTrials.gov/show/NCT00397124"
381,"NCT00701532","Brain Imaging Study of the Effects of Modafinil in Cocaine Addiction","CAIMAN","Completed","No Results Available","Cocaine Addiction|Cocaine Dependence","Drug: Modafinil and PET (brain imaging)|Drug: placebo","Decreased DAT occupation rates in the modafinil group versus placebo from day 3 to day of cocaine detoxification.|Evaluation of the clinical efficacy of modafinil during therapeutic cocaine withdrawal.|Correlation between craving measurements, depressive symptom measurements and cognitive deficit measurements observed and modifications of DAT density.|Study of DAT from D3 to D21 versus a pre-existing data base of control subjects.|Tolerance and safety evaluation of high modafinil doses, measured by adverse events and biological parameters.","Assistance Publique - Hôpitaux de Paris|Mission Interministérielle de Lutte contre la Drogue et la Toxicomanie","Male","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","29","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","P070150","April 2009","October 2012","January 2013","June 19, 2008","null","April 11, 2013","Unité de recherche U797 Inserm - CEA - Université Paris-Sud. "" Neuroimagerie & Psychiatrie "" Service Hospitalier Frédéric Joliot, Orsay, France|Centre d'Enseignement, de Recherche et de Traitements des Addictions - Hopital Universitaire Paul Brousse, Villejuif, France","","https://ClinicalTrials.gov/show/NCT00701532"
382,"NCT03003715","Brain as a Therapeutic and Research Target in Trigeminal Neuropathic Pain",,"Completed","No Results Available","Trigeminal Neuropathic Pain","Procedure: PET Scans|Procedure: transcranial direct current stimulation (tDCS)|Procedure: MRI|Other: sham tDCS (prior to real tDCS)","Change in MOR BPND levels","University of Michigan","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","13","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","HUM00024607","September 2011","December 2012","December 2012","December 28, 2016","null","November 24, 2017","University of Michigan, Ann Arbor, Michigan, United States","","https://ClinicalTrials.gov/show/NCT03003715"
383,"NCT00686413","Positron Emission Tomography Study Using 2-[18F]-F-A85380 to Determine α4β2 Neuronal Nicotinic Receptor Occupancy of AZD3480 After Oral Administration to Healthy Male Subjects","PET","Completed","No Results Available","Healthy","Drug: AZD3480|Radiation: 2-[18F]-F-A85380","Plasma concentration (AUC, Cmax, tmax)|The whole brain uptake and regional distribution of radioligand 2-[18F]-F-A85380 following single intravenous (iv) microdose will be assessed (using derived radioactivity measurements).|SafetyAEs and vital signs.","AstraZeneca","Male","20 Years to 80 Years   (Adult, Older Adult)","Phase 1","9","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D3690C00018|EudraCT No. 2007-004852-35","January 2008","August 2008","August 2008","May 29, 2008","null","December 10, 2010","Research Site, Stockholm, Sweden","","https://ClinicalTrials.gov/show/NCT00686413"
384,"NCT01691092","PET Imaging of mGLuR5 With Drug Challenge",,"Completed","Has Results","Major Depressive Disorder|Post-Traumatic Stress Disorder (PTSD)","Drug: Ketamine","Change in Glutamate Levels at Baseline and After Ketamine Administration as Confirmed by Positron Emission Tomography (PET) Imaging","Yale University","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","79","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","1111009365","June 2012","February 2016","February 2016","September 24, 2012","April 21, 2017","April 21, 2017","Connecticut Mental Health Center, New Haven, Connecticut, United States|Yale University Magnetic Resonance Research Center (MRRC), New Haven, Connecticut, United States|Yale University PET Center, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT01691092"
385,"NCT03130036","Biodistribution of [11C]Acetoacetate/[18F]Fluorodeoxyglucose Using Positron Emission Tomography (PET) Scanning",,"Completed","No Results Available","Alzheimer Disease|Mild Cognitive Impairment","Other: Low-Carbohydrate Diet|Other: Low-Fat Diet","Brain biodistribution of [11C]AcAc/[18F]FDG","Wake Forest University Health Sciences","All","50 Years to 85 Years   (Adult, Older Adult)","Not Applicable","34","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Basic Science","IRB00033365","June 9, 2015","June 2017","June 2017","April 26, 2017","null","August 1, 2018","Wake Forest School of Medicine, Winston-Salem, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT03130036"
386,"NCT00288782","PET Neuroimaging of [11C]Mirtazapine",,"Completed","No Results Available","Mental Disorders|Mood Disorders|Affective Disorders|Depressive Disorders","Drug: Mirtazapine","Binding potential in brain regions at tine of each PET scan|Serum concentration at time of each PET scan","University of Aarhus|The Danish Medical Research Council|Fund for Advancement of Medical Science|Max Woerzner's Research Award","All","20 Years to 60 Years   (Adult)","Phase 4","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Diagnostic","Mirtazapine_Occupancy_01_2005","February 2006","null","April 2007","February 8, 2006","null","April 19, 2007","Center for Psychiatric Research, Psychiatric Hospital of Aarhus University, Risskov, Denmark","","https://ClinicalTrials.gov/show/NCT00288782"
387,"NCT01819675","Effect of Repetitive Transcranial Magnetic Stimulation (rTMS) Over the Brain on the Neurotransmitter Binding",,"Terminated","No Results Available","Stroke|Hemiplegia","Device: Low frequency rTMS|Device: High frequency rTMS|Device: Sham rTMS","[18F]flumazenil binding potential|Purdue pegboard test score","Seoul National University Bundang Hospital|Ministry of Health & Welfare, Korea","All","18 Years to 50 Years   (Adult)","Not Applicable","6","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Basic Science","E-1211-178-001","March 2013","February 2016","February 2016","March 27, 2013","null","June 27, 2017","Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT01819675"
388,"NCT01290354","Exploratory Lapatinib (Positron Emission Tomography) PET Study in Subjects With Breast Cancer",,"Completed","No Results Available","Cancer","Drug: Lapatinib|Drug: [11C] lapatinib","Brain penetration of [11C]lapatinib|Brain tumour penetration of [11C]lapatinib|Safety as assessed by number of subjects with adverse events|[11C]lapatinib uptake in non-brain tumour sites","GlaxoSmithKline","Female","18 Years and older   (Adult, Older Adult)","Phase 1","10","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","112867","September 12, 2011","March 18, 2013","March 18, 2013","February 7, 2011","null","November 13, 2017","GSK Investigational Site, London, United Kingdom|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, London, United Kingdom","","https://ClinicalTrials.gov/show/NCT01290354"
389,"NCT00418301","Changes in Cerebral Blood Flow in Patients Treated With Spinal Cord Stimulation for Low Back and Leg Pain",,"Completed","No Results Available","Pain|Low Back Pain|Leg Pain","Other: Precision Spinal Cord Stimulation and PET Scan","Cumulative frequency of adverse events and events per subject|Cerebral blood flow and VAS with optimal paresthesia coverage compared with SCS off|Cerebral blood flow and VAS with partial paresthesia coverage and subthreshold stimulation compared with optimal coverage and with SCS off","Boston Scientific Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 4","15","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","SCS0305","January 2007","April 2009","April 2009","January 4, 2007","null","July 22, 2009","Center for Clinical Research, Winston Salem, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT00418301"
390,"NCT00628940","PET Imaging of High-grade Glioma Using 18F-fluoromethylcholine: a Tool for the Early Detection of Tumour Recurrence After Combined Radiochemotherapy?",,"Completed","No Results Available","High-grade Glioma of the Brain","Radiation: PET images with 18F-fluoromethylcholine","time to local recurrence after neurosurgery and adjuvant radiochemotherapy","University Ghent|FWO, Belgium|Special Research Fund, Belgium","All","18 Years and older   (Adult, Older Adult)","Phase 1","90","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2008/085","January 12, 2010","March 14, 2017","March 22, 2018","March 5, 2008","null","May 18, 2018","University Hospital Ghent, Ghent, Belgium","","https://ClinicalTrials.gov/show/NCT00628940"
391,"NCT01459237","Effects of Hormone Stimulation on Brain Scans for Cushing s Disease",,"Completed","No Results Available","Pituitary Neoplasm","Drug: Acthrel","To determine effect of CRH stimulation on 18F-FDG uptake in high-resolution PET-imaging of ACTH-adenomas in CD.|To determine if CRH stimulation (compared to without CRH stimulation) enhances the detection of ACTH-adenomas as demonstrated on 18F-FDG high-resolution PET-imaging in CD.|To assess the accuracy and sensitivity of 18F-FDG high-resolution PET-imaging detection of ACTH-adenomas in CD compared to MR-imaging.","National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)","All","8 Years and older   (Child, Adult, Older Adult)","Early Phase 1","30","NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Diagnostic","120007|12-N-0007","October 11, 2011","January 30, 2018","June 12, 2018","October 25, 2011","null","June 14, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT01459237"
392,"NCT03457493","TSPO-PET for Neuroinflammation in Parkinson's Disease",,"Recruiting","No Results Available","Parkinson Disease","Drug: DPA-714-PET/MRI","Comparison of TSPO-PET measures of neuroinflammation between PD patients and healthy controls.|Correlation of DPA-714-PET/MRI with demographics, clinical and biospecimen assessments from Neuroinflammation in PD study","University of Alabama at Birmingham","All","30 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","IRB-300001025","March 22, 2018","March 2020","March 2021","March 7, 2018","null","April 18, 2018","UAB Advanced Imaging Facility, Birmingham, Alabama, United States","","https://ClinicalTrials.gov/show/NCT03457493"
393,"NCT01667367","A Molecular and Functional Brain Imaging Study in Individuals With Down Syndrome and Healthy Controls Following Single Dose RG1662",,"Completed","No Results Available","Healthy Volunteer, Down Syndrome","Drug: RG1662|Drug: placebo","Brain GABAA receptor alpha5 subunit localization/density assessed by positron emission tomography (PET)|Brain GABAA receptor alpha5 subunit occupancy following single dose of RG1662|Correlation of RG1662 plasma concentrations and GABAAalpha5 receptor occupancy|Safety: Incidence of adverse events|Resting state functional brain connectivity following a single dose of either RG1662 or placebo, assessed by functional magnetic resonance imaging (fMRI)|Functional brain connectivity of individuals with Down syndrome versus healthy controls receiving placebo","Hoffmann-La Roche","All","18 Years to 40 Years   (Adult)","Phase 1","13","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)","BP25611|2012-001301-24","August 2012","October 2013","October 2013","August 17, 2012","null","September 2, 2015","London, United Kingdom","","https://ClinicalTrials.gov/show/NCT01667367"
394,"NCT01904487","Characterization of [11C]Flumazenil to Image GABA Transmission in Healthy Adult Subjects and Subjects With Alcohol Dependence",,"Completed","No Results Available","Alcoholism","Radiation: [11C]flumazenil|Drug: Tiagabine","To measure changes in [11C]flumazenil binding in the brain using PET scans|Tiagabine induced change in [C-11]flumazenil distribution volume (VT)","Rajesh Narendran|University of Pittsburgh","All","18 Years to 45 Years   (Adult)","Phase 1","11","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","PRO#10100519","April 19, 2011","October 1, 2013","October 1, 2013","July 22, 2013","null","August 29, 2017","University of Pittsburgh, Pittsburgh, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT01904487"
395,"NCT00752778","Magnetic Resonance Imaging (MRI) Follow-up of Macrophagic Infiltration in MS Patients Treated With Tysabri",,"Terminated","No Results Available","Multiple Sclerosis","Other: pet-scan FDG-F18","Number of enhanced lesions on MRI before and after treatment. PET scan modification in brain (in enhanced lesions and in the whole brain).|Correlation with relapses.","University Hospital, Strasbourg, France|Biogen","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","8","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","4118","December 2008","March 2011","March 2011","September 15, 2008","null","November 12, 2012","Service de Neurologie, Hôpital Civil, Hôpitaux Universitaires de Strasbourg, Strasbourg, France|Service de Médecine Nucléaire, Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg, Strasbourg, France|Service de Radiologie 2, Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg, Strasbourg, France","","https://ClinicalTrials.gov/show/NCT00752778"
396,"NCT00953745","Dopaminergic Effects of Adjunctive Aripiprazole on the Brain in Treatment-Resistant Depression",,"Completed","Has Results","Major Depressive Disorder","Drug: Escitalopram|Drug: Aripiprazole|Drug: Placebo Capsule|Drug: Placebo Tablet","Fluorodopa Uptake Values in Brain Images of Aripiprazole Augmentation Responders|Depression Symptom Change on The Montgomery-Åsberg Depression Rating (MADRS) Scale Between ARP Responders and Non-responders.","Washington University School of Medicine|Bristol-Myers Squibb","All","18 Years to 55 Years   (Adult)","Not Applicable","43","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Other","201101790-2","May 2009","June 2012","December 2012","August 6, 2009","April 19, 2018","April 19, 2018","Washington University in St. Louis, School of Medicine, Saint Louis, Missouri, United States","","https://ClinicalTrials.gov/show/NCT00953745"
397,"NCT00945503","Positron Emission Tomography (PET) Study to Describe the Relationship Between Plasma Concentrations and Brain Gly-T1 Occupancy of GSK1018921 Over Time.",,"Completed","No Results Available","Schizophrenia","Drug: GSK1018921","PET occupancy with GSK1018921|To assess the safety the AEs and SAEs will be collected during the study such as vital signs, physical exams and laboratory safety tests.","GlaxoSmithKline","Male","18 Years to 55 Years   (Adult)","Phase 1","12","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","109731","May 19, 2008","December 22, 2008","December 22, 2008","July 24, 2009","null","July 18, 2017","GSK Investigational Site, Barcelona, Spain","","https://ClinicalTrials.gov/show/NCT00945503"
398,"NCT01680588","Efficacy and Safety of the PET Imaging Agent [18F]NAV4694 in Subjects With Probable Alzheimer's Disease",,"Active, not recruiting","No Results Available","Alzheimer Disease","Drug: [18F]NAV4694","[18F]NAV4694 PET visual assessment by centralized readers|Assess the incidence of adverse events after a single dose of [18F]NAV4694|Evaluate [18F]NAV4694 PET quantitative assessment|Determine correlation of neuro-psychiatric tests with [18F]NAV4694 imaging|Assess changes in laboratory values after a single dose of [18F]NAV4694","Navidea Biopharmaceuticals","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 2","70","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","NAV4-01","August 2012","December 2018","December 2018","September 7, 2012","null","March 30, 2016","Molecular NeuroImaging, LLC, New Haven, Connecticut, United States|Rush University Medical Center, Chicago, Illinois, United States|Alexian Brothers Neurosciences Institute, Elk Grove Village, Illinois, United States|Indiana Medical Research, Indianapolis, Indiana, United States|Brigham & Women's Hospital, Boston, Massachusetts, United States|Alzheimer's Disease Center, Quincy Medical Center, Quincy, Massachusetts, United States|Neurological Associates of Albany, Albany, New York, United States","","https://ClinicalTrials.gov/show/NCT01680588"
399,"NCT02621606","[11C]MK-6884 Positron Emission Tomography (PET) Tracer Validation Trial (MK-6884-001)",,"Completed","No Results Available","Alzheimer's Disease","Drug: [11C]MK-6884","Number of Participants With Adverse Events (AEs)|Number of Participants Who Discontinued Study Due to an AE|Effective Dose of [11C]MK-6884 (Part I)|Organ Effective Dose of [11C]MK-6884 (Part I)|Volume of Distribution (VT) or Surrogate (e.g., Non-displaceable Binding Potential [BPND]) of [11C]MK-6884 in Brain Regions of Interest (Part II)|Intra-subject T-RT Variability of [11C]MK-6884 in Brain Regions of Interest (Part II)|BPND or Surrogate (e.g., Standardized Uptake Value Ratio [SUVR]) of [11C]MK-6884 in Brain Regions of Interest (Part III)","Merck Sharp & Dohme Corp.","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 1","20","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","6884-001|2015-001631-20","January 8, 2016","December 28, 2017","December 28, 2017","December 3, 2015","null","January 11, 2018","","","https://ClinicalTrials.gov/show/NCT02621606"
400,"NCT00074503","PET Imaging of DHA Metabolism",,"Completed","No Results Available","Healthy","","","National Institute on Alcohol Abuse and Alcoholism (NIAAA)|National Institutes of Health Clinical Center (CC)","All","18 Years to 65 Years   (Adult, Older Adult)","","85","NIH","Observational","","040058|04-AA-0058","December 12, 2003","null","July 13, 2010","December 15, 2003","null","July 2, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00074503"
401,"NCT00253461","11C Topotecan PET Imaging",,"Terminated","No Results Available","Lung Cancer|Metastatic Cancer|Ovarian Cancer|Unspecified Adult Solid Tumor, Protocol Specific","Procedure: computed tomography|Procedure: positron emission tomography|Radiation: 11C topotecan|Radiation: fludeoxyglucose F 18","Pharmacokinetics on day of positron-emission tomography scan|Disease response","Case Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","7","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","CWRU6Y02|P30CA043703|CASE-CWRU-6Y02","December 2004","November 2009","November 2009","November 15, 2005","null","March 20, 2012","Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States","","https://ClinicalTrials.gov/show/NCT00253461"
402,"NCT03347331","[18F]-F13640 as a New Brain Radiopharmaceutical","F13640","Not yet recruiting","No Results Available","Neurological Pathology|Healthy Subjects","Drug: [18F]F13640","Binding potentials","Hospices Civils de Lyon","Male","20 Years to 45 Years   (Adult)","Early Phase 1","15","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","69HCL16-0770","December 1, 2017","December 1, 2019","December 1, 2019","November 20, 2017","null","November 20, 2017","","","https://ClinicalTrials.gov/show/NCT03347331"
403,"NCT02605785","A Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear Palsy",,"Recruiting","No Results Available","Progressive Supranuclear Palsy","Drug: F-18 AV 1451","The investigators will be looking at the amount of Tau protein in the brain of patients with PSP.|Rates of change in tau-PET burden over time.","Mayo Clinic","All","40 Years and older   (Adult, Older Adult)","Not Applicable","134","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","15-004618","November 2015","November 2020","November 2020","November 16, 2015","null","March 20, 2018","Mayo Clinic, Rochester, Minnesota, United States","","https://ClinicalTrials.gov/show/NCT02605785"
404,"NCT01987830","Bevacizumab w / Temozolomide PET & Vascular MRI For GBM",,"Recruiting","No Results Available","Recurrent Glioblastoma","Device: MRI-PET|Device: TMZ-PET","To assess temozolomide delivery before and after bevacizumab in glioblastoma|To explore the link between flow, permeability, and tumor temozolomide retention.","Massachusetts General Hospital|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","17","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","13-322","November 2013","January 2019","September 2020","November 19, 2013","null","August 15, 2018","Massachuesett General Hospital, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT01987830"
405,"NCT00396669","A Brain Imaging Study Into Nicotine Induced Dopamine Release in Cigarette Smokers.",,"Unknown status","No Results Available","Tobacco Use Disorder","Drug: Bupropion","Dopamine D2 receptor occupancy before and after smoking a cigarette with nicotine|Subjective measures of craving, anxiety and depression.","Hadassah Medical Organization","Male","21 Years to 50 Years   (Adult)","Not Applicable","24","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","291006 HMO-CTIL","July 2007","July 2012","July 2012","November 7, 2006","null","March 27, 2012","Hadassah Medical Organization, Jerusalem, Israel","","https://ClinicalTrials.gov/show/NCT00396669"
406,"NCT03019289","A Study to Evaluate Sigma-1 and Dopamine-2 Receptor Occupancy by Pridopidine in the Human Brain of Healthy Volunteers and in Patients With Huntington's Disease",,"Completed","No Results Available","Health Volunteers, Huntington Disease","Drug: pridopidine (90 mg)","Pharmacodynamic Assessment- Positron Emission Tomography (PET) acquisition|Pharmacokinetic Assessment- maximum observed concentration (Cmax)|Pharmacokinetic Assessment- time to reach maximum (peak) concentration (tmax)|Pharmacokinetic Assessment- area under the drug concentration by time curve (AUC)|Pharmacokinetic Assessment- terminal elimination half-life (t1/2)|Pharmacokinetic Assessment- apparent volume of distribution of the drug following extravascular administration (Vd/F)|Percentage of Participants with Adverse Events","Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries","Male","25 Years and older   (Adult, Older Adult)","Phase 1","23","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","TV7820-IMG-10082|2016-001757-41","March 20, 2017","January 26, 2018","January 31, 2018","January 12, 2017","null","May 30, 2018","Teva Investigational Site 32648, Leipzig, Germany","","https://ClinicalTrials.gov/show/NCT03019289"
407,"NCT01622764","89Zr-RO5323441 PET Imaging in Glioblastoma",,"Withdrawn","No Results Available","Glioblastoma","Radiation: Molecular imaging with 89Zr-RO5323441","Assess the penetration of RO5323441 into recurrent GBM by 89Zr-RO5323441 PET imaging and to quantify its uptake|Visualize and quantify 89Zr-RO5323441 non-tumor organ distribution|Assess the effect of bevacizumab treatment on 89Zr-RO5323441 uptake in recurrent GBM lesions","University Medical Center Groningen","All","18 Years and older   (Adult, Older Adult)","Phase 2","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)","BP28015|2011-004974-27","September 2014","September 2015","September 2016","June 19, 2012","null","March 28, 2014","University Medical Center Groningen, Groningen, Netherlands","","https://ClinicalTrials.gov/show/NCT01622764"
408,"NCT02317783","Amyloid Plaque Deposition in Chemotherapy-Induced Cognitive Impairment",,"Recruiting","No Results Available","Breast Cancer","Drug: FDG-PET, [18F]Flutemetamol","[18F]Flutemetamol and [18F]fluoro-2-deoxy-D-glucose (FDG) PET imaging agents and MRI in breast cancer patients with Chemotherapy-Induced Cognitive Impairment (CICI) to check brain changes.","University of Utah","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","HCI69515","December 2015","January 2019","January 2019","December 16, 2014","null","May 7, 2018","Huntsman Cancer Institute, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT02317783"
409,"NCT02560753","Feasibility Study in Subjects With Mild to Moderate Alzheimer's Disease",,"Completed","Has Results","Alzheimer's Disease","Drug: T3D-959","Change From Baseline (End of Treatment - Baseline) for FDG-PET Imaging With Whole Brain and White Matter as Reference Region|The Effect of Treatment With T3D-959 on Changes in Resting State Blood Oxygen Level Dependent (BOLD) Signal in Functional Magnetic Resonance Imaging (fMRI) of the Brain Areas Associated With Cognitive Tasks.|Change From Baseline in the Score of the Digit Symbol Substitution Test|Change From Baseline in the Total Score of the 11-item Alzheimer's Disease Assessment Scale - Cognitive Subscale","T3D Therapeutics, Inc.","All","50 Years to 90 Years   (Adult, Older Adult)","Phase 1|Phase 2","36","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","T3D959-201","July 2015","May 30, 2016","June 30, 2016","September 25, 2015","July 30, 2018","July 30, 2018","Brain Matters Research, Delray Beach, Florida, United States|Miami Jewish Health Systems, Miami, Florida, United States|New Hope Clinical Research, Charlotte, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT02560753"
410,"NCT00392743","A Study to Compare Two Different Brain Imaging Techniques in Healthy Volunteers and in Schizophrenic Patients",,"Completed","No Results Available","Schizophrenia","Procedure: pet/spect scan","PET and SPECT striatal binding potential|plasma concentrations at the time of scanning,","GlaxoSmithKline","All","18 Years and older   (Adult, Older Adult)","","60","Industry","Observational","","TMT108154","December 2006","May 2007","May 2007","October 26, 2006","null","November 5, 2012","GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Espluges de Llobregat, Spain|GSK Investigational Site, Sant Boi de Llobregat, Spain","","https://ClinicalTrials.gov/show/NCT00392743"
411,"NCT02167256","A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Drug: AZD0530 100mg daily|Drug: AZD0530 125mg daily|Drug: Placebo","The effect of treatment with AZD0530 on 12-month reductions in 18F-FDG PET measurements of the cerebral metabolic rate for glucose (CMRgl) using statistical parametric mapping (SPM) statistical region of in|Safety and tolerability of treatment with AZD0530 over a 12-month period in subjects with mild AD as assessed by analysis of adverse events, including symptoms, and abnormal findings on physical and neurological examinations, and standard labs.|The effect of treatment with AZD0530 on cognitive and behavioral function in participants with mild AD.|To assess the effect of treatment with AZD0530 on the rate of brain atrophy using volumetric magnetic resonance imaging (MRI).|To assess the effect of treatment with AZD0530 on CSF biomarkers of AD (particularly CSF total Tau and CSF pTau).|To assess the influence of APOE genotype on the effects of treatment with AZD0530.","Yale University|Alzheimer's Therapeutic Research Institute","All","55 Years to 85 Years   (Adult, Older Adult)","Phase 2","159","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1404013830|4UH3TR000967-02","December 2014","February 27, 2018","February 27, 2018","June 19, 2014","null","June 27, 2018","Barrow Neurological Institute, Phoenix, Arizona, United States|Banner Sun Health Research Institute, Sun City, Arizona, United States|University of California, Los Angeles, Los Angeles, California, United States|Yale Alzheimer's Disease Research Unit, New Haven, Connecticut, United States|Georgetown University, Washington, District of Columbia, United States|Wien Center for Clinical Research/Mount Sinai Medical Center, Miami Beach, Florida, United States|University of South Florida - Health Byrd Alzheimer Institute, Tampa, Florida, United States|Northwestern University, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|Indiana University, Indianapolis, Indiana, United States|University of Iowa, Iowa City, Iowa, United States|University of Kentucky, Lexington, Kentucky, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Ann Arbor, Michigan, United States|Mount Sinai School of Medicine, New York, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Oregon Health & Science University, Portland, Oregon, United States|University of Pittsburgh, Alzheimer's Disease Research Center, Pittsburgh, Pennsylvania, United States|Roper St. Francis Hospital, Charleston, South Carolina, United States|University of Washington, Seattle, Washington, United States|University of British Columbia, Clinic for AD & Related Disorders, Vancouver, British Columbia, Canada","","https://ClinicalTrials.gov/show/NCT02167256"
412,"NCT02952391","Assessing Cholinergic Innervation in Parkinson's Disease Using the PET Imaging Marker [18F]Fluoroethoxybenzovesamicol",,"Recruiting","No Results Available","Parkinson's Disease","Other: [18F] FEOBV PET scan","[18F]FEOBV binding|Test-retest reliability|Neuropsychological performance","University Medical Center Groningen","All","45 Years to 65 Years   (Adult, Older Adult)","","20","Other","Observational","Observational Model: Case Control|Time Perspective: Cross-Sectional","NL56173.042.15","September 2016","February 2017","null","November 2, 2016","null","November 29, 2016","University Medical Center Groningen, Groningen, Netherlands","","https://ClinicalTrials.gov/show/NCT02952391"
413,"NCT03088644","A Study to Investigate P2X7 Receptor Occupancy by JNJ-54175446 With the Newly Developed P2X7 Receptor Positron Emission Tomography (PET) Tracer 18F-JNJ-64413739",,"Completed","No Results Available","Healthy","Drug: JNJ-54175446|Drug: 18F-JNJ-64413739","Part A: Effective Radiation Dose Following Injection of 18F-JNJ-64413739|Part B: Total and Regional Brain Compartmental Kinetics for Volume of Distribution of 18F-JNJ-64413739|Part C: Test Retest Variability in the Distribution of 18F-JNJ-64413739|Part D: Plasma Concentrations of JNJ-54175446|Part D: Percentage of P2X7 Receptor Occupancy|Part A, B and C: Number of Subjects With Adverse Events as a Measure of Safety and Tolerability of 18F-JNJ-64413739|Part D: Number of Subjects With Adverse Events as a Measure of Safety and Tolerability of JNJ-54175446","Janssen-Cilag International NV","Male","18 Years to 55 Years   (Adult)","Phase 1","16","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","CR108269|2016-004007-31|54175446EDI1004","March 24, 2017","November 14, 2017","November 14, 2017","March 23, 2017","null","March 29, 2018","UZ Leuven, Leuven, Belgium","","https://ClinicalTrials.gov/show/NCT03088644"
414,"NCT00323076","Imaging Study in Patients With Cancer of the Head & Neck, Lung, Renal Cell, Brain, Lymphoma and Neuroendocrine Tumours",,"Unknown status","No Results Available","Renal Cell Carcinoma|Neuroendocrine Tumours","Drug: 18F-FAZA PET Imaging","Phase I: demonstrate the safety of 18F-FAZA manufactured at the Edmonton Radiopharmaceutical Centre/Edmonton PET Centre. Phase II: determine the general biodistribution pattern of18F-FAZA.|Determine the relative tumour uptake of 18F-FAZA|Confirm the safety of 18F-FAZA manufactured at the Edmonton Radiopharmaceutical Centre/Edmonton PET Centre","AHS Cancer Control Alberta","All","16 Years and older   (Child, Adult, Older Adult)","Phase 1|Phase 2","160","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","SP-14-0050/DX-FAZ-001/22390","September 2004","April 2015","April 2015","May 9, 2006","null","October 2, 2014","Cross Cancer Institute, Edmonton, Alberta, Canada","","https://ClinicalTrials.gov/show/NCT00323076"
415,"NCT01268020","Evaluation of [18F] FMH3 and PET as a Marker of Histamine-3 Receptor Activity in Subjects With AD Compared w/ HC","FMH3","Completed","No Results Available","Alzheimer Disease","Drug: [18F]-FMH3","To assess the dynamic uptake and washout of 18F-FMH3","Institute for Neurodegenerative Disorders","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","5","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","FMH3-01","December 2010","October 2012","October 2012","December 29, 2010","null","November 11, 2013","Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT01268020"
416,"NCT00871650","Neurobiological Correlates of Post Traumatic Stress Disorder (PTSD) During Rapid Eye Movement (REM) Sleep","REM-P","Completed","No Results Available","Post-Traumatic Stress Disorder","Other: Sleep data recording|Other: PET scan - waking|Other: PET scan - REM Sleep","Brain glucose metabolism","University of Pittsburgh","Male","18 Years to 50 Years   (Adult)","","24","Other","Observational","Observational Model: Case Control|Time Perspective: Cross-Sectional","MH083035-01","March 2009","March 2011","November 2011","March 30, 2009","null","January 16, 2013","University of Pittsburgh, Pittsburgh, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT00871650"
417,"NCT01759888","Development of a Novel 18F-DTBZ PET Imaging as a Biomarker to Monitor Neurodegeneration of PARK6 and PARK8 Parkinsonism",,"Completed","No Results Available","Parkinson's Disease","Drug: 18F-DTBZ","To calculate the decline rate of striatal 18F-FP-(+)-DTBZ binding and to evaluate whether the degenerative rate differs between idiopathic PD patients and genetic-proving PARK6/PARK8 patients|To analyze the correlation between decline rate of 18F-FP-(+)-DTBZ uptake and clinical severity, and access the feasibility of 18F-DTBZ PET imaging as an in vivo biomarker to monitor neurodegeneration in PD","Chang Gung Memorial Hospital|National Science Council, Taiwan","All","20 Years to 80 Years   (Adult, Older Adult)","Phase 2","49","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","100-1926A","August 2011","December 2014","December 2014","January 3, 2013","null","January 26, 2015","Chang Gung Memory Hpspital, Taoyuan, Taiwan","","https://ClinicalTrials.gov/show/NCT01759888"
418,"NCT01701089","A Study of RO4602522 in Patients With Alzheimer Disease and in Healthy Volunteers",,"Completed","No Results Available","Healthy Volunteer, Alzheimer's Disease","Drug: 11C-L-deprenyl-D2|Drug: RO4602522","Change in monoamine oxidase (MAO-B) enzyme activity as measured by in vivo positron emission tomography (PET)|Pharmacokinetics: Plasma concentration of RO4602522|Reduction of 11C-L-deprenyl-D2 tracer uptake by in vivo positron emission tomography (PET)|Safety: incidence of adverse events","Hoffmann-La Roche","All","50 Years to 80 Years   (Adult, Older Adult)","Phase 1","17","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BP28253","September 2012","May 2013","May 2013","October 4, 2012","null","November 2, 2016","Stockholm, Sweden","","https://ClinicalTrials.gov/show/NCT01701089"
419,"NCT02323685","Safety and Effect of SANGUINATE™ Infusion in Patients at Risk of Delayed Cerebral Ischemia (DCI) Following Subarachnoid Hemorrhage (SAH)",,"Completed","No Results Available","Cerebral Ischemia","Biological: SANGUINATE™","Safety of study drug during and following infusion as measured by vital signs, clinical signs, bioanalytical measures, or investigational drug-related adverse events|Impact of SANGUINATE on brain oxygenation and blood flow assessed using Postitron Emission Tomography (PET)|Changes in neurological function measured by National Institutes of Health Stroke Scale (NIHSS)|Incidence, location, and size of cerebral infarction as measured by MRI|Changes in Blood Gases as measured by Hemoximetry","Prolong Pharmaceuticals","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","12","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)","SGCI-002","December 2014","June 2016","October 2016","December 23, 2014","null","October 27, 2016","Barnes Jewish Hospital/Washington University, St. Louis, Missouri, United States","","https://ClinicalTrials.gov/show/NCT02323685"
420,"NCT01065805","A Study to Demonstrate the Safety and Preliminary Efficacy of 18F-FLT in Patients With Solid Tumours or Lymphoma",,"Unknown status","No Results Available","Brain Cancer|Cancer|Solid Tumor|Lymphoma","Biological: 18F-FLT","Phase I: to determine the safety of 18 F-FLT.|Phase II: To determine general biodistribution of 18F-FLT and correlate 18F-FLT uptake with hENT1 expression and Ki-67 scores.|Phase I: To determine general biodistribution of 19F-FLT|Phase II: to confirm safety of 18F-FLT; to determine the relative uptake of 18F-FLT (SUV, RUS, T/N); and to correlate 18F-FLT uptake with patient outcomes.|Phase II: to correlate 18F-FLT uptake with patient outcomes (treatment response, progression-free survival, overall survival), over the first 12 months of follow-up after completion of tx, subsequently over the remainder of the disease course","AHS Cancer Control Alberta","All","16 Years and older   (Child, Adult, Older Adult)","Phase 1|Phase 2","170","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","SP-24513/DX-FLT-002","February 2009","December 2015","December 2015","February 9, 2010","null","June 12, 2014","Cross Cancer Institute, Edmonton, Alberta, Canada","","https://ClinicalTrials.gov/show/NCT01065805"
421,"NCT03215381","AZD1390 Administration of a Microdose [11C]AZD1390 to Healthy Volunteers",,"Completed","No Results Available","Healthy Volunteer Male Subjects","Drug: [11C]AZD1390","Brain distribution of AZD1390","AstraZeneca|Karolinska Institutet, Quintiles IMS","Male","20 Years to 65 Years   (Adult, Older Adult)","Phase 1","8","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","D6940C00001","October 10, 2017","February 19, 2018","February 19, 2018","July 12, 2017","null","February 26, 2018","Research Site, Stockholm, Sweden","","https://ClinicalTrials.gov/show/NCT03215381"
422,"NCT02138500","A Study to Examine the Distribution of PF-06372865 in the Brain of Healthy Volunteers Using Positron Emission Tomography and a Radioactive Tracer Following Oral Administration of One Dose of PF-06372865",,"Completed","No Results Available","Healthy","Drug: PF-06372865","GABAA RO in the whole brain|Average plasma concentration of PF-06372865 in post-dose PET scans after single oral doses of PF-06372865","Pfizer","All","18 Years to 55 Years   (Adult)","Phase 1","5","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","B7431004","May 2014","August 2014","August 2014","May 14, 2014","null","September 25, 2014","New Haven Clinical Research Unit, New Haven, Connecticut, United States|Anlyan Center, New Haven, Connecticut, United States|Yale University School of Medicine, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT02138500"
423,"NCT02323217","I2PETHV - Imidazoline2 Binding Site in Healthy Volunteers","I2PETHV","Completed","No Results Available","Healthy Volunteers|Alzheimer Disease|Molecular Imaging","Radiation: [11C]BU99008|Drug: Idazoxan|Drug: Isocarboxazid","Density and distribution of Imidazoline 2 binding sites using either Total Volume of Distribution (VT) or Binding Potential (BP)|Intra- and Inter-Subject Variability in brain expression of Imidazoline 2 binding sites, measured using coefficient of variability (%COV), determined from either Total Volume of Distribution (VT) or Binding Potential (BP).|Peripheral distribution of Imidazoline 2 binding sites using either Total Volume of Distribution (VT) or Binding Potential (BP)","Imperial College London|GlaxoSmithKline","Male","40 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","20","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","14HH2250|MR/L01307X/1","January 2015","February 2016","July 2016","December 23, 2014","null","August 18, 2016","Centre for Neuropsychopharmacology; Division of Brain Sciences; Imperial College London; Burlington Danes Building; Hammersmith Hospital campus; 160 Du Cane Road, London, United Kingdom","","https://ClinicalTrials.gov/show/NCT02323217"
424,"NCT03068442","The Role of Large Artery Plaque Imaging Features in Predicting Inflammation and Cognition",,"Recruiting","No Results Available","Cognitive Impairment|Carotid Artery Plaque|Inflammation","Drug: Imaging with flutemetamol F 18 PET/CT","Carotid intraplaque hemorrhage correlation with carotid plaque inflammation on immunohistochemistry.|Carotid MRI-detected intraplaque hemorrhage and prediction of brain inflammation on PET/CT.|Preoperative MRI-detected carotid intraplaque hemorrhage and prediction of cognitive improvement after endarterectomy.","Scott Mcnally|American Heart Association|University of Utah","All","18 Years and older   (Adult, Older Adult)","Phase 2","45","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","17SDG33460420","February 17, 2017","December 31, 2019","December 31, 2019","March 1, 2017","null","May 3, 2018","University of Utah, Salt Lake City, Utah, United States|George E. Wahlen Department of Veterans Affairs Medical Center, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT03068442"
425,"NCT02297035","Characterisation of Primary Progressives Aphasias","CAPP","Recruiting","No Results Available","Aphasia Primary Progressive","Behavioral: Behavioural testing|Other: Brain imaging|Genetic: Genetic screening","Composite outcome mesure using multiple cognitive, imaging and biological parameters","Assistance Publique - Hôpitaux de Paris","All","18 Years and older   (Adult, Older Adult)","Not Applicable","155","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","P100137","March 2012","March 2017","November 2017","November 21, 2014","null","August 14, 2017","Département de Neurologie - Centre des maladies neurologiques, cognitives et comportementales, France, France","","https://ClinicalTrials.gov/show/NCT02297035"
426,"NCT02288845","Receptor Occupancy of ITI-007 Using Positron Emission Tomography (PET) in Patients With Stable Schizophrenia",,"Completed","No Results Available","Schizophrenia","Drug: ITI-007","Brain Receptor Occupancy as Measured by Positron Emission Tomography|Safety and Tolerability as Measured by Number of Participants with Adverse Events","Intra-Cellular Therapies, Inc.","All","18 Years to 60 Years   (Adult)","Phase 2","14","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","ITI-007-008","October 2014","July 2015","September 2015","November 11, 2014","null","March 10, 2017","Johns Hopkins Medical Institutions, Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT02288845"
427,"NCT03372317","Tau PET in Imaging and Cognition: Healthy Adults From 55-90",,"Recruiting","No Results Available","Mild Cognitive Impairment|Aging","Drug: 18F-MK-6240","Total number of individuals with tau present|Cognition|Functional imaging (fMRI)","Yaakov Stern|National Institute on Aging (NIA)|Columbia University","All","55 Years to 90 Years   (Adult, Older Adult)","","65","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","AAAR6959|2RF1AG038465-06","June 1, 2018","January 2023","December 2023","December 13, 2017","null","July 18, 2018","Columbia University Medical Center, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT03372317"
428,"NCT02781220","Implications for Management of PET Amyloid Classification Technology in the Imaging Dementia(IDEAS) Trial","IMPACT2","Recruiting","No Results Available","Mild Cognitive Impairment|Dementia|Alzheimer's Disease","","Percentage of change in care practices after amyloid PET scan|Percentage of change in drug management options after amyloid PET|Change in % likelihood of Alzheimer's disease (AD) diagnosis after amyloid PET scan|Percentage of change in leading diagnosis after amyloid PET|Change in physician confidence in leading diagnosis|Change in care partner's confidence in diagnosis after amyloid PET|Change in care partner satisfaction with evaluation after amyloid PET|Change in care partner assessment of the quality of evaluation after amyloid PET|Proportion of care partners finding amyloid PET scan worthwhile|Proportion exhibiting increased behavior disturbance during amyloid scan visit|Percentage of change exhibiting increased behavior disturbance when the diagnosis is given|Care partner's sustained confidence in diagnosis received after amyloid PET scan|Care partner's sustained confidence in ability to adhere to management plan received after amyloid PET scan|Percentage of recommended care practices adhered to after amyloid PET scan|Percentage of recommended drug management adhered to after amyloid PET scan","University of Utah","All","65 Years and older   (Older Adult)","","100","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","IMPACT-2","July 2016","July 2018","July 2019","May 24, 2016","null","July 11, 2017","Center for Alzheimer's Care, Imaging & Research, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT02781220"
429,"NCT01381419","First Time in Human Study (FTIH) With Positron Emission Tomography (PET)",,"Completed","No Results Available","Schizophrenia","Drug: GSK1144814","Safety and tolerability: Adverse event monitoring, vital signs (blood pressure, heart rate, respiratory rate, oral body temperature, ECGs (12 lead and Holter), clinical laboratory assessments (standard laboratory parameters).|Pharmacokinetics: time-point immediately prior to the first quantifiable plasma concentration (tlag), Cmax, time of occurrence of Cmax (tmax), AUC from time zero (pre dose) to the time of the last quantifiable concentration (AUC0-infinity),|Volume of distribution (VT) of [11C] GR205171 in the brain at Baseline and following oral doses of GSK1144814.|NK1 receptor occupancy in the brain at Baseline and following oral doses of GSK1144814.","GlaxoSmithKline","All","18 Years to 55 Years   (Adult)","Phase 1","21","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","111321","October 20, 2008","April 1, 2009","April 1, 2009","June 27, 2011","null","July 7, 2017","GSK Investigational Site, Harrow, Middlesex, United Kingdom","","https://ClinicalTrials.gov/show/NCT01381419"
430,"NCT03319810","Effect of IVIG on Cerebral and Retinal Amyloid in Mild Cognitive Impairment Due to Alzheimer Disease",,"Enrolling by invitation","No Results Available","Mild Cognitive Impairment","Biological: Octagam 10%","Change in baseline standard uptake ratio values (SUVr) of Florbetapir PET at 3 months|Change in baseline retinal amyloid imaging (RAI) at 3 months","Sutter Health","All","50 Years to 84 Years   (Adult, Older Adult)","Phase 2","5","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SIMR_Kile_IVIG POC","January 4, 2018","January 2019","May 2019","October 24, 2017","null","May 7, 2018","Sutter Neuroscience Medical Group, Sacramento, California, United States","","https://ClinicalTrials.gov/show/NCT03319810"
431,"NCT00767754","Changes of Cerebral Glucose Metabolism After 12 Weeks of Paroxetine Treatment in Panic Disorder",,"Completed","No Results Available","Panic Disorder","Drug: Paxil CR","18FDG PET, PDSS & HAM-A","Samsung Medical Center","All","20 Years to 60 Years   (Adult)","Phase 4","37","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SMC IRB 2006-07-091","January 2007","June 2007","December 2008","October 7, 2008","null","July 25, 2011","Samsung Medical Center, Seoul, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT00767754"
432,"NCT03004313","Structural and Molecular Neuroplasticity in Migraine",,"Completed","No Results Available","Migraine","Procedure: Pet Scan|Procedure: MRI scan|Procedure: Quantitative Sensory Testing (QST)","Level of mu-opioid receptor binding potential in the brain of episodic migraineurs during and outside the headache attack and compared to healthy controls.|Correlation of migraine attack severity in migraineurs with mu-opioid receptor binding potential","University of Michigan","All","18 Years to 45 Years   (Adult)","Not Applicable","32","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","HUM00027383","January 2011","October 2014","October 2014","December 28, 2016","null","November 24, 2017","University of Michigan - Michigan Center for Oral Health Research, Ann Arbor, Michigan, United States","","https://ClinicalTrials.gov/show/NCT03004313"
433,"NCT02061722","[PETDE10] Imaging of PDE10A Enzyme Levels in Huntington's Disease Gene Expansion Carriers and Healthy Controls With PET.","PEARL-HD","Completed","No Results Available","Huntington's Disease","Radiation: PET Imaging with [18F]MNI-659","The primary outcome measure will be the distribution volume (VT) in the striatum (caudate and putamen), globus pallidus, and ventral striatum estimated using kinetic and graphical analysis. Thalamus, cortex and cerebellum will also be examined.","CHDI Foundation, Inc.","All","18 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","90","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","CHDIKI1201/PET-HD-PDE10A","January 2013","May 2016","May 2016","February 13, 2014","null","June 1, 2016","The Memory Clinic, Rigshopitalet, Copenhagen, Denmark|Leiden University Medical Center, Department of Neurology, Leiden, Netherlands|University of Oslo, Nevrologisk poliklinikk, Oslo, Norway|Skane Universitetssjukhus Lund, Neurologiska kliniken, Lund, Sweden|Karolinska Universitetssjukhus, Huddinge, Stockholm, Sweden|Karolinska University Hospital, Stockholm, Sweden|KTA Karolinska Trial Alliance, Stockholm, Sweden|Neurologkliniken Akademiska sjukhuset, ing 85, Uppsala, Sweden","","https://ClinicalTrials.gov/show/NCT02061722"
434,"NCT01881646","Postoperative Neuroinflammation and Cognitive Dysfunction After Abdominal Surgery","POPE","Completed","No Results Available","Anesthesia|Surgery|Neurogenic Inflammation|Cognitive Disorders","Radiation: Positron emission tomography (PET) using [11C]PBR28","Binding of the PET probe [11C]PBR28|Cognitive testing|Inflammatory biomarkers","Karolinska University Hospital|University of Copenhagen","All","60 Years to 75 Years   (Adult, Older Adult)","Phase 4","8","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","POPE","June 2013","February 2016","February 2016","June 19, 2013","null","January 11, 2017","","","https://ClinicalTrials.gov/show/NCT01881646"
435,"NCT01889004","The Neural Mechanisms of Anesthesia and Human Consciousness","LOC-2013","Completed","No Results Available","Consciousness, Level Altered","Drug: Dexmedetomidine|Drug: Propofol","Regional cerebral blood flow|EEG|Functional magnetic resonance imaging (fMRI)|Event related potentials","University of Turku|Academy of Finland|Hospital District of Southwestern Finland","Male","20 Years to 30 Years   (Adult)","Phase 4","47","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","LOC-2013|266467|2013-001496-21|KLnro 72/2013","February 2014","January 2016","January 2016","June 28, 2013","null","January 11, 2016","Turku PET Centre, Turku, Finland","","https://ClinicalTrials.gov/show/NCT01889004"
436,"NCT03554551","Imaging the Vesicular Acetylcholine Transporter Using 18F-FEOBV PET in Parkinsons Disease",,"Recruiting","No Results Available","Parkinson Disease","","Density of vesicular acetylcholine transporter|Correlation to measurements of gastrointestinal denervation|Correlation to measurements of dysautonomia|Correlation to measurements of neuropsychological tests","Aarhus University Hospital","All","50 Years to 85 Years   (Adult, Older Adult)","","30","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","FEO-PD","August 8, 2018","December 31, 2020","March 31, 2021","June 13, 2018","null","August 9, 2018","Aarhus University Hospital, Aarhus, Region Midt, Denmark","","https://ClinicalTrials.gov/show/NCT03554551"
437,"NCT03370614","Pilot Study of the Physiological Effects of an Integrative Medicine Approach in Irritable Bowel Syndrome","IBS","Enrolling by invitation","No Results Available","Irritable Bowel Syndrome","Other: IBS Group|Other: Healthy Control Group","Combined PET/MRI to define IBS activity and inflammation pattern.|Use combined PET/MRI to demonstrate brain and body activity in responders and non-responders.","Thomas Jefferson University","All","18 Years and older   (Adult, Older Adult)","","50","Other","Observational","Observational Model: Other|Time Perspective: Prospective","17D.184","May 4, 2017","May 3, 2019","May 3, 2020","December 12, 2017","null","January 5, 2018","Thomas Jefferson University, Marcus Institute of Integrative Health Centers, Philadelphia, Pennsylvania, United States|Thomas Jefferson University, Marcus Institute of Integrative Health Centers, Villanova, Pennsylvania, United States","""Study Protocol and Statistical Analysis Plan: Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/14/NCT03370614/Prot_SAP_000.pdf|""Study Protocol and Statistical Analysis Plan: Cover Page"", https://ClinicalTrials.gov/ProvidedDocs/14/NCT03370614/Prot_SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03370614"
438,"NCT02005991","A Study To Examine The Distribution Of PF-05212377 In The Brain Of Healthy Volunteer Subjects Using Positron Emission Tomography And A Radioactive Tracer Following Oral Administration Of One Dose Of PF-05212377",,"Completed","No Results Available","Healthy","Drug: PF-05212377","5-HT2a receptor occupancy of PF-05212377 in the frontal cortex using PET|Plasma PF-05212377 exposure associated with PF-05212377 5-HT2a receptor occupancy|5-HT2a receptor occupancy of PF-05212377 in other cortical regions","Pfizer","All","18 Years to 55 Years   (Adult)","Phase 1","4","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","B2081015","November 2013","January 2014","January 2014","December 9, 2013","null","April 16, 2014","Pfizer Investigational Site, New Haven, Connecticut, United States|Pfizer Investigational Site, New Haven, Connecticut, United States|Pfizer Investigational Site, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT02005991"
439,"NCT02191267","Tau Imaging of Chronic Traumatic Encephalopathy",,"Completed","Has Results","Chronic Traumatic Encephalopathy","Radiation: [F18]-T807|Radiation: [F18]-Florbetapir|Device: MRI/MRS|Genetic: Genetic Analysis for Genetic Risk Score for Tau.","Tau Protein Uptake..|Beta-Amyloid (Aβ) Protein Uptake.","Brigham and Women's Hospital|U.S. Army Medical Research and Materiel Command|Boston University","Male","40 Years to 69 Years   (Adult, Older Adult)","Phase 2","30","Other|U.S. Fed","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2014P000035","January 2015","September 30, 2016","September 30, 2016","July 16, 2014","May 17, 2018","May 17, 2018","Boston University Medical Center, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT02191267"
440,"NCT03119961","Blood Brain Barrier Opening in Alzheimer' Disease","BOREAL1","Recruiting","No Results Available","Alzheimer Disease","Device: SONOCLOUD®","Florbetapir SUVr and Fluorodeoxyglucose MUV changes in BBB opening region of interest (ROI)|Adverse events recording","Assistance Publique - Hôpitaux de Paris|CarThera|BPIfrance","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 1|Phase 2","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P150101|2016-004145-82|B2016-A01637-44","June 26, 2017","April 1, 2019","July 1, 2019","April 19, 2017","null","August 3, 2017","APHP - Pitié-Salpêtrière Hospital, Paris, France","","https://ClinicalTrials.gov/show/NCT03119961"
441,"NCT02188914","Brain Imaging Studies of the Effect of Inhalant Use Disorder",,"Completed","No Results Available","Inhalant Use Disorder","Radiation: Positron emission tomography scan|Other: Magnetic resonance imaging","Brain metabolic activity|Abnormalities in the fractional anisotropy|Behavioral performance measures on the executive functions|Severity inhalant use disorder|Ratings and scores in the Pittsburgh Sleep Quality Index|Age at which inhalants use began|Duration of regular inhalant use","Miguel Ángel Mendoza Meléndez|National Institute of Neurology and Neurosurgery, Mexico|Instituto para la Atención y Prevención de las Adicciones en la Ciudad de México","Male","18 Years to 40 Years   (Adult)","","70","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","11/13 protocol","November 1, 2014","July 30, 2016","July 30, 2016","July 14, 2014","null","August 17, 2017","National Institute of Neurology and Neurosurgery Manuel Velasco Suarez, Mexico city, Mexico","","https://ClinicalTrials.gov/show/NCT02188914"
442,"NCT03030365","Orientation in AD Patients: PET-MR Study",,"Not yet recruiting","No Results Available","Alzheimer Disease|Mild Cognitive Impairment","Device: Siemens ""Biograph mMR"" PET-MR (3T)","Orientation performance|Cortical atrophy|Functional connectivity analysis|Mental-orientation evoked fMRI activity|[18]F-fluorodeoxyglucose (FDG) uptake","Assuta Medical Center|Hadassah Medical Organization","All","50 Years to 79 Years   (Adult, Older Adult)","","30","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","AssutaMC","February 15, 2017","February 15, 2019","February 15, 2020","January 25, 2017","null","January 25, 2017","","","https://ClinicalTrials.gov/show/NCT03030365"
443,"NCT02035761","PET Imaging Study of Neurochemical and Autonomic Disorders in Multiple System Atrophy (MSA)",,"Recruiting","No Results Available","Multiple System Atrophy - Parkinsonian Subtype (MSA-P)|Multiple System Atrophy - Cerebellar Subtype (MSA-C)","","Cardiac denervation|MSA Rate of Progression","University of Michigan|National Institute of Neurological Disorders and Stroke (NINDS)","All","30 Years to 80 Years   (Adult, Older Adult)","","26","Other|NIH","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","NS044233","July 2011","July 2018","July 2018","January 14, 2014","null","September 25, 2017","University of Michigan - Department of Neurology, Ann Arbor, Michigan, United States","","https://ClinicalTrials.gov/show/NCT02035761"
444,"NCT02585219","Pilot Viability of 11C-MET-PET as a Post-surgery Baseline Scan in High-grade Gliomas",,"Unknown status","No Results Available","Glioblastoma","","Visual comparison of pre- and post-surgery 11C-MET-PET","University Medical Center Groningen","All","18 Years and older   (Adult, Older Adult)","","10","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","NL50485.042.14","January 2016","January 2017","July 2017","October 23, 2015","null","October 23, 2015","","","https://ClinicalTrials.gov/show/NCT02585219"
445,"NCT02079766","18F-AV-1451 and Florbetapir F 18 PET Imaging in Subjects at Risk for Chronic Traumatic Encephalopathy",,"Completed","No Results Available","Chronic Traumatic Encephalopathy","Drug: florbetapir F 18|Drug: 18F-AV-1451","CTE Biomarker Analysis|Relationship Between Clinical Presentation and Tau Deposition","Avid Radiopharmaceuticals","Male","Child, Adult, Older Adult","Phase 2","40","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","18F-AV-1451-A07","June 2014","October 2015","October 2015","March 6, 2014","null","February 9, 2017","Banner Alzheimer's Institute, Phoenix, Arizona, United States|Boston University, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT02079766"
446,"NCT01851356","Brain Inflammation in Major Depressive Disorder Background",,"Completed","No Results Available","Major Depression","","Comparison of VT values obtained in MDD subject with those from healthy controls.","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)","","61","NIH","Observational","Time Perspective: Prospective","130100|13-M-0100","May 8, 2013","July 27, 2017","March 22, 2018","May 10, 2013","null","August 23, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT01851356"
447,"NCT02932488","Cerebral Pharmacodynamic Effects of 5-HT1B Receptor Stimulation",,"Recruiting","No Results Available","Healthy Volunteers","Drug: Sumatriptan","Changes in 5-HT1B receptor binding as measured with [11C]AZ10419369|Changes in cerebral blood flow measured with pseudo continuous Arterial Spin Labeling|Change in [11C]AZ10419369 concentration in blood and plasma|Plasma concentration of sumatriptan","Gitte Moos Knudsen|Rigshospitalet, Denmark","All","18 Years to 60 Years   (Adult)","Phase 1","42","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","NP3","September 2016","June 2018","June 2018","October 13, 2016","null","October 13, 2016","Neurobiology Research Unit, Rigshospitalet, Copenhagen, Denmark","","https://ClinicalTrials.gov/show/NCT02932488"
448,"NCT03378453","Narcolepsy Protect Against Alzheimer's Disease?","PROTECMAN","Completed","No Results Available","Narcolepsy|Amyloid Pathology","Device: PET-scan18F-AV-45","Mean of cortical SuVr based of the PET-scan18F-AV-45 imaging|Mean regional SuVr with PET-scan AV45|CSF Amyloid Aβ42|CSF Amyloid Aβ40|CSF Tau protein|CSF Orexin concentration|Night-time sleep duration|Day-time sleep duration|Cataplexy|Epworth sleepiness scale (ESS)|Beck Depression Inventory (BDI)|European Quality of Life Dimension (EQL-5)","University Hospital, Montpellier","All","65 Years to 85 Years   (Older Adult)","Not Applicable","38","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other","9636","April 7, 2016","November 2017","November 2017","December 19, 2017","null","December 19, 2017","Montpellier University Hospital, Gui de Chauliac, Montpellier, France","","https://ClinicalTrials.gov/show/NCT03378453"
449,"NCT01435213","Competition With Striatal [11C]ORM-13070 Binding by Atipamezole and Endogenous Noradrenaline","AIMI","Completed","No Results Available","Healthy","Drug: Atipamezole|Drug: Atomoxetine|Drug: Ketamine|Other: Cold pressor test|Drug: Insulin|Drug: Placebo","Receptor occupancy","University of Turku|Orion Corporation, Orion Pharma","Male","20 Years to 40 Years   (Adult)","Phase 1","10","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","3099002","September 2011","January 2012","January 2012","September 16, 2011","null","February 18, 2013","University of Turku, Clinical Research Services Turku CRST, Turku, Finland|University of Turku, Turku PET Centre, Turku, Finland","","https://ClinicalTrials.gov/show/NCT01435213"
450,"NCT02664571","Florbetaben as an Amyloid Plaque Marker in Elderly Patients With Focal or Disseminated Superficial Hemosiderosis","FBB ACC","Not yet recruiting","No Results Available","Amyloid Cerebral Angiopathy|Alzheimer Disease","Device: Pet scan with FBB|Device: MRI scan|Biological: APO E genotyping","PET scan with Florbetaben: Standardized Uptake Value Ratio|On the reference MRI: the number of lobar hemorrhages|On the reference MRI: the locations of lobar hemorrhages|On the reference MRI: The presence/absence classification for superficial siderosis|On the reference MRI: the locations of superficial siderosis|On the reference MRI: the absolute quantitative count of microbleeds|On the reference MRI: microbleed count category|On the reference MRI: The predominant location of microbleeds|On the reference MRI: a measure of leukoencephalopathy using the ARWMC scale|Apolipoprotein E genotype","Centre Hospitalier Universitaire de Nīmes","All","60 Years and older   (Adult, Older Adult)","Not Applicable","32","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","LOCAL/2015/DM-01|2015-004583-11","January 2019","January 2020","January 2020","January 27, 2016","null","March 9, 2018","CHRU de Nîmes - Hôpital Universitaire Carémeau, Nîmes Cedex 09, France|CH de Perpignan - Hôpital Saint Jean, Perpignan, France","","https://ClinicalTrials.gov/show/NCT02664571"
451,"NCT01455207","From Uncomplicated Alcoholism to Korsakoff's Syndrome","ALCOBRAIN","Unknown status","No Results Available","Alcoholism|Alcohol Amnestic Disorder","Behavioral: Neuropsychological testing|Biological: blood draw|Genetic: genetic testing|Other: Brain imaging examination","Evidence of brain dysfunctioning measured by neuropsychological testing and brain examination(MRI and PET)|treatment outcomes (sobriety or relapse)","University Hospital, Caen|Institut National de la Santé Et de la Recherche Médicale, France|National Research Agency, France","All","21 Years to 70 Years   (Adult, Older Adult)","Not Applicable","220","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2011-A00495-36|11-050","January 2012","January 2015","January 2015","October 19, 2011","null","April 9, 2014","Caen University Hospital, Caen, France","","https://ClinicalTrials.gov/show/NCT01455207"
452,"NCT03406273","Standardized Protocol of Surgery and Radiation for Patients With Brain Metastases in Relapsed Neuroblastoma",,"Recruiting","No Results Available","Relapsed Neuroblastoma","Radiation: Cerebral Spinal (CS) radiation|Radiation: Focal radiotherapy (SRS)","Overall Response Rate (ORR) of Participants by the presence of radiologically measurable CNS disease by cross-sectional CT or MRI imaging and/or by MIBG or PET scans and/or CSF Sampling.|Number of Participants with Adverse Events as a Measure of Safety|Progression Free Survival (PFS) interval for CNS lesions will be measured by days from start of treatment (surgery/radiation) to the date of any future progressive disease (PD) in CNS lesions per RESIST criteria.|Length of time that participants experience Overall Survival (OS)","Giselle Sholler|Spectrum Health Hospitals","All","up to 21 Years   (Child, Adult)","Not Applicable","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HITC001","September 1, 2018","January 1, 2022","January 1, 2023","January 23, 2018","null","July 10, 2018","Helen DeVos Children's Hospital, Grand Rapids, Michigan, United States","","https://ClinicalTrials.gov/show/NCT03406273"
453,"NCT03437590","A Positron Emission Tomography (PET) Study to Investigate P2X7 Receptor Occupancy by JNJ-55308942 Using [18F]-JNJ-64413739",,"Recruiting","No Results Available","Healthy","Drug: JNJ-55308942|Drug: [18F]-JNJ-64413739","Parts 1 and Part 2: Percentage of P2X7 Receptor Occupancy|Part 2: Percentage of P2X7 Receptor Occupancy|Part 1 and 2: Number of Participants With Adverse Events as a Measure of Safety and Tolerability","Janssen-Cilag International NV","Male","18 Years to 55 Years   (Adult)","Phase 1","24","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","CR108439|2017-004517-55|55308942EDI1002","March 15, 2018","August 15, 2018","October 28, 2018","February 19, 2018","null","July 30, 2018","UZ Leuven Gasthuisberg, Leuven, Belgium","","https://ClinicalTrials.gov/show/NCT03437590"
454,"NCT02778971","Implications for Management of PET Amyloid Classification Technology","IMPACT","Recruiting","No Results Available","Mild Cognitive Impairment|Dementia|Alzheimer's Disease","Drug: [18F]Flutemetamol","Proportion of care practices changed after amyloid PET scan|Proportion of drug management options changed after amyloid PET|Change in % likelihood of Alzheimer's disease (AD) diagnosis after amyloid PET scan|Proportion of change in leading diagnosis after amyloid PET|Change in physician confidence in leading diagnosis|Change in care partner's confidence in diagnosis after amyloid PET|Change in care partner satisfaction with evaluation after amyloid PET|Change in care partner assessment of the quality of evaluation after amyloid PET|Proportion of care partners finding amyloid PET scan worthwhile|Proportion exhibiting increased behavior disturbance during amyloid scan visit|Proportion exhibiting increased behavior disturbance when the diagnosis is given|Percentage of recommended care practices adhered to after amyloid PET scan|Percentage of recommended drug management adhered to after amyloid PET scan","University of Utah","All","45 Years to 90 Years   (Adult, Older Adult)","","50","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","IMPACT-1","June 2016","June 2018","June 2019","May 20, 2016","null","July 11, 2017","Center for Alzheimer's Care, Imaging & Research, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT02778971"
455,"NCT02886585","Pembrolizumab In Central Nervous System Metastases",,"Recruiting","No Results Available","Brain Metastases","Drug: Pembrolizumab|Radiation: MRI|Radiation: PET/CT|Procedure: Stereotactic Radiosurgery","Objective Response Rate|Overall Survival Rate|Extracranial Overall Response Rate|Number of Participants with grade-3 or higher hematologic toxicities or grade-3 or higher neurologic toxicities|Intracranial Response Rate|Extracranial Response Rate|Extracranial PFS|Intracranial PFS","Massachusetts General Hospital|Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Older Adult)","Phase 2","102","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16-153","October 2016","April 2020","January 2024","September 1, 2016","null","March 8, 2018","Priscilla Brastianos, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT02886585"
456,"NCT02104310","A Pilot Study Using 18F-DOPA PET-guided Radiotherapy in Gliomas",,"Active, not recruiting","No Results Available","Malignant Glioma","Drug: Fluorine-18-L-dihydroxyphenylalanine","Reduce non-central failure rates|Time to progression|Time to death|Number of patients with acute serious and non-serious adverse events|Number of patients with late serious and non-serious adverse events","Mayo Clinic|Brains Together for the Cure","All","18 Years and older   (Adult, Older Adult)","Phase 2","16","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","11-002165","April 2014","April 2019","April 2019","April 4, 2014","null","April 23, 2018","Mayo Clinic, Rochester, Minnesota, United States","","https://ClinicalTrials.gov/show/NCT02104310"
457,"NCT03465098","Evaluation of a Metabolic Preparation by a Low-carbohydrate Diet as Atkins-diet to Help in Detecting Infective Endocarditis by 18F-FDG PET","TEPEIR","Not yet recruiting","No Results Available","Infective Endocarditis","Other: Strict low carbohydrate diet (< 3gr/day of carbohydrate) before a 18F-FDG PET/CT","Infectious focus 18F-FDG activity measured with SUV (standardized uptake value )|Visual analysis to detect and locate infective area|SUV (standardized uptake value) of target organs (myocardium, muscles, liver, brain, blood, kidney..)|metabolic biomarker assay: ß-hydroxybutyrate","Central Hospital, Nancy, France","All","18 Years and older   (Adult, Older Adult)","Not Applicable","33","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","N°IDRCB: 2017-A01104-49","April 2, 2018","April 2, 2020","October 2, 2020","March 14, 2018","null","March 14, 2018","","","https://ClinicalTrials.gov/show/NCT03465098"
458,"NCT01325259","FluoroAv45 Imaging Research-in Alzheimer's Disease","FAIR-AD","Completed","No Results Available","Alzheimer's Disease|Mild Cognitive Impairment","Other: neuropsychologic assessment|Radiation: [18F]AV-45 PET|Radiation: 18-FDG PET|Other: MRI","Standard Uptake Value Ratios (SUVr)","University Hospital, Tours","All","60 Years and older   (Adult, Older Adult)","Phase 2","54","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic","PHRN08-VC / FAIR AD","April 2009","December 2011","December 2013","March 29, 2011","null","February 8, 2016","university hospital of CAEN, Caen, France|University Hospital of Lille, Lille, France|University Hospital of Toulouse, Toulouse, France|University Hospital of Tours, Tours, France","","https://ClinicalTrials.gov/show/NCT01325259"
459,"NCT02559869","Imaging and BioFluid Biomarkers in Amyotrophic Lateral Sclerosis","TRACK-ALS","Recruiting","No Results Available","Amyotrophic Lateral Sclerosis (ALS)","Drug: [18F] GE-180","Measure & localize brain inflammation in people with ALS via [18F] GE-180 PET imaging.|Define anatomical, structural, and functional changes in the brain via MRI of ALS Subjects vs. Healthy Controls at Baseline|Determine systemic inflammatory factors that may modify the progression or other clinical or imaging correlates of ALS.|Determine the longitudinal changes in brain inflammation in people with ALS in correlation with ALS severity and rate of progression.|Determine the longitudinal changes in the anatomical, structural, and functional measures in people with ALS, and build ALS prediction models using the clinical and MRI data.","Massachusetts General Hospital|The Methodist Hospital System|Cedars-Sinai Medical Center|ALS Association","All","18 Years to 80 Years   (Adult, Older Adult)","","200","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","2015P000140","November 2015","January 2020","May 2021","September 24, 2015","null","March 23, 2018","Massachusetts General Hospital, Boston, Massachusetts, United States|Houston Methodist Hospital, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT02559869"
460,"NCT01565330","A Study of Two Doses of 18F-AV-45 in Alzheimer's Disease and Healthy Volunteers",,"Completed","Has Results","Alzheimer Disease","Drug: florbetapir F 18","Florbetapir-PET Scan Quality|Mean Cortical to Cerebellum SUVR","Avid Radiopharmaceuticals","All","35 Years and older   (Adult, Older Adult)","Phase 1","20","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic","18F-AV-45-A03","March 2008","August 2008","August 2008","March 28, 2012","May 2, 2012","June 18, 2012","Research Site, West Palm Beach, Florida, United States|Research Site, North East, Maryland, United States|Research Site, Clementon, New Jersey, United States","","https://ClinicalTrials.gov/show/NCT01565330"
461,"NCT02726906","Lifestyle Enriching Activities for Research in Neuroscience Intervention Trial: LEARNit Study",,"Recruiting","No Results Available","Aging|Cognitive Ability, General","Behavioral: Moderate-aerobic walking|Radiation: Positron Emission Tomography (PET) scan|Behavioral: Healthy living education|Device: Physical activity monitor","Functional Magnetic Resonance Imaging (fMRI) brain scan as a measure of brain function|Mnemonic Similarity Test as a measure of memory (cognition)|Positron Emission Tomography (PET) scan as a measure of tracer binding|Single-stage treadmill test and modified physical function test as measures of physical function|Brain-derived neurotropic factor (BDNF) as a measure from blood","University of Southern California","All","60 Years to 80 Years   (Adult, Older Adult)","Phase 2","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","AG046928","July 2016","April 2020","April 2020","April 4, 2016","null","June 14, 2018","University of Southern California, Los Angeles, California, United States","","https://ClinicalTrials.gov/show/NCT02726906"
462,"NCT00480246","A Positron Emission Tomography (PET) Study to Assess the Degree of Dopamine-2 (D2) Receptor Occupancy in the Human Brain After Single Doses of BL-1020 or Perphenazine in Healthy Male Subjects Using [11C]Raclopride as PET Tracer",,"Completed","No Results Available","Healthy","Drug: BL 1020|Drug: Perphenazine","","BioLineRx, Ltd.","Male","21 Years to 35 Years   (Adult)","Phase 1","null","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","BL- 1020.02","May 2007","null","null","May 30, 2007","null","July 21, 2009","Quintiles Phase I facility, Uppsala, Sweden","","https://ClinicalTrials.gov/show/NCT00480246"
463,"NCT02791191","A Study of LY3202626 on Disease Progression in Participants With Mild Alzheimer's Disease Dementia","NAVIGATE-AD","Terminated","No Results Available","Alzheimer's Disease","Drug: LY3202626|Drug: Placebo","Change from Baseline in Positron Emission Tomography (PET) Standard Uptake Value Ratio (SUVr) of ¹⁸F-AV-1451|Percentage of Participants with Emergent Magnetic Resonance Imaging (MRI) Findings|Percentage of Participants with Amyloid-Related Imaging Abnormalities (ARIA)|Percentage of Participants with Suicidal Ideation and Behaviors Assessed by the Columbia Suicide Severity Rating Scale (C-SSRS) Scores|Pharmacokinetics (PK): Area Under the Plasma Concentration-Time Curve at Steady State of LY3202626|Change From Baseline in Plasma Amyloid Beta Aβ₁₋₄₀, ₁₋₄₂, and 1-x Concentration|Change from Baseline on the 13-item Alzheimer's Disease Assessment Scale-Cognition (ADAS-Cog₁₃)|Change from Baseline on the Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-iADL)|Change from Baseline on the Integrated Alzheimer's Disease Rating Scale (iADRS)","Eli Lilly and Company","All","55 Years to 85 Years   (Adult, Older Adult)","Phase 2","316","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","16223|I7X-MC-LLCF","June 16, 2016","July 2, 2018","July 2, 2018","June 6, 2016","null","August 23, 2018","Irvine Clinical Research Center, Irvine, California, United States|Sutter Medical Group, Sacramento, California, United States|Pacific Research Network Inc, San Diego, California, United States|Sharp Mesa Vista Hospital, San Diego, California, United States|Ray Dolby Brain Health Center/Sutter Health/CPMC, San Francisco, California, United States|Syrentis Clinical Research, Santa Ana, California, United States|North Bay Neuroscience Institute, Sebastopol, California, United States|New England Institute for Clinical Research, Stamford, Connecticut, United States|Christiana Care Health Service, Wilmington, Delaware, United States|Clinical Neuroscience Solutions Inc, Jacksonville, Florida, United States|Compass Research, Melbourne, Florida, United States|Florida International Research Center, Miami, Florida, United States|New Horizon Research Center, Miami, Florida, United States|The Neurology Research Group, LLC, Miami, Florida, United States|Suncoast Clinical Research, New Port Richey, Florida, United States|Renstar Medical Research, Ocala, Florida, United States|Sensible Healthcare, Ocoee, Florida, United States|Meridien Research, Spring Hill, Florida, United States|Axiom Research, Tampa, Florida, United States|United Osteoporosis Center, Gainesville, Georgia, United States|Fort Wayne Neurological Center, Fort Wayne, Indiana, United States|Indiana University School of Medicine, Indianapolis, Indiana, United States|Cotton O'Neil Clinic, Topeka, Kansas, United States|Heartland Research Associates, Wichita, Kansas, United States|Johns Hopkins University School of Medicine, Baltimore, Maryland, United States|Boston Center for Memory, Newton, Massachusetts, United States|Missouri Memory Center, Bolivar, Missouri, United States|Clinical Research Professionals, Chesterfield, Missouri, United States|Millenium Psychiatric Associates LLC, Creve Coeur, Missouri, United States|St Lukes Hospital, Kansas City, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Las Vegas Medical Research, Las Vegas, Nevada, United States|Memory Enhancement Center of America, Inc., Eatontown, New Jersey, United States|Pyramid Clinical Research, Monroe, New Jersey, United States|Advanced Memory Research Institute of New Jersey, Toms River, New Jersey, United States|Bio Behavioral Health, Toms River, New Jersey, United States|Albany Medical College, Albany, New York, United States|Dent Neurological Institute, Amherst, New York, United States|Valley Medical Primary Care, Centerville, Ohio, United States|University of Cincinnati Health Neurology, Dayton, Ohio, United States|Neurology Diagnostics, Inc., Dayton, Ohio, United States|Insight Clinical Trials, Shaker Heights, Ohio, United States|Abington Neurological Associates, Abington, Pennsylvania, United States|Lehigh Center for Clinical Research, Allentown, Pennsylvania, United States|Clinical Trial Center, LLC, Psychiatry, Jenkintown, Pennsylvania, United States|Clinical Trials of South Carolina, Charleston, South Carolina, United States|Baylor AT&T Memory Center, Dallas, Texas, United States|Nantz National Alzheimer Center, Houston, Texas, United States|University of Texas Health Services Center - Houston, Houston, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Box Hill, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chermside, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Darlinghurst, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Erina, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Glen Iris, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Heidelberg, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Herston, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nedlands, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Parkville, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., West Perth, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gatineau, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ottawa, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Verdun, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Akashi, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hachioji, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ikeda, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kasukabe-shi, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kyoto, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nagoya, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nerima-ku, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Osaka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Osaka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Setagaya-ku, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Takamatsu, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wako, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Yokosuka-shi, Japan","","https://ClinicalTrials.gov/show/NCT02791191"
464,"NCT01931995","Investigation of Brain Network Dynamics in Depression",,"Active, not recruiting","No Results Available","Major Depressive Disorder, Recurrent","Device: TMS positively correlated DLPFC|Procedure: TMS to negatively correlated DLPFC","Relative changes in corticolimbic functional connectivity as a result of TMS|Changes in local glucose metabolism at corticolimbic network nodes","Brigham and Women's Hospital","All","18 Years to 50 Years   (Adult)","Not Applicable","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","2012p001784","February 2013","December 2017","July 2018","August 30, 2013","null","June 14, 2017","Martinos Center for Biomedical Imaging/Massachusetts General Hospital, Charlestown, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT01931995"
465,"NCT00034398","Study of GABA-A Receptors in the Generation of Tics in Patients With Tourette's Syndrome",,"Completed","No Results Available","Tourette Syndrome","","","National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)","All","18 Years to 65 Years   (Adult, Older Adult)","","26","NIH","Observational","","020181|02-N-0181","April 24, 2002","null","March 11, 2010","April 29, 2002","null","July 2, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00034398"
466,"NCT02740634","Molecular and Structural Imaging in Atypical Alzheimer's Disease: A Longitudinal Study",,"Recruiting","No Results Available","Atypical Alzheimer's Disease|Logopenic Progressive Aphasia (LPA)|Posterior Cortical Atrophy (PCA)","Drug: F-18 AV 1451|Drug: C-11 PiB","Amount of Amyloid protein in the brain of patients with Logopenic Aphasia (LPA) or Posterior Cortical Atrophy (PCA).|Amount of Tau protein in the brain of patients with Logopenic Aphasia (LPA) or Posterior Cortical Atrophy (PCA).|Rates of change in amyloid-PET burden over time.|Rates of change in tau-PET burden over time.","Mayo Clinic","All","21 Years to 80 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","15-008682","May 2016","March 2021","March 2021","April 15, 2016","null","March 26, 2018","Mayo Clinic, Rochester, Minnesota, United States","","https://ClinicalTrials.gov/show/NCT02740634"
467,"NCT01447719","Autopsy Follow-up of Subjects Previously Imaged With Florbetapir F 18 (18F-AV-45) PET in Trial 18F-AV-45-A07",,"Completed","Has Results","Alzheimer's Disease","Drug: florbetapir F 18","Sensitivity Analysis in All Autopsy Population|Specificity Analysis in All Autopsy Population|Correlation of Florbetapir-PET Image and Amyloid Plaque Density|Sensitivity Analysis in Subjects With Autopsy Within 1 Year of Scan|Specificity Analysis in Subjects With Autopsy Within 1 Year of Scan","Avid Radiopharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","110","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","18F-AV-45-A16","March 2010","March 2011","July 2011","October 6, 2011","May 7, 2012","May 22, 2012","Research Site, Phoeniz, Arizona, United States|Research Site, Sun City, Arizona, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Irvine, California, United States|Research Site, Fort Myers, Florida, United States|Research Site, Miami Beach, Florida, United States|Research Site, Miami Springs, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Sarasota, Florida, United States|Research Site, St. Petersburg, Florida, United States|Research Site, West Palm Beach, Florida, United States|Research Site, Baltimore, Maryland, United States|Research Site, Hattiesburg, Mississippi, United States|Research Site, St. Louis, Missouri, United States|Research Site, Albany, New York, United States|Research Site, New Hyde Park, New York, United States|Research Site, Durham, North Carolina, United States|Research Site, Centerville, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Charleston, South Carolina, United States|Research Site, Johnson City, Tennessee, United States","","https://ClinicalTrials.gov/show/NCT01447719"
468,"NCT00108173","Brain Reaction to Treatment of Nicotine Dependence",,"Completed","No Results Available","Nicotine Dependence","Drug: Zyban","2-FA PET scan results","US Department of Veterans Affairs|VA Office of Research and Development","All","21 Years to 60 Years   (Adult)","Phase 1","104","U.S. Fed","Interventional","Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","ADRD-018-02S","October 2002","April 2007","June 2011","April 15, 2005","null","April 9, 2013","VA Greater Los Angeles Healthcare System, West LA, West Los Angeles, California, United States","","https://ClinicalTrials.gov/show/NCT00108173"
469,"NCT02240797","Kappa Opioid Receptor Imaging in Anorexia",,"Terminated","No Results Available","Anorexia Nervosa","Other: Positron emission tomography (PET) imaging","Volume of distribution (VT) (i.e., KOR binding) using [11C]PKAB and PET imaging","New York University School of Medicine|Yale University|Icahn School of Medicine at Mount Sinai","Female","18 Years to 55 Years   (Adult)","","7","Other","Observational","Observational Model: Case Control|Time Perspective: Cross-Sectional","S13-00990","September 2014","March 2016","March 2016","September 16, 2014","null","August 17, 2016","NYU School of Medicine, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT02240797"
470,"NCT01606488","Effects of Brain Beta-Amyloid on Postoperative Cognition",,"Recruiting","No Results Available","Postoperative Cognitive Dysfunction","Drug: Florbetapir F 18 (18F-AV-45)|Other: no intervention","Cognitive Decline|Genetic Polymorphisms|Vagus nerve tone assessment|Inflammatory Markers|Perioperative Complications|Delirium|Coma Assessment|Hospital Length of Stay|Postoperative Complications|Change in Cognition|Quality of Life|Mortality|Pain intensity|Pain unpleasantness|Post-traumatic Stress Disorder symptomatology","University of California, San Francisco|Alzheimer’s Drug Discovery Foundation|Avid Radiopharmaceuticals","All","65 Years and older   (Older Adult)","Phase 4","100","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","20110506|18F-AV-45-A14","May 2012","June 2019","June 2019","May 25, 2012","null","May 17, 2018","San Francisco VA Medical Center, San Francisco, California, United States","","https://ClinicalTrials.gov/show/NCT01606488"
471,"NCT00884702","Regional Rates of Cerebral Protein Synthesis: Effects of Sleep and Memory Consolidation",,"Completed","No Results Available","Brain Mapping","","Regional rates of cerebral protein synthesis|Sleep state and performance on visual discrimination task.","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years to 28 Years   (Adult)","","538","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","090123|09-M-0123","April 16, 2009","null","April 18, 2017","April 21, 2009","null","October 6, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00884702"
472,"NCT02514720","Nicotine Metabolizers and [11C]-(+)-PHNO","MET","Completed","No Results Available","Nicotine Dependence","Other: cigarette","Occupancy of D2/3 receptors by [11C]-(+)-PHNO","Centre for Addiction and Mental Health","All","18 Years and older   (Adult, Older Adult)","Not Applicable","16","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","111/2014","June 2015","January 2017","January 2017","August 4, 2015","null","June 19, 2017","Centre for Addiction and Mental Health, Toronto, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT02514720"
473,"NCT00580814","Brain Dopamine Function in Adults With ADHD","Brookhaven","Completed","No Results Available","Attention Deficit Hyperactivity Disorder","Drug: Methylphenidate","Two PET scans.One at baseline and the second a year later.","University of California, Irvine|Icahn School of Medicine at Mount Sinai|Duke University","All","18 Years to 45 Years   (Adult)","Not Applicable","24","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","CORIHS ID# 20055906","February 2006","March 2009","April 2009","December 27, 2007","null","April 8, 2011","UCI Child Development Center, Irvine, California, United States","","https://ClinicalTrials.gov/show/NCT00580814"
474,"NCT02233829","Dopamine Rhythms in Health and Addiction",,"Suspended","No Results Available","Cocaine Abuse","Drug: Methylphenidate|Drug: C-11 Raclopride","To assess if there are diurnal rhythms in DA signaling and in reward brain circuits and to determine if these are disrupted in cocaine addiction.|To determine if differences in measures of DA signaling between morning and evening correlate with circadian typology.|To determine if measures of DA signaling correlate with measures of spontaneous motor activity and with sleeping patterns.|To assess if DA signaling correlates with reactivity of brain regions to exposure of drug and with functional connectivity of the reward network and to assess if the reactivity of reward network shows circadian variability.","National Institute on Alcohol Abuse and Alcoholism (NIAAA)|National Institutes of Health Clinical Center (CC)","All","21 Years to 55 Years   (Adult)","Early Phase 1","112","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","140187|14-AA-0187","September 6, 2014","December 31, 2021","December 31, 2021","September 9, 2014","null","July 6, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT02233829"
475,"NCT02874820","I2PETPG - Imidazoline2 Binding Sites in a Group of Participants Diagnosed With AD","I2PETPG","Completed","No Results Available","Alzheimer Disease","Radiation: [11C]BU99008|Drug: Idazoxan","Density and distribution of Imidazoline 2 binding sites using either Total Volume of Distribution (VT) or Binding Potential (BP)","Imperial College London|GlaxoSmithKline","Male","50 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","2","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","16HH3243|MR/L01307X/1","July 2016","March 2017","July 2017","August 22, 2016","null","March 7, 2018","Centre for Neuropsychopharmacology; Division of Brain Sciences; Imperial College London; Burlington Danes Building; Hammersmith Hospital campus; 160 Du Cane Road, London, United Kingdom","","https://ClinicalTrials.gov/show/NCT02874820"
476,"NCT01236508","Relation of Carotid Artery Plaque Inflammation, Covert Stroke and White Matter Disease",,"Terminated","No Results Available","TIA|Stroke|Carotid Artery Stenosis","Radiation: PET/CT imaging with F-18 fluorodeoxyglucose","Plaque Inflammation","Ottawa Heart Institute Research Corporation|The Ottawa Hospital","All","60 Years and older   (Adult, Older Adult)","Phase 4","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening","20100606-01H","November 2010","October 27, 2016","October 27, 2016","November 8, 2010","null","April 24, 2017","The Ottawa Hospital, Civic Campus, Ottawa, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT01236508"
477,"NCT00305513","Effectiveness of Rehabilitation on the Recovery of Patients Post Right Stroke With Unilateral Spatial Neglect",,"Unknown status","No Results Available","Cerebrovascular Accident|Perceptual Disorders","Procedure: The phasic alerting treatment","This study's aim is to examine the functional reorganization of the attentional network in the brain of USN patients while performing visual tasks, by means of functional neuroimaging techniques, in light of specific rehabilitation techniques.|The aim of this study is to try and contribute to both efforts by examining treatment effectiveness of two methods; one targeting general arousal (phasic alerting), and the other targeting increasing awareness to left side stimuli and habit changes.","Hadassah Medical Organization","All","25 Years to 85 Years   (Adult, Older Adult)","Phase 2","6","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Treatment","10-17.02.06-HMO-CTIL","null","null","null","March 22, 2006","null","June 3, 2010","Hadassah Medical Organization, Jerusalem, Israel","","https://ClinicalTrials.gov/show/NCT00305513"
478,"NCT02715232","Effects of Sex Steroids on the Serotonin System",,"Recruiting","No Results Available","Gender Dysphoria","Drug: Testosterone|Drug: Lynestrenol|Drug: Cyproterone Acetate|Drug: Estradiol|Drug: Triptorelin acetate","blood-to-brain clearance/trapping (K*) of [11C]AMT|distribution volume (DV) of [11C]harmine|white and gray matter microstructure|gray matter volume/density and cortical thickness|cerebral blood flow (CBF)|Scores on the Klein Sexual Orientation Grid (KSOG)|Scores on the Utrecht Gender Dysphoria Scale","Medical University of Vienna","All","18 Years to 50 Years   (Adult)","Phase 4","92","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","1.1-20150511","February 6, 2017","December 2020","December 2020","March 22, 2016","null","April 13, 2017","Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria","","https://ClinicalTrials.gov/show/NCT02715232"
479,"NCT01922388","Early Versus Late Introduction of STN DBS in PD Patients With Motor Complications",,"Recruiting","No Results Available","Parkinson Disease","Device: Bilateral deep brain stimulation of the subthalamic nucleus|Drug: 18F-AV-133","Change from baseline in 39-item Parkinson's disease questionnaire(PDQ-39) scores|Change from baseline in Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III scores|Change from baseline in time spent in the 'on' state without troubling dyskinesia based on Parkinson's disease home diary|Change from baseline in MDS-UPDRS patient questionnaire(Part I B and Part II) scores|Integrity of dopaminergic neurons measured by reuptake of a PET imaging agent, [18F]-AV-133","Chen Ling|Prince of Wales Hospital, Shatin, Hong Kong|Shenzhen Second People's Hospital|First Affiliated Hospital, Sun Yat-Sen University","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","200","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","[2013]19","August 2013","December 2020","null","August 14, 2013","null","August 9, 2016","the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China","","https://ClinicalTrials.gov/show/NCT01922388"
480,"NCT01547754","Mild Neurocognitive Disorder in HIV Infection of the Brain",,"Terminated","No Results Available","HIV-Associated Cognitive Motor Complex","","Brain uptake of [11C]dLop after pharmacological challenge with the P-gp inhibitor tariquidar.|Cerebrospinal fluid concentrations of antiretroviral drugs and inflammatory markers.","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years to 60 Years   (Adult)","","8","NIH","Observational","Time Perspective: Prospective","120059|12-M-0059","January 9, 2012","null","August 25, 2014","March 8, 2012","null","August 23, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT01547754"
481,"NCT00267163","Brain Imaging and Mental Disorders of Aging Intervention",,"Completed","No Results Available","Cognition Disorders","Drug: donepezil|Drug: Placebo","Changes in cognition and brain metabolism measured by PET and MRI scans, and neuropsychological testing","National Institute on Aging (NIA)","All","40 Years to 90 Years   (Adult, Older Adult)","Phase 4","64","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Prevention","IA0090|9R01AG018487-06","September 2000","July 2007","July 2007","December 20, 2005","null","August 29, 2008","UCLA, The Semel Institute for Neuroscience and Human Behavior, Los Angeles, California, United States","","https://ClinicalTrials.gov/show/NCT00267163"
482,"NCT03591861","Therapeutic Targeting of Sex Differences in Pediatric Brain Tumor Glycolysis",,"Not yet recruiting","No Results Available","Pediatric Brain Tumor","Procedure: Ketogenic diet|Drug: BCNU","Feasibility of combining a ketogenic diet with chemotherapy in children with relapsed brain tumors as measured by the number of patients who can recruited with 3 years|Feasibility of combining a ketogenic diet with chemotherapy in children with relapsed brain tumors as measured by if at least 80% of the patients comply with the intervention|Tolerability of combining a ketogenic diet with chemotherapy in male children with relapsed brain tumors versus female children with relapsed brain tumors as measured by toxicity|Tumor response of male children with relapsed brain tumors to a ketogenic diet combined with chemotherapy versus female children with relapsed brain tumors as measured by progression-free survival (PFS)","Washington University School of Medicine","All","up to 21 Years   (Child, Adult)","Phase 1","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","201806141","September 30, 2018","September 30, 2023","September 30, 2031","July 19, 2018","null","August 9, 2018","Washington University School of Medicine, Saint Louis, Missouri, United States","","https://ClinicalTrials.gov/show/NCT03591861"
483,"NCT00865332","Psychology of Reward and Punishment: Functional and Molecular Brain Imaging and Monoaminergic Correlates",,"Withdrawn","No Results Available","Cocaine Addiction|Cocaine Abuse","","","National Institute on Drug Abuse (NIDA)|National Institutes of Health Clinical Center (CC)","All","18 Years to 50 Years   (Adult)","","0","NIH","Observational","","080437|08-DA-0437","December 12, 2007","null","December 21, 2010","March 19, 2009","null","July 2, 2017","National Institute on Drug Abuse, Biomedical Research Center (BRC), Baltimore, Maryland, United States|National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00865332"
484,"NCT00392912","Effect of Testosterone Therapy in Men With Alzheimer's Disease and Low Testosterone",,"Completed","No Results Available","Alzheimer's Disease|Hypogonadism","Drug: AndroGel (Solvay Pharmaceuticals)","Calculated difference image of pre-treatment and on-treatment PET scans.|Change in cognitive function at 8-week intervals over a 6-month period.","VA Medical Center, Houston|Solvay Pharmaceuticals","Male","55 Years and older   (Adult, Older Adult)","Not Applicable","10","U.S. Fed|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GR-294","April 2007","November 2009","July 2010","October 26, 2006","null","August 19, 2010","Michael E. DeBakey VA Medical Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT00392912"
485,"NCT02278367","Clinical Evaluation of 18F-AV-1451",,"Recruiting","No Results Available","Alzheimer's Disease|Traumatic Brain Injury|Depression","Drug: 18F-AV-1451","Safety Assessment: Adverse event frequency related to 18F-AV-1451 administration|Efficacy Assessment: 18F-AV-1451 standard uptake value ratios (SUVRs)","Avid Radiopharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 2","250","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","18F-AV-1451-A14","December 2014","September 2018","September 2018","October 30, 2014","null","March 26, 2018","Banner Alzheimer's Institute, Phoenix, Arizona, United States|Yale University, New Haven, Connecticut, United States|Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, Nevada, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Center for Vital Longevity at the University of Texas at Dallas, Dallas, Texas, United States","","https://ClinicalTrials.gov/show/NCT02278367"
486,"NCT01092546","Positron Emission Tomography Imaging of Brain Amyloid in Normal Pressure Hydrocephalus",,"Terminated","Has Results","Normal Pressure Hydrocephalus","Drug: [18F]Flutemetamol","Standard Uptake Value Ratio (SUVR) at the Site of the Biopsy Based on the ""Cerebellum"" (CER) as the Reference Region.|Standard Uptake Value Ratio (SUVR) at the Site of the Biopsy Based on the ""Pons"" as the Reference Region.","GE Healthcare|i3 Statprobe","All","50 Years and older   (Adult, Older Adult)","Phase 3","12","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","GE-067-009","March 2010","April 2011","April 2011","March 25, 2010","November 19, 2013","December 13, 2013","GE Healthcare, Princeton, New Jersey, United States","","https://ClinicalTrials.gov/show/NCT01092546"
487,"NCT01065415","Whole-Body Magnetic Resonance Imaging/Positron Emission Tomography (MRI/PET) in the Staging of Non-Small-Cell Lung Cancer (NSCLC)",,"Completed","No Results Available","Non-small Cell Lung Cancer","","","Samsung Medical Center","All","20 Years and older   (Adult, Older Adult)","","272","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","2008-07-019","February 2010","null","October 2011","February 9, 2010","null","December 29, 2011","Samsung Medical Center, Seoul, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT01065415"
488,"NCT02736513","Intracranial Activity of AZD9291 (TAGRISSO) in Advanced EGFRm NSCLC Patients With Asymptomatic Brain Metastases",,"Recruiting","No Results Available","Lung Cancer","Drug: AZD9291","Intracranial overall response rate as defined by modified RECIST|Intracranial disease control rate (IDCR) as defined by mRECIST|median time to intracranial response (mTTIR) as defined by mRECIST|median intracranial progression free survival (mIPFS) as defined by mRECIST","Rabin Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 2","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0785-15-RMC","May 2016","May 2020","May 2020","April 13, 2016","null","June 21, 2016","Rabin Medical Center, Petach Tikva, Israel","","https://ClinicalTrials.gov/show/NCT02736513"
489,"NCT02707978","F 18 T807 Tau PET Imaging of Frontotemporal Dementia (FTD)",,"Withdrawn","No Results Available","Alzheimer Disease","Drug: F 18 T807","F 18 T807 Standard Uptake Value Ratios (SUVR) will be correlated with other imaging modalities (MRI, PET amyloid imaging) and cognitive performance.","Washington University School of Medicine","All","18 Years and older   (Adult, Older Adult)","Phase 2","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","IND 123119 Protocol C","April 2016","March 2020","September 2020","March 14, 2016","null","September 21, 2017","Washington University School of Medicine, Saint Louis, Missouri, United States","","https://ClinicalTrials.gov/show/NCT02707978"
490,"NCT00296920","Deep Brain Stimulation for Refractory Major Depression",,"Completed","No Results Available","Major Depressive Disorder","Device: Deep Brain Stimulation","Hamilton Rating Scale for Depression, 24-item version (HRSD-24)|Clinical Global Impression (CGI) of Severity/Improvement|Psychiatric assessments will be performed every two weeks in the clinic. Once final stimulation parameters are established, psychiatric symptoms will be monitored monthly.","University Health Network, Toronto|National Alliance for Research on Schizophrenia and Depression","All","30 Years to 70 Years   (Adult, Older Adult)","Phase 3","10","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","02-0118-B","June 2002","November 2007","null","February 27, 2006","null","February 17, 2009","University Health Network, Toronto, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT00296920"
491,"NCT01931540","Developmental ORIgins of Healthy and Unhealthy AgeiNg: the Role of Maternal Obesity","DORIAN","Completed","No Results Available","Maternal-Fetal Relations|Muscle Weakness|Insulin Resistance","Behavioral: Exercise Training","Baseline group comparison and Change from Baseline in Insulin-stimulated whole body and organ-specific glucose uptake at 4 months|Baseline group comparison and Change from Baseline in Epigenetic characterization of DNA samples (Telomere length, H2A.X phosphorilation, mtDNA deletion, p66) at 4 months|Baseline group comparison and Change from Baseline in Fat masses and content via MRI and MRS at 4 months|Baseline group comparison and Change from Baseline in MRI brain anatomy and fMRI characterization of activation response to food stimuli of different brain regions at 4 months","Turku University Hospital|University of Turku|Helsinki University|Fondazione C.N.R./Regione Toscana ""G. Monasterio"", Pisa, Italy|Istituto Superiore di Sanità","Female","Child, Adult, Older Adult","Not Applicable","48","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","T55/2012b|EC-FP7-278603","June 2012","April 2014","June 2015","August 29, 2013","null","March 22, 2016","University of Helsinki, Department of General Practice and Primary Health Care, Helsinki, Finland|Turku PET Centre (Turku University Hospital), Turku, Finland","","https://ClinicalTrials.gov/show/NCT01931540"
492,"NCT00037479","Brain Imaging and Retreatment Study of Persistent Lyme Disease",,"Completed","No Results Available","Lyme Disease|Lyme Neuroborreliosis","Drug: ceftriaxone","","National Institute of Neurological Disorders and Stroke (NINDS)","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","65","NIH","Interventional","Allocation: Randomized|Primary Purpose: Treatment","R01NS038636","December 1999","null","null","May 20, 2002","null","December 7, 2005","Columbia Presbyterian Medical Center, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT00037479"
493,"NCT01818661","Longitudinal Multi-Modality Imaging in Progressive Apraxia of Speech",,"Recruiting","No Results Available","PPA|Non-fluent Aphasia|Apraxia of Speech|Primary Progressive Non-fluent Aphasia|Primary Progressive Aphasia","Drug: AV-1451","measurement of longitudinal change in neuroimaging and the correlation between change on serial imaging measures and concurrent change on longitudinal measures of clinical performance in neurodegenerative AOS with or without non-fluent aphasia (NFA)","Mayo Clinic","All","18 Years and older   (Adult, Older Adult)","Phase 4","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","12-008988, 17-010087","July 1, 2018","June 1, 2023","June 1, 2023","March 26, 2013","null","August 20, 2018","Mayo Clinic, Rochester, Minnesota, United States","","https://ClinicalTrials.gov/show/NCT01818661"
494,"NCT00553748","Phase I, Open Label, Single Center Safety Study of [F-18]FLT",,"Completed","No Results Available","Brain Cancer","Drug: F-18 FLT","Safety will be demonstrated through analysis of adverse events in subjects enrolled in the trial who received study drug","Siemens Molecular Imaging","All","18 Years and older   (Adult, Older Adult)","Phase 1","11","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","D0008186","November 2007","May 2008","May 2008","November 6, 2007","null","July 3, 2008","Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT00553748"
495,"NCT03117530","Measuring Brain Inflammation in Autism",,"Recruiting","No Results Available","Autism Spectrum Disorder","Drug: Minocycline","Evaluate differences in CNS microglial activation in adults with ASD versus healthy volunteers via in vivo CNS binding of [11C]-DAA1106|Evaluate the effect of 12-weeks of minocycline exposure on CNS microglial activation in adults with ASD by measuring change in [11C]-DAA1106 binding pre- and post- treatment|Effect of minocycline exposure on cognition across seven cognitive domains before and after low dose intervention and regular dose intervention as measured by MCCB (MATRICS Consensus Cognitive Battery) subdomain scores|Effect of minocycline exposure on self-rated anxiety and emotion regulation as measured by ADAMS (Anxiety and Depression Mood Scale)|Effect of minocycline exposure on peripheral inflammatory cytokine profiles as measured by DNA and RNA expression in blood samples","University of California, Los Angeles","Male","18 Years to 35 Years   (Adult)","Phase 1","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16-001784","April 11, 2017","December 2019","December 2019","April 18, 2017","null","May 14, 2018","UCLA, Los Angeles, California, United States","","https://ClinicalTrials.gov/show/NCT03117530"
496,"NCT03290326","tACS for Amyloid-β Reduction in Alzheimer's Disease",,"Recruiting","No Results Available","Alzheimer Disease","Device: Transcranial Alternating Current Stimulation (tACS)","Incidence of Treatment-Emergent Adverse Events|PET Amyloid burden|EEG gamma-band spectral power|Adas-Cog score","Beth Israel Deaconess Medical Center","All","45 Years and older   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2017P000373","November 27, 2017","November 1, 2018","November 1, 2018","September 21, 2017","null","December 26, 2017","Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT03290326"
497,"NCT02359864","Study of Low Dose Whole Brain Irradiation in the Treatment of Alzheimer's Disease",,"Not yet recruiting","No Results Available","Alzheimer's Disease","Radiation: 5 daily fractions of 2 Gy|Radiation: 10 daily fractions of 2 Gy","Common Terminology Toxicity Criteria (Version 4.0) - 6 weeks|Common Terminology Toxicity Criteria (Version 4.0) - 3 months|Common Terminology Toxicity Criteria (Version 4.0) - 9 months|Common Terminology Toxicity Criteria (Version 4.0) - 12 months|AMYVID (florbetaben F 18 Injection) PET Scan|Neurocognitive Function - MMSE (Mini Mental Status Exam) 6 weeks change from baseline|Neurocognitive Function - MMSE (Mini Mental Status Exam) 3 months change from baseline|Neurocognitive Function - MMSE (Mini Mental Status Exam) 9 months change from baseline|Neurocognitive Function - MMSE (Mini Mental Status Exam) 12 months change from baseline|Neurocognitive Function - ADAS-Cog - 6 weeks change from baseline|Neurocognitive Function - ADAS-Cog - 3 months change from baseline|Neurocognitive Function - ADAS-Cog - 9 months change from baseline|Neurocognitive Function - ADAS-Cog - 12 months change from baseline|Neurocognitive Function - QOL-AD - 6 weeks change from baseline|Neurocognitive Function - QOL-AD - 3 months change from baseline|Neurocognitive Function - QOL-AD - 9 months change from baseline|Neurocognitive Function - QOL-AD - 12 months change from baseline|Neurocognitive Function - QUALID- 6 weeks change from baseline|Neurocognitive Function - QUALID- 3 months change from baseline|Neurocognitive Function - QUALID- 9 months change from baseline|Neurocognitive Function - QUALID- 12 months change from baseline","William Beaumont Hospitals","All","55 Years and older   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2016-088; 2017-471","September 2018","December 2020","December 2020","February 10, 2015","null","August 20, 2018","Beaumont Health, Farmington Hills, Michigan, United States|Beaumont Health, Royal Oak, Michigan, United States","","https://ClinicalTrials.gov/show/NCT02359864"
498,"NCT01668082","An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection",,"Recruiting","No Results Available","Brain Mass","Procedure: surgical resection of a brain tumor","metabolic phenotype correlation to clinical endpoints|baseline imaging data review|molecular profiling","University of Texas Southwestern Medical Center","All","18 Years and older   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","STU 062010-157","August 2009","February 2020","February 2022","August 17, 2012","null","February 13, 2018","University of Texas Southwestern, Dallas, Texas, United States","","https://ClinicalTrials.gov/show/NCT01668082"
499,"NCT00840047","Methionine PET/CT Studies In Patients With Cancer",,"Recruiting","No Results Available","Brain Tumors and/or Solid Tumors Including|Brain Stem Glioma|High Grade CNS Tumors|Ependymoma|Medulloblastoma|Craniopharyngioma|Low Grade CNS Tumors|Hodgkin Lymphoma|Non Hodgkin Lymphoma|Ewing Sarcoma|Osteosarcoma|Rhabdomyosarcoma|Neuroblastoma|Other","Drug: Methionine","Success rate of methionine (MET) for visualizing tumors|Association of methionine uptake with tumor grade|Bio-distribution of MET in organs","St. Jude Children's Research Hospital","All","Child, Adult, Older Adult","Phase 2","650","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","METPET|NCI-2011-02414","July 20, 2009","May 31, 2020","May 31, 2023","February 10, 2009","null","June 18, 2018","St. Jude Children's Research Hospital, Memphis, Tennessee, United States","","https://ClinicalTrials.gov/show/NCT00840047"
500,"NCT03361410","Impact of Grape Consumption on Brain Metabolism and Neuropsychological Performance Over 1 Year",,"Recruiting","No Results Available","Mild Cognitive Impairment","Dietary Supplement: Grape Powder|Dietary Supplement: Placebo Powder","Regional Cerebral Metabolism|Changes in neuropsychological performance measures|Changes in neuropsychological performance measures: Mini-Mental State Examination|Changes in neuropsychological performance measures: Wechsler Adult Intelligence Scale (WAIS-III) Digit Span|Changes in neuropsychological performance measures: Trail Making Test Part B|Changes in neuropsychological performance measures: Functional Activities Questionnaire|Changes in neuropsychological performance measures: Verbal Memory|Changes in neuropsychological performance measures: Non-Verbal Memory|Changes in neuropsychological performance measures: Verbal Function|Changes in neuropsychological performance measures: Stroop Interference|Changes in neuropsychological performance measures: Problem Solving|Changes in neuropsychological performance measures: Visual Spatial Processing","University of California, Los Angeles|California Table Grape Commission","All","65 Years to 85 Years   (Older Adult)","Phase 2","32","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","17-001290","November 18, 2017","May 2019","May 2019","December 4, 2017","null","May 8, 2018","University of California, Los Angeles, Los Angeles, California, United States","","https://ClinicalTrials.gov/show/NCT03361410"
501,"NCT02534207","Basmisanil Positron Emission Tomography Study in Japanese Volunteers",,"Completed","No Results Available","Healthy Volunteer","Drug: Basmisanil","Percentage of Brain α5 Subunit-Containing GABAA Receptors Occupied by Basmisanil (Receptor Occupancy) Following a Single Dose of Basmisanil in Selected Regions of Interest (ROIs) Assessed by PET Imaging|Correlation Between Basmisanil Plasma Concentration and Occupancy of Brain α5 Subunit-Containing GABAA Receptors|Brain GABAA Receptor α5 Subunit Levels in Selected ROIs Assessed by PET Imaging|Percentage of Participants With Adverse Events","Hoffmann-La Roche","All","20 Years to 45 Years   (Adult)","Phase 1","6","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","BP29784|2015-001621-16","August 2015","October 2015","November 2015","August 27, 2015","null","January 26, 2017","Hammersmith Medicines Research; Central Middlesex Hospital, London, United Kingdom|London, United Kingdom|Imanova Limited, London, United Kingdom|London, United Kingdom","","https://ClinicalTrials.gov/show/NCT02534207"
502,"NCT01880957","PET and MRI Brain Imaging of Bipolar Disorder",,"Unknown status","No Results Available","Bipolar Disorder|Bipolar Depression|Unipolar Depression","Drug: Lithium|Drug: Lamotrigine","Hamilton Depression Rating Scale","Stony Brook University|National Institute of Mental Health (NIMH)|The Dana Foundation","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","76","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","2012-1826-F|7R01MH090276-03","August 2012","May 2017","null","June 19, 2013","null","July 19, 2016","Stony Brook University, Stony Brook, New York, United States","","https://ClinicalTrials.gov/show/NCT01880957"
503,"NCT01424449","A PET Study in Healthy Volunteers",,"Completed","No Results Available","Depressive Disorder","Radiation: [11C]PHNO|Drug: Aripiprazole","volume of distribution","GlaxoSmithKline","Male","22 Years to 55 Years   (Adult)","Phase 1","7","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)","113549","January 2010","July 2010","July 2010","August 29, 2011","null","December 17, 2012","GSK Investigational Site, London, United Kingdom","","https://ClinicalTrials.gov/show/NCT01424449"
504,"NCT03623828","Treating Severe Brain-injured Patients With Apomorphine",,"Recruiting","No Results Available","Disorder of Consciousness","Drug: Apomorphine Hydrochloride 50Mg/10mL Prefilled Syringe","Change from baseline in Coma Recovery Scale - Revised (CRS-R)|Nociception Coma Scale - Revised (NCS-R)|resting-state EEG|EEG with auditory paradigms|PET|fMRI|Circadian rythmycity using body movements|Circadian rythmycity using body temperature variations|Number of sleep cycles using night EEG|Glasgow Outcome Scale - Extended (GOS-E)|Phone-adapted CRS-R","University Hospital of Liege|Université Catholique de Louvain","All","18 Years to 55 Years   (Adult)","Phase 2","6","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2017/81a","September 15, 2018","October 2019","August 2021","August 9, 2018","null","August 9, 2018","Neurological Hospital Center William Lennox, Ottignies, Brabant Wallon, Belgium|University Hospital of Liège, Liège, Belgium","","https://ClinicalTrials.gov/show/NCT03623828"
505,"NCT02619084","Subthalamic Stimulation in Tourette's Syndrome","STN-DBSinTS","Completed","No Results Available","Tourette's Syndrome|Tourette Syndrome|Gilles de la Tourette Syndrome|Tourette Disorder","Procedure: STN DBS","Change in Yale Global Tic Severity Scale|Change in Milan Overall Dementia Assessment (MODA)|Change in brain activity recorded by PET|STN DBS safety in treating medically-refractory Tourette syndrome|Change in Yale-Brown Obsessive Compulsive scale (Y-BOCS)|Change in Global assessment scale (GAS).|Change in Global Clinical Impression Scale (GCI-S)|Change in Gilles de la Tourette syndrome-quality of life scale (GTS-QOL)|Change in Montgomery-Åsberg Depression Rating Scale (MADRS)|Change in ADHD Rating Scale-IV (ADHD-RS)|Change in Hamilton Anxiety Rating Scale (HAM-A)","Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta|Ministry of Health, Italy","All","18 Years to 60 Years   (Adult)","Phase 2","10","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","RF-131|GR-2009-1594645","December 2011","December 2015","December 2015","December 2, 2015","null","February 23, 2016","Fondazione IRCCS Istituto neurologico Carlo Besta, Milan, Italy","","https://ClinicalTrials.gov/show/NCT02619084"
506,"NCT02927327","Clinical Evaluation Of MP26 Features in Adults",,"Completed","No Results Available","Brain Imaging|Whole Body Imaging","Device: Zero Echo Time (ZTE) scan for head attenuation|Device: Q.Static (Q. MRAC) for respiratory motion correction","Diagnostic Image Quality|Determination of Diagnostic Acceptability","GE Healthcare","All","18 Years and older   (Adult, Older Adult)","Not Applicable","75","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","114.03-2016-GES-0001","November 2016","September 20, 2017","September 20, 2017","October 7, 2016","null","October 18, 2017","Mayo Clinic, Rochester, Minnesota, United States","","https://ClinicalTrials.gov/show/NCT02927327"
507,"NCT00672776","Effects of Paxil CR on Neural Circuits in Posttraumatic Stress Disorder (PTSD)",,"Completed","No Results Available","Posttraumatic Stress Disorder (PTSD)","Drug: paroxetine|Drug: placebo","Brain Function with Traumatic Reminders","Emory University","All","18 Years to 50 Years   (Adult)","Phase 4","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","IRB00024970","May 2003","September 2007","September 2007","May 6, 2008","null","March 1, 2017","","","https://ClinicalTrials.gov/show/NCT00672776"
508,"NCT00226304","Evaluation of Brain Lesions in HIV-infected Patients for Diagnosis of Primary Central Nervous System Lymphoma",,"Completed","No Results Available","HIV Infections|Lymphoma, AIDS-Related","","","National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)","","120","NIH","Observational","","050246|05-CC-0246","September 20, 2005","null","April 15, 2009","September 26, 2005","null","July 2, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00226304"
509,"NCT01382849","F-18-AV-45 Uptake, Spot Sign Presence and Cerebral Amyloid Angiopathy (CAA) in Primary Intracranial Hemorrhage (ICH)",,"Withdrawn","No Results Available","Cerebral Amyloid Angiopathy","","Type of Bleed|Spot Sign Status|Amyloid uptake|ApoE genotype","Sunnybrook Health Sciences Centre","All","18 Years and older   (Adult, Older Adult)","","0","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","18F-AV-45-A14","August 2011","August 2012","August 2012","June 27, 2011","null","November 19, 2014","Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT01382849"
510,"NCT01609335","Normative Values for Cognitive Testing and Alzheimer's Imaging Biomarkers in Young Adults",,"Completed","No Results Available","Alzheimer's Disease","Drug: F-18 FDG|Drug: C-11 PiB","Normal values for amyloid PET, FDG and Magnetic Resonance Imaging","Mayo Clinic","All","30 Years to 49 Years   (Adult)","Phase 1","41","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","11-006972","July 2012","August 2013","August 2013","May 31, 2012","null","August 8, 2014","Mayo Clinic Rochester, Rochester, Minnesota, United States","","https://ClinicalTrials.gov/show/NCT01609335"
511,"NCT00643591","Positron Emission Tomography-Computed Tomography (PET-CT) High-grade Glioma",,"Terminated","No Results Available","Cerebral Astrocytoma, High Grade","Other: imaging (dynamic PET-CT scan)","To determine the localisation within the primary tumour of the therapy resistant cells, before and during radiotherapy to determine the accurate boost volume. To determine changes during treatment intra- and extratumoral within the irradiated area.","Maastricht Radiation Oncology|Maastricht University Medical Center","All","19 Years and older   (Adult, Older Adult)","","10","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","MAASTRO 07-12-12/09|EudraCT Number 2007-005530-36","June 2008","June 2009","June 2010","March 26, 2008","null","April 10, 2015","Maastricht Radiation Oncology, Maastricht, Netherlands","","https://ClinicalTrials.gov/show/NCT00643591"
512,"NCT00626080","Insulin Detemir Action in Cerebro","INcEREBRO","Completed","No Results Available","Type 1 Diabetes","Drug: Insulin detemir|Drug: Insulin NPH","Cerebral metabolic rate of glucose, in brain regions associated with appetite control, as determined by FDG-PET|Cerebral blood flow, in brain regions associated with appetite control, as determined by H2O-PET|CSF insulin concentration|Activity in brain regions associated with appetite control, as determined by fMRI|Weight change","VU University Medical Center","Male","18 Years to 60 Years   (Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)","DC2007Det001|2007-007255-13","January 2009","December 2011","December 2011","February 29, 2008","null","December 30, 2011","VU University Medical Center, Amsterdam, Netherlands","","https://ClinicalTrials.gov/show/NCT00626080"
513,"NCT02869360","Correlation Between PET and Advanced MRI in Multiple Sclerosis",,"Recruiting","No Results Available","Multiple Sclerosis","","Whole Brain PBR28 binding|Lesional PiB binding|Myelin Water Imaging|MR Spectroscopy (Total NAA, NAA/Cr, mI)|Optical Coherence Tomography (RNFL thickness)","University of British Columbia|Teva Pharmaceuticals USA","All","18 Years to 60 Years   (Adult)","","20","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","CNS-2016-293","October 2016","November 2018","November 2018","August 16, 2016","null","November 7, 2017","MS Clinical Trials Group - UBC, Vancouver, British Columbia, Canada","","https://ClinicalTrials.gov/show/NCT02869360"
514,"NCT00633958","A Pilot Study of 18F-FLT in Pediatric Patients With Central Nervous System (CNS) Tumors","FLT","Terminated","No Results Available","Tumors of the Central Nervous System","Other: [18F]-Fluorothymidine","To determine the distribution, localization and kinetics of localization of 18F-FLT in pediatric patients with central nervous system tumors|To correlate the activity of administering 18F-FLT in newly diagnosed pediatric brain tumor patients to standard immunohistochemical markers of cellular activation and MRI imaging","Dana-Farber Cancer Institute|Boston Children’s Hospital","All","up to 21 Years   (Child, Adult)","Not Applicable","2","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","DFCI 05-303","March 2008","March 2010","March 2010","March 12, 2008","null","April 9, 2018","Children's Hospital Boston, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT00633958"
515,"NCT01530438","Study of Cognitive and Emotional Disorders in Amyotrophic Lateral Sclerosis","SLAMEM","Unknown status","No Results Available","Amyotrophic Lateral Sclerosis","Other: MRI + 18FDG-PET + neuropsychological assessments ; 18FDG performed especially for the research","Cognitive, behavioural and emotional changes assesed with Neuropsychological tests.|brain imaging (anatomical MRI, functional MRI, PET using 18FDG)","University Hospital, Caen","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","90","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","08-067","April 2009","December 2014","May 2015","February 10, 2012","null","April 9, 2014","University Hospital Center, Caen, France|University Hospital Center, Rouen, France","","https://ClinicalTrials.gov/show/NCT01530438"
516,"NCT00329524","Using PET-CT to Target and Validate Low-frequency TMS as Treatment for Tinnitus",,"Completed","Has Results","Tinnitus","Device: Repetitive Transcranial Magnetic Stimulation (rTMS)","Change in PET Asymmetry Index|Psychomotor Vigilance|Difference in Visual Analog Rating of Tinnitus (VAR)Following Active and Sham Tx","University of Arkansas|Tinnitus Research Consortium","All","19 Years to 65 Years   (Adult, Older Adult)","Not Applicable","5","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","51817","June 2006","June 2008","August 2008","May 24, 2006","August 7, 2009","May 4, 2015","University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States","","https://ClinicalTrials.gov/show/NCT00329524"
517,"NCT03491059","Feasibility of PET/CT to Detect the Oral/Pulmonary Distribution of Nicotine Following E-cigarette Use",,"Recruiting","No Results Available","E-cigarette Use","Drug: C-11 labeled nicotine|Radiation: PET/CT imaging","Nicotine biodistribution|Nicotine uptake|Nicotine clearance","Ohio State University","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 4","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","SP0232/2017H0463","February 16, 2018","February 16, 2019","February 16, 2021","April 9, 2018","null","May 18, 2018","The Ohio State University Wexner Medical Center, Columbus, Ohio, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/59/NCT03491059/Prot_000.pdf","https://ClinicalTrials.gov/show/NCT03491059"
518,"NCT01679743","GRN1005 for Brain Metastases From Breast or Lung Cancer",,"Withdrawn","No Results Available","Breast Cancer|Lung Neoplasms|Breast Neoplasms|Lung Cancer","Drug: Trastuzumab|Drug: GRN 1005","Effect of GRN therapy on PET uptake after treatment cycle 1","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 2","0","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","120199|12-C-0199","August 29, 2012","August 11, 2014","August 11, 2014","September 6, 2012","null","August 23, 2018","","","https://ClinicalTrials.gov/show/NCT01679743"
519,"NCT00603018","PET Imaging Study of Recovered Anorexics",,"Completed","Has Results","Anorexia Nervosa","Drug: Fluoxetine","Serotonin Receptor 1A Binding Potential In Regions of Interest (ROI) Accounting for Binding Potential in a Region Without Serotonin 1A Receptors","University of Pittsburgh|National Institute of Mental Health (NIMH)","Female","18 Years to 45 Years   (Adult)","Not Applicable","23","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","PRO06110005","June 2007","December 2008","December 2008","January 28, 2008","September 23, 2016","September 23, 2016","University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT00603018"
520,"NCT03592329","Vagus Nerve Stimulation and Stress Reduction Training for Migraine",,"Not yet recruiting","No Results Available","Migraine","Behavioral: Stress Reduction Training A|Device: active tVNS|Behavioral: Stress Reduction Training B|Device: sham tVNS","Brain activity changes in migraine patients in response to treatment|Brain inflammation changes in migraine patients in response to treatment|Brain activity differences between Migraine patients and healthy controls|Brain inflammation differences between Migraine patients and healthy controls","Massachusetts General Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","P01AT009965","February 2019","July 2023","July 2023","July 19, 2018","null","July 19, 2018","Anthinoula A. Martinos Center, Charlestown, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT03592329"
521,"NCT00063180","Evaluating the Remote Effects of Stroke With MRI and PET Scans",,"Completed","No Results Available","Cerebrovascular Accident","","","National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)","","70","NIH","Observational","","030224|03-N-0224","June 19, 2003","null","April 20, 2009","June 23, 2003","null","July 2, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00063180"
522,"NCT02667496","Safety Study of Sargramostim in Treating Patients With Mild Cognitive Impairment Due to Alzheimer's Disease",,"Withdrawn","No Results Available","Dementia Alzheimer's Type","Drug: Sargramostim GZ402664|Drug: Placebo|Drug: Florbetapir F18","Change from baseline in standardized uptake value ratio as measured by PET using florbetapir F18 (Amyvid)|Number of patients experiencing treatment-emergent adverse events (TEAEs)|Change from baseline in CSF analysis|MRI to assess for emergence of amyloid related imaging abnormalities (ARIA)|Measurement of antidrug antibody levels","Sanofi|National Institute on Aging (NIA)","All","40 Years to 80 Years   (Adult, Older Adult)","Phase 2","0","Industry|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ACT14019|U1111-1163-0793|1UF1AG046143","November 2016","March 31, 2017","March 31, 2017","January 29, 2016","null","April 7, 2017","Investigational Site Number 840001, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT02667496"
523,"NCT01059578","First Study in Humans With GSK206136","NSB101909","Completed","No Results Available","Depressive Disorder and Anxiety Disorders","Drug: GSK206136|Drug: PLACEBO|Radiation: PET","Adverse event monitoring, vital signs (blood pressure, heart rate, ECGs, clinical laboratory assessments (standard laboratory parameters); pharmacokinetics parameters: AUC, Cmax, t1/2|Brain receptor occupancy","GlaxoSmithKline","Male","18 Years to 45 Years   (Adult)","Phase 1","33","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","101909","May 23, 2006","December 18, 2006","December 18, 2006","February 1, 2010","null","August 10, 2017","GSK Investigational Site, London, United Kingdom","","https://ClinicalTrials.gov/show/NCT01059578"
524,"NCT01059591","First Study in Humans With GSK424887",,"Completed","No Results Available","Depressive Disorder and Anxiety Disorders","Drug: GSK424887|Drug: Placebo|Radiation: PET","Adverse event monitoring, vital signs (blood pressure, heart rate, ECGs, clinical laboratory assessments (standard laboratory parameters); Area under the concentration-time curve (AUC), Maximum observed concentration (Cmax) , tmax|Brain receptor occupancy","GlaxoSmithKline","Male","18 Years to 45 Years   (Adult)","Phase 1","26","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","105011","May 25, 2006","January 25, 2007","January 25, 2007","February 1, 2010","null","August 11, 2017","GSK Investigational Site, London, United Kingdom","","https://ClinicalTrials.gov/show/NCT01059591"
525,"NCT01623284","PiB PET Scanning in Speech and Language Based Dementias",,"Completed","No Results Available","PPA|Primary Progressive Aphasia|Aphasia|Non-fluent Aphasia|Semantic Dementia|Apraxia of Speech|Primary Progressive Nonfluent Aphasia|Progressive Aphasia","Drug: C-11 PiB|Drug: F-18 FDG","Percentage of patients with different speech and language based dementia (SLD) subtypes who have a [N-methyl-11C]2-(4'-methylaminophenyl)-6-hydroxybenzothiazole (PiB) positive positron emission tomography (PET) scan at presentation|Percentage of patients who exhibit apraxia of speech as measured by the Apraxia of Speech Rating Scale at presentation|Temporoparietal hypometabolism as shown on [18-F]-fluoro-deoxy-glucose positron emission tomography (FDG-PET) scan at presentation|Grey matter loss as shown on magnetic resonance imaging (MRI) at presentation","Mayo Clinic","All","18 Years and older   (Adult, Older Adult)","Phase 1","168","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","09-008772","March 2010","January 2015","January 2015","June 19, 2012","null","December 22, 2015","Mayo Clinic, Rochester, Minnesota, United States","","https://ClinicalTrials.gov/show/NCT01623284"
526,"NCT02414178","F 18 T807 Tau PET Imaging in Dominantly Inherited Alzheimer's Network (DIAN Project)",,"Recruiting","No Results Available","Alzheimer Disease","Drug: F 18 T807","F 18 T807 Standard Uptake Value Ratios (SUVR) will be correlated with other imaging modalities (MRI, PET amyloid imaging) and cognitive performance.","Washington University School of Medicine","All","18 Years and older   (Adult, Older Adult)","Phase 2","130","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","IND 123119 Protocol D","February 2015","February 2020","September 2020","April 10, 2015","null","September 21, 2017","Washington University School of Medicine, Saint Louis, Missouri, United States","","https://ClinicalTrials.gov/show/NCT02414178"
527,"NCT01681849","Neural Circuits in Women With Abuse and Posttraumatic Stress Disorder",,"Completed","Has Results","PTSD","Drug: Placebo|Drug: Paroxetine|Other: Positron Emission Tomography (PET) Imaging","Mean Clinical Administered PTSD Scale for DSM-IV (CAPS) Score|Change in Brain Blood Flow Assessed by Statistical Parametric Mapping (SPM)","Emory University|National Institute of Mental Health (NIMH)","Female","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","91","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IRB00000857|R01MH056120","July 2009","July 2015","July 2015","September 10, 2012","June 28, 2017","June 28, 2017","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01681849"
528,"NCT03446001","Brain Imaging and Safety Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease",,"Recruiting","No Results Available","Alzheimer Disease","Drug: TRx0237 8 mg/day|Drug: Placebo","Change in Standardized Uptake Value Ratio based on temporal lobe 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET)|Number of participants with serious and non-serious adverse events|Change in annualized rate of whole brain atrophy|Change in annualized rate of atrophy in other brain regions|Change in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-cog11) compared to imaging measures|Change in Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL23) compared to imaging measures|Change from Baseline on Standardized Uptake Value Ratio (using temporal lobe 18F-FDG-PET) based on the presence or absence of Apolipoprotein E4 allele in subjects by or for whom legally acceptable consent is separately provided","TauRx Therapeutics Ltd","All","up to 90 Years   (Child, Adult, Older Adult)","Phase 2|Phase 3","180","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TRx-237-039","January 10, 2018","February 2019","February 2019","February 26, 2018","null","February 26, 2018","Arizona Research Center, Phoenix, Arizona, United States|Arizona Health Science Center, Tucson, Arizona, United States|ATP Clinical Research, Costa Mesa, California, United States|Fullerton Neurology and Headache Center, Fullerton, California, United States|Irvine Center for Clinical Research, Irvine, California, United States|Sharp Mesa Vista Hospital Behavorial Health, San Diego, California, United States|CITrials, Santa Ana, California, United States|Viking Clinical Research, Temecula, California, United States|MCB Clinical Research Centers, Colorado Springs, Colorado, United States|Meridien Research, Brooksville, Florida, United States|Clinovation Research, Doral, Florida, United States|Alzheimers Research & Treatment Center, Lake Worth, Florida, United States|L&C Professional Medical Research Institute, Miami, Florida, United States|Advanced Medical Research Institute (AMRI) - Miami, Miami, Florida, United States|Miami Dade Medical Research Institute, Miami, Florida, United States|Florida Neurological Center, Ocala, Florida, United States|Combined Research Orlando, Orlando, Florida, United States|Health Care Family Rehab and Research Center, Pembroke Pines, Florida, United States|Progressive Medical Research, Port Orange, Florida, United States|iResearch Atlanta, Decatur, Georgia, United States|NeuroStudies.net, LLC, Decatur, Georgia, United States|GA Neurology and Sleep Medicine, Suwanee, Georgia, United States|Advanced Clinical Research (ACR) - Boise, Boise, Idaho, United States|Healthcare Research Network, Blue Island, Illinois, United States|Heartland Research Associates, LLC, Wichita, Kansas, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Clinical Research Consortium, Las Vegas, Nevada, United States|Neuro-Behavioral Clinical Research, Inc., Canton, Ohio, United States|The Carl and Edyth Lindner Research Center, Cincinnati, Ohio, United States|Rapid Medical Research Inc., Cleveland, Ohio, United States|The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Texas Center for Drug Development, Inc., Houston, Texas, United States|Advanced Clinical Research (ACR) - West Jordan, West Jordan, Utah, United States|Benaroya Research Institute at Virginia Mason Hospital, Seattle, Washington, United States|Universal Research Group, LLC, Tacoma, Washington, United States|UZ Antwerpen, Edegem, Belgium|Jessa Ziekenhuis - Campus Virga Jesse, Hasselt, Belgium|AZ Sint Augustinus [Neurologie], Wilrijk, Belgium|JBN Medical Diagnostic Services, Inc., Burlington, Canada|Clinique de la Memorie de l'Outaouais, Gatineau, Canada|Okanagan Clinical Trials, Ltd., Kelowna, Canada|ALPHA Recherche Clinique, Québec, Canada|Q&T Research Sherbrooke, Sherbrooke, Canada|Podlaskie Centrum Psychogeriatrii, Bialystok, Poland|Uniwersyteckie Centrum Kliniczne, Gdansk, Poland|Care Clinic SP. Z.O.O., Katowice, Poland|NZOZ Wielospecjalistyczna Poradnia Lekarska SYNAPSIS, Katowice, Poland|Poradnia Neurologiczna, Szczecin, Poland|Centrum Medyczne NeuroProtect, Warsaw, Poland|Barberry National Centre for Mental Health, Birmingham, United Kingdom|Re-Cognition Health, Birmingham, United Kingdom|Re-Cognition Health, Guildford, United Kingdom|Re-Cognition Health, London, United Kingdom|St. Pancras Clinical Research, London, United Kingdom|Re-Cognition Health, Plymouth, United Kingdom","","https://ClinicalTrials.gov/show/NCT03446001"
529,"NCT01793532","Study of [11C]DPA-713 for Temporal Lobe Epilepsy",,"Completed","No Results Available","Epilepsy|Temporal Lobe","","Brain uptake of radioligand","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)","","38","NIH","Observational","Observational Model: Case-Control|Time Perspective: Prospective","130070|13-M-0070","January 31, 2013","June 8, 2016","June 8, 2016","February 15, 2013","null","August 23, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT01793532"
530,"NCT00677885","P-glycoprotein Function in Brain Diseases",,"Completed","No Results Available","Alzheimer Disease|Parkinson Disease|Frontotemporal Lobar Degeneration","","P-gp function in AD, PD, and FTD patients and in healthy volunteers. P-gp function will be determined by calculating the brain uptake of [11C]dLop|Comparing P-gp function with the severity of disease","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","35 Years and older   (Adult, Older Adult)","","20","NIH","Observational","Time Perspective: Prospective","080124|08-M-0124","May 9, 2008","null","August 25, 2014","May 15, 2008","null","August 10, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00677885"
531,"NCT00747968","The Effect of the GLP-1 Analogue Exenatide on Type 2 Diabetes in CNS and Heart During Hyperglycemia Assessed by PET",,"Completed","No Results Available","Type 2 Diabetes","Drug: Byetta, Exenatide","steady glucose metabolism in the heart and brain during hyperglycemia with GLP-1-analogue infusion compared to placebo.","University of Aarhus|Eli Lilly and Company|Aarhus University Hospital","Male","50 Years to 70 Years   (Adult, Older Adult)","Phase 2|Phase 3","8","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","Brainandheart","February 2010","November 2010","March 2011","September 8, 2008","null","June 30, 2011","Aarhus University Hospital, Investigational Dept. M of Endocrinology, Aarhus, Aarhus C, Denmark|Aarhus University Hospital, Investigational Dept. M of Endocrinology, Aarhus, Denmark|Aarhus University Hospital, Investigational Dept. M of Endocrinology, Aarhus, Denmark","","https://ClinicalTrials.gov/show/NCT00747968"
532,"NCT01573611","Impact of Grape Consumption on Brain Metabolism and Cognitive Function",,"Completed","No Results Available","Mild Cognitive Impairment","Dietary Supplement: Grape Powder|Dietary Supplement: Placebo Powder","Change from baseline in neuropsychological (cognitive, functional) test results|Change from baseline in regional cerebral metabolism","University of California, Los Angeles","All","65 Years and older   (Older Adult)","Phase 1","12","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","11002966","April 2012","April 2013","November 2014","April 9, 2012","null","December 4, 2014","UCLA Medical Center, Los Angeles, California, United States","","https://ClinicalTrials.gov/show/NCT01573611"
533,"NCT02187627","Evaluation of [11C]RO6924963, [11C]RO6931643, and [18F]RO6958948 as Tracers for Positron Emission Tomography (PET) Imaging of Tau in Healthy and Alzheimer's Disease (AD) Participants",,"Completed","No Results Available","Alzheimer's Disease, Healthy Volunteer","Drug: [11C]RO6924963|Drug: [11C]RO6931643|Drug: [18F]RO6958948","Part 1: Standard Uptake Value (SUV), as Assessed by Tau PET Brain Scan|Part 1: Standard Uptake Value Ratio (SUVR), as Assessed by Tau PET Brain Scan|Part 1: SUV, as Assessed by Tau PET Scan of Whole Body|Part 1: SUVR, as Assessed by Tau PET Scan of Whole Body|Mean Residence Times for Each Organ, as Assessed by Tau PET Scan of Whole Body|Part 1: Distribution Volume (VT), as Assessed by Tau PET Brain Scan|Part 2A: Absolute Percentage Difference Between Test and Retest of SUVR|Part 2A: Absolute Percentage Difference Between Test and Retest of VT|Part 2B: Effective dose (ED), as Assessed by Whole Body PET Scan|Part 2A: Absolute Percentage Difference Between Test and Retest of SUV|Percentage of Participants With Adverse Events (AEs)","Hoffmann-La Roche","All","25 Years and older   (Adult, Older Adult)","Phase 1","52","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","BP29409","August 2014","February 2016","February 2016","July 11, 2014","null","January 8, 2018","Parexel International; Harbor Hospital Center, Baltimore, Maryland, United States|Johns Hopkins Universtiy; Radiology Dept, Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT02187627"
534,"NCT02763683","Dementia in Parkinson Disease","PIB","Recruiting","No Results Available","Parkinsons","Radiation: PiB and VAT","Investigations of Dementia in Parkinsons Disease","Washington University School of Medicine|National Institutes of Health (NIH)","All","50 Years and older   (Adult, Older Adult)","","320","Other|NIH","Observational","Observational Model: Case-Control|Time Perspective: Prospective","201512032","June 2016","March 2030","March 2030","May 5, 2016","null","November 6, 2017","Washington University in St. Louis, Saint Louis, Missouri, United States","","https://ClinicalTrials.gov/show/NCT02763683"
535,"NCT02713087","Vasopressor Effects in Anesthetized Patients",,"Recruiting","No Results Available","Brain Tumor","Drug: Ephedrine|Drug: Phenylephrine","Capillary Transit Time Heterogeneity|Cerebral Metabolic Rate of Oxygen","University of Aarhus","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Vasobrain01","September 2015","January 2018","August 2021","March 18, 2016","null","December 4, 2017","Aarhus University Hospital, Aarhus, Jylland, Denmark","","https://ClinicalTrials.gov/show/NCT02713087"
536,"NCT01560013","The Effects of Treatment With Naltrexone in Alcohol and Cannabis-dependent Patients",,"Unknown status","No Results Available","Alcohol-dependence","Drug: Naltrexone","Verified abstinence from alcohol|Changes in subjective responses to alcohol-cue reactivity and brain's metabolic rates","Tel-Aviv Sourasky Medical Center|Ministry of Health, Israel","All","22 Years to 64 Years   (Adult)","Not Applicable","24","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","112-10-TLV","October 2012","October 2014","October 2014","March 21, 2012","null","March 21, 2012","Dept. of Nuclear Medicine, TASMC, Tel Aviv, Israel","","https://ClinicalTrials.gov/show/NCT01560013"
537,"NCT02945774","Molecular Neuroimaging of Neuroinflammation in Neurodegenerative Dementias",,"Recruiting","No Results Available","Frontotemporal Dementia","Radiation: (18F)-FEPPA","Group differences in regional PET FEPPA ligand imaging|Correlation between PET FEPPA ligand images and specified MR images","Lawson Health Research Institute","All","30 Years to 95 Years   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","107561","August 2016","February 2020","August 2021","October 26, 2016","null","February 5, 2018","Parkwood Institute, London, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT02945774"
538,"NCT02169310","Neural Basis of Decision-Making Deficits in Traumatic Brain Injury",,"Recruiting","No Results Available","Traumatic Brain Injury","","Performance in a computerized decision making task.","National Institute of Neurological Disorders and Stroke (NINDS)|Uniformed Services University of the Health Sciences|National Institutes of Health Clinical Center (CC)","All","18 Years to 60 Years   (Adult)","","80","NIH|U.S. Fed","Observational","Observational Model: Cohort|Time Perspective: Prospective","140083|14-N-0083","June 19, 2014","August 3, 2019","March 1, 2020","June 23, 2014","null","August 16, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT02169310"
539,"NCT00857506","Observational Study of Cognitive Outcomes for Subjects Who Have Had Prior PET Amyloid Imaging With Florbetapir F 18 (18F-AV-45)",,"Completed","Has Results","Alzheimer's Disease|Mild Cognitive Impairment","Drug: florbetapir F 18","Change in ADAS-Cog for MCI Subjects|Cognitive Decline in MCI Subjects|Change in ADAS-Cog in CN and AD Subjects|Cognitive Decline in CN and AD Subjects|Covariate Adjusted Psychometric Score Change|Correlation of Change in ADAS-Cog and SUVR","Avid Radiopharmaceuticals","All","50 Years and older   (Adult, Older Adult)","Phase 2","152","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic","18F-AV-45-A11","January 2009","December 2011","December 2011","March 6, 2009","March 28, 2013","March 28, 2013","Research Site, Scottsdale, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Costa Mesa, California, United States|Research Site, Brooksville, Florida, United States|Research Site, Hallandale Beach, Florida, United States|Research Site, West Palm Beach, Florida, United States|Research Site, Albany, New York, United States|Research Site, Durham, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT00857506"
540,"NCT03606473","Brain Mechanisms in Young Adults","MHP","Recruiting","No Results Available","Cocaine-Related Disorders","Drug: d-amphetamine|Radiation: [C-11]NPA","Percent change in Binding potential (BPnd)","Gale Richardson|National Institute on Drug Abuse (NIDA)|University of Pittsburgh","All","25 Years to 30 Years   (Adult)","Early Phase 1","30","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","PRO17080203","January 24, 2018","January 1, 2022","January 1, 2022","July 30, 2018","null","July 30, 2018","University of Pittsburgh, Pittsburgh, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT03606473"
541,"NCT02706964","Imaging the Patterns of Breast Cancer Early Metastases","BCMetPats","Active, not recruiting","No Results Available","Breast Cancer","Device: Positron emission tomography/x-ray computed tomography|Device: Magnetic resonance imaging|Device: x-ray computed tomography (CT)","Proportion of patients with oligometastatic presentation|Histogram of the number and size of metastases at first presentation.|Measure time to first instance of metastatic presentation.|Measure the growth rates of metastases in each of the target organs.|Measure the incidence of metastatic spread to each target organ.|Prognosis for oligometastases based on patient and tumor factors.|Local control outcomes of treatment of metastases|Acute and late clinical side effects for ablative local therapy of the metastases|Patterns of secondary recurrence","University of Florida|Florida Academic Cancer Center Alliance","Female","18 Years to 110 Years   (Adult, Older Adult)","Not Applicable","13","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","IRB201500683","April 2016","January 2018","March 2021","March 11, 2016","null","March 23, 2018","Department of Radiation Oncology Davis Cancer Pavilion, Gainesville, Florida, United States|University of Miami, Sylvester Comprehensive Cancer Center, Miami, Florida, United States","","https://ClinicalTrials.gov/show/NCT02706964"
542,"NCT02602860","A Brain Imaging Study With Positron Emission Tomography and the Radiotracer [11C]UCB-J to Estimate How Fast Brivaracetam and Levetiracetam Enter the Brain in Healthy Volunteers",,"Completed","No Results Available","Healthy Volunteers","Radiation: [11C]UCB-J|Drug: Brivaracetam|Drug: Levetiracetam","Level of synaptic vesicle glycoprotein 2A (SV2A) receptor occupancy during the displacement scans|Equilibrium tissue to plasma activity ratio (VT) of [11C]UCB-J|Tracer displacement halftimes|Tracer-exit corrected halftimes of Brivaracetam or Levetiracetam entry","UCB Pharma|PRA Health Sciences|Yale University","All","18 Years to 55 Years   (Adult)","Phase 1","13","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","EP0074","November 2015","September 2017","September 2017","November 11, 2015","null","October 30, 2017","Ep0074 001, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT02602860"
543,"NCT01485380","Combined Electroencephalogram, Magnetic Resonance Imaging-Positron Emission Tomography of Dexmedetomidine Induced Sleep",,"Completed","Has Results","Dexmedetomidine Induced Sedation","Drug: dexmedetomidine","Number of Participants With Changes in the Brains Default Mode Network.","Massachusetts General Hospital","All","18 Years to 35 Years   (Adult)","Not Applicable","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)","2011-P-002333","September 2012","July 2013","July 2013","December 5, 2011","October 10, 2014","June 21, 2016","Massachusetts General Hospital, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT01485380"
544,"NCT02178696","Predictors of Antidepressant Response",,"Completed","Has Results","Depression","Other: Placebo, identified as placebo to participants|Drug: Celexa or other antidepressant as clinically indicated|Other: Placebo, identifed to participants as ""Active medication""","Changes in Mu-opioid Binding Potential During PET|Changes in BOLD Response During Reward fMRI Task (Monetary Incentive Delay, MID)|Changes in Dopamine (D 2/3) Binding Potential During PET.|Changes From Baseline in Quick Inventory of Depressive Symptomatology-Self-Report (QIDS-SR-16) Score|Changes From Baseline in PHQ-9 Depression Scores.|Hamilton Depression Rating Scale Scores|Montgomery-Asberg Depression Rating Scale","University of Michigan","All","18 Years to 60 Years   (Adult)","Phase 4","44","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Other","HUM00033328","January 2011","October 2015","October 2015","July 1, 2014","December 5, 2017","December 5, 2017","Department of Psychiatry, Ann Arbor, Michigan, United States","","https://ClinicalTrials.gov/show/NCT02178696"
545,"NCT03291093","18F-Flutemetamol and Plaque Vulnerability",,"Recruiting","No Results Available","Atherosclerosis","Drug: 18F-Flutemetamol PET/MRI","18F-Flutemetamol uptake carotids|18F-Flutemetamol uptake coronaries|18F-Flutemetamol uptake in the brain|CEA - plaque inflammation|MRI plaque characteristics carotid|CEA - plaque amyloid burden","Maastricht University Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","25","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic","NL58543.068.16","February 1, 2018","September 30, 2018","September 30, 2018","September 25, 2017","null","April 10, 2018","Maastricht University Medical Centre (MUMC+), Maastricht, Limburg, Netherlands","","https://ClinicalTrials.gov/show/NCT03291093"
546,"NCT00833209","Orbitofrontal Cortex (OFC) Influence on Addictive Medication Overuse Headache (MOH) Deriving From Migraine","MOH-PET","Completed","No Results Available","Medication Overuse Headache","Procedure: PET (withdrawal)|Procedure: Imaging","basal cerebral metabolism using (18F)FDG-PET|Relapse|Magnetic Resonance Imaging data","University Hospital, Bordeaux","All","18 Years and older   (Adult, Older Adult)","Not Applicable","53","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","CHUBX 2008/28","February 2009","July 2011","May 2012","January 30, 2009","null","August 1, 2012","C.H.U. de Bordeaux - Groupe Hospitalier Pellegrin - Service Médecine nucléaire, Bordeaux, France|CHU de Bordeaux - Hôpital Tastet Girard Centre Anti douleur, Bordeaux, France","","https://ClinicalTrials.gov/show/NCT00833209"
547,"NCT03527485","Imaging Synaptic Density in Cocaine and Opiate Addiction In Vivo Using 11UCB-J PET",,"Not yet recruiting","No Results Available","Opiate Dependence|Cocaine Dependence","Diagnostic Test: 11UCB-J PET Scan","11C-UCB-J PET synaptic density","Yale University","All","21 Years to 55 Years   (Adult)","Not Applicable","90","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2000021843","July 2018","December 2023","December 2023","May 17, 2018","null","May 17, 2018","","","https://ClinicalTrials.gov/show/NCT03527485"
548,"NCT00375778","Parkinson's Disease Evaluated by PET and the Effect of Memantine",,"Completed","No Results Available","Parkinson's Disease","Drug: memantine (drug)","","University of Aarhus|Lundbeck Foundation","All","50 Years to 70 Years   (Adult, Older Adult)","Not Applicable","12","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2004-004139-74","April 2005","null","September 2006","September 13, 2006","null","September 13, 2006","PET center, Aarhus University Hospital, Aarhus, Denmark","","https://ClinicalTrials.gov/show/NCT00375778"
549,"NCT02769000","Low Dose RT to Reduce Cerebral Amyloidosis in Early Alzheimer's",,"Recruiting","No Results Available","Alzheimer's Disease","Radiation: 10 GY in 5 daily fractions|Radiation: 20 GY in 10 daily fractions","Evaluate safety and toxicity/adverse events associated with delivery of low dose fractionated whole brain irradiation in subjects with early Alzheimer's dementia according to NINCDS-ADRDA Criteria.|Evaluate low dose whole brain irradiation in subjects with early Alzheimer's dementia using neurcognitive testing methods.|Evaluate low dose whole brain irradiation in subjects with early Alzheimer's dementia using psychological functioning tests.|Evaluate low dose whole brain irradiation in subjects with early Alzheimer's dementia using Quality of Life indices.","Virginia Commonwealth University","All","55 Years and older   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HM20004955","May 2016","April 2019","April 2019","May 11, 2016","null","March 29, 2018","Virginia Commonwealth University, Richmond, Virginia, United States","","https://ClinicalTrials.gov/show/NCT02769000"
550,"NCT03089918","A Study to Investigate the Regional Brain Kinetics of Brain Drug Transporters Using P-glycoprotein and Breast Cancer Resistance Protein Substrates and by Using the Positron Emission Tomography Ligand 11C-JNJ-63779586 in the Human Brain",,"Recruiting","No Results Available","Alzheimer Disease","Drug: 11C-JNJ-63779586","Effective Radiation Dose Following Injection of 11C-JNJ-63779586 (Part A)|Total and Regional Brain Compartmental Kinetics for Volume of Distribution of 11C-JNJ-63779586 (Part B)|Percent Intact Tracer of 11C-JNJ-63779586 in Blood Samples (Part B)|Radiometabolite Fraction of 11C-JNJ-63779586 in Blood Samples (Part B)|Number of Participants with Adverse Events as a Measure of Safety and Tolerability (Part A and Part B)","Janssen Research & Development, LLC","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 1","23","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","CR108288|63779586NAP1001|2016-001756-21","May 17, 2017","September 28, 2018","December 31, 2018","March 24, 2017","null","May 4, 2018","UZ Leuven, Leuven, Belgium|University of Antwerpen, Wilrijk, Belgium","","https://ClinicalTrials.gov/show/NCT03089918"
551,"NCT01687153","A Study of Brain Aging in Vietnam War Veterans","DOD-ADNI","Recruiting","No Results Available","Traumatic Brain Injury|Post Traumatic Stress Disorder|Alzheimer's Disease|Mild Cognitive Impairment","","Rates of change in brain regions based on neuroimaging|Rates of change in CSF amyloid beta and CSF tau/P tau levels based on biomarkers|Rates of change in neuropsychological measures of memory and general cognitive performance|Correlations within each group (TBI and PTSD) to assess whether baseline levels or rates of atrophy or cognitive decline are associated with severity of TBI or PTSD|Group differences in the patterns of amyloid deposition (from Florbetapir F 18) and brain atrophy|Group differences in white matter integrity as assessed with Diffusion Tension Imaging (DTI)|Rate of change of tau deposition as measured by 18F-AV-1451","University of Southern California|United States Department of Defense|Telemedicine & Advanced Technology Research Center|Northern California Institute of Research and Education|San Francisco Veterans Affairs Medical Center|Alzheimer's Therapeutic Research Institute","All","50 Years to 90 Years   (Adult, Older Adult)","","420","Other|U.S. Fed","Observational","Observational Model: Cohort|Time Perspective: Prospective","ADC-044|W81XWH-12-2-0012|W81XWH-13-1-0259|W81XWH-14-1-0462","October 2012","October 2018","October 2018","September 18, 2012","null","December 11, 2017","Banner Sun Health Research Institute, Sun City, Arizona, United States|University of California, Irvine, Irvine, California, United States|University of California, San Diego, La Jolla, California, United States|University of Southern California, Los Angeles, California, United States|VA Palo Alto HSC / Stanford School of Medicine, Palo Alto, California, United States|University of California, San Francisco, San Francisco, California, United States|Georgetown University, Washington, District of Columbia, United States|Howard University, Washington, District of Columbia, United States|Wien Center for Clinical Research, Miami Beach, Florida, United States|Premiere Research Institute, West Palm Beach, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Cornell Medical Center, New York, New York, United States|Columbia University, New York, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Ralph H. Johnson Veterans Affairs Medical Center (VAMC Charleston), North Charleston, South Carolina, United States|U of WA / VA Puget Sound Alzheimer's Disease Research Center, Seattle, Washington, United States|University of Wisconsin, Madison, Wisconsin, United States","","https://ClinicalTrials.gov/show/NCT01687153"
552,"NCT01065220","Sex Steroids and the Serotonin Transporter",,"Completed","No Results Available","Transsexualism","Drug: Testolactone undecanoate|Drug: Lynestrenol|Drug: Cyproterone Acetate|Drug: Estradiol|Drug: 5-alpha reductase inhibitor","change in serotonin-transporter binding potential (BP) in predefined brain regions, measured by Positron Emission Tomography","Medical University of Vienna","All","18 Years to 55 Years   (Adult)","Phase 4","32","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","AP13214ONB","February 2010","January 2014","January 2014","February 9, 2010","null","January 3, 2014","Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria","","https://ClinicalTrials.gov/show/NCT01065220"
553,"NCT01824056","The Differential Diagnosis of Parkinson's Disease and Parkinsonism by Positron-emission Tomography",,"Completed","No Results Available","Parkinson's Disease","Drug: 18F-FDG","To analyze the sensitivity and specificity of 18F-DTBZ PET to the differential diagnosis of PD ,PSP,MSA,CBD.","Chang Gung Memorial Hospital|National Science Council, Taiwan","All","20 Years to 80 Years   (Adult, Older Adult)","Phase 2","120","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","98-3626A","August 2010","July 2013","July 2013","April 4, 2013","null","November 13, 2013","Chang Gung Memory Hpspital, Taoyuan, Taiwan","","https://ClinicalTrials.gov/show/NCT01824056"
554,"NCT03466177","Multimodal Retinal Imaging in the Detection and Follow-up of Alzheimer's Disease","RetAD","Recruiting","No Results Available","Alzheimer Disease|Alzheimer Dementia|Mild Cognitive Impairment|Dementia","Diagnostic Test: Non-invasive, multimodal retinal imaging|Diagnostic Test: Cerebral imaging|Diagnostic Test: Neuropsychiatric testing|Diagnostic Test: Venous blood sampling","Retinal biomarkers for AD: specificity|Retinal biomarkers for AD: sensitivity|Retinal biomarkers for AD: number needed to image|Retinal biomarkers for AD: area under the curve (AUC)|Retinal biomarkers for AD: receiver operating characteristic (ROC)|Retinal biomarkers for AD: quantification of cerebral Aβ load by non-invasive retinal imaging against the cerebral Aβ load measured by cerebral imaging|Retinal biomarkers for AD: disease progression by measuring the change from baseline at 2 years","Universitaire Ziekenhuizen Leuven","All","50 Years to 85 Years   (Adult, Older Adult)","","90","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","S60932","April 1, 2018","December 31, 2018","December 31, 2020","March 15, 2018","null","March 15, 2018","UZ Leuven, Leuven, Vlaams Brabant, Belgium","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/77/NCT03466177/Prot_000.pdf","https://ClinicalTrials.gov/show/NCT03466177"
555,"NCT02414347","F 18 T807 Tau PET Imaging of Alzheimer's Disease","T807IND","Enrolling by invitation","No Results Available","Alzheimer Disease","Drug: F 18 T807","F 18 T807 Standard Uptake Value Ratios (SUVR) will be correlated with other imaging modalities (MRI, PET amyloid imaging) and cognitive performance.","Washington University School of Medicine","All","18 Years and older   (Adult, Older Adult)","Phase 2","100","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","IND 123119 Protocol A","October 2014","October 2019","December 2019","April 10, 2015","null","June 27, 2018","Washington University School of Medicine, Saint Louis, Missouri, United States","","https://ClinicalTrials.gov/show/NCT02414347"
556,"NCT01089270","Ioflupane I123 (DaTSCAN) and Positron Emission Tomography-computed Tomography Fludeoxyglucose (PET-CT FDG) to Assess Brain Function of Parkinson Patients' First Degree Relatives",,"Unknown status","No Results Available","Parkinson Disease","","","Tel-Aviv Sourasky Medical Center","All","30 Years to 80 Years   (Adult, Older Adult)","","80","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","TASMC-10-EES-0519-CTIL","March 2010","March 2011","null","March 18, 2010","null","March 18, 2010","Department of Nuclear Medicine, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel","","https://ClinicalTrials.gov/show/NCT01089270"
557,"NCT01095744","Influence of Age on Amyloid Load in Alzheimer's Disease and in Atypical Focal Cortical Alzheimer's Disease","BIOMAGE","Completed","No Results Available","Alzheimer's Disease|Posterior Cortical Atrophy|Logopenic Progressive Aphasia","","PIB-PET imaging of amyloid load|FDG-PET imaging of glucose metabolism|clinical phenotypic assessment|MRI|ApoE gene sequencing|amyloid and Tau measurements in cerebro-spinal fluid (csf)","Institut National de la Santé Et de la Recherche Médicale, France","All","18 Years and older   (Adult, Older Adult)","","60","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","C08-30|2008-A00939-46","March 2009","May 2012","May 2012","March 30, 2010","null","October 10, 2012","Pitie Salpêtrière Hospital, Paris, Ile de France, France","","https://ClinicalTrials.gov/show/NCT01095744"
558,"NCT02063451","Neurohormonal & Behavioral Correlates of Obesity and Weight Loss",,"Enrolling by invitation","No Results Available","Obesity","Dietary Supplement: Very Low Calorie Diet (VLCD)","Change in [11C]carfentanil binding in brain in response to feeding prior to weight loss|Change in [11C]carfentanil binding in brain in response to feeding post weight loss|Change in Hunger scores on a visual analog scale in response to feeding at pre weight-loss|Change in Hunger scores on a visual analog scale in response to feeding post weight-loss","University of Michigan|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|The Brain Research Foundation","All","18 Years and older   (Adult, Older Adult)","Not Applicable","60","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","IWMCNI_01|5K01DK092322","February 2011","August 2018","August 2019","February 14, 2014","null","September 19, 2017","University of Michigan Medical School, Ann Arbor, Michigan, United States","","https://ClinicalTrials.gov/show/NCT02063451"
559,"NCT01672021","Initial Assessment of 18FDG-PET/MRIin Determining the Extent of Systemic Disease in Breast Cancer Patients",,"Active, not recruiting","No Results Available","Breast Cancer","Procedure: PET/MRI","Number of metastatic lesions seen on PET/MRI as compared with PET/CT|Patient stage as imaged by PET/MRI as compared with PET/CT","New York University School of Medicine","All","20 Years to 80 Years   (Adult, Older Adult)","Not Applicable","81","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","12-02243","July 2012","November 2018","November 2018","August 24, 2012","null","January 29, 2018","NYU School of Medicine, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT01672021"
560,"NCT01117155","A Pilot Study Evaluating 18F-L-Thymidine (FLT) PET Imaging in Children With Gliomas",,"Withdrawn","No Results Available","Ependymoma|Brainstem Glioma|Astrocytoma|Glioblastoma Multiforme|PNET","","","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","1 Year to 17 Years   (Child)","","0","NIH","Observational","Time Perspective: Prospective","100105|10-C-0105","April 23, 2010","null","October 22, 2012","May 5, 2010","null","August 17, 2018","","","https://ClinicalTrials.gov/show/NCT01117155"
561,"NCT01480050","Mibefradil Dihydrochloride and Temozolomide in Treating Patients With Recurrent Glioma",,"Completed","No Results Available","Brain and Central Nervous System Tumors","Drug: temozolomide|Other: 3'-deoxy-3'-[18F]fluorothymidine|Other: pharmacological study|Drug: Mibefradil","Maximum-tolerated dose of mibefradil dihydrochloride|Dose-limiting toxicity|Toxicity and adverse events according to CTCAE v. 4.0|Biological activity of treatment determined by radiographic response|Pharmacokinetics of mibefradil dihydrochloride|Potential effect of mibefradil dihydrochloride on tumor metabolism as determined by [F-18]FLT PET scans in the dose-expansion cohort","Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI)|Cavion, Inc.","All","18 Years to 120 Years   (Adult, Older Adult)","Phase 1","28","Other|NIH|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ABTC-1101 CDR0000716313|ABTC-1101","April 2012","August 2015","June 1, 2017","November 28, 2011","null","June 26, 2018","UAB Comprehensive Cancer Center, Birmingham, Alabama, United States|Winship Cancer Institute of Emory University, Atlanta, Georgia, United States|Johns Hopkins University, Baltimore, Maryland, United States|Henry Ford Hospital, Detroit, Michigan, United States|Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States|Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Hillman Cancer Center at University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT01480050"
562,"NCT03587649","Evaluation of [18F]MNI-1126 as an Imaging Marker for Synaptic Density Loss",,"Recruiting","No Results Available","Alzheimer Disease|Parkinson Disease|Healthy Volunteers","Drug: [18F]MNI-1126","Regions in the VOI template will be used to quantify the regional tracer uptake and used for comparison of potential uptake differences across the different groups.","Invicro","All","18 Years to 55 Years   (Adult)","Phase 1","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","[18F]MNI-1126","May 7, 2018","May 7, 2019","May 7, 2019","July 16, 2018","null","July 16, 2018","Invicro, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT03587649"
563,"NCT02078531","A Prospective Pilot Study to Evaluate the Effect of Systemic Adjuvant Therapy on the Cognitive and Brain Function of Breast Cancer Patients",,"Unknown status","No Results Available","Breast Cancer","","Change the relationship between chemotherapy/anti-hormonal therapy and possible cognitive decline in patients undergoing such therapy","National University Hospital, Singapore","Female","21 Years to 65 Years   (Adult, Older Adult)","","130","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","2013/01005","null","February 2016","null","March 5, 2014","null","March 5, 2014","Nationa University Hospital, Singapore, Singapore","","https://ClinicalTrials.gov/show/NCT02078531"
564,"NCT02590276","Predict to Prevent Frontotemporal Lobar Degeneration (FDT) and Amyotrophic Lateral Sclerosis (ALS)","PREV-DEMALS","Recruiting","No Results Available","Frontotemporal Lobar Degeneration|Amyotrophic Lateral Sclerosis","Behavioral: characterization","Change in behavioral assessment (20 scales)|Change in MRI morphological criteria|Change in cerebral perfusion by SPECT / PET|correlations between behavioral assessment, MRI morphological criteria, Cerebral perfusion and metabolism by SPECT / PET and transcriptome analysis","Assistance Publique - Hôpitaux de Paris","All","18 Years and older   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","P140705 -|IDRCB : 2015-A00856-43","September 2015","October 2019","October 2019","October 29, 2015","null","September 15, 2016","Groupe Hospitalier Pitié-Salpêtrière - Charles Foix, Paris, France","","https://ClinicalTrials.gov/show/NCT02590276"
565,"NCT02137460","Korean Brain Aging Study for Early Diagnosis and Prediction of Alzheimer's Disease","KBASE","Active, not recruiting","No Results Available","Alzheimer's Disease|Mild Cognitive Impairment","","The amount of brain amyloid deposition|Group difference for each clinical, neuropsychological, structural and functional neuroimaging, tau imaging, genetic, biochemical measures|Change of brain amyloid deposition|Change of clinical, neuropsychological measures|Change of structural and functional neuroimaging measures|Change of biochemical measures|Chage of tau imaging measures","Dong Young Lee|Ministry of Science and ICT, Republic of Korea|Seoul National University|Seoul National University Hospital","All","20 Years to 90 Years   (Adult, Older Adult)","","920","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","KBASE01|NRF-2013M3C7A1072998|NRF-2013M3C7A1069644|NRF-2014M3C7A1046042|NRF-2014M3C7A1046037","May 2014","February 2020","February 2020","May 13, 2014","null","October 5, 2017","Seoul National University College of Medicine, Seoul, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT02137460"
566,"NCT03620552","18F-S16 PET/CT in Healthy Volunteers and Patients With Neurodegenerative Dementia",,"Recruiting","No Results Available","Neurodegenerative Dementia","Drug: 18F-S16","Semiquantitative assessment of lesions and biodistribution|Blood pressure|Pulse|Respiration frequency|Temperature|Serum alanine aminotransferase|Serum albumin|Serum creatinine|Adverse events collection","Oriental Neurosurgery Evidence-Based-Study Team","All","40 Years and older   (Adult, Older Adult)","Early Phase 1","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","S16AD2018","August 20, 2017","October 20, 2018","February 20, 2019","August 8, 2018","null","August 8, 2018","PET/CT center,Tianjin Medical University General Hospital, Tianjin, Tianjin, China","","https://ClinicalTrials.gov/show/NCT03620552"
567,"NCT01663545","Brain P-gp and Inflammation in People With Epilepsy",,"Completed","No Results Available","Epilepsies, Partial","","Amount of differential [11C]dLop and [11C]PBR28 uptake between the epileptic focus and the homologous contralateral region|Secondary Outcome Measure: A secondary goal is to determine if inhibiting P-gp with tariquidar results in increased concentrations of anti-epileptic medications into the CSF, as a surrogate marker for increased penetration of these medication...","National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)","All","18 Years to 60 Years   (Adult)","","38","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","120182|12-N-0182","July 31, 2012","null","October 4, 2017","August 13, 2012","null","July 4, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT01663545"
568,"NCT02679235","Brain Energy and Aging With Triheptanoin","BEAT7","Completed","No Results Available","Frontal Lobe Hypometabolism","Drug: Triheptanoin","Global change in brain glucose uptake|Global change in brain ketone uptake|Change in brain volumes|Change in seed-based correlation maps|Change in integrity of brain white matter tracts|Change in global cognitive score","Université de Sherbrooke|Ultragenyx Pharmaceutical Inc|Fonds de la Recherche en Santé du Québec","All","65 Years and older   (Older Adult)","Phase 1|Phase 2","15","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2016-617|188505","April 2016","August 8, 2018","August 8, 2018","February 10, 2016","null","August 10, 2018","Research Centre on Aging (CSSS-IUGS - CIUSSS de l'Estrie - CHUS), Sherbrooke, Quebec, Canada","","https://ClinicalTrials.gov/show/NCT02679235"
569,"NCT01699607","Test-retest Reproducibility of [11C]PHNO PET Using the Constant Infusion Paradigm","phno_amth","Completed","Has Results","Nicotine Dependence|Healthy","Drug: Amphetamine","Change in Dopamine Levels at Baseline and After Amphetamine Administration as Measured by Percent Change in PET Tracer Binding Potential.","Yale University","All","18 Years to 55 Years   (Adult)","Not Applicable","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)","0910005822","June 2012","July 2013","July 2013","October 3, 2012","September 18, 2015","February 9, 2017","Yale University, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT01699607"
570,"NCT02370524","Quantitative Evaluation of [18F]T807 as a Potential PET Radioligand for Imaging Tau in Patients With Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease (AD)","Drug: [18F]T807","Quantitative evaluation of [18F]T807 as a potential PET radioligand for imaging Tau in patients with clinically characterized tauopathies","Molecular NeuroImaging|Institute for Neurodegenerative Disorders|Roche Pharma AG","All","20 Years to 90 Years   (Adult, Older Adult)","Phase 1","16","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","[18F]T807","January 2015","January 2016","January 2016","February 25, 2015","null","March 8, 2017","Molecular NeuroImaging, LLC, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT02370524"
571,"NCT00959166","Study to Assess Neuroinflammation and Neurocognitive Function in Patients With Acute Hepatitis C and Chronic HIV Co-Infection - A Positron Emission Tomography (PET) Study",,"Completed","No Results Available","Acute Hepatitis C|HIV|HIV Infections","","Association of 11C-labelled PK11195 uptake using PET with acute HCV and HIV infection|Association of CNS metabolite ratios and neurocognitive performance with acute HCV and HIV infection. Association between patient characteristics and 11C-labelled PK11195 uptake using PET, CNS metabolite ratios and neurocognitive performance.","Imperial College London","Male","25 Years and older   (Adult, Older Adult)","","24","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","09/H0712/17","June 2009","June 2011","September 2011","August 14, 2009","null","February 22, 2016","St Mary's Hospital, London, United Kingdom","","https://ClinicalTrials.gov/show/NCT00959166"
572,"NCT00267865","Chemotherapy and HAART to Treat AIDS-related Primary Brain Lymphoma",,"Recruiting","No Results Available","Lymphoma-AIDS-Related|Brain Neoplasm","Drug: Methotrexate|Drug: Rituximab|Drug: Leucovorin","Survival; without recurrent lymphoma or severe cognitive problems at two years","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 2","28","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","060051|06-C-0051","December 16, 2005","July 31, 2019","July 31, 2021","December 21, 2005","null","August 23, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00267865"
573,"NCT03027869","Normal Brain Imaging Database for Brain Disorder Studies","Normal_tDCS","Recruiting","No Results Available","Healthy","Device: transcranial direct current stimulation","functional connectivity|Stroop task performance","University of Manitoba","All","18 Years and older   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Basic Science","B2016:074","June 28, 2017","December 2018","December 2019","January 23, 2017","null","June 27, 2018","University of Manitoba, Winnipeg, Manitoba, Canada","","https://ClinicalTrials.gov/show/NCT03027869"
574,"NCT01788943","Nicotine Receptor Levels and Smoking Cessation",,"Completed","Has Results","Smoking Cessation|Nicotine Addiction","","Acetylcholinergic Nicotine Receptor Availability as Determined by 2FA -PET Brain Imaging.|Change in Cigarette Craving as Measured by the Questionnaire on Smoking Urges.","University of Pennsylvania","All","18 Years to 65 Years   (Adult, Older Adult)","","24","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","nAChR-PET-quit","February 2013","July 2015","July 2015","February 11, 2013","March 12, 2018","March 12, 2018","Center for Interdisciplinary Research on Nicotine Addiction, University of Pennsylvania, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT01788943"
575,"NCT00463203","Bevacizumab and Irinotecan for Patients With Primary Brain Tumors and Progression After Standard Therapy",,"Completed","No Results Available","Brain Neoplasms|Glioma","Drug: Bevacizumab|Drug: Irinotecan","progression-free survival|Response rate - Response according to MacDonald criteria|Adverse event according to CTCAE 3.0","Rigshospitalet, Denmark","All","18 Years and older   (Adult, Older Adult)","Phase 2","54","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BI-Brain-01","March 2007","March 2011","June 2011","April 20, 2007","null","June 29, 2011","Aalborg University Hospital, Aalborg, Denmark|Rigshospitalet, Copenhagen, Denmark|Odense University Hospital, Odense, Denmark","","https://ClinicalTrials.gov/show/NCT00463203"
576,"NCT01867593","MET-PET for Newly Diagnosed Glioblastoma",,"Completed","No Results Available","Glioblastoma","Device: C-11 methionine PET","Effect of C-11 methionine PET on progression free survival|Evaluate for discordance in tumor volumes|Compare pre-radiation and follow-up C-11 methionine PET imaging in predicting sites of failure|Compare pre-radiation and follow-up C-11 methionine PET in predicting occurrence of pseudoprogression","Massachusetts General Hospital","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","13-018","January 2014","September 2016","September 2016","June 4, 2013","null","October 13, 2017","Massachusetts General Hospital, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT01867593"
577,"NCT02062099","PET Imaging of the Translocator Proteine Ligands (TSPO) With [18 F] DPA-714 Biomarker of NeuroInflammation in Cognitive Decline (NIDECO)","NIDeCo","Unknown status","No Results Available","Memory Complaint|Mild Cognitive Impairment|Alzheimer Disease","Drug: [18F]DPA-714 PET/ [18F]AV-45 PET/neuropsychological assessment","Fixation and distribution of [18F]DPA-714 (Binding Potential BP)|[18F]AV-45 Standard Uptake Values ratio|Relationship between [18F]DPA-714 uptake and cognitive, affective symptoms at baseline.","University Hospital, Tours","All","60 Years to 80 Years   (Adult, Older Adult)","Phase 1","36","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","PHAO13-CH/ NIDeCo","January 2014","January 2016","January 2018","February 13, 2014","null","February 13, 2014","University Hospital of Tours, Tours, France","","https://ClinicalTrials.gov/show/NCT02062099"
578,"NCT00832221","Positron Emission Tomography (PET) Study With [11C]Raclopride to Determine Central D2 Dopamine Occupancy of SEROQUEL","PET","Completed","No Results Available","Depression","Drug: SEROQUEL XR (quetiapine)|Drug: SEROQUEL IR (quetiapine)|Drug: radioligand [11C]raclopride","Positron emission tomography using the radioligand [11C]raclopride|Adverse Events (AEs), vital signs and changes in laboratory parameters, physical examinations, Alertness Visual Analogue Scale.|Pharmacokinetics of quetiapine and its main active metabolite","AstraZeneca","Male","20 Years to 45 Years   (Adult)","Phase 1","10","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","D1443C00038|EudractCT 2008-006553-40","January 2009","null","September 2009","January 30, 2009","null","September 14, 2009","Research Site, Stockholm, Sweden","","https://ClinicalTrials.gov/show/NCT00832221"
579,"NCT00001288","Brain Blood Flow Studies of Language and Memory",,"Completed","No Results Available","Cerebrovascular Disorder|Epilepsy","Drug: 15 O Water|Drug: FDG","","National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult","","303","NIH","Observational","","910134|91-N-0134","May 1991","null","June 2003","November 4, 1999","null","March 4, 2008","National Institute of Neurological Disorders and Stroke (NINDS), Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00001288"
580,"NCT02615756","Molecular and Functional Neurobiology of Physical Exercise","EXEBRAIN","Unknown status","No Results Available","Physical Exercise Behavior (Liking/Aversion)","Behavioral: Exercise","Binding of [11C]carfentanil in brain confirmed by positron emission tomography","Turku University Hospital|Academy of Finland|Novo Nordisk A/S|Juho Vainio Foundation|University of Turku","Male","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","50","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","19/180/2013","April 2013","June 2016","June 2016","November 26, 2015","null","November 26, 2015","Turku PET Centre, Turku, Finland","","https://ClinicalTrials.gov/show/NCT02615756"
581,"NCT03581305","PET Imaging of the Dopaminergic and Serotonergic Systems in Treated HIV Positive Subjects",,"Recruiting","No Results Available","Depression|HIV Infections|HIV-Associated Cognitive Motor Complex","","Influx constant (Ki) for 18F-FDOPA PET; Binding potential relative to non-displaceable binding (BPND) values for 11C-DASB PET|Correlation of 18F-FDOPA with co-morbidities; Correlation of 11C-DASB with Neuropsychiatric evaluation; Correlation of 18F-FDOPA and 11C-DASB with HIV infection parameters","National Institutes of Health Clinical Center (CC)","All","18 Years to 66 Years   (Adult, Older Adult)","","155","NIH","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","180117|18-CC-0117","August 28, 2018","March 1, 2021","March 1, 2021","July 10, 2018","null","August 23, 2018","National Institutes of Health Clinical Center, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT03581305"
582,"NCT01373892","Prospective, Randomised Study: Metabolic and Functional Effects of Bariatric Surgery Accessed Using PET and MRI.","Sleevepet2","Completed","No Results Available","Morbid Obesity","Procedure: Bariatric surgery","Tissue metabolism among morbidly obese persons assessed using PET, MRI and fMRI","Turku University Hospital","Female","18 Years to 60 Years   (Adult)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","Sleevepet2","January 2011","December 2013","January 2016","June 15, 2011","null","March 7, 2017","Turku PET Centre, Turku, Finland","","https://ClinicalTrials.gov/show/NCT01373892"
583,"NCT02058043","Study of MRI 3Tesla Infusion Without Arterial Spin Labeling Injection (ASL) in Cognitive Atypical and Comparison to the FDG-PET","ASLDEM DS","Completed","No Results Available","Atypical Cognitive Disorders","","detection of hypoperfusions","Rennes University Hospital","All","18 Years and older   (Adult, Older Adult)","","1","Other","Observational","Observational Model: Other|Time Perspective: Prospective","2012-A00147|LOC1202 Gauvrit ASLDEM DS","November 2012","December 2017","December 2017","February 7, 2014","null","February 19, 2018","CHU de Rennes, Rennes, IV, France","","https://ClinicalTrials.gov/show/NCT02058043"
584,"NCT02194491","A Positron Emission Tomography Occupancy Study Using Ligand [11C]AS2471907 and Following Oral Dosing of ASP3662",,"Completed","No Results Available","Pharmacokinetics of ASP3662|Displacement of Radiotracer|Healthy Volunteers","Other: [11C]AS2471907|Radiation: Positron Emission Tomography (PET)|Drug: ASP3662","Positron Emission Tomography measure: volume of distribution|Positron Emission Tomography measure: brain time-activity curves|Positron Emission Tomography measure: enzyme occupancy|Positron Emission Tomography measure: binding potentials|Pharmacokinetic parameter of ASP3662 and its metabolite (AS2570469): AUClast (Part 2 only)|Pharmacokinetic parameter of ASP3662 and its metabolite (AS2570469): Cmax (Part 2 only)|Pharmacokinetic parameter of ASP3662 and its metabolite (AS2570469): tmax (Part 2 only)|Safety as assessed by laboratory tests, 12-lead electrocardiograms, vital signs, adverse events, physical exams, neurological exams and Columbia Suicide Severity Rating Scale","Astellas Pharma Global Development, Inc.|Yale University|Astellas Pharma Inc","Male","18 Years to 55 Years   (Adult)","Phase 1","18","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","3662-CL-0011","April 2014","May 2016","May 2016","July 18, 2014","null","June 28, 2016","Site US10001, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT02194491"
585,"NCT03189485","Tau PET Imaging in the NACC Study Cohort","TPI","Enrolling by invitation","No Results Available","Normal Controls","Drug: the radiotracer 18F-AV-1451","Examine uptake of 18F-AV-1451 in the medial temporal lobe (MTL) and its relationship with high-resolution structural and functional MRI measures of MTL subregions.|Determine relationship to clinical, cognitive, and other biomarker data","University of Pennsylvania|National Institutes of Health (NIH)|National Institute on Aging (NIA)","All","60 Years and older   (Adult, Older Adult)","Early Phase 1","100","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","825944|R01AG055005","November 22, 2017","May 31, 2022","May 31, 2022","June 16, 2017","null","January 23, 2018","UPenn, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT03189485"
586,"NCT03207464","Molecular Imaging of Norepinephrine Transporter (NET) Using [C-11]Methylreboxetine PET in Multiple Sclerosis",,"Recruiting","No Results Available","Multiple Sclerosis","Drug: [C-11]Methylreboxetine","Tissue Volume of Distribution","Brigham and Women's Hospital","All","18 Years to 60 Years   (Adult)","Phase 1|Phase 2","19","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2016D007737","October 10, 2017","December 31, 2018","December 31, 2018","July 2, 2017","null","July 3, 2018","Partners MS Center, 60 Fenwood Road, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT03207464"
587,"NCT01246869","Assessment of Primary and Metastatic Brain Tumor Hypoxia With Fluoromisonidazole, FDG and Water",,"Recruiting","No Results Available","Brain Cancer","","Determination of multi-tracer update times as related to overall survival and time to progression","University of Utah","All","18 Years and older   (Adult, Older Adult)","","30","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","HCI44704","August 2011","August 2021","December 2021","November 23, 2010","null","August 13, 2018","Huntsman Cancer Institute, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT01246869"
588,"NCT02124941","Glutamate-Glutamine Cycling (VCYC) During Cocaine Abstinence Using 1H-MRS",,"Recruiting","No Results Available","Cocaine Dependence|Healthy","Drug: N-acetyl cysteine|Diagnostic Test: [18F]FDG PET scan|Diagnostic Test: 1H MRS|Diagnostic Test: [11C]APP311 PET scan","GLU and GLU/GLN ratios","Yale University","All","18 Years to 55 Years   (Adult)","Phase 1","60","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","1311013082","February 2014","January 2023","November 2023","April 28, 2014","null","July 13, 2018","Connecticut Mental Health Center, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT02124941"
589,"NCT01040338","Effects of Nicotine on Brain Opioid Receptors",,"Terminated","No Results Available","Nicotine Dependence","Drug: Nicotine","MOR binding potential|Subjective reward/liking and cravings to smoke","University of Pennsylvania|National Institute on Drug Abuse (NIDA)","All","18 Years to 50 Years   (Adult)","","15","Other|NIH","Observational","Observational Model: Case-Crossover|Time Perspective: Prospective","809187|R21DA027066","February 2010","March 2011","March 2011","December 29, 2009","null","July 19, 2013","Center for Interdisciplinary Research on Nicotine Addiction, University of Pennsylvania, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT01040338"
590,"NCT00050700","Brain Imaging in Depression",,"Completed","No Results Available","Depression|Bipolar Disorder","","","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years to 45 Years   (Adult)","","107","NIH","Observational","","030001|03-M-0001","December 16, 2002","null","May 14, 2010","December 18, 2002","null","July 2, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00050700"
591,"NCT03556280","Multi-Center Study of Sensory Stimulation to Improve Brain Function","Overture","Recruiting","No Results Available","Alzheimer Disease|Cognitive Impairment|Mild Cognitive Impairment|Dementia Alzheimers|Dementia, Mild|Dementia, Alzheimer Type|Dementia of Alzheimer Type|Dementia|Cognitive Impairment, Mild|Cognitive Decline","Device: GammaSense Stimulation System (Active Settings)|Device: GammaSense Stimulation System (Sham Settings)","Alzheimer's Disease Assessment Scale- Cognitive Subscale (ADAS-Cog)|Amyloid PET/CT","Cognito Therapeutics, Inc.","All","55 Years and older   (Adult, Older Adult)","Not Applicable","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","CA-0005","April 24, 2018","August 2019","October 2019","June 14, 2018","null","August 15, 2018","ActivMed Practices & Research, Inc, Methuen, Massachusetts, United States|ActivMed Practices & Research, Inc, Portsmouth, New Hampshire, United States","","https://ClinicalTrials.gov/show/NCT03556280"
592,"NCT02933645","Effects of Intranasal Insulin Administration on Tissue Specific Insulin Sensitivity","NASO-PET","Completed","No Results Available","Insulin Resistance","Drug: Actrapid|Drug: Placebo|Radiation: [18F]-FDG PET-CT|Drug: Hyperinsulinemic euglycemic clamp","Skeletal muscle glucose uptake|Endogenous glucose production|Liver glucose uptake","Turku University Hospital|University Hospital Tuebingen","Male","20 Years to 35 Years   (Adult)","Not Applicable","10","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Basic Science","T210/2015|2015-005392-24","April 2016","December 2016","December 2016","October 14, 2016","null","January 26, 2018","Turku PET Centre, Turku, Finland","","https://ClinicalTrials.gov/show/NCT02933645"
593,"NCT02817698","Imaging the Neurochemistry of Drug Addiction With PET",,"Recruiting","No Results Available","Smoking|Cannabis","Drug: cannabis","Change in dopamine levels at baseline and after drug of dependence administration as confirmed by PET images.|Change in beta endorphin levels at baseline and after drug of dependence administration as confirmed by PET images.","Yale University","All","18 Years to 55 Years   (Adult)","Early Phase 1","90","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","1604017594","November 29, 2017","September 2021","September 2021","June 29, 2016","null","March 15, 2018","Connecticut Mental Health Center, New Haven, Connecticut, United States|Yale Magnetic Resonance Research Center, New Haven, Connecticut, United States|Yale PET Center, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT02817698"
594,"NCT03573986","Pilot Study of 18F-FMISO PET/CT and MRI Imaging to Explore Tissue Hypoxia and Arteriovenous Shunting in Subjects With Recurrent Glioblastoma Before and After Bevacizumab Treatment",,"Recruiting","No Results Available","Recurrent Glioblastoma","Biological: [18F]fluoromisonidazole|Drug: Bevacizumab|Radiation: positron emission tomography (PET/CT).","Number of Adverse Events","Abramson Cancer Center of the University of Pennsylvania","All","18 Years and older   (Adult, Older Adult)","Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","UPCC 02318","April 18, 2018","April 18, 2020","April 18, 2021","June 29, 2018","null","June 29, 2018","Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT03573986"
595,"NCT00540176","The Safety and Efficacy of DCA for the Treatment of Brain Cancer",,"Completed","No Results Available","Malignant Gliomas, Glioblastoma Multiforme","Drug: Dichloroacetate (DCA)","To determine the therapeutic response to oral Dichloroacetate (DCA) in patients with malignant gliomas, utilizing standard criteria for the objective response of tumor size to treatment (CT and/or MRI).|To evaluate the safety and tolerability of oral (DCA) in patients with gliomas.|To determine the progression-free survival (PFS) and overall survival achieved with oral DCA in patients with gliomas.|• To evaluate the in vitro effects of DCA on cell proliferation/apoptosis and mitochondrial function in malignant glioma tissues taken from enrolled patients at the time of surgery and correlate them with clinical data.|• To evaluate glucose uptake using 18F-FDG Positron Emission Tomography (PET) scanning as a biological marker for predicting subsequent therapeutic response to oral DCA in patients with malignant gliomas.","University of Alberta|Capital Health, Canada","All","18 Years and older   (Adult, Older Adult)","Phase 2","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DCA 10002","October 2007","August 2009","August 2009","October 5, 2007","null","October 13, 2014","University of Alberta Hospital, Edmonton, Alberta, Canada","","https://ClinicalTrials.gov/show/NCT00540176"
596,"NCT02624401","The Neural Mechanisms of Anesthesia and Human Consciousness (Part 6)",,"Completed","No Results Available","Anesthesia|Unconsciousness","Drug: Dexmedetomidine|Drug: Propofol|Drug: S-ketamine|Drug: Sevoflurane|Drug: Placebo","Regional cerebral metabolism of glucose|EEG|Immunological effects|Metabolomic effects|Gene expression|Psychological well-being|Dream report","University of Turku|University of California, Irvine|University of Michigan|Yale University|Helsinki University","Male","18 Years to 30 Years   (Adult)","Phase 4","160","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","LOC-2016","January 2016","March 13, 2017","March 13, 2017","December 8, 2015","null","March 27, 2017","Turku PET Centre, Turku, Finland","","https://ClinicalTrials.gov/show/NCT02624401"
597,"NCT03493516","Prediction of ARrhythmic Events With Positron Emission Tomography II","PAREPET II","Recruiting","No Results Available","Sudden Cardiac Arrest|Ischemic Cardiomyopathy|Congestive Heart Failure","Diagnostic Test: PET scan quantifying sympathetic denervation using [18F]-LMI1195","Sudden Cardiac Arrest Events","State University of New York at Buffalo|National Heart, Lung, and Blood Institute (NHLBI)|Lantheus Medical Imaging","All","18 Years and older   (Adult, Older Adult)","","302","Other|NIH|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","HL-130266|R01HL130266-01","April 8, 2018","December 31, 2022","December 31, 2023","April 10, 2018","null","April 10, 2018","University at Buffalo Clinical and Translational Research Center, Buffalo, New York, United States","","https://ClinicalTrials.gov/show/NCT03493516"
598,"NCT03239561","Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants",,"Recruiting","No Results Available","Alzheimer Disease","Drug: [18F]MNI-1020","Standardized Uptake Value Ratio (SUVR) of [18F]MNI-1020|Plasma Concentration of 18F]MNI-1020 in AD Participants Compared With age Matched Healthy Participants|Number of Participants With Adverse Events|Distribution of tau (Using [18F]MNI-1020) Compared to Amyloid Beta (Using Florbetapir) in Participants With Probable AD","Janssen Research & Development, LLC","All","50 Years and older   (Adult, Older Adult)","Early Phase 1","6","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","CR108349|64326067EDI0001","September 6, 2017","April 30, 2018","April 30, 2018","August 4, 2017","null","April 5, 2018","Molecular NeuroImaging, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT03239561"
599,"NCT01565369","Evaluation of Physician Training Methods to Read Florbetapir-PET Scans",,"Completed","Has Results","Alzheimer's Disease","Drug: florbetapir F 18","Sensitivity of Florbetapir PET Scans to Detect Moderate to Frequent Amyloid Plaque|Specificity of Florbetapir PET Scans to Detect Moderate to Frequent Amyloid Plaque|Inter-reader Agreement","Avid Radiopharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Not Applicable","35","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic","18F-AV-45-A08","January 2011","January 2011","January 2011","March 28, 2012","June 7, 2012","June 7, 2012","","","https://ClinicalTrials.gov/show/NCT01565369"
600,"NCT01554202","Multi-modal Neuroimaging in Alzheimer's Disease","IMAP","Active, not recruiting","No Results Available","Alzheimer's Disease","Behavioral: assessment of memory|Biological: circulating tPA dosage|Genetic: ApoE4|Other: Brain imaging examination MRI and PET examinations","Rate of volume change of whole brain, hippocampus and other structural MRI measures|Rate of Decline as measured by: Cognitive Tests, Activities of Daily Living, and CDR Sum of Boxes|Rates of change on each specified biochemical biomarker|Rates of change of glucose metabolism (FDG-PET)|Extent of amyloid deposition as measured by 18F-AV45|Group differences for each imaging and biomarker measurement|APOE genotype","University Hospital, Caen|Institut National de la Santé Et de la Recherche Médicale, France","All","18 Years and older   (Adult, Older Adult)","Not Applicable","295","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2007-A00414-49","January 2008","December 2021","null","March 14, 2012","null","March 6, 2013","University Hospital Côte de Nacre, Caen, France|University Hospital Roger Salengro, Lille, France|University Hospital Pontchaillou, Rennes, France|University Hospital Rouen, Rouen, France|University Hospital Tours, Tours, France","","https://ClinicalTrials.gov/show/NCT01554202"
601,"NCT02971319","Technical Performance Assessment of Tc-99m Tetrofosmin for Differentiation of Recurrence vs Radiation Necrosis in Patients With Glioma",,"Completed","No Results Available","Glioma (Diagnosis)","Device: Tc-99M-Tetrofosmin SPECT|Device: F-18 FDG PET","Technical performance of Tc-99m tetrofosmin SPECT","Proactina S.A.|ConsulTech GmbH|pharmtrace|Pharmathen S.A.","All","18 Years and older   (Adult, Older Adult)","Phase 2","32","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","Gliomark","September 2016","November 17, 2017","December 17, 2017","November 22, 2016","null","January 26, 2018","Service de Neurologie Mazarin Hôpital Pitié-Salpêtrière, Paris, France|Országos Klinikai Idegtudományi Intézet (OKITI), Budapest, Hungary|Országos Onkológiai Intézet, Budapest, Hungary|Pozitron-Diagnosztika Ltd., Budapest, Hungary|Scanomed Budapest, Budapest, Hungary|Uzsoki Utcai Kórház, Budapest, Hungary|Debreceni Egyetem Orvos- és Egészségtudományi Centrum, Debrecen, Hungary|Scanomed Debrecen, Debrecen, Hungary|Pécsi Tudományegyetem, Általános, Pecs, Hungary","","https://ClinicalTrials.gov/show/NCT02971319"
602,"NCT00686504","Positron Emission Tomography (PET) Study With [11C]AZ12713580 to Determine Central mGluR5 Receptor Occupancy of AZD2066","PET","Completed","No Results Available","Healthy","Drug: AZD2066|Drug: radioligand [11C] AZ12713580","Positron emission tomography using the radioligand radioligand [11C]AZ12713580|To investigate the safety and tolerability of AZD2066 by assessment of Adverse Events (AEs), vital signs measurements (blood pressure and pulse), electrocardiogram (ECG), physical examination, clinical chemistry, haematology and urinalysis.|To investigate pharmacokinetics of AZD2066","AstraZeneca","All","20 Years to 45 Years   (Adult)","Phase 1","6","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","D0475C00013|EudractCT 2008-000064-17","April 2008","June 2008","June 2008","May 29, 2008","null","December 10, 2010","Research Site, Stockholm, Sweden","","https://ClinicalTrials.gov/show/NCT00686504"
603,"NCT02441062","Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors",,"Recruiting","No Results Available","Neuroendocrine Tumors|Carcinoid Tumors|Neuroblastoma|Medulloblastoma","Drug: 68Ga-DOTATOC PET/CT","Evaluate impact of 68Gallium-DOTATOC PET/CT imaging on tumor management","Sue O'Dorisio|University of Iowa Foundation|University of Iowa","All","6 Months and older   (Child, Adult, Older Adult)","Phase 2","200","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","201503708","September 2015","June 2019","June 2021","May 12, 2015","null","August 22, 2018","University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States","","https://ClinicalTrials.gov/show/NCT02441062"
604,"NCT01859767","Efficacy and Safety of MNI-672 SPECT for Detection/Exclusion of Cerebral B-amyloid in AD Subjects Compared to HVs.",,"Completed","No Results Available","Alzheimer's Disease","Drug: [123I]MNI-672 SPECT","Number of subjects with adverse events|Clinically significant changes in vital signs|Total I-123 radioactivity in plasma|Standard uptake values (SUV)|Visual analysis","Molecular NeuroImaging","All","20 Years and older   (Adult, Older Adult)","Phase 1","6","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)","MNI-672-01","April 2013","March 2015","April 2015","May 22, 2013","null","December 16, 2016","Molecular NeuroImaging, LLC, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT01859767"
605,"NCT03001349","An Expanded Access Imaging of Neuroendocrine Tumors Using 68Ga-DOTA-TOC",,"No longer available","No Results Available","Malignant Neoplasms of Digestive Organs|Neuroendocrine Tumor|Malignant Neoplasms of Eye Brain and Other Parts of Central Nervous System","Drug: 68Ga-DOTATOC|Procedure: PET/CT","","M.D. Anderson Cancer Center","All","Child, Adult, Older Adult","","null","Other","Expanded Access","","2016-0030","null","null","null","December 23, 2016","null","June 21, 2018","University of Texas MD Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT03001349"
606,"NCT00343070","Functional Neuroimaging in Depression",,"Completed","No Results Available","Major Depression","Drug: Oral administration of escitalopram during 8 weeks","Brain metabolism|Cognitive functions|Efficacy scales (mood, anxiety, anger and hopelessness)","University Hospital, Ghent|Fund for Scientific Research, Flanders, Belgium|H. Lundbeck A/S","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","40","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2006/176","March 2007","October 2009","October 2009","June 22, 2006","null","August 31, 2010","University Hospital Ghent, Ghent, Belgium|AZ Groeninge campus Sint Maarten, Kortrijk, Belgium","","https://ClinicalTrials.gov/show/NCT00343070"
607,"NCT03082768","Phase 0 Study of [18F]MNI-968 as a Marker for D1 Receptor in Healthy Subjects",,"Completed","No Results Available","Healthy Volunteers","Drug: [18F]MNI-968","Tracer uptake will be evaluated in regions of interest for analysis of regional [18F]MNI-968 binding/uptake and expressed in SUV by using established methods for normalization for 7 HV subjects.","Molecular NeuroImaging","All","18 Years to 50 Years   (Adult)","Early Phase 1","6","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","[18F]MNI-968","March 3, 2017","March 1, 2018","March 1, 2018","March 17, 2017","null","March 6, 2018","Molecular NeuroImaging, LLC, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT03082768"
608,"NCT03218332","Post-Concussion Syndrome in Professional Athletes: A Multidisciplinary Study",,"Recruiting","No Results Available","Chronic Traumatic Encephalopathy","Diagnostic Test: Biomarkers for detecting possible CTE invivo","Biomarkers for possible CTE","University Health Network, Toronto|The Weston A. Price Foundation","Male","25 Years to 85 Years   (Adult, Older Adult)","","150","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","11-0088-B","July 4, 2011","December 30, 2017","December 30, 2020","July 14, 2017","null","July 14, 2017","Canadian Concussion Centre, Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT03218332"
609,"NCT02538315","Using [18F]FDOPA PET/CT to Monitor the Effectiveness of Fetal Dopaminergic Grafts in Parkinson Disease Patients",,"Recruiting","No Results Available","Parkinson`s Disease","Drug: [18F]FDOPA PET/CT","Differences (assessed by standard uptake values (SUV)) between pre and post-surgical nigrostriatal uptake of [18F]FDOPA","University of Saskatchewan|University of Manitoba","All","18 Years and older   (Adult, Older Adult)","","30","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","Bio 15-21","October 2016","September 2018","September 2018","September 2, 2015","null","May 3, 2017","University Of Saskatchewan, Saskatoon, Saskatchewan, Canada","","https://ClinicalTrials.gov/show/NCT02538315"
610,"NCT02516046","18F-AV-1451 Autopsy Study",,"Completed","No Results Available","Alzheimer's Disease","Drug: 18F-AV-1451","Diagnostic Performance Individual Readers (NFT Score)|Diagnostic Performance Individual Readers (NIA-AA Autopsy Diagnosis)|Diagnostic Performance (NFT Score)|Diagnostic Performance (NIA-AA Autopsy Diagnosis)|Inter-Reader Agreement (NFT Score)|Inter-Reader Agreement (NIA-AA Autopsy Diagnosis)","Avid Radiopharmaceuticals","All","50 Years and older   (Adult, Older Adult)","Phase 3","156","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","18F-AV-1451-A16","September 2015","June 13, 2018","July 15, 2018","August 5, 2015","null","July 23, 2018","Banner Alzheimer's Institute, Phoenix, Arizona, United States|St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States|Cherlin Research, Los Gatos, California, United States|Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States|California Research Foundation, San Diego, California, United States|Pacific Research Network, San Diego, California, United States|Ray Dolby Brain Health Center, San Francisco, California, United States|Syrentis Clinical Research, Santa Ana, California, United States|Neuropsychiatric Research Center of Southwest Florida, Fort Myers, Florida, United States|Galiz Research, Hialeah, Florida, United States|Merritt Island Medical Research, Merritt Island, Florida, United States|Miami Jewish Health Systems, Miami, Florida, United States|D de la Vega MD Research Group, Miami, Florida, United States|Bioclinica, Orlando, Florida, United States|Emory University Brain Health Center, Atlanta, Georgia, United States|Alzheimer's Disease Center, Quincy, Massachusetts, United States|Steinberg Diagnostics, Henderson, Nevada, United States|Adirondack Medical Research Center, Glens Falls, New York, United States|Clarity Clinical Research, LLC, Syracuse, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Wake Forest School of Medicine, Winston-Salem, North Carolina, United States|Valley Medical Primary Care, Centerville, Ohio, United States|Hospice of the Western Reserve, Cleveland, Ohio, United States|American Clinical Trials, LLC (Site 1216), Oklahoma City, Oklahoma, United States|Oklahoma Behavioral Health, Oklahoma City, Oklahoma, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Houston Methodist Research Institute, Houston, Texas, United States|Sante Clinical Research, Kerrville, Texas, United States|Overlake Internal Medicine Associates, PS, Bellevue, Washington, United States|University of Washington Medicine, Seattle, Washington, United States|University of Melbourne, Parkville, Victoria, Australia","","https://ClinicalTrials.gov/show/NCT02516046"
611,"NCT01877538","Study to Investigate the Ability of [11C]Donepezil PET to Image the Parasympathetic Nervous System",,"Completed","Has Results","Parkinson's Disease","Other: [11C]donepezil PET","Distribution Volume (DV) of [11C]Donepezil - BASELINE|Standard Uptake Value (SUV) of [11C]Donepezil - BASELINE","Per Borghammer|Lundbeck Foundation|University of Aarhus","Male","45 Years to 75 Years   (Adult, Older Adult)","","7","Other","Observational","Time Perspective: Cross-Sectional","01-01","May 2013","July 2013","July 2013","June 13, 2013","March 23, 2016","March 23, 2016","Dep. of Nuclear Medicine and PET centre, Aarhus University Hospital, Aarhus, Denmark","","https://ClinicalTrials.gov/show/NCT01877538"
612,"NCT02210624","Safety and Efficacy Assessment of Autologous Bone-marrow Derived Adult Mesenchymal Stem Cell Therapy in Patients With Anoxic(or Hypoxic) Brain Injury Pilot Trial",,"Recruiting","No Results Available","Anoxic Brain Injury","Biological: HYNR-CS inj.","safety assessment|Glasgow Coma Scale(GCS)|FOUR score|Functional Independence Measure(FIM)|Disability Rating Scale(DRS)|Cerebral Performance Category(CPC)scale","Hyun Young Kim|Hanyang University Seoul Hospital","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","4","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HYNR_CS_ABI001","March 2013","December 2018","December 2018","August 7, 2014","null","August 10, 2017","Hanyang University Hospital, Seoul, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT02210624"
613,"NCT01105988","Evaluating Tumor Pseudoprogression With FLT-PET and MRI",,"Terminated","No Results Available","Glioblastoma","Other: Radiologic exams","Primary Outcome Measure|Secondary Outcome Measure","Massachusetts General Hospital|Dana-Farber Cancer Institute","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","2","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","10-008","May 2011","October 2011","October 2011","April 19, 2010","null","January 6, 2012","Massachusetts General Hospital, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT01105988"
614,"NCT01132898","Long-term Clinical Correlates of Traumatic Brain Injury",,"Recruiting","No Results Available","Traumatic Brain Injury","","To observe changes in the TBI Common Data Elements over time|Changes in other clinical phenotyping measures over time|Changes in MRI findings over time","National Institutes of Health Clinical Center (CC)|Center for Neuroscience and Regenerative Medicine (CNRM)|United States Department of Defense","All","18 Years and older   (Adult, Older Adult)","","480","NIH|U.S. Fed","Observational","Observational Model: Cohort|Time Perspective: Prospective","100118|10-CC-0118","May 7, 2010","null","null","May 28, 2010","null","August 9, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT01132898"
615,"NCT03093064","Inflammatory Response In Schizophrenia","IRIS","Active, not recruiting","No Results Available","Schizophrenia","Drug: Natalizumab|Other: Placebo: normal saline","Change in Translocator Protein (TSPO) availability pre- and post-natalizumab or placebo administration|Correlation of TSPO availability with brain functional measures at baseline.|Correlation of cerebrospinal fluid (CSF) inflammatory markers with brain functional measures at baseline.|Correlation of blood inflammatory markers with brain functional measures at baseline.|Longitudinal change in TSPO availability correlated with longitudinal change in brain functional measures.","King's College London|South London and Maudsley NHS Foundation Trust","All","18 Years to 50 Years   (Adult)","Phase 1","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","208083","April 1, 2017","April 1, 2022","April 1, 2022","March 28, 2017","null","August 18, 2017","Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom","","https://ClinicalTrials.gov/show/NCT03093064"
616,"NCT01854944","PET Trial to Assess the Receptor Occupancy of Brexpiprazole in Adult Subjects With Schizophrenia",,"Completed","Has Results","Schizophrenia","Drug: Brexpiprazole 1mg to 4mg","Change in Percentage Dopamine D2/D3 Receptor Occupancy|Change in Percentage 5-HT1A Receptor Occupancy|Change in Percentage 5-HT2A Receptor Occupancy|Change in Occupancy at Serotonin Transporter (SERT)|Area Under the Concentration-time Curve (AUCτ) During a Dosing Interval at Steady-state for Brexpiprazole and Its Metabolite DM-3411|Peak (Maximal) Concentration of Drug in Plasma (Cmax) for Brexpiprazole and Its Metabolite DM-3411|Apparent Clearance of Drug From Plasma After Extravascular Administration (CL/F; Only Brexpiprazole)|Time to Maximum (Peak) Plasma Concentration (Tmax) for Brexpiprazole and Its Metabolite DM-3411|Mean Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Score|Mean Change From Baseline in Simpson-Angus Scale (SAS) Total Score|Mean Change From Baseline in Barnes Akathisia Rating Scale (BARS) Score|Percentage of Participants Who Reported at Least One Occurrence of Suicidality, Suicidal Behavior and Suicidal Ideation on the Columbia-Suicide Severity Rating Scale (C-SSRS)|Mean Change From Baseline in Positive and Negative Symptom Scale (PANSS) Total Score|Mean Change From Baseline in PANNS Positive Subscale Score|Mean Change From Baseline in PANSS Negative Subscale Score|Mean Change From Baseline in Clinical Global Impression-Severity (CGI-S) Score|Mean Change From Baseline in Clinical Global Impression-Improvement (CGI-I) Score","Otsuka Pharmaceutical Development & Commercialization, Inc.","All","18 Years to 45 Years   (Adult)","Phase 1","12","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","331-09-219","September 2013","July 2014","August 2014","May 16, 2013","February 4, 2016","February 4, 2016","Columbia University, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT01854944"
617,"NCT03100136","Test Re-Test Reliability of [11C]PF-06809247 as a Novel PET Tacer",,"Completed","No Results Available","Neuroinflammation","Drug: [11C]PF-06809247","binding kinetics of the novel tracer|Change in Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Test - Retest reliability|Change in Physical examination|Change in Neurological Exam|Change in 12-lead ECG (electrocardiogram)|Change in Vital signs|Change in Clinical laboratory tests (haematology: haemoglobin; haematocrit/erythrocytes; haemoglobin/erythroctes; Erythro-, leuco-,lympho-, mono-Cytes; Platelets)","Pfizer","Male","18 Years to 55 Years   (Adult)","Phase 1","7","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","A9001493|PET TRACER METHODOLOGY","November 16, 2016","March 10, 2017","March 10, 2017","April 4, 2017","null","April 4, 2017","Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States|Anylan Center, New Haven, Connecticut, United States|Yale University School of Medicine, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT03100136"
618,"NCT02709356","Medium Chain Triglycerides and Brain Metabolism in Alzheimer's Disease","MCT-MA","Recruiting","No Results Available","Alzheimer's Disease","Dietary Supplement: 1-month of 60-40 MCT oil|Dietary Supplement: 1-month of C8 MCT oil","Quantification of brain glucose uptake|Quantification of brain acetoacetate uptake","Université de Sherbrooke|Fondation Vitae","All","65 Years and older   (Older Adult)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","2016-547","October 2015","December 2018","December 2018","March 16, 2016","null","December 21, 2017","Research Centre on Aging (CSSS-IUGS - CIUSSS de l'Estrie - CHUS), Sherbrooke, Quebec, Canada","","https://ClinicalTrials.gov/show/NCT02709356"
619,"NCT02012595","[11C]Donepezil PET For Imaging The Autonomous Nervous System In Parkinsons Disease",,"Completed","No Results Available","Parkinson's Disease","Other: [11C]donepezil PET","Distribution volume of [11C]donepezil in internal organs","Per Borghammer|Lundbeck Foundation|Jascha Fonden|Fonden af 2. Juli 1984 til bekæmpelse af Parkinsons Sygdom, Denmark|University of Aarhus","All","40 Years to 80 Years   (Adult, Older Adult)","","24","Other","Observational","Observational Model: Case Control|Time Perspective: Cross-Sectional","2013-01|2013-003775-35","October 2013","January 2015","January 2015","December 16, 2013","null","June 2, 2015","Dept. of Nuclear Medicine & PET Center, Aarhus University Hospital, Aarhus, Denmark","","https://ClinicalTrials.gov/show/NCT02012595"
620,"NCT01923025","A PET Study With RO5545965 in Healthy Male Volunteers",,"Completed","No Results Available","Schizophrenia","Drug: RO5545965","Pharmacodynamics: Brain PDE10 occupancy by RO5545965|PK/PD: Brain PDE10 inhibition in relationship to RO5545965 plasma concentrations|Safety: Incidence of adverse events|Pharmacokinetics: Plasma concentrations of RO5545965","Hoffmann-La Roche","Male","25 Years to 50 Years   (Adult)","Phase 1","9","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)","BP28844|2013-000538-36","August 2013","November 2013","November 2013","August 14, 2013","null","November 2, 2016","London, United Kingdom","","https://ClinicalTrials.gov/show/NCT01923025"
621,"NCT00001489","Effect of Vigabatrin on Brain Blood Flow and Glucose Metabolism",,"Completed","No Results Available","Epilepsy|Epilepsy, Complex Partial","","","National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult","","20","NIH","Observational","","950008|95-N-0008","October 1994","null","August 2000","December 10, 2002","null","March 4, 2008","National Institute of Neurological Disorders and Stroke (NINDS), Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00001489"
622,"NCT01296802","Investigation of Serotonin Neurotransmission in MDMA Users Using Combinated Dexfenfluramine Challenge and PET Imaging","DEXFEN_PET","Completed","No Results Available","Amphetamine-Related Disorders|Amphetamine Abuse","Drug: dexfenfluramine","Serotonin release capacity|Cognition|Prolactin and cortisol|Mood and mental state","University of Zurich","Male","18 Years to 45 Years   (Adult)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","PUK_Study_72","April 2006","July 2008","July 2008","February 15, 2011","null","December 15, 2011","University Hospital of Psychiatry Zurich, Zurich, ZH, Switzerland","","https://ClinicalTrials.gov/show/NCT01296802"
623,"NCT01283347","18F-DTBZ for l Diagnosis of Parkinson's Disease and Monitoring the Severity of Disease by VMAT2 PET Imaging","8F-DTBZ","Completed","No Results Available","Parkinson's Disease","Drug: 18F-DTBZ","To evaluate the sensitivity and specificity of 18F-DTBZ PET to the differential diagnosis of PD and normality for drug safety assessment|To analyze the correlation between the regionally reduced 18F-DTBZ binding and the severity of disease of PD.","Chang Gung Memorial Hospital","All","50 Years to 80 Years   (Adult, Older Adult)","Phase 2","100","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","98-2160A","May 2010","April 2012","December 2012","January 26, 2011","null","December 27, 2012","Chang Gung Memory Hpspital, Taoyuan, Taiwan","","https://ClinicalTrials.gov/show/NCT01283347"
624,"NCT01813877","Response Monitoring Trial in Patients With Suspected Recurrence of Glioblastoma",,"Recruiting","No Results Available","Glioma|Glioblastoma","Radiation: FDOPA PET/CT","Diagnostic accuracy compared to standard diagnostics without PET|Impact of FDOPA PET on patient management","Jonsson Comprehensive Cancer Center|Kaiser Permanente|The Methodist Hospital System","All","18 Years to 99 Years   (Adult, Older Adult)","Not Applicable","360","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","FDOPA12-000939","September 22, 2012","September 22, 2018","September 22, 2020","March 19, 2013","null","November 30, 2017","UCLA, Los Angeles, California, United States","","https://ClinicalTrials.gov/show/NCT01813877"
625,"NCT02371031","FDOPA-PET/MRI for the Pre-operative Evaluation of Gliomas",,"Terminated","No Results Available","Glioma|Malignant Glioma","Drug: 6-[F-18]-Fluoro-L-3,4,-dihydroxyphenylalanine|Device: PET/MRI|Procedure: Surgical resection (standard of care)","Percentage of cases in which the addition of FDOPA-PET to MRI changes the surgical plan","Washington University School of Medicine","All","18 Years and older   (Adult, Older Adult)","Phase 1","11","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","201502019","March 2015","July 2016","July 2016","February 25, 2015","null","November 30, 2016","Washington University School of Medicine, St. Louis, Missouri, United States","","https://ClinicalTrials.gov/show/NCT02371031"
626,"NCT03106688","Neuromolecular Risk Factors for Obesity (PROSPECT)",,"Recruiting","No Results Available","Obesity","Diagnostic Test: fMRI imaging|Diagnostic Test: [11C]carfentanil PET scan|Diagnostic Test: [18F]FMPEP-d2 PET scan|Diagnostic Test: [18F]-FDG PET scan|Diagnostic Test: Physical activity measures and fitness tests|Diagnostic Test: Laboratory measurements|Diagnostic Test: Questionnaires|Diagnostic Test: Hyperinsulinemic euglycemic clamp","Neuromolecular risk score for weight gain|Localization of on-going neural activity during various cognitive and affective tasks|Brain and body glucose uptake|Brain and body CB1 availability|Brain MOR availability|Genes regulating MOR (OPRM1) and D2R (DRD2) expression|Genetic risk score from all known obesity-risk genes|Behavioural patterns involving dysfunctional reward learning and inhibitory control|Physical activity level|Maximal physical performance|Physical strength|BMI change in five years|Body adiposity","Turku University Hospital","Male","20 Years to 35 Years   (Adult)","Not Applicable","60","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","PROSPECT","April 4, 2017","December 1, 2022","December 1, 2022","April 10, 2017","null","May 1, 2017","Turku PET Centre (Turku University Hospital), Turku, Finland","","https://ClinicalTrials.gov/show/NCT03106688"
627,"NCT00026832","Examination of Brain Serotonin Receptors in Patients With Mood Disorders",,"Completed","No Results Available","Mood Disorder|Bipolar Disorder|Depression","","","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years to 60 Years   (Adult)","","214","NIH","Observational","","020047|02-M-0047","October 4, 2001","null","November 27, 2012","November 15, 2001","null","July 4, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00026832"
628,"NCT01132872","PET Whole Body Distribution Studies Using [11C]CUMI",,"Completed","No Results Available","Depression|Major Depression|Unipolar Depression|Anxiety Disorder|Anxiety Disorders","","","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years to 65 Years   (Adult, Older Adult)","","12","NIH","Observational","Time Perspective: Prospective","100110|10-M-0110","April 30, 2010","null","April 12, 2012","May 28, 2010","null","July 2, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT01132872"
629,"NCT01719497","Imaging of Cannabinoid 1 Receptors Using [11C]OMAR and PET",,"Active, not recruiting","No Results Available","Obesity|Alcohol Dependence|High Stress","Drug: [C-11]OMAR","No outcome measures for this study, this is an imaging study only","Yale University","All","18 Years to 50 Years   (Adult)","","120","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","0906005296","June 2009","June 2015","June 2019","November 1, 2012","null","July 4, 2018","Yale University School of Medicine, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT01719497"
630,"NCT00108056","Enzastaurin to Treat Recurrent Brain Tumor",,"Terminated","No Results Available","Glioma","Drug: Enzastaurin (LY317615) monohydronchloride","To establish the maximally tolerated dose of enzastaurin in patients with refractory primary brain tumors not on any enzyme-inducing anti-epileptic drugs (EIAED) and for patients on EIAEDs.","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)","Phase 1","26","NIH","Interventional","Primary Purpose: Treatment","050136|05-C-0136","April 7, 2005","April 1, 2014","April 1, 2014","April 13, 2005","null","August 17, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00108056"
631,"NCT01835652","The Effects of Exercise in Parkinson's Disease","PET","Completed","No Results Available","Parkinson Disease 10","Other: Active Exercise|Other: Passive Exercise","PET|fMRI","Pacific Parkinson's Research Centre","All","40 Years to 70 Years   (Adult, Older Adult)","Not Applicable","18","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Basic Science","H13-00276","April 2013","March 2015","March 2015","April 19, 2013","null","May 12, 2015","Pacific Parkinson's Research Centre, Vancouver, British Columbia, Canada","","https://ClinicalTrials.gov/show/NCT01835652"
632,"NCT03121118","Return of Amyloid Imaging Results (Result Study)",,"Enrolling by invitation","No Results Available","Mild Cognitive Impairment","Other: Scan Opportunity","Understanding of mild cognitive impairment as a potential precursor to dementia--knowledge|Understanding of mild cognitive impairment as a potential precursor to dementia-Coherence|Perceived efficacy to cope with mild cognitive impairment as a potential precursor to dementia","University of Pittsburgh","All","18 Years and older   (Adult, Older Adult)","","80","Other","Observational","Observational Model: Other|Time Perspective: Prospective","PRO13100338","September 17, 2014","December 31, 2018","September 30, 2019","April 19, 2017","null","March 13, 2018","","","https://ClinicalTrials.gov/show/NCT03121118"
633,"NCT02289118","Tau Imaging in Young Onset Dementia",,"Active, not recruiting","No Results Available","Alzheimer's Disease, Early Onset|Logopenic Progressive Aphasia|Posterior Cortical Atrophy (PCA)","Drug: [18F]-T807 imaging tracer","Determine and compare the similarities and differences in regional brain uptake of [18F]T807 by using standardized uptake value ratio (SUVr) in patients with typical AD, PCA and lvPPA|Correlate patterns of [18F]T807 binding based on standardized uptake value ratio (SUVr) with MRI-based regional volumetric (mm3) and cortical thickness (mm) measures|Correlate CSF markers of amyloid (Aβ1-42) and/or tau (total tau, phospho-tau) pathology (pg/mL) to uptake of [18F]T807 based on standardized uptake value ratio (SUVr).|Correlate [18F]T807 binding based on standardized uptake value ratio (SUVr) with standard cognitive tests.","University of Pennsylvania","All","45 Years to 70 Years   (Adult, Older Adult)","Not Applicable","16","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","820665","November 2014","December 2018","January 31, 2019","November 13, 2014","null","January 26, 2018","University of Pennsylvania, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT02289118"
634,"NCT03414333","To Determine the Effect of GLP1 on Cognitive Function, Brain Glucose Metabolism and Neuroplasticity.",,"Completed","No Results Available","Glucose Metabolism Disorders|Obesity|Degenerative Brain Disorder","Procedure: RYGB|Drug: GLP-1","sustained Weight Loss|glycemic Control","University of Pisa","All","18 Years to 60 Years   (Adult)","Not Applicable","14","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PRA 2016","June 29, 2016","June 2017","June 2018","January 29, 2018","null","July 19, 2018","Dept.Clinical and Experimental Medicine.Section of Diabetes., Pisa, Italy","","https://ClinicalTrials.gov/show/NCT03414333"
635,"NCT00001478","Effects of Drugs on Cerebral Blood Flow in Patients With Mood Disorders",,"Completed","No Results Available","Healthy|Mood Disorders","","","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult","","170","NIH","Observational","","950016|95-M-0016","October 1994","null","January 2001","December 10, 2002","null","March 4, 2008","National Institute of Mental Health (NIMH), Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00001478"
636,"NCT00795288","Statins and Cerebral Blood Flow in Subarachnoid Hemorrhage (SAH)",,"Completed","Has Results","Subarachnoid Hemorrhage","Drug: Simvastatin, 80 mg/day for 21 days|Drug: placebo","Resting Cerebral Blood Flow During Peak Period of Vasospasm Risk|Cerebral Autoregulation During Peak Period of Vasospasm Risk|Impact of Statin on Oxygen Extraction Fraction and Cerebral Metabolism During Peak Period of Vasospasm Risk","Washington University School of Medicine","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","42","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","3857 - 54118B","August 2008","February 2013","December 2013","November 21, 2008","January 16, 2015","March 21, 2016","Washington Univeristy, ST Louis, Missouri, United States","","https://ClinicalTrials.gov/show/NCT00795288"
637,"NCT01999530","The Effects of Prazosin on Dopamine in Healthy Humans: A PET Pilot Study",,"Completed","No Results Available","Healthy","Drug: Prazosin Hydrochloride","Changes in [11C]-(+)-PHNO binding","Centre for Addiction and Mental Health|Ontario Lung Association|Pfizer","All","19 Years to 45 Years   (Adult)","Phase 1","7","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","224/2012","November 2013","August 2016","August 2016","December 3, 2013","null","October 24, 2017","Centre for Addiction and Mental Health, Toronto, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT01999530"
638,"NCT00249847","Study of PET Scans and Serotonin in Hot Flashes Treatment",,"Terminated","No Results Available","Hot Flashes","Drug: Paroxetine controlled-release|Drug: Conjugated equine estrogen","To estimate the proportion of women who have a 50% or greater reduction in frequency of hot flashes following 4 weeks of paroxetine or conjugated equine estrogen.|To evaluate baseline and change in binding of the serotonin transporter in postmenopausal women who suffer hot flashes before and after 4 weeks of paroxetine or conjugated equine estrogen using PET.|To correlate baseline and change in binding of the serotonin transporter using PET with reduction of hot flashes after 4 weeks of conjugated equine estrogen or paroxetine.","Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","5","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SKCCC J0360","October 2005","July 2007","April 2008","November 7, 2005","null","October 2, 2014","Johns Hopkins University School of Medicine, Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00249847"
639,"NCT01287819","Apolipoprotein E Gene and Functional MRI","fMRI","Unknown status","No Results Available","Dementia","","amyloid load by amyloid-PET examination","Taipei Medical University Shuang Ho Hospital|Chang Gung Memorial Hospital","All","45 Years to 65 Years   (Adult, Older Adult)","","200","Other","Observational","Observational Model: Case Control|Time Perspective: Cross-Sectional","CRC-12-10-04","May 2012","April 2013","June 2013","February 1, 2011","null","October 19, 2012","Chaur-Jong Hu, New Taipei City, Taiwan","","https://ClinicalTrials.gov/show/NCT01287819"
640,"NCT02945826","uPAR-PET/MRI in Glioblastoma Multiforme",,"Recruiting","No Results Available","Glioblastoma Multiforme","Drug: One injection of 68Ga-NOTA-AE105|Device: PET/MRI","uPAR PET/MRI imaging of uPAR expression|uPAR PET/MRI prognostic factor for overall survival|uPAR PET/MRI prognostic factor for progression free survival","Rigshospitalet, Denmark","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 2","35","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","AK2016-2|2016-002417-21","January 2017","December 2020","December 2020","October 26, 2016","null","April 10, 2018","Department of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet, Copenhagen, Denmark","","https://ClinicalTrials.gov/show/NCT02945826"
641,"NCT02238769","18F-FluoroethylCholine Positron Emission Tomography: a Promising Diagnostic Tool for Hepatocellular Carcinoma",,"Unknown status","No Results Available","Hepatocellular Carcinoma","Device: 18F-FluoroethylCholine PET","SUVratio of FECH PET|Patients' lifespan","Peking Union Medical College Hospital","All","18 Years to 80 Years   (Adult, Older Adult)","","80","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","FECH-PET-2014","July 2014","October 2015","October 2017","September 12, 2014","null","September 12, 2014","Department of liver surgery; Peking Union Medical College Hospital, Beijing, Beijing, China","","https://ClinicalTrials.gov/show/NCT02238769"
642,"NCT01409564","Cilostazol Augmentation Study in Dementia",,"Completed","Has Results","Alzheimer's Dementia","Drug: Cilostazol|Drug: Placebo","Regionally Averaged Cerebral Glucose Uptake Changes Measured by FDG PET Uptake With Voxel-based Method|Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-cog)|Mini-Mental State Examination (MMSE) in the Korean Version of the CERAD Assessment Packet)|Activities of Daily Living (ADCS-ADL)|Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB)|Fazekas Scale","Seoul National University Hospital|Korea OIAA","All","60 Years and older   (Adult, Older Adult)","Phase 4","46","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","06-2009-145","May 2010","June 2012","July 2013","August 4, 2011","May 13, 2014","May 13, 2014","SMG-SNU Boramae Medical Center, Seoul, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT01409564"
643,"NCT01735032","Multimodal Imaging in Pre-surgical Evaluation of Epilepsy","EPIMAGE","Unknown status","No Results Available","Partial Epilepsy","","Localizing value of MEG, FDG-PET and MRI for the determination of the Epileptogenic Zone defined by SEEG recordings|sensitivity and specificity","Hospices Civils de Lyon","All","18 Years to 65 Years   (Adult, Older Adult)","","140","Other","Observational","","2011-703","October 2012","November 2012","May 2016","November 28, 2012","null","November 30, 2012","Hospices Civils de Lyon, Lyon, France","","https://ClinicalTrials.gov/show/NCT01735032"
644,"NCT02752178","Peripheral Immunomarker Validation in Treatment-resistant Depression","BIODEP","Recruiting","No Results Available","Depressive Disorder, Major","Other: MA|Other: DEP","C-reactive protein (CRP) levels (mg/l)|Flow cytometric immunophenotype|Structural parameters of the brain|Response to stimulus|Microglial activation in the brain|Pro-inflammatory (M1-like) phenotype-producing cytokines, such as interleukin (IL)-1, IL-6, and tumor necrosis factor (TNF)-α circulating in cerebrospinal fluid","University of Cambridge|University of Oxford|University of Glasgow|University of Sussex|King's College London|Janssen, LP|H. Lundbeck A/S|GlaxoSmithKline","All","25 Years to 50 Years   (Adult)","","250","Other|Industry","Observational","Observational Model: Case-Control|Time Perspective: Prospective","15/EE/0092","June 2015","June 2018","December 2018","April 26, 2016","null","January 23, 2018","University of Sussex, Brighton, United Kingdom|University of Cambridge, Cambridge, United Kingdom|University of Glasgow, Glasgow, United Kingdom|King's College London, London, United Kingdom|University of Oxford, Oxford, United Kingdom","","https://ClinicalTrials.gov/show/NCT02752178"
645,"NCT00029146","Carotid Occlusion Surgery Study","COSS","Terminated","Has Results","Stroke|Ischemic Attack, Transient|Cerebral Infarction","Procedure: extracranial-intracranial bypass surgery|Drug: best medical therapy","Surgical Group:Ipsilateral Ischemic Stroke in 2 Yrs From Randomization and All Stroke & Death Through 30d Post-surgery; Non-surgical Group:Ipsilateral Ischemic Stroke in 2 Yrs From Randomization and All Stroke & Death Through 30d Post-randomization|All Stroke|Disabling Stroke|Fatal Stroke|Death|Modified Rankin 0-1|Modified Rankin 0-2|Modified Barthel Index 19-20|Summary SS-QOL Score|Ipsilateral Ischemic Stroke in 2 Yrs From Randomization and All Stroke & Death Through 30d Post-surgery; Non-surgical Group:Ipsilateral Ischemic Stroke in 2 Yrs From Randomization and All Stroke & Death Through 30d Post-randomization","University of North Carolina, Chapel Hill|National Institute of Neurological Disorders and Stroke (NINDS)|Washington University School of Medicine|University of Iowa","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 3","700","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","R01NS042167|R01NS041895","July 2002","June 2010","June 2010","January 9, 2002","March 26, 2012","March 27, 2012","Washington University School of Medicine, St. Louis, Missouri, United States","","https://ClinicalTrials.gov/show/NCT00029146"
646,"NCT03279523","F 18 T807 PET (Positron Emission Tomograph )Scan for HIV Infected & Uninfected",,"Recruiting","No Results Available","Alzheimer Disease|HIV","Drug: F 18 T807","Perform human in vivo tau imaging using F 18 T807 in 30 older (≥ 40 years old) HIV+ participants and 30 HIV- controls.|: Correlate regional quantitative T807 binding potentials (BPs) with cognitive impairment, as documented by neuropsychological performance tests, in HIV+ and HIV- individuals.","Washington University School of Medicine","All","40 Years and older   (Adult, Older Adult)","Phase 2","80","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","IND 123119 Protocol G","May 2016","May 2021","November 2021","September 12, 2017","null","July 17, 2018","Washington University School of Medicine, Saint Louis, Missouri, United States","","https://ClinicalTrials.gov/show/NCT03279523"
647,"NCT02165410","MRI Study of Cerebral Blood Flow in Development Disorders in Children","IRM-Aut","Recruiting","No Results Available","Autism","Procedure: ASL-MRI|Procedure: Diffusion tensor imaging (diffusion MRI)|Procedure: Eye-tracking|Procedure: Cognitive profile","CBF|anatomical connectivity|eye-tracking method","Assistance Publique - Hôpitaux de Paris","All","18 Months to 18 Years   (Child, Adult)","Not Applicable","300","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","P120204|2012-A01695-38","November 13, 2013","November 12, 2018","December 2018","June 17, 2014","null","December 21, 2017","Hôpital Necker-Enfants Malades Service de Radiologie Pédiatrique, Paris, France","","https://ClinicalTrials.gov/show/NCT02165410"
648,"NCT01454453","Optimisation of Antipsychotic Drug Use in Older People",,"Terminated","No Results Available","Alzheimer's Disease|Schizophrenia","Drug: Patients- dose titration","dose titration","Institute of Psychiatry, London","All","60 Years to 95 Years   (Adult, Older Adult)","Phase 4","64","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2167SR","May 2012","July 2015","July 2015","October 19, 2011","null","April 19, 2017","Institute of Psychiatry, Kings College London, London, United Kingdom","","https://ClinicalTrials.gov/show/NCT01454453"
649,"NCT03033680","Establishing 18F-PBR06 PET Imaging as a Viable Pharmacodynamic Endpoint in MSA",,"Not yet recruiting","No Results Available","MSA","Drug: [F-18]PBR06","Tissue Volume of Distribution","Brigham and Women's Hospital","All","18 Years to 60 Years   (Adult)","Phase 1|Phase 2","4","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2016P002373","January 2017","January 2018","January 2018","January 27, 2017","null","January 27, 2017","","","https://ClinicalTrials.gov/show/NCT03033680"
650,"NCT02086240","Reproducibility of the 11C-PBR28 PET Signal",,"Recruiting","No Results Available","Neurodegenerative Disorders","Drug: XBD173","TSPO Binding Status","Imperial College London","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","120","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","13HH1842","March 2014","January 2017","May 2017","March 13, 2014","null","September 16, 2016","NIHR/Wellcome Trust Imperial Clinical Research Facility, London, United Kingdom","","https://ClinicalTrials.gov/show/NCT02086240"
651,"NCT01138111","Florbetaben (BAY94-9172) PET (Positron Emission Tomography) Imaging in MCI (Mild Cognitive Impairment) Patients",,"Completed","Has Results","Alzheimer Disease|Amyloid Beta-Protein","Drug: Florbetaben (BAY94-9172)","Quantitative Assessment of Neocortical SUVRs (Mean Standard Uptake Value Ratios) as a Measure of Florbetaben Uptake|Number of Normal and Abnormal Scans in Patients With MCI Progressing to AD and Those Who do Not Progress Based on a Threshold of Neocortical SUVR=1.4|Number and Proportion of Normal and Abnormal Scans Based on Brain ß-amyloid Plaque Load (BAPL) in Subjects With MCI Converting to AD and Those Who do Not Progress|Sensitivity/Specificity/Negative Predictive Value (NPV)/Positive Predictive Value (PPV) at Baseline, 12, and 24 Months in the Detection of Significant Brain ß-amyloid Plaque Load in Patients With MCI Progressing to AD Compared to Those Who do Not Progress","Piramal Imaging SA","All","60 Years and older   (Adult, Older Adult)","Phase 1","45","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","312043","June 2008","December 2011","December 2011","June 7, 2010","June 25, 2014","June 25, 2014","Heidelberg, Victoria, Australia","","https://ClinicalTrials.gov/show/NCT01138111"
652,"NCT00062946","PET Imaging of Dopamine in Healthy Study Participants",,"Completed","No Results Available","Healthy","Drug: (18F)fallypride","","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years to 45 Years   (Adult)","Phase 2","45","NIH","Interventional","Primary Purpose: Treatment","030104|03-M-0104","June 17, 2003","null","August 15, 2007","June 18, 2003","null","July 2, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00062946"
653,"NCT01758614","The Carotid and Middle Cerebral Artery Occlusion Surgery Study","CMOSS","Unknown status","No Results Available","Carotid Artery Occlusion|Middle Cerebral Artery Occlusion|Stroke","Procedure: bypass surgery|Drug: Aspirin|Drug: Clopidogrel","the number of participants who suffer from stroke or death after EC-IC bypass surgery or medical therapy|the number of participants who suffer from ipsilateral ischemic stroke|the number of participants who suffer from severe transit ischemic attack (TIA)|the number of participants who suffer from all stroke or death during 30 days to 24 months|the changes from baseline in mRS, national institutes of health stroke scale (NIHSS) and Barthel Index|the changes from baseline of cerebral blood flow (CBF) ratio in CT perfusion|the number of participants who suffer from all kinds of adverse events related to surgery","Xuanwu Hospital, Beijing","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","330","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","XW125-S001","December 2012","December 2016","December 2017","January 1, 2013","null","January 1, 2013","Department of neurosurgery, Xuanwu hospital, Beijing, Beijing, China","","https://ClinicalTrials.gov/show/NCT01758614"
654,"NCT00178074","The Effects of Sleep Deprivation on Antidepressant Response",,"Completed","No Results Available","Unipolar Depression","Behavioral: total sleep deprivation|Procedure: PET imaging","To gain an understanding of the neurochemical processes that may lead to development of pharmacologic strategies that would accelerate antidepressant response or more directly to the development of antidepressant treatments.|PET study|Regional glucose metabolic rates and regional [18F]-altanserin binding|MRI scan|Beck Depression Inventory|Profile of Mood States|Serum anticholinergicity and paroxetine blood levels|SCID|Hamilton Depression Rating Scale|Folstein Mini-Mental State Exam","University of Pittsburgh","All","55 Years and older   (Adult, Older Adult)","Phase 4","80","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","R01MH037869-03|980753|DATR A4-GPS","February 1999","null","April 2003","September 15, 2005","null","August 2, 2013","University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT00178074"
655,"NCT01046513","PET Imaging of Nicotinic Acetylcholine Receptors",,"Completed","No Results Available","Healthy Volunteers|Nicotine Dependence|Pharmacokinetics","","","National Institute on Drug Abuse (NIDA)|National Institutes of Health Clinical Center (CC)","All","21 Years to 45 Years   (Adult)","","14","NIH","Observational","Time Perspective: Other","999906364|06-DA-N364","August 31, 2007","null","September 28, 2011","January 12, 2010","null","July 2, 2017","National Institute on Drug Abuse, Biomedical Research Center (BRC), Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT01046513"
656,"NCT00618631","Effects of Smoking on Opioid Receptor Binding: A PET Study",,"Completed","No Results Available","Substance-related Discorder","Drug: Nicotine|Drug: Carfentanil","Changes in carfentanil binding.|Cardiovascular and subjective responses to smoking one cigarette.","National Institute on Drug Abuse (NIDA)|Johns Hopkins University|National Institutes of Health Clinical Center (CC)","All","21 Years to 50 Years   (Adult)","Phase 1","26","NIH|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Screening","999908060|08-DA-N060","January 17, 2008","null","January 8, 2015","February 20, 2008","null","April 5, 2018","National Institute on Drug Abuse, Baltimore, Maryland, United States|Johns Hopkins Medical Institute, Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00618631"
657,"NCT01834560","SubGenual CG25 Deep Brain Stimulation in Severe Resistant Depression","CG25","Active, not recruiting","No Results Available","Depression","","Change from Baseline of the Score at the Hamilton Depression Rating Scale|neurological examination","University Hospital, Grenoble","All","30 Years to 55 Years   (Adult)","","5","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CG25","December 2007","December 2014","June 2018","April 18, 2013","null","May 4, 2018","Neurosurgery department, Grenoble, France","","https://ClinicalTrials.gov/show/NCT01834560"
658,"NCT00696371","PET Imaging of Peripheral Benzodiazepine Receptors",,"Completed","No Results Available","Healthy","","The first goal of this study is to compare [11C]PBR28 and [11C](R)-PK 11195 as radioligands in the measurement of PBR in healthy human subjects. Our primary outcome measures will be the distribution volume and time stability of each radioligand.|The second goal is to identify non-binders, that is, subjects that do not demonstrate any binding to [11C]PBR28.","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)","","15","NIH","Observational","Time Perspective: Prospective","080158|08-M-0158","June 6, 2008","null","August 19, 2014","June 12, 2008","null","August 23, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00696371"
659,"NCT02278354","Tau Imaging in Professional Fighters",,"Completed","No Results Available","Alzheimer's Disease","Drug: 18F-AV-1451","18F-AV-1451 Uptake","Avid Radiopharmaceuticals|The Cleveland Clinic","Male","18 Years and older   (Adult, Older Adult)","Phase 1","30","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","18F-AV-1451-A11","December 2014","February 3, 2017","February 3, 2017","October 30, 2014","null","April 14, 2017","Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, Nevada, United States","","https://ClinicalTrials.gov/show/NCT02278354"
660,"NCT02095639","Inflammation and Electroconvulsive Therapy",,"Terminated","No Results Available","Major Depressive Disorder","","Change in translocator protein distribution volume (TSPO Vt) measured by [18F]FEPPA PET|17-item Hamilton Depression Rating Scale (HDRS)|Neurocognitive Battery|Peripheral Inflammatory Markers","Centre for Addiction and Mental Health","All","18 Years to 80 Years   (Adult, Older Adult)","","5","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","074-2012","August 2012","March 2017","May 2017","March 26, 2014","null","February 14, 2018","Centre for Addiction and Mental Health, Toronto, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT02095639"
661,"NCT01625611","Kappa-PET Imaging and Naltrexone in Alcohol Drinking Behaviors",,"Completed","No Results Available","Alcohol Drinking","Drug: Naltrexone","Occupancy of KOR by NTX and drinking|Relationship between NTX responsivity and occupancy of KOR|Baseline KOR differences","Yale University","All","21 Years to 50 Years   (Adult)","Phase 1","97","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1011007710","February 2011","March 15, 2018","March 22, 2018","June 21, 2012","null","May 24, 2018","Sac, Cmhc, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT01625611"
662,"NCT03037060","Exploring Regulation and Function of Dopamine D3 Receptors in Alcohol Use Disorders: A [11C]-(+)-PHNO Study",,"Recruiting","No Results Available","Alcohol Use Disorder","Other: [11C]-(+)-PHNO PET scan|Other: Alcohol Self-Administration|Other: Craving Task|Other: MRI scan|Other: Neuropsychological Assessment","Dopamine D2/D3 receptor occupancy|Alcohol craving ratings|Effort to obtain alcohol","Centre for Addiction and Mental Health","All","19 Years and older   (Adult, Older Adult)","Not Applicable","25","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","052/2016","December 2016","February 2019","February 2019","January 31, 2017","null","May 15, 2018","Centre for Addiction and Mental Health, Toronto, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT03037060"
663,"NCT02139150","Serial FLT PET Imaging in Cancer Patients for Monitoring of Response to Therapy",,"Suspended","No Results Available","Histologically-confirmed Malignancies","Radiation: [18F] FLT|Device: PET/CT scans","change from pre- to posttreatment","Memorial Sloan Kettering Cancer Center","All","18 Years and older   (Adult, Older Adult)","Not Applicable","200","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","14-050","May 2014","May 2019","May 2019","May 15, 2014","null","June 4, 2018","Memorial Sloan Kettering Cancer Center, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT02139150"
664,"NCT01999270","Evaluation of FDOPA-PET/MRI in Pediatric Patients With CNS Tumors",,"Completed","No Results Available","Astrocytoma, Oligoastrocytoma, Mixed|Ganglioneuroma|Glioma|Ganglioglioma|Glioblastoma Multiforme Glioma","Drug: Irinotecan|Drug: Bevacizumab|Device: FDOPA-PET/MRI imaging","FDOPA-PET/MRI imaging","Washington University School of Medicine","All","up to 21 Years   (Child, Adult)","Phase 1","6","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","201303069","April 2013","May 2016","May 2016","December 3, 2013","null","October 21, 2016","Washington University School of Medicine, St. Louis, Missouri, United States","","https://ClinicalTrials.gov/show/NCT01999270"
665,"NCT00355329","Randomized Control Trial of Using Tongue Acupuncture in Autistic Spectrum Disorder Using PET Scan for Clinical Correlation",,"Completed","No Results Available","Autism|Autistic Disorder","Procedure: Tongue Acupuncture (Procedure)","Autism Treatment Evaluation Checklist (ATEC) consisting of 4 subscales before (Week 0) and after (Week 8) acupuncture|Reynell Language Developmental Scale (RLDS) before (Week 0) and after (Week 8) acupuncture|Symbolic Play Test (SPT) before (Week 0) and after (Week 8) acupuncture|Functional Independence Measure for children (WeeFIM) with 3 domains before (Week 0) and after (Week 8) acupuncture|Clinical Global Impression Scale (CGIS) before (Week 0) and after (Week 8) acupuncture|18F-fluorodeoxyglucose Positron Emission Tomography (PET) before (Week 0) and after (Week 8) acupuncture","The University of Hong Kong","All","3 Years to 16 Years   (Child)","Phase 3","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","PET-001","null","null","null","July 21, 2006","null","October 20, 2006","Duchess of Kent of Children Hospital, Hong Kong, Hong Kong","","https://ClinicalTrials.gov/show/NCT00355329"
666,"NCT01085123","Determine Central 5-HT1B Receptor Occupancy of ZOMIG® Rapimelt (Zolmitriptan) in Healthy Male Volunteers",,"Completed","No Results Available","Migraine","Drug: Rapimelt|Drug: [11C]AZ10419369","To determine zolmitriptan and/or its active metabolite 183C91 occupancy at 5-HT1B receptors in the living human brain|To describe the relation between Zomig® Rapimelt dose and 5-HT1B receptor occupancy|To describe the relation between plasma concentrations of zolmitriptan and 183C91 and 5-HT1B receptor occupancy","AstraZeneca","Male","20 Years to 45 Years   (Adult)","Phase 1","10","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","D1220C00005","May 2010","October 2010","October 2010","March 11, 2010","null","November 3, 2010","Research Site, Uppsala, Sweden","","https://ClinicalTrials.gov/show/NCT01085123"
667,"NCT03493282","Effect of CT1812 Treatment on Brain Synaptic Density",,"Recruiting","No Results Available","Alzheimer Disease","Drug: Active Treatment- CT1812 100 mg|Drug: Placebo|Drug: Active Treatment- CT1812 300 mg","To evaluate the effect of CT1812 on Activities of Daily Living (ADCS-ADL) in AD patients","Cognition Therapeutics","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 1|Phase 2","21","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","COG0105","April 20, 2018","December 31, 2019","January 31, 2020","April 10, 2018","null","May 28, 2018","Yale University School of Medicine, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT03493282"
668,"NCT01479920","A Positron Emission Topographic (PET) Study on Depression Patient With Electroacupuncture",,"Completed","No Results Available","Major Depressive Disorder|Depression","Drug: Fluoxetine|Procedure: DCEAS (Hwato®/ Dongbang®)|Procedure: n-CEA (Strietberger®)","HAMD-17|SDS|PET scanning|Clinical response|Remission|Latency|Adverse events","The University of Hong Kong|Queen Mary Hospital, Hong Kong|Kowloon Hospital, Hong Kong|Southern Medical University, China","All","22 Years to 65 Years   (Adult, Older Adult)","Not Applicable","36","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","UW 09-091","June 2012","May 2015","May 2015","November 28, 2011","null","December 7, 2015","School of Traditional Chinese Medicine, Southern Medical University, Guangzhou, China|Department of Psychiatry, Queen Mary Hospital, Hong Kong, China|Department of Psychiatry, Kowloon Hospital, Kowloon, China|Department of Diagnostic Radiology, The University of Hong Kong, Hong Kong, Hong Kong","","https://ClinicalTrials.gov/show/NCT01479920"
669,"NCT01502917","Convection-Enhanced Delivery of 124I-8H9 for Patients With Non-Progressive Diffuse Pontine Gliomas Previously Treated With External Beam Radiation Therapy",,"Recruiting","No Results Available","Brain Cancer|Brain Stem Glioma","Radiation: Radioactive iodine-labeled monoclonal antibody 8H9","maximum tolerated dose|safety|overall survival","Y-mAbs Therapeutics|Weill Medical College of Cornell University|Johns Hopkins University","All","2 Years to 21 Years   (Child, Adult)","Phase 1","64","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","11-011","December 2011","December 2018","December 2018","January 2, 2012","null","June 20, 2018","Weill Medical College of Cornell University, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT01502917"
670,"NCT01799837","Norepinephrine Transporter Availability in PTSD",,"Completed","No Results Available","Posttraumatic Stress Disorder","Drug: [C-11]MENET","Measurement of norepinephrine availability","Emory University","Male","30 Years to 70 Years   (Adult, Older Adult)","Phase 1","9","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","IRB00057641|URC-00025435","June 2012","April 2013","July 2013","February 27, 2013","null","September 11, 2013","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01799837"
671,"NCT01962753","Depression in the Elderly and Cerebral Amyloid Plaques: Characterization by [18F] AV-45 Affectives Symptoms and Amyloïd Plaques (ASAP)","ASAP","Unknown status","No Results Available","Elderly|Major Depression","Drug: 18FAV45","standards uptakes values (SUVr)|Residual cognitive deficits","University Hospital, Tours","All","55 Years and older   (Adult, Older Adult)","Not Applicable","150","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","PHRN10-VC/ ASAP","May 2012","May 2018","May 2018","October 14, 2013","null","February 16, 2015","University Hospital of Besançon- Jean Minjoz, Besançon, France|University Hospital of Caen, Caen, France|University Hospital of Lille, Lille, France|University Hospital of Nice, Nice, France|Sainte-Anne Hospital, Paris, France|Le Rouvray Hospital, Sotteville lès Rouen, France|University Hospital of Strasbourg - HUS, Strasbourg, France|University Hospital of Toulouse - Purpan, Toulouse, France|University Hospital of Tours, Tours, France","","https://ClinicalTrials.gov/show/NCT01962753"
672,"NCT00951314","Brain Glutamate Receptors and Cocaine Dependence",,"Terminated","No Results Available","Drug Abuse|Cocaine Dependence","","Determine if cocaine dependent participants have a different mGluR5 density than healthy controls|Determine if mGluR5 density in ventral striatum in cocaine dependent participants is associated with craving.","National Institute on Drug Abuse (NIDA)|National Institutes of Health Clinical Center (CC)","All","20 Years to 55 Years   (Adult)","","30","NIH","Observational","Time Perspective: Prospective","090188|09-DA-0188","July 14, 2009","null","March 19, 2013","August 4, 2009","null","July 4, 2018","National Institute on Drug Abuse, Biomedical Research Center (BRC), Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00951314"
673,"NCT01970943","Molecular and Functional PET-fMRI Measures of Analgesia in Migraine",,"Unknown status","No Results Available","Migraine|Healthy","Other: Placebo","VAS Pain rating|fMRI BOLD signal|PET Diprenorphine","Massachusetts General Hospital|National Institutes of Health (NIH)|National Center for Complementary and Integrative Health (NCCIH)","All","21 Years to 50 Years   (Adult)","Phase 2","28","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","AT007530-01|R21AT007530-01","March 2013","April 2014","null","October 28, 2013","null","January 30, 2015","Athinoula A. Martinos. Center for Biomedical Imaging, Charlestown, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT01970943"
674,"NCT02552758","The Influence of Omega-3 Fatty Acid on the Violence of Schizophrenia Patient and the Possible Mechanism",,"Unknown status","No Results Available","Schizophrenia","Biological: omega-3 fatty acid|Biological: placebo|Device: positron emission tomography (PET)","violent behavior of Participants as Assessed by Modified Overt Aggression Scale(MOAS)|psychiatry symptoms of participants as assessed by Positive and Negative Syndrome Scale (PANSS)|blood level of eicosapentaenoic acid(EPA), docosahexaenoic acid (DHA), noradrenalin(NE), dopamine(DA) and serotonin(5-HT) of participants|the density of 5-HT1A receptor in brain tested by positron emission tomography (PET)","Shanghai Mental Health Center","All","18 Years to 60 Years   (Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2014-25","May 2015","December 2016","December 2016","September 17, 2015","null","September 17, 2015","Shanghai Mental Health Center, Shanghai, Shanghai, China","","https://ClinicalTrials.gov/show/NCT02552758"
675,"NCT02559466","Efficacy of Deep Transcranial Magnetic Stimulation (TMS) for Treatment-resistant Depression and Neuroanatomical Correlates: a Clinical Study Coupled With Positon Emission Tomography (PET)",,"Unknown status","No Results Available","Pharmacoresistant Depression","Device: Transcranial Magnetic Stimulation (TMS - ) - MagPro®|Device: Positon Emission Tomography (PET) - Discovery 710®","The depression score in Montgomery-Åsberg Depression Rating Scale (MADRS).|Short self-completion questionnaire on symptoms of depression","Assistance Publique Hopitaux De Marseille","All","18 Years and older   (Adult, Older Adult)","Not Applicable","36","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","2015-08|RCAPHM15_0084|2015-A00345-44","September 2015","September 2017","null","September 24, 2015","null","October 7, 2015","Assistance Publique Hôpitaux de Marseille, Marseille, France","","https://ClinicalTrials.gov/show/NCT02559466"
676,"NCT01313403","Imaging Serotonin 5HT1A Receptors in Patients With Major Depressive Disorder",,"Withdrawn","No Results Available","Major Depression|Unipolar Depression|Depression|Anxiety Disorder","Other: Antidepressant (SSRI)","","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years to 55 Years   (Adult)","Not Applicable","0","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","110097|11-M-0097","February 10, 2011","April 25, 2012","April 25, 2012","March 11, 2011","null","July 2, 2017","","","https://ClinicalTrials.gov/show/NCT01313403"
677,"NCT00082030","Function of Catecholamines in the Brain During Depression",,"Completed","No Results Available","Depression|Involutional","","","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years to 45 Years   (Adult)","","71","NIH","Observational","","040160|04-M-0160","April 19, 2004","null","November 18, 2011","April 28, 2004","null","July 2, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00082030"
678,"NCT00025974","Brain Chemical Receptor Effects in Patients With Panic Disorder and Post-Traumatic Stress Disorder",,"Completed","No Results Available","Panic Disorder|Posttraumatic Stress Disorder|Major Depressive Disorder","","","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years to 50 Years   (Adult)","","230","NIH","Observational","","020002|02-M-0002","October 31, 2001","null","July 21, 2008","November 5, 2001","null","July 2, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00025974"
679,"NCT00082550","Serotonin Transporters in Obsessive-Compulsive-Related Disorders",,"Completed","No Results Available","Obsessive-Compulsive Disorder","","","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years to 65 Years   (Adult, Older Adult)","","30","NIH","Observational","","040180|04-M-0180","May 10, 2004","null","April 9, 2007","May 12, 2004","null","July 2, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00082550"
680,"NCT01094756","Brain, Obesity, Dopamine and You Study","BODY","Completed","No Results Available","Obesity","Dietary Supplement: meal replacements, psychotherapy, dietary education","To determine the status of postsynaptic D2-like receptor binding in humans with obesity.|To determine the relationship between D2-like receptor binding, reward sensitivity and hedonic response to sweet tastes.","Washington University School of Medicine|National Institutes of Health (NIH)","All","18 Years to 40 Years   (Adult)","Not Applicable","82","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","75-01","July 2010","June 2015","October 2016","March 29, 2010","null","November 2, 2016","Washington University Medical School, St. Louis, Missouri, United States","","https://ClinicalTrials.gov/show/NCT01094756"
681,"NCT02414230","F 18 T807 Tau PET Imaging in Familial Amyotrophic Lateral Sclerosis","T807ALS","Active, not recruiting","No Results Available","Amyotrophic Lateral Sclerosis (ALS)","Drug: Drug: F 18 T807","F 18 T807 Standard Uptake Value Ratios (SUVR) will be correlated with other imaging modalities (MRI, PET amyloid imaging) and cognitive performance.","Washington University School of Medicine","All","18 Years and older   (Adult, Older Adult)","Phase 2","9","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","IND 123119 Protocol B","February 2015","March 2020","September 2020","April 10, 2015","null","July 2, 2018","Washington University School of Medicine, Saint Louis, Missouri, United States","","https://ClinicalTrials.gov/show/NCT02414230"
682,"NCT02494531","Illiteracy and Vulnerability to Alzheimer's Disease: Evaluation of Amyloid Pathology by PET Imaging","AVILL","Recruiting","No Results Available","Alzheimer Disease","Radiation: Fluorodeoxyglucose-PET|Radiation: florbetapir F 18-PET","Comparison of the amount of amyloid deposits using florbetapir-18 Fluor-PET between illiterate and literate MCI patients|Comparison of the amount of amyloid deposits using florbetapir-18 Fluor-PET between illiterate and literate AD patients,|Comparison of the amyloid deposit location between the 2 groups (literate and illiterate)|correlation between amyloid load and metabolism dysfunction using Fluorodeoxyglucose (FDG)-PET in each groups","Assistance Publique - Hôpitaux de Paris","All","18 Years and older   (Adult, Older Adult)","Not Applicable","80","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","P120134","May 2015","January 2019","January 2020","July 10, 2015","null","December 5, 2016","Hospital Avicenne-Neurology, Bobigny, France","","https://ClinicalTrials.gov/show/NCT02494531"
683,"NCT00117221","MRI Measurement of Brain Metabolism Across the Sleep-Wake Cycle",,"Completed","No Results Available","Sleep","","","National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)","All","18 Years to 65 Years   (Adult, Older Adult)","","56","NIH","Observational","","050179|05-N-0179","June 28, 2005","null","February 11, 2014","July 4, 2005","null","August 17, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00117221"
684,"NCT02824666","Study to Evaluate D2 Receptor Occupancy Following Single Intravenous Administration of ATI-9242",,"Completed","No Results Available","Schizophrenia","Drug: ATI-9242|Radiation: [18F]Fallypride Imaging","Target receptor occupancy after single intravenous(IV) of ATI-9242 in 6 healthy adults using the D2 receptor ligand [18F]Fallypride and PET imaging.|Explore the relationship between ATI-9242 dose, plasma concentrations of ATI-9242 and target receptor occupancy in 6 subjects.","Braeburn Pharmaceuticals","Male","18 Years to 50 Years   (Adult)","Phase 1","7","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BB-ATI9242-001","June 20, 2016","September 6, 2016","November 8, 2016","July 7, 2016","null","July 17, 2017","Indiana Clinical Research Center, IU Health University Hospital, Indianapolis, Indiana, United States","","https://ClinicalTrials.gov/show/NCT02824666"
685,"NCT00527579","PET Imaging of Peripheral Benzodiazepine Receptors in Patients With Neurocysticercosis Using [F-18]FB",,"Completed","No Results Available","Neurocysticercosis|Healthy","Drug: [F-18]FBR","Binding of [F-18]FBR at peripheral benzodiazepine receptor.|MRI","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","24","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","070209|07-M-0209","September 4, 2007","November 26, 2013","November 26, 2013","September 11, 2007","null","July 4, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00527579"
686,"NCT00526916","PET Imaging of Peripheral Benzodiazepine Receptors in Patients With Neurocysticercosis Using [C-11]PBR28",,"Completed","No Results Available","Neurocysticercosis|Healthy","Drug: [C-11]PBR28","Binding of [C-11]PBR28 at peripheral benzodiazepine receptors|MRI","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","18","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","070208|07-M-0208","September 4, 2007","null","September 5, 2014","September 10, 2007","null","August 23, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00526916"
687,"NCT01009866","Study of Immunotoxin, MR1-1","MR1-1","Terminated","No Results Available","Supratentorial Malignant Brain Tumor","Biological: MR1-1","Maximum tolerated dose and dose limiting toxicity|Disease Progression","Darell D. Bigner, MD, PhD|National Institute of Neurological Disorders and Stroke (NINDS)|Duke University","All","18 Years and older   (Adult, Older Adult)","Phase 1","9","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00011617|P50NS020023","November 2006","December 2012","December 2012","November 9, 2009","null","March 20, 2015","Duke University Health System, Durham, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT01009866"
688,"NCT00136890","PET Imaging in Potentially Surgically Resectable Non-small Cell Lung Cancers","ELPET","Completed","No Results Available","Non-small-cell Lung Carcinoma","Procedure: PET Imaging","Patients correctly upstaged by PET versus conventional staging|Patients erroneously understaged by PET versus conventional staging|Overall survival|Prognostic ability of PET standard uptake value|Sensitivity and specificity of PET in the mediastinum|Cost-effectiveness of using PET versus conventional staging","Ontario Clinical Oncology Group (OCOG)|Ontario Ministry of Health and Long Term Care","All","18 Years and older   (Adult, Older Adult)","Phase 3","337","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","CTA-Control-088145","July 2004","November 2008","January 2013","August 29, 2005","null","January 15, 2013","St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada|London Health Sciences Centre, London, Ontario, Canada|Credit Valley, Mississauga, Ontario, Canada|The Ottawa Hospital - General Campus, Ottawa, Ontario, Canada|Scarborough Hospital, Scarborough, Ontario, Canada|Sunnybrook/TEGH, Toronto, Ontario, Canada|Toronto General Hospital, Toronto, Ontario, Canada|St. Joseph's Health Care, Toronto, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT00136890"
689,"NCT00610558","Neocortical Epilepsies - Do They Progress?",,"Completed","No Results Available","Epilepsy","Device: positron emission tomography (PET)","We hope to provide evidence that temporal lobe epilepsy is not the only syndrome which suffers from progressive memory loss, volume loss, hypometabolism and loss of seizure control.|We hope to be able to reassure subjects with primary generalized epilepsy (JME) that while they may have some isolated difficulties with certain tasks, they do not have a progressive disorder.","University of California, Irvine","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","43","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","UCI-HS-2003-3252|VA-821/103","July 2003","June 2009","September 2010","February 8, 2008","null","June 21, 2013","Center for Functional Onco-Imaging, University of California, Irvine, California, United States","","https://ClinicalTrials.gov/show/NCT00610558"
690,"NCT01063335","Imaging Cannabinoid CB1 Receptors in Schizophrenia",,"Terminated","No Results Available","Schizophrenia","","Brain distribution volume of 18F-FMPEP-d2.","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years to 55 Years   (Adult)","","1","NIH","Observational","Time Perspective: Prospective","100058|10-M-0058","February 1, 2010","null","September 20, 2012","February 5, 2010","null","July 4, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT01063335"
691,"NCT00254358","A Brain Imaging Study of Nicotine Release in Cigarette Smokers",,"Terminated","No Results Available","Nicotine Dependence","","","Hadassah Medical Organization|Herzog Hospital","All","20 Years to 65 Years   (Adult, Older Adult)","","0","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","842902-HMO-CTIL","April 2007","null","April 2007","November 16, 2005","null","July 4, 2008","","","https://ClinicalTrials.gov/show/NCT00254358"
692,"NCT01036516","PET Assays of Striatal Dopamine Marker in Cocaine Craving",,"Completed","No Results Available","Neural Systems|Drug Abuse|Cocaine Dependence","","","National Institute on Drug Abuse (NIDA)|National Institutes of Health Clinical Center (CC)","All","21 Years to 50 Years   (Adult)","","14","NIH","Observational","Time Perspective: Prospective","999998391|98-DA-N391","June 23, 1998","null","March 27, 2012","December 21, 2009","null","July 2, 2017","Johns Hopkins University, Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT01036516"
693,"NCT02869035","Treatment Outcome in Major Depressive Disorder",,"Recruiting","No Results Available","Major Depressive Disorder","Drug: Escitalopram|Drug: Duloxetine","Binary treatment outcome in terms of remission from depression.|Baseline cerebral 5-HT4R binding as imaged by 11C-SB207145 PET.|Changes from baseline in cerebral 5-HT4R binding as imaged by 11C-SB207145 PET|Baseline hippocampus volume|Changes from baseline in hippocampus volume.|Baseline fMRI BOLD response to an emotional faces paradigm|Changes from baseline in fMRI BOLD response to an emotional faces paradigm|Baseline fMRI BOLD response to reward paradigm.|Changes from baseline in fMRI BOLD response to reward paradigm|Baseline rsfMRI based spontaneous co-fluctuations in low frequency BOLD signal (functional connectivity)|Changes from baseline in rsfMRI spontaneous co-fluctuations in low frequency BOLD signal (functional connectivity)|Sexual function in depression|Changes in sexual function|Baseline EEG including event related potentials (ERP)|Changes in EEG including event related potentials (ERP)|Cortisol awakening response|Changes in cortisol awakening response (HPA-axis dynamics)|Systemic inflammation peripheral blood hsCRP and immunoactive cytokines|Changes in systemic inflammation peripheral blood hsCRP and immunoactive cytokines|Systemic oxidative stress in terms of 8-oxodG and 8-oxoGuo in urine|Changes in systemic oxidative stress in terms of 8-oxodG and 8-oxoGuo in urine|Early life Stress|Performance on Verbal Affective Memory Tasks (VAMT-26).|Performance on Moral Judgement Task|Performance on Letter-Number Sequence Task.|Changes from baseline in HAMD-6 score|HAMD-6 score after 8 and 12 weeks of antidepressant treatment|Regional 5-HT4R binding|Sexual side-effects from antidepressant treatment|Baseline latent variable construct of self-reported mental state|Baseline self reported family history of mood disorders|Changes from baseline in self-reported mental state questionnaire-based latent variable construct|Total daily cortisol output|Changes in total daily cortisol output|Parental bonding quality|5-HTTLPR genotype status|Epigenetic FK506-binding protein 51 (FKBP5) status at baseline|Changes in epigenetic FKBP5 status from baseline|Epigenetic 5-HTTLPR status at baseline|Changes in epigenetic 5-HTTLPR status from baseline|Epigenetic spindle and kinetochore associated complex subunit 2 (SKA2) status at baseline|Changes in epigenetic SKA2 status from baseline|Performance on Face and Eyes Emotion Recognition Task|Performance on Intensity Morphing Task|Performance on Social Information Preference Task|Performance on Simple Reaction Time.","Rigshospitalet, Denmark|Center for Integrated Molecular Brain Imaging|Psychiatric Centre Copenhagen|Central Visitation, Region Hovedstaden","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","100","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","NP1","August 2016","July 2019","July 2019","August 16, 2016","null","June 2, 2017","Neurobiology Research Unit, Rigshospitalet, Copenhagen, Denmark","","https://ClinicalTrials.gov/show/NCT02869035"
694,"NCT00273897","Electrical Polarization of the Brain in Corticobasal Syndrome",,"Completed","No Results Available","Corticobasal Syndrome","Device: Phoresor II","Validated test of ideational and ideomotor apraxia.|Measures of hand dexterity and coordination.","National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)","All","40 Years to 90 Years   (Adult, Older Adult)","Phase 2","20","NIH","Interventional","Primary Purpose: Treatment","060067|06-N-0067","December 30, 2005","December 11, 2007","null","January 9, 2006","null","July 2, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00273897"
695,"NCT00455741","Postmenopausal Women Estrogen and Progesterone Infusion",,"Completed","Has Results","Postmenopause|Aging","Drug: Estradiol infusion|Drug: Progesterone infusion","Effect of Aging on Estrogen Negative Feedback on LH|Effect of Aging on Estrogen Positive Feedback on LH|18 FDG Uptake at the Pituitary During Estrogen Infusion: LH Negative Feedback|18 FDG Uptake at the Hypothalamus During Estrogen Infusion: LH Negative Feedback|18 FDG Uptake at the Pituitary During Estrogen Infusion: LH Positive Feedback|18 FDG Uptake at the Hypothalamus During Estrogen Infusion: LH Positive Feedback","Massachusetts General Hospital|National Institute on Aging (NIA)","Female","45 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","20","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","2000P-002496|R01AG013241","November 2000","February 2007","August 22, 2015","April 4, 2007","May 18, 2018","May 18, 2018","Massachusetts General Hospital, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT00455741"
696,"NCT00243451","Early Detection of Mild Cognitive Impairment in Individual Patients",,"Completed","No Results Available","Mild Cognitive Impairment|Mild Alzheimer's Disease","Other: PET scan & fMRI","Determine if the Cognitive Decline Index will discriminate subtle lesions earlier than the standard analysis of the Nuclear Medicine physician.|Determine if sensitivity, specificity, receiver-operator characteristics, and predictive value of our method are appropriate for translation into a clinically useful tool.","Louisiana State University Health Sciences Center Shreveport","All","55 Years to 85 Years   (Adult, Older Adult)","","34","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","LSUHSC H04-049","September 2003","July 2011","July 2011","October 24, 2005","null","September 7, 2011","Louisiana State University Health Sciences Center, Shreveport, Louisiana, United States","","https://ClinicalTrials.gov/show/NCT00243451"
697,"NCT02719951","Glutaminergic Transmission in Autism : Molecular Imaging Exploration","TANGAU","Recruiting","No Results Available","Autism|Fragile-X Syndrome (FXS)|Healthy Volunteers","Drug: [18F]FPEB PET imaging|Other: Biological samples|Other: MRI","cerebral glutaminergic activity assessed by binding potential of [18F]FPEB|distribution volume of [18F]FPEB","University Hospital, Tours","Male","18 Years to 45 Years   (Adult)","Phase 1","42","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","PRIA 14 FBB / TANGAU","April 2016","May 2019","May 2019","March 25, 2016","null","August 10, 2016","CHU Tours, Tours, France","","https://ClinicalTrials.gov/show/NCT02719951"
698,"NCT02631655","POSitron Emission Imaging Using 18F-FDOPA in Neurooncology","POSEIDON","Recruiting","No Results Available","Glioblastoma","Other: impact of device 18F-FDOPA PET on treatment decisions","percentage of modified therapeutic decisions connected to the data supplied by 18F-FDOPA PET|Percentage of variation in the confidence level of diagnosis incorporating 18F-FDOPA PET findings (reduced, unchanged, increased).","Centre Antoine Lacassagne","All","18 Years and older   (Adult, Older Adult)","Not Applicable","110","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2014/60","December 2015","January 2019","January 2020","December 16, 2015","null","January 29, 2018","Centre Antoine Lacassagne, Nice, France","","https://ClinicalTrials.gov/show/NCT02631655"
699,"NCT02492074","Gene-Environment-Interaction: Influence of the COMT Genotype on the Effects of Different Cannabinoids - a PET Study",,"Not yet recruiting","No Results Available","Healthy Volunteers|Modeling Psychosis","Drug: Delta-9-tetrahydrocannabinol|Drug: Cannabidiol|Drug: Placebo","Change in Positive and Negative Syndrome Scale (total score, PANSS T) from baseline to post drug intake of both on induction of psychotic symptoms, endocannabinoid levels in human body fluids, neuronal processing, and D2-receptor availability|Change in PANSS subscores and clusters (baseline to post drug intake)|Change in Digit Symbol Coding|Change in Letter-Number-Sequencing|Change in emotional state (EWL, ""Eigenschaftswörterliste"")|Change in attentional state (d2-test of attention d2-R)|Change in imagination (Bett's Questionaire upon Mental Imagery)|Change in binocular depth inversion illusion (BDII)|Change in Wisconsin Card Sorting Test Performance|Assessment of hallucinogenic states scale (APZ) (post drug intake)|Safety and tolerability assessments including (S)AEs, physical examination, vital signs (including heart rate and systolic and diastolic blood pressure in both supine and standing positions), and detailed laboratory assessments|Metabolic markers post drug intake (blood)|Metabolic markers post drug intake (cerebrospinal fluid)|D2-receptor availability post drug intake","Central Institute of Mental Health, Mannheim","Male","18 Years to 45 Years   (Adult)","Phase 1","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","GEI-TCP I","April 2019","April 2020","May 2020","July 8, 2015","null","March 15, 2018","Central Institute of Mental Health, Mannheim, BW, Germany","","https://ClinicalTrials.gov/show/NCT02492074"
700,"NCT00222781","Multi-Tracer PET Quantitation of Skeletal Muscle Insulin Resistance in Type 2 Diabetes Mellitus",,"Completed","No Results Available","Diabetes|Obesity","","Compare triple tracer PET imaging of skeletal muscle in lean, obese and T2DM|Mathematical modeling of PET data.","University of Pittsburgh|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","30 Years to 55 Years   (Adult)","","24","Other|NIH","Observational","Time Perspective: Prospective","0311010|R01DK060555","January 2004","null","December 2006","September 22, 2005","null","December 19, 2007","University of Pittsburgh, Pittsburgh, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT00222781"
701,"NCT02811744","11C-Acetate PET/CT Imaging As a Biomarker of Amyloid-Induced Neuroinflammation",,"Recruiting","No Results Available","Mild Cognitive Impairment","Drug: 11C-acetate","Evaluate whether 11C-acetate uptake is increased in amyloid positive Mild Cognitive Impairment (MCI) subjects compared to amyloid negative healthy controls|Correlate 11C-acetate uptake to areas of greater amyloid plaque burden quantified on Amyloid PET/CT|Compare 11C-acetate in areas of mildly elevated PET SUVR to areas with high or sub-threshold amyloid burden|Correlate 11C-acetate uptake to levels of inflammatory markers in CSF","University of Pennsylvania","All","65 Years and older   (Older Adult)","Phase 2","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","824822","January 2017","June 2021","June 2024","June 23, 2016","null","July 3, 2018","University of Pennsylvania, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT02811744"
702,"NCT02265900","Parkinson's Disease Exercise TMS PET Study",,"Recruiting","No Results Available","Parkinson Disease","Other: Exercise","Change in Dopamine release measured by RAC PET","Pacific Parkinson's Research Centre","All","40 Years to 80 Years   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","H14-02200","November 2014","November 2018","November 2018","October 16, 2014","null","November 7, 2017","Pacific Parkinson's Research Centre, Vancouver, British Columbia, Canada","","https://ClinicalTrials.gov/show/NCT02265900"
703,"NCT00222885","Multi-Tracer PET Quantitation of Insulin Action in Muscle (Phase 1, Phase 2, Phase 3, Phase 4)",,"Completed","No Results Available","Diabetes|Obesity","","Triple tracer PET method development for in vivo imaging of skeletal muscle metabolism|Testing of mathematical modeling of PET data","University of Pittsburgh|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","20 Years to 45 Years   (Adult)","","50","Other|NIH","Observational","Time Perspective: Prospective","011178|R01DK060555","December 2002","null","December 2006","September 22, 2005","null","December 19, 2007","University of Pittsburgh, Pittsburgh, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT00222885"
704,"NCT02020408","Monoamine Contributions to Neurocircuitry in Eating Disorders",,"Completed","No Results Available","Eating Disorder","Drug: [11C]raclopride|Drug: [11C]DASB|Drug: amphetamine","1. 5-HT transporter binding and Dopamine (DA) D2/D3 binding as measured during the PET scan|Change in [11C]raclopride binding potential from baseline to post-amphetamine administration as measured during the two 90 min PET scans.","University of California, San Diego|National Institute of Mental Health (NIMH)","Female","18 Years to 45 Years   (Adult)","Phase 4","88","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","090661|R01MH092793","May 2011","April 2016","April 2016","December 24, 2013","null","May 18, 2016","University of California San Diego, San Diego, California, United States","","https://ClinicalTrials.gov/show/NCT02020408"
705,"NCT03537794","Characterizing Dopamine Receptor Binding in Treatment Resistant Depression",,"Not yet recruiting","No Results Available","Treatment Resistant Depression","Diagnostic Test: PET scans","Dopamine potential","St. Michael's Hospital, Toronto|Centre for Addiction and Mental Health","All","25 Years to 55 Years   (Adult)","","45","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","TPET-01","June 2018","June 2021","June 2021","May 25, 2018","null","May 25, 2018","","","https://ClinicalTrials.gov/show/NCT03537794"
706,"NCT01000181","Imaging 61CuATSM Uptake in Atherosclerotic Plaque Using PET-CT",,"Suspended","No Results Available","Carotid Atherosclerosis","Other: PET-CT with CuATSM","Uptake of CuATSM in carotid plaque|Relationship of CuATSM uptake to plaque histology","King's College London|Guy's and St Thomas' NHS Foundation Trust","All","55 Years and older   (Adult, Older Adult)","","10","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","KCLADS09/1|GSTT Charity 251983|EudraCT 2009-011476-30","October 2012","null","null","October 22, 2009","null","April 6, 2012","St Thomas' Hospital, London, United Kingdom","","https://ClinicalTrials.gov/show/NCT01000181"
707,"NCT00818298","24-Hour Time Course of Striatal Dopamine D2 Receptor Occupancy of Ziprasidone: A PET Study",,"Completed","No Results Available","Schizophrenia|Schizoaffective Disorder","Drug: ziprazidone","PET Scan","Centre for Addiction and Mental Health|Pfizer","All","18 Years to 60 Years   (Adult)","Not Applicable","12","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","245/2008","January 2009","January 2011","June 2011","January 7, 2009","null","July 9, 2012","Centre for Addiction and Mental Health - PET Centre, Toronto, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT00818298"
708,"NCT02181582","Specific PET Radioligand Binding to Translocator Protein",,"Completed","No Results Available","Baseline|Blocking Receptor Binding","Drug: Emapunil|Device: PET","Signal noise ratio [C-11](R)-PK 11195","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years to 55 Years   (Adult)","Phase 1","32","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","140141|14-M-0141","June 24, 2014","June 16, 2016","November 23, 2016","July 4, 2014","null","July 4, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT02181582"
709,"NCT03334045","Neurobiological Effects of Work-related Adjustment Disorder","NeuroWAD","Recruiting","No Results Available","Adjustment Disorder With Work Inhibition","Radiation: PET/MR scans","Glucose metabolism|Dopamine binding potential","Odense University Hospital|University of Southern Denmark|Rigshospitalet, Denmark","Female","34 Years to 54 Years   (Adult)","","82","Other","Observational","Observational Model: Case-Control|Time Perspective: Other","OP_483","August 2018","December 2020","December 2022","November 7, 2017","null","April 4, 2018","Odense University Hospital, Odense, Denmark","","https://ClinicalTrials.gov/show/NCT03334045"
710,"NCT01794975","Changes in Striatal [11C]ORM-13070 Binding Elicited by Changing Levels of Endogenous Noradrenaline","AIMI2","Completed","No Results Available","Changes in Striatal [11C]ORM-13070 Binding.","Drug: Ketamine|Drug: Atomoxetine|Other: Cold pressor test|Drug: Placebo","Receptor occupancy","University of Turku|Turku University Hospital|Orion Corporation, Orion Pharma","Male","20 Years to 40 Years   (Adult)","Phase 1","8","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","AIMI 2","August 2012","December 2012","December 2012","February 20, 2013","null","February 20, 2013","Clinical Research Services Turku (CRST) / Turku PET Centre, Turku, Finland","","https://ClinicalTrials.gov/show/NCT01794975"
711,"NCT00001932","Serotonin Receptors in Seizure Disorders",,"Completed","No Results Available","Partial Epilepsy","","","National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)","All","18 Years to 60 Years   (Adult)","","95","NIH","Observational","","990122|99-N-0122","June 21, 1999","null","August 15, 2007","November 4, 1999","null","July 2, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00001932"
712,"NCT01222728","Using Positron Emission Tomography to Predict Intracranial Tumor Growth in Neurofibromatosis Type II Patients",,"Completed","No Results Available","Neoplasms|Nervous System Disease|Vestibular Disease","","To determine whether FDG and/or FLT uptake correlate with growth rate of meningiomas and Vestibular Schwannomas (VSs) in NF2 patients, and can be used to predict their future growth pattern.|To characterize glucose metabolism and cellular proliferative activity in meningiomas and VSs in NF2 patients, using FDG and FLT PET/CT imaging. To determine the degree to which glucose metabolism and cell proliferation are coupled in meningioma...","National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)","All","18 Years to 50 Years   (Adult)","","5","NIH","Observational","Time Perspective: Prospective","100193|10-N-0193","September 22, 2010","null","June 3, 2015","October 18, 2010","null","August 23, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT01222728"
713,"NCT03129269","Cognitive Function and Prevalence of Amyloid Marker in Frail Older Adults","COGFRAIL","Recruiting","No Results Available","Frail Elderly","Procedure: MRI and PET scan","Amyloid physiological parameter|Change in cognitive function with Clinical Dementia Rating Scale (CDR)|Changes in functional capacities with scales IADL|Changes in functional capacities with scales ADL|Changes in functional capacities with scales SPPB","University Hospital, Toulouse|MSDAVENIR","All","70 Years and older   (Older Adult)","Not Applicable","345","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","RC31/16/8753","January 2, 2017","September 30, 2018","December 31, 2021","April 26, 2017","null","April 26, 2017","Toulouse University Hospital (CHU de Toulouse), Toulouse, France","","https://ClinicalTrials.gov/show/NCT03129269"
714,"NCT01741246","Neuroimaging Studies of Chronic Primary Headaches Using Positron Emission Tomography and Magnetic Resonance Imaging",,"Completed","No Results Available","Migraine|Chronic Migraine","","Pattern of brain metabolism using positron emission tomography(PET).|Changes of resting state brain networks using magnetic resonance imaging (MRI)","University of California, San Francisco|Allergan","All","18 Years to 65 Years   (Adult, Older Adult)","","78","Other|Industry","Observational","Time Perspective: Prospective","1107004","September 2011","June 2015","June 2015","December 4, 2012","null","June 30, 2015","UCSF, San Francisco, California, United States","","https://ClinicalTrials.gov/show/NCT01741246"
715,"NCT02999607","Brain Glucose Metabolism During Transcranial Direct Current Stimulation",,"Completed","No Results Available","Depression","Other: transcranial direct current stimulation","FDG-rCMRglu","Medical University of Vienna","All","18 Years to 55 Years   (Adult)","Not Applicable","15","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","3.0.30.11.16","December 2016","September 1, 2017","September 1, 2017","December 21, 2016","null","January 16, 2018","Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria","","https://ClinicalTrials.gov/show/NCT02999607"
716,"NCT00005111","PET Scans in Normal Volunteers and Patients With Fabry Disease",,"Completed","No Results Available","Fabry Disease|Healthy","","","National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)","Male","Child, Adult, Older Adult","","24","NIH","Observational","","000106|00-N-0106","April 2000","null","March 2001","December 10, 2002","null","March 4, 2008","National Institute of Neurological Disorders and Stroke (NINDS), Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00005111"
717,"NCT02355054","Detecting Recurrent Prostate Cancer With C-11 Choline Positron Emission Tomography: An Expanded Access Study",,"Approved for marketing","No Results Available","Cancer of the Prostate","Drug: C-11 Choline PET Imaging","","Washington University School of Medicine","Male","18 Years and older   (Adult, Older Adult)","","null","Other","Expanded Access","","201411142","null","null","null","February 4, 2015","null","January 20, 2017","Washington University School of Medicine, Barnes-Jewish Hospital, Saint Louis, Missouri, United States","","https://ClinicalTrials.gov/show/NCT02355054"
718,"NCT02798185","The DIAGNOSE-CTE Research Project","DIAGNOSE-CTE","Recruiting","No Results Available","Chronic Traumatic Encephalopathy","","Neuroimaging Positron Emission Tomography for Amyloid Biomarker|Fluid Biomarkers|Neuropsychiatric and Neurocognitive Tests|Neurological Evaluation|Magnetic Resonance Imagining Biomarkers|Neuroimaging Positron Emission Tomography for Tau Biomarker|Magnetic Resonance Spectroscopy Biomarkers","Boston University|Mayo Clinic|Banner Health|Brigham and Women's Hospital|New York University School of Medicine|The Cleveland Clinic|National Institute of Neurological Disorders and Stroke (NINDS)","Male","45 Years to 74 Years   (Adult, Older Adult)","","240","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","H-34799|U01NS093334","August 2016","July 2023","July 2023","June 14, 2016","null","August 8, 2018","Boston University School of Medicine, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT02798185"
719,"NCT02189785","Endogenous Opioid Mechanisms for Rejection Sensitivity",,"Recruiting","No Results Available","Rejection Sensitivity","","Mu-opioid binding potential|fMRI blood-oxygen-level-dependent (BOLD) response|Plasma cortisol","Stony Brook University|University of Michigan|National Institute of Mental Health (NIMH)","All","18 Years to 25 Years   (Adult)","","96","Other|NIH","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","R01MH102264","August 2016","June 2020","June 2020","July 15, 2014","null","January 2, 2018","University of Michigan, Ann Arbor, Michigan, United States","","https://ClinicalTrials.gov/show/NCT02189785"
720,"NCT03324646","Evaluation of a Novel PET Radioligand to Image Cyclooxygenase-1 (COX-1)",,"Recruiting","No Results Available","Adult","","The identifiability and time stability of distribution volume calculated with compartmental modeling.","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years to 100 Years   (Adult, Older Adult)","","51","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","170179|17-M-0179","October 3, 2017","January 31, 2022","December 31, 2022","October 30, 2017","null","August 22, 2018","National Institutes of Health Clinical Center, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT03324646"
721,"NCT01703117","Riluzole in Mild Alzheimer's Disease",,"Recruiting","No Results Available","Alzheimer's Disease","Drug: Riluzole|Drug: Placebo","Imaging Biomarkers N-acetylaspartate (NAA) and FDG-PET values in regions of interest|Cognitive function (neuropsychological tests); Glutamate levels obtained through MRS","Rockefeller University","All","60 Years to 85 Years   (Adult, Older Adult)","Phase 2","48","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","APE-0792","November 2013","November 2019","November 2019","October 10, 2012","null","September 25, 2017","The Rockefeller University, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT01703117"
722,"NCT03352258","Effect of Low Dose Radiotherapy on Brain Amyloidosis in the Treatment of Alzheimer's Disease",,"Recruiting","No Results Available","Alzheimer Disease","Radiation: Low dose radiotherapy","Safety and adverse event associated with low dose brain RT|Change in brain amyloid deposits|Neuropsychological performances","Thomas Zilli|University Hospital, Geneva","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2017-01715","November 17, 2017","December 30, 2019","December 30, 2020","November 24, 2017","null","April 30, 2018","Geneva University Hospital, Geneva 14, Switzerland","","https://ClinicalTrials.gov/show/NCT03352258"
723,"NCT02764892","A Study in Healthy Male Volunteers to Investigate a New Drug for the Treatment of Parkinson's Disease",,"Completed","No Results Available","Parkinson's Disease","Drug: V81444","Plasma concentration V81444 corresponding with 50% brain A2A receptor occupancy.|Cognitive function using functional MRI|Change versus placebo in proportion of subjects with adverse events|Change versus placebo in proportion of subjects with abnormal laboratory findings|Change versus placebo in proportion of subjects with clinically significant abnormalities on vital signs|Change versus placebo in proportion of subjects with clinically significant abnormalities in 12-lead ECG|Change versus placebo in proportion of subjects with clinically significant abnormalities on physical examination","Vernalis (R&D) Ltd","Male","25 Years to 55 Years   (Adult)","Phase 1","6","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","V81444-1PD-02","August 2012","November 2012","March 2013","May 6, 2016","null","May 6, 2016","","","https://ClinicalTrials.gov/show/NCT02764892"
724,"NCT01460706","Imaging Malignant Glioma With 68Ga-DOTATOC PET/CT","DOTAGLI","Completed","No Results Available","Glioma","Drug: [68Ga]DOTATOC","Malignant glioma uptake of 68Ga-DOTATOC|Immunohistochemical SST2 receptor status of the tumor specimen","Turku University Hospital","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2|Phase 3","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","77/180/2010","October 2011","December 2013","December 2013","October 27, 2011","null","December 12, 2013","Turku PET Centre, Turku University Hospital, Turku, Finland","","https://ClinicalTrials.gov/show/NCT01460706"
725,"NCT01565473","PET Study of Non-Motor Symptoms of Parkinson Disease",,"Completed","No Results Available","Parkinson Disease","","To asses the non-motor aspects of PD","University of Michigan","All","50 Years and older   (Adult, Older Adult)","","242","Other","Observational","Observational Model: Case Control|Time Perspective: Cross-Sectional","P01NS015655","September 2008","July 2014","July 2014","March 28, 2012","null","December 2, 2014","University of Michigan Health System, Ann Arbor, Michigan, United States","","https://ClinicalTrials.gov/show/NCT01565473"
726,"NCT03104257","The Neural Correlates of Cannabis Use",,"Recruiting","No Results Available","Cannabis Dependence|Healthy","Other: [11-C]OMAR","CB1R availability using [11-C]OMAR PET imaging|Changes in Cognition during withdrawal using a computerized battery|Changes in brain rhythms measured by Electroencephalography","Yale University|National Institute on Drug Abuse (NIDA)","All","18 Years to 55 Years   (Adult)","","37","Other|NIH","Observational","Observational Model: Case-Control|Time Perspective: Prospective","1308012514|1R01DA040698-01A1","December 2016","January 2021","July 2021","April 7, 2017","null","May 17, 2018","Conneticut Mental Health Center, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT03104257"
727,"NCT01052350","PET Imaging in Parkinson Disease Dementia",,"Active, not recruiting","No Results Available","Parkinson's Disease","","","Washington University School of Medicine","All","50 Years and older   (Adult, Older Adult)","","320","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","06-0706","August 2006","July 2030","July 2030","January 20, 2010","null","November 6, 2017","NeuroClinical Research Unit (NCRU), Washington University School of Medicine, Saint Louis, Missouri, United States","","https://ClinicalTrials.gov/show/NCT01052350"
728,"NCT01239550","Insulin Detemir in Obesity Management","IDIOM","Active, not recruiting","No Results Available","Diabetes|Obesity","Drug: Detemir","Low dose basal insulin detemir will potentiate weight loss in obese patients with type 2 diabetes mellitus undergoing a hypocaloric diet intervention by improving dopamine signaling|Neuropsychiatric functions","Vanderbilt University|Novo Nordisk A/S|Vanderbilt University Medical Center","All","31 Years to 60 Years   (Adult)","Not Applicable","240","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","KDN2010","April 2011","December 2019","December 2019","November 11, 2010","null","April 25, 2018","Vanderbilt University, Nashville, Tennessee, United States","","https://ClinicalTrials.gov/show/NCT01239550"
729,"NCT01417182","Biodistribution and Pharmacokinetic Study of 18F-DCFBC Prostate Specific Membrane Antigen Based PET in Patients With Advanced Prostate Cancer",,"Unknown status","No Results Available","Prostate Cancer","Drug: 18F-DCFBC","Serial PET scans will be used to obtain biodistribution and radiation dosimetry calculations.|Assess the ability of 18F-DCFBC PET to detect metastatic prostate cancer by visual qualitative and quantitative SUV analysis","Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","Male","18 Years to 90 Years   (Adult, Older Adult)","Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening","J1057","September 2010","September 2014","null","August 16, 2011","null","June 18, 2014","Johns Hopkins Outpatient Center, Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT01417182"
730,"NCT01246128","Nicotinic Receptor Density in Smoking and Nonsmoking Schizophrenics",,"Withdrawn","No Results Available","Schizophrenia","","","National Institute on Drug Abuse (NIDA)|National Institutes of Health Clinical Center (CC)","All","18 Years to 50 Years   (Adult)","","0","NIH","Observational","Time Perspective: Other","999911463|11-DA-N463","October 31, 2010","null","July 12, 2011","November 23, 2010","null","July 2, 2017","Johns Hopkins University, Baltimore, Maryland, United States|Maryland Psychiatric Research Center (MPRC) 55 Wade Avenue, Catonsville, Maryland, United States","","https://ClinicalTrials.gov/show/NCT01246128"
731,"NCT01723553","Amyloid-related Imaging Abnormalities (Microbleeds) in Atypical AD",,"Completed","No Results Available","Atypical Alzheimers Disease|Logopenic Variant of Primary Progressive Aphasia (LPA)|Posterior Cortical Atrophy (PCA)","Drug: C-11 PiB","Proportion of subjects with and without microbleeds|Percentage of white matter hyperintensity burden on MRI and ratio of amyloid burden on PiB PET scan|Number of microbleeds per subject","Mayo Clinic","All","18 Years and older   (Adult, Older Adult)","Phase 1","27","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","12-007139","November 2012","March 2015","March 2015","November 8, 2012","null","December 21, 2015","Mayo Clinic, Rochester, Minnesota, United States","","https://ClinicalTrials.gov/show/NCT01723553"
732,"NCT03026309","PET-MRI F-DOPA Activity in the Mesocorticolimbic System and Depressive Symptoms in the Prediction of Treatment Compatibility",,"Not yet recruiting","No Results Available","Depression","Other: no intervantion","3,4-dihydroxy-6-[18F]-fluoro-l-phenylalanine ([18F] FDOPA) uptake rate constant (K(i)) that reflects L-dopa transport.","Assuta Medical Center","Male","30 Years to 50 Years   (Adult)","","60","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","0112-16-ASMC","March 2017","March 2019","March 2019","January 20, 2017","null","January 20, 2017","","","https://ClinicalTrials.gov/show/NCT03026309"
733,"NCT00376558","Imaging the Neurobiology of a Behavioral Treatment for Cocaine Dependence","PET-CRA","Completed","Has Results","Cocaine Dependence","Behavioral: Community Reinforcement Approach","Change From Baseline in the Binding Potential of [11C]Raclopride|Cocaine Craving, Withdrawal Symptoms, Pattern of Cocaine Use","New York State Psychiatric Institute|National Institute on Drug Abuse (NIDA)","All","21 Years to 45 Years   (Adult)","Not Applicable","50","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","#5158|R01DA020855-02","July 2006","July 2010","January 2011","September 15, 2006","July 1, 2016","July 1, 2016","New York State Psychiatric Institute, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT00376558"
734,"NCT01704573","Nicotinic Receptor Levels After Stopping Smoking",,"Completed","No Results Available","Nicotine Addiction","Drug: 2-[18F]-fluro-3-[2(S)-2-azethidinylmethoxy]-pyridine","Change in α4β2* nAChR binding potential|Cigarette craving|Behavioral Performance on cognitive tasks","University of Pennsylvania|Pfizer|National Cancer Institute (NCI)","All","18 Years to 65 Years   (Adult, Older Adult)","","20","Other|Industry|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","812051|P50CA143187","October 2010","March 2012","December 2012","October 11, 2012","null","June 16, 2017","Center for Interdisciplinary Research on Nicotine Addiction, University of Pennsylvania, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT01704573"
735,"NCT02801110","PET/MR Imaging in Patients With Short and Long Standing Parkinson's Disease",,"Unknown status","No Results Available","Idiopathic Parkinson's Disease","","correlation between SUV to DTI measurements","david groshar|Assuta Medical Center","All","30 Years to 80 Years   (Adult, Older Adult)","","40","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","0015-16-ASMC","June 2016","June 2018","June 2018","June 15, 2016","null","June 17, 2016","","","https://ClinicalTrials.gov/show/NCT02801110"
736,"NCT01588769","A Phase I Study to Investigate Tolerability and Efficacy of ALECSAT Administered to Glioblastoma Multiforme Patients","ALECSAT-GBM","Completed","No Results Available","Glioblastoma Multiforme","Biological: ALECSAT cell based immunotherapy","Observation of tolerability and sideeffects of treatment monitored by objective medical examinations, Karnofsky score and QOL interviews.|Potential clinical effect will be monitored by PET-MRI and SPECT scanning of the brain.","CytoVac A/S","All","18 Years and older   (Adult, Older Adult)","Phase 1","23","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CV003|2011-002180-22","August 2011","November 2012","April 2013","May 1, 2012","null","June 6, 2016","Department of Neurosurgery, Rigshospitalet, Copenhagen, Denmark","","https://ClinicalTrials.gov/show/NCT01588769"
737,"NCT00597285","Relationship of HHV-6B Virus to Seizures and Brain Injury",,"Terminated","No Results Available","Epilepsy|HHV6B Infection","","Detection of evidence for HHV6 infection in CSF|Detection of lesions on 7T compared to 3T MRI","National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)","All","18 Years to 55 Years   (Adult)","","33","NIH","Observational","Time Perspective: Prospective","080027|08-N-0027","January 3, 2008","null","November 1, 2013","January 18, 2008","null","August 23, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00597285"
738,"NCT00088738","Evaluation of Substance P Neurotransmission in Panic Disorder by PET Imaging of NK1 Receptors With [18F]SPA-RQ",,"Completed","No Results Available","Panic Disorder|Healthy","Drug: [18F] SPA-RQ","","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","84","NIH","Interventional","Primary Purpose: Treatment","040189|04-M-0189","July 27, 2004","null","September 10, 2008","August 2, 2004","null","July 2, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00088738"
739,"NCT02473250","Prediction of Clinical Response to SSRI Treatment in Bipolar Disorder Using Serotonin 1A Receptor PET Imaging",,"Recruiting","No Results Available","Bipolar Disorder","Drug: Fluoxetine|Drug: Citalopram","Montgomery-Asberg Depression Rating Scale|Hamilton Anxiety Rating Scale|Young Mania Rating Scale|Clinical Global Impression-1","New York State Psychiatric Institute","All","18 Years to 60 Years   (Adult)","Phase 4","25","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","#7056","January 2015","September 2019","September 2019","June 16, 2015","null","March 30, 2017","New York State Psychiatric Institute/Columbia University Medical Center, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT02473250"
740,"NCT00001308","Central Mechanisms in Speech Motor Control Studied With H215O PET",,"Terminated","No Results Available","Communication Disorder|Healthy|Stuttering|Tourette Syndrome|Voice Disorder","","","National Institute on Deafness and Other Communication Disorders (NIDCD)|National Institutes of Health Clinical Center (CC)","All","18 Years to 85 Years   (Adult, Older Adult)","","1163","NIH","Observational","","920178|92-DC-0178","April 28, 1992","null","October 6, 2016","November 4, 1999","null","August 21, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00001308"
741,"NCT02907073","PET (Positron Emission Tomography) Imaging Studies With NIS Reporter",,"Terminated","No Results Available","Myeloma|Endometrial Cancer","Drug: BF4","Evaluation of tissue distribution of F-18 BF4 in healthy volunteers|Amount of imaging agent in tumor (uptake) in myeloma and endometrial cancer patients","Mayo Clinic","All","21 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","8","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","15-002494","September 2016","December 2017","December 2017","September 20, 2016","null","June 13, 2018","Mayo Clinic in Rochester, Rochester, Minnesota, United States","","https://ClinicalTrials.gov/show/NCT02907073"
742,"NCT01699828","Exploring Occupancy of Dopamine D3 Receptor by Buspirone in Humans Using PET",,"Completed","No Results Available","Smoking Cessation|Tobacco Use Cessation","Drug: Buspirone|Drug: Placebo","Dose-response occupancy of buspirone at DRD3","Centre for Addiction and Mental Health","All","19 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","6","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","186/2011","October 2012","June 2014","June 2014","October 4, 2012","null","June 4, 2014","Center for Addiction and Mental Health, Toronto, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT01699828"
743,"NCT00001917","Brain Imaging in Elderly People and Individuals With Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease|Healthy","Drug: O15|Drug: [F-18] FP-TZTP","","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult","","150","NIH","Observational","","990073|99-M-0073","April 1999","null","April 2005","November 4, 1999","null","March 4, 2008","National Institute of Mental Health (NIMH), Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00001917"
744,"NCT00563537","Molecular Imaging Modality by Positron Emission Tomography Using 18F-X : Study of Microglial Activation in Amyotrophic Lateral Sclerosis",,"Unknown status","No Results Available","Amyotrophic Lateral Sclerosis|Bulbar Disease|Spinal Disease","Radiation: 18F-X PET SCAN","Quantitative in vivo-imaging of 18F-X microglial binding site as a mesure of disease activity followed up by non invasive quantification of patients using imaging modality.|Evidence of the localisation of benzodiazepine binding site related to microglial activation in ALS|Evidence of the difference of microglial localisation and activation between bulbar and spinal form of amyotrophic lateral sclerosis","University Hospital, Tours","All","40 Years to 70 Years   (Adult, Older Adult)","Phase 1","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","PHRC05-PC / SLA","January 2007","null","December 2010","November 26, 2007","null","March 19, 2010","Service de Médecine Nucléaire et Ultrasons - Hôpital Bretonneau, Tours, Region Centre, France","","https://ClinicalTrials.gov/show/NCT00563537"
745,"NCT00222768","PET Imaging of Regional Variation in Insulin Sensitivity of Adipose Tissue in Humans",,"Completed","No Results Available","Diabetes|Obesity","","Method development of dose-responsive measurement of insulin-stimulated glucose uptake of adipose tissue using 18-FDG and Positron Emission Tomography|To assess regional variation in insulin-stimulated glucose uptake in adipose tissue.","University of Pittsburgh|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","25 Years to 45 Years   (Adult)","","20","Other|NIH","Observational","Time Perspective: Prospective","0502008|R01DK060555","April 2005","null","December 2006","September 22, 2005","null","February 18, 2008","University of Pittsburgh, Pittsburgh, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT00222768"
746,"NCT02656407","Intraoperative Functional Ultrasound","FUSIMAGINE","Unknown status","No Results Available","Brain Tumor|Brain Lesion","Device: Ultrasound device","Activation maps through intraoperative ultrasensitive Doppler compared to gold standards cortical simulation mapping and functional MRI|Sensitivity test of the new Doppler mode|In depth micro vessel localization","Institut National de la Santé Et de la Recherche Médicale, France","All","18 Years and older   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","C14-66|2015-A00661-48","February 2016","June 2017","June 2017","January 15, 2016","null","February 17, 2016","Pitié Salpetriere Hospital, Paris, Ile de France, France","","https://ClinicalTrials.gov/show/NCT02656407"
747,"NCT03470857","Oxidoreductive Balance and Lysosomal Activity in Cancer Patients.",,"Recruiting","No Results Available","Neoplasms|Antioxidants|Oxidative Stress|Lipid Peroxidation|Inflammation|Lysosome Alteration","Diagnostic Test: Patients","Superoxide Dismutase|Catalase|Glutathione Peroxidase|Thiobarbituric acid reactive substances (Malondialdehyde)|Conjugated Dienes|8-iso-Prostaglandin F2alpha|4-Hydroxynonenal|Total Antioxidant Capacity|Acid Phosphatase|Cathepsin D|Arylsulfatase|Alpha-1-Antitrypsin|Vitamins A and E|FDG PET/CT scanning","Nicolaus Copernicus University","All","18 Years and older   (Adult, Older Adult)","","450","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","KB 363/2017","June 19, 2017","December 31, 2019","December 31, 2019","March 20, 2018","null","March 22, 2018","Department of Positron Emission Tomography and Molecular Diagnostics, Collegium Medicum of Nicolaus Copernicus University, Bydgoszcz, Kujawsko Pomorskie, Poland|The Chair of Medical Biology, Collegium Medicum of Nicolaus Copernicus University, Bydgoszcz, Kujawsko-Pomorskie, Poland|Department of Nuclear Medicine of Center Oncology in Bydgoszcz, Bydgoszcz, Kujawsko-Pomorskie, Poland","","https://ClinicalTrials.gov/show/NCT03470857"
748,"NCT00667394","Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors",,"Completed","Has Results","Glioblastoma|Gliosarcoma|Anaplastic Astrocytoma|Anaplastic Oligodendroglioma|Anaplastic Mixed Oligoastrocytoma","Biological: Bevacizumab|Drug: MLN-518 (Tandutinib)|Procedure: Quality-of-life assessment","Progression-free Survival at 6 Months|Number of Participants With Adverse Events","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)","Phase 2","42","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","080101|08-C-0101","April 2008","July 2011","July 2011","April 28, 2008","August 31, 2012","November 5, 2015","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00667394"
749,"NCT00024622","PET Scanning in Parkinson s Disease",,"Recruiting","No Results Available","Parkinson's Disease","","","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)","","460","NIH","Observational","","010232|01-M-0232","September 17, 2001","null","null","September 24, 2001","null","July 10, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00024622"
750,"NCT02021604","Fluorodopa F 18 in Congenital Hyperinsulinism",,"Recruiting","No Results Available","Congenital Hyperinsulinism","Drug: Fluorodopa F 18","Positron Emission Tomography|Comparative evaluation of PET image and surgical pathology map","Cook Children's Health Care System","All","up to 18 Years   (Child, Adult)","Phase 1","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: Single|Primary Purpose: Diagnostic","2012-060","December 2013","January 2019","June 2019","December 27, 2013","null","September 1, 2017","Cook Children's Medical Center, Fort Worth, Texas, United States","","https://ClinicalTrials.gov/show/NCT02021604"
751,"NCT00108069","Tamoxifen and Bortezomib to Treat Recurrent Brain Tumors",,"Completed","Has Results","Glioma","Drug: Tamoxifen citrate|Drug: Bortezomib","Response, Defined as Stable Disease or Objective (Partial or Complete) Response.|Number of Participants With Adverse Events|Adverse Event Grades","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)","Phase 2","43","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","050137|05-C-0137","April 2005","March 2013","March 2013","April 13, 2005","June 12, 2014","November 5, 2015","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00108069"
752,"NCT00123760","Study of 18F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Cancer or Suspected Cancer",,"Completed","No Results Available","Brain Neoplasms|Lung Neoplasms|Thyroid Neoplasms|Colorectal Neoplasms|Lymphoma","Procedure: Positron Emission Tomography (PET) scan","To demonstrate the safety of 18F-FDG synthesized from cyclotron produced radiofluoride in the Coincidence Technologies automated synthesis unit (ASU) in the Edmonton PET Centre facility|To confirm the diagnostic effectiveness of 18F-FDG in subjects with known or suspected oncologic disease and compare this to literature values","AHS Cancer Control Alberta|Cross Cancer Institute","All","15 Years and older   (Child, Adult, Older Adult)","Phase 2|Phase 3","10838","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","SP-11-0035/DX-FDG-001/21221","February 2004","December 2008","December 2008","July 26, 2005","null","February 25, 2016","Cross Cancer Institute, Edmonton, Alberta, Canada","","https://ClinicalTrials.gov/show/NCT00123760"
753,"NCT02409238","Insulin Resistance and Mild Cognitive Impairment (IRMCI) Study","IRMCI","Unknown status","No Results Available","Mild Cognitive Impairment|Insulin Resistance|Diabetes Mellitus, Type 2","Drug: Metformin|Behavioral: Intensive Lifestyle Intervention|Behavioral: Standard LIfestyle Recommendation","Primary efficacy endpoint (Cerebral Glucose Metabolic Rate)|Primary cognitive endpoint (Neuropsychological Performance)|Secondary clinical endpoints Subjective Memory and Cognitive Complaint (SMCC|Secondary clinical endpoints Basic Activities of Daily Liver (ADL)|Secondary clinical endpoints Cognitive Instrumental Activities of Daily Living Scale|Secondary clinical endpoints Global Clinical Dementia Rating Sum of Boxes|Secondary clinical endpoints Mini-Mental State Examination|Secondary clinical endpoints Montreal Cognitive Assessment scale|Secondary adherence endpoints fasting plasma insulin|Secondary adherence endpoints Homeostatic Model Assessment (HOMA)|Secondary adherence endpoints Lifestyle Intervention (Change in Weight)|Secondary adherence endpoints Body Mass Index|Secondary adherence endpoints Waist Circumference|Secondary adherence endpoints Fasting plasma glucose|Secondary adherence endpoints Glycated Hemoglobin (HbA1c)|Secondary adherence endpoints Fasting Lipids","SingHealth Polyclinics|National University, Singapore|Singapore General Hospital|Changi General Hospital|National University Hospital, Singapore|Singapore Clinical Research Institute|Agency for Science, Technology and Research|Khoo Teck Puat Hospital|Duke-NUS Graduate Medical School","All","55 Years and older   (Adult, Older Adult)","Phase 4","360","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MCI-LM 3","April 2015","December 2017","null","April 6, 2015","null","March 31, 2016","SingHealth Polyclinics - Marine Parade Polyclinic, Singapore, Singapore","","https://ClinicalTrials.gov/show/NCT02409238"
754,"NCT00766987","Cardiac FDG PET Viability Registry","CADRE","Recruiting","No Results Available","Heart Failure|Ischemic Heart Disease|Myocardial Dysfunction","","The primary outcome is the composite clinical endpoint of cardiac death, myocardial infarction, transplantation, or re-hospitalization for unstable angina or heart failure.|Other outcomes will include death from any cause, revascularization, and downstream diagnostic utilization.","Ottawa Heart Institute Research Corporation|Ontario Ministry of Health and Long Term Care","All","18 Years and older   (Adult, Older Adult)","","2000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2007437-01H|MOH-06374","April 2007","March 2020","March 2022","October 6, 2008","null","May 30, 2018","Hamilton Health Sciences Centre, Hamilton, Ontario, Canada|London Health Sciences Centre, London, Ontario, Canada|University of Ottawa Heart Institute, Ottawa, Ontario, Canada|University Health Network, Toronto, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT00766987"
755,"NCT01973543","Safety Study of AADC Gene Therapy (VY-AADC01) for Parkinson's Disease","AADC","Active, not recruiting","No Results Available","Parkinson's Disease","Biological: VY-AADC01","Safety of AADC Gene Transfer|Parkinson's Symptoms|PET Scan Imaging","Voyager Therapeutics|University of California, San Francisco|Veristat, Inc.|Feinstein Institute for Medical Research|Oregon Health and Science University","All","40 Years to 70 Years   (Adult, Older Adult)","Phase 1","15","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","PD-1101|1302-1209","October 2013","December 2019","December 2019","October 31, 2013","null","August 13, 2018","University of California, San Francisco, San Francisco, California, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT01973543"
756,"NCT00470483","A Study To Compare Emotional Changes In Subjects With Social Anxiety Disorder",,"Completed","No Results Available","Social Phobia","Drug: Placebo treatment during 8 weeks|Drug: Paroxetine treatment during 8 weeks","fMRI BOLD response in the amygdala and insula elicited by the Matching Emotional Face paradigm at baseline and after 8 weeks of treatment. State-anxiety inventory (STAI-S) after the Public Speaking challenge (only patients).|fMRI BOLD response in selected neuroanatomical ROI elicited by the by Resting State and by other exploratory paradigms at baseline (all subjects) and after 8 weeks of treatment with paroxetine compared to placebo (only patients).","GlaxoSmithKline","All","18 Years to 60 Years   (Adult)","Phase 1","56","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","TMT106386","January 22, 2007","January 7, 2009","January 7, 2009","May 7, 2007","null","July 18, 2017","GSK Investigational Site, Barcelona, Spain","","https://ClinicalTrials.gov/show/NCT00470483"
757,"NCT01407796","PET Imaging of Endotoxin-induced iNOS Activation",,"Completed","No Results Available","Pneumonia","Drug: Endotoxin (E. coli O:113, Reference Endotoxin)|Drug: [18F](+/-)NOS","Distribution volume ratio (DVR), determined by Logan plot analysis, in the right middle lobe.|Bronchoalveolar lavage (BAL) fluid cell counts.|Number and percent of iNOS-stained BAL cells.","Washington University School of Medicine|Barnes-Jewish Hospital","All","19 Years to 44 Years   (Adult)","Phase 1","19","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","BJHF/ICTS 7326-01","December 2010","April 2012","April 2012","August 2, 2011","null","April 21, 2014","Washington University School of Medicne, St. Louis, Missouri, United States","","https://ClinicalTrials.gov/show/NCT01407796"
758,"NCT01946243","The Feasibility of Florbetapir Quantitation",,"Completed","Has Results","Alzheimers Disease","Drug: Florbetapir F18","Change in Total Accuracy (MIMNeuro Software, Low Accuracy Readers)|Change in Total Accuracy (Siemens Syngo.PET Software, Experimental Arm Low Accuracy Readers)|Change in Total Accuracy (MIMNeuro Software, All Readers)|Change in Reliability (MIMNeuro Software)|Change in Total Accuracy (Siemens Syngo.PET Software, Experimental Arm All Readers)|Change in Reliability (Siemens Syngo.PET Software)","Avid Radiopharmaceuticals","All","Child, Adult, Older Adult","Phase 4","96","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic","18F-AV-45-QP01","August 2013","April 2014","April 2014","September 19, 2013","June 1, 2015","June 29, 2015","Research Site, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT01946243"
759,"NCT00207298","18F-fluorodeoxyglucose (18F-FDG) Positron Emission Tomography in Oncology",,"Unknown status","No Results Available","Brain Neoplasms|Lung Neoplasms|Lymphoma|Melanoma|Colorectal Neoplasms","Procedure: Positron Emission Tomography","Change in management based on PET procedure|Sensitivity of PET","British Columbia Cancer Agency","All","19 Years to 90 Years   (Adult, Older Adult)","Phase 3","5000","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","R05-0076","June 2005","null","November 2008","September 21, 2005","null","November 5, 2010","BCCA, Vancouver Centre, Vancouver, British Columbia, Canada","","https://ClinicalTrials.gov/show/NCT00207298"
760,"NCT02884492","Imaging Tau in Alzheimer's Disease and Normal Aging",,"Completed","No Results Available","Alzheimer's Disease","Drug: 18F-THK-5351|Procedure: Lumbar Puncture (optional)","Change in 18F-THK-5351 uptake value ratio|Change in CSF concentration of inflammatory markers|Change in CSF concentration of β-amyloid , tau and phospho-tau","William Charles Kreisl|National Institute on Aging (NIA)|Columbia University","All","50 Years and older   (Adult, Older Adult)","Phase 2","17","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","AAAQ7868|1K23AG052633-01","July 2016","June 2017","June 2017","August 31, 2016","null","May 16, 2018","Columbia University Medical Center, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT02884492"
761,"NCT03373604","Imaging Tau in Alzheimer's Disease and Normal Aging",,"Enrolling by invitation","No Results Available","Alzheimer Disease","Drug: 18F-MK-6240|Procedure: Lumbar Puncture (optional)","18F-MK-6240 binding (standardized uptake value ratio)|Correlation of 18F-MK-6240 binding and CSF markers of neurodegeneration and inflammation.","William Charles Kreisl|National Institute on Aging (NIA)|Columbia University","All","50 Years to 100 Years   (Adult, Older Adult)","Phase 2","175","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","AAAR4352|K23AG052633-02|2R56AG034189-06A1|K24AG045334|R01AG055299|R01AG050440-02S1","December 11, 2017","August 20, 2021","August 20, 2021","December 14, 2017","null","August 1, 2018","Columbia University Medical Center, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT03373604"
762,"NCT00330109","Identification of Clinically Occult Glioma Cells and Characterization of Glioma Behavior Through Machine Learning Analysis of Advanced Imaging Technology",,"Unknown status","No Results Available","Glioma","Procedure: MRS Imaging|Procedure: PET Scanning|Procedure: Diffusion Tensor Imaging","image glioma patients with advanced imaging techniques to help us better characterize gliomas in the future|create an image-based database to allow machine learning analysis of all the clinically available data|through machine learning analysis, develop computer algorithms to allow us to automate tumour segmentation, predict tumour behaviour and predict location of clinically occult glioma cells","AHS Cancer Control Alberta","All","18 Years and older   (Adult, Older Adult)","Not Applicable","113","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","CNS-9-0032 / 22151-22523","June 2006","December 2017","December 2017","May 25, 2006","null","January 16, 2017","Cross Cancer Institute, Edmonton, Alberta, Canada","","https://ClinicalTrials.gov/show/NCT00330109"
763,"NCT03370926","FET-PET and Multiparametric MRI for High-grade Glioma Patients Undergoing Radiotherapy","IMAGG","Recruiting","No Results Available","Glioblastoma Multiforme|Anaplastic Astrocytoma|Radiotherapy","","Target volumes contoured on standard MRI and planning CT, FET-PET and multiparametric MRI images|Treatment failure pattern in respect to the target volume based on standard MRI, multiparametric MRI and FET-PET.|Sites of failures with composite and standard MRI based RT planning|Progression-free Survival","University Hospital, Brest","All","18 Years and older   (Adult, Older Adult)","","30","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","IMAGG","October 31, 2016","October 31, 2019","October 31, 2019","December 13, 2017","null","December 13, 2017","CHRU de Brest, Brest, France","","https://ClinicalTrials.gov/show/NCT03370926"
764,"NCT00553150","Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma",,"Active, not recruiting","Has Results","Brain and Central Nervous System Tumors","Drug: everolimus|Drug: temozolomide|Radiation: radiation","Maximum Tolerated Dose (MTD) of Everolimus (RAD001) in Combination With Temozolomide (TMZ) and 3D-conformal Radiotherapy (RT) or Intensity-modulated Radiotherapy (IMRT) Followed by Adjuvant TMZ With or Without RAD001 (Phase I)|Overall Survival at 12 Months (Phase II)|Response Rate, as Measured in Patients Receiving FLT-PET Imaging (Phase II)|Time to Progression (Phase II)|Progression-free-survival at 6 Months (Phase II)|Overall Survival Time","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","122","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCCTG-N057K|NCI-2009-00654|CDR0000573917","March 2009","January 2012","null","November 5, 2007","January 11, 2017","May 8, 2018","Mayo Clinic Scottsdale, Scottsdale, Arizona, United States|Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center, Hartford, Connecticut, United States|Mayo Clinic - Jacksonville, Jacksonville, Florida, United States|Saint Alphonsus Cancer Care Center at Saint Alphonsus Regional Medical Center, Boise, Idaho, United States|Illinois CancerCare - Bloomington, Bloomington, Illinois, United States|St. Joseph Medical Center, Bloomington, Illinois, United States|Graham Hospital, Canton, Illinois, United States|Illinois CancerCare - Canton, Canton, Illinois, United States|Illinois CancerCare - Carthage, Carthage, Illinois, United States|Memorial Hospital, Carthage, Illinois, United States|Eureka Community Hospital, Eureka, Illinois, United States|Illinois CancerCare - Eureka, Eureka, Illinois, United States|Galesburg Clinic, PC, Galesburg, Illinois, United States|Illinois CancerCare - Galesburg, Galesburg, Illinois, United States|Illinois CancerCare - Havana, Havana, Illinois, United States|Mason District Hospital, Havana, Illinois, United States|Illinois CancerCare - Kewanee Clinic, Kewanee, Illinois, United States|Illinois CancerCare - Macomb, Macomb, Illinois, United States|McDonough District Hospital, Macomb, Illinois, United States|Trinity Cancer Center at Trinity Medical Center - 7th Street Campus, Moline, Illinois, United States|Moline, Illinois, United States|Illinois CancerCare - Monmouth, Monmouth, Illinois, United States|OSF Holy Family Medical Center, Monmouth, Illinois, United States|BroMenn Regional Medical Center, Normal, Illinois, United States|Community Cancer Center, Normal, Illinois, United States|Illinois CancerCare - Community Cancer Center, Normal, Illinois, United States|Community Hospital of Ottawa, Ottawa, Illinois, United States|Oncology Hematology Associates of Central Illinois, PC - Ottawa, Ottawa, Illinois, United States|Cancer Treatment Center at Pekin Hospital, Pekin, Illinois, United States|Illinois CancerCare - Pekin, Pekin, Illinois, United States|CCOP - Illinois Oncology Research Association, Peoria, Illinois, United States|Oncology Hematology Associates of Central Illinois, PC - Peoria, Peoria, Illinois, United States|Methodist Medical Center of Illinois, Peoria, Illinois, United States|OSF St. Francis Medical Center, Peoria, Illinois, United States|Illinois CancerCare - Peru, Peru, Illinois, United States|Illinois Valley Community Hospital, Peru, Illinois, United States|Illinois CancerCare - Princeton, Princeton, Illinois, United States|Perry Memorial Hospital, Princeton, Illinois, United States|Illinois CancerCare - Spring Valley, Spring Valley, Illinois, United States|St. Francis Hospital and Health Centers - Beech Grove Campus, Beech Grove, Indiana, United States|Reid Hospital & Health Care Services, Richmond, Indiana, United States|McFarland Clinic, PC, Ames, Iowa, United States|Bettendorf, Iowa, United States|Cedar Rapids Oncology Associates, Cedar Rapids, Iowa, United States|Mercy Regional Cancer Center at Mercy Medical Center, Cedar Rapids, Iowa, United States|Siouxland Hematology-Oncology Associates, LLP, Sioux City, Iowa, United States|Mercy Medical Center - Sioux City, Sioux City, Iowa, United States|St. Luke's Regional Medical Center, Sioux City, Iowa, United States|Cancer Center of Kansas, PA - Chanute, Chanute, Kansas, United States|Cancer Center of Kansas, PA - Dodge City, Dodge City, Kansas, United States|Cancer Center of Kansas, PA - El Dorado, El Dorado, Kansas, United States|Cancer Center of Kansas - Fort Scott, Fort Scott, Kansas, United States|Cancer Center of Kansas-Independence, Independence, Kansas, United States|Cancer Center of Kansas, PA - Kingman, Kingman, Kansas, United States|Lawrence Memorial Hospital, Lawrence, Kansas, United States|Cancer Center of Kansas, PA - Liberal, Liberal, Kansas, United States|Cancer Center of Kansas, PA - McPherson, McPherson, Kansas, United States|Cancer Center of Kansas, PA - Newton, Newton, Kansas, United States|Cancer Center of Kansas, PA - Parsons, Parsons, Kansas, United States|Cancer Center of Kansas, PA - Pratt, Pratt, Kansas, United States|Cancer Center of Kansas, PA - Salina, Salina, Kansas, United States|Cancer Center of Kansas, PA - Wellington, Wellington, Kansas, United States|Associates in Womens Health, PA - North Review, Wichita, Kansas, United States|Cancer Center of Kansas, PA - Wichita, Wichita, Kansas, United States|CCOP - Wichita, Wichita, Kansas, United States|Via Christi Cancer Center at Via Christi Regional Medical Center, Wichita, Kansas, United States|Wesley Medical Center, Wichita, Kansas, United States|Cancer Center of Kansas, PA - Winfield, Winfield, Kansas, United States|Saint Joseph Mercy Cancer Center, Ann Arbor, Michigan, United States|CCOP - Michigan Cancer Research Consortium, Ann Arbor, Michigan, United States|Oakwood Cancer Center at Oakwood Hospital and Medical Center, Dearborn, Michigan, United States|Green Bay Oncology, Limited - Escanaba, Escanaba, Michigan, United States|Genesys Hurley Cancer Institute, Flint, Michigan, United States|Hurley Medical Center, Flint, Michigan, United States|Genesys Regional Medical Center, Grand Blanc, Michigan, United States|Van Elslander Cancer Center at St. John Hospital and Medical Center, Grosse Pointe Woods, Michigan, United States|Dickinson County Healthcare System, Iron Mountain, Michigan, United States|Foote Memorial Hospital, Jackson, Michigan, United States|Sparrow Regional Cancer Center, Lansing, Michigan, United States|St. Mary Mercy Hospital, Livonia, Michigan, United States|St. Joseph Mercy Oakland, Pontiac, Michigan, United States|Mercy Regional Cancer Center at Mercy Hospital, Port Huron, Michigan, United States|Seton Cancer Institute at Saint Mary's - Saginaw, Saginaw, Michigan, United States|St. John Macomb Hospital, Warren, Michigan, United States|MeritCare Bemidji, Bemidji, Minnesota, United States|Fairview Ridges Hospital, Burnsville, Minnesota, United States|Mercy and Unity Cancer Center at Mercy Hospital, Coon Rapids, Minnesota, United States|Duluth Clinic Cancer Center - Duluth, Duluth, Minnesota, United States|CCOP - Duluth, Duluth, Minnesota, United States|Miller - Dwan Medical Center, Duluth, Minnesota, United States|Fairview Southdale Hospital, Edina, Minnesota, United States|Mercy and Unity Cancer Center at Unity Hospital, Fridley, Minnesota, United States|Hutchinson Area Health Care, Hutchinson, Minnesota, United States|HealthEast Cancer Care at St. John's Hospital, Maplewood, Minnesota, United States|Minnesota Oncology - Maplewood, Maplewood, Minnesota, United States|Virginia Piper Cancer Institute at Abbott - Northwestern Hospital, Minneapolis, Minnesota, United States|Hennepin County Medical Center - Minneapolis, Minneapolis, Minnesota, United States|New Ulm Medical Center, New Ulm, Minnesota, United States|Humphrey Cancer Center at North Memorial Outpatient Center, Robbinsdale, Minnesota, United States|Mayo Clinic Cancer Center, Rochester, Minnesota, United States|CCOP - Metro-Minnesota, Saint Louis Park, Minnesota, United States|Park Nicollet Cancer Center, Saint Louis Park, Minnesota, United States|Regions Hospital Cancer Care Center, Saint Paul, Minnesota, United States|United Hospital, Saint Paul, Minnesota, United States|St. Francis Cancer Center at St. Francis Medical Center, Shakopee, Minnesota, United States|Lakeview Hospital, Stillwater, Minnesota, United States|Ridgeview Medical Center, Waconia, Minnesota, United States|Willmar Cancer Center at Rice Memorial Hospital, Willmar, Minnesota, United States|Minnesota Oncology - Woodbury, Woodbury, Minnesota, United States|Mercy Clinic Cancer and Hematology - Rolla, Rolla, Missouri, United States|CCOP - Cancer Research for the Ozarks, Springfield, Missouri, United States|St. John's Regional Health Center, Springfield, Missouri, United States|Hulston Cancer Center at Cox Medical Center South, Springfield, Missouri, United States|CCOP - Montana Cancer Consortium, Billings, Montana, United States|St. Vincent Healthcare Cancer Care Services, Billings, Montana, United States|Hematology-Oncology Centers of the Northern Rockies - Billings, Billings, Montana, United States|Billings Clinic - Downtown, Billings, Montana, United States|Bozeman Deaconess Cancer Center, Bozeman, Montana, United States|St. James Healthcare Cancer Care, Butte, Montana, United States|Great Falls Clinic - Main Facility, Great Falls, Montana, United States|Sletten Cancer Institute at Benefis Healthcare, Great Falls, Montana, United States|Northern Montana Hospital, Havre, Montana, United States|St. Peter's Hospital, Helena, Montana, United States|Glacier Oncology, PLLC, Kalispell, Montana, United States|Kalispell Medical Oncology at KRMC, Kalispell, Montana, United States|Kalispell Regional Medical Center, Kalispell, Montana, United States|Montana Cancer Specialists at Montana Cancer Center, Missoula, Montana, United States|Montana Cancer Center at St. Patrick Hospital and Health Sciences Center, Missoula, Montana, United States|Cancer Resource Center - Lincoln, Lincoln, Nebraska, United States|CCOP - Missouri Valley Cancer Consortium, Omaha, Nebraska, United States|Immanuel Medical Center, Omaha, Nebraska, United States|Alegant Health Cancer Center at Bergan Mercy Medical Center, Omaha, Nebraska, United States|Lakeside Hospital, Omaha, Nebraska, United States|Creighton University Medical Center, Omaha, Nebraska, United States|MeritCare Broadway, Fargo, North Dakota, United States|CCOP - MeritCare Hospital, Fargo, North Dakota, United States|Roger Maris Cancer Center at MeritCare Hospital, Fargo, North Dakota, United States|Altru Cancer Center at Altru Hospital, Grand Forks, North Dakota, United States|Adena Regional Medical Center, Chillicothe, Ohio, United States|Charles M. Barrett Cancer Center at University Hospital, Cincinnati, Ohio, United States|Riverside Methodist Hospital Cancer Care, Columbus, Ohio, United States|CCOP - Columbus, Columbus, Ohio, United States|Grant Medical Center Cancer Care, Columbus, Ohio, United States|Mount Carmel Health - West Hospital, Columbus, Ohio, United States|Doctors Hospital at Ohio Health, Columbus, Ohio, United States|Grandview Hospital, Dayton, Ohio, United States|Good Samaritan Hospital, Dayton, Ohio, United States|David L. Rike Cancer Center at Miami Valley Hospital, Dayton, Ohio, United States|Samaritan North Cancer Care Center, Dayton, Ohio, United States|CCOP - Dayton, Dayton, Ohio, United States|Grady Memorial Hospital, Delaware, Ohio, United States|Blanchard Valley Medical Associates, Findlay, Ohio, United States|Middletown Regional Hospital, Franklin, Ohio, United States|Wayne Hospital, Greenville, Ohio, United States|Charles F. Kettering Memorial Hospital, Kettering, Ohio, United States|Fairfield Medical Center, Lancaster, Ohio, United States|Strecker Cancer Center at Marietta Memorial Hospital, Marietta, Ohio, United States|Knox Community Hospital, Mount Vernon, Ohio, United States|Licking Memorial Cancer Care Program at Licking Memorial Hospital, Newark, Ohio, United States|Community Hospital of Springfield and Clark County, Springfield, Ohio, United States|UVMC Cancer Care Center at Upper Valley Medical Center, Troy, Ohio, United States|Precision Radiotherapy at University Pointe, West Chester, Ohio, United States|Mount Carmel St. Ann's Cancer Center, Westerville, Ohio, United States|Ruth G. McMillan Cancer Center at Greene Memorial Hospital, Xenia, Ohio, United States|Genesis - Good Samaritan Hospital, Zanesville, Ohio, United States|Morgan Cancer Center at Lehigh Valley Hospital - Cedar Crest, Allentown, Pennsylvania, United States|Lehigh Valley Hospital - Muhlenberg, Bethlehem, Pennsylvania, United States|Rapid City Regional Hospital, Rapid City, South Dakota, United States|Medical X-Ray Center, PC, Sioux Falls, South Dakota, United States|Sanford Cancer Center at Sanford USD Medical Center, Sioux Falls, South Dakota, United States|Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center, Green Bay, Wisconsin, United States|Green Bay Oncology, Limited at St. Mary's Hospital, Green Bay, Wisconsin, United States|St. Mary's Hospital Medical Center - Green Bay, Green Bay, Wisconsin, United States|St. Vincent Hospital Regional Cancer Center, Green Bay, Wisconsin, United States|Bay Area Cancer Care Center at Bay Area Medical Center, Marinette, Wisconsin, United States|Green Bay Oncology, Limited - Oconto Falls, Oconto Falls, Wisconsin, United States|Green Bay Oncology, Limited - Sturgeon Bay, Sturgeon Bay, Wisconsin, United States|Welch Cancer Center at Sheridan Memorial Hospital, Sheridan, Wyoming, United States","","https://ClinicalTrials.gov/show/NCT00553150"
765,"NCT02810717","Effects of TBS on 5-HT1A Receptor Binding",,"Recruiting","No Results Available","Treatment Resistant Depression","Device: theta-burst stimulation using a MagPro X1000|Device: sham stimulation using a MagPro X1000","Regional 5-HT1A receptor binding|Regional white matter microstructure using DWI-TBSS|Regional white matter microstructure using DWI-Tractography|Regional grey matter volume using MRI|Regional brain perfusion|Functional connectivity at rest and during tasks","Rupert Lanzenberger|Medical University of Vienna","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","1.3","December 2016","November 2019","November 2019","June 23, 2016","null","August 16, 2018","Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria","","https://ClinicalTrials.gov/show/NCT02810717"
766,"NCT01608061","ADvance DBS-f in Patients With Mild Probable Alzheimer's Disease","ADvance","Active, not recruiting","No Results Available","Alzheimer Disease","Device: DBS-f on|Device: DBS-f off","The study will assess the acute and long-term safety of the system. A detailed assessment of all device and/or therapy related adverse events will be conducted.|Efficacy outcomes include: improvement in ADAS-cog 13 at twelve months, improvement in the CDR and changes in glucose metabolism measured by FDG-PET at twelve months","Functional Neuromodulation Ltd","All","45 Years to 85 Years   (Adult, Older Adult)","Not Applicable","50","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","FNMI-001","May 2012","June 2015","September 2018","May 30, 2012","null","February 16, 2017","Banner Alzheimer's Institute, Phoenix, Arizona, United States|Banner Research Institute at Sun City, Sun City, Arizona, United States|University of Florida at Gainesville, Gainesville, Florida, United States|Johns Hopkins Bayview, Baltimore, Maryland, United States|Hospital of the University of Pennsylvania: Penn Memory Clinic, Philadelphia, Pennsylvania, United States|Brown University, Providence, Rhode Island, United States|Toronto Western Hospital, Toronto, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT01608061"
767,"NCT01880008","Evaluation of FLT PET and MRI as Imaging Biomarkers of Early Treatment Response in Patients With Glioblastoma",,"Completed","No Results Available","Glioblastoma","","Change in FLT uptake, measured by SUV tumor/SUV normal contralateral white matter|Survival|Ki-67|Radiographic progression defined by MacDonald criteria|O(6)-methylguanine DNA-methyltransferase (MGMT) activity|Time to progression","Washington University School of Medicine|Barnes-Jewish Hospital","All","18 Years and older   (Adult, Older Adult)","","5","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","08-0073","April 2008","February 2010","August 2012","June 18, 2013","null","June 18, 2013","Washington University School of Medicine/Barnes-Jewish Hospital, St. Louis, Missouri, United States","","https://ClinicalTrials.gov/show/NCT01880008"
768,"NCT01284387","Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Mild to Moderate Alzheimer's Disease","ACCTION","Completed","No Results Available","Alzheimer's Disease","Biological: ACC-001 (vanutide cridificar)","To evaluate the effect of ACC-001 in combination with an adjuvant immunostimulatory agent (QS-21), administered intramuscularly compared to placebo on cerebral amyloid burden in subjects with mild to moderate Alzheimer's disease.|To evaluate the safety and tolerability of 2 dosage levels of ACC-001 plus QS-21 vs. placebo in subjects with mild to moderate AD.|Exploratory Outcome Measure: To assess the effects of ACC-001 compared to placebo as measured by change from baseline in disease biomarkers.|Exploratory Outcome Measure: To assess the effects of ACC-001 compared to placebo as measured by change from baseline in measurements of immunogenicity.|Exploratory Outcome Measure: To assess the effects of ACC-001 compared to placebo as measured by change from baseline in cognitive and functional scales.|Exploratory Outcome Measure: To assess the effects of ACC-001 compared to placebo as measured by change from baseline in health outcome measures.","JANSSEN Alzheimer Immunotherapy Research & Development, LLC|Pfizer","All","50 Years to 89 Years   (Adult, Older Adult)","Phase 2","126","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ACC-001-ALZ-2001","January 2011","January 2014","February 2014","January 27, 2011","null","January 5, 2015","Janssen AI Investigational Site, Sun City, Arizona, United States|Janssen AI Investigational Site, La Jolla, California, United States|Janssen AI Investigational Site, Long Beach, California, United States|Janssen AI Investigational Site, Los Angeles, California, United States|Janssen AI Investigational Site, Oxnard, California, United States|Janssen AI Investigational Site, San Diego, California, United States|Janssen AI Investigational Site, San Francisco, California, United States|Janssen AI Investigational Site, Washington, District of Columbia, United States|Janssen AI Investigational Site, Miami, Florida, United States|Janssen AI Investigational Site, Miami, Florida, United States|Janssen AI Investigational Site, Ocala, Florida, United States|Janssen AI Investigational Site, Orlando, Florida, United States|Janssen AI Investigational Site, Sunrise, Florida, United States|Janssen AI Investigational Site, Tampa, Florida, United States|Janssen AI Investigational Site, Tampa, Florida, United States|Janssen AI Investigational Site, West Palm Beach, Florida, United States|Janssen AI Investigational Site, Scarborough, Maine, United States|Janssen AI Investigational Site, Boston, Massachusetts, United States|Janssen AI Investigational Site, Kansas City, Missouri, United States|Janssen AI Investigational Site, Las Vegas, Nevada, United States|Janssen AI Investigational Site, Princeton, New Jersey, United States|Janssen AI Investigational Site, Albany, New York, United States|Janssen AI Investigational Site, New York, New York, United States|Janssen AI Investigational Site, Centerville, Ohio, United States|Janssen AI Investigational Site, Oklahoma City, Oklahoma, United States","","https://ClinicalTrials.gov/show/NCT01284387"
769,"NCT03022955","Effects of Cocoa on Gastrointestinal Function",,"Completed","No Results Available","Gastrointestinal and Digestive Disorder","Dietary Supplement: Dark chocolate bar|Dietary Supplement: Dark chocolate mousse|Dietary Supplement: White chocolate bar|Dietary Supplement: White chocolate mousse","Gastric emptying half time|Oro-caecal transit time (OCTT)|Colonic transit time|Post-prandial satiety|Gastrointestinal well-being","University Hospital, Basel, Switzerland","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","16","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","Chocolate Study","January 2017","June 2017","June 2017","January 18, 2017","null","February 12, 2018","St Claraspital, Basel, Switzerland","","https://ClinicalTrials.gov/show/NCT03022955"
770,"NCT01992380","A Study of 18F-AV-1451 in Healthy Volunteers and Cognitively Impaired Subjects",,"Completed","No Results Available","Alzheimer's Disease","Drug: 18F-AV-1451","Test-Retest Reproducibility","Avid Radiopharmaceuticals","All","50 Years and older   (Adult, Older Adult)","Phase 1","24","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic","18F-AV-1451-A03","November 2013","May 2014","May 2014","November 25, 2013","null","June 9, 2014","Research Site, Newport Beach, California, United States|Research Site, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT01992380"
771,"NCT00906893","Evaluation of [18F]-FMISO for Non Operated Glioblastoma","MISOGLIO","Completed","No Results Available","Glioblastoma","Procedure: 18F]-FMISO PET-CT","determine acquisition protocol and robust quantification parameters representative of tumour hypoxia using [18F]-FMISO PET-CT in glioblastomas|prognostic value of [18F]-FMISO PET-CT in glioblastomas treated by conformational radiotherapy and/or chemotherapy|Evaluate the potential role of a new biological tumour volume (BTV) taking into account hypoxia for the delineation of radiotherapy treatment planning when patients undergone this treatment|Study of pathological processes contributing to [18F]-FMISO uptake such as: microvessel density and endogenous markers (Hypoxia Inducible Factor (HIF1), Carbonic Anhydrase isoenzyme IX (CAIX), Lysyl Oxidase (LOX), p53) determined on biopsy tissues.","University Hospital, Bordeaux","All","18 Years and older   (Adult, Older Adult)","Phase 2","14","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","CHUBX2008/31","June 2009","January 2012","January 2013","May 21, 2009","null","February 28, 2013","CHU de Bordeaux - Hôpital Pellegrin, Bordeaux, France","","https://ClinicalTrials.gov/show/NCT00906893"
772,"NCT02225106","Dopamine Receptor Imaging to Predict Response to Stimulant Therapy in Chronic TBI",,"Completed","No Results Available","Cognition Disorder|Attention Deficit Disorder|Traumatic Brain Injury","Drug: Methylphenidate","Sustained Arousal and Attention Task 50/50|Dual Task|Distraction Task|Sustained Attention to Response Task|Test of Everday Attention|Inattentive Behavior Task|Glasgow Outcome Scale-Extended (GOS-E)|Learning Trials Portion of the California Verbal Learning Test (CVLT-ll)|The Trial Making Tests A and B|Subsets of the Wechsler Adult Intelligence Scale (WAIS-IV)|BSI-18|Satisfaction with Life Scale (SWLS)|Word Reading Subtest of Wide Range Achievement Test (WRAT)-4|Rivermead Post-Concussion Symptom Questionnaire","National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)","All","18 Years to 55 Years   (Adult)","Phase 2","11","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Primary Purpose: Treatment","140169|14-N-0169","August 6, 2014","June 21, 2017","June 21, 2017","August 26, 2014","null","March 29, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT02225106"
773,"NCT02850146","18F-AV-1451 PET Imaging in Participants Enrolled in the LEARN Study","LEARN-Tau","Active, not recruiting","No Results Available","Cognition Disorders","Drug: 18F-AV-1451","Rate of change of tau deposition as measured by 18F-AV-1451|Change in tau deposition as measured by 18F-AV-1451 standardized uptake value ratio (SUVR) from the baseline scan","University of Southern California|Alzheimer's Therapeutic Research Institute|Alzheimer's Association|Avid Radiopharmaceuticals","All","65 Years to 85 Years   (Older Adult)","Phase 1","50","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","18F-AV-1451-A17|15-338729","August 2016","June 2019","June 2019","July 29, 2016","null","September 21, 2017","Banner Alzheimer's Institute, Phoenix, Arizona, United States|University of Southern California, Los Angeles, California, United States|University of California, Irvine - Neuropsychiatric Center, Orange, California, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Georgetown University, Washington, D.C., District of Columbia, United States|Bioclinica Research Orlando, Orlando, Florida, United States|Bioclinica Research North, The Villages, Florida, United States|University of Iowa, Iowa City, Iowa, United States|University of Kentucky, Lexington, Kentucky, United States|Brigham & Women's Hospital, Boston, Massachusetts, United States|University of Rochester Medical Center, Rochester, New York, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Butler Hospital Memory and Aging Program, Providence, Rhode Island, United States","","https://ClinicalTrials.gov/show/NCT02850146"
774,"NCT00892944","An Open Label Positron Emission Tomography (PET) Study to Determine Central mGluR5 Receptor Occupancy of AZD2516",,"Completed","No Results Available","Healthy","Drug: AZD2516","Positron emission tomography to determine if AZD2516 can displace the radioligand [11C]AZ12713580 and describe relationship between AZD2516 exposure and mGluR5 receptor occupancy|Safety and tolerability of AZD2516 by adverse events, vitals signs, ECG, body temperature and laboratory variables|To investigate the Pharmacokinetics of AZD2516","AstraZeneca","All","20 Years to 45 Years   (Adult)","Phase 1","6","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","D2080C00009","April 2009","null","October 2009","May 5, 2009","null","October 28, 2009","Research Site, Stockholm, Sweden","","https://ClinicalTrials.gov/show/NCT00892944"
775,"NCT01662414","Effect of Undenatured Cysteine-Rich Whey Protein Isolate (HMS 90®) in Patients With Parkinson's Disease",,"Completed","No Results Available","Parkinson Disease|Parkinsonian Disorders|Basal Ganglia Diseases|Brain Diseases|Central Nervous System Diseases|Nervous System Diseases|Movement Disorders|Neurodegenerative Diseases","Dietary Supplement: Whey protein|Dietary Supplement: Soy protein","Biomarkers of oxidative stress, i.e., plasma glutathione (reduced and oxidized forms), urinary 8-hydroxydeoxyguanosine, and urinary total antioxidant status|Concentrationsrofiles of plasma amino acids and their derivatives Brain function by PET-Scan|Unified Parkinson's Disease Rating Scale (UPDRS) Section III (motor) score change from baseline to week 24|Unified Parkinson's Disease Rating Scale (UPDRS) Section II (ADL) score change baseline to week 24|• Clinical Global impression (CGI) - Change scale score, change from baseline to week 24|• Clinical Global impression (CGI) - Severity scale score change from baseline to week 24|• Parkinson's Disease quality of life questionnaire score change from baseline to week 24|Nutrition Questionnaire score change baseline to week 24","Chulalongkorn University","All","30 Years to 80 Years   (Adult, Older Adult)","Phase 4","38","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Supportive Care","53653","April 2011","December 2012","December 2012","August 10, 2012","null","September 30, 2013","Chulalongkorn University Hospital, Pathumwan, Bangkok, Thailand","","https://ClinicalTrials.gov/show/NCT01662414"
776,"NCT00001258","Studies of Frontal Lobe Brain Functioning in Schizophrenia",,"Completed","No Results Available","Healthy|Schizophrenia","","","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years to 90 Years   (Adult, Older Adult)","","1039","NIH","Observational","","900014|90-M-0014","October 26, 1989","null","null","November 4, 1999","null","August 3, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00001258"
777,"NCT01637584","Neurobiology of Sleep and Sleep Treatment Response in Returning Veterans","NOSSTIP","Completed","Has Results","Non PTSD|PTSD","Drug: Prazosin|Drug: Placebo","Whole Brain Relative Regional Cerebral Metabolic Rate of Glucose|Pittsburgh Sleep Quality Index (PSQI):","University of Pittsburgh","All","18 Years to 50 Years   (Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","PRO08050307","April 2010","November 2012","November 2012","July 11, 2012","April 17, 2017","May 23, 2017","Western Psychiatric Institute and Clinic, Pittsburgh, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT01637584"
778,"NCT01800032","PET/MRI in CNS and Extra-CNS Tumors of Patients With Neurofibromatosis-1 (NF1)",,"Active, not recruiting","No Results Available","Neurofibromatosis-1|Optic Glioma|Plexiform Neurofibroma","","Plexiform Neurofibroma Cohort: Difference in FDG-avidity between progressive and non-progressive lesions|Optic Glioma Patients: Compare FDG-avidity between patients with progressive and non-progressive disease|Report descriptive statistics for FDG-PET-MRI results|Explore impact of FDG-PET-MRI surveillance on patient and family caregiver uncertainty and psychological distress","UNC Lineberger Comprehensive Cancer Center","All","6 Years and older   (Child, Adult, Older Adult)","","30","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","LCCC1222","January 16, 2013","December 2018","December 2018","February 27, 2013","null","October 4, 2017","University of North Carolina-Chapel Hill, Chapel Hill, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT01800032"
779,"NCT00524914","Apomorphine Effect on Nociceptive Perception in Parkinson's: a Clinical and Imaging Study","APODOUL","Completed","No Results Available","Parkinson's Disease","Drug: apomorphine|Drug: placebo","The primary outcome of this study is subjective nociceptive threshold using thermotest. We determinate thermal nociceptive threshold using a Peltier- based contact temperature stimulation device with a contact thermode.|Objective nociceptive threshold using the nociceptive flexion reflex (RIII) which can be elicited by a nociceptive electrical stimulation to the sural nerve and recorded in the ipsilateral Biceps Femoris muscle.|Cerebral activity using H215O PET analysis of regional Cerebral Blood Flow (rCBF) on subjects while they received alternate randomized noxious (defined as pain threshold) and innocuous stimuli.","University Hospital, Toulouse","All","30 Years to 70 Years   (Adult, Older Adult)","Not Applicable","16","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","0602308|PHRC 2006","September 2007","January 2008","March 2008","September 5, 2007","null","April 11, 2008","Service de Neurologie, Toulouse, France","","https://ClinicalTrials.gov/show/NCT00524914"
780,"NCT00085865","Serotonin Transporters in Alcoholism",,"Completed","No Results Available","Alcoholism","","","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years to 75 Years   (Adult, Older Adult)","","60","NIH","Observational","","040208|04-M-0208","June 2004","null","July 2006","June 16, 2004","null","March 4, 2008","National Institute of Mental Health (NIMH), Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00085865"
781,"NCT00246870","PET Imaging of GABA Receptors in Succinic Semialdehyde Dehydrogenase Deficiency",,"Completed","No Results Available","Succinic Semialdehyde Dehydrogenase Deficiency|SSADH Deficiency","","","National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)","All","5 Years to 55 Years   (Child, Adult)","","42","NIH","Observational","","060022|06-N-0022","October 24, 2005","null","October 19, 2010","October 31, 2005","null","July 2, 2017","Childrens National Medical Center, Washington, D.C., District of Columbia, United States|National Institute of Neurological Disorders and Stroke (NINDS), 9000 Rockville, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00246870"
782,"NCT02759887","Relationship Between Down Syndrome (DS) and Alzheimer's Disease (AD)",,"Recruiting","No Results Available","Down Syndrome|Alzheimer's Dementia","Procedure: biospecimen collection|Other: cognitive assessments|Other: caregiver questionnaire|Procedure: Florbetapir F18 imaging|Procedure: MRI|Procedure: Fludeoxyglucose F18 (FDG)|Procedure: Tau Pet|Procedure: Actigraphy","Florbetapir PET - change between timeframes|tau PET - change between timeframes|FDG PET - change between timeframes|MRI - change between timeframes|dried blood spot collection (DBSC) analysis - change between timeframes","St. Joseph's Hospital and Medical Center, Phoenix|Banner Alzheimer's Institute, Phoenix|Translational Genomics Research Institute (TGEN), Phoenix","All","21 Years and older   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","PHX-16-0028-70-03","November 2016","March 2019","June 2019","May 3, 2016","null","November 3, 2016","St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States","","https://ClinicalTrials.gov/show/NCT02759887"
783,"NCT01565174","The Pharmaco-genetic and Brain Mechanisms Associated With Cannabis- Induced Psychosis",,"Unknown status","No Results Available","Cannabis Dependence|Psychosis","","Genetic variations of Dopamine, GABA, glutamate, cannabis CB1 receptor|Measures of dopamine D2 receptor occupancy before and after smoking a cigarette containing THC.","Hadassah Medical Organization","Male","18 Years to 26 Years   (Adult)","","100","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","0541-11-HMO-CTIL","October 2012","October 2014","October 2014","March 28, 2012","null","April 3, 2012","Hadassah Medical Organization, Jerusalem, Israel, Jerusalem, Israel","","https://ClinicalTrials.gov/show/NCT01565174"
784,"NCT03019757","Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease",,"Not yet recruiting","No Results Available","Alzheimer's Disease|Lewy Body Dementia|Parkinson's Disease","Radiation: DaTscan|Radiation: F18-AV-45|Radiation: FDG-PET|Genetic: APOE genotype|Procedure: Polysomnogram|Behavioral: Clinical Assessment","Mini Mental State Examination (MMSE-1)|Wechsler Adult Intelligence Scale 4th edition (WAIS-4) Vocabulary|Wechsler Adult Intelligence Scale 4th edition (WAIS-4) Digit Span|Wechsler Adult Intelligence Scale 4th edition (WAIS-4) Block Design|Wechsler Adult Intelligence Scale 4th edition (WAIS-4) Matrix Reasoning|Wechsler Adult Intelligence Scale 4th edition (WAIS-4) Reliable Digits (embedded measure)|Wechsler Memory Scale 3rd ed. (WAIS-3) Spatial Span|Wechsler Memory Scale 3rd ed. (WAIS-3) Logical Memory 1 & 2|Trail Making Test A|Trail Making Test B|Boston Naming Test|Controlled Oral Word Association Test (COWAT)- Animal Naming|Judgment of Line Orientation Standardized Test|Brief Visuospatial Memory Test (BVMT)|California Verbal Learning Test (CVLT-2)|Wisconsin Card Sorting Task|California Verbal Learning Test (CVLT-2) Forced Choice (embedded measure)|Self Administered Gerocognitive Examination- A brief cognitive assessment instrument for mild cognitive impairment and early dementia|Apolipoprotein E (APOE) Genotyping of a whole blood sample|Clinical Dementia Rating Scale (CDR)|The Activities of Daily Living (ADL) Standardized Scale|Mayo Fluctuations Scale|Neuropsychiatric Inventory (NPI)|Beck Depression Inventory 2nd ed.|The Modified Somatic Perception Questionnaire|The Epworth Sleepiness Scale|Mayo Sleep Questionnaire-Informant|Functional Outcomes of Sleep Questionnaire-10|Part III and IV of the Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS)|Berg Balance Scale (BBS)|Florbetapir (F18-AV-45) positron emission tomography (amyloid PET)|Single-photon emission computed tomography (SPECT) with the radioligand [123I]FP-CIT|Positron emission tomography with 2-(18F) fluoro-2-deoxy-d-glucose (FDG-PET)|Brain MRI|Polysomnogram","Douglas Scharre|Avid Radiopharmaceuticals|Mangurian Foundation|Ohio State University","All","18 Years and older   (Adult, Older Adult)","","76","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","2014H0415","August 2018","December 2020","December 2020","January 13, 2017","null","July 20, 2018","The Ohio State University, Columbus, Ohio, United States","","https://ClinicalTrials.gov/show/NCT03019757"
785,"NCT01558687","Cilengitide Imaging Trial in Glioblastoma",,"Terminated","No Results Available","Supratentorial Newly Diagnosed Inoperable Gliobastoma","Drug: Drug (including placebo)|Other: Standard therapy","Rate constant for passive contrast agent plasma/interstitium transfer (ktrans)|Fractional blood plasma volume (vp)|Maximum tumor to brain ratio (TBRmax)|Total tumor volume and enhancing tumor volume|Interstitial space volume fraction (putative contrast agent distribution volume) (=ve)|Apparent Diffusion coefficient (ADC)|Fractional anisotropy (FA)|Kinetic behavior of [18F]FET uptake|Mean spin-lattice relaxation time of unbound protons in water","Merck KGaA","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","1","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","EMR062041-017|2011-003794-29","August 2012","February 2013","February 2013","March 20, 2012","null","February 4, 2014","Merck KGaA Communication Center located in, Darmstadt, Germany","","https://ClinicalTrials.gov/show/NCT01558687"
786,"NCT00199615","Follow-up of Patients With Curative-Intent Surgical Resection for NSCLC",,"Completed","No Results Available","Non-Small Cell Lung Cancer","Procedure: PET","Disease-free survival from the date of operation to the date of recurrence or censured at the date of last follow-up visit or date of the death.|- Overall survival from the date of the operation to the death|- Specificity, sensibility and accuracy of TEP to detect recurrence|- Direct cost of follow-up from the Frenc Healthcare insurance","University Hospital, Limoges","All","18 Years and older   (Adult, Older Adult)","Not Applicable","73","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","I00021","April 2001","null","December 2006","September 20, 2005","null","October 31, 2007","Pathologie Respiratoire, Limoges, France","","https://ClinicalTrials.gov/show/NCT00199615"
787,"NCT00670800","Study of Brain Function in Women With Insulin Resistant Polycystic Ovary Syndrome",,"Completed","Has Results","Polycystic Ovary Syndrome","Drug: Metformin","Mu-opioid Binding Potential Measured in Left Nucleus Accumbens|Mu-opioid Binding Potential Measured in Right Nucleus Accumbens|Mu-opioid Binding Potential Measured in Left Amygdala|Mu-opioid Binding Potential Measured in Right Amygdala","University of Michigan","Female","21 Years to 40 Years   (Adult)","Not Applicable","14","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","2276|HUM00008330","January 2008","August 2009","August 2009","May 2, 2008","May 15, 2014","May 21, 2014","University of Michigan, Michigan Clinical Research Unit, Ann Arbor, Michigan, United States","","https://ClinicalTrials.gov/show/NCT00670800"
788,"NCT02350634","18F-AV-1451 High Resolution Autopsy Study",,"Active, not recruiting","No Results Available","Alzheimer's Disease","Drug: 18F-AV-1451","Relationship of 18F-AV-1451 scan and pathology","Avid Radiopharmaceuticals","All","60 Years to 89 Years   (Adult, Older Adult)","Phase 1","10","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","18F-AV-1451-A13","June 2015","June 2018","June 2018","January 30, 2015","null","May 3, 2018","Banner Alzheimer's Institute, Phoenix, Arizona, United States|University of California, San Francisco, San Francisco, California, United States","","https://ClinicalTrials.gov/show/NCT02350634"
789,"NCT01297114","Imaging of Cognition, Learning, and Memory in Aging",,"Completed","No Results Available","Alzheimer's Disease","Drug: Florbetaben","Cognition as measured with cognitive evaluations","Yaakov Stern|National Institute on Aging (NIA)|Columbia University","All","20 Years to 70 Years   (Adult, Older Adult)","","294","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","AAAB0596|R01AG026158","March 2011","October 1, 2017","October 1, 2017","February 16, 2011","null","November 1, 2017","Columbia University Medical Center, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT01297114"
790,"NCT00032812","The Role of Dopamine in Motor Learning in Healthy Subjects and Patients With Parkinson's Disease",,"Completed","No Results Available","Parkinson Disease|Healthy","Drug: Raclopride","","National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult","","64","NIH","Observational","","020153|02-N-0153","March 2002","null","April 2004","April 3, 2002","null","March 4, 2008","National Institute of Neurological Disorders and Stroke (NINDS), Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00032812"
791,"NCT01772654","Arterial Spin Labeling MRI Focal Abnormalities in Refractory Epilepsy",,"Completed","Has Results","Focal Epilepsy","Device: Arterial Spin Labeled (ASL) MRI sequence","Intensity of the MRI Signal in the Left Temporal Precentral Zone","Mayo Clinic","All","18 Years and older   (Adult, Older Adult)","Not Applicable","73","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","12-006882","January 2013","November 2013","November 2013","January 21, 2013","March 6, 2015","March 6, 2015","Mayo Clinic, Rochester, Minnesota, United States","","https://ClinicalTrials.gov/show/NCT01772654"
792,"NCT03285945","FDG Uptake in Large-Vessel Giant Cell Arteritis After Short-term, High-Dose Steroid Treatment",,"Completed","No Results Available","Giant Cell Arteritis","Drug: PET3|Drug: PET10","Proportion of large vessel-GCA patients with post-therapeutic FDG uptake consistent with a diagnosis of large vessel giant cell arteritis|Change in quantitive uptake values (SUV)|Change in quantitive uptake values (TBR)","University of Aarhus","All","50 Years and older   (Adult, Older Adult)","","24","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","akutPET","October 2014","September 2016","September 2016","September 18, 2017","null","September 18, 2017","Department of Rheumatology, Aarhus, Denmark","","https://ClinicalTrials.gov/show/NCT03285945"
793,"NCT00713414","Role of Neurotransmission and Functional CNS Networks in Spasmodic Dysphonia",,"Completed","No Results Available","Spasmodic Dysphonia|Focal Dystonia","","Identify GABAergic and dopaminergic transmission in patients with spasmodic dysphonia and healthy subjects|Determine the functional brain networks during speech and at rest in patients with spasmodic dysphonia compared to healthy subjects.","National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)","All","21 Years to 80 Years   (Adult, Older Adult)","","37","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","080181|08-N-0181","July 9, 2008","null","September 21, 2016","July 11, 2008","null","July 4, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00713414"
794,"NCT00011752","Serotonin in Alcoholism",,"Completed","No Results Available","Alcoholism|Healthy","Drug: FCWAY","","National Institute on Alcohol Abuse and Alcoholism (NIAAA)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult","","75","NIH","Observational","","010090|01-AA-0090","February 2001","null","September 2005","March 1, 2001","null","March 4, 2008","National Institute on Alcohol Abuse and Alcoholism (NIAAA), Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00011752"
795,"NCT00033787","Serotonin Function During Depression",,"Completed","No Results Available","Depression, Involutional|Healthy","","","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years to 60 Years   (Adult)","","450","NIH","Observational","","020162|02-M-0162","April 5, 2002","April 30, 2005","April 30, 2005","April 10, 2002","null","July 2, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00033787"
796,"NCT00088517","Positron Emission Tomography Imaging of Dopamine Receptors Using the Tracer [11C]NNC-112",,"Completed","No Results Available","Healthy","Drug: [11C]NNC-112","","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult","Phase 1","10","NIH","Interventional","Primary Purpose: Treatment","040170|04-M-0170","July 2004","null","March 2006","July 28, 2004","null","March 4, 2008","National Institute of Mental Health (NIMH), Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00088517"
797,"NCT00624728","Assessment of 18FLT PET-CT for Volume Definition of High-grade Gliomas (GLIO-TEP)","GLIO-TEP","Completed","No Results Available","High-grade Glioma|Astrocytoma|Glioblastoma","Radiation: 18F Fluorothymidine PET CT","Predictive positive value of PET uptake for detection of malignant tissue (defined with Ki-67 proliferation index >15% in PET+ volumes)|Comparison of volumes defined by PET and MRI|Description of a quantitative PET proliferation index (""standardized uptake value"")","University Hospital, Bordeaux","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","21","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","9420-04|2004-033","February 2008","November 2011","November 2011","February 27, 2008","null","May 4, 2012","Hôpital St André, CHU de Bordeaux, Bordeaux, France|Hôpital Pellegrin-tripode , CHU de Bordeaux, Bordeaux, France","","https://ClinicalTrials.gov/show/NCT00624728"
798,"NCT02964741","Investigation and Modulation of the Mu-Opioid Mechanisms in Migraine (in Vivo)",,"Recruiting","No Results Available","Migraine","Device: Active Comparator|Device: Sham Comparator","Change in pain intensity level measured by the Visual Analog Scale in migraineurs (active or sham)|Change in mu-opioid receptor non-displaceable binding potential (BPND) in the brains of migraineurs during sustained thermal pain threshold stress challenge subsequent to treatment by HD-tDCS (active or sham).|Change in mu-opioid receptor non-displaceable binding potential (BPND) in the brains of migraineurs at rest subsequent to treatment by HD-tDCS (active or sham).","University of Michigan|National Institute of Neurological Disorders and Stroke (NINDS)","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","90","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HUM00107286|R01NS094413","February 22, 2017","April 2020","June 2020","November 16, 2016","null","August 14, 2018","University of Michigan School of Dentistry, Ann Arbor, Michigan, United States","","https://ClinicalTrials.gov/show/NCT02964741"
799,"NCT00923117","Sunitinib to Treat Recurrent Brain Cancer",,"Terminated","Has Results","Glioblastoma Multiforme|Malignant Gliomas|Anaplastic Gliomas","Drug: Sutent (sunitinib)","6-month Progression-free Survival.|Number of Participants With Adverse Events","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)","Phase 2","87","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","080168|08-C-0168","June 2008","June 2012","June 2012","June 18, 2009","June 25, 2013","September 30, 2015","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00923117"
800,"NCT00106899","ADNI: Alzheimer's Disease Neuroimaging Initiative",,"Completed","No Results Available","Alzheimer's Disease","Procedure: Magnetic Resonance Imaging (MRI)|Procedure: Positron Emission Tomography (PET)|Procedure: Lumbar Puncture (LP)","","Alzheimer's Disease Cooperative Study (ADCS)|Northern California Institute of Research and Education|National Institute on Aging (NIA)|National Institute for Biomedical Imaging and Bioengineering (NIBIB)|Foundation for the National Institutes of Health|Alzheimer’s Drug Discovery Foundation|Alzheimer's Association","All","55 Years to 90 Years   (Adult, Older Adult)","","818","Other|NIH","Observational","Observational Model: Case Control|Time Perspective: Prospective","IA0068|1RC2AG036535|1U01AG024904","July 2005","June 2011","June 2011","April 1, 2005","null","September 16, 2014","University of Alabama, Birmingham, Alabama, United States|Banner Good Samaritan Medical Center, Phoenix, Arizona, United States|Sun Health / Arizona Consortium, Sun City, Arizona, United States|University of California, Irvine, Irvine, California, United States|University of California, Irvine - Brain Imaging Center, Irvine, California, United States|University of California, San Diego, La Jolla, California, United States|University of Southern California, Los Angeles, California, United States|University of California, Los Angeles, Los Angeles, California, United States|University of California, Davis, Sacramento, California, United States|University of California, San Francisco, San Francisco, California, United States|Stanford University, Stanford, California, United States|Olin Neuropsychiatry Research Center, Hartford, Connecticut, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Georgetown University, Washington, District of Columbia, United States|Howard University, Washington, District of Columbia, United States|Mayo Clinic, Jacksonville, Jacksonville, Florida, United States|Wein Center, Miami, Florida, United States|Byrd Alzheimer's Institute, Tampa, Florida, United States|Premiere Neurological Group, West Palm Beach, Florida, United States|Emory University, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Rush University Medical Center/Presbyterian St. Luke's Medical Center, Chicago, Illinois, United States|Indiana University, Indianapolis, Indiana, United States|University of Kansas, Kansas City, Kansas, United States|University of Kentucky, Lexington, Kentucky, United States|Johns Hopkins University, Baltimore, Maryland, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Boston University Schools of Medicine and Public Health, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Mayo Clinic, Rochester, Rochester, Minnesota, United States|Washington University, St. Louis, Missouri, United States|University of Nevada School of Medicine, Las Vegas, Nevada, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Albany Medical College, Albany, New York, United States|Dent Neurological Institute, Amherst, New York, United States|New York University, New York, New York, United States|Mount Sinai School of Medicine, New York, New York, United States|Columbia University, New York, New York, United States|Dent Neurological Institute, Orchard Park, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|Neurological Care of CNY, Syracuse, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Wake Forest University, Winston Salem, North Carolina, United States|Case Western Reserve University, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Jefferson University, Philadelphia, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Medical University of South Carolina, North Charleston, South Carolina, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|University of Wisconsin, Madison, Wisconsin, United States|University of British Columbia, Vancouver, British Columbia, Canada|Parkwood Hospital, London, Ontario, Canada|Saint Joseph's Hospital, London, Ontario, Canada|Sunnybrook and Women's College, Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada|Jewish Hospital Memory Clinic, Quebec, Montreal, Quebec, Canada","","https://ClinicalTrials.gov/show/NCT00106899"
801,"NCT00033995","Study of Tics in Patients With Tourette's Syndrome and Chronic Motor Tic Disorder",,"Completed","No Results Available","Tourette Syndrome|Tic Disorders","","","National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)","All","18 Years to 65 Years   (Adult, Older Adult)","","46","NIH","Observational","","020175|02-N-0175","April 17, 2002","null","February 17, 2009","April 19, 2002","null","July 2, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00033995"
802,"NCT03215563","PET-MRI Imaging in Patients With Acute Neurovascular Syndrome",,"Recruiting","No Results Available","Stroke|Carotid Stenosis","Radiation: 18F PET-MRI|Diagnostic Test: Transcranial Doppler","18F-fluoride uptake in the culprit plaque in carotid, aortic and intra-cranial vessels.","University of Edinburgh","All","40 Years and older   (Adult, Older Adult)","","80","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","AC17058","October 12, 2017","August 1, 2019","August 1, 2019","July 12, 2017","null","August 14, 2018","Centre for Cardiovascular Science, Edinburgh, United Kingdom","","https://ClinicalTrials.gov/show/NCT03215563"
803,"NCT02702102","Imaging Inflammation in Patients With Parkinson's Disease Dementia or Dementia With Lewy Bodies",,"Active, not recruiting","No Results Available","Diffuse Lewy Body Disease|Dementia With Lewy Bodies|Parkinson's Disease Dementia","Drug: 11C-PBR28","Absolute 11C-PBR28 binding (total distribution volume corrected for free fraction in plasma)|Relative 11C-PBR28 binding","William Charles Kreisl|National Institute on Aging (NIA)|Columbia University","All","60 Years and older   (Adult, Older Adult)","Phase 2","16","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","AAAQ0756|2P50AG008702-26","December 2015","August 2018","August 2018","March 8, 2016","null","December 13, 2017","Columbia University Medical Center, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT02702102"
804,"NCT02696993","Trial of Nivolumab With Radiation or Nivolumab and Ipilimumab With Radiation for the Treatment of Intracranial Metastases From Non-Small Cell Lung Cancer",,"Recruiting","No Results Available","Metastatic Brain Cancer","Drug: Nivolumab|Drug: Ipilimumab|Radiation: Stereotactic Radiosurgery (SRS)|Radiation: Whole Brain Radiation Therapy (WBRT)|Behavioral: Neurocognitive Exam","Recommended Phase 2 Dose (RP2D) of Nivolumab in Combination with Stereotactic Radiosurgery (SRS)|Recommended Phase 2 Dose (RP2D) of Nivolumab in Combination with Whole Brain Radiation Therapy (WBRT)|Recommended Phase 2 Dose (RP2D) of Nivolumab in Combination with Ipilimumab and Stereotactic Radiosurgery (SRS)|Recommended Phase 2 Dose (RP2D) of Nivolumab in Combination with Ipilimumab and Whole Brain Radiation Therapy (WBRT)|Intracranial Progression Free Survival|Neurocognitive Changes","M.D. Anderson Cancer Center|Bristol-Myers Squibb","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","80","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2015-0883|NCI-2016-00661","December 2016","December 2020","December 2020","March 2, 2016","null","May 31, 2018","University of Texas MD Anderson Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT02696993"
805,"NCT02711215","Patient Stratification and Treatment Response Prediction in Neuropharmacotherapy Using Hybrid Positron Emmission Tomography/Magnetic Resconance Imaging (PET/MR)",,"Recruiting","No Results Available","Major Depressive Disorder","Diagnostic Test: PET/MR [11C]DASB|Drug: Citalopram|Drug: Escitalopram (Mirtazapine/Duloxetine/Venlafaxine)|Drug: Placebo","Hamilton Depression Scale (HDRS)","Medical University of Vienna","All","18 Years to 55 Years   (Adult)","Phase 4","80","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","1.6_20180316","May 2015","March 2019","March 2019","March 17, 2016","null","April 2, 2018","Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria","","https://ClinicalTrials.gov/show/NCT02711215"
806,"NCT03353207","Striatal Dopamine Transmission in Individuals With Isolated Rapid Eye Movement Sleep With Atonia: a Search for Precursor Biomarker for Neurodegeneration",,"Recruiting","No Results Available","REM Sleep Behavior Disorder|Neurodegenerative Diseases","","Dopamine neurotransmission|REMREEA","Chinese University of Hong Kong","All","45 Years to 65 Years   (Adult, Older Adult)","","66","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","HMRF04153036","October 30, 2017","January 1, 2019","September 30, 2019","November 27, 2017","null","November 28, 2017","Shatin Hospital, Shatin, Hong Kong","","https://ClinicalTrials.gov/show/NCT03353207"
807,"NCT02689466","Cholinergic Receptor Imaging in Dystonia",,"Recruiting","No Results Available","Cervical Dystonia|Dystonia|Movement Disorder|Focal Dystonia","","Characterize the M2 muscarinic acetycholine receptor binding in cervical dystonia patients as measured with high-resolution positron emission tomography (PET) using [18F]FP-TZTP","National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)","","54","NIH","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","160064|16-N-0064","February 20, 2016","October 1, 2018","October 1, 2018","February 24, 2016","null","August 2, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT02689466"
808,"NCT02831283","Imaging Inflammation in Alzheimer's Disease",,"Enrolling by invitation","No Results Available","Alzheimer's Disease","Drug: 11C-PBR28|Drug: 18F-Florbetaben|Procedure: Lumbar puncture (optional)","11C-PBR28 binding (standardized uptake value ratio)|18F-Florbetaben binding (standardized uptake value ratio)|Cerebral spinal fluid (CSF) biomarkers","William Charles Kreisl|National Institute on Aging (NIA)|Columbia University","All","60 Years and older   (Adult, Older Adult)","Phase 2","100","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","AAAO1151|1K23AG052633-01","June 2016","June 2021","June 2021","July 13, 2016","null","January 10, 2018","Columbia University Medical Center, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT02831283"
809,"NCT01898273","Imaging Trial With I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma",,"Terminated","No Results Available","Glioblastoma","Drug: I-124-CLR1404","Optimal Imaging Parameters - Dose|Optimal Imaging Parameters - Imaging Time Point","Cellectar Biosciences, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","7","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","DCL-13-002","February 2014","September 2015","December 2015","July 12, 2013","null","September 9, 2015","City of Hope, Duarte, California, United States|Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|University of Maryland School of Medicine, Baltimore, Maryland, United States|Cleveland Clinic, Cleveland, Ohio, United States|Ohio State University Medical Center, Columbus, Ohio, United States|Kettering Medical Center, Kettering, Ohio, United States|Hospital of University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Wisconsin, Madison, Wisconsin, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States","","https://ClinicalTrials.gov/show/NCT01898273"
810,"NCT00302146","Positron Emission Tomography (PET) Imaging in People With Gaucher Mutations",,"Completed","No Results Available","Glucocerebrosidase Mutations|Gaucher Disease","","","National Human Genome Research Institute (NHGRI)|National Institutes of Health Clinical Center (CC)","All","21 Years and older   (Adult, Older Adult)","","64","NIH","Observational","","060055|06-HG-0055","March 10, 2006","null","null","March 13, 2006","null","July 10, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00302146"
811,"NCT02175745","18F-FDOPA PET/CT or PET/MRI in Measuring Tumors in Patients With Newly-Diagnosed or Recurrent Gliomas",,"Terminated","Has Results","Adult Anaplastic Ependymoma|Adult Anaplastic Oligodendroglioma|Adult Brain Stem Glioma|Adult Diffuse Astrocytoma|Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Adult Mixed Glioma|Adult Oligodendroglioma|Adult Pilocytic Astrocytoma|Adult Pineal Gland Astrocytoma|Adult Subependymal Giant Cell Astrocytoma|Childhood High-grade Cerebellar Astrocytoma|Childhood High-grade Cerebral Astrocytoma|Childhood Low-grade Cerebellar Astrocytoma|Childhood Low-grade Cerebral Astrocytoma|Recurrent Adult Brain Tumor|Recurrent Childhood Anaplastic Astrocytoma|Recurrent Childhood Anaplastic Oligoastrocytoma|Recurrent Childhood Anaplastic Oligodendroglioma|Recurrent Childhood Brain Stem Glioma|Recurrent Childhood Cerebellar Astrocytoma|Recurrent Childhood Cerebral Astrocytoma|Recurrent Childhood Diffuse Astrocytoma|Recurrent Childhood Fibrillary Astrocytoma|Recurrent Childhood Gemistocytic Astrocytoma|Recurrent Childhood Giant Cell Glioblastoma|Recurrent Childhood Glioblastoma|Recurrent Childhood Gliomatosis Cerebri|Recurrent Childhood Gliosarcoma|Recurrent Childhood Oligoastrocytoma|Recurrent Childhood Oligodendroglioma|Recurrent Childhood Pilomyxoid Astrocytoma|Recurrent Childhood Protoplasmic Astrocytoma|Recurrent Childhood Subependymal Giant Cell Astrocytoma|Recurrent Childhood Visual Pathway and Hypothalamic Glioma|Recurrent Childhood Visual Pathway Glioma|Untreated Childhood Anaplastic Astrocytoma|Untreated Childhood Anaplastic Oligoastrocytoma|Untreated Childhood Anaplastic Oligodendroglioma|Untreated Childhood Brain Stem Glioma|Untreated Childhood Cerebellar Astrocytoma|Untreated Childhood Cerebral Astrocytoma|Untreated Childhood Diffuse Astrocytoma|Untreated Childhood Fibrillary Astrocytoma|Untreated Childhood Gemistocytic Astrocytoma|Untreated Childhood Giant Cell Glioblastoma|Untreated Childhood Glioblastoma|Untreated Childhood Gliomatosis Cerebri|Untreated Childhood Gliosarcoma|Untreated Childhood Oligoastrocytoma|Untreated Childhood Oligodendroglioma|Untreated Childhood Pilomyxoid Astrocytoma|Untreated Childhood Protoplasmic Astrocytoma|Untreated Childhood Subependymal Giant Cell Astrocytoma|Untreated Childhood Visual Pathway and Hypothalamic Glioma|Untreated Childhood Visual Pathway Glioma","Drug: 18F-fluoro-dihydroxyphenylalanine|Procedure: Positron emission tomography (PET)|Procedure: Computed tomography (CT)|Procedure: Magnetic resonance imaging","Number of Suspicious Lesions Identified by 18F FDOPA PET|Percent Agreement of 18F FDOPA PET With Pathology","Erik Mittra|National Cancer Institute (NCI)|Stanford University","All","16 Years and older   (Child, Adult, Older Adult)","Not Applicable","2","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","IRB-29364|NCI-2014-01289|BRN0024|P30CA124435","December 2014","August 2015","December 2015","June 26, 2014","March 20, 2017","March 20, 2017","Stanford University Hospitals and Clinics, Stanford, California, United States","","https://ClinicalTrials.gov/show/NCT02175745"
812,"NCT00620191","Metformin in Amnestic Mild Cognitive Impairment","MCI","Completed","No Results Available","Amnestic Mild Cognitive Impairment","Drug: metformin|Drug: placebo","Total Recall in the Selective Reminding Test|ADAS-cog|rCMRgl in the posterior cingulate-precuneus.","Columbia University|Institute for the Study of Aging (ISOA)|National Institute on Aging (NIA)","All","55 Years to 90 Years   (Adult, Older Adult)","Phase 2","80","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","AAAC7231|R0153596","February 2008","February 2012","February 2012","February 21, 2008","null","March 14, 2013","Columbia University Medical Center, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT00620191"
813,"NCT00931619","GABA/Glutamate Balance in Temporal Lobe Epilepsy With and Without Major Depression",,"Completed","No Results Available","Epilepsy|Epilepsy, Temporal Lobe|Depression|Depressive Disorder, Major","","The primary outcome measures will include GABA(A) binding potential and regional glucose metabolic rate as measured by PET, and GABA and glutamate levels as measured by MRS.|Secondary outcome measures will include brain structure on MRI, blood oxygenation level dependent contrast in functional resting state scans, genetic data, and scores on depression rating scales.","National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)","All","18 Years to 55 Years   (Adult)","","29","NIH","Observational","Time Perspective: Prospective","090182|09-N-0182","June 29, 2009","null","April 2, 2013","July 2, 2009","null","August 15, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00931619"
814,"NCT02813434","Cerebral Amyloid Imaging Using Florbetapir (AV-45)","IDEA3","Recruiting","No Results Available","Dementia|Cognition Disorders","Biological: florbetapir","presence of positive amyloid retention|Final diagnosis","Centre Hospitalier Universitaire, Amiens","All","40 Years to 80 Years   (Adult, Older Adult)","Phase 3","100","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","PI2013_843_0011","September 2014","September 2022","September 2022","June 27, 2016","null","August 3, 2018","CHU Amiens, Amiens, France","","https://ClinicalTrials.gov/show/NCT02813434"
815,"NCT00009035","Natural History of Patients With Brain and Spinal Cord Tumors",,"Active, not recruiting","No Results Available","Astrocytoma|Oligodendroglioma|Glioblastoma|Glioma|Anaplastic Glioma","","To evaluate patients with tumors of the central nervous system (CNS) who are probable future candidates for NCI Phase I and II protocols.","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","1 Year to 100 Years   (Child, Adult, Older Adult)","","3050","NIH","Observational","Observational Model: Case-Only|Time Perspective: Prospective","010070|01-C-0070","January 22, 2001","null","null","January 24, 2001","null","August 9, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00009035"
816,"NCT00633763","PET-CT Scan Method to Monitor Pancreatic B-Cell Loss in Diabetes Mellitus",,"Completed","No Results Available","Type1 Diabetes Mellitus","Drug: 18F-fallypride","Difference in fallypride binding in the pancreas of long-standing T1DM patients versus healthy controls","University of California, Irvine|Juvenile Diabetes Research Foundation","All","18 Years and older   (Adult, Older Adult)","","30","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","2007-5785","February 2008","July 2008","July 2008","March 12, 2008","null","May 29, 2009","University of California Irvine Medical Center, Orange, California, United States","","https://ClinicalTrials.gov/show/NCT00633763"
817,"NCT02092883","Evaluation of Neuroinflammation in Children With Infantile Spasms",,"Completed","No Results Available","Infantile Spasms","Drug: ACTH","Neuroinflammation in cortical and/or subcortical structures","Wayne State University","All","Child, Adult, Older Adult","Phase 4","8","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","25QNC","March 2013","July 2016","July 2017","March 20, 2014","null","November 7, 2017","Children's Hospital of Michigan, Detroit, Michigan, United States","","https://ClinicalTrials.gov/show/NCT02092883"
818,"NCT01039090","Efficacy of Continuous Apomorphine Infusion on Cognitive and Neuropsychological Functions in Parkinson's Disease","APO-TEP","Unknown status","No Results Available","Parkinsons's Disease","Drug: Continuous Apomorphine infusion|Drug: Usual dopaminergic per os treatment","Neuropsychological results: Montgomery-Åsberg Depression Rating Scale (MADRS), The Lille Apathy Rating Scale (LARS), Spielberger","Rennes University Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 3","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2008-006045-10|LOC/08-08","February 2009","February 2014","August 2014","December 24, 2009","null","December 3, 2012","Rennes University Hospital, Rennes, France","","https://ClinicalTrials.gov/show/NCT01039090"
819,"NCT00102102","Role of Substance P in Post-Traumatic Stress Disorder",,"Completed","No Results Available","Post-Traumatic Stress Disorder","Drug: [18F]SPA-RQ","","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult","","40","NIH","Observational","","050080|05-M-0080","January 2005","null","January 2006","January 21, 2005","null","March 4, 2008","National Institute of Mental Health (NIMH), Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00102102"
820,"NCT00585741","Pilot Study of 18F-FLT PET",,"Terminated","No Results Available","CNS Brain Metastasis|Head and Neck Cancer|Lung Cancer|Prostate Cancer|Esophageal Cancer","Procedure: Imaging with 18F-FLT PET","To test whether the cellular response to fractionated radiotherapy leads to observable global change in the uptake of 18F-FLT as assessed by PET imaging|To assess the technical and logistic feasibility of 18F-FLT scans in a population of cancer patients","University of Wisconsin, Madison","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","15","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HSC-2006-0280","December 2006","December 2011","December 2011","January 3, 2008","null","February 23, 2012","University of Wisconsin Hospital and clinis, Madison, Wisconsin, United States","","https://ClinicalTrials.gov/show/NCT00585741"
821,"NCT02488720","Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study","LEARN","Active, not recruiting","No Results Available","Cognition Disorders","","Change from Baseline of the ADCS Preclinical Alzheimer Cognitive Composite (ADCS-PACC) to Week 168|Change from Baseline in Cognitive Function Index (CFI) to Week 168|Change from Baseline in Mean Composite Summary Uptake Value Ratio (SUVr) to Week 168|Change from Baseline in Cerebral Spinal Fluid (CSF) Tau Biomarkers to Week 168|Change from Baseline of Cerebrospinal Fluid (CSF) Concentrations of Amyloid Beta (Abeta) to Week 168|Change from Baseline of Volumetric Magnetic Resonance Imaging (vMRI) to Week 168","University of Southern California|Alzheimer's Association|National Institute on Aging (NIA)|Alzheimer's Therapeutic Research Institute","All","65 Years to 85 Years   (Older Adult)","","500","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","ADC-051|U19AG010483|15-338729","June 2015","June 2019","June 2019","July 2, 2015","null","January 9, 2018","University of Alabama, Birmingham, Birmingham, Alabama, United States|Banner Alzheimer's Institute, Phoenix, Arizona, United States|Banner Sun Health Research Institute, Sun City, Arizona, United States|University of California, Irvine, Irvine, California, United States|University of Southern California, Los Angeles, California, United States|University of California, Los Angeles, Los Angeles, California, United States|University of California, Irvine - Neuropsychiatric Center, Orange, California, United States|VA Palo Alto HSC / Stanford School of Medicine, Palo Alto, California, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Georgetown University, Washington, District of Columbia, United States|Howard University, Washington, District of Columbia, United States|Mayo Clinic, Jacksonville, Jacksonville, Florida, United States|Wien Center for Clinical Research, Miami Beach, Florida, United States|Bioclinica Research Orlando, Orlando, Florida, United States|University of South Florida - Health Byrd Alzheimer Institute, Tampa, Florida, United States|Bioclinica Research North, The Villages, Florida, United States|Emory University, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Iowa, Iowa City, Iowa, United States|University of Kansas, Fairway, Kansas, United States|University of Kentucky, Lexington, Kentucky, United States|Johns Hopkins University, Baltimore, Maryland, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Boston University, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Ann Arbor, Michigan, United States|Mayo Clinic, Rochester, Rochester, Minnesota, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, Nevada, United States|Dent Neurologic Institute, Amherst, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Case Western Reserve University, Beachwood, Ohio, United States|Tulsa Clinical Research, Tulsa, Oklahoma, United States|Oregon Health & Science University, Portland, Oregon, United States|Drexel University College of Medicine, Philadelphia, Pennsylvania, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Butler Hospital Memory and Aging Program, Providence, Rhode Island, United States|Roper St. Francis Healthcare, Charleston, South Carolina, United States|University of Wisconsin, Madison, Wisconsin, United States","","https://ClinicalTrials.gov/show/NCT02488720"
822,"NCT01144988","Avastin / Irinotecan in Patients With Recurrent or Progressive Malignant Glioma","AVIRMA01-09","Unknown status","No Results Available","Recurrent Malignant Glioma","Drug: Bevacizumab / Irinotecan","To determine the objective tumor response criteria (RR, ORR, ORD) assessed by Standard MRI and FET-/FLT-PET during Avastin / Irinotecan chemotherapy.|Evaluation of the predictive / prognostic value of the VEGF pathway and tumor cell proliferation rate in tumor and vascular cells of malignant gliomas treated with Avastin / Irinotecan Chemotherapy","Medical University Innsbruck|Roche, Austria","All","18 Years and older   (Adult, Older Adult)","Phase 2","35","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","EUDRACT-Nr: 2009-015036-15","March 2010","March 2013","March 2013","June 16, 2010","null","August 2, 2011","Medical University Innsbruck, Department for Neurology, Innsbruck, Austria|Paracelsus Medical University, Christian Doppler Klinik, Salzburg, Austria","","https://ClinicalTrials.gov/show/NCT01144988"
823,"NCT00040196","How the Loss of Dopamine and Dopamine-Restoring Medicines Affect Movement Performance",,"Completed","No Results Available","Parkinson Disease","","","National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)","All","21 Years and older   (Adult, Older Adult)","","133","NIH","Observational","","020216|02-N-0216","June 19, 2002","July 9, 2009","July 9, 2009","June 24, 2002","null","July 2, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00040196"
824,"NCT03103750","Vitamin D as a Therapeutic Adjunct in the Stimulant Treatment of ADHD",,"Recruiting","No Results Available","ADHD","Procedure: Magnetic Resonance Imaging (MRI)|Drug: Raclopride|Dietary Supplement: calcitriol|Drug: Placebo oral capsule|Procedure: high-resolution research tomography|Drug: Dextro Amphetamine","non-displaceable tracer binding potentials|continuous Performance Task (CPT-AX)","Yale University|Brain & Behavior Research Foundation","All","18 Years to 50 Years   (Adult)","Phase 1|Phase 2","24","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","1612018712|M# 25288","August 15, 2017","January 2022","January 2022","April 6, 2017","null","July 4, 2018","Connecticut Mental Health Center, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT03103750"
825,"NCT02073968","PET-Adjusted Intensity Modulated Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage II-IV Non-small Cell Lung Cancer","PAINT","Active, not recruiting","No Results Available","Metastatic Malignant Neoplasm in the Brain|Recurrent Non-Small Cell Lung Carcinoma|Stage IIA Non-Small Cell Lung Carcinoma|Stage IIB Non-Small Cell Lung Carcinoma|Stage IIIA Non-Small Cell Lung Cancer|Stage IIIB Non-Small Cell Lung Cancer|Stage IV Non-Small Cell Lung Cancer","Drug: Carboplatin|Procedure: Computed Tomography|Radiation: Intensity-Modulated Radiation Therapy|Drug: Paclitaxel|Procedure: Positron Emission Tomography|Radiation: Proton Beam Radiation Therapy","Metabolic response of all pulmonary lesions and thoracic lymph nodes, defined as having maximum SUV less than 6.0 on post-treatment PET/CT|Incidence of grade >= 2 radiation-induced lung toxicity, scored using Common Terminology Criteria for Adverse Events (CTCAE), version (v.) 4|Incidence of grade >= 3 treatment-related toxicity, scored using CTCAE, v. 4|Locoregional progression-free survival assessed using the Response Evaluation Criteria in Solid Tumors (RECIST) criteria|Lung cancer cause-specific survival|Overall survival|Progression-free survival assessed using the RECIST criteria","Albert Einstein College of Medicine, Inc.|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","39","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2013-252|NCI-2014-00216|P30CA013330","July 2013","December 2017","May 2021","February 28, 2014","null","May 28, 2018","Albert Einstein College of Medicine, Bronx, New York, United States|Montefiore Medical Center - Moses Campus, Bronx, New York, United States","","https://ClinicalTrials.gov/show/NCT02073968"
826,"NCT01677572","Multiple Dose Study of Aducanumab (BIIB037) (Recombinant, Fully Human Anti-Aβ IgG1 mAb) in Participants With Prodromal or Mild Alzheimer's Disease",,"Active, not recruiting","No Results Available","Alzheimer's Disease","Drug: Aducanumab (recombinant, fully human anti-Aβ IgG1 mAb)|Drug: Placebo","Number of Participants with Adverse Events|Change from baseline in florbetapir-fluorine-18 (18F-AV-45F-AV-45) positron emission tomography (PET) imaging in certain brain areas.|Multiple dose pharmacokinetic (PK) serum concentrations of Aducanumab|Change from Baseline in Incidence of Anti-Aducanumab Antibodies in Serum.","Biogen","All","50 Years to 90 Years   (Adult, Older Adult)","Phase 1","197","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","221AD103|2012-000349-10","October 5, 2012","October 21, 2019","October 21, 2019","September 3, 2012","null","June 26, 2018","NNS Clinical Research, LLC, Tucson, Arizona, United States|Senior Clinical Trials, Inc., Laguna Hills, California, United States|Torrance Clinical Research Institute, Inc., Lomita, California, United States|Collaborative Neuroscience Network, LLC, Long Beach, California, United States|University of California, Los Angeles, Los Angeles, California, United States|Pacific Neuroscience Medical Group, Oxnard, California, United States|Pacific Research Network, Inc., San Diego, California, United States|San Francisco Clinical Research Center, San Francisco, California, United States|Stanford University Medical Center, Stanford, California, United States|Alzheimer's Disease Research Unit, Yale University, New Haven, Connecticut, United States|Georgetown University Hospital, Washington, District of Columbia, United States|Brain Matters Research, Inc., Delray Beach, Florida, United States|Neuropsychiatric Research Center of Southwest Florida, Fort Myers, Florida, United States|MD Clinical Trials, Inc., Hallandale Beach, Florida, United States|Galiz Research, LLC, Miami Springs, Florida, United States|Miami Jewish Health Systems, Miami, Florida, United States|Compass Research, LLC, Orlando, Florida, United States|Infinity Clinical Research, Inc., Sunrise, Florida, United States|Axiom Clinical Research of Florida, Tampa, Florida, United States|Stedman Clinical Trials, LLC, Tampa, Florida, United States|Neurostudies.net, LLC, Decatur, Georgia, United States|Alexian Brothers Neurosciences Institute, Elk Grove Village, Illinois, United States|Indiana University School of Medicine, Indianapolis, Indiana, United States|St. Louis Clinical Trials, LLC, Saint Louis, Missouri, United States|Memory Enhancement Center of America, Inc., Eatontown, New Jersey, United States|CRI Lifetree, Marlton, New Jersey, United States|Advanced Memory Research Institute of NJ, Toms River, New Jersey, United States|Empire Neurology, PC, Latham, New York, United States|Insight Clinical Trials LLC, Beachwood, Ohio, United States|Summit Research Network (Oregon) Inc., Portland, Oregon, United States|Brown Hospital, East Providence, Rhode Island, United States|Rhode Island Hospital, Providence, Rhode Island, United States","","https://ClinicalTrials.gov/show/NCT01677572"
827,"NCT02008292","Acetylcholine, Tobacco Smoking, Genes and Nicotinic Receptors","nic_physo","Recruiting","No Results Available","Smoking|Schizophrenia","Drug: Physostigmine","Change in ACh levels at baseline and after physostigmine administration as confirmed by PET images.|Change in DA levels at baseline and after amphetamine administration as confirmed by PET images.","Yale University|National Institutes of Health (NIH)|National Institute on Drug Abuse (NIDA)","All","18 Years to 60 Years   (Adult)","Not Applicable","130","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","1210010989|2R01DA015577-05","September 2013","September 2018","September 2018","December 11, 2013","null","January 9, 2018","Connecticut Mental Health Center, New Haven, Connecticut, United States|Yale Magnetic Resonance Research Center, New Haven, Connecticut, United States|Yale PET Center, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT02008292"
828,"NCT00888056","Chronic Electrical Stimulation of Hypothalamus/Fornix in Alzheimer's Disease",,"Unknown status","No Results Available","Alzheimer's Disease","Procedure: Bilateral chronic electrical stimulation of the hypothalamus/fornix","Evaluation criteria for feasibility will be the proportion of patients undergoing the procedure, chronic stimulation and evaluation process without adverse event.|Efficacy will be evaluated using numerous cognitive and memory testing. Neuro-imaging changes after stimulation will be evaluate by morphological MRI and functional imaging (PET). Changes in behavioral and mood scales: evaluate safety","Centre Hospitalier Universitaire de Nice","All","50 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","5","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","09-PP-01","June 2009","null","null","April 24, 2009","null","June 27, 2012","CHU de Nice - 4 avenue Reine Victoria - Hôpital de Cimiez, Nice, Alpes-Maritimes, France","","https://ClinicalTrials.gov/show/NCT00888056"
829,"NCT02152670","Understanding Dopamine Mechanisms in Cocaine Addiction Using AMPT and Methylphenidate With [11C]RAC/[11C]PHNO PET",,"Recruiting","No Results Available","Cocaine Dependence","Drug: Methylphenidate|Drug: Alpha Methyl Para Tyrosine (AMPT)|Other: [11C]PHNO|Other: [11C]raclopride","BPND","Yale University","All","18 Years to 50 Years   (Adult)","Not Applicable","48","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Other","1403013567","May 2014","May 2021","May 2021","June 2, 2014","null","July 6, 2018","Connecticut Mental Health Center, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT02152670"
830,"NCT00418288","The Effect of GLP-1 on Glucose Uptake in the Brain and Heart in Healthy Men During Hypoglycemia",,"Completed","No Results Available","Type 2 Diabetes|Stroke|Myocardial Infarction","Drug: glucagon-like-peptide-1|Drug: placebo","The acute effect of GLP-1 on glucose uptake in the brain|The acute effect of GLP-1 on glucose uptake in the heart|The acute effect of GLP-1 on glucose metabolic rate in the brain|The acute effect of GLP-1 on intracerebral glucose concentration|The acute effect of GLP-1 on lumped constant in the brain","University of Aarhus","Male","20 Years to 50 Years   (Adult)","Not Applicable","10","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2005-0089","January 2007","October 2007","February 2008","January 4, 2007","null","June 10, 2008","Department of pharmacology, Aarhus university, Aarhus, Denmark","","https://ClinicalTrials.gov/show/NCT00418288"
831,"NCT02309567","Is There Any Relation Between Serum Anti-p53 Antibody and TLG, MTV and SUV as PET Parameters in Lung Cancer Patients?",,"Completed","No Results Available","Lung Neoplasms|Gene, p53","Other: Blood Collection","Serum anti-p53 antibody level measurement.","Cumhuriyet University","All","Child, Adult, Older Adult","","146","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","T-597","May 2014","May 2015","April 2016","December 5, 2014","null","November 1, 2016","Cumhuriyet University, School of Medicine, department of Nuclear Medicine, Sivas, Campus, Turkey","","https://ClinicalTrials.gov/show/NCT02309567"
832,"NCT03215550","PET-MRI Imaging in Patients With Symptomatic Carotid Artery Stenosis",,"Not yet recruiting","No Results Available","Stroke|Carotid Stenosis","Procedure: CEA|Radiation: 18F PET-MRI|Diagnostic Test: Transcranial Doppler","18F-fluoride uptake in the culprit plaque in carotid, aortic and intra-cranial vessels.","University of Edinburgh","All","40 Years and older   (Adult, Older Adult)","","40","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","AC17046","August 2017","July 2019","August 2019","July 12, 2017","null","July 12, 2017","Centre for Cardiovascular Science, Edinburgh, United Kingdom","","https://ClinicalTrials.gov/show/NCT03215550"
833,"NCT00585117","Pilot Study of (61)CuATSM-PET Imaging in Cancer Patients",,"Terminated","No Results Available","CNS Brain Metastases|Head and Neck Cancer|Lung Cancer|Prostate Cancer|Esophageal Cancer","Procedure: PET-imaging with CuATSM|Procedure: PET Imaging|Procedure: PET CuATSM|Procedure: PET imaging|Procedure: PET imaging with CuATSM","To validate the CuATSM-PET imaging by correlation to the serum level of osteopontin, a marker of hypoxia|To test reliability of the CuATSM uptake by quantifying the reproducibility of the pre-treatment CuATSM_PET scans|To assess the technical and logistic feasibility of CuATSM-PET scans in a population of cancer patients","University of Wisconsin, Madison","All","18 Years and older   (Adult, Older Adult)","Not Applicable","9","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","HSC 2006-0282|RO06309","December 2006","January 2012","January 2012","January 3, 2008","null","February 24, 2012","University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States","","https://ClinicalTrials.gov/show/NCT00585117"
834,"NCT02964637","Diagnosing Frontotemporal Lobar Degeneration",,"Recruiting","No Results Available","Corticobasal Syndrome|Progressive Supranuclear Palsy|Behavioral Variant Frontotemporal Dementia|Semantic Dementia|Progressive Nonfluent Aphasia|Amyotrophic Lateral Sclerosis and/or Frontotemporal Dementia","Other: Observational Study","Structural and Functional Diffferences between the FTLD groups via MRI of the brain|Differences between the FTLD groups via PET imaging of the brain","University Health Network, Toronto","All","18 Years to 90 Years   (Adult, Older Adult)","","100","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","14-8398-A","August 2015","December 2018","December 2019","November 16, 2016","null","November 16, 2016","Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT02964637"
835,"NCT01638949","Multi-modal Neuroimaging in Alzheimer's Disease","IMAP+","Recruiting","No Results Available","Alzheimer's Disease","Behavioral: Memory assessment|Biological: Circulating biomarkers measure|Genetic: ApoE4|Other: Brain imaging examination MRI and PET examinations","Rate of volume change of whole brain, hippocampus and other structural MRI measures|Rate of Decline as measured by: Cognitive Tests, Activities of Daily Living, and CDR Sum of Boxes|Rates of change on each specified biochemical biomarker|Rates of change of glucose metabolism (FDG-PET)|Extent of amyloid deposition as measured by 18F-AV45|Group differences for each imaging and biomarker measurement|APOE genotype","University Hospital, Caen|Institut National de la Santé Et de la Recherche Médicale, France","All","18 Years and older   (Adult, Older Adult)","Not Applicable","295","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2011-A01493-38","May 2012","December 2021","null","July 12, 2012","null","April 9, 2014","GIP Cyceron, Caen, Calvados, France|Inserm - EPHE - University of Caen U1077, Caen, France|University Hospital Côte de Nacre, Caen, France|University Hospital Roger Salengro, Lille, France|University Hospital Pontchaillou, Rennes, France|University Hospital Rouen, Rouen, France|University Hospital Tours, Tours, France","","https://ClinicalTrials.gov/show/NCT01638949"
836,"NCT02210286","Magnesium L-Threonate for the Enhancement of Learning and Memory in People With Dementia",,"Completed","No Results Available","Dementia|Alzheimer's Disease","Dietary Supplement: Magtein","Cognitive Function|FDG-PET|RBC Magnesium chemistry","Stanford University|Magceutics, Inc.","All","60 Years and older   (Adult, Older Adult)","Not Applicable","20","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","29329","July 2014","April 2016","July 2016","August 6, 2014","null","October 13, 2016","Stanford University School of Medicine, Stanford, California, United States","","https://ClinicalTrials.gov/show/NCT02210286"
837,"NCT03577262","A Non-therapeutic Feasibility Study of the Radioligand [11C]-UCB-J for Imaging Synaptic Density",,"Recruiting","No Results Available","Healthy|Alzheimer Disease","Other: [11C]-UCB-J","Measure [11C]-UCB-J plasma radioactivity levels in plasma over time|Measure concentration of radioactivity as a function of time according to pre-defined brain regions","Rodin Therapeutics|QPS Netherlands B.V.|University Medical Center Groningen|VU University Medical Center","All","55 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","20","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","RDN-NI-001","July 23, 2018","December 20, 2018","January 20, 2019","July 4, 2018","null","July 25, 2018","VU Medical Center, Dept. Radiology and Nuclear Medicine, Amsterdam, Netherlands|QPS Netherlands B.V., Groningen, Netherlands|University Medical Center Groningen, Nuclear Medicine and Molecular Imaging, Groningen, Netherlands","","https://ClinicalTrials.gov/show/NCT03577262"
838,"NCT02623205","Advancing Personalized Antidepressant Treatment Using PET/MRI",,"Recruiting","No Results Available","Depression","Drug: Escitalopram|Drug: Placebo","Change from Baseline in Hamilton Depression Rating Scale at 8 weeks|Change from Baseline in MRGlu (quantified using arterial blood analysis) at 8 weeks|Quantification of brain MRGlu without an arterial catheter by training SimE|FDG concentration measured at the wrist, arm, ankle, or leg with a novel synchronized PET scanner","Stony Brook University","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","2014-2911-F","May 2015","May 2019","May 2019","December 7, 2015","null","April 19, 2017","Stony Brook University, Stony Brook, New York, United States","","https://ClinicalTrials.gov/show/NCT02623205"
839,"NCT02393027","Quantification of Dopamine Active Transporter (DAT) in Humans: Validation of a New Radiophamaceutical, the [18F] LBT-999","LBT 999","Terminated","No Results Available","Idiopathic Parkinson Disease","Drug: [18F] LBT-999 PET","Binding potential of [18F] LBT-999|DAT striatal density by estimating the LBT-999 distribution volume|presence of lipophilic metabolites","University Hospital, Tours","All","45 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","16","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","PHAO14-MJR / LBT-999","March 2015","November 2016","May 2017","March 19, 2015","null","May 30, 2017","University Hospital, Tours, France","","https://ClinicalTrials.gov/show/NCT02393027"
840,"NCT01428505","[18F]PBR111 and Microglial Activation in Multiple Sclerosis",,"Terminated","No Results Available","Multiple Sclerosis","Radiation: [18F]PBR111","VT of [18F]PBR111|Test-retest variability of regional [18F]PBR111|regional [18F]PBR111 VT|White matter lesion load and distribution|Cortical grey matter lesion load and distribution|Genetic polymorphisms related to the TSPO gene","GlaxoSmithKline","All","20 Years to 70 Years   (Adult, Older Adult)","Phase 2","50","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","115241","July 2011","March 2013","March 2013","September 5, 2011","null","February 8, 2016","GSK Investigational Site, London, United Kingdom","","https://ClinicalTrials.gov/show/NCT01428505"
841,"NCT02384993","aeRobic Exercise and Cognitive Health","REACH","Completed","No Results Available","Alzheimer's Disease|Aging","Behavioral: Enhanced Physical Activity","Cerebral Glucose Metabolism","University of Wisconsin, Madison|Alzheimer's Association","All","45 Years to 80 Years   (Adult, Older Adult)","Not Applicable","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","2014-1434|2014-NIRGD-305257","January 2015","August 2016","August 2016","March 10, 2015","null","December 30, 2016","University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, United States","","https://ClinicalTrials.gov/show/NCT02384993"
842,"NCT00381797","Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma",,"Completed","Has Results","Childhood Cerebral Anaplastic Astrocytoma|Childhood Oligodendroglioma|Childhood Spinal Cord Neoplasm|Recurrent Childhood Brain Stem Glioma|Recurrent Childhood Ependymoma|Recurrent Childhood Medulloblastoma","Biological: Bevacizumab|Radiation: Fludeoxyglucose F-18|Drug: Irinotecan Hydrochloride","Objective Response Rate Sustained for ≥ 8 Weeks|Sustained Disease Stabilization Rate Associated With Bevacizumab and Irinotecan in Patients With Recurrent or Progressive Low-grade Glioma (Stratum E)|Number of Study Participants With Grade 3 or 4 Treatment-related Toxicity|Cumulative Incidence of Sustained Objective Responses|Progression-free Survival|Change in Perfusion Ratio Between the Baseline and Day 15 Brain Imaging|Change in Diffusion Ratio Between the Baseline and Day 15 Brain Image|Association of Log-transformed Tumor Volume Based on FLAIR With Progression-free Survival (PFS) Using Hazard Ratio Estimates|Association of Log-transformed Tumor Enhancing Volume With Progression-free Survival (PFS) Using Hazard Ratio Estimates|Association of Log-transformed Volume of Cystic Necrosis With Progression-free Survival (PFS) Using Hazard Ratio Estimates|Association of Log-transformed Tumor Diffusion Ratio With Progression-free Survival (PFS) Using Hazard Ratio Estimates|Association of Log-transformed Tumor Perfusion Ratio With Progression-free Survival (PFS) Using Hazard Ratio Estimates|Volume of Distribution|Systemic Clearance|Terminal Half-life|Change in Vascular Endothelial Growth Factor Receptor-2 (VEGF-R2) Expression in Peripheral Blood Mononuclear Cells (PBMC) From Baseline to Day-15|Descriptive Statistics for the Changes in Vascular Endothelial Growth Factor Receptor-2 (VEGF-R2) Expression in Peripheral Blood Mononuclear Cells (PBMC) Concurrently Measured With the Changes in Perfusion From Magnetic Resonance Imaging|Descriptive Statistics for the Change of Perfusion in Magnetic Resonance Imaging Concurrently Measured With the Change in Vascular Endothelial Growth Factor Receptor-2 (VEGF-R2) Expression in Peripheral Blood Mononuclear Cells (PBMC)|Correlation of the Change in Vascular Endothelial Growth Factor Receptor-2 (VEGF-R2) Expression in Peripheral Blood Mononuclear Cells (PBMC) From Baseline With the Change in Perfusion From Magnetic Resonance Imaging|Number of Patients With High Hypoxia Inducible Factor-2alpha Expression at Baseline|Number of Patients With High Carbonic Anhydrase 9 Expression at Baseline|Number of Patients With High VEGF-A Expression at Baseline|Number of Patients With High VEGF-R2 Expression at Baseline|Progression-free Survival Hazard Ratio by Hypoxia Inducible Factor-2alpha Expression|Progression-free Survival Hazard Ratio by Carbonic Anhydrase 9 (CA9) Expression|Progression-free Survival Hazard Ratio by VEGF-A Expression|Progression-free Survival Hazard Ratio by VEGF-R2 Expression","National Cancer Institute (NCI)","All","up to 21 Years   (Child, Adult)","Phase 2","97","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2009-01090|PBTC-022|CDR0000499832|U01CA081457","August 2006","October 2015","October 2015","September 28, 2006","January 15, 2013","November 28, 2017","UCSF Medical Center-Mount Zion, San Francisco, California, United States|Children's National Medical Center, Washington, D.C., District of Columbia, United States|Lurie Children's Hospital-Chicago, Chicago, Illinois, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Duke University Medical Center, Durham, North Carolina, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States|Pediatric Brain Tumor Consortium, Memphis, Tennessee, United States|St. Jude Children's Research Hospital, Memphis, Tennessee, United States|Texas Children's Hospital, Houston, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States","","https://ClinicalTrials.gov/show/NCT00381797"
843,"NCT00954538","Safety, Radiation Dosimetry, Biokinetics, and Effectiveness of [18F]MK3328 (MK-3328-001)",,"Completed","Has Results","Alzheimer's Disease","Drug: [18F]MK-3328","Number of Participants With an Adverse Event (AE)|Number of Participants Who Discontinued Study Due to an AE|Effective Dose of [18F]MK-3328|Organ Effective Dose of [18F]MK-3328|Mean Brain Cortical [18F]MK-3328 Standard Uptake Value Ratio (SUVR) in AD Participants and HE Participants|Least Squares (LS) Mean [18F]MK-3328 SUVR in Brain Posterior Cingulate Gyrus in AD Participants and HE Participants","Merck Sharp & Dohme Corp.","All","50 Years and older   (Adult, Older Adult)","Phase 1","19","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","3328-001|2009_630","August 2009","May 2011","May 2011","August 7, 2009","February 5, 2014","November 3, 2015","","","https://ClinicalTrials.gov/show/NCT00954538"
844,"NCT00781482","Positron Emission Tomography Assessment of the Central Nervous System Effects of Eszopiclone and Zolpidem",,"Withdrawn","No Results Available","Healthy","Drug: eszopiclone, zolpidem, placebo","We will measure GABA receptor binding by PET imageing after each dose of study medication or placebo.","Kettering Health Network|Abiant, Inc.|Sunovion","Male","18 Years to 35 Years   (Adult)","Phase 4","0","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","07-104-SEPR","null","null","null","October 29, 2008","null","February 26, 2016","Kettering Medical Center, Kettering, Ohio, United States","","https://ClinicalTrials.gov/show/NCT00781482"
845,"NCT01254773","Amyloid Imaging And Safety Study Of Subcutaneous Bapineuzumab In Subjects With Mild to Moderate Alzheimer's Disease","SUMMIT AD","Completed","No Results Available","Alzheimer's Disease","Drug: Experimental Bapineuzumab","To evaluate the effect of bapineuzumab administered subcutaneously (SC) at monthly intervals compared to placebo on cerebral amyloid burden in subjects with mild to moderate AD.|To assess the safety of bapineuzumab administered SC at monthly intervals compared to placebo in subjects with mild to moderate AD|To assess the effect of bapineuzumab administered SC at monthly intervals compared to placebo on cognitive and functional endpoints.","JANSSEN Alzheimer Immunotherapy Research & Development, LLC|Pfizer","All","50 Years to 89 Years   (Adult, Older Adult)","Phase 2","146","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AAB-001-SC-ALZ-2003","December 2010","January 2013","March 2013","December 7, 2010","null","May 9, 2014","Janssen AI Investigational Site, Tucson, Arizona, United States|Janssen AI Investigational Site, Tucson, Arizona, United States|Janssen AI Investigational Site, La Habra, California, United States|Janssen AI Investigational Site, Lomita, California, United States|Janssen AI Investigational Site, Long Beach, California, United States|Janssen AI Investigational Site, Oceanside, California, United States|Janssen AI Investigational Site, Pasadena, California, United States|Janssen AI Investigational Site, Santa Monica, California, United States|Janssen AI Investigational Site, Sherman Oaks, California, United States|Janssen AI Investigational Site, Deerfield Beach, Florida, United States|Janssen AI Investigational Site, Delray Beach, Florida, United States|Janssen AI Investigational Site, Fort Meyers, Florida, United States|Janssen AI Investigational Site, Miami Springs, Florida, United States|Janssen AI Investigational Site, South Miami, Florida, United States|Janssen AI Investigational Site, Atlanta, Georgia, United States|Janssen AI Investigational Site, Indianapolis, Indiana, United States|Janssen AI Investigational Site, Kansas City, Kansas, United States|Janssen AI Investigational Site, Lexington, Kentucky, United States|Janssen AI Investigational Site, Plymouth, Massachusetts, United States|Janssen AI Investigational Site, Farmington Hills, Michigan, United States|Janssen AI Investigational Site, Creve Coeur, Missouri, United States|Janssen AI Investigational Site, St. Louis, Missouri, United States|Janssen AI Investigational Site, Latham, New York, United States|Janssen AI Investigational Site, Winston-Salem, North Carolina, United States|Janssen AI Investigational Site, Dayton, Ohio, United States|Janssen AI Investigational Site, Portland, Oregon, United States|Janssen AI Investigational Site, Philadelphia, Pennsylvania, United States|Janssen AI Investigational Site, Providence, Rhode Island, United States","","https://ClinicalTrials.gov/show/NCT01254773"
846,"NCT03053908","Orexin and Tau Pathology in Cognitively Normal Elderly",,"Recruiting","No Results Available","Elderly|Alzheimer Disease","Procedure: Actigraphy|Procedure: Nocturnal Polysomnograpahy (NPSG)","Cerebral Spinal Fluid (CSF) P-Tau measured with PET-MR|18MK6240 binding amount measured with PET-MR","New York University School of Medicine","All","55 Years to 75 Years   (Adult, Older Adult)","Not Applicable","19","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16-01529","March 27, 2018","November 2018","August 2019","February 15, 2017","null","March 30, 2018","New York University School of Medicine, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT03053908"
847,"NCT02076295","Cholinergic Nicotinic Receptors and Cognition in PD","CHONI","Completed","No Results Available","Parkinson's Disease","","Cerebral cholinergic nicotinic receptor expression|Cognitive performance","University of Michigan|Michael J. Fox Foundation for Parkinson's Research","All","50 Years and older   (Adult, Older Adult)","","48","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","HUM00083054","February 2014","December 30, 2016","December 30, 2016","March 3, 2014","null","April 17, 2017","University of Michigan Health System, Ann Arbor, Michigan, United States","","https://ClinicalTrials.gov/show/NCT02076295"
848,"NCT00802204","Dopamine and Insulin Resistance",,"Completed","Has Results","Obesity","Radiation: PET scan|Procedure: Oral glucose tolerance test|Procedure: MRI|Behavioral: Psychological scales to assess attitudes and behaviors related to eating and quality of life|Other: Caloric Restriction","Striatal DRD2 Receptor Binding|Insulin|Glucose|Leptin|Acyl Ghrelin|Insulin Sensitivity From Oral Glucose Tolerance Test (OGTT_SI)|Binge Eating Score Questionnaire","Vanderbilt University|Vanderbilt University Medical Center","All","18 Years to 60 Years   (Adult)","Not Applicable","28","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Other","IRB#080861 and 061246","December 2008","April 2011","December 2012","December 4, 2008","May 10, 2017","May 10, 2017","Vanderbilt University Medical Center, Nashville, Tennessee, United States","","https://ClinicalTrials.gov/show/NCT00802204"
849,"NCT02599766","Effects of Animal-assisted Therapy on Brain-injured Patients",,"Completed","No Results Available","Impaired Social Functioning","Other: animal assisted therapy|Other: standard therapy","social functioning: verbal communication|social functioning: nonverbal communication|social functioning: physical contact|social functioning: attention|Positive emotional display|Negative emotional display|Neutral emotional display|Mood|heart rate|Motor activity","Swiss Tropical & Public Health Institute|Institute for Interdisciplinary Research on the Human-Pet Relationship","All","18 Years and older   (Adult, Older Adult)","Not Applicable","25","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Ref.Nr.EK:296/13","February 2014","February 2016","February 2016","November 9, 2015","null","October 7, 2016","REHAB Basel, Basel, Switzerland","","https://ClinicalTrials.gov/show/NCT02599766"
850,"NCT01445119","A Phase I Trial of Enzastaurin (LY317615) in Combination With Carboplatin in Adults With Recurrent Gliomas",,"Completed","No Results Available","Recurrent Gliomas","Drug: Enzastaurin (LY317615)|Drug: Carboplatin","To establish the maximally tolerated dose of enzastaurin in combination with carboplatin in patients with refractory primary brain tumors not on any enzyme-inducing anti-epileptic drugs (EIAED) and for patients on EIAEDs.|To obtain exploratory data regarding the relationship between clinical outcome and GSK3-b activation in peripheral blood mononuclear cells in treated patients.","Eli Lilly and Company|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1","58","Industry|NIH","Interventional","Primary Purpose: Treatment","070053|07-C-0053","January 2007","July 2013","July 2013","October 3, 2011","null","August 28, 2013","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT01445119"
851,"NCT01660815","A Study of Florbetapir (18F) in Japanese Healthy Volunteers",,"Completed","Has Results","Alzheimer's Disease","Drug: florbetapir (18F)","Whole Body Radiation Dosimetry","Avid Radiopharmaceuticals|Eli Lilly and Company","All","45 Years and older   (Adult, Older Adult)","Phase 1","7","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","18F-AV-45-J02|I6E-AV-AVBA","August 2012","January 2013","January 2013","August 9, 2012","September 19, 2013","September 19, 2013","Research Site, Kobe, Japan","","https://ClinicalTrials.gov/show/NCT01660815"
852,"NCT02407587","Neuroplastic Changes Seen in Cochlear Implants With Preserved Hearing",,"Unknown status","No Results Available","Hearing Loss","Device: cochlear implants","Increase our understanding of why outcomes following a cochlear implant are heterogenous. This information may be used to provide targeted rehabilitation for candidates performing poorly with their implants and minimise rejection of the implant.|Combine the data from both of our studies and future studies in order to conduct meta-analysis to investigate further how language is processed in patients with cochlear implants.|Determine if functional neuroimaging modalities have a future role in the selection process for potential cochlear implant candidates and in predicting outcome for each individual.","Hayley Brooks|Manchester University NHS Foundation Trust","All","18 Years and older   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","R01997","May 2013","October 2015","October 2015","April 3, 2015","null","April 3, 2015","Central Manchester University Hospitals NHS Foundation Trust, Manchester, Manchester (Manchester borough), United Kingdom","","https://ClinicalTrials.gov/show/NCT02407587"
853,"NCT01615055","Fluoxetine Prevention Trial",,"Not yet recruiting","No Results Available","Cognitive Dysfunction","Drug: Fluoxetine|Other: Placebo","Change from baseline in regional cerebral metabolism|Durability of the protective effect of fluoxetine|Change from baseline in neuropsychological (cognitive, functional) test results|Correlation between cognitive functioning and cerebral metabolism by correlating neuropsychological testing results with PET imaging|Correlation between inflammatory cytokines and cerebral metabolism by correlating blood cytokine marker levels with PET imaging","University of California, Los Angeles|City of Hope Medical Center","All","21 Years and older   (Adult, Older Adult)","Early Phase 1","376","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","12-000568","June 2018","October 2020","October 2020","June 8, 2012","null","October 31, 2017","City of Hope, Duarte, California, United States|UCLA Medical Center, Los Angeles, California, United States","","https://ClinicalTrials.gov/show/NCT01615055"
854,"NCT01933269","FACBC for Head and Neck Cancers",,"Withdrawn","No Results Available","Cancers of the Head and Neck","Drug: FACBC","The presence of FACBC radiotracer uptake in Head and neck tumors on PET scans","Emory University","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","IRB00062214","May 2015","February 1, 2018","February 1, 2018","September 2, 2013","null","February 5, 2018","","","https://ClinicalTrials.gov/show/NCT01933269"
855,"NCT01469351","Identifying Potential Effects of Liraglutide on Degenerative Changes",,"Completed","No Results Available","Alzheimers Disease","Drug: Liraglutide|Drug: non-active study drug","PIB PET scan|Neuro-psychological tests|FDG PET Scan","University of Aarhus","All","50 Years to 80 Years   (Adult, Older Adult)","Not Applicable","34","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2011-000794-31","January 2012","April 2013","April 2013","November 10, 2011","null","April 19, 2013","Aarhus University, Aarhus, Denmark","","https://ClinicalTrials.gov/show/NCT01469351"
856,"NCT00469534","Minimized Time to Beam in Patients With High Grade Gliomas",,"Withdrawn","No Results Available","High Grade Glioma","Procedure: IMRT","Time from initial OPD visit to start of RT compared with historical controls receiving helical tomotherapy base IMRT (Time to Beam).|Overall survival, disease-free survival, patterns of recurrence, toxicity, quality of life, number of patients who complete treatment.","Alberta Health Services|AHS Cancer Control Alberta","All","18 Years and older   (Adult, Older Adult)","Not Applicable","0","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CNS-9-0039","null","null","null","May 4, 2007","null","September 22, 2011","","","https://ClinicalTrials.gov/show/NCT00469534"
857,"NCT01556100","Long-Term Vesicular Monoamine Transporter II Imaging and Clinical Assessment of Parkinson's Disease Progression",,"Completed","Has Results","Parkinson Disease","Drug: 18F-DTBZ AV-133","Change in 18F-DTBZ Uptake in a Cohort of Parkinson's Disease Patients From Baseline to Month 36|To Determine the Test/Retest 18F-DTBZ PET Measurements of Vesicular Monoamine Transporter II Binding in PD Patients.","Chang Gung Memorial Hospital","All","20 Years and older   (Adult, Older Adult)","Phase 2","40","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","99-3989A","November 2011","May 2015","December 2015","March 16, 2012","December 15, 2017","December 15, 2017","","","https://ClinicalTrials.gov/show/NCT01556100"
858,"NCT00776347","Donepezil Therapy and Changes of Symptoms and Glucose Metabolism in Patients With Dementia With Lewy Bodies (DLB)",,"Completed","No Results Available","Dementia With Lewy Bodies (DLB)","Drug: Donepezil","FDG-PET|Cognitive function, psychiatric symptoms, global clinical function, and burden of caregiver","Osaka University","All","60 Years to 85 Years   (Adult, Older Adult)","Not Applicable","24","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","OSK-08096","October 2008","February 2015","February 2015","October 21, 2008","null","October 15, 2015","Osaka University Hospital, Suita,, Osaka, Japan","","https://ClinicalTrials.gov/show/NCT00776347"
859,"NCT00816439","Imaging Cannabinoid CB1 Receptors in Alcohol Dependence",,"Completed","No Results Available","Alcoholism","","","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","Male","18 Years to 65 Years   (Adult, Older Adult)","","101","NIH","Observational","Time Perspective: Prospective","090040|09-M-0040","December 29, 2008","null","August 28, 2014","January 1, 2009","null","July 4, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00816439"
860,"NCT02578849","Common Noradrenergic Mechanisms in Parkinson´s Disease and L-DOPA Induced Dyskinesia","NORAPARK","Unknown status","No Results Available","Parkinson´s Disease","Drug: L-DOPA","Noradrenaline release|Noradrenaline transporters","Aarhus University Hospital|University of Copenhagen","All","50 Years to 80 Years   (Adult, Older Adult)","","45","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","0602_Parkinson´s disease","January 2012","January 2016","January 2016","October 19, 2015","null","October 19, 2015","Department of Nuclear Medicine and PET-Centre, Aarhus University Hospital, Aarhus C, Denmark","","https://ClinicalTrials.gov/show/NCT02578849"
861,"NCT02414282","F 18 T807 Tau PET Imaging of Progressive Posterior Cortical Dysfunction (IND 123119, Protocol E)","Protocol E","Enrolling by invitation","No Results Available","Alzheimer Disease|Progressive Posterior Cortical Dysfunction (PPCD)","Drug: F 18 T807","F 18 T807 Standard Uptake Value Ratios (SUVR) will be correlated with other imaging modalities (MRI, PET amyloid imaging) and cognitive performance.","Washington University School of Medicine","All","45 Years and older   (Adult, Older Adult)","Phase 2","25","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","IND 123119 Protocol E","March 2015","March 2020","September 2020","April 10, 2015","null","June 27, 2018","Washington University School of Medicine, Saint Louis, Missouri, United States","","https://ClinicalTrials.gov/show/NCT02414282"
862,"NCT01811381","Curcumin and Yoga Therapy for Those at Risk for Alzheimer's Disease",,"Recruiting","No Results Available","Mild Cognitive Impairment","Drug: Curcumin|Behavioral: aerobic yoga|Behavioral: non aerobic yoga|Dietary Supplement: Placebo","Curcumin effects (first six month period) or curcumin and aerobic yoga effects (second six month period) on the changes in the levels of blood biomarkers for Mild Cognitive Impairment relative to baseline or relative to placebo or non-aerobic yoga.|Changes in 18F-fluorodeoxyglucose (FDG) Positron Emission Tomography (PET) glucose metabolism neuroimaging after supplementation compared to baseline and compared to placebo|Curcumin effects on changes in Neuropsychological parameters compared to baseline and to placebo (first six month period) and in combination with aerobic yoga, compared to baseline and to non-aerobic yoga with curcumin or aerobic yoga with supplement|Number of Participants with Adverse Events","VA Office of Research and Development","All","50 Years to 90 Years   (Adult, Older Adult)","Phase 2","80","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","E0669-I|VA_RX00069","January 20, 2014","June 1, 2019","December 31, 2019","March 14, 2013","null","February 2, 2018","VA Greater Los Angeles Healthcare System, West Los Angeles, CA, West Los Angeles, California, United States","","https://ClinicalTrials.gov/show/NCT01811381"
863,"NCT01824121","Clinical Trial to Evaluate Bone Marrow Stem Cell Therapy for PSP, a Rare Form of Parkinsonism",,"Unknown status","No Results Available","Progressive Supranuclear Palsy","Biological: stem cell therapy","incidence of adverse events|changes in brain images","Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","All","40 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","25","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","032011|2011-004051-39","December 2012","December 2014","December 2014","April 4, 2013","null","April 4, 2013","ICP Parkinson Institute, Milano, Italy","","https://ClinicalTrials.gov/show/NCT01824121"
864,"NCT02591069","Vagal Nerve Stimulation in Coma Patients","SNV","Recruiting","No Results Available","Chronic Consciousness Disorders|Vegetative State|Minimally Conscious State|Akinetic Mutism","Device: stimulation device","Change over time of clinical scores on the Coma Recovery Scale - Revised|Evaluation of brain activity changes using EEG|MRI (anisotropy and fibers density) evaluation of anatomo-connectivity changes|fMRI evaluation of bold signal resting state activity and functional connectivity changes|PET scan evaluation of brain metabolism (Glucose consumption) changes|Monitoring heart rate variability|: Monitoring changes of serum free serotonin concentration|Monitoring changes of thermal reaction to emotional stimuli","Hospices Civils de Lyon","All","18 Years to 60 Years   (Adult)","Not Applicable","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)","2013-833","October 2015","January 2016","January 2020","October 29, 2015","null","October 5, 2016","Hôpital Neurologique de Lyon Pierre Wertheimer, Bron, France","","https://ClinicalTrials.gov/show/NCT02591069"
865,"NCT00205621","Positron Emission Tomography of Amyloid in Alzheimer's Disease",,"Suspended","No Results Available","Alzheimer's Disease","Device: Positron Emission Tomography","quantification of amyloid binding","VU University Medical Center","Male","60 Years to 80 Years   (Adult, Older Adult)","Phase 1","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2005/90","October 2005","null","December 2009","September 20, 2005","null","September 8, 2006","VU University Medical Center, Amsterdam, Netherlands","","https://ClinicalTrials.gov/show/NCT00205621"
866,"NCT01031810","PET Biomarkers in Treatment Resistant Depression",,"Terminated","Has Results","Major Depressive Disorder","Drug: tranylcypromine","Hamilton Depression Rating Scale Scores 17 at Baseline|Hamilton Depression Rating Scale Scores 17 at week12|Quick Inventory of Depression- Self Report 16","New York State Psychiatric Institute|National Institute of Mental Health (NIMH)","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","13","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","6025|RC1MH088405-01","November 2009","March 2013","March 2013","December 15, 2009","September 18, 2014","September 18, 2014","New York State Psychiatric Institute, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT01031810"
867,"NCT00302380","An Open Label Phase I/II Study of the Safety and Dopamine Transporter Binding Properties of C-11 Altropane in Normal Human Subjects and in Subjects With ADHD",,"Completed","No Results Available","Attention Deficit Hyperactivity Disorder","Radiation: PET imaging using C-11 altropane as the ligand.","The DAT receptor occupancy of OROS MPH and Metadate CD in adults with and without ADHD using PET scanning with C-11 Altropane.|Neuropsychological tests|Genotyping","Massachusetts General Hospital|National Institute of Mental Health (NIMH)","All","18 Months to 55 Years   (Child, Adult)","","300","Other|NIH","Observational","Observational Model: Case Control|Time Perspective: Prospective","2000-p-001975","October 2000","March 2006","March 2006","March 14, 2006","null","June 28, 2011","","","https://ClinicalTrials.gov/show/NCT00302380"
868,"NCT01749592","Single-sided Deafness and Cochlear Implants",,"Active, not recruiting","No Results Available","Sensorineural Hearing Loss (Disorder)","Device: cochlear implant","Audiometry|PET scan","University of Zurich","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2012-0034","December 2012","January 2018","December 2018","December 13, 2012","null","June 21, 2018","University Hospital Zurich, Division of Otorhinolaryngology ORL, Zurich, ZH, Switzerland","","https://ClinicalTrials.gov/show/NCT01749592"
869,"NCT00954369","Exploratory and Safety Study of [F-18]W372",,"Completed","No Results Available","Alzheimer's Disease","Drug: [F-18]W372","Safety will be the outcome demonstrated in this clinical trial through analyses of adverse events in subjects who receive study drug.","Siemens Molecular Imaging","All","55 Years and older   (Adult, Older Adult)","Early Phase 1","24","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","W372000","August 2009","February 2010","February 2010","August 7, 2009","null","August 22, 2012","University of California, Irvine, Irvine, California, United States","","https://ClinicalTrials.gov/show/NCT00954369"
870,"NCT00590954","Clinical and Molecular-Metabolic Phase II Trial of Perifosine for Recurrent/Progressive Malignant Gliomas",,"Active, not recruiting","No Results Available","Malignant Gliomas|CNS|Brain Cancer|Cancer","Drug: Perifosine","Determine the efficacy of perifosine in patients with recurrent/progressive GBMs not taking EIAEDs as measured by 6mPFS.|Determine molecular effects of perifosine on AKT, RAS, and proliferation in malignant gliomas; Determine metabolic effects of perifosine on malignant gliomas by PET imaging; Identify molecular features that predict perifosine response.","Memorial Sloan Kettering Cancer Center|Keryx Biopharmaceuticals|Keryx / AOI Pharmaceuticals, Inc.|Online Collaborative Oncology Group|University of Wisconsin, Madison|Columbia University","All","18 Years and older   (Adult, Older Adult)","Phase 2","31","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","06-044","May 2006","May 2019","May 2019","January 11, 2008","null","June 4, 2018","Memorial Sloan-Kettering Cancer Center, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT00590954"
871,"NCT02896816","EMG Modules as a Novel Biomarker of Basal Ganglia Plasticity in Parkinson's Disease",,"Recruiting","No Results Available","Parkinson","Other: Surface EMG, MRI and PET Scan|Other: Surface EMG","Surface electromyography recording|Structural MRI|Functional MRI|Diffusion weighted imaging|Altropane PET scan","Spaulding Rehabilitation Hospital|Michael J. Fox Foundation for Parkinson's Research","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening","2015-P-002526","August 2016","December 2018","June 2019","September 12, 2016","null","April 26, 2018","Spaulding Rehabilitation Hospital, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT02896816"
872,"NCT01979419","Korea Alzheimer's Disease Neuroimaging Initiative","K-ADNI","Active, not recruiting","No Results Available","Mild Cognitive Impairment|Alzheimer's Disease|Subcortical Vascular Dementia","","Rate of dementia conversion or disease severity worsening, evaluated by neuropsychological, MRI, PET, biomarker indices.|Change from baseline in cognitive, neuroimaging, and biomarker assessments","Korean Alzheimers' Disease Neuroimaing Intitiative","All","50 Years to 80 Years   (Adult, Older Adult)","","500","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","HI12C0713","November 2012","October 2018","October 2018","November 8, 2013","null","May 7, 2015","Seong Yoon Kim, Seoul, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT01979419"
873,"NCT03349606","Cocaine Use Disorder and Cortical Dopamine",,"Recruiting","No Results Available","Cocaine Dependence","Drug: d-amphetamine|Radiation: [C-11]FLB 457","Percent change in Binding potential (BPnd)","University of Pittsburgh|National Institute on Drug Abuse (NIDA)","All","18 Years to 40 Years   (Adult)","Early Phase 1","30","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","PRO10030625|R01DA026472|PRO14080588","June 2, 2010","December 31, 2020","December 31, 2020","November 21, 2017","null","November 22, 2017","University of PIttsburgh PET Facility, Pittsburgh, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT03349606"
874,"NCT02839187","Neuro Imaging and Multimodal Alzheimer's Disease","NIMAD","Completed","No Results Available","Alzheimer Disease","Radiation: Neuroimaging","fixing the AV-45 during PET|Deposition of amyloid protein|Standard Cognitive function|Specific memory evaluation","University Hospital, Toulouse","All","60 Years to 85 Years   (Adult, Older Adult)","Not Applicable","59","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","07 306 02","June 2010","May 2012","May 2012","July 20, 2016","null","May 11, 2017","University Hospital of Toulouse, Toulouse, France","","https://ClinicalTrials.gov/show/NCT02839187"
875,"NCT00932061","Developing Biomarkers for Fibromyalgia","Biomarkers","Completed","No Results Available","Fibromyalgia","Other: Traditional Acupuncture|Other: Sham Treatment","fMRI signal|PET signal|H-MRS Glutamate|H-MRS - Glutamate|Pain","University of Michigan|The Dana Foundation|United States Department of Defense","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","105","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Diagnostic","Hum 00010061|F017513|Sponsor(DOD) W81XWH-07-20050","June 2008","December 2010","December 2010","July 2, 2009","null","July 19, 2013","University of Michigan, Chronic Pain and Fatigue Research Center, Ann Arbor, Michigan, United States","","https://ClinicalTrials.gov/show/NCT00932061"
876,"NCT02714036","A Biomarker Study to Evaluate MN-166 (Ibudilast) in Subjects With Amyotrophic Literal Sclerosis (ALS)",,"Active, not recruiting","No Results Available","Amyotrophic Lateral Sclerosis","Drug: ibudilast","To measure the impact of MN-166 (ibudilast) on [11C]-PBR28 uptake in the motor cortices and brain stem measured by positron emission tomography (PET) imaging at 24 weeks|To measure the impact of MN-166 (ibudilast) on several markers of neuro-inflammation measured by blood biomarkers|To evaluate the safety and tolerability of MN-166 by assessing the number of treatment-related adverse events.|To evaluate the effect of ibudilast on ALS functional rating scale-revised (ALSFRS-R)|To evaluate the effect of ibudilast on slow vital capacity (SVC)|To evaluate the effect of ibudilast on strength as measured by Hand-held dynamometry (HHD)","MediciNova|Massachusetts General Hospital|South Shore Neurologic Associates","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","35","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MN-166-ALS-1202","March 2016","June 28, 2018","April 2019","March 21, 2016","null","July 20, 2018","Massachusetts General Hospital, Boston, Massachusetts, United States|South Shore Neurologic Associates, P.C., Patchogue, New York, United States","","https://ClinicalTrials.gov/show/NCT02714036"
877,"NCT02661789","Neuropsychobiological Correlates of Sex-steroid Hormone Manipulation in Healthy Women: a Risk Model for Depression","GnRHa","Completed","No Results Available","Postpartum Depression|Major Depressive Disorder|Postpartum Psychosis|Menopause|Neurodegeneration|Schizophrenia","Drug: Goserelin 3.6 mg implant|Drug: Placebo","Changes from baseline in symptoms of depression|Changes from baseline in serotonin transporter binding in volumes of interest (VOIs)|Changes from baseline in fMRI response to emotional faces|Changes from baseline in fMRI response to gambling paradigm|Changes from baseline in rsfMRI changes in functional connectivity|Changes from baseline in affective cognition (VAMT-24 test)|Changes from baseline in reaction time|Serial mood fluctuations (SD of total mood disturbance (TMD) score of daily POMS across intervention period)|Changes from baseline in hippocampal volume|Changes in pre-pulse-inhibition (PPI) from baseline|Changes in a set of markers of immunoactivity across study period|Changes in epigenetic markers of estrogen sensitivity|Changes in HPA-axis dynamics (the cortisol awakening response)|Changes in sensorimotor gating (P50 suppression) from baseline|Changes from baseline in hippocampal microstructure|Changes from baseline in fMRI responses to emotional memory paradigm|Changes from baseline in Cohens perceived stress score|Changes in Pittsburg Sleep Quality Inventory (PSQI)|Side effects scores (project specific 15 items questionnaire)|Changes in SCL-R (Symptom check-list revised)|Major Depression Inventory (MDI)|Changes in profile of mood states (POMS TMD score)","Gitte Moos Knudsen|Center for Integrated Molecular Brain Imaging|Fertility Clinic Rigshospitalet|CNSR, Glostrup Psychiatric Center|Danish Multiple Sclerosis Center Rigshospitalet|Dept. of Clinical Immunology, Rigshospitalet|Rigshospitalet, Denmark","Female","18 Years to 40 Years   (Adult)","Not Applicable","63","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","GnRHa|H-2-2010-108","January 2011","December 2012","December 2012","January 22, 2016","null","January 22, 2016","Neurobiology Research Unit, Rigshospitalet, Copenhagen, Denmark","","https://ClinicalTrials.gov/show/NCT02661789"
878,"NCT01208675","The Swedish BioFINDER Study",,"Active, not recruiting","No Results Available","Mild Cognitive Impairment|Alzheimer's Disease|Dementia With Lewy Bodies|Vascular Dementia","","To compare the time to conversion to clinically probable AD in MCI subjects or healthy elderly subjects with normal and abnormal biomarkers (CSF, blood, MRI, PET)|Rate of cognitive decline as measured by various cognitive tests, Activities of Daily Living (FAQ) and Global Deterioration Scale.|Group differences for imaging and wet biomarker measurements.|Rate of volume change of structural MRI measures and amyloid PET|Rates of change on each specified biochemical biomarker|Correlations between biomarkers and biomarker change|Subgroups analyses: Abnormal CSF biomarkers, positive amyloid imaging, APOE genotype.","Skane University Hospital|Lund University","All","60 Years to 80 Years   (Adult, Older Adult)","","900","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","TiDiS-2010","September 2010","December 2022","December 2022","September 24, 2010","null","April 17, 2018","Memory Clinic, Skåne University Hospital, Malmö, Sweden|Memory Clinic, Hospital of Ängelholm, Ängelholm, Sweden","","https://ClinicalTrials.gov/show/NCT01208675"
879,"NCT02959892","A Single-Dose Positron Emission Tomography (PET) Study to Determine the Effect of TAK-041 on Amphetamine-Induced Dopamine Release in the Central Nervous System (CNS)",,"Completed","No Results Available","Healthy Volunteers","Drug: Amphetamine|Drug: TAK -041","Relative Change in Non-displaceable Binding Potential (BP-ND)|Relative Change in BP-ND as a Function of the Dose of TAK-041 Administered","Takeda","Male","20 Years to 55 Years   (Adult)","Phase 1","12","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","TAK-041-1002|U1111-1184-1947|2016-002346-23","January 18, 2017","August 23, 2017","August 23, 2017","November 9, 2016","null","May 11, 2018","Hammersmith Medicines Research, London, United Kingdom","","https://ClinicalTrials.gov/show/NCT02959892"
880,"NCT02866461","Endogenous Opioid Systems and Symptom Change in Fibromyalgia",,"Not yet recruiting","No Results Available","Fibromyalgia","Other: No treatment","change in mu opioid-mediated neurotransmission|change in Biomarkers of pain response|change in Pain","University of Utah","All","18 Years to 55 Years   (Adult)","","80","Other","Observational","Observational Model: Ecologic or Community|Time Perspective: Prospective","R01 3589819","September 2018","August 2020","August 2020","August 15, 2016","null","July 17, 2018","","","https://ClinicalTrials.gov/show/NCT02866461"
881,"NCT00256256","The Effect of GLP-1 on Glucose Uptake in the Brain and Heart in Healthy Men",,"Completed","No Results Available","Type 2 Diabetes|Stroke|Myocardial Infarction","Drug: glucagon-like-peptide-1","FDG-uptake in the brain and heart visualized by Positron emission tomography with and without GLP-1|Laboratory values (insulin secretion and counter-regulatory hormones)","University of Aarhus","Male","20 Years to 50 Years   (Adult)","Not Applicable","10","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","2005-0079","November 2005","null","January 2007","November 21, 2005","null","October 30, 2007","Department of pharmacology, Aarhus university, Aarhus, Denmark","","https://ClinicalTrials.gov/show/NCT00256256"
882,"NCT00965835","Amyloid Plaque and Tangle Imaging in Alzheimer's Disease and Down Syndrome",,"Unknown status","No Results Available","Down Syndrome|Alzheimer's Disease","","","National Institute on Aging (NIA)","All","21 Years and older   (Adult, Older Adult)","","40","NIH","Observational","Observational Model: Case Control|Time Perspective: Prospective","IA0166|1R21AG030681-01A2","August 2009","May 2011","May 2011","August 26, 2009","null","December 29, 2009","UCLA, Los Angeles, California, United States","","https://ClinicalTrials.gov/show/NCT00965835"
883,"NCT00866502","A Safety and Tolerability Study of Intracerebroventricular Administration of sNN0031 to Patients With Parkinson's Disease",,"Completed","No Results Available","Parkinson's Disease","Drug: sNN0031|Drug: Placebo","Safety and tolerability through assessment of adverse events, ECGs, vital signs, clinical laboratory variables, MRI of brain and spinal cord, CSF sampling, and device performance as characterized by catheter tip placement and infusion accuracy.|Time course of PD disease activity as measured by the UPDRS, MADRS and MMT rating scales.|Change in caudate and putamen dopamine turnover using PET scans of 11C-PE2I uptake","Newron Sweden AB|Medtronic|Quintiles, Inc.","All","30 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","12","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","sNN0031-001|Q-26239","March 2009","March 2011","March 2011","March 20, 2009","null","January 12, 2015","Lund University Hospital, Lund, Sweden|Karolinska University Hospital, Huddinge, Stockholm, Sweden","","https://ClinicalTrials.gov/show/NCT00866502"
884,"NCT01281982","(11C)dLop as a Marker of P-Glycoprotein Function in Patients With Gliomas",,"Terminated","No Results Available","Low Grade Glioma|Glioblastoma Multiforme|Anaplastic Astrocytoma|Anaplastic Oligodendroglioma|Oligoastrocytoma","","","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 99 Years   (Adult, Older Adult)","","2","NIH","Observational","Time Perspective: Prospective","110081|11-C-0081","January 13, 2011","null","September 24, 2012","January 24, 2011","null","July 4, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT01281982"
885,"NCT01565382","Evaluation of Inter-reader Reliability Using Images From Subjects With Alzheimer's Disease (AD) or Mild Cognitive Impairment (MCI)",,"Completed","Has Results","Alzheimer's Disease","Drug: florbetapir F 18","Inter-reader Agreement - Median Kappa Statistic|Overall Inter-reader Agreement - Fleiss' Kappa","Avid Radiopharmaceuticals","All","50 Years and older   (Adult, Older Adult)","Not Applicable","40","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic","18F-AV-45-A09","February 2011","February 2011","February 2011","March 28, 2012","June 27, 2012","June 27, 2012","","","https://ClinicalTrials.gov/show/NCT01565382"
886,"NCT01193660","Allogenic Umbilical Cord Blood and Erythropoietin Combination Therapy for Cerebral Palsy",,"Completed","Has Results","Cerebral Palsy","Biological: Umbilical Cord Blood Infusion|Drug: Erythropoietin Injection|Other: Active Rehabilitation|Other: Placebo Umbilical Cord Blood|Other: Placebo Erythropoietin","Changes in Motor Performance|Changes in Standardized Gross Motor Function|Changes in Cognitive Neurodevelopmental Outcome|Changes in Motor Neurodevelopmental Outcome|Changes in Brain MRI|Comparison of Changes in Brain Glucose Metabolism Using by Brain 18F-FDG PET: Increased and Decreased Areas of Brain Glucose Metabolism|Changes in Functional Performance in Daily Activities|Changes in Functional Independence in Daily Activities|Changes in Muscle Strength|Changes in Hand Function|Number of Participants With Serious Adverse Events as a Measure of Safety,Which Are Related to Umbilical Cord Blood, Erythropoietin, or Immunosuppressant","Sung Kwang Medical Foundation","All","10 Months to 10 Years   (Child)","Not Applicable","105","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","RCTUBSC|PBC09-095","May 2010","April 2011","April 2011","September 2, 2010","March 1, 2012","March 5, 2012","CHA Bundang Medical Center, Seongnam-si, Gyeonggi-do, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT01193660"
887,"NCT00065169","Delaying Alzheimer Disease Symptoms With Anti-Inflammatory Drugs",,"Completed","No Results Available","Alzheimer Disease|Dementia","Drug: Celecoxib","","University of California, Los Angeles|National Institute of Mental Health (NIMH)","All","40 Years to 90 Years   (Adult, Older Adult)","Not Applicable","138","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Prevention","R01MH058156|DSIR AT-GP","November 2000","November 2005","November 2005","July 18, 2003","null","May 4, 2017","UCLA Neuropsychiatric Institute, Los Angeles, California, United States","","https://ClinicalTrials.gov/show/NCT00065169"
888,"NCT02315781","tDCS in Parkinson's Disease With Depression",,"Terminated","No Results Available","Depression|Parkinson's","Device: active tDCS|Device: Sham tDCS","HAMD score|Dopamine levels","Pacific Parkinson's Research Centre","All","19 Years and older   (Adult, Older Adult)","Not Applicable","3","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","H14-00867","January 2015","December 6, 2017","December 6, 2017","December 12, 2014","null","May 14, 2018","Pacific Parkinson's Research Centre, Vancouver, British Columbia, Canada","","https://ClinicalTrials.gov/show/NCT02315781"
889,"NCT00265148","Brain Imaging Study Of Rosiglitazone Efficacy And Safety In Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Drug: Rosiglitazone|Other: Placebo","Change from baseline in global and regional functional brain activity at 12 months|Change in functional brain activity at other timepoints; changes in cognition and clinical scales of AD status; changes in brain structure; safety and tolerability; changes in blood biomarkers and insulin sensitivity; genetic (apolipoprotein E) status|Changes in global and regional CMRglu between baseline and other scan time points as measured by [18F]FDG uptake.|Changes in cognitive tests and clinical scales of AD status from baseline.|Global changes in brain structure from baseline as measured by structural MRI from baseline.|Changes in blood borne biomarkers from baseline: Markers of glucose metabolism (fasting plasma glucose; fasting plasma insulin: HbA1C); Lipid levels; Inflammatory markers; Immunology markers; Putative markers of disease burden.|Changes in insulin sensitivity from baseline: Homeostasis Model Assessment; Body Mass Index|Polymorphism status with respect to genetic markers: Apolipoprotein-E|Measures of safety and tolerability: Vital signs, 12-Lead ECGs, Haematology and clinical chemistry evaluations, Adverse events, Measures of fluid retention: body weight; haematocrit; clinical examination","GlaxoSmithKline","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 2","80","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","BRL-49653/461","May 2004","July 2008","July 2008","December 14, 2005","null","November 16, 2016","GSK Investigational Site, Litchfield Park, Arizona, United States|GSK Investigational Site, Phoenix, Arizona, United States|GSK Investigational Site, Scottsdale, Arizona, United States|GSK Investigational Site, Sun City, Arizona, United States|GSK Investigational Site, Tucson, Arizona, United States|GSK Investigational Site, Los Angeles, California, United States|GSK Investigational Site, Belmont, Massachusetts, United States|GSK Investigational Site, Ann Arbor, Michigan, United States|GSK Investigational Site, Durham, North Carolina, United States|GSK Investigational Site, Montreal, Quebec, Canada|GSK Investigational Site, Montreal, Quebec, Canada|GSK Investigational Site, Liverpool, United Kingdom|GSK Investigational Site, Manchester, United Kingdom|GSK Investigational Site, Swindon, United Kingdom|GSK Investigational Site, West End, Southampton, United Kingdom","","https://ClinicalTrials.gov/show/NCT00265148"
890,"NCT02310360","Striatal and Extra-striatal Dopamine Release in Response to Food in Healthy Humans","DA-Fallypride","Active, not recruiting","No Results Available","Appetite Regulation","Radiation: Fallypride","DA release in both striatal and extra-striatal brain regions","Universitaire Ziekenhuizen Leuven","Female","18 Years to 60 Years   (Adult)","","12","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","S56186","November 2014","December 2015","March 2017","December 8, 2014","null","October 27, 2016","University Hospitals Leuven, campus Gasthuisberg, Leuven, Belgium","","https://ClinicalTrials.gov/show/NCT02310360"
891,"NCT03640806","QOL Efficacy of Adapted Physical Activity for Patients With Fibromyalgia",,"Not yet recruiting","No Results Available","Fibromyalgia","Other: PHYSICAL ACTIVITY","The Fibromyalgia Impact Questionnaire","Assistance Publique Hopitaux De Marseille","All","18 Years and older   (Adult, Older Adult)","Not Applicable","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","2017-57","November 2018","May 2020","May 2021","August 21, 2018","null","August 21, 2018","Assistance Publique Des Hopitaux de Marseille, Marseille, Paca, France","","https://ClinicalTrials.gov/show/NCT03640806"
892,"NCT02727972","Examination of Glutamate and mGluR5 in Psychiatric Disorders",,"Recruiting","No Results Available","Major Depressive Disorder|Post-Traumatic Stress Disorder|Bipolar Disorder","Behavioral: Cognitive Testing|Other: MRI|Radiation: PET","Evidence of glutamate availability (mGluR5) in psychiatric disorders confirmed by MRI and PET data.","Yale University|VA Office of Research and Development","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","180","Other|U.S. Fed","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","1101007933","August 2011","August 2020","August 2020","April 5, 2016","null","January 9, 2018","PET Center, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT02727972"
893,"NCT03310502","Variation of Genes Controlling Carbohydrate and Lipid Metabolism","CMgene","Recruiting","No Results Available","Diabetes Mellitus, Type 2|Cardiovascular Diseases|Obesity|Insulin Resistance|Lipid Metabolism Disorders|PreDiabetes","","Skeletal muscle insulin sensitivity|Whole body insulin sensitivity|Visceral adipose tissue insulin sensitivity to glucose uptake|Abdominal subcutaneous adipose tissue insulin sensitivity to glucose uptake|Brown adipose tissue insulin sensitivity|Brown adipose tissue glucose uptake during cold exposure|Insulin sensitivity of adipose tissue lipolysis|Myocardial insulin sensitivity|Liver insulin sensitivity to glucose uptake|Endogenous glucose production|Brain insulin sensitivity to glucose uptake|Abdominal subcutaneous adipose tissue mass|Visceral adipose tissue mass|Liver fat content|Myocardial fatty acid uptake|Liver fatty acid uptake|Abdominal subcutaneous adipose tissue fatty acid uptake|Visceral adipose tissue fatty acid uptake|Brown adipose tissue fatty acid uptake at fasting state|Brown adipose tissue fatty acid uptake during cold exposure|Skeletal muscle fatty acid uptake|Coronary flow reserve","Turku University Hospital|University of Eastern Finland|Kuopio University Hospital|University of Turku","All","18 Years and older   (Adult, Older Adult)","","2050","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","CMgene","April 17, 2002","December 31, 2019","December 31, 2019","October 16, 2017","null","October 16, 2017","Turku PET Centre (Turku University Hospital), Turku, Finland","","https://ClinicalTrials.gov/show/NCT03310502"
894,"NCT02734602","Imaging SV2A in Mood Disorders",,"Recruiting","No Results Available","Major Depressive Disorder|Post-Traumatic Stress Disorder","Drug: Ketamine|Behavioral: Cognitive Testing|Radiation: PET|Device: MRI","Evidence of synaptic changes in psychiatric disorders confirmed by PET data.|Evidence of synaptic density at time of its greatest anti-depressant response in psychiatric disorders confirmed with PET data.","Yale University|VA Office of Research and Development","All","18 Years to 55 Years   (Adult)","Not Applicable","30","Other|U.S. Fed","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","1511016789","April 2016","January 2021","March 2021","April 12, 2016","null","March 15, 2018","PET Center, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT02734602"
895,"NCT01890343","Imaging Characteristics of Florbetapir 18F in Patients With Frontotemporal Dementia, Alzheimer's Disease and Normal Controls.",,"Completed","Has Results","Alzheimer's Disease|Frontotemporal Dementia","Drug: florbetapir 18F|Drug: 18F-FDG","Qualitative Amyloid Image Assessment|Quantitative Amyloid Image Assessment","Avid Radiopharmaceuticals","All","45 Years and older   (Adult, Older Adult)","Phase 2","34","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic","18F-AV-45-010","September 2009","December 2012","April 2013","July 1, 2013","September 17, 2014","September 29, 2014","Research Site, Manchester, United Kingdom","","https://ClinicalTrials.gov/show/NCT01890343"
896,"NCT03341078","Pilot Study of the Effect of Ibudilast on Neuroinflammation in Methamphetamine Users","Ibudilast","Not yet recruiting","No Results Available","Methamphetamine Dependence in Remission","Drug: Ibudilast|Drug: Placebo Oral Tablet","Effects of ibudilast on neuroinflammation as assessed by magnetic resonance spectroscopy (MRS)|Effects of ibudilast on neuroinflammation as assessed by positron emission tomography (PET)|Effects of ibudilast on brain function as assessed by magnetic resonance imaging (MRI)|Effects of ibudilast on overall cognitive battery score.","Oregon Health and Science University|Portland VA Medical Center","All","18 Years to 55 Years   (Adult)","Phase 2","65","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","16768|18176","September 2018","January 2020","January 2020","November 14, 2017","null","July 10, 2018","","","https://ClinicalTrials.gov/show/NCT03341078"
897,"NCT02094196","The Role of Dopaminergic and Glutamatergic Neurotransmission for Dysfunctional Learning in Alcohol Use Disorders","LeAD P5","Active, not recruiting","No Results Available","Alcohol Use Disorder","Other: Alcohol detoxification","Striatal D2-receptor availability (PET) and prefrontal glutamate concentration (MRS)|behavioral data in reward-habit-learning paradigms|Treatment response","Technische Universität Dresden|Charite University, Berlin, Germany","All","18 Years to 65 Years   (Adult, Older Adult)","","60","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","GA707/6-1","December 2012","April 2018","December 2018","March 21, 2014","null","August 17, 2018","Charité Berlin, Division of Neuroimaging, Berlin, Germany|Charité - Universitätsmedizin Berlin, Berlin, Germany","","https://ClinicalTrials.gov/show/NCT02094196"
898,"NCT00195143","Safety Study of Subthalamic Nucleus Gene Therapy for Parkinson's Disease",,"Completed","No Results Available","Parkinson's Disease","Genetic: Surgical infusion of AAV-GAD into the subthalamic nucleus","Safety|Improvement in brain metabolism measured by PET scans|Improvement in standard clinical rating scales","Neurologix, Inc.|Weill Medical College of Cornell University|North Shore University Hospital","All","25 Years to 75 Years   (Adult, Older Adult)","Phase 1","12","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0902-478","August 2003","null","August 2005","September 19, 2005","null","March 27, 2008","North Shore University Hospital, Manhasset, New York, United States","","https://ClinicalTrials.gov/show/NCT00195143"
899,"NCT01834716","Exercise in Asymptomatic Pre-Alzheimer's Disease Pilot Study",,"Completed","No Results Available","Alzheimer's Disease Prevention","Behavioral: Aerobic vs. Non-Aerobic exercise","Number of subjects retained in the study at 6 months","Mayo Clinic","All","65 Years and older   (Older Adult)","Not Applicable","16","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","12-002817","April 2013","December 2014","December 2014","April 18, 2013","null","April 8, 2015","Mayo Clinic in Florida, Jacksonville, Florida, United States","","https://ClinicalTrials.gov/show/NCT01834716"
900,"NCT00205595","Normal Binding of R-[11C]PK11195 in Human Subjects",,"Unknown status","No Results Available","Normal Aging","Device: Positron Emission Tomography","specific binding of tracer depending on age|tracer kinetic method","VU University Medical Center","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2001/001|no other ID's","February 2001","null","January 2007","September 20, 2005","null","July 8, 2008","VU University Medical Centre, Amsterdam, Netherlands","","https://ClinicalTrials.gov/show/NCT00205595"
901,"NCT02562560","Neuropsycholgy and Neuroimaging in Transient Global Amnesia","2NIA","Terminated","No Results Available","Transient Global Amnesia (TGA)","Behavioral: Neuropsychological tests|Device: Cerebral imaging (MRI, PET-FDG)","Episodic memory scores","University Hospital, Caen","All","30 Years to 90 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Primary Purpose: Diagnostic","2007-A00910-53","September 2008","July 2015","null","September 29, 2015","null","November 3, 2015","","","https://ClinicalTrials.gov/show/NCT02562560"
902,"NCT01036061","GSK618334 Repeat Dose Study",,"Completed","No Results Available","Substance Dependence","Drug: GSK618334 Low Dose|Drug: GSK618334 PET subjects|Drug: GSK618334 Medium Dose|Drug: GSK618334 High Dose","The safety and tolerability endpoints will be: adverse events, laboratory values, cardiovascular variables (blood pressure, heart rate, ECG), temperature, respiratory rate, assessment of mood and abnormal movements, and GSK618334 blood levels.|To assess blood concentrations of GSK618334 after repeated oral doses.|To assess the effect of food on GSK618334 blood concentrations after a single dose.|The dopamine type 3 receptor binding in the brain (by PET scan) of GSK618334 following the repeat dose session.","GlaxoSmithKline","All","18 Years to 50 Years   (Adult)","Phase 1","46","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other","108414","September 28, 2009","February 17, 2010","February 17, 2010","December 21, 2009","null","June 22, 2017","GSK Investigational Site, London, United Kingdom","","https://ClinicalTrials.gov/show/NCT01036061"
903,"NCT00001307","Positron Emission Tomography to Measure Pain and Pain Control",,"Completed","No Results Available","Healthy|Hyperalgesia|Pain|Peripheral Nervous System Disease","Drug: Oxygen-15 Water|Drug: Capsaicin","","National Institute of Dental and Craniofacial Research (NIDCR)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult","","273","NIH","Observational","","920243|92-D-0243","August 1992","null","August 2005","November 4, 1999","null","March 4, 2008","National Institute of Dental And Craniofacial Research (NIDCR), Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00001307"
904,"NCT01360190","Neurophysiologic Monitoring of Antidepressant Treatment","Lilly","Completed","No Results Available","Major Depressive Disorder","Drug: fluoxetine","Change in Hamilton Rating Scale For Depression Score","University of California, Los Angeles","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","94-08-273-13","August 1994","August 1996","August 1996","May 25, 2011","null","May 25, 2011","","","https://ClinicalTrials.gov/show/NCT01360190"
905,"NCT03289949","The Neurobiological Effect of 5-HT2AR Modulation",,"Recruiting","No Results Available","Basic Science","Drug: Psilocybine|Drug: Ketanserin","Psilocin/ketanserin blood concentrations and 5-HT2A receptor occupancy (i.e., binding potential).|Effects of psilocybin on Cimbi-36 binding potential at baseline and at one and twelve weeks|Effects of psilocybin and ketanserin on brain function assessed with fMRI","Gitte Moos Knudsen|Rigshospitalet, Denmark","All","18 Years and older   (Adult, Older Adult)","Phase 1","45","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","2016-004000-61","March 3, 2017","December 31, 2019","December 31, 2019","September 21, 2017","null","September 21, 2017","Neurobiology Research Unit, Rigshospitalet, Copenhagen, Denmark","","https://ClinicalTrials.gov/show/NCT03289949"
906,"NCT03526809","Molecular Imaging and Spectroscopy With Stable Isotopes in Oncology and Neurology","MISSION-ovary","Recruiting","No Results Available","Ovarian Cancer","Diagnostic Test: MRI scan and FDG-PET scan","Imaging of the metabolism of hyperpolarized 13C-pyruvate in ovarian cancer tissue to hyperpolarized 13C-lactate.|Correlation of the hyperpolarized 13C images from tumour with histological, biochemical and genetic information gained after surgery and/or biopsy.|Detection of the change in the metabolism of hyperpolarized 13C-pyruvate following systemic anticancer therapy.","Cambridge University Hospitals NHS Foundation Trust","Female","18 Years to 99 Years   (Adult, Older Adult)","","40","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","A093768","June 1, 2016","December 31, 2018","December 31, 2019","May 16, 2018","null","May 16, 2018","Addenbrooke's Hospital, Cambridge, Please Select An Option Below, United Kingdom","","https://ClinicalTrials.gov/show/NCT03526809"
907,"NCT01962779","Sleep, Aging and Risk for Alzheimer's Disease","SARA","Active, not recruiting","No Results Available","Sleep Disordered Breathing|Alzheimer's Disease","Device: Continuous positive airway pressure (CPAP)","Observational. Cerebrospinal fluid (CSF) biomarkers of risk for Alzheimer's disease (AD) in sleep disordered breathing (SDB) subjects.|Observational. Structural MRI hippocampal volume in SDB subjects.|Observational. MRI-ASL vasoreactivity response to CO2 challenge in subjects with SDB|Interventional CPAP Clinical Trial, memory changes after CPAP treatment|Interventional CPAP Clinical Trial, CSF biomarker changes after CPAP treatment|Interventional CPAP Clinical Trial, MRI biomarker changes","New York University School of Medicine|National Heart, Lung, and Blood Institute (NHLBI)","All","50 Years and older   (Adult, Older Adult)","Not Applicable","224","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","12-03068|R01HL118624","July 31, 2013","April 30, 2017","April 30, 2019","October 14, 2013","null","March 7, 2018","NYU Sleep Disorders Center, New York, New York, United States|NYU Center for Brain Health, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT01962779"
908,"NCT03533530","Clinical Utility of ESI in Presurgical Evaluation of Patients With Epilepsy","CUESIPE","Recruiting","No Results Available","Electroencephalography|Refractory Epilepsy|Brain Imaging|Surgery","Diagnostic Test: Low-density ESI (LD ESI)|Diagnostic Test: High-density ESI (HD ESI)|Diagnostic Test: No electrical source imaging (ESI)","Clinical utility of LD ESI and of HD ESI: change in clinical decision following ESI|Change to stop|Change from stop to implantation of intracranial electrodes|Change in the strategy (location) of implanted intracranial electrodes|Change from stop to operation|Change from implantation of intracranial electrodes to operation|Change from operation to implantation of intracranial electrodes","Rigshospitalet, Denmark|Filadelfia, Danish Epilepsy Center, Dianalund, Denmark|Lundbeck Foundation|Lennart Grams Mindefond, Danish Epilepsy Society","All","10 Years and older   (Child, Adult, Older Adult)","Not Applicable","70","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic","LD&HD-ESI","December 2, 2015","August 1, 2018","October 1, 2018","May 23, 2018","null","May 23, 2018","Rigshospitalet, Copenhagen, Select, Denmark","","https://ClinicalTrials.gov/show/NCT03533530"
909,"NCT02616679","Cognitive Detection of Preclinical AD: Validation Using Biomarkers",,"Recruiting","No Results Available","Mild Cognitive Impairment","","Correlation of composite score on cognitive tests with biomarkers|Presence of ApoE allele","New York University School of Medicine|Janssen Scientific Affairs, LLC","All","60 Years to 85 Years   (Adult, Older Adult)","","80","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","13-00706","January 2016","October 2018","October 2018","November 30, 2015","null","January 26, 2018","NYU Langone Medical Center, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT02616679"
910,"NCT02374242","Anti‐PD 1 Brain Collaboration for Patients With Melanoma Brain Metastases","ABC","Active, not recruiting","No Results Available","Melanoma|Brain Metastases","Drug: Nivolumab|Drug: Ipilimumab","Intracranial response rate|Extracranial response rate|Overall response rate|Progression free survival in intracranial disease|Progression free survival in extracranial disease|Overall progression free survival|Overall survival|Safety and tolerability of nivolumab and nivolumab + ipilimumab (verse events by type, frequency and severity using National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.)|Patient rated quality of life|Clinical response using immune related response criteria (irRC)|Tissue and blood biomarkers of response and progression|FET‐PET response in the brain at 6 and 12 weeks on therapy (Proportion of patients with a lower standardised uptake value from baseline in intracranial metastases, following at least ONE dose of study treatment)","Melanoma Institute Australia|Australia and New Zealand Melanoma Trials Group|Bristol-Myers Squibb","All","18 Years and older   (Adult, Older Adult)","Phase 2","76","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CA209‐170|ACTRN12614001315606|ANZMTG 01.14","November 4, 2014","September 4, 2017","December 2022","February 27, 2015","null","April 11, 2018","Melanoma Institute Australia, North Sydney, New South Wales, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia","","https://ClinicalTrials.gov/show/NCT02374242"
911,"NCT02967536","Investigating the Effect of Continuous Positive Airway Pressure on the Neuropathology of Obstructive Sleep Apnoea","INcOSA","Recruiting","No Results Available","Obstructive Sleep Apnoea|Inflammation","Device: Continuous Positive Airway Pressure (CPAP)","Levels of neuroinflammation and discrete changes in brain morphology and physiology will be measured via MRI, PET-MRI imaging at baseline and after 3 months of CPAP treatment.|Cognitive performance using the CANTAB battery at baseline and after 3 months of CPAP.|Genetic analysis and linkage to clinical and neuroimaging data will be measured using biological samples (blood or saliva) analysed and stored in the BioResource for Mental and Neurological Health at before and after CPAP treatment.","King's College London|Guy's and St Thomas' NHS Foundation Trust","Male","18 Years to 70 Years   (Adult, Older Adult)","","14","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","170912","November 1, 2017","October 2020","October 1, 2020","November 18, 2016","null","March 7, 2018","Guy's Hospital Sleep Centre, London, United Kingdom","","https://ClinicalTrials.gov/show/NCT02967536"
912,"NCT02353845","Construction of Diagnosis System for Early AD Based on Multi-Modality MRI Technology",,"Completed","No Results Available","Mild Cognitive Impairment|Alzheimer's Disease","","number of participants correctly classified by the support vector machine (SVM) classifier for the aMCI diagnosis|number of participants correctly predicted by the SVM classifier for predicting conversion from aMCI to AD|regional cerebral metabolism (CMgl) measured by FDG-PET|changed regional cerebral blood flow measured by FDG-PET","XuanwuH 2|Xuanwu Hospital, Beijing","All","Child, Adult, Older Adult","","297","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","hanying2","November 2013","October 2015","August 2016","February 3, 2015","null","August 23, 2016","Department of Neurolgy,Xuanwu Hospital of Capital Medical University, Beijing, Beijing, China","","https://ClinicalTrials.gov/show/NCT02353845"
913,"NCT00001325","Metabolic Abnormalities in Children With Epilepsy",,"Completed","No Results Available","Generalized Epilepsy|Infantile Spasms|Metabolic Disease|Partial Epilepsy|Seizures","Drug: 18 FDG","","National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult","","80","NIH","Observational","","920175|92-N-0175","April 1992","null","June 2004","November 4, 1999","null","March 4, 2008","National Institute of Neurological Disorders and Stroke (NINDS), Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00001325"
914,"NCT01174056","Evaluation of Rosiglitazone Anti-inflammatory Effect With FDG-PET Imaging",,"Completed","No Results Available","Lung Inflammation","Drug: Zileuton|Drug: Pioglitazone placebo|Drug: Zileuton placebo|Drug: Pioglitazone","Ki, measure of FDG uptake|Bronchoalveolar lavage (BAL) fluid cell counts","Washington University School of Medicine|Doris Duke Charitable Foundation","All","19 Years to 44 Years   (Adult)","Early Phase 1","39","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","DDCF-2010060","July 2011","March 2014","March 2014","August 3, 2010","null","April 23, 2014","Washington University / Barnes Jewish Hospital, St. Louis, Missouri, United States","","https://ClinicalTrials.gov/show/NCT01174056"
915,"NCT02683824","Integrin Alpha-v-Beta and [18F]-R01-MG-F2 PET/CT in Measuring Response in Patients With Pancreatic Cancer and Healthy Volunteers",,"Active, not recruiting","No Results Available","Healthy Subject|Pancreatic Carcinoma","Diagnostic Test: Computed Tomography|Other: Laboratory Biomarker Analysis|Diagnostic Test: PET/MRI scan|Drug: [18F]FP-R01-MG-F2","Biodistribution of [18F]FP-R01-MG-F2 (%ID/g)|Biodistribution of [18F]FP-R01-MG-F2 (SUV)|Dosimetry of [18F]FP-R01-MG-F2 (rem/mCi)|Dosimetry of [18F]FP-R01-MG-F2 (mSv/MBq)","Sanjiv Sam Gambhir|National Cancer Institute (NCI)|Stanford University","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","7","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","PANC0020|NCI-2015-01887|4593|P30CA124435","January 12, 2016","December 2018","December 2019","February 17, 2016","null","August 2, 2018","Stanford University, School of Medicine, Palo Alto, California, United States","","https://ClinicalTrials.gov/show/NCT02683824"
916,"NCT03239899","PD-1 Inhibition to Determine CNS Reservoir of HIV-Infection",,"Recruiting","No Results Available","HIV Infections","Drug: Pembrolizumab","The primary goal of the study is to determine the safety of a single dose of pembrolizumab in HIV-positive patients.|To determine the effect of pembrolizumab on HIV-specific T-cell responses.|To determine the effect of pembrolizumab on CSF PD-1 expression.|To examine if pembrolizumab changes the CSF expression of HIV-specific antibody responses or CSF cytokine profiles.","National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)","Phase 1","20","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","170145|17-N-0145","April 9, 2018","December 31, 2019","December 31, 2020","August 4, 2017","null","August 14, 2018","National Institutes of Health Clinical Center, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT03239899"
917,"NCT02213575","Study 3: Minocycline Decreases Microglia Activation",,"Recruiting","No Results Available","Hypertension","Drug: Minocycline","MRI changes in the paraventricular nucleus|PET changes in the paraventricular nucleus","University of Florida|National Heart, Lung, and Blood Institute (NHLBI)","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","9","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2013-00102 Study 3-N|RO1HL3361028|2013-00102 Study 3","July 15, 2017","August 2018","August 2018","August 11, 2014","null","April 5, 2018","UF Health Cardiovascular Clinic, Gainesville, Florida, United States","","https://ClinicalTrials.gov/show/NCT02213575"
918,"NCT00602667","Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma",,"Active, not recruiting","No Results Available","Brain and Central Nervous System Tumors","Drug: Induction Chemotherapy|Drug: Low-Risk Therapy|Drug: High-Risk Therapy|Drug: Intermediate-Risk Therapy","Progression-free survival|DNA methylation in peripheral blood or tissue|Event-free survival|Chromosomal abnormalities|Gene expression patterns|Molecular abnormalities by tumor type|Number of successful collections for frozen and fixed tumor samples|Event free survival compared to historical controls|Overall survival compared to historical controls|Rate of disease progression|Objective response rate|Number of participants who successfully complete induction therapy|Number of participants who successfully complete consolidation therapy|Sustained objective response rate|Percent of total scheduled doses received during oral maintenance therapy|Change in neurostructure, especially white matter volume and integrity|Percent of PET scans with loss of signal intensity|Pharmacokinetic variables of methotrexate|Pharmacokinetic variables of intravenous and oral cyclophosphamide and its metabolites by age, gender, race, and weight|Number of participants who successfully achieve target systemic exposure of intravenous topotecan|Pharmacokinetic variables of intravenous and oral topotecan by age, gender, race and weight|Pharmacokinetic variables of oral erlotinib by age, gender, race and weight|Change in concentration of cerebrospinal fluid (CSF) neurotransmitters|Change in neurocognitive performance|Number and type of genetic polymorphisms|Pharmacogenetic variation on CNS transmitters|Change in neuropsychological performance|Change in quantitative magnetic resonance (MR) measures in the frontal lobe|Change in neurocognitive performance in attention, working memory, and fluency|Change in quantitative MR measures in the right frontal-parietal regions|Change in neurocognitive performance in visual-spatial reasoning and processing speed|Number of participants with endocrinopathy|Longitudinal change in growth hormone secretion","St. Jude Children's Research Hospital|University of Florida|National Cancer Institute (NCI)|The Pew Charitable Trusts","All","up to 5 Years   (Child)","Phase 2","293","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SJYC07|R01CA154619|NCI-2011-01193","December 17, 2007","September 27, 2017","April 30, 2023","January 28, 2008","null","June 20, 2018","Lucile Packard Children's Hospital at Stanford University Medical Center, Palo Alto, California, United States|Rady Children's Hospital, San Diego, California, United States|Children's Hospitals and Clinics of Minnesota - St. Paul, Saint Paul, Minnesota, United States|St. Jude Children's Research Hospital, Memphis, Tennessee, United States|University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States|Lady Cilento Children's Hospital, Brisbane, Brisbane, Queensland, Australia","","https://ClinicalTrials.gov/show/NCT00602667"
919,"NCT03134716","Role of Microglia in the Pathogenesis of Progressive Multiple Sclerosis","PROMS","Active, not recruiting","No Results Available","Multiple Sclerosis","","Change in microglial activation during 5-year follow-up as assesed by distibution volume ratio of 11C-PK11195 radioligand|Correlation of 11C-TMSX radioligand binding and MS progression","Turku University Hospital","All","40 Years to 50 Years   (Adult)","","35","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","T99/2016","April 2016","April 2022","April 2023","May 1, 2017","null","May 10, 2018","Turku PET Centre, Turku, Finland Proper, Finland","","https://ClinicalTrials.gov/show/NCT03134716"
920,"NCT00185848","Assessing the Suitability of an Imaging Probe for Use in Clinical Cell and Gene Therapy Trials in Cancer and Rheumatoid Arthritis",,"Completed","No Results Available","Brain Cancer|Arthritis, Rheumatoid|Central Nervous System Neoplasms|Glioma","Radiation: [18F]FHBG","The primary endpoint of the study for each patient is acquisition of PET/CT image.|Collection of vital signs, EKG, blood chemistry and CBC data","Sanjiv Sam Gambhir|Stanford University","All","18 Years and older   (Adult, Older Adult)","Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","BRNCNS0003|95908","April 2005","June 2013","June 2013","September 16, 2005","null","March 14, 2017","University of California Los Angeles, Los Angeles, California, United States|Stanford University School of Medicine, Stanford, California, United States","","https://ClinicalTrials.gov/show/NCT00185848"
921,"NCT03539575","CB1R in Synthetic Psychoactive Cannabinoids","CB1R in Spice","Recruiting","No Results Available","Drug Dependence","Other: [11-C]OMAR","Positron Emission Tomography (PET Imaging)|CogState Battery|Electroencephalogram","Yale University|National Institutes of Health (NIH)|National Institute on Drug Abuse (NIDA)","All","18 Years to 55 Years   (Adult)","Not Applicable","15","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","1308012514A|1R21DA041580-01A1","May 1, 2018","April 2021","December 2021","May 28, 2018","null","May 28, 2018","Connecticut Mental Health Center, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT03539575"
922,"NCT01163825","Encapsulated Cell Biodelivery of Nerve Growth Factor to Alzheimer´s Disease Patients","NsG0202","Unknown status","No Results Available","Alzheimer's Disease","Drug: Nerve Growth Factor","Adverse events|Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-Cog)","NsGene A/S|Karolinska Institutet|Stockholm County Council, Sweden","All","50 Years to 80 Years   (Adult, Older Adult)","Phase 1","6","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NsG0202-001","January 2008","December 2011","null","July 16, 2010","null","July 16, 2010","Karolinska University Hospital, Stockholm, Sweden","","https://ClinicalTrials.gov/show/NCT01163825"
923,"NCT01194986","Evaluation of Histamine H3 Receptor Radioligand [11C]AZ12807110 and Histamine H3 Receptor Occupancy of AZD5213 After Oral Administration",,"Completed","No Results Available","Brain Distribution of [11C]AZ12807110 and AZD5213","Other: [11C]AZ12807110|Drug: AZD5213","Distribution volume (VT)|Estimation of the plasma concentration resulting in 50% receptor occupancy (Ki, pl).|Adverse events|Vital signs (body temperature, BP and pulse)","AstraZeneca","Female","20 Years to 45 Years   (Adult)","Phase 1","13","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","D3030C00003|2009-010702-11","November 2010","June 2011","June 2011","September 3, 2010","null","January 28, 2015","Research Site, Uppsala, Sweden","","https://ClinicalTrials.gov/show/NCT01194986"
924,"NCT02764437","AsthMatic Inflammation and Neurocircuitry Activation (MINA)","MINA","Recruiting","No Results Available","Allergic Asthma","Biological: Whole lung antigen challenge, segmental allergen challenge","Bronchoalveolar Eosinophils pre vs post antigen challenge|Sputum Eosinophils pre stress condition vs post stress condition|Sputum Eosinophils pre control condition vs post control condition","University of Wisconsin, Madison|National Institutes of Health (NIH)|National Heart, Lung, and Blood Institute (NHLBI)","All","18 Years to 50 Years   (Adult)","Not Applicable","50","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","2016-0021|1R01HL123284-01A1","July 28, 2016","March 2021","March 2021","May 6, 2016","null","August 22, 2018","UW Madison School of Medicine and Public Health, Madison, Wisconsin, United States","","https://ClinicalTrials.gov/show/NCT02764437"
925,"NCT00001977","The Effect of Acetylcholine on Memory and Attention",,"Completed","No Results Available","Alzheimer's Disease|Healthy","","","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult","","70","NIH","Observational","","000056|00-M-0056","January 2000","null","April 2001","December 10, 2002","null","March 4, 2008","National Institute of Mental Health (NIMH), Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00001977"
926,"NCT02624778","A Study of LY3002813 in Participants With Memory Damage Due to Alzheimer's Disease (AD) or AD",,"Active, not recruiting","No Results Available","Alzheimer Disease","Biological: LY3002813|Drug: Placebo","Florbetapir Positron Emission Tomography (PET) Standardized Uptake Value Ratio (SUVr)|Pharmacokinetics: Serum Concentrations of LY3002813|Change from Baseline in Incidence of Anti-Drug Antibodies","Eli Lilly and Company","All","50 Years and older   (Adult, Older Adult)","Phase 1","150","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science","16233|I5T-MC-AACD","December 2015","September 2019","May 2020","December 8, 2015","null","June 25, 2018","Brain Matters Research, Delray Beach, Florida, United States|Compass Research, Orlando, Florida, United States|Compass Research, The Villages, Florida, United States|SNBL Clinical Pharmacology Center Inc, Baltimore, Maryland, United States|St. Louis Clinical Trials, LC, Saint Louis, Missouri, United States|PRA Health Sciences, Salt Lake City, Utah, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Shinjuku-Ku, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Shinjuku-Ku, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Sumida-ku, Japan","","https://ClinicalTrials.gov/show/NCT02624778"
927,"NCT00001657","Use of Repetitive Transcranial Magnetic Stimulation (rTMS) in Chronic Posttraumatic Stress Disorder (PTSD)",,"Completed","No Results Available","Posttraumatic Stress Disorder","","","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult","","30","NIH","Observational","","970128|97-M-0128","June 1997","null","May 2000","December 10, 2002","null","March 4, 2008","National Institute of Mental Health (NIMH), Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00001657"
928,"NCT02051608","A Study of Gantenerumab in Participants With Mild Alzheimer Disease",,"Active, not recruiting","No Results Available","Alzheimer's Disease","Drug: Gantenerumab|Drug: Placebo","Mean Change From Baseline in Alzheimer's Disease Activity Scale-Cognitive subscale 13 (ADAS-Cog13) scores at Week 104|Mean Change From Baseline in Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) scores at week 104|Part 2: Percentage of Participants with Adverse Events (AEs) or Serious Adverse Events (SAEs)|Change From Baseline in Total Tau (t-tau) in CSF at Week 104|Change From Baseline in phosphorylated tau [p-tau]in CSF at Week 104|Change From Baseline in Abeta 1-42 levels in CSF at Week 104|Change From Baseline in Hippocampal Volume, as Assessed by Magnetic Resonance Image (MRI) at Week 104|Change From Baseline in Whole Brain Volume, as assessed by MRI at Week 104|Change From Baseline in Cortical thickness, as assessed by MRI at Week 104|Change From Baseline in Ventricular Volume, as Assessed by MRI at Week 104|Change From Baseline in Clinical Dementia Rating Global Score (CDR-GS) at Week 104|Change From Baseline in CDR Sum of Boxes (SB) at Week 104|Change From Baseline in Neuropsychiatric Inventory (NPI) Total Score at Week 104|Change From Baseline in NPI Domain Score at Week 104|Change From Baseline in Mini Mental State Examination (MMSE) Total Score at Week 104|Safety: Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs)|Percentage of Participants with anti-gantenerumab antibodies|Change From Baseline in Columbia - Suicide Severity Rating Scale (C-SSRS) Over Week 152|Pharmacokinetics: Apparent Total Clearance (CL/F) of gantenerumab|Pharmacokinetics: Apparent Volume of Distribution (V/F) of gantenerumab|Pharmacokinetics: Maximum Observed Plasma Concentration (Cmax) of gantenerumab|Pharmacokinetics: Time to Reach Maximum Plasma Concentrations (Tmax) of gantenerumab|Pharmacokinetics: Minimum Observed Plasma Concentration (Cmin) of gantenerumab|Pharmacokinetics: Area Under Plasma Concentration (AUC) -Time Curve of gantenerumab|Quality of Life - Change From Baseline in Alzheimer's Dementia (QoL-AD) Global Score at Week 104|Efficacy: Change From Baseline in Symptom Guide Facilitated (GAS) at Week 104|Efficacy: Change from Baseline in Dependence Scale (DS) at Week 104|Efficacy: Change From Baseline in Resource Utilization Dementia-Lite (RUD - Life) Scale at Week 104|Change From Baseline in Zarit Caregiver Interview for Alzheimer's Disease (ZCI-AD) at Week 104|Time to Clinical Decline (as measured by Confirmed greater than or equal to [>=] 2-point decline on MMSE, Loss of >= 1 or 2 points on one or more ADL and I ADL, respectively)|Change from Baseline in Clinical Composite Score (Prespecified Items From The ADAS-Cog, MMSE, and CDR) at Week 104","Hoffmann-La Roche","All","50 Years to 90 Years   (Adult, Older Adult)","Phase 3","389","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","WN28745|2013-003390-95","March 27, 2014","April 12, 2018","November 20, 2020","January 31, 2014","null","August 7, 2018","Banner Alzheimer's Institute, Phoenix, Arizona, United States|Banner Sun Health Research Insitute, Sun City, Arizona, United States|Territory Neurology and Research Institute, Tucson, Arizona, United States|ATP Clinical Research, Inc, Costa Mesa, California, United States|Neuropsychiatric Research Center of Orange County, Orange, California, United States|Pacific Research Network - PRN, San Diego, California, United States|California Neuroscience Research Medical Group, Inc, Sherman Oaks, California, United States|Radiant Research, Inc., Denver, Colorado, United States|Meridien Research, Brooksville, Florida, United States|Brain Matters Research, Inc., Delray Beach, Florida, United States|Neuropsychiatric Research; Center of Southwest Florida, Fort Myers, Florida, United States|Infinity Clinical Research, Hollywood, Florida, United States|Alzheimer's Research and Treatment Center, Lake Worth, Florida, United States|Miami Jewish Health Systems; Clinical Research, Miami, Florida, United States|Collier Neurologic Specialists, Naples, Florida, United States|Bioclinica Research, Orlando, Florida, United States|Progressive Medical Research, Port Orange, Florida, United States|University of South Florida, Tampa, Florida, United States|Bioclinica The Villages, The Villages, Florida, United States|Indiana University, Indianapolis, Indiana, United States|Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States|Louisiana Research Associates, New Orleans, Louisiana, United States|Western Michigan University Homer Stryker M.D. School of Medicine Center for Clinical Research, Kalamazoo, Michigan, United States|Millennium Psychiatric Associates, LLC, Creve Coeur, Missouri, United States|Alzheimer's Research Corporation, Manchester, New Jersey, United States|Ocean Rheumatology, Toms River, New Jersey, United States|Nathan Kline Institute, Orangeburg, New York, United States|Richmond Behavioral Associates, Staten Island, New York, United States|Alzheimer's Memory Center, Charlotte, North Carolina, United States|Richard H Weisler, MD, Raleigh, North Carolina, United States|Tulsa Clinical Research LLC, Tulsa, Oklahoma, United States|Northeastern Pennsylvania Memory, Plains, Pennsylvania, United States|Abington Neurological Associates, Willow Grove, Pennsylvania, United States|Rhode Island Mood & Memory Research Institute, East Providence, Rhode Island, United States|Neurology Clinic PC, Cordova, Tennessee, United States|Senior Adults Specialty Research, Austin, Texas, United States|University of Utah, Center for Alzheimer's Care Imaging & Research, Salt Lake City, Utah, United States|Instituto Neurologia Bs As, Ciudad Autonoma de Bs As, Argentina|Instituto de Neurología y Neurorehabilitación del Litoral (INNEL), Santa Fé, Argentina|Hornsby Ku-ring-gai Hospital; Division of Rehabilitation & Aged Care, Hornsby, New South Wales, Australia|Royal Adelaide Hospital; Memory Trials Centre, Adelaide, South Australia, Australia|The Queen Elizabeth Hospital; Neurology, Woodville, South Australia, Australia|Heidelberg Repatriation Hospital; Medical and Cognitive Research Centre, Heidelberg West, Victoria, Australia|Australian Alzheimer's Research Foundation, Nedlands, Western Australia, Australia|Cliniques Universitaires St-Luc, Bruxelles, Belgium|UZ Leuven Gasthuisberg, Leuven, Belgium|Shat Np Sveti Naum; 3Rd Clinic of Neurology, Sofia, Bulgaria|MBAL St. Marina; First Neurology Department, Varna, Bulgaria|University of Calgary; Heritage Medical Research Clinic, Calgary, Alberta, Canada|The Medical Arts Health Research Group, Powell River, British Columbia, Canada|True North Clinical Research-Halifax, Halifax, Nova Scotia, Canada|True North Clinical Research Kentville, Kentville, Nova Scotia, Canada|Jbn Medical Diagnostic Services Inc., Burlington, Ontario, Canada|Queens University - Hotel Dieu Hospital, Kingston, Ontario, Canada|Parkwood Hospital; Geriatric Medicine, London, Ontario, Canada|Kawartha Centre - Redefining Healthy Aging, Peterborough, Ontario, Canada|Toronto Memory Program (Neurology Research Inc.), Toronto, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|Recherches Neuro-Hippocame, Gatineau, Quebec, Canada|NeuroSearch Developpements inc, Greenfield Park, Quebec, Canada|Jewish General Hospital / McGill University, Montreal, Quebec, Canada|CHAUQ Hopital Enfant-Jesus, Quebec City, Quebec, Canada|McGill Univeristy; Douglas Mental Health University Institute; Neurological and Psychiatric, Verdun, Quebec, Canada|ALPHA Recherche Clinique, Quebec, Canada|Aarhus Universitetshospital, Neurologisk Afdeling F, Demensklinikken, Aarhus C, Denmark|Rigshospitalet, Hukommelsesklinikken, København Ø, Denmark|University of Eastern Finland, Kuopio, Finland|CRST Oy, Turku, Finland|Hopital Pellegrin; Cmrr Aquitaine, Bordeaux, France|Hopital Pierre Wertheimer; Laboratoire De Neuro Psychologie, Bron, France|CHU de Limoges Hopital Dupuytren; Service de Medecine Geriatrique, Limoges, France|CHU de la Timone - Hopital d Adultes; Service de Neurologie, Marseille, France|CHU Rennes - hopital Hotel Dieu; Consultation Memoire - Gerontologie, Rennes, France|Hop Guillaume Et Rene Laennec; Cmrr St Herblain, St Herblain, France|Hopital Hautepierre; Centre dInvestigation Clinique, Strasbourg, France|Hopital la Grave; Gerontopole - Centre de Recherche Clinique, Toulouse, France|ECRC Experimental and Clinical Research Center, Charité Campus Berlin Buch, Memory Clinic, Berlin, Germany|Universitätsklinik Göttingen; Klinik für Psychiatrie und Psychotherapie; Gedächtnisambulanz, Göttingen, Germany|AFL Arzneimittelforschung Leipzig GmbH, Leipzig, Germany|Pharmakologisches Studienzentrum, Mittweida, Germany|Neurologische Praxis Dr. Andrej Pauls, München, Germany|Klinikum rechts der Isar der TU München; Klinikapotheke, München, Germany|Universitätsklinikum Ulm; Klinik für Neurologie, Ulm, Germany|Studienzentrum Nordwest, Dr. med. Joachim Springub / Herr Wolfgang Schwarz, Westerstede, Germany|Clinica Humanamente, Ciudad de Guatemala, Guatemala|Edificio Multimédica, Ciudad De Guatemlala, Guatemala|Semmelweis University; Department of Neurology, Budapest, Hungary|University of Szeged; Department of Psychiatry, Szeged, Hungary|Nuovo Ospedale Civile S. Agostino-Estense; Clinica Neurologica - Dipartimento di Neuroscienze, Modena, Emilia-Romagna, Italy|Azienda Ospedaliera Universitaria Policlinico Tor Vergata; Neurologia, Roma, Lazio, Italy|Umberto I Policlinico di Roma-Università di Roma La Sapienza, Roma, Lazio, Italy|IRCCS ""Centro S. Giovanni di Dio"" Fatebenefratelli -UO Alzheimer, Brescia, Lombardia, Italy|Irccs Multimedica Santa Maria; Unita' Di Neurologia, Castellanza, Lombardia, Italy|Fondazione San Raffaele Del Monte Tabor; Dipartimento Di Neurologia, Milano, Lombardia, Italy|ASST DI MONZA; Neurologia, Monza, Lombardia, Italy|A.O. Universitaria Pisana; Neurologia, Pisa, Toscana, Italy|Medical Corporation Hakuyokai Kashiwado Hospital, Chiba, Japan|National Hospital Organization Chiba-east Hospital; Neurology, Chiba, Japan|Juntendo University Urayasu Hospital; Neurology, Chiba, Japan|Fukuoka University Hospital; Neurology and Health Care, Fukuoka, Japan|Maebashi Red Cross Hospital; Neurology, Gunma, Japan|National Hospital Organization Hiroshima-Nishi Medical Center, Hiroshima, Japan|Hyogo Brain and Heart Center at Himeji; Department of Aging Brain and Cognitive Disorders, Hyogo, Japan|Shonan Kamakura General Hospital; Neurology, Kanagawa, Japan|National Hospital Organization Utano National Hospital; Neurology, Kyoto, Japan|Nagasaki kita Hospital; Neurology, Nagasaki, Japan|Mishima Hospital; psychiatry, Niigata, Japan|Oita University Hospital; Neurology, Oita, Japan|Kurashiki Heisei Hospital; Neurology, Okayama, Japan|Osaka City University Hospital; Geriatric Medicine and Neurology, Osaka, Japan|Shizuoka City Shimizu Hospital; Neurology, Shizuoka, Japan|Dong-A University Medical Center, Busan, Korea, Republic of|Seoul National University Bundang Hospital; Neurology Department, Gyeonggi-do, Korea, Republic of|Inha University Hospital; Neurology Department, Incheon, Korea, Republic of|Konkuk University Medical Center, Seoul, Korea, Republic of|The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Korea, Republic of|Asan Medical Center., Seoul, Korea, Republic of|Ewha Womans University Mokdong Hospital; Dept of Neurology, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Brain Research Center B.V, Amsterdam, Netherlands|Erasmus Mc - Locatie Centrum; Dept of Neurology, Rotterdam, Netherlands|Hospital Prof. Dr. Fernando Fonseca; Servico de Neurologia, Amadora, Portugal|Hospital de Santa Maria; Servico de Neurologia, Lisboa, Portugal|Republican clinical hospital of regenerative treatment of Ministry of Health of Tatarstan republic, Kazan, Russian Federation|State autonomous institution of healthcare Inter-regional clinical and diagnostic center, Kazan, Russian Federation|Institution of RAMS (Mental Health Research Center of RAMS), Moscow, Russian Federation|SBEI of HPI The 1st Moscow State Medical University n.a. I.M. Sechenov of MOH of RF, Moscow, Russian Federation|Saint Petersburg State Institution of Healthcare City Geriatric Medico-Social Center, Saint Petersburg, Russian Federation|City Clinical Hospital # 2 n.a. V.I. Razumovsky, Saratov, Russian Federation|St. Petersburg GUZ City Psychiatric Hospital #6, St Petersburg, Russian Federation|Russian Medical Military Academy n.a. S.M.Kirov; Neurology Department, St. Petersburg, Russian Federation|Hospital General Universitario de Elche; Servicio de Neurología, Elche, Alicante, Spain|Fundació ACE, BArcelon, Barcelona, Spain|Policlínica Guipuzkoa; Servicio de Neurología, Donosti-San Sebastián, Guipuzcoa, Spain|Hospital de Cruces; Servicio de Neurologia, Barakaldo, Vizcaya, Spain|Hospital del Mar; Servicio de Neurologia, Barcelona, Spain|Hospital Universitario 12 de Octubre; Servicio de Neurologia, Madrid, Spain|Hospital Universitario Virgen Macarena; Servicio de Neurologia, Sevilla, Spain|Hospital Universitari i Politecnic La Fe, Valencia, Spain|Skånes Universitetssjukhus Malmö, Minneskliniken, Malmoe, Sweden|Karolinska Uni Hospital, Huddinge; Dept. of Geriatric Med, Stockholm, Sweden|Universitäres Zentrum für Altersmedizin und Rehabilitation, Basel, Switzerland|CHUV; Centre Leenaards de la Mémoire, Lausanne, Switzerland|Akdeniz University School of Medicine, Neurology Department, Antalya, Turkey|Osmangazi University School of Medicine,Neurology Department, Eskişehir, Turkey|Istanbul University Istanbul School of Medicine; Neurology, Istanbul, Turkey|Dokuz Eylul University Medicine Faculty; Noroloji Departmani, Izmir, Turkey|Kocaeli University Hospital; Department of Neurology, Kocaeli, Turkey|Ondokuz Mayis University School of Medicine; Neurology, Samsun, Turkey|Sussex Partnership NHS Foundation Trust; Cognitive Treatment and Research unit, Crowborough, United Kingdom|Glasgow Memory Clinic, Glasgow, United Kingdom|Charing Cross Hospital; Dept of Neurosciences, London, United Kingdom|Manchester Royal Infirmary, Manchester, United Kingdom|Royal Preston Hosptial, Preston, United Kingdom|Memory Service North, Sheffield, United Kingdom|Memory Assesment and Research Centre (MARC), Southampton, United Kingdom|Victoria Centre; Kingshill Research Centre, Swindon, United Kingdom","","https://ClinicalTrials.gov/show/NCT02051608"
929,"NCT02727361","Role of the Striatal Cholinergic System in the Pathophysiology of Dystonia","DYSCHOL","Recruiting","No Results Available","Dystonia","Radiation: PET (Positron Emission Tomography) imaging|Other: MRI : Magnetic Resonance Imaging","Binding potential","University Hospital, Bordeaux","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","CHUBX2014/20","January 2016","January 2018","January 2018","April 4, 2016","null","August 4, 2017","CHU de Bordeaux, Bordeaux, France","","https://ClinicalTrials.gov/show/NCT02727361"
930,"NCT03156335","Trial of MR-guided Focused Ultrasound (MRgFUS) Bilateral Capsulotomy for the Treatment of Refractory Obsessive-compulsive Disorder (OCD)",,"Recruiting","No Results Available","Obsessive-Compulsive Disorder","Device: Focused Ultrasound","Incidence of Treatment-Emergent Adverse Events [Safety]|Clinically meaningful reduction in symptoms [Efficacy]","Sunnybrook Health Sciences Centre","All","20 Years to 80 Years   (Adult, Older Adult)","Not Applicable","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility","002-2017","April 20, 2017","April 2019","April 2019","May 17, 2017","null","August 3, 2018","Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT03156335"
931,"NCT00935090","3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer",,"Recruiting","No Results Available","Brain and Central Nervous System Tumors|Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Lymphoproliferative Disorder|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms|Unspecified Adult Solid Tumor, Protocol Specific","Device: 3'-deoxy-3'-[18F]fluorothymidine","Measurement of the uptake and retention of 3'-deoxy-3'-[18F] fluorothymidine (FLT) in tumors and normal organs|Changes in thymidine kinase, thymidylate synthase, and standardized uptake values|FLT PET response rate","Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI)","All","18 Years to 120 Years   (Adult, Older Adult)","Not Applicable","80","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","CDR0000647210|P30CA022453|WSU-2006-127|PFIZER-WSU-2006-127","September 2009","September 2018","September 2018","July 8, 2009","null","December 7, 2017","Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States","","https://ClinicalTrials.gov/show/NCT00935090"
932,"NCT01696591","The Long-Term Safety and Efficacy Follow-Up Study of Subjects Who Completed the Phase I Clinical Trial of Neurostem®-AD",,"Unknown status","No Results Available","Alzheimer Disease|Dementia|Brain Diseases|Central Nervous System Diseases|Nervous System Diseases|Tauopathies|Neurodegenerative Diseases|Delirium, Dementia, Amnestic, Cognitive Disorders|Mental Disorders","Biological: NEUROSTEM®-AD","Safety|Efficacy","Duk Lyul Na|Medipost Co Ltd.|Samsung Medical Center","All","50 Years to 75 Years   (Adult, Older Adult)","","14","Other|Industry","Observational","Observational Model: Case Control|Time Perspective: Prospective","MP-CR-007-F/U","March 2012","September 2013","September 2013","October 1, 2012","null","October 1, 2012","Samsung Medical Center, Seoul, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT01696591"
933,"NCT02138864","Targeting Monoaminergic Neuronal Networks in the Parkinsonian Patients After Carbon Monoxide Intoxication",,"Unknown status","No Results Available","Carbon Monoxide-induced Parkinsonism","Radiation: 18F-FP-(+)-DTBZ","Assess the regional decline in 18F-DTBZ uptake of Parkinsonism after carbon monoxide intoxication","Chang Gung Memorial Hospital","All","20 Years to 65 Years   (Adult, Older Adult)","Phase 3","25","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","101-4350A|CDE102IND01009","August 2013","May 2016","May 2016","May 15, 2014","null","June 1, 2016","Chang Gung Memorial Hospital, Kaohsiung, Taiwan","","https://ClinicalTrials.gov/show/NCT02138864"
934,"NCT01224106","A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease",,"Active, not recruiting","No Results Available","Alzheimer's Disease","Drug: Gantenerumab|Drug: Placebo","Mean Change From Baseline in Clinical Dementia Rating Scale Sum of Boxes (CDR-SOB) Total Score at Week 104|Mean Change From Baseline in Alzheimer Disease Assessment Scale-Cognitive Subscale 11 (ADAS-Cog-11) Scores at Week 104|Time to Onset of Dementia|Mean Change From Baseline in Cambridge Neuropsychological Test Automated Battery (CANTAB) Composite Score at Week 104|Mean Change from Baseline in Free and Cued Selective Reminding Test (FCSRT) Score at Week 104|Mean Change From Baseline in Functional Activities Questionnaire (FAQ) Score at Week 104|Mean Change From Baseline in CDR-Global Score at Week 104|Mean Change from Baseline in Neuropsychiatric Inventory (NPI) Questionnaire Score at Week 104|Percent Change from Baseline in Cerebrospinal Fluid Biomarkers (Phosphorylated-tau [p-tau], Amyloid Beta 1-42 [Abeta 1-42], Total tau [t-tau]) at Week 104|Percent Change from Baseline in Hippocampal Volume at Week 104|Percent Change From Baseline in Cortical Composite Sustained Uptake Volume Ratio (SUVr) in Different Brain Regions at Week 156|Gantenerumab Plasma Concentration at Different Time Points|Mean Change From Baseline in Mini Mental State Exam (MMSE) Score at Week 104","Hoffmann-La Roche","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 3","799","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","WN25203|2010-019895-66","November 30, 2010","June 22, 2015","July 22, 2020","October 19, 2010","null","July 31, 2018","Banner Alzheimer's Institute, Phoenix, Arizona, United States|University of California, San Diego, La Jolla, California, United States|Pacific Neuroscience Med Grp, Oxnard, California, United States|Yale University ADRU, New Haven, Connecticut, United States|Brain Matters Research, Inc., Delray Beach, Florida, United States|Infinity Clinical Research, Hollywood, Florida, United States|Bioclinica Research, Orlando, Florida, United States|Roskamp Institute, Inc., Sarasota, Florida, United States|Compass Research, The Villages, Florida, United States|Premiere Research Institute, West Palm Beach, Florida, United States|Atlanta Center For Medical Research, Atlanta, Georgia, United States|Indiana University, Indianapolis, Indiana, United States|Boston Center for Memory, Newton, Massachusetts, United States|Western Michigan University Homer Stryker M.D. School of Medicine Center for Clinical Research, Kalamazoo, Michigan, United States|Neurological Research Center, Hattiesburg, Mississippi, United States|CRI Lifetree Marlton, Marlton, New Jersey, United States|Princeton Medical Institute, Princeton, New Jersey, United States|Nathan Kline Institute, Orangeburg, New York, United States|University of Rochester Medical Center; Monroe Community Hospital, Rochester, New York, United States|Alzheimer's Memory Center, Charlotte, North Carolina, United States|Raleigh Neurology Associates, Raleigh, North Carolina, United States|Oregon Health and Science University, Layton Aging and Alzheimer's Disease Center, Portland, Oregon, United States|The Clinical Trial Center, LLC, Jenkintown, Pennsylvania, United States|Northeastern Pennsylvania Memory, Plains, Pennsylvania, United States|Rhode Island Mood & Memory Research Institute, East Providence, Rhode Island, United States|Butler Hospital, Providence, Rhode Island, United States|Senior Adults Specialty Research, Austin, Texas, United States|Texas Neurology PA, Dallas, Texas, United States|Lifetree Clinical Research, Salt Lake City, Utah, United States|Clinical Neuroscience Research Associates, Inc., Bennington, Vermont, United States|Hospital Italiano, Buenos Aires, Argentina|IME - Instituto Médico Especializado; Ensayos Clínicos, Buenos Aires, Argentina|ALPI-Inst. de Rehabilitacion Marcelo Fitte, Buenos Aires, Argentina|CEMIC, Buenos Aires, Argentina|Mulieris, Caba, Argentina|Instituto De Neurología Cognitiva - INECO, Caba, Argentina|FLENI, Caba, Argentina|Instituto Kremer, Córdoba, Argentina|CENPIA; Neurología - Psicología, La Plata, Argentina|Hornsby Ku-ring-gai Hospital; Division of Rehabilitation & Aged Care, Hornsby, New South Wales, Australia|Prince of Wales Hospital, Academic Department for Old Age Psychiatry, Randwick, New South Wales, Australia|Royal Adelaide Hospital; Memory Trials Centre, Adelaide, South Australia, Australia|The Queen Elizabeth Hospital; Neurology, Woodville, South Australia, Australia|Heidelberg Repatriation Hospital; Medical and Cognitive Research Centre, Heidelberg West, Victoria, Australia|Australian Alzheimer's Research Foundation, Nedlands, Western Australia, Australia|UZ Antwerpen, Edegem, Belgium|UZ Leuven Gasthuisberg, Leuven, Belgium|Hospital das Clinicas - UFPR; Ciencias da Saude, Curitiba, PR, Brazil|Hospital das Clinicas - UFRGS, Porto Alegre, RS, Brazil|Hospital Mae de Deus, Porto Alegre, RS, Brazil|Universidade Federal de Sao Paulo - UNIFESP; Neurologia, Sao Paulo, SP, Brazil|Hospital das Clinicas - FMUSP; Psiquiatria, Sao Paulo, SP, Brazil|True North Clinical Research Kentville, Kentville, Nova Scotia, Canada|Kawartha Centre - Redefining Healthy Aging, Peterborough, Ontario, Canada|Toronto Memory Program (Neurology Research Inc.), Toronto, Ontario, Canada|The Centre for Memory and Aging, Toronto, Ontario, Canada|NeuroSearch Developpements inc, Greenfield Park, Quebec, Canada|McGill University; Sir Mortimer B Davis Jewish General Hospital; Neurological and Psychiatric, Montreal, Quebec, Canada|CHAUQ - Hôpital Enfant-Jésus, Quebec City, Quebec, Canada|Diex Recherche Sherbrooke, Sherbrooke, Quebec, Canada|Biomedica Research Group, Santiago, Chile|Especialidades Medicas LYS, Santiago, Chile|CIMN Centro de Investigaciones Medicas Neurologicas, Viña De Mar, Chile|St. Anne´s University Hospital; Clinical Trials Department, Brno, Czechia|Fakultní Nemocnice Olomouc; Neurologicka Klinika, Olomouc, Czechia|Vestra Clinics s.r.o., Rychnov nad Kneznou, Czechia|Aarhus Universitetshospital, Neurologisk Afdeling F, Demensklinikken, Aarhus C, Denmark|Rigshospitalet, Hukommelsesklinikken, København Ø, Denmark|Turku Hospital; PET (Positron Emission Tomography) Center, Turku, Finland|Hopital Avicenne; Neurologie, Bobigny, France|Hopital Pellegrin; Cmrr Aquitaine, Bordeaux, France|Hopital Pierre Wertheimer; Laboratoire De Neuro Psychologie, Bron, France|CHU De Caen; Service De Neurologie Dejerine, Caen, France|Hopital B Roger Salengro; Cmrr Lille, Lille, France|Ch Pitie Salpetriere; Cmrr Ile De France Salpetriere, Paris, France|CHU de Rouen Hopital; Service de Neurologie, Rouen, France|Hop Guillaume Et Rene Laennec; Cmrr St Herblain, St Herblain, France|Hopital Hautepierre; Centre dInvestigation Clinique, Strasbourg, France|Hopital de La Grave, Toulouse, France|Univ Berlin; Klin fur Psychi & Psycho Charite, Berlin, Germany|Universitätsklinikum Bonn; Medizinische Klinik und Poliklinik I; Allgemeine Innere Medizin, Bonn, Germany|Klinikum Joh.Wolfg.Goethe-UNI Zentrum d. Psychiatrie Klinik f. Psychiatrie Psychosomatik, Frankfurt, Germany|AFL Arzneimittelforschung Leipzig GmbH, Leipzig, Germany|Zentralinstitut für Seelische Gesundheit Abt.Gerontopsychiatrie, Mannheim, Germany|Pharmakologisches Studienzentrum, Mittweida, Germany|Neurologische Praxis Dr. Andrej Pauls, München, Germany|Klinikum rechts der Isar der TU München; Klinik für Psychiatrie und Psychotherapie, München, Germany|Office of Dr Klaus Steinwachs Neurology & Psychiatry, Nürnberg, Germany|Universitätsklinikum Rostock Zentrum für Nervenheilkunde, Rostock, Germany|Universitätsklinikum Ulm; Klinik für Neurologie, Ulm, Germany|Rambam Medical Center, Haifa, Israel|Sheba Medical Center; Psychiatry Department, Ramat Gan, Israel|Nuovo Ospedale Civile S. Agostino-Estense; Clinica Neurologica - Dipartimento di Neuroscienze, Modena, Emilia-Romagna, Italy|Universita' Di Parma Istituto Neurologia, Parma, Emilia-Romagna, Italy|Azienda Ospedaliera Spedali Civili; Scienze Neurologiche, Brescia, Lombardia, Italy|IRCCS ""Centro S. Giovanni di Dio"" Fatebenefratelli -UO Alzheimer, Brescia, Lombardia, Italy|Irccs Multimedica Santa Maria; Unita' Di Neurologia, Castellanza, Lombardia, Italy|Irccs Ospedale Maggiore Policlinico Di Milano; Scienze Neurologiche, Milano, Lombardia, Italy|Fondazione San Raffaele Del Monte Tabor; Dipartimento Di Neurologia, Milano, Lombardia, Italy|Azienda Ospedaliero Universitaria Ospedali Riuniti Umberto I-G.M. Lancisi-G. Salesi Di Ancona, Torrette - Ancona, Marche, Italy|Uni Di Firenze Dip. Scienze Neurol Psic Sod Neurologia 1, Firenze, Toscana, Italy|Azienda Ospedaliera Universitaria Integrata; Neuroscienze Centro Alzheimer e Disturbi Cognitivi, Verona, Veneto, Italy|Seoul National University Bundang Hospital; Neurology Department, Gyeonggi-do, Korea, Republic of|Konkuk University Medical Center, Seoul, Korea, Republic of|Seoul St Mary's Hospital, Seoul, Korea, Republic of|Asan Medical Center., Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Hospital Angeles de Culiacán, Neurociencias Estudios Clínicos SC, Culiacan, Mexico|Hospital Mexico Americano, Guadalajara, Mexico|Unidad de Investigacion en Enfermedades Cronico-Degenerativa; Reumatologia, Guadalajara, Mexico|Estimulacion Magnetica Trnscraneal de Mexico SC., Mexico City, Mexico|Hospital Uni; Dr. Jose E. Gonzalez, Monterrey, Mexico|Centro Medico San Francisco; Geriatrics, Monterrey, Mexico|Hospital Universitario de Saltillo, Saltillo, Mexico|Jeroen Bosch Ziekenhuis; Polikliniek Geriatrie, 'S Hertogenbosch, Netherlands|Brain Research Center B.V, Amsterdam, Netherlands|Podlaskie Centrum Psychogeriatrii, Białystok, Poland|Szpital Uniwersytecki nr 1 im. dr Antoniego Jurasza w Bydgoszczy Klinika Psychiatrii, Bydgoszcz, Poland|PALLMED Sp. z o.o. prowadząca NZOZ DOM SUE RYDER, Bydgoszcz, Poland|NEURO - KARD Ośrodek Badań Klinicznych, Poznań, Poland|Przychodnia Specjalistyczna PROSEN, Warszawa, Poland|mMED Maciej Czarnecki, Warszawa, Poland|Hospital Prof. Dr. Fernando Fonseca; Servico de Neurologia, Amadora, Portugal|Hospital de Santa Maria; Servico de Neurologia, Lisboa, Portugal|Sverdlovsk Regional Clinical Psychoneurological War Veteran Hospital, Ekaterinburg, Russian Federation|State autonomous institution of healthcare Inter-regional clinical and diagnostic center, Kazan, Russian Federation|Saint Petersburg State Institution of Healthcare City Geriatric Medico-Social Center, Saint Petersburg, Russian Federation|City Clinical Hospital # 2 n.a. V.I. Razumovsky, Saratov, Russian Federation|Russian Medical Military Academy n.a. S.M.Kirov; Neurology Department, St. Petersburg, Russian Federation|Fundació ACE, BArcelon, Barcelona, Spain|Hospital Mutua De Terrasa; Servicio de Neurologia, Terrasa, Barcelona, Spain|Hospital de Cruces; Servicio de Neurologia, Barakaldo, Vizcaya, Spain|Hospital del Mar; Servicio de Neurologia, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau; Servicio de Neurologia, Barcelona, Spain|Hospital Clinic i Provincial; Servicio de Neurologia, Barcelona, Spain|Hospital Ramon y Cajal; Servicio de Neurologia, Madrid, Spain|Hospital Clinico Universitario San Carlos; Servicio de Geriatria, Madrid, Spain|Hospital Universitario 12 de Octubre; Servicio de Neurologia, Madrid, Spain|Hospital Universitario La Paz; Servicio de Neurologia, Madrid, Spain|Hospital Universitario Dr. Peset; Servicio de Neurologia, Valencia, Spain|Skånes Universitetssjukhus Malmö, Minneskliniken, Malmoe, Sweden|Universitäres Zentrum für Altersmedizin und Rehabilitation, Basel, Switzerland|HUG; Département de santé mentale et de psychiatrie Unité de psychiatrie gériatrique, Chêne-Bourg, Switzerland|Akdeniz University School of Medicine, Neurology Department, Antalya, Turkey|Istanbul University Istanbul School of Medicine; Neurology, Istanbul, Turkey|Ondokuz Mayis University School of Medicine; Neurology, Samsun, Turkey|Addenbrooke's Hospital, Cambridge, United Kingdom|Llandough Hospital; Llandough Hospital Memory Team 3rd Floor Academic Building, Cardiff, United Kingdom|St Margaret's Hospital, Epping, United Kingdom|Glasgow Memory Clinic, Glasgow, United Kingdom|Charing Cross Hospital; Dept of Neurosciences, London, United Kingdom|Campus for Ageing & Vitality; Clincal Ageing Research Unit, Newcastle, United Kingdom|John Radcliffe Hospital; Nuffield dept. Of medicine, Oxford, United Kingdom|Moorgreen Hospital; Memory Assessment & Rsch Ctr, Southampton, United Kingdom|Victoria Centre; Kingshill Research Centre, Swindon, United Kingdom|Hollins Park Hospital, Warrington, United Kingdom","","https://ClinicalTrials.gov/show/NCT01224106"
935,"NCT03289143","A Study to Evaluate the Efficacy and Safety of RO7105705 in Patients With Prodromal to Mild Alzheimer's Disease",,"Recruiting","No Results Available","Alzheimer's Disease","Drug: RO7105705|Drug: Placebo|Drug: [18F]GTP1","Change from baseline on the CDR-Sum of Boxes|Nature, frequency, severity, and timing of adverse events and serious adverse events|Change from baseline on the Repeatable Battery for Assessment of Neuropsychological Status (RBANS)|Change from baseline on the Alzheimer's Disease Assessment Scale−Cognitive Subscale 13|Change from baseline on the Amsterdam Instrumental Activity of Daily Living questionnaire|Change from baseline on the Alzheimer's Disease Cooperative Study Group−Activities of Daily Living Inventory|Serum concentrations of RO7105705 at specified timepoints|Presence of anti-drug antibodies during the study relative to their presence at baseline","Genentech, Inc.","All","50 Years to 80 Years   (Adult, Older Adult)","Phase 2","360","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GN39763|2017-001800-31","October 4, 2017","September 30, 2020","September 20, 2022","September 20, 2017","null","August 21, 2018","University of Alabama at Birmingham, Birmingham, Alabama, United States|California Clinical Trials, Glendale, California, United States|Institute for Memory Impairments, Irvine, California, United States|Pharmacology Research Inst, Newport Beach, California, United States|Pacific Neuroscience Med Grp, Oxnard, California, United States|Stanford Neuroscience Health Center (SNHC), Palo Alto, California, United States|Pacific Research Network - PRN, San Diego, California, United States|UCSF Medical Center, San Francisco, California, United States|Neurological Research Inst, Santa Monica, California, United States|Collaborative Neuroscience Network Inc., Torrance, California, United States|Molecular NeuroImaging, New Haven, Connecticut, United States|Yale University, New Haven, Connecticut, United States|KI Health Partners, LLC; New England Institute for Clinical Research, Stamford, Connecticut, United States|Georgetown University Hospital, Washington, District of Columbia, United States|JEM Research LLC, Atlantis, Florida, United States|Florida Atlantic University; College of Medicine, Boca Raton, Florida, United States|Bradenton Research Center, Bradenton, Florida, United States|Brain Matters Research, Inc., Delray Beach, Florida, United States|Neuropsychiatric Research; Center of Southwest Florida, Fort Myers, Florida, United States|Alzheimer's Research and Treatment Center, Lake Worth, Florida, United States|Miami Jewish Health Systems, Miami, Florida, United States|Collier Neurologic Specialists, Naples, Florida, United States|Compass Research East, LLC, Orlando, Florida, United States|Stedman Clinical Trials, LLC, Tampa, Florida, United States|Premiere Research Institute, West Palm Beach, Florida, United States|Emory University; Global Health, Atlanta, Georgia, United States|Rush Alzheimer's Disease Cntr., Chicago, Illinois, United States|Alexian Brothers Neuroscience Institute, Elk Grove Village, Illinois, United States|Southern Illinois University, School of Medicine, Springfield, Illinois, United States|Eastern Maine Medical Center, Bangor, Maine, United States|Brigham & Women's Hosp; TIMI Study Grp, Boston, Massachusetts, United States|Alzheimers Disease Center, Quincy, Massachusetts, United States|Health Partners Institute for Education and Research, Saint Paul, Minnesota, United States|NeuroCognitive Institute, Mount Arlington, New Jersey, United States|Advanced Memory Research Institute of NJ, Toms River, New Jersey, United States|Albany Medical College; Neurology, Albany, New York, United States|Empire Neurology PC; MS Center of Northeastern NY, Latham, New York, United States|Columbia Univ Medical Center, New York, New York, United States|University of Rochester; AD-CARE, Rochester, New York, United States|Summit Research Network Inc., Portland, Oregon, United States|Oregon Health Sciences Uni, Portland, Oregon, United States|Abington Neurological Associates, Willow Grove, Pennsylvania, United States|Rhode Island Mood & Memory Research Institute, East Providence, Rhode Island, United States|Butler Hospital, Providence, Rhode Island, United States|Neurology Clinic PC, Cordova, Tennessee, United States|New Orleans Center For Clinical Research, Knoxville, Tennessee, United States|Clinical Neuroscience Research Associates, Inc., Bennington, Vermont, United States|St Vincents Medical Centre, Darlinghurst, New South Wales, Australia|Southern Neurology, Kogarah, New South Wales, Australia|Queensland University of Technology, Mermaid Waters, Queensland, Australia|Box Hill Hospital; Department of Neurology, Box Hill, Victoria, Australia|HammondCare Aged Psychiatry Clinical Trials, Malvern, Victoria, Australia|The Alfred Hospital, Melbourne; Thrombosis and Haemostasis Unit, Melbourne, Victoria, Australia|Neuro Trials Victoria, Noble Park, Victoria, Australia|Royal Melbourne Hospital, Parkville, Victoria, Australia|AZ Sint Jan, Brugge, Belgium|UZ Brussel, Brussel, Belgium|AZ Groeninge, Kortrijk, Belgium|UZ Leuven, Leuven, Belgium|AZ Delta Campus Westlaan, Roeselare, Belgium|Vancouver Island Health Research Centre, Victoria, British Columbia, Canada|True North Clinical Research Kentville, Kentville, Nova Scotia, Canada|JBN Medical Diagnostic Services; Clinical Trials Division, Burlington, Ontario, Canada|Parkwood Institute, Mental Health Care Building, London, Ontario, Canada|Bruyere Continuing Care, Ottawa, Ontario, Canada|Toronto Memory Program (Neurology Research Inc.), Toronto, Ontario, Canada|The Centre for Memory and Aging, Toronto, Ontario, Canada|Toronto Sunnybrook Hospital, Toronto, Ontario, Canada|Toronto Western Hospital, Toronto, Ontario, Canada|Recherches Neuro-Hippocame, Gatineau, Quebec, Canada|Neuro Rive-Sud, Greenfield Park, Quebec, Canada|Institut Universitaire de gériatrie de Sherbrooke, Sherbrooke, Quebec, Canada|Center For Clinical and Basic Research (Ccbr); Site Management Organisation, Aalborg, Denmark|CCBR - Ballerup - DK, Ballerup, Denmark|CCBR - Vejle - DK, Vejle, Denmark|University of Eastern Finland, Kuopio, Finland|Groupe Hospitalier Pellegrin; Service de Neurologie - 3ème étage, Bordeaux, France|Hopital Neurologique Pierre Wertheimer, Bron, France|Hopital Roger Salengro, Lille, France|CHU de la Timone - Hopital d Adultes; Service de Neurologie, Marseille, France|Hopital Gui de Chauliac; Neurologie, Montpellier, France|Hopital Fernand Widal Centre, Paris, France|Groupe Hospitalier Pitie-Salpetriere, Paris, France|CHU Rennes - Hopital Hôtel Dieu, Rennes, France|CHU Hautepierre; ACTR Association Recherche Clinique Rhumatologie, Strasbourg, France|CHU Strasbourg - Hôpital Hautepierre, Strasbourg, France|Hopital de La Grave, Toulouse, France|Hopital des Charpennes, Villeurbanne, France|Klinikum Bayreuth; Krankenhaus Hohe Warte, Bayreuth, Germany|Praxis Dr. med. Volker Shumann, Berlin, Germany|Studienambulanz emovis GmbH; St. Joseph Krankenhaus, Berlin, Germany|Charite Campus Benjamin Franklin, Berlin, Germany|Neurologisch-psychiatrische Praxis am Brosepark, Berlin, Germany|Bezirkskrankenhaus Günzburg, Günzburg, Germany|Klinische Forschung Hannover-Mitte GmbH, Hannover, Germany|AFL Arzneimittelforschung Leipzig GmbH, Leipzig, Germany|Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz; Kardiologie, Mainz, Germany|Klinikum rechts der Isar der TU München; Klinik & Poliklinik für Neurologie, München, Germany|Universitätsklinikum Münster, Stabsstelle Apotheke, Münster, Germany|Universitätsklinikum Rostock, Zentrum für Nervenheilkunde; Klinik und Poliklinik für Neurologie, Rostock, Germany|ZNS Siegen im MVZ Weidenau, Siegen, Germany|Universitätsklinik Tübingen; Psychiatrie und Psychotherapie, Tubingen, Germany|Universitätsklinikum Ulm; Klinik für Neurologie, Ulm, Germany|Azienda Ospedaliera Città della Salute e della Scienza di Torino; Radiology, Torino, Abruzzo, Italy|Umberto I Policlinico di Roma-Università di Roma La Sapienza, Roma, Lazio, Italy|Ospedale San Giovanni Calibita Fatebenefratell;Neurologia, Roma, Lazio, Italy|Ente Ospedaliero Ospedali Galliera; Neurologia, Genova, Liguria, Italy|Azienda Ospedaliero Universitaria San Martino; Dip. di Neuroscienze Oftalmologia e Genetica, Genova, Liguria, Italy|Asst Degli Spedali Civili Di Brescia, Brescia, Lombardia, Italy|IRCCS Centro San Giovanni di Dio FBF, Brescia, Lombardia, Italy|Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Lombardia, Italy|IRCCS Neuromed; Neurologia I-Centro studio e cura delle demenze e UVA, Pozzilli, Molise, Italy|Az. Osp. C. Panico; Rep. Ematologia E Trapianto, Tricase - LE, Puglia, Italy|A.O. Universitaria Pisana, Pisa, Toscana, Italy|Jeroen Bosch Ziekenhuis, 'S Hertogenbosch, Netherlands|Brain Research Center B.V, Amsterdam, Netherlands|Podlaskie Centrum Psychogeriatrii, Białystok, Poland|PALLMED Sp. z o.o. prowadząca NZOZ DOM SUE RYDER, Bydgoszcz, Poland|NZOZ VITO-MED Sp.z o.o., Gliwice, Poland|M.A. - LEK A.M.Maciejowscy SC., Katowice, Poland|Novo-Med Zielinski i wspolnicy Sp. j., Katowice, Poland|Malopolskie Centrum Medyczne, Krakow, Poland|Samodzielny Publiczny Szpital Kliniczny Nr 4; Klinika Nefrologii, Lublin, Poland|NEURO - KARD Ośrodek Badań Klinicznych, Poznań, Poland|NEURO-CARE Sp. z o.o. Sp. Komandytowa, Siemianowice Śląskie, Poland|Senior Sp. Z O.O. Poradnia Psychogeriatryczna, Sopot, Poland|NZOZ EroMedis, Szczecin, Poland|mMED Maciej Czarnecki, Warszawa, Poland|Optimum, Warszawa, Poland|NZOZ WCA, Wrocław, Poland|Hospital Mutua de Terrassa, Terrassa, Barcelona, Spain|Policlinica Guipuzcoa, San Sebastian, Guipuzcoa, Spain|Clinica Universitaria de Navarra; Servicio de Neurología, Pamplona, Navarra, Spain|Hospital Virgen del Puerto, Plasencia, Palencia, Spain|Hospital de Cruces; Servicio de Neurologia, Barakaldo, Vizcaya, Spain|Hospital Perpetuo Socorro, Servicio de Geriatria, Albacete, Spain|Fundación ACE; Servicio de Neurología, Barcelona, Spain|Hospital Clinic i Provincial de Barcelona, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Universitario Reina Sofia; Servicio de Neurologia, Cordoba, Spain|Clinica Ruber, 4 planta; Servicio de Neurologia, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital de Cantoblanco; Servicio de Geriatria, Madrid, Spain|Hospital Universitario Virgen Macarena, Sevilla, Spain|Hospital Universitario Dr. Peset; Servicio de Neurologia, Valencia, Spain|Hospital Universitari i Politecnic La Fe de Valencia, Valencia, Spain|Länssjukhuset Ryhov, Jönköping, Sweden|Länssjukhuset Kalmar; Oncology, Kalmar, Sweden|Skane University Hospital Malmo/Lund, Dept.of Hematology and Coagulation Disorders, Malmö, Sweden|Sahlgrenska Univ Hospital Mölndal; Department of Nephrology, Mölndal, Sweden|Karolinska Trial Alliance,Karolinska University Hospital, Huddinge M62, Stockholm, Sweden|Karolinska Universitetssjukhuset Huddinge, Stockholm, Sweden|Murray Royal Hospital; Psychiatry of Old Age (POA) Hub, Dundee, United Kingdom|Glasgow Memory Clinic, Glasgow, United Kingdom|Stobhill Hospital; Respiratory Department, Glasgow, United Kingdom|The National Hospital for Neurology & Neurosurgery, London, GT LON, United Kingdom|RE:Cognition Health, London, United Kingdom|Charing Cross Hospital; Dept of Neurosciences, London, United Kingdom|St. George's Park Hospital, Morpeth, United Kingdom|Derriford Hospital; Neurology, Plymouth, United Kingdom|Southampton General Hospital, Southampton, United Kingdom|Re:Cognition Health Guildford, Surrey, United Kingdom|Victoria Centre; Kingshill Research Centre, Swindon, United Kingdom","","https://ClinicalTrials.gov/show/NCT03289143"
936,"NCT02997371","IL-1ra Dose-range Study for Moderate-to-severe TBI Patients","IL1ra","Not yet recruiting","No Results Available","Traumatic Brain INjury","Drug: Anakinra Prefilled Syringe|Drug: Isotonic saline","Decrease of pro-inflammatory cytokines in brain extracellular fluid (ECF)|Patient outcome GOSe|Patient outcome SF36|Imaging outcome - PET-MRI|Imaging outcome - DTI-MRI|Biochemical outcome - S100B|Biochemical outcome - NF-L|Biochemical outcome - Tau|Biochemical outcome - APP|Biochemical outcome - Autoreactivity versus MBP|Monitoring outcome - ICP|Monitoring outcome - CPP|Monitoring outcome - Cerebral Metabolism LPR|Monitoring outcome - Brain tissue oxygenation|Monitoring outcome - PRx|Pharmacological outcome - Concentration of IL1ra in brain tissue|Pharmacological outcome - Concentration of IL1ra in serum|Side effects of the IL1ra","Adel Helmy|Cambridge University Hospitals NHS Foundation Trust|University of Cambridge","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CCTU0185","October 2017","October 2021","October 2021","December 20, 2016","null","May 8, 2017","Cambridge University Hospital NHS Trust, Cambridge, Cambridgeshire, United Kingdom","","https://ClinicalTrials.gov/show/NCT02997371"
937,"NCT01806675","18F FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy",,"Active, not recruiting","No Results Available","Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Male Breast Cancer|Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma|Recurrent Adenoid Cystic Carcinoma of the Oral Cavity|Recurrent Adult Brain Tumor|Recurrent Basal Cell Carcinoma of the Lip|Recurrent Breast Cancer|Recurrent Colon Cancer|Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Recurrent Hypopharyngeal Cancer|Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Recurrent Laryngeal Cancer|Recurrent Lip and Oral Cavity Cancer|Recurrent Lymphoepithelioma of the Nasopharynx|Recurrent Lymphoepithelioma of the Oropharynx|Recurrent Metastatic Squamous Neck Cancer With Occult Primary|Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Recurrent Mucoepidermoid Carcinoma of the Oral Cavity|Recurrent Nasopharyngeal Cancer|Recurrent Non-small Cell Lung Cancer|Recurrent Oropharyngeal Cancer|Recurrent Pancreatic Cancer|Recurrent Paranasal Sinus and Nasal Cavity Cancer|Recurrent Rectal Cancer|Recurrent Renal Cell Cancer|Recurrent Salivary Gland Cancer|Stage IIIA Breast Cancer|Stage IIIA Non-small Cell Lung Cancer|Stage IIIB Breast Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer|Stage IV Non-small Cell Lung Cancer|Stage IV Pancreatic Cancer|Stage IV Renal Cell Cancer|Stage IVA Colon Cancer|Stage IVA Rectal Cancer|Stage IVA Salivary Gland Cancer|Stage IVB Colon Cancer|Stage IVB Salivary Gland Cancer|Stage IVC Salivary Gland Cancer|Tongue Cancer|Unspecified Adult Solid Tumor, Protocol Specific","Drug: fludeoxyglucose F 18|Drug: 2-fluoropropionyl-labeled pegylated dimeric RGD peptide|Diagnostic Test: positron emission tomography|Diagnostic Test: computed tomography|Other: laboratory biomarker analysis","Change in maximum standard uptake values (SUVmax) on 18F FPPRGD2 and 18F FDG PET|Progression-free survival","Sanjiv Sam Gambhir|National Cancer Institute (NCI)|Stanford University","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","25","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","VARIMG0002|NCI-2013-00535","March 2013","December 7, 2016","March 2019","March 7, 2013","null","June 5, 2018","Stanford University, School of Medicine, Stanford, California, United States","","https://ClinicalTrials.gov/show/NCT01806675"
938,"NCT01287936","A Study of Modified Stem Cells in Stable Ischemic Stroke",,"Completed","No Results Available","Chronic Ischemic Stroke","Biological: SB623","Safety|Improvement in stroke symptoms and brain metabolism","SanBio, Inc.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","18","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SB-STR01","January 2011","August 2015","August 2015","February 2, 2011","null","December 21, 2016","University of Alabama, Birmingham, Alabama, United States|Stanford University School of Medicine, Stanford, California, United States|Emory University, Atlanta, Georgia, United States|Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT01287936"
939,"NCT00755963","Effects of Hormone Replacement Therapy on the Serotonergic System and Mood in Postmenopausal Women",,"Completed","No Results Available","Hormone Replacement","Drug: estradiol valerate|Drug: micronized progesterone|Drug: placebo","Serotonin-1A receptor binding potential","Medical University of Vienna","Female","50 Years to 65 Years   (Adult, Older Adult)","Phase 4","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science","PM-20070724|EudraCT: 2007-005685-12|EC 593/2007","May 2009","July 2011","July 2011","September 19, 2008","null","July 22, 2011","Medical University of Vienna, Dept. of Psychiatry and Psychotherapy, Vienna, Austria","","https://ClinicalTrials.gov/show/NCT00755963"
940,"NCT01528436","Umbilical Cord Blood Therapy for Cerebral Palsy",,"Completed","No Results Available","Cerebral Palsy","Biological: Umbilical Cord Blood Infusion|Other: Placebo Umbilical Cord Blood|Other: Active Rehabilitation","Changes in Motor Performance|Changes in Standardized Gross Motor Function|Changes in Cognitive Neurodevelopmental Outcome|Changes in Motor Neurodevelopmental Outcome|Changes in Functional Independence in Daily Activities|Changes in Visual Perception Test|Changes in Muscle Strength|Changes in Functional Performance in Daily Activities|Changes in Brain Glucose Metabolism Using by Brain 18F-FDG PET","MinYoung Kim, M.D.|Bundang CHA Hospital","All","6 Months to 20 Years   (Child, Adult)","Phase 2","37","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CPUCBRCT","February 2012","July 2012","July 2012","February 8, 2012","null","July 18, 2012","CHA Bundang Medical Center, CHA University, Seongnam-si, Gyeonggi-do, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT01528436"
941,"NCT01082926","Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2",,"Completed","No Results Available","Anaplastic Astrocytoma|Anaplastic Ependymoma|Anaplastic Meningioma|Anaplastic Oligodendroglioma|Brain Stem Glioma|Ependymoblastoma|Giant Cell Glioblastoma|Glioblastoma|Gliosarcoma|Grade III Meningioma|Meningeal Hemangiopericytoma|Mixed Glioma|Pineal Gland Astrocytoma|Brain Tumor","Biological: therapeutic allogeneic lymphocytes|Biological: aldesleukin|Other: laboratory biomarker analysis|Procedure: positron emission tomography","Safety of GRm13Z40-2 CTL CNS loco-regional cellular immunotherapy|Safety of convection enhanced delivery (CED) of recombinant human Interleukin-2 (rhuIL-2) used in conjunction with GRm13Z40-2 CTL adoptive transfer|Toxicity as assessed by NCI CTCAE version 4.0|Ability of 9-(4-fluoro-3-hydroxy-methyl-butyl) guanine (18FHBG) positron emission tomography PET to image GRm13Z40-2 CTLs|Impact of concurrent dexamethasone on the tempo and magnitude of T cell allograft rejection responses by tracking the frequency of anti-GRm13Z40-2 immune responses in serially acquired peripheral blood samples|Evaluation of ganciclovir administration for ablating transferred GRm13Z40-2 in vivo should significant graft-mediated toxicities be encountered","City of Hope Medical Center","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","6","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","07082|NCI-2010-00303","May 2010","September 2013","September 2013","March 9, 2010","null","June 8, 2015","City of Hope, Duarte, California, United States","","https://ClinicalTrials.gov/show/NCT01082926"
942,"NCT03290040","Identification of Predictors for Early Cognitive Decline in Men",,"Recruiting","No Results Available","Healthy Test Persons","","Gamma band EEG power during evoked potentials correlates to cognitive decline|Alpha band EEG-power during evoked potentials correlates to cognitive decline|Examination of how visual attention effects cognitive deterioration.|Clarification of how processing speed (ms), short term memory and visual perceptive threshold effect cognitive capacity.|Changes in mitochondrial respiration as predictor of cognitive impairment|Microstructural parameters, derived from diffusion tensor imaging as predictor of cognitive impairment|Correlation between basal ganglia volumes and structure and cognitive functions|Correlation between patterns of brain perfusion and patterns of cognitive function|Correlation between Subjective sleep quality and patterns of cognitive function|Objective sleep measures: Sleep stages as determined by standard international scoring and quantitated measures using - spectral analysis from sleep EEG in relation to cognitive impairment|Effects of demographic, social and health predictors on change in cognitive function from young adulthood to late midlife|Correlation between daytime sleepiness and patterns of cognitive function|Gamma band EEG power distribution across the scalp during simultaneous auditory and visual stimulation correlates to cognitive decline|Change of source location of gamma band EEG power of visual evoked potentials correlates to cognitive decline|The investigators would like to describe how visual attention correlates with the background EEG recorded before the examination.|Change in levels of reactive oxygen species in PBMCs quantified by flow cytometry after application of dedicated fluorophores as predictor of cognitive impairment|Change in levels of mitochondrial bioenergetics in PBMCs using the Seahorse XF24 extracellular flux analyser as predictor of cognitive impairment|Change of levels of whole cell dNTP levels in PBMCs using polymerase extension assay and by quantification of tritiated nucleotides by scintillation counting as predictor of cognitive impairment|Change of mutation frequency of mitochondrial DNA using deep sequencing as predictor of cognitive impairment|Change of mtDNA copy number by qPCR as predictor of cognitive impairment|Correlation between regional cortical thickness and cognitive parameters|Correlation between regional cortical surface and cognitive parameters|Correlation between macrostructural parameters and candidate genes|Correlation between microstructural parameters and candidate genes|Correlation between macrostructural parameters and cognition|Correlation between microstructural parameters and cognition|Correlation between cognition and candidate genes|Correlation between sleep stages and microstructural parameters.|Correlation between sleep stages and regional volumes.|Autonomic activity as measured by electrocardiography determined from the polysomnography during wakefulness and sleep in relation to cognitive impairment|Presence of REM Sleep muscle activity (REM sleep without atonia (RSWA), REM Behavior disorder(RBD)) in relation to cognitive impairment|Cognitive correlates of cognitive change","Rigshospitalet, Denmark|University of Copenhagen|Center for Healthy Aging, University of Copenhagen","Male","60 Years and older   (Adult, Older Adult)","","350","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","H-1-2014-032","January 2015","December 2018","February 2030","September 21, 2017","null","September 25, 2017","Dept. of Clinical Neurophysiology, Department of Clinical Biochemistry and Department of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet - Glostrup, Glostrup, Denmark","","https://ClinicalTrials.gov/show/NCT03290040"
943,"NCT03056170","Neurophysiological Impact of a Fronto-temporal tDCS Stimulation in Healthy Subjects: a Multimodal Imaging Approach","COMBI-STIM","Completed","No Results Available","Healthy","Device: real tDCS","Change in dopamine transmission induced by 1 session of 30min tDCS|Change in spontaneous functional connectivity (using rs fMRI) during and after 1 session of 30min tDCS|Change in cerebral blood flow (using ASL) during and after 1 session of 30min tDCS|Change in structural connectivity (using DTI) after 1 session of 30min tDCS","Hospices Civils de Lyon","All","18 Years to 45 Years   (Adult)","Not Applicable","37","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","69HCL16_0682","November 13, 2015","April 19, 2017","June 20, 2017","February 17, 2017","null","July 11, 2017","Le Vinatier, Bron, France","","https://ClinicalTrials.gov/show/NCT03056170"
944,"NCT02069080","Imaging CXCR4 Expression in Subjects With Cancer Using 64 Cu-Plerixafor",,"Terminated","No Results Available","Cancer","Drug: 64-Cu-plerixafor","Uptake of 64Cu-plerixafor in the target lesion(s) of subjects expressing CXCR4 versus the uptake of 64Cu-plerixafor in the surrounding non-tumor tissues.|64Cu-plerixafor SUV in the target lesion(s) versus the level of CXCR4 expression detected via immunohistochemical staining.|Human-absorbed doses of 64Cu-plerixafor|The incidence and severity of adverse events (AEs) by dose group.","National Institute of Allergy and Infectious Diseases (NIAID)|Lombardi Comprehensive Cancer Center|National Institutes of Health Clinical Center (CC)","All","18 Years to 99 Years   (Adult, Older Adult)","Early Phase 1","2","NIH|Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","140050|14-I-0050","February 20, 2014","July 10, 2018","July 10, 2018","February 21, 2014","null","July 12, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT02069080"
945,"NCT03174938","The Swedish BioFINDER 2 Study","BioFINDER2","Recruiting","No Results Available","Dementia|Alzheimer Disease|Parkinson Disease|Lewy Body Disease|Parkinson-Dementia Syndrome|Frontotemporal Degeneration|Semantic Dementia|Progressive Nonfluent Aphasia|Progressive Supranuclear Palsy|Corticobasal Degeneration|Multiple System Atrophy|Mild Cognitive Impairment","Diagnostic Test: Flutemetamol F18 Injection|Diagnostic Test: [18F]-RO6958948|Diagnostic Test: Elecsys (Roche) Abeta42, Ttau and Ptau|Diagnostic Test: Lumipulse (Fujirebio) Abeta42, Ttau and Ptau","Clinical diagnosis|Clinical Dementia Rating-Sum of Boxes (CDR-SB)|Rate of cognitive decline as measured by MMSE.|Rate of cognitive decline as measured in ADL-function.|Rate of volume change of structural MRI measures and amyloid PET|Rates of change on cerebrospinal fluid AD biomarkers","Skane University Hospital|Lund University","All","20 Years to 100 Years   (Adult, Older Adult)","Not Applicable","1505","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","BioFINDER 2","May 15, 2017","December 31, 2028","December 31, 2028","June 5, 2017","null","April 17, 2018","Memory Clinic, Skåne University Hospital, Malmö, Sweden|Memory Clinic, Hospital of Ängelholm, Ängelholm, Sweden","","https://ClinicalTrials.gov/show/NCT03174938"
946,"NCT03644043","Evidence Amyloid Scan EEG Study","EASES","Recruiting","No Results Available","Alzheimer Disease|Dementia Frontal|Mild Cognitive Impairment","Device: EEG scan","Patient meeting Appropriate Use Criteria (AUC) with EEG brain scan - P300 and P50 will be measured for correlation between P300 and P50 with amyloid deposition.","Metabolic Therapy Inc.|Institute of Asian American Adult Development","All","60 Years and older   (Adult, Older Adult)","","2000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","1R02TCR0072518","July 20, 2018","November 15, 2020","November 30, 2020","August 23, 2018","null","August 23, 2018","Translational Cognitive Research, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT03644043"
947,"NCT00942981","Functional Relevance of Dopamine Receptors in Healthy Controls and Patients With Schizophrenia: Characterization Through [11C]NNC-112 and [18F]Fallypride Positron Emission Tomography",,"Recruiting","No Results Available","Schizoaffective Disorder|Schizophrenia","","Regional binding potentials of [11C]NNC-112 and [18F]Fallypride","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years to 90 Years   (Adult, Older Adult)","","330","NIH","Observational","Time Perspective: Other","090176|09-M-0176","July 17, 2009","null","null","July 21, 2009","null","July 13, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00942981"
948,"NCT01756352","FET-PET for Evaluation of Response of Recurrent GBM to Avastin",,"Active, not recruiting","No Results Available","Glioblastoma Multiforme|GBM","Drug: 18F-FET","Change in FET uptake between baseline and follow-upm, relative to survival and progression on MRI","Marcelo F. Di Carli, MD, FACC|Brigham and Women's Hospital","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 2","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2012P002678","February 2013","August 2018","August 2018","December 25, 2012","null","August 29, 2017","Brigham and Women's Hospital, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT01756352"
949,"NCT01836562","A Clinical Trial to Study the Safety and Efficacy of Bone Marrow Derived Autologous Cells for the Treatment of Autism","BMCA","Unknown status","No Results Available","Autism","Biological: STEM CELL THERAPY","Improvement in childhood autism rating scale|Improvement in perfusion of brain with PET scan report","Chaitanya Hospital, Pune","All","3 Years to 70 Years   (Child, Adult, Older Adult)","Phase 1|Phase 2","100","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","00105","September 2014","June 2016","June 2016","April 22, 2013","null","September 17, 2014","Chaitanya Hospital, Pune, Maharashtra, India","","https://ClinicalTrials.gov/show/NCT01836562"
950,"NCT01991145","Allogeneic UCB Therapy With EPO in Children With CP",,"Completed","No Results Available","Cerebral Palsy","Procedure: Umbilical Cord Blood therapy|Biological: Erythropoietin alfa|Other: Rehabilitation|Procedure: Placebo UCB|Biological: Placebo EPO","Changes in Standardized Gross Motor Function|Changes in Motor Performance|Changes in Cognitive Neurodevelopmental Outcome|Changes in Motor Neurodevelopmental Outcome|Changes in Gross Motor Function Classification System|Changes in Functional Independence in Daily Activities|Changes in Functional Performance in Daily Activities|Changes in Upper Extremity Function|Changes in Visual Perception Test|Changes in Selective Movement of Lower Extremity|Changes in Spasticity|Changes in Dynamic Component of Spasticity|Changes in Muscle Strength|Changes in Brain MRI|Changes in Brain 18F-FDG PET|Changes in EEG|Changes in EP|Number of adverse events and participants with those adverse events","MinYoung Kim, M.D.|Ministry of Health & Welfare, Korea|LG Life Sciences|Chong Kun Dang Pharmaceutical|CHA University|Bundang CHA Hospital","All","10 Months to 6 Years   (Child)","Not Applicable","92","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","UCBnEPOinCP","November 2013","June 24, 2017","June 24, 2017","November 25, 2013","null","October 12, 2017","CHA Bundang Medical Center, CHA University, Seongnam-si, Gyeonggi-do, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT01991145"
951,"NCT00116077","Dopamine Receptor Imaging in Mood Disorders",,"Completed","No Results Available","Mood Disorders|Depressive Disorder, Major|Bipolar Disorder","","","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years to 55 Years   (Adult)","","145","NIH","Observational","","050169|05-M-0169","June 21, 2005","null","November 12, 2010","June 27, 2005","null","July 2, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00116077"
952,"NCT02025972","Allogeneic Umbilical Cord Blood Therapy in Children With CP",,"Completed","No Results Available","Cerebral Palsy","Procedure: Allogeneic umbilical cord blood therapy","Cytokine analysis|Changes in Standardized Gross Motor Function|Changes in Motor Performance|Changes in Cognitive Neurodevelopmental Outcome|Changes in Motor Neurodevelopmental Outcome|Changes in Gross Motor Function Classification System|Changes in Functional Independence in Daily Activities|Changes in Functional Performance in Daily Activities|Changes in Upper Extremity Function|Changes in Visual Perception Test|Changes in Selective Movement of Lower Extremity|Changes in Spasticity|Changes in Dynamic Component of Spasticity|Changes in Muscle Strength|Changes in Brain MRI|Changes in Brain 18F-FDG PET|Changes in EEG|Changes in EP|Number of adverse events and participants with those adverse events","MinYoung Kim, M.D.|CHA University|Bundang CHA Hospital","All","up to 15 Years   (Child)","Not Applicable","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UCBCP","December 2013","November 15, 2015","November 15, 2015","January 1, 2014","null","October 12, 2017","CHA Bundang Medical Center, CHA University, Seongnam-si, Gyeonggi-do, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT02025972"
953,"NCT02286024","Study of Morphological and Perfusion Imaging Predictors of Pejorative Outcome in Major Depressive Disorder","LONGIDEP","Recruiting","No Results Available","Depressive Disorder","","Cortical thickness|Cerebral Blood Flow (after treatment of ASL data)","Rennes University Hospital","All","18 Years and older   (Adult, Older Adult)","","300","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","2013-A01733-42|829","November 2014","November 2018","May 2019","November 7, 2014","null","April 9, 2018","Centre Hospitalier Guillaume Regnier, Rennes, Britanny, France","","https://ClinicalTrials.gov/show/NCT02286024"
954,"NCT00594737","Open Label Pilot Study of the Effects of Memantine on FDG-PET in Frontotemporal Dementia",,"Completed","No Results Available","Frontotemporal Dementia","Drug: memantine hydrochloride","Metabolic activity in frontal and temporal lobes.|Behavioural inventories, UPDRS Motor scale.","Tiffany Chow, MD|H. Lundbeck A/S|Rotman Research Institute at Baycrest","All","40 Years to 80 Years   (Adult, Older Adult)","Phase 3","17","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Baycrest.Ebixa.FTD-001|Lundbeck 11627A","October 2007","June 2012","June 2012","January 16, 2008","null","June 4, 2012","Baycrest, Toronto, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT00594737"
955,"NCT02218775","FASTMAS (Fast-Fail Trials in Mood and Anxiety Spectrum Disorders) Kappa Opioid Receptor Phase 1 Study","KOR1","Withdrawn","No Results Available","Anxiety Disorders","Drug: LY2456302","Primary: Kappa opioid receptor occupancy determined with LY2879788 PET imaging; Mu opioid receptor occupancy determined with [11C]-Carfentanil PET imaging|Peak PET Mu Occupancy|Reward Circuit Engagement Outcome|Clinical Anhedonia Outcome Utilizing the Snaith-Hamilton Pleasure Scale (SHAPS)|Anhedonia Outcome Utilizing the Snaith-Hamilton Pleasure Scale (SHAPS)|Behavioral Anhedonia Outcome as measured by the Probabilistic Reward Task (PRT)","Andrew Krystal|Yale University|Duke University","All","21 Years to 65 Years   (Adult, Older Adult)","Phase 1","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","Pro00052483|HHSN271201200006I","October 2014","April 2015","April 2015","August 18, 2014","null","May 28, 2015","Yale University, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT02218775"
956,"NCT01991977","18F-DOPA-PET in Finding Tumors in Patients With Newly Diagnosed Gliomas Undergoing Radiation Therapy",,"Recruiting","No Results Available","Malignant Glioma","Procedure: Diffusion Weighted Imaging|Drug: Fluorine F 18 Fluorodopa|Radiation: Intensity-Modulated Radiation Therapy|Procedure: Perfusion Magnetic Resonance Imaging|Procedure: Positron Emission Tomography|Other: Quality-of-Life Assessment|Drug: Temozolomide","Proportion of grade IV patients that experience confirmed progression-free survival|Overall survival|Progression free survival|Quality of life evaluated with the MD Anderson Symptom Inventory Brain Tumor Module and Mini-Mental Status Exam questionnaires|Rate of acute treatment-related toxicities graded using Common Terminology Criteria for Adverse Events version 4.0|Rate of late treatment-related toxicities using the Radiation Therapy Oncology Group/European Organization for Research and the Treatment of Cancer toxicity criteria","Mayo Clinic|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 2","150","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","MC1374|NCI-2013-02242|P30CA015083","December 2013","July 1, 2019","July 1, 2019","November 25, 2013","null","April 17, 2018","Mayo Clinic, Rochester, Minnesota, United States","","https://ClinicalTrials.gov/show/NCT01991977"
957,"NCT03560960","Multi-Center Development of a Novel Diagnostic Test for Alzheimer's Disease","DTAD","Enrolling by invitation","No Results Available","Alzheimer Disease|Mild Cognitive Impairment","Drug: Pramlintide challenge test","Plasma Aβ and t-tau changes|Plasma inflammatory changes|Plasma metabolic changes in blood|Change in MMSE|Change in CDR|Change in NAB|Change in WMS-III Logical Memory|Change in CLOX paradigm|Change in Trailmaking Test Part B|Change in Controlled Oral Word Association Test","Boston University","All","60 Years to 90 Years   (Adult, Older Adult)","Early Phase 1","240","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","H-37432","August 6, 2018","June 2023","June 2023","June 19, 2018","null","August 16, 2018","Indiana University Alzheimer Disease Center, Indianapolis, Indiana, United States|BU Alzheimer Disease Center, Boston, Massachusetts, United States|Memory Center VA Boston Healthcare, Jamaica Plain, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT03560960"
958,"NCT00103987","Neurobiological Mechanisms in Panic Disorder",,"Completed","No Results Available","Panic Disorder","","","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years to 60 Years   (Adult)","","54","NIH","Observational","","050102|05-M-0102","February 14, 2005","null","November 12, 2010","February 18, 2005","null","July 2, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00103987"
959,"NCT00267813","The Effects of Craving and Abstinence From Cigarettes on Brain Metabolism in Smokers",,"Completed","No Results Available","Nicotine Dependence","Drug: Bupropion (Zyban)","Brain metabolic activity (FDG) in response to craving and neutral cues.|Subjective ratings of craving","Tel-Aviv Sourasky Medical Center","All","20 Years to 65 Years   (Adult, Older Adult)","Not Applicable","24","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TASMC-O5-EE-065-CTIL","July 2004","October 2007","October 2007","December 21, 2005","null","May 7, 2008","Department of Nuclear Medicine, Tel Aviv, Israel","","https://ClinicalTrials.gov/show/NCT00267813"
960,"NCT00741559","Combined Role of Position Emission Tomography (PET) and Magnetoencephalography (MEG) in Nonlesional Epilepsy",,"Completed","No Results Available","Epilepsy","Device: magnetoencephalography|Device: Positron emission tomography (PET)|Device: Magnetic resonance imaging","The concordance rate of FDG-PET and MEG with video EEG|The positive and negative predictive values of each modality and combined modalities in assessing the epileptogenic zone.","The Hospital for Sick Children","All","up to 18 Years   (Child, Adult)","Phase 3","59","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","1000011429","March 2008","March 2011","June 2011","August 26, 2008","null","May 13, 2014","The Hospital for Sick Children, Toronto, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT00741559"
961,"NCT00299988","Phase II Study of Intravenous Immunoglobulin (IVIg) for Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Drug: Intravenous Immunoglobulin","ADAS-Cog|ADCS-CGIC|3MS|ADCS-ADL|NPI|GDS|QOL|ADCS Pharmacoeconomic Assessment|Plasma and CSF anti-amyloid antibody titers|Plasma and CSF beta amyloid levels|FDG Cerebral Glucose Utilization|PIB Cerebral Amyloid Distribution (PET)|PK11195 Microglial Activation (PET)|Adverse Event Frequency and Severity","Weill Medical College of Cornell University|Baxter BioScience|National Institutes of Health (NIH)","All","50 Years and older   (Adult, Older Adult)","Phase 2","24","Other|Industry|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","0512008265","February 2006","January 2009","April 2010","March 7, 2006","null","November 10, 2010","Weill Medical College of Cornell University, New York City, New York, United States","","https://ClinicalTrials.gov/show/NCT00299988"
962,"NCT02511509","Bifrontal and Bitemporal Electroconvulsive Therapy (ECT) in Treatment of Patients With Schizophrenia","ESBECT","Recruiting","No Results Available","Schizophrenia","Device: Bifrontal electroconvulsive therapy|Device: Bitemporal electroconvulsive therapy","Positive and Negative Syndrome Scale|Clinical Global Impression|Memorial Delirium Assessment Scale|Confusion Assessment Method|Verbal Memory Test|Visual Memory Test|Finger Tapping Test|Symbol Digit Coding Test|Stroop Test|Shifting Attention Test|Continuous Performance Test|Positron Emission Tomography to assess the impact of ECT on the dopaminergic system activity|The concentration of brain-derived neurotrophic factor.|The concentration of neuron specific enolase.|The concentration of protein S100B","Medical Universtity of Lodz","All","18 Years to 64 Years   (Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","RNN/535/10/KB","September 2015","July 2018","July 2019","July 30, 2015","null","October 3, 2016","Department of Old Age Psychiatry and Psychotic Disorders Medical University of Lodz, Lodz, Poland","","https://ClinicalTrials.gov/show/NCT02511509"
963,"NCT01724749","Cardiovascular Molecular Calcification Assessed by 18F-NaF PET CT","CAMONA","Unknown status","No Results Available","Cardiovascular Disease|Atherosclerosis|Angina Pectoris","","Standardized uptake value (SUV) of 18F-NaF|Target to background ratio (TBR) of 18F-NaF|Standardized uptake value (SUV) of 18F-Fluorodeoxyglucose (18F-FDG)|Target to background ratio (TBR) of 18F-FDG|Correlation between the TBR of 18F-NaF/18F-FDG and traditional cardiovascular risk factors.|Correlation between the TBR of 18F-NaF/18F-FDG and blood markers of atherosclerosis.|Correlations between 18F-NaF TBR, 18F-FDG TBR, and CT calcification scoring|Correlation between 18F-NaF / 18F-FDG uptake and 18F-FDG uptake in the brain|Correlation between 18F-NaF TBR and 18F-NaF TBR two years after the baseline scan.|Correlation between 18F-FDG TBR and 18F-FDG TBR two years after the baseline scan.|Correlation between the TBR of 18F-NaF/18F-FDG and HeartSCORE|Correlation between the TBR of 18F-NaF/18F-FDG and Framingham Risk Score|Correlation between 18F-NaF / 18F-FDG uptake and 18F-NaF / 18F-FDG uptake in the vertebral body|Arterial Calcification Score","Odense University Hospital","All","21 Years to 80 Years   (Adult, Older Adult)","","144","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","s-20120056","November 2012","November 2014","December 2016","November 12, 2012","null","November 12, 2012","Department of Cardiology, Odense University Hospital, Odense, Region Syddanmark, Denmark|Department of Nuclear Medicine, Odense University Hospital, Odense, Region Syddanmark, Denmark","","https://ClinicalTrials.gov/show/NCT01724749"
964,"NCT02329795","Image-derived Prediction of Response to Chemo-radiation in Glioblastoma","IDEPREG","Terminated","No Results Available","Glioblastoma","Radiation: Radiotherapy|Drug: Temozolomide","Sensitivity and specificity of predicted response|DICE-similarity coefficient and percentage overlap of 64Cu-ATSM and contrast-enhanced T1-weighted MRI|Correlation (volume and maximum values) between lactate and hypoxia","Rigshospitalet, Denmark","All","18 Years and older   (Adult, Older Adult)","","16","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","192/13","October 2014","October 2016","October 2016","January 1, 2015","null","October 12, 2017","Department of Oncology, Section for Radiotherapy, Rigshospitalet, Copenhagen, Denmark","","https://ClinicalTrials.gov/show/NCT02329795"
965,"NCT00001926","The Connection Between Areas in the Brain of Blind Patients",,"Completed","No Results Available","Blindness|Brain Mapping|Healthy","Drug: O15|Device: Cadwell rTMS","","National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult","","45","NIH","Observational","","990031|99-N-0031","April 1999","null","November 2003","November 4, 1999","null","March 4, 2008","National Institute of Neurological Disorders and Stroke (NINDS), Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00001926"
966,"NCT00439387","The Role of Serotonin in Seizures",,"Terminated","No Results Available","Epilepsy|Seizures","","","National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)","All","18 Years to 60 Years   (Adult)","","46","NIH","Observational","","070103|07-N-0103","February 20, 2007","null","June 5, 2015","February 23, 2007","null","July 4, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00439387"
967,"NCT01658748","A Pilot Study of Deep Brain Stimulation of the Amygdala for Treatment-Refractory Combat Post-Traumatic Stress Disorder","ADIP","Withdrawn","No Results Available","Post Traumatic Stress Disorder","Device: Week 0 Medtronic 3387 electrodes/Activa PC amygdala DBS|Device: Week 12 Medtronic 3387 electrodes/Activa PC amygdala DBS","The Clinician-Administered PTSD scale (CAPS) will be the primary outcome measure. A clinical response will be defined as a reduction of 30 % in CAPSSx from baseline to 12 months post-stimulation, without adverse events leading to stopping stimulation.|The Clinician-Administered PTSD scale (CAPS) change from week 0|Hamilton Anxiety Rating Scale (HAM-A) change from week 0|Montgomery Asberg Depression Rating Scale (MADRS) change from week 0|Young Mania Rating Scale (YMRS) change from week 0|Columbia-Suicide Severity Rating Scale (C-SSRS) change from week 0|Clinical Global Impression and Improvement Scales (CGI-S and CGI-I) change from week 0|Veterans Quality of Life Assessment Scale (SF-36v) change from week 0|Davidson Trauma Scale (DTS) change from week 0|Global Assessment of Functioning Scale (GAF) change from week 0|Wechsler Adult Intelligence Scale III (WAIS-III)-Digit Span Subtest change from baseline|Controlled Oral Word Association Test (COWAT) change from baseline|Ruff Figural Fluency Test (RFFT) change from baseline|Hopkins Verbal Learning Test - Revised (HVLT-R) change from baseline|Brief Visual Memory Test - Revised (BVMT-R) change from baseline|Boston Naming Test (BNT) change from baseline|Hooper Visual Organization Test (VOT) change from baseline|Rey-Osterrieth Complex Figure (CFT) change from baseline|Clock Drawing Test change from baseline|Wisconsin Card Sorting Test (WCST) change from baseline|Stroop Color and Word Test (STROOP) change from baseline|Iowa Gambling Task (IGT) change from baseline|Mini Mental State Exam (MMSE) change from baseline|Change in PET CT 18-fluorodeoxyglucose metabolism from baseline","US Department of Veterans Affairs|VA Greater Los Angeles Healthcare System|VA Office of Research and Development","Male","25 Years to 65 Years   (Adult, Older Adult)","Not Applicable","0","U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","N1112-I|1/01RX001112-01|PCC-2012","January 2013","December 2015","December 2015","August 7, 2012","null","May 29, 2013","VA Greater Los Angeles Healthcare System, Los Angeles, California, United States","","https://ClinicalTrials.gov/show/NCT01658748"
968,"NCT01572142","Decrease in Sense of Smell and Associated Cognitive Decline in Parkinson's Disease","OLF","Completed","No Results Available","Parkinson's Disease","","Olfactory testing","University of Michigan","All","50 Years and older   (Adult, Older Adult)","","74","Other","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","R01N5070856","August 2010","July 2016","July 2016","April 6, 2012","null","September 29, 2017","Universtiy of Michigan Functional Neuroimaging, Cognitive and Mobility Laboratory, Ann Arbor, Michigan, United States","","https://ClinicalTrials.gov/show/NCT01572142"
969,"NCT01889693","Imaging of Atherosclerosis With 68Ga-MSA",,"Completed","No Results Available","Atherosclerosis|Noninvasive Imaging of Atherosclerosis","","comparison of SUV(standard uptake unit) at atherosclerotic plaque of aorta and carotid arteries among 3 groups|side effect of PET imaging with 68Ga-MSA","Korea University|Ministry of Health & Welfare, Korea","All","Child, Adult, Older Adult","","60","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","GaMSA-Atherosclerosis","August 2012","August 2013","August 2013","June 28, 2013","null","August 27, 2013","Korea University Guro Hospital, Seoul, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT01889693"
970,"NCT01565291","A Preliminary Study of 18F-AV-45 in Alzheimer's Disease and Healthy Elderly Volunteers",,"Completed","Has Results","Alzheimer Disease","Drug: florbetapir F 18","Mean Cortical to Cerebellum SUVR|Precuneus to Cerebellum SUVR","Avid Radiopharmaceuticals","All","50 Years and older   (Adult, Older Adult)","Early Phase 1","32","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","18F-AV-45-A01","June 2007","January 2008","January 2008","March 28, 2012","May 3, 2012","May 18, 2012","Research Site, Baltimore, Maryland, United States|Research Site, North East, Maryland, United States|Research Site, Long Branch, New Jersey, United States","","https://ClinicalTrials.gov/show/NCT01565291"
971,"NCT01864655","Safety and Tolerability of AZD0530 (Saracatinib) in Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Drug: saracatinib|Drug: Placebo","Number of Participants with Adverse Events on AZD0530|CNS availability of AZD0530 after oral dosing|Effects of AZD0530 on cognitive function in patients with Alzheimer's disease|Effect of AZD0530 on brain glucose metabolism in patients with Alzheimer's disease","Stephen M. Strittmatter|Yale University","All","50 Years to 90 Years   (Adult, Older Adult)","Phase 1","24","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1UH2TR000967-01","July 2013","March 2014","null","May 29, 2013","null","June 13, 2014","Yale Alzheimer's Disease Research Unit, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT01864655"
972,"NCT01985100","The Use of Hyperbaric Oxygen to Increase the Blood Supply in the Injured, But Still Alive Tissue, Around an Old Stroke","HBO","Withdrawn","No Results Available","Ischemic Cerebrovascular Accident","Other: hyperbaric oxygen chamber","Increase in cellular metabolic activity in ischemic post stroke-penumbra PET scans|Change in the motor function deficit post-stroke by Physical Therapists' measurements of motor strength","John Davidson|Washington University School of Medicine|St. Luke's Hospital, Chesterfield, Missouri","All","50 Years to 80 Years   (Adult, Older Adult)","Not Applicable","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","StLukesMO # 2013.021","November 21, 2013","September 27, 2014","September 27, 2014","November 15, 2013","null","October 27, 2017","St. Luke's Hospital, Chesterfield, Missouri, United States","","https://ClinicalTrials.gov/show/NCT01985100"
973,"NCT01297088","PET/CT (Positron Emission Tomography / Computed Tomography) Investigations With BAY86-9596 (18F) (300 MBq) Following Single Intravenous Administration in Patients With Cancer or Inflammations.",,"Completed","No Results Available","Diagnostic Imaging","Drug: BAY86-9596","BAY86-9596 lesion detection rate (overall number of lesions identified).|Overall image quality (poor, satisfactory, excellent; based on investigator's experience with 18F-labeled PET tracers)|BAY86-9596 accumulation score in identified lesions (low accumulation, high accumulation).|Comparative score BAY86-9596 versus FDG. If an FDG PET/CT is not available (in malignant brain tumors or in brain metastasis), this comparison will be done with routine imaging modalities such as CT or MRI, or choline PET/CT.|Comparison of BAY86-9596 accumulation with lesions identified in histology of prostate cancer.","Piramal Imaging SA","All","30 Years to 80 Years   (Adult, Older Adult)","Phase 1","24","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","15146","May 2011","December 2011","December 2011","February 16, 2011","null","January 21, 2013","Singapore, Singapore|Singapore, Singapore","","https://ClinicalTrials.gov/show/NCT01297088"
974,"NCT00581009","The Role of Dopamine Metabolism in the Antidepressant Effects of Sleep Deprivation and Sertraline in Depressed Patients",,"Unknown status","No Results Available","Major Depressive Disorder|Bipolar Disorder","Other: chronobiological augmentation|Drug: sertraline, lithium|Radiation: one night of sleep deprivation and two FDG PET scans","Hamilton Rating Score for Depression","University of California, Irvine|University of California, San Diego","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","180","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HS#2001-1616","March 2001","January 2018","January 2018","December 27, 2007","null","November 2, 2010","University of California, Irvine, Irvine, California, United States|University of California, San Diego, La Jolla, California, United States","","https://ClinicalTrials.gov/show/NCT00581009"
975,"NCT01383161","18-Month Study of Memory Effects of Curcumin","Curcumin","Completed","Has Results","Age-associated Cognitive Impairment|Mild Cognitive Impairment (MCI)","Drug: Curcumin|Other: Placebo","Change From Baseline to 18 Months on Brief Visual Memory Test-Revised, Recall|Change From Baseline to 18 Months on Brief Visual Memory Test-Revised, Delay|Change From Baseline on Buschke Selective Reminding Task, Consistent Long-Term Retrieval|Change From Baseline on Buschke Selective Reminding Task, Total Score|Change From Baseline to 18 Months on Trail Making Test, Part A|Change From Baseline to 18 Months on Beck Depression Inventory (BDI)","University of California, Los Angeles","All","50 Years to 90 Years   (Adult, Older Adult)","Phase 2","46","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","11-001740|IND 112714","March 2012","April 2017","April 2017","June 28, 2011","March 19, 2018","March 19, 2018","UCLA Longevity Center, Los Angeles, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/61/NCT01383161/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT01383161"
976,"NCT00459550","A Clinical Study to Assess Single and Repeat Doses of a New Medication (GSK933776) in Patients With Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Drug: GSK933776|Drug: Placebo to match GSK933776","Adverse events. Changes suggesting potential adverse events detected in the physical & neurological examination, brain MRI, cognitive status, laboratory parameters, ECG & vital signs.|Plasma pharmacokinetic parameters of GSK933776. Pharmacodynamic effects of GSK 933776. CSF detectable levels of GSK933776. Effects of GSK933776 on plasma and CSF biomarkers. Titre & neutralising activity of anti-GSK933776 antibodies. Exploratory PET scan","GlaxoSmithKline","All","55 Years to 80 Years   (Adult, Older Adult)","Phase 1","50","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","106006","March 12, 2007","May 30, 2011","May 30, 2011","April 12, 2007","null","July 21, 2017","GSK Investigational Site, Herston, Queensland, Australia|GSK Investigational Site, Heidelberg Heights, Victoria, Australia|GSK Investigational Site, Fremantle, Western Australia, Australia|GSK Investigational Site, Lørenskog, Norway|GSK Investigational Site, Malmö, Sweden|GSK Investigational Site, Mölndal, Sweden|GSK Investigational Site, Stockholm, Sweden","","https://ClinicalTrials.gov/show/NCT00459550"
977,"NCT00067275","The Effect of Dopamine on Motor Skills Training",,"Completed","No Results Available","Cerebrovascular Accident","","","National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)","All","18 Years to 80 Years   (Adult, Older Adult)","","98","NIH","Observational","","030266|03-N-0266","August 8, 2003","null","August 15, 2007","August 14, 2003","null","July 2, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00067275"
978,"NCT00192998","The Serotonergic Transmitter System in Dementia and Affective Disorders",,"Unknown status","No Results Available","Mood Disorders|Alzheimer Disease","","","Rigshospitalet, Denmark","All","18 Years and older   (Adult, Older Adult)","","100","Other","Observational","Observational Model: Defined Population|Observational Model: Natural History|Time Perspective: Cross-Sectional|Time Perspective: Prospective","SERT-AD","October 2003","null","null","September 19, 2005","null","September 27, 2007","Neurobiological Research Unit, Copenhagen, Denmark","","https://ClinicalTrials.gov/show/NCT00192998"
979,"NCT00736671","Striatal and Extra-striatal Mechanisms of Falling in Parkinson's Disease",,"Completed","No Results Available","Parkinson's Disease","","","University of Michigan","All","50 Years to 85 Years   (Adult, Older Adult)","","88","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","HUM00003450","July 2006","April 2010","August 2010","August 18, 2008","null","March 4, 2016","University of Michigan Functional Neuroimaging, Cognnitive and Mobility Laboratory, Ann Arbor, Michigan, United States","","https://ClinicalTrials.gov/show/NCT00736671"
980,"NCT00094601","Relationship of Dopamine to Cognitive Function in Parkinson's Disease",,"Completed","No Results Available","Parkinson Disease","","","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","40 Years to 85 Years   (Adult, Older Adult)","","75","NIH","Observational","","050011|05-M-0011","October 18, 2004","null","January 22, 2008","October 21, 2004","null","July 2, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00094601"
981,"NCT00013845","Evaluation and Treatment of Patients With Epilepsy",,"Terminated","No Results Available","Epilepsy","","","National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)","All","2 Years and older   (Child, Adult, Older Adult)","","1278","NIH","Observational","","010139|01-N-0139","May 1, 2001","null","June 26, 2018","April 2, 2001","null","August 23, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00013845"
982,"NCT03040713","Flortaucipir PET Imaging in Subjects With FTD",,"Recruiting","No Results Available","Frontotemporal Dementia","Drug: 18F-AV-1451|Drug: 18F-AV-45","18F-AV-1451 tracer uptake measured by regional SUVr","Avid Radiopharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 1","25","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","18F-AV-1451-A19","April 11, 2017","December 2018","December 2018","February 2, 2017","null","January 9, 2018","Movement Disorder Center, UCSD, La Jolla, California, United States|Memory and Aging Center, UCSF, San Francisco, California, United States|UT Southwestern Medical Center, Dallas, Texas, United States","","https://ClinicalTrials.gov/show/NCT03040713"
983,"NCT00271609","Bevacizumab for Recurrent Malignant Glioma",,"Completed","Has Results","Recurrent High-Grade Gliomas|Malignant Gliomas","Drug: Bevacizumab","Percentage of Participants With Progression Free Survival at 6 Months.|Number of Participants With Adverse Events","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)","Phase 2","88","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","060064|06-C-0064","December 2005","March 2011","February 2014","January 2, 2006","June 8, 2012","April 29, 2014","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00271609"
984,"NCT03174119","Light Therapy in Disorders of Consciousness: Behavioral, Neuroimaging and (Neuro)Physiological Assessments.",,"Not yet recruiting","No Results Available","Disorder of Consciousness","Device: Light therapy - active|Device: Placebo light","Changes in the Coma Recovery Scale-Revised scores.|Change in sleep-wake cycles through the Nociception Coma Scale-Revised, after the exposition of real light instead of placebo light.|Change in sleep-wake cycles through the actimetry, after the exposition of real light instead of placebo light.|Change in sleep-wake cycles through the brain metabolism with Positron Emission Tomography, after the exposition of real light instead of placebo light.|Change in sleep-wake cycles through the hemodynamic function of the brain with functional Magnetic Resonance Imaging, after the exposition of real light instead of placebo light.|Change in sleep-wake cycles through the electrical activity of the brain with electroencephalography, after the exposition of real light instead of placebo light.|Change in sleep-wake cycles through analyses of melatonine hormone, after the exposition of real light instead of placebo light.|Change in sleep-wake cycles through temperature measurements, after the exposition of real light instead of placebo light.|Change in the outcomes by the assessment of the Glasgow Outcome Scale Extended, after the study.","University Hospital of Liege","All","16 Years to 80 Years   (Child, Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","OGosseries","January 2018","January 2021","January 2021","June 2, 2017","null","October 26, 2017","","","https://ClinicalTrials.gov/show/NCT03174119"
985,"NCT01281956","PRX-00023 Therapy in Localization-Related Epilepsy",,"Terminated","No Results Available","Epilepsy|Epilepsy, Temporal Lobe|Partial Epilepsy","Drug: PRX-00023","Seizure frequency counts during the 3 month placebo and active treatment phases|Proportion of patients with greater than or equal to 50% lower seizure rate on PRX-0023 than placebo, Hamilton Depression and Anxiety Rating scales, and performance on neuropsychological testing scales.|Safety assessment for adverse events, changes in vital signs, laboratory test results and physical examination.","National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","12","NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","110039|11-N-0039","January 7, 2011","October 5, 2017","October 5, 2017","January 24, 2011","null","July 4, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT01281956"
986,"NCT02020824","Virtual Reality and Concept of Control in the Treatment of Acrophobia","CTRLSTRESS","Unknown status","No Results Available","Phobic Disorders","Behavioral: Exposure to anxiogenous environments|Other: Imagery with functional MRI initial|Other: Imagery with PET-scanner initial|Other: Imagery with functional MRI final|Other: Imagery with PET-scanner final","Behavioural Avoidance Test (BAT)|Brain activity (functional MRI)|Synaptic activity (PET-scan)|Cognitive measurements|Quality of life|Ergonomy|Psychophysiological|Adverse events","Qualissima|Centre National de la Recherche Scientifique, France","All","18 Years to 60 Years   (Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CTRLSTRESS|2013-A01280-45 ID-RCB","April 2014","June 2017","July 2017","December 25, 2013","null","October 30, 2015","Service hospitalo-universitaire de psychologie médicale de psychiatrie d'adultes du Pr Lançon - CHU Marseille, Marseille, France","","https://ClinicalTrials.gov/show/NCT02020824"
987,"NCT03414021","Interest of the SPECT-CT Scan SUVspect in the New Generation of Gamma-cameras With Semiconductor","GAMMA-CAM","Recruiting","No Results Available","Thyroid Diseases|Heart Diseases|Bone Diseases|Brain Diseases|Kidney Diseases","Diagnostic Test: SPECT-CT Scan","SUVspect|Matrix size|duration of image acquisition","Lille Catholic University","All","18 Years and older   (Adult, Older Adult)","","250","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","OBS-0030","January 31, 2018","January 30, 2023","January 30, 2023","January 29, 2018","null","July 24, 2018","Humanitep, Lomme, Hauts De France, France|Hopital Privé Le Bois, Lille, Hauts-de-France, France","","https://ClinicalTrials.gov/show/NCT03414021"
988,"NCT01103726","Evaluation Of Striatal Glucose Metabolism With Positron Emission Tomography Following PF-02545920 In Healthy Subjects",,"Completed","No Results Available","Healthy","Drug: PF-02545920|Drug: placebo|Drug: Placebo","Glucose metabolic rates in striatum using standard Region of Interest (ROI) analysis method.|Whole brain glucose metabolic rate.|Relative glucose metabolic rate in striatum.|Glucose metabolic rate in striatal subregions: putamen and caudate nucleus.|Relative glucose metabolic rate in striatal subregions: putamen and caudate nucleus.|Glucose metabolic rate in striatum determined using data-driven ROI analysis method.|Relative glucose metabolic rate in striatum determined using data-driven ROI analysis method.|Effect size comparison between standard ROI and data-driven ROI analysis methods using both regional glucose metabolic rate and relative regional glucose metabolic rate.","Pfizer|Yale University","All","18 Years to 55 Years   (Adult)","Phase 1","34","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","A8241013","May 2010","November 2011","November 2011","April 15, 2010","null","November 16, 2011","Pfizer Investigational Site, New Haven, Connecticut, United States|Pfizer Investigational Site, New Haven, Connecticut, United States|Pfizer Investigational Site, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT01103726"
989,"NCT00979173","Pharmacokinetics (PK) Study of AC480 for Recurrent Glioma",,"Completed","No Results Available","Glioma","Drug: AC480","Intratumoral and plasma pharmacokinetics of AC480 will be obtained on surgical tissue specimens from 5 patients treated pre-operatively with AC480.|Anti-proliferative effect of AC480 by FDG-PET|Intratumoral and plasma pharmacodynamics of AC480|6-month progression-free survival (PFS)|Radiographic response|Adverse event and toxicity monitoring","Annick Desjardins|Ambit Biosciences Corporation|Duke University","All","18 Years and older   (Adult, Older Adult)","Phase 1","5","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00018751","November 2009","October 2010","June 2012","September 17, 2009","null","January 29, 2014","The Preston Robert Tisch Brain Tumor Center at Duke University Medical Center, Durham, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT00979173"
990,"NCT00775853","Biomarkers of Risk of Parkinson Disease",,"Active, not recruiting","No Results Available","Parkinson Disease|Autonomic Nervous System Diseases|Pure Autonomic Failure","","Diagnosis of Parkinson disease (PD) based on the characteristic movement disorder in PD, confirmed by Unified Parkinson Disease Rating Scale (UPDRS).|Brain 6-[18F]fluorodopa-derived radioactivity; cardiac 6-[18F]fluorodopamine-derived radioactivity; CSF neurochemicals; olfactory testing; autonomic function tests; neurobehavioral rating scales.","National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)","All","18 Years to 70 Years   (Adult, Older Adult)","","88","NIH","Observational","Time Perspective: Prospective","090010|09-N-0010","October 16, 2008","null","null","October 20, 2008","null","July 10, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00775853"
991,"NCT01388478","Safety Study of R(+)Pramipexole to Treat Early Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Drug: R-pramipexole","Number of Patients with Adverse Events|Reduction of Oxidative Stress|Changes in cerebral glucose metabolism|Effects on Cognitive Performance","Virginia Commonwealth University|University of Kansas Medical Center|Alzheimer’s Drug Discovery Foundation","All","55 Years and older   (Adult, Older Adult)","Phase 2","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VCU-KU-ADDF-2011|20101202","July 2011","January 2014","April 2014","July 6, 2011","null","April 25, 2016","University of Kansas Medical Center, Kansas City, Kansas, United States","","https://ClinicalTrials.gov/show/NCT01388478"
992,"NCT00737217","Executive, Activities of Daily Living, and Cholinergic Functions in Parkinson's Disease",,"Completed","No Results Available","Parkinson's Disease","Behavioral: Behavioral assessment/questionnaire","","University of Michigan|Michael J. Fox Foundation for Parkinson's Research","All","50 Years to 85 Years   (Adult, Older Adult)","","74","Other","Observational","Observational Model: Case Control|Time Perspective: Prospective","2005-0464","March 2006","April 2009","April 2009","August 18, 2008","null","June 26, 2013","University of Michigan Functional, Cognitive and Mobility Laboratory, Ann Arbor, Michigan, United States","","https://ClinicalTrials.gov/show/NCT00737217"
993,"NCT00142597","Effectiveness of Acupuncture in Relieving Pain Due to Fibromyalgia",,"Completed","Has Results","Fibromyalgia","Device: Acupuncture|Other: Sham treatment","Change in Mu-opioid Receptor Occupancy","University of Michigan|National Center for Complementary and Integrative Health (NCCIH)","Female","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","46","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","K01AT001111-01|1K01AT001111-01","May 2005","March 2011","March 2011","September 2, 2005","April 13, 2015","April 13, 2015","University of Michigan, Ann Arbor, Michigan, United States","","https://ClinicalTrials.gov/show/NCT00142597"
994,"NCT02945904","IS Metomidate PET-CT Superior to Adrenal Venous Sampling in Predicting Outcome From Adrenalectomy in Patients With Primary Hyperaldosteronism","MATCH","Recruiting","No Results Available","Primary Aldosteronism|Hyperaldosteronism","Procedure: adrenalectomy","Aldosterone renin ratio changes in patients with primary aldosteronism (Conn's adenoma) from baseline to 6 months after treatment.|Home systolic blood pressure in mmHg change from baseline to 6 months after treatment.|Number of patients achieving Home systolic blood pressure <140mmHg on no treatment 6 months post treatment.|Number of Participants requiring less numbers of antihypertensive medication following treatment.|SUV max ratios between adenoma and normal adrenal|Reduction in home systolic blood pressure mmHg on 4 week spironolactone therapy|High sensitivity Troponin serum level changes from baseline to post 6 month post treatment|Serum Brain natriuretic Peptide level changes from baseline to 6 month post treatment.","Queen Mary University of London|National Institute for Health Research, United Kingdom|WBIC), Cambridge. University of Cambridge Addenbrookes Hospital, Cambridge CB2 2QQ|Robertson Centre for Biostatistics University of Glasgow Glasgow G12 8QQ|Barts and the London School of Medicine and Dentistry W Smithfield London - City of London EC1A 7BE","All","18 Years and older   (Adult, Older Adult)","","140","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","011149","October 2016","October 2020","October 2020","October 26, 2016","null","March 6, 2018","Queen Mary University of London, City Of London, United Kingdom","","https://ClinicalTrials.gov/show/NCT02945904"
995,"NCT00401999","OPRM1 A118G SNP, Alcohol Response, and Striatal Dopamine",,"Completed","No Results Available","Alcoholism","","","National Institute on Alcohol Abuse and Alcoholism (NIAAA)|National Institutes of Health Clinical Center (CC)","All","21 Years to 45 Years   (Adult)","","35","NIH","Observational","Time Perspective: Prospective","070026|07-AA-0026","November 16, 2006","null","January 28, 2011","November 22, 2006","null","July 2, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00401999"
996,"NCT01325402","An Open Positron Emission Tomography Study to Assess the Effects of Varying Mass of AZD4694 on Radioligand Binding Parameters in Healthy Volunteers and Patients With Alzheimer's Disease",,"Completed","No Results Available","Maximum Diagnostic Mass of [18Fluor]AZD4694","Other: [18Fluor]AZD4694","The Maximum Diagnostic Mass by assessing the visual read out of amyloid status according to and quantification of an [18F]AZD4694 PET image in a high mass experiment compared to the image in a low mass experiment in the same subject.|Number of Adverse Events as a measure of Safety and tolerability of [18F]AZD4694|Correlation between early uptake of [18F]AZD4694 images and cerebral blood flow images as measured by Arterial Spin Labeling Magnetic resonance imaging|Correlation between estimates of β-amyloid load in brain obtained using [18F]AZD4694 Position Emission Tomography imaging and concentrations of β-amyloid in Cerebrospinal fluid","AstraZeneca","Male","50 Years to 85 Years   (Adult, Older Adult)","Phase 1","16","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","D2750C00002|EudraCT # 2011-000095-34","August 2011","November 2012","November 2012","March 29, 2011","null","December 10, 2012","Research Site, Stockholm, Sweden|Research Site, Uppsala, Sweden","","https://ClinicalTrials.gov/show/NCT01325402"
997,"NCT01274988","Deep Brain Stimulation of Nucleus Accumbens to Prevent Opiate Relapse",,"Unknown status","No Results Available","Addiction","Procedure: Deep brain stimulation|Other: methadone maintenance treatment","Treatment retention|Change of participants' craving for opioid drugs|Change in Addiction Severity Index (ASI lite) composite scores|Psychological evaluation|Personality evaluation|Cognitive evaluation|Evaluation of quality of life|Change in two static positron emission tomography(PET) images study","Tang-Du Hospital","All","18 Years and older   (Adult, Older Adult)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","NACDBS","February 2011","June 2015","December 2015","January 12, 2011","null","April 16, 2014","Department of neurosurgery, Tangdu Hospital, Xi'an, Shaanxi, China","","https://ClinicalTrials.gov/show/NCT01274988"
998,"NCT00186186","Depakote ER in Bipolar Depression",,"Completed","Has Results","Depression, Bipolar","Drug: Depakote ER","Montgomery Asberg Depression Rating Scale (MADRS)|Response to the Divalproex-ER in Acute Bipolar 2 Depression.","Stanford University|Abbott|National Alliance for Research on Schizophrenia and Depression","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 4","28","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","79130","January 2004","January 2009","January 2009","September 16, 2005","April 12, 2017","April 12, 2017","Stanford University Bipolar Disorders Clinic, Stanford, California, United States","","https://ClinicalTrials.gov/show/NCT00186186"
999,"NCT00987090","Early-onset and Late-onset Sporadic Alzheimer's Disease (AD)",,"Unknown status","No Results Available","Alzheimer's Disease","Biological: Clinic and neuropsychologic evaluation|Radiation: MRI|Procedure: PET|Biological: Apolipoprotein E genotyping|Biological: Study of cerebrospinal fluid","to establish the impact of age on the clinical and neuroimaging picture of sporadic Alzheimer Disease in a multicentric setting.|to describe for each age group, and in particular for the younger patient group, the functional impact of disability in everyday life on both, patients and caregivers.","Assistance Publique Hopitaux De Marseille","All","45 Years to 90 Years   (Adult, Older Adult)","Not Applicable","240","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2008/24|2008-A01213-52","October 2009","September 2016","null","September 30, 2009","null","October 23, 2015","Assistance Publique - Hôpitaux de Marseille, Marseille, France","","https://ClinicalTrials.gov/show/NCT00987090"
1000,"NCT02486250","Online Neuropsychological Test Validation Project With Imaging Pilot","NVP","Active, not recruiting","No Results Available","Validation of Online Cognitive Testing","Other: Validation Study","Number of people recruited online for in-clinic study|Difference between unsupervised cognitive test score vs. supervised cognitive test score","University of California, San Francisco|Johnson & Johnson|Avid Radiopharmaceuticals","All","60 Years and older   (Adult, Older Adult)","","1000","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","13-12765","January 2015","August 2017","December 2020","July 1, 2015","null","June 19, 2018","BrainHealthRegistry.org, San Francisco, California, United States","","https://ClinicalTrials.gov/show/NCT02486250"
1001,"NCT02844179","(+)-Alpha-Dihydrotetrabenazine Phase I",,"Completed","No Results Available","Healthy Subjects","Drug: HTBZ","VMAT2 occupancy by HTBZ determined by positron emission tomography (PET) scanning","Kirk A. Frey|Adeptio Pharmaceuticals|University of Michigan","All","18 Years and older   (Adult, Older Adult)","Phase 1","6","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","HUM00105810 -1","July 2016","June 27, 2017","June 27, 2017","July 26, 2016","null","August 22, 2017","University of Michigan hospitals, Ann Arbor, Michigan, United States","","https://ClinicalTrials.gov/show/NCT02844179"
1002,"NCT02931136","Early Diagnosis and Early Treatment of Alzheimer's Disease Based on Senile Plaque Imaging",,"Not yet recruiting","No Results Available","Mild Cognitive Impairment|Biomarker|Diagnosis|Treatment","Drug: Huperzine A|Drug: Placebo","The average annual conversion rate in patients of MCI due to AD convert to the AD.","Shanghai Mental Health Center","All","55 Years to 85 Years   (Adult, Older Adult)","Phase 4","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Shanghai Mental Health Center","November 2016","December 2017","December 2018","October 12, 2016","null","October 12, 2016","Shanghai Mental Health Center, Shanghai, Shanghai, China","","https://ClinicalTrials.gov/show/NCT02931136"
1003,"NCT02601677","Deep Brain Stimulation of NAc/ALIC to Prevent Treatment-Refractory Obsessive Compulsive Disorder",,"Not yet recruiting","No Results Available","Obsessive Compulsive Disorder","Procedure: Deep brain stimulation|Drug: Fluoxetine","Yale-Brown Obsessive Compulsive Scale (Y-BOCS)|Clinical Global Impression (CGI)|Global assessment of functioning (GAF)|The Hamilton Anxiety Scale (HAM-A)|The Hamilton Rating Scale for Depression (HAM-D)|Sheehan Disability Scale (SDS)|Event related potentials(ERPs)|local field potential(LFP)|Change in two static positron emission tomography(PET) images study","Tang-Du Hospital","All","18 Years to 60 Years   (Adult)","Not Applicable","10","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","OCD-DBS","November 2015","November 2018","November 2018","November 10, 2015","null","November 10, 2015","","","https://ClinicalTrials.gov/show/NCT02601677"
1004,"NCT00024960","Dopamine Function in Developmental Stuttering",,"Completed","No Results Available","Developmental Stuttering","","","National Institute on Deafness and Other Communication Disorders (NIDCD)|National Institutes of Health Clinical Center (CC)","All","18 Years to 55 Years   (Adult)","","12","NIH","Observational","","020008|02-DC-0008","October 3, 2001","null","October 29, 2010","October 10, 2001","null","July 2, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00024960"
1005,"NCT00084162","Neurocardiac Control in Major Depression",,"Completed","No Results Available","Depression, Involutional","","","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years to 50 Years   (Adult)","","41","NIH","Observational","","040136|04-M-0136","March 30, 2004","null","March 17, 2010","June 8, 2004","null","July 2, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00084162"
1006,"NCT01701050","Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index","COMETI P2","Completed","No Results Available","Metastatic Breast Cancer","Other: Blood collection","Rapid Disease Progression|Progression Free Survival (PFS)","Janssen Diagnostics, LLC","Female","18 Years and older   (Adult, Older Adult)","","121","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","COMETI-P2-2012","April 1, 2013","November 10, 2016","November 10, 2016","October 4, 2012","null","March 8, 2017","Arizona Oncology Associates, Phoenix, Arizona, United States|Florida Cancer Specialists, Ft. Myers, Florida, United States|Florida Cancer Specialists, St. Petersburg, Florida, United States|Dana-Faber Cancer Institute, Boston, Massachusetts, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Minnesota Oncology Hematology, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Nebraska Cancer Specialists, Omaha, Nebraska, United States|Comprehensive Cancer Centers of Nevada, Henderson, Nevada, United States|New York Oncology Hematology, New York, New York, United States|Waverly Hematology Oncology, Cary, North Carolina, United States|Duke University, Durham, North Carolina, United States|Northwest Cancer Specialists, Portland, Oregon, United States|Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Texas Oncology - Baylor, Dallas, Texas, United States|Texas Oncology, Houston, Texas, United States|Mt. Sinai Hosp., Marvette Koffler Breast Center, Toronto, Ontario, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT01701050"
1007,"NCT02409121","A Novel Health Information Technology System (BMT Roadmap) for Pediatric BMT Patients and Caregivers",,"Recruiting","No Results Available","Leukemia|Lymphoma|Brain Tumor","Behavioral: Education information system","Number of subjects who participate in the health information technology educational intervention","Sung Choi, M.D.|Agency for Healthcare Research and Quality (AHRQ)|University of Michigan Cancer Center","All","10 Years to 75 Years   (Child, Adult, Older Adult)","Not Applicable","20","Other|U.S. Fed","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","HUM00100126","September 2015","November 2018","December 2018","April 6, 2015","null","June 14, 2018","University of Michigan, Ann Arbor, Michigan, United States","","https://ClinicalTrials.gov/show/NCT02409121"
1008,"NCT00095940","Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors",,"Completed","Has Results","Recurrent Childhood Anaplastic Astrocytoma|Recurrent Childhood Brain Stem Glioma|Recurrent Childhood Ependymoma|Recurrent Childhood Giant Cell Glioblastoma|Recurrent Childhood Glioblastoma|Recurrent Childhood Gliosarcoma|Recurrent Childhood Medulloblastoma|Recurrent Childhood Oligodendroglioma","Drug: lapatinib ditosylate|Procedure: therapeutic conventional surgery|Other: laboratory biomarker analysis|Other: pharmacological study|Procedure: positron emission tomography|Procedure: magnetic resonance imaging","Relative Phosphorylation of ERBB2 (Molecular Biology Objective)|Number of Participants With a Sustained Objective Response (Complete or Partial Response) (Phase II Objective)|Tumor to Plasma Lapatinib Concentration (Molecular Biology Objective)|Maximum Concentration of Lapatinib in Plasma (Phase II Objective)|Number of Participants With Tumors Expressing Total ERBB2|Number of Participants With Tumors Expressing Phosphorylated ERBB2 (Phase II Objective)","National Cancer Institute (NCI)","All","up to 21 Years   (Child, Adult)","Phase 1|Phase 2","52","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCI-2012-03007|PBTC-016|U01CA081457","October 2004","July 2010","July 2010","November 9, 2004","February 6, 2012","May 23, 2014","Pediatric Brain Tumor Consortium, Memphis, Tennessee, United States","","https://ClinicalTrials.gov/show/NCT00095940"
1009,"NCT00367341","Imaging Predictors of Treatment Response in Depression",,"Completed","Has Results","Major Depressive Disorder","Drug: escitalopram|Behavioral: Cognitive Behavioral Therapy (CBT)","Remission Defined as Hamilton Depression Rating Scale-17 Score of Less Than or Equal to 7 at 12 Weeks|Response Defined as 50% Change in Hamilton Depression Rating Scale-17 Score at 12 Weeks","Emory University|National Institute of Mental Health (NIMH)","All","21 Years to 60 Years   (Adult)","Not Applicable","82","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00026176","August 2006","August 2011","July 2013","August 22, 2006","January 9, 2014","January 9, 2014","Emory University School of Medicine, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00367341"
1010,"NCT00001247","Inpatient Evaluation of Adults With Schizophrenia",,"Recruiting","No Results Available","Psychotic Disorder|Schizophrenia|Schizoaffective|Paranoia|Psychosis","","","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)","","700","NIH","Observational","","890160|89-M-0160","September 13, 1989","null","null","November 4, 1999","null","August 22, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00001247"
1011,"NCT00812227","Neural Correlates of Psychodynamic Psychotherapy for Depression",,"Completed","No Results Available","Major Depressive Disorder","Behavioral: Psychodynamic Psychotherapy","Correlation between changes in HAMD-17 and changes in QEEG measurements (theta cordance) from treatment initiation to two weeks after starting treatment|PET: Treatment-related change in FDG metabolism within regions-of-interest identified at baseline as related to depression severity.","Massachusetts General Hospital|Hope for Depression Research Foundation","All","18 Years to 60 Years   (Adult)","Not Applicable","35","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2008-P-001181","August 2008","February 2013","February 2013","December 22, 2008","null","May 13, 2013","Depression Clinical and Research Program, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT00812227"
1012,"NCT03478852","Investigating Epilepsy: Screening, Evaluation and Treatment",,"Recruiting","No Results Available","Seizures|Epilepsy|Epilepsy, Temporal Lobe|Partial Epilepsy","","Screening and characterization of patients with drug-resistant epilepsy for epilepsy-related protocols|Teaching and training of clinical fellows and residents|Provision of standard care evaluation and medical management of enrolled patients","National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)","All","8 Years and older   (Child, Adult, Older Adult)","","500","NIH","Observational","Observational Model: Case-Control|Time Perspective: Prospective","180066|18-N-0066","March 28, 2018","July 30, 2027","August 31, 2027","March 27, 2018","null","July 20, 2018","National Institutes of Health Clinical Center, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT03478852"
1013,"NCT01659814","Dopamine Neurotransmission in Major Depression",,"Completed","No Results Available","Major Depressive Disorder|Anhedonia","","Event-Related Potentials (ERPs) during PSST task|[11C]raclopride binding potential|Behavioral Performance in Monetary Incentive Delay task|Behavioral Performance in Probabilistic Stimulus Selection Task (PSST)|Questionnaire Data","Mclean Hospital","All","18 Years to 45 Years   (Adult)","","71","Other","Observational","Observational Model: Case Control","2009P000038","March 2011","December 2012","December 2012","August 8, 2012","null","April 23, 2014","McLean Hospital, Belmont, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT01659814"
1014,"NCT00595582","Early Intervention in Mild Cognitive Impairment (MCI) With Curcumin + Bioperine",,"Terminated","Has Results","Mild Cognitive Impairment","Dietary Supplement: curcumin + bioperine","Neuropsychological Scores in Patients With MCI or Mild AD.","Louisiana State University Health Sciences Center Shreveport","All","55 Years to 85 Years   (Adult, Older Adult)","Not Applicable","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","LSU#H05-168","May 2005","June 2008","June 2008","January 16, 2008","May 28, 2012","May 28, 2012","Louisiana State University Health Sciences Center, Shreveport, Louisiana, United States","","https://ClinicalTrials.gov/show/NCT00595582"
1015,"NCT01522404","Effects of Atomoxetine in Mild Cognitive Impairment","ATX-001","Completed","No Results Available","Mild Cognitive Impairment","Drug: Atomoxetine|Drug: Placebo","Change in Interleukin1 (IL1-alpha) in Cerebrospinal fluid (CSF) in subjects with Mild Cognitive Impairment MCI treated with Atomoxetine compared to subjects treated with Placebo|Change in Thymus-Expressed Chemokine (TECK) in Cerebrospinal fluid (CSF) in subjects with Mild Cognitive Impairment MCI treated with Atomoxetine compared to subjects treated with Placebo|Number of adverse events with Mild Cognitive Impairment MCI treated with Atomoxetine compared to subjects treated with Placebo|Percentage of subject drop out rate that are treated with Atomoxetine|Change in rate of cerebral blood flow in subjects with Mild Cognitive Impairment MCI treated with Atomoxetine compared to subjects treated with Placebo|Change in Fluoro Deoxy Glucose [FDG] uptake in subjects with Mild Cognitive Impairment MCI treated with Atomoxetine compared to subjects treated with Placebo","Emory University|National Institute on Aging (NIA)","All","50 Years to 90 Years   (Adult, Older Adult)","Phase 2","39","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","IRB00054397|5U01AG010483|ATX-001","March 2012","October 31, 2017","June 30, 2018","January 31, 2012","null","August 6, 2018","Emory University School of Medicine, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT01522404"
1016,"NCT03294434","Predicting Sites of Tumour Progression in the Invasive Margin of Glioblastomas (PRaM-GBM Study)","PRaM-GBM","Recruiting","No Results Available","High Grade Glioma","Other: Diffusion tensor Imaging (DTI)","Site of glioblastoma true progression correctly predicted by DTI scan|Accuracy of DTI as a biomarker|Perfusion imaging|Time to progression|Extent of resection and volume of tumour that remains post-surgery by standard imaging and DTI|Radiotherapy dose according to DTI-defined invasive region","CCTU- Cancer Theme|Cambridge University Hospitals NHS Foundation Trust|Cancer Research UK|Experimental Cancer Medicine Centres (ECMC)","All","16 Years to 75 Years   (Child, Adult, Older Adult)","","120","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","PRaM-GBM","March 2, 2017","April 30, 2019","December 31, 2019","September 27, 2017","null","September 27, 2017","Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom","","https://ClinicalTrials.gov/show/NCT03294434"
1017,"NCT00001783","Motor Recovery in Recent Stroke Patients Treated With Amphetamine and Physical Therapy",,"Completed","No Results Available","Cerebrovascular Accident|Paralysis","Drug: 0-15 Water","","National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult","Phase 2","34","NIH","Interventional","Primary Purpose: Treatment","980115|98-N-0115","April 1998","null","June 2004","November 4, 1999","null","March 4, 2008","National Institute of Neurological Disorders and Stroke (NINDS), Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00001783"
1018,"NCT02046330","Deep Brain Stimulation (DBS) Therapy for Treatment Resistant Depression",,"Recruiting","No Results Available","Major Depressive Disorder|Treatment Resistant Depression","Device: Deep Brain Stimulation Model 3387 Model 3389","Changes in patients MADRS scores|Accuracy of Electrode placement|Frequency and Charge of Stimulation|Determine Feasibility of a Double Blind Study|Decrease in Neurocognitive scores on CSTC|Assess maintenance of treatment response (or remission) associated with chronic DBS:|Number of Adverse Events","The University of Texas Health Science Center, Houston|Medtronic","All","22 Years to 65 Years   (Adult, Older Adult)","Not Applicable","10","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HSC-MS-13-0004","November 2013","November 2022","November 2022","January 27, 2014","null","March 30, 2018","UT Center of Excellence on Mood Disorders, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT02046330"
1019,"NCT01701141","Depression and Dopamine Transporter Function Study Using C-11 Altropane",,"Completed","No Results Available","Major Depressive Disorder|Anhedonia","","11C-Altropane Binding|Behavioral Performance in Probabilistic Reward Task|Brain Activity during Instrumental Learning Task|Behavioral Performance in Instrumental Learning Task|Behavioral Performance in the Social Reinforcement Learning Task|Questionnaire Data|Behavioral Performance in Implicit Learning Serial Reaction Time Task","Mclean Hospital","All","18 Years to 45 Years   (Adult)","","150","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","2009-P-001360","January 2012","July 2014","July 2014","October 4, 2012","null","May 21, 2018","McLean Hospital, Belmont, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT01701141"
1020,"NCT00009230","Anti-Inflammatory Treatment for Age-Associated Memory Impairment: A Double-Blind Placebo-Controlled Trial",,"Completed","No Results Available","Memory Disorders","Drug: Celecoxib","","University of California, Los Angeles|National Institute of Mental Health (NIMH)","All","40 Years to 90 Years   (Adult, Older Adult)","Phase 3","null","Other|NIH","Interventional","Allocation: Randomized|Masking: Double|Primary Purpose: Treatment","IA0015|R01MH058156","June 2000","June 2005","August 2005","January 24, 2001","null","May 8, 2017","UCLA Neuropsychiatric Institute, Los Angeles, California, United States","","https://ClinicalTrials.gov/show/NCT00009230"
1021,"NCT00672685","Omega-3 Fatty Acids and/or Multi-domain Intervention in the Prevention of Age-related Cognitive Decline","MAPT","Completed","No Results Available","Frail Elderly Subjects","Dietary Supplement: omega-3|Behavioral: multi-domain intervention|Drug: Placebo","Change in cognitive function at 36 months determined by a composite score (sum of Z-score of 4 tests: FCRST test (free recall + total recall) score, MMSE orientation score, Wais-R score (Digit Substitution Symbol test), and the Category Naming Test score|Changes in other cognitive functions. Changes in functional capacities. To study the long-term safety and tolerability of V0137 CA treatment. To study compliance and adhesion to the ""multi-domain"" intervention program.","University Hospital, Toulouse","All","70 Years and older   (Older Adult)","Not Applicable","1680","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","07 116 03","May 2008","April 2014","April 2014","May 6, 2008","null","April 17, 2015","University Hospital Bordeaux, Bordeaux, France|Regional Hospital, Castres, France|University Hospital of Dijon, Dijon, France|Regional Hospital, Foix, France|Regional Hospital, Lavaur, France|University Hospital Limoges, Limoges, France|UH of LYON SUD, Lyon, France|Chg Montauban, Montauban, France|University Hospital Montpellier, Montpellier, France|University Hospital of Nice, Nice, France|Regional Hospital, Tarbes, France|University Hospital Toulouse, Toulouse, France|Princesse Grace Hospital, Monaco, Monaco","","https://ClinicalTrials.gov/show/NCT00672685"
1022,"NCT01636596","Efficacy of Pulsatile IV Insulin on Cognition and Amyloid Burden in Patients With Alzheimer's Disease",,"Withdrawn","No Results Available","Alzheimer's Disease|Mild Cognitive Impairment","Drug: Insulin LISPRO","cerebral glucose metabolism|cognition|general clinical improvement|basal metabolism","Louisiana State University Health Sciences Center Shreveport|Acuity Center","All","50 Years to 95 Years   (Adult, Older Adult)","Not Applicable","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","H12-166","September 2013","January 2015","January 2015","July 10, 2012","null","March 13, 2014","LSUHSC Shrevport Psychopharmacology Research Clinic, Shreveport, Louisiana, United States","","https://ClinicalTrials.gov/show/NCT01636596"
1023,"NCT02009826","Psychosis-Associated Neuroinflammation in Schizophrenia","PANS","Completed","No Results Available","Schizophrenia|Psychosis","Radiation: [18F]-PBR111 Positron Emission Tomography (PET)|Behavioral: Cognitive and psychomotor tasks|Biological: Blood sampling","Regional VT of [18F]PBR111|Peripheral markers","Universiteit Antwerpen|Agentschap voor Innovatie door Wetenschap en Technologie|Janssen Research & Development, LLC","All","18 Years to 40 Years   (Adult)","","106","Other|Industry","Observational","Observational Model: Case-Control|Time Perspective: Prospective","CAPRI13/37/348|B300201318710","November 2013","February 2017","February 2017","December 12, 2013","null","August 31, 2017","Psychiatrisch Ziekenhuis Broeders Alexianen, Boechout, Antwerpen, Belgium|Psychiatrisch Ziekenhuis St Norbertus, Duffel, Antwerpen, Belgium|Psychiatrisch Ziekenhuis Sint-Amedeus, Mortsel, Antwerp, Belgium","","https://ClinicalTrials.gov/show/NCT02009826"
1024,"NCT01528670","Monitoring of Patients Treated With Particle Therapy Using Positron-Emission-Tomography (PET): The MIRANDA Study","MIRANDA","Withdrawn","No Results Available","Particle Therapy","","TBA","University Hospital Heidelberg","All","18 Years and older   (Adult, Older Adult)","","0","Other","Observational","Observational Model: Other|Time Perspective: Prospective","MIRANDA","May 2019","May 2022","May 2022","February 8, 2012","null","May 17, 2018","Department of Radiation Oncology, Heidelberg, Germany","","https://ClinicalTrials.gov/show/NCT01528670"
1025,"NCT03278210","National Study on the Interest of EEG-fMRI in the Presurgical Evaluation of Partial Epilepsies Drug","ENERGY","Recruiting","No Results Available","Epilepsy Intractable|Focal Epilepsy","","Efficacity of surgery measured by the International League Against Epilepsy (ILAE) scale|Number of patients who finally underwent a surgery after EEG-fMRI results even if they were considered as non surgical after standard presurgical evaluation|Percentage of inter-ictal and ictal discharges for localizing the epileptogenic zone by EEG|Quality of life score (QOLIE 31)|Number of patients who finally underwent a surgery after EEG-fMRI results on SEEG implantation strategy after standard presurgical evaluation(concluded to a surgical management or an SEEG)|Distinction of patients according to the type of their epilepsy: temporal / extra temporal.","University Hospital, Lille","All","8 Years and older   (Child, Adult, Older Adult)","","290","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","2009_54/1021|2010-A01101-38","April 13, 2011","April 2019","April 2019","September 11, 2017","null","April 20, 2018","Hôpital Roger Salengro, CHRU de Lille, Lille, France","","https://ClinicalTrials.gov/show/NCT03278210"
1026,"NCT01979679","A D2 Receptor Occupancy and fMRI Study in Schizophrenic Subjects Treated With Lurasidone",,"Completed","No Results Available","Schizophrenia","Drug: Lurasidone 80 mg|Drug: Lurasidone 120 mg|Drug: Lurasidone 160 mg","D2 receptor occupancy","University of California, Irvine|Dainippon Sumitomo Pharma America","All","18 Years to 60 Years   (Adult)","Phase 3","28","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2008-6481","December 2008","October 2013","null","November 8, 2013","null","November 8, 2013","UCI Medical Center, Orange, California, United States","","https://ClinicalTrials.gov/show/NCT01979679"
1027,"NCT00005903","Continuously Infused Recombinant-Methionyl Human Glial Cell Line-Derived Neurotrophic Factor (GDNF) to Treat Progressive Supranuclear Palsy",,"Completed","No Results Available","Progressive Supranuclear Palsy","Drug: GDNF & Synchro Med Infusion System","","National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult","Phase 2","15","NIH","Interventional","Primary Purpose: Treatment","000145|00-N-0145","June 2000","null","May 2005","June 8, 2000","null","March 4, 2008","National Institute of Neurological Disorders and Stroke (NINDS), Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00005903"
1028,"NCT00001933","Nefiracetam in the Treatment of Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Drug: Nefiracetam","","National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult","Phase 2","50","NIH","Interventional","Primary Purpose: Treatment","990139|99-N-0139","July 1999","null","January 2002","November 4, 1999","null","March 4, 2008","National Institute of Neurological Disorders and Stroke (NINDS), Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00001933"
1029,"NCT00879892","Effect of Xenon and Therapeutic Hypothermia, on the Brain and on Neurological Outcome Following Brain Ischemia in Cardiac Arrest Patients","Xe-hypotheca","Completed","No Results Available","Ischemic Brain Injury","Drug: xenon|Other: Hypothermia","Primary outcome is to show a significant reduction in the degree of severity of the ischemic brain injury in the hypothermia+Xenon group as compared with the hypothermia group, reflected by various MRI techniques|Neurological outcome|A transthoracic echocardiography will be performed for all feasible patients to investigate cardiac safety of the treatments|Mortality|Complication rate|Morbidity","Turku University Hospital|Academy of Finland (Risto O Roine)|University of Turku","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","110","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Eudra CT2009-009505-25","May 2009","September 2014","September 2014","April 13, 2009","null","January 19, 2015","Department of Anesthesia and Perioperative Care, San Fransisco, California, United States|Department of Neurology, Meilahti, Helsinki University Hospital, Helsinki, Finland|Department of Radiology, HUSRontgen, Meilahti, Helsinki University Hospital, Helsinki, Finland|Intensive Care Unit, Meilahti, Helsinki University Hospital, Helsinki, Finland|Department of Cardiology, Meilahti, Helsinki University Hospital, Helsinki, Finland|Adult Intensive Care Unit, Turku University Hospital, Turku, Finland|Department of Internal Medicine, Division of Cardiology, Turku University Hospital, Turku, Finland|Department of Neurology; Turku University Hospital, Turku, Finland|Department of Radiology, Turku University Hospital, Turku, Finland|PET Centre, Turku, Finland","","https://ClinicalTrials.gov/show/NCT00879892"
1030,"NCT02530580","Effects of GABA Modulator AZD7325 on Cutaneous Sensation",,"Completed","No Results Available","Healthy","Drug: 20 mg AZD7325|Drug: Placebo","Change in peak grip force in an object manipulation task|Changes in parameters of object manipulation in a object manipulation task (grip force rate)|Changes in parameters of object manipulation in a object manipulation task (load force rate)|Changes in parameters of object manipulation in a object manipulation task (static load force)|Changes in parameters of object manipulation in a object manipulation task (static grip force)|Changes in parameters of object manipulation in a object manipulation task (9-hole pegboard test)|Changes in performance in the psychophysical tests of cutaneous sensation (""bumps"" test)|Changes in performance in the psychophysical tests of cutaneous sensation (grating orientation task)|Changes in performance in the psychophysical tests of cutaneous sensation (vibrotactile sensitivity)|Changes in performance in the psychophysical tests of cutaneous sensation (thermal sensitivity)|Change in the rating on a 0-100 mm Visual Analogue Scale (VAS) of degree of sedation|Change in the score of Symbol Digit Modalities Test (SDMT)|Safety and tolerability of a single dose of AZD7325 by assessment of adverse events, vital signs, physical examination, ECG, and laboratory variables","University College, London","Male","18 Years to 55 Years   (Adult)","Phase 1","12","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","13/0261|2015-000642-35","February 2016","July 2016","July 2016","August 21, 2015","null","July 27, 2016","National Hospital for Neurology and Neurosurgery, London, United Kingdom","","https://ClinicalTrials.gov/show/NCT02530580"
1031,"NCT01400672","Imiquimod/Brain Tumor Initiating Cell (BTIC) Vaccine in Brain Stem Glioma",,"Completed","No Results Available","Diffuse Intrinsic Pontine Glioma","Biological: Tumor Lysate Vaccine|Drug: Imiquimod|Radiation: Radiation therapy","Dose-limiting toxicity|Time to Tumor Progression|Drop-out rate","Masonic Cancer Center, University of Minnesota","All","3 Years and older   (Child, Adult, Older Adult)","Phase 1","8","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2009LS136|1004M81213","July 17, 2012","June 17, 2015","October 10, 2015","July 22, 2011","null","December 2, 2017","Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States","","https://ClinicalTrials.gov/show/NCT01400672"
1032,"NCT00050219","Role of Dopamine in Response to Alcohol",,"Completed","No Results Available","Alcohol Consumption","","","National Institute on Alcohol Abuse and Alcoholism (NIAAA)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult","","60","NIH","Observational","","030042|03-AA-0042","November 2002","null","September 2004","December 2, 2002","null","March 4, 2008","National Institute on Alcohol Abuse and Alcoholism (NIAAA), Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00050219"
1033,"NCT00585221","Study of Imatinib and Peginterferon α-2b in Gastrointestinal Stromal Tumor (GIST) Patients",,"Terminated","Has Results","Gastrointestinal Stromal Tumors|Cancer Brain|Solid Tumors","Drug: Peginterferon-alpha 2b (PegIFNa2b);|Drug: Imatinib","Decrease in Tumor Size.|Time to Progression (TTP).","University of Utah|Schering-Plough","All","18 Years and older   (Adult, Older Adult)","Phase 2","8","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB_00022172","July 2007","July 2009","July 2009","January 3, 2008","November 21, 2012","February 10, 2017","University of Utah, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT00585221"
1034,"NCT00025792","Clinical Trial of Pramipexole in Bipolar Depression",,"Completed","No Results Available","Bipolar Disorder","Drug: Pramipexole","","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult","Phase 2","200","NIH","Interventional","Primary Purpose: Treatment","020018|02-M-0018","October 2001","null","November 2005","October 25, 2001","null","March 4, 2008","National Institute of Mental Health (NIMH), Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00025792"
1035,"NCT03185208","Lithium As a Treatment to Prevent Impairment of Cognition in Elders","LATTICE","Recruiting","No Results Available","Mild Cognitive Impairment","Drug: Lithium Carbonate|Drug: Placebo oral capsule","Change from baseline cognitive testing measures over 2 years|Change from baseline biomarker values over 2 years|Change from baseline brain volume values over 2 years as measured by structural imaging (7T MRI)|Change from baseline brain integrity measures over 2 years as measured by structural imaging (7T MRI)|Change from baseline cerebrospinal phospho tau levels over 2 years","Ariel Gildengers|National Institute on Aging (NIA)|University of Pittsburgh","All","60 Years and older   (Adult, Older Adult)","Phase 4","80","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","PRO17030527|R01AG055389-01","September 1, 2017","March 31, 2022","March 31, 2022","June 14, 2017","null","February 15, 2018","University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT03185208"
1036,"NCT02947893","Impact of Nilotinib on Safety, Biomarkers and Clinical Outcomes in Mild to Moderate Alzheimer's Disease","AD","Recruiting","No Results Available","Alzheimer's Disease","Drug: Placebo Capsule(s) Once a Day by Mouth|Drug: Nilotinib Capsule(s) Once a Day by Mouth","Safety will be measured by number of participants experiencing the occurrence of adverse events and/or abnormal laboratory values|Effects of Nilotinib treatment on measurement of Nilotinib in the CSF","Georgetown University","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 2","42","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2016-0315","January 2017","February 2019","December 2019","October 28, 2016","null","February 20, 2018","Georgetown University Medical Center, Washington, District of Columbia, United States","","https://ClinicalTrials.gov/show/NCT02947893"
1037,"NCT01834625","Prognostic Value of Aβ Imaging in NPH Prior to Shunt Placement",,"Terminated","No Results Available","Normal Pressure Hydrocephalus Patients","Diagnostic Test: PET scan","Comparison of change between florbetapir +ve and -ve patients from baseline to one year in the Montreal Cognitive Assessment (MoCA)","Mayo Clinic","All","60 Years and older   (Adult, Older Adult)","","2","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","11-004532","April 2013","March 2017","October 2017","April 18, 2013","null","February 8, 2018","Mayo Clinic, Jacksonville, Florida, United States","","https://ClinicalTrials.gov/show/NCT01834625"
1038,"NCT02135198","Effects of GABA Modulator AZD7325 on Cortical Excitability",,"Completed","No Results Available","Healthy","Drug: 2 mg AZD7325|Drug: 10 mg AZD7325|Drug: Placebo","Change in conventional measure of percentage short interval intracortical inhibition (SICI) at an interstimulus interval (ISI) of 2.5 ms and conditioning stimulus intensity of 70 percent of resting motor threshold|Change in the variables of kinematic analysis of circle drawing|Change in the rating on a 0-100 mm Visual Analogue Scale (VAS) of degree of sedation and the score of Symbol Digit Modalities Test (SDMT)|Safety and tolerability of a single dose of AZD7325 by assessment of adverse events, vital signs, physical examination, ECG, and laboratory variables","University College, London","Male","18 Years to 55 Years   (Adult)","Phase 1","12","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","13/0231|2013-005472-17","September 2014","August 2015","August 2015","May 9, 2014","null","August 28, 2015","National Hospital for Neurology and Neurosurgery, UCLH NHS Foundation Trust, London, United Kingdom","","https://ClinicalTrials.gov/show/NCT02135198"
1039,"NCT00263588","Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer",,"Completed","No Results Available","Neoplasms, Breast","Drug: lapatinib","Response to lapatinib in patients with progressive brain metastases from ErbB2-overexpressing breast cancer.|Improvement in neurological signs and symptoms (NSS), measured using the Neurological Examination Worksheet|Percentage of patients who obtain a CNS objective response or improvement in baseline NSS|Duration of CNS objective response|Percentage of patients with CNS disease control (complete response, partial response or stable disease) at 6 months of lapatinib therapy|Time to progression at any site|Overall survival|Site of first progression and cause of death|Qualitative and quantitative toxicities associated with oral lapatinib, given at a dose of 750 mg twice a day|Relationship of PET uptake at Baseline and Week 1, as predictors of response (for those patients whose site obtained PET qualifications).|Relationship between genetic variants in select candidate genes in the host and the efficacy and safety of lapatinib","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 2","244","Industry","Interventional","Allocation: Non-Randomized|Masking: None (Open Label)|Primary Purpose: Treatment","EGF105084","December 2, 2005","September 25, 2007","March 15, 2018","December 9, 2005","null","May 1, 2018","Novartis Investigative Site, San Francisco, California, United States|Novartis Investigative Site, Vallejo, California, United States|Novartis Investigative Site, Denver, Colorado, United States|Novartis Investigative Site, Washington, District of Columbia, United States|Novartis Investigative Site, Boca Raton, Florida, United States|Novartis Investigative Site, Jacksonville, Florida, United States|Novartis Investigative Site, Indianapolis, Indiana, United States|Novartis Investigative Site, Indianapolis, Indiana, United States|Novartis Investigative Site, Sioux City, Iowa, United States|Novartis Investigative Site, Kansas City, Kansas, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Ann Arbor, Michigan, United States|Novartis Investigative Site, Minneapolis, Minnesota, United States|Novartis Investigative Site, Saint Louis, Missouri, United States|Novartis Investigative Site, Albuquerque, New Mexico, United States|Novartis Investigative Site, Albuquerque, New Mexico, United States|Novartis Investigative Site, Albuquerque, New Mexico, United States|Novartis Investigative Site, Santa Fe, New Mexico, United States|Novartis Investigative Site, New York, New York, United States|Novartis Investigative Site, Chapel Hill, North Carolina, United States|Novartis Investigative Site, Philadelphia, Pennsylvania, United States|Novartis Investigative Site, Pittsburgh, Pennsylvania, United States|Novartis Investigative Site, Nashville, Tennessee, United States|Novartis Investigative Site, Dallas, Texas, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, Tyler, Texas, United States|Novartis Investigative Site, Seattle, Washington, United States|Novartis Investigative Site, Yakima, Washington, United States|Novartis Investigative Site, North Sydney, New South Wales, Australia|Novartis Investigative Site, Herston, Queensland, Australia|Novartis Investigative Site, South Brisbane, Queensland, Australia|Novartis Investigative Site, Box Hill, Victoria, Australia|Novartis Investigative Site, Ringwood East, Victoria, Australia|Novartis Investigative Site, Perth, Western Australia, Australia|Novartis Investigative Site, Adelaide, Australia|Novartis Investigative Site, Salzburg, Austria|Novartis Investigative Site, Vienna, Austria|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Vancouver, British Columbia, Canada|Novartis Investigative Site, Ottawa, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Weston, Ontario, Canada|Novartis Investigative Site, Dijon Cedex, France|Novartis Investigative Site, Paris Cedex 05, France|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Toulouse cedex, France|Novartis Investigative Site, Muenchen, Bayern, Germany|Novartis Investigative Site, Muenchen, Bayern, Germany|Novartis Investigative Site, Frankfurt am Main, Hessen, Germany|Novartis Investigative Site, Neo Faliro, Greece|Novartis Investigative Site, Bangalore, India|Novartis Investigative Site, Mumbai, India|Novartis Investigative Site, Reggio Emilia, Emilia-Romagna, Italy|Novartis Investigative Site, Milano, Lombardia, Italy|Novartis Investigative Site, Perugia, Umbria, Italy|Novartis Investigative Site, Aichi, Japan|Novartis Investigative Site, Saitama, Japan|Novartis Investigative Site, Saitama, Japan|Novartis Investigative Site, Tokyo, Japan|Novartis Investigative Site, Tokyo, Japan|Novartis Investigative Site, Tokyo, Japan|Novartis Investigative Site, Olsztyn, Poland|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Uppsala, Sweden|Novartis Investigative Site, Geneve, Switzerland|Novartis Investigative Site, Locarno, Switzerland|Novartis Investigative Site, Tainan County, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Manchester, Lancashire, United Kingdom|Novartis Investigative Site, Brighton, United Kingdom","","https://ClinicalTrials.gov/show/NCT00263588"
1040,"NCT02377505","Deep Brain Stimulation in Treatment Resistant Schizophrenia","DBS-SCHIZO","Recruiting","No Results Available","Refractory Schizophrenia","Device: On-Stimulation|Device: Off-Stimulation","Positive and Negative Syndrome Scale for Schizophrenia (PANSS)|Clinical Global Impression-Schizophrenia (CGI-SCH)|Global Functioning Scale (GFS)|Social Functioning Scale (SFS)|Personal and Social Performance (PSP)|Psychotic Symptom Rating Scales (PSYRATS)|Scale for the Assessment of Negative Symptoms (SANS)|Calgary Depression Scale for Schizophrenia (CDSS)|Performance-Based Skills Assessment (UPSA)|Neuropsychological Assessment|Cerebral metabolism (PET scans)|n-Back (fMRI scan)|Adverse events (AEs)","Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|Fondo de Investigacion Sanitaria","All","18 Years to 55 Years   (Adult)","Not Applicable","8","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","IIBSP-ECP-2013-20|PI12/00042","January 2013","February 2017","December 2017","March 3, 2015","null","February 27, 2017","FIDMAG Germanes Hospitalàries Research Foundation, Sant Boi de Llobregat, Barcelona, Spain|Department of Psychiatry. Hospital Santa Creu i Sant Pau, Barcelona, Spain","","https://ClinicalTrials.gov/show/NCT02377505"
1041,"NCT00324909","Effects of Hyperbaric Oxygen Therapy in Autistic Children: A Pilot Study",,"Completed","No Results Available","Autism|Oxidative Stress|Inflammation","Drug: Hyperbaric Oxygen Therapy","Scores on autism rating scales before and after HBOT|Measure of inflammation before and after HBOT|Measures of oxidative stress before and after HBOT","International Hyperbarics Association","All","2 Years to 18 Years   (Child, Adult)","Not Applicable","18","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HBA-1","null","null","null","May 11, 2006","null","April 10, 2007","Blue Ridge Medical Center, Arrington, Virginia, United States","","https://ClinicalTrials.gov/show/NCT00324909"
1042,"NCT02076711","Myocardial Efficiency of the Left Ventricle in Asymptomatic Patients With Aortic Valve Stenosis - a Prognostic Marker and a Target for Intervention?","MELVAS","Completed","No Results Available","Aortic Stenosis","Drug: Metoprololsuccinate|Drug: Placebo","LV myocardial efficiency|LV oxygen consumption|LV perfusion|LV myocardial function|LVmass|Aortic valve area|Transaortic valve velocities|6 minute walking distance|N-terminal prohormone of brain natriuretic peptide|Quality of life - estimated by Minnesota living with heart failure questionnaire|LV wall stress","Aarhus University Hospital","All","20 Years and older   (Adult, Older Adult)","Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","201300114731","June 2013","September 2015","September 2015","March 4, 2014","null","November 11, 2015","Aarhus University Hospital, Department of Cardiology, Brendstrupgaardsvej 100, Aarhus N, Denmark","","https://ClinicalTrials.gov/show/NCT02076711"
1043,"NCT01787240","Neurobiological Bases of Placebo Response in Major Depressive Disorder",,"Terminated","Has Results","Major Depressive Disorder","Drug: Escitalopram 10mg|Drug: Placebo","Feasibility|Effects of Acute Tryptophan Depletion on Mood","Massachusetts General Hospital","All","18 Years to 60 Years   (Adult)","Phase 4","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","2012P001241","November 2012","August 2016","August 2016","February 8, 2013","April 14, 2017","May 16, 2017","Massachusetts General Hospital Depression Clinical and Research Program, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT01787240"
1044,"NCT02199483","Metabolic and Neural Adaptations to Weight Loss, Plateau, and Regain",,"Withdrawn","No Results Available","Healthy Volunteers","","To measure metabolic and neural adaptations after 4-12 weeks, 6-10 months, and 22-26 months following the start of a lifestyle intervention resulting in weight loss.|To determine whether the degree of metabolic or neural adaptation at 4-12 weeks is correlated with the weight plateau at 6-10 months or the rate of weight regain in the subsequent months.|To investigate changes in circulating hormone and metabolites that correlate with metabolic and neural adaptations as well as changes in appetitive behaviors following a lifestyle intervention resulting in weight loss.","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC)","All","18 Years to 55 Years   (Adult)","","0","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","140154|14-DK-0154","July 21, 2014","June 29, 2017","June 29, 2017","July 24, 2014","null","August 21, 2018","","","https://ClinicalTrials.gov/show/NCT02199483"
1045,"NCT00029458","Clozapine for Treatment-Resistant Mania",,"Completed","No Results Available","Bipolar Disorder","Drug: Clozapine","","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult","Phase 2","42","NIH","Interventional","Primary Purpose: Treatment","020085|02-M-0085","January 2002","null","October 2005","January 14, 2002","null","March 4, 2008","National Institute of Mental Health (NIMH), Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00029458"
1046,"NCT02398318","China Refractory Obsessive-Compulsive Disorder Deep Brain Stimulation Study","CRODS","Withdrawn","No Results Available","Obsessive Compulsive Disorder","Device: Bilateral Nucleus Accumbens DBS (Suzhou Sceneray)|Device: Sham Bilateral Nucleus Accumbens DBS","Change in Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) Score|Change in Obsessive-Compulsive Inventory - Revised (OCI-R) Score|Change in Hamilton Anxiety Scale, Hamilton Depression Scale-17, Beck Anxiety Scale, Beck Depression Scale-1 Score|Change in Temperament and Character Inventory revised version (TCI-R) Score|Iowa Gambling Task (change in task performance scores)|Change in functional magnetic resonance imaging (fMRI) images|Change in positron emission tomography (PET) brain glucose metabolism images|Quality of life: Global assessment of function|Disability: WHO disability assessment 2.0|Model Task (change in task performance scores)","Ruijin Hospital|Suzhou Sceneray Medical Co. , Ltd|National Natural Science Foundation of China|Icahn School of Medicine at Mount Sinai","All","18 Years to 60 Years   (Adult)","Phase 2|Phase 3","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","RCT-YY2015-CRODS","April 2015","October 2016","April 2018","March 25, 2015","null","December 6, 2016","Guangzhou psychiatric hospital, Guangzhou, Guangdong, China|Shanghai Mental Health Center, Shanghai, Shanghai, China|West China Hospital, Chengdu, Sichuan, China","","https://ClinicalTrials.gov/show/NCT02398318"
1047,"NCT00039715","Effects of Hydrocortisone in Patients With Post-Traumatic Stress Disorder",,"Completed","No Results Available","Post-Traumatic Stress Disorders|Healthy","","","National Institute of Mental Health (NIMH)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult","","93","NIH","Observational","","020209|02-M-0209","June 2002","null","September 2004","June 7, 2002","null","March 4, 2008","National Institute of Mental Health (NIMH), Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00039715"
1048,"NCT02504892","Everolimus Therapy in People With Birt-Hogg-Dube Syndrome (BHD)-Associated Kidney Cancer or Sporadic Chromophobe Renal Cancer",,"Terminated","No Results Available","Renal Cancer|Birt-Hogg-Dube Syndrome","Drug: Everolimus","Overall response rate with everolimus treatment.|Assess changes in tumor growth rates and ability to delay surgical management in BHD patients.|Assess progression-free survival (PFS) and overall survival (OS).|Evaluate the effect of everolimus on mTOR activity in renal tumors (using pre- and on-treatment biopsies when available).|Assess the effect of therapy on BHD associated lung cysts and cutaneous fibrofolliculomas.|Safety and totlerability of everolimus in patients with BHD-associated localized renal tumors.","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 2","3","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","150166|15-C-0166","July 21, 2015","April 17, 2018","April 17, 2018","July 22, 2015","null","April 19, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT02504892"
